(19) DANMARK

(10) DK/EP 3681885 T3

(12) Oversættelse af europæisk patentskrift

Patent- og Varemærkestyrelsen

(51) Int.Cl.: *C 07 D 471/04 (2006.01)* *A 61 K 31/437 (2006.01)* *A 61 P 35/00 (2006.01)*

(45) Oversættelsen bekendtgjort den: **2024-04-15**

(80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-02-28**

(86) Europæisk ansøgning nr.: **18833127.6**

(86) Europæisk indleveringsdag: **2018-09-14**

(87) Den europæiske ansøgnings publiceringsdag: **2020-07-22**

(86) International ansøgning nr.: **US2018051235**

(87) Internationalt publikationsnr.: **WO2019055877**

(30) Prioritet: **2017-09-15 US 201762559436 P** **2018-06-29 US 201862692593 P**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **Forma Therapeutics, Inc., 300 North Beacon Street Suite 501, Watertown MA 02472, USA**

(72) Opfinder: **SCHILLER, Shawn E.R., c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA**
HERBERTZ, Torsten, c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA
LI, Hongbin, c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA
GRAVES, Bradford, c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA
MISCHKE, Steven, c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA
WEST, Angela V., c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA
ERICSSON, Anna, c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA
DOWNING, Jennifer R., c/o FORMA THERAPEUTICS INC., 500 Arsenal Street Suite 100, Watertown, Massachusetts 02472, USA

(74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**

(54) Benævnelse: **TETRAHYDRO-IMIDAZO-QUINOLINSAMMENSÆTNINGER SOM CBP/P300-INHIBITORER**

(56) Fremdragne publikationer:
EP-A1- 2 412 710
WO-A1-2016/086200
WO-A2-2011/150156

Fortsættes ...

DESCRIPTION

Description

Cross-Reference to Related Applications

[0001] This application claims the benefit of priority of U.S. Provisional Application No. 62/559,436, filed September 15, 2017 and U.S. Provisional Application No. 62/692,593, filed June 29, 2018.

Field of Disclosure

[0002] The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. Specifically, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains. Also provided are methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Background of Disclosure

[0003] p300 (also known as EP300 and KAT3B) is a large protein with multiple domains that bind to diverse proteins including many DNA-binding transcription factors. The cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP, also known as KAT3A) is a cellular paralog of p300. p300 and CBP share extensive sequence identity and functional similarity. As such, they are often referred to as CBP/p300 in the scientific literature. CBP/p300 are lysine acetyltransferases that catalyze the attachment of an acetyl group to a lysine side chain of histones and other protein substrates. As large proteins, CBP/p300 were proposed to activate transcription in part by bridging DNA-binding transcription factors to RNA polymerase machinery or by helping assemble the transcriptional pre-initiation complex (PIC). Importantly, CBP/p300-catalyzed acetylation of histones and other proteins is pivotal to gene activation. Heightened p300 expression and activities have been observed in advanced human cancers such as prostate and liver (cancer and appear to be associated with poor prognosis of these cancer types. Compared to normal tissue counterparts, the expression levels of p300 are higher in human primary breast cancer specimens and in mouse mammary carcinomas induced by polyomavirus middle-T oncogene. WO 2016/086200 A1 relates to compounds


which are identified as being of use as inhibitors of CBP and/or EP300, and pharmaceutical compositions comprising the same.

Summary of Disclosure

[0004] Novel compounds useful for inhibiting CBP, including CBP Inhibitor Compounds and Selective CBP Inhibitor Compounds, are disclosed herein. The invention is as defined in the enclosed claims. In one embodiment the invention is directed to a compound of Formula (I-d) or a pharmaceutically acceptable salt thereof as defined in claim 1. In another embodiment the invention is directed to a compound of Formula (I-e) or a pharmaceutically acceptable salt thereof as defined in claim 9. In another embodiment the invention is directed to a compound of the invention or a pharmaceutically acceptable salt thereof as listed in claim 17. In another embodiment the invention is directed to a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0005] The references to methods of treatment in the subsequent paragraphs of this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments for use in a method for treatment of the human (or animal) body by therapy (or for diagnosis).

[0006] The present disclosure relates to compounds of Formula (I):



(I),

or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer thereof,
wherein:

R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OR^5, -$N(R^5)_2$, or -NHR^5;

R^2 is -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^6;

R^3 is -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or

aryl is optionally substituted with one or more R^7;

R^4 and $R^{4'}$ are each independently -H, halogen, -OH, -CN, or $-NH_2$;

each R^5 is independently $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^6 and R^7 are each independently, at each occurrence, $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, - C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, $-SR^8$, $-OR^8$, $-(CH_2)_n-OR^8$, $-NHR^8$, $-NR^8R^9$, $-S(O)_2NR^8R^9$, $-S(O)_2R^{8'}$, - $C(O)R^{8'}$, - $C(O)OR^8$, $-C(O)NR^8R^9$, $-NR^8C(O)R^{9'}$, $-NR^8S(O)_2R^{9'}$, $-S(O)R^{8'}$, $-S(O)NR^8R^9$, or $-NR^8S(O)R^{9'}$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10};

wherein any two R^6 or any two R^7, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^6 or any two R^7, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^8 and R^9 are each independently, at each occurrence, -H, $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and R^9 may combine with the atom to which they are both attached to form a $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10} or R^{11};

$R^{8'}$ and $R^{9'}$ are each independently, at each occurrence, $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and $R^{9'}$ may combine with the atom to which they are both attached to form a $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10} or R^{11};

R^{10} and R^{11} are each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};

wherein any two R^{10} or any two R^{11}, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} or any two R^{11}, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl); and

n is an integer from 1 to 4.

[0007] An aspect of the present invention relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can further include an excipient, diluent, or surfactant. The pharmaceutical composition can be effective for treating a disease or disorder associated with CBP/p300 modulation in a subject in need thereof. The pharmaceutical compositions can comprise the compounds of the present invention for use in treating diseases described herein. The compositions can contain at least one compound of the invention and a pharmaceutically acceptable carrier.

[0008] In one aspect, the present disclosure relates to a method of modulating one or more of CBP/p300-family bromodomains. The method can comprise administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. Another aspect of the present disclosure relates to a method of inhibiting one or more of CBP/p300-family bromodomains. The method can comprise administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In another aspect, the present disclosure relates to a method of inhibiting one or more of CBP/p300-family

bromodomains. The method can comprise administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition described herein.

[0009] Another aspect of the present disclosure relates to a method of treating, preventing, inhibiting, or eliminating a disease or condition in a patient associated with the inhibition of one or more of CBP/p300-family bromodomains. The method can comprise administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, such as a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein said disease or condition is selected from the group consisting of cancer

[0010] The present disclosure further provides compounds and compositions with an improved efficacy and safety profile relative to known CBP/p300 domain inhibitors. The present disclosure also provides agents with novel mechanisms of action toward CBP/p300 proteins in the treatment of various types of diseases including cancers. The present disclosure can provide the medical community with a novel pharmacological strategy for the treatment of diseases and disorders associated with inhibition of CBP/p300 proteins, including the inhibition of CBP in the HTRF biochemical assay of Example 963 disclosed herein, with an IC_{50} value of 0.001-1 micromolar.

Detailed Description of the Disclosure

[0011] The present disclosure relates to compounds and compositions that are capable of modulating the activity of the CBP/p300 family bromodomains. The disclosure features methods of treating, preventing or ameliorating a disease or disorder in which CBP/p300 bromodomains play a role by administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. The methods of the present disclosure can be used in the treatment of a variety of CBP/p300 bromodomain dependent diseases and disorders by inhibiting the activity of a CBP/p300 bromodomains. Inhibition of CBP/p300 bromodomains provides a novel approach to the treatment, prevention, or amelioration of diseases including, but not limited to, cancer, inflammatory diseases, diabetes and obesity, and to develop male contraceptives.

[0012] The details of the disclosure are set forth in the accompanying description below. The compounds of the invention are those defined in the enclosed claims e.g. compounds of Formulae (I-d) (as defined in claim 1), compounds of Formula (I-e) (as defined in claim 9), and the compounds listed in claim 17. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein

have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

Definitions

[0013] Unless otherwise indicated, "CBP Inhibitor Compound" as used herein refers to a compound having one or more of the following characteristics when tested according to the HTRF biochemical Assay Protocol of Example 963 below: (1) a CBP IC_{50} value of less than 1 μM; and (2) a CBP IC_{50} value of between 0.001 and 1 μM.

[0014] Unless otherwise indicated, a "Selective CBP Inhibitor Compound" as used herein refers to a CBP Inhibitor having a BRD4 IC_{50} value greater than that of its CBP IC_{50} value, preferably wherein its BRD4 IC_{50} value greater than 1 μM (e.g., 1 micromolar to 10 micomolar, or greater), wherein the IC_{50} values are as determined in the procedures set forth in Example 963.

[0015] The articles "a" and "an" are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0016] The term "and/or" is used in this disclosure to mean either "and" or "or" unless indicated otherwise.

[0017] The term "optionally substituted" is understood to mean that a given chemical moiety (e.g. an alkyl group) can (but is not required to) be bonded other substituents (e.g. heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e. a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus the term "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups.

[0018] The term "aryl" refers to cyclic, aromatic hydrocarbon groups that have 1 to 2 aromatic rings, including monocyclic or bicyclic groups. In some embodiments, aryl groups have a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H, -halogen, -O-C_1-C_6alkyl, -C_1-C_6alkyl, -OC_2-C_6alkenyl, -OC_2-C_6alkynyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -OH, -OP(O)$(OH)_2$, -OC(O)C_1-C_6alkyl, -C(O)C_1-

C_6alkyl, -OC(O)OC_1-C_6alkyl, -NH_2, -NH(C_1-C_6alkyl), -N(C_1-C_6alkyl)$_2$, -S(O)$_2$-C_1-C_6alkyl, -S(O)NHC_1-C_6alkyl, and -S(O)N(C_1-C_6alkyl)$_2$. The substituents can themselves be optionally substituted. Furthermore when containing two fused rings the aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these aryl groups include indanyl, indenyl, tetrahydronaphthalenyl, and tetrahydrobenzoannulenyl.

[0019] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic aromatic radical or a polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from N, S, P, and O, the remaining ring atoms being C. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, S, P, and O. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydro pyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1λ^2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d] thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4] thiazinyl, benzooxazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo [1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c] [1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo [1,5-b] [1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b] [1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore when containing two fused rings the heteroaryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl. In some embodiments, "heteroaryl" refers to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and/or having, in addition to carbon atoms, from one to five heteroatoms wherein the term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.

[0020] "Alkyl" refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms. C_1-C_6alkyl groups contain 1 to 6 carbon atoms. Examples of a C_1-C_6alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.

[0021] "Alkenyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted. Alkenyl, as herein defined, may be straight or branched.

[0022] "Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkynyl" group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propanyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.

[0023] The term "cycloalkyl" means monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl. A C_3-C_8 cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. A cycloalkyl group can be fused (e.g., decalin) or bridged (e.g., norbornane).

[0024] The term "cycloalkenyl" means monocyclic, non-aromatic unsaturated carbon rings containing 4-18 carbon atoms. Examples of cycloalkenyl groups include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl. A C_4-C_8 cycloalkenyl is a cycloalkenyl group containing between 4 and 8 carbon atoms.

[0025] The terms "heterocyclyl" or "heterocycloalkyl" or "heterocycle" refer to monocyclic or polycyclic 3 to 24-membered rings containing carbon and heteroatoms taken from oxygen, phosphorous, nitrogen, or sulfur and wherein there is not delocalized π electrons (aromaticity) shared among the ring carbon or heteroatoms. In some embodiments, "heterocyclyl" refers to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms selected from N, S, P, or O. Heterocyclyl rings can be fully saturated or partially unsaturated. Heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, pyridonyl, and homotropanyl. A heteroycyclyl or heterocycloalkyl ring can also be fused or bridged, e.g., can be a bicyclic ring.

[0026] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at

least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0027] The term "spirocycle" is understood as a bicyclic ring system with both rings connected through a single atom. A spirocycle can be fully saturated or can be partially unsaturated.

[0028] The term "spirocycloalkyl" is understood to mean a fully carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycloalkyl can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring. A (C_5-C_{12}) spirocycloalkyl is a spirocycle containing between 5 and 12 carbon atoms.

[0029] The term "spiroheterocycloalkyl" or "spiroheterocyclyl" is understood to mean a spirocycle as defined above wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl). Spiroheterocycloalkyl groups can be for instance, without limitation, azapiroheptanes; azaspirooctanes; azaspirononanes; azaspirodecanes; oxaspiroheptanes; oxaspirooctanes; octaspirononanes; or oxaspirodecanes.

[0030] As used herein, the term "halo" or "halogen" means a fluoro, chloro, bromo, or iodo group.

[0031] The term "carbonyl" refers to a functional group composing a carbon atom double-bonded to an oxygen atom. It can be abbreviated herein as C(O), or as C=O.

[0032] The term "oxo" refers to an oxygen atom that is double-bonded to another atom. An "oxo" group can be connected to a carbon atom (e.g., to form a carbonyl, as defined above) or can be connected to a heteroatom such as sulfur (e.g., to form a sulfoxide or a sulfone) or phosphorous (e.g., to form a phosphorous ylide).

[0033] The disclosure also includes pharmaceutical compositions comprising an effective amount of a disclosed compound and a pharmaceutically acceptable carrier. Representative "pharmaceutically acceptable salts" include, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, sethionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate),

pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

[0034] The term "tautomers" refers to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another. A "tautomer" is a single member of this set of compounds. Typically a single tautomer is drawn but it is understood that this single structure is meant to represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it is understood that both the enol and ketone forms are part of the disclosure.

[0035] The term "prodrug," as used in this disclosure, means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound. Furthermore, as used herein a prodrug is a drug which is inactive in the body, but is transformed in the body typically either during absorption or after absorption from the gastrointestinal tract into the active compound. The conversion of the prodrug into the active compound in the body may be done chemically or biologically (i.e., using an enzyme).

[0036] The term "solvate" refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.

[0037] The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.

[0038] The term "stereoisomers" refers to the set of compounds which have the same number and type of atoms and share the same bond connectivity between those atoms, but differ in three dimensional structure. The term "stereoisomer" refers to any member of this set of compounds. For instance, a stereoisomer may be an enantiomer or a diastereomer.

[0039] The term "enantiomers" refers to a pair of stereoisomers which are non-superimposable mirror images of one another. The term "enantiomer" refers to a single member of this pair of stereoisomers. The term "racemic" refers to a 1:1 mixture of a pair of enantiomers.

[0040] The term "diastereomers" refers to the set of stereoisomers which cannot be made superimposable by rotation around single bonds. Diastereomerism occurs when two or more

stereoisomers of a compound have different configurations at one or more (but not all) of the equivalent (related) stereocenters and are not mirror images of each other. Compounds containing multiple stereogenic centers with different relative configurations are considered to be diastereomers. The term "diastereomer" refers to any member of this set of compounds. In some examples presented, the synthetic route may produce a single diastereomer or a mixture of diastereomers. In some cases these diastereomers were separated and in other cases a wavy bond is used to indicate the structural element where configuration is variable.

[0041] An "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.

[0042] The term "carrier", as used in this disclosure, encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.

[0043] The term "treating" with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.

[0044] The term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

[0045] The term "administer", "administering", or "administration" as used in this disclosure refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.

[0046] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.

[0047] It should be understood that all isomeric forms are included within the present disclosure, including mixtures thereof. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans configuration. All tautomeric forms are also intended to be included.

[0048] Compounds of Formula (I), and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present disclosure.

[0049] The compounds of Formula (I), may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present disclosure. In addition, the present disclosure embraces all geometric and positional isomers. For example, if a compound of Formula (I), incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. The assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereochemistry.

[0050] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this disclosure. Enantiomers can also be separated by use of a chiral HPLC column.

[0051] It is also possible that the compounds of Formula (I), may exist in different tautomeric forms, and all such forms are embraced within the scope of the disclosure. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the disclosure.

[0052] All stereoisomers (for example, geometric isomers, and optical isomers) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this disclosure, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the disclosure.) Individual stereoisomers of the compounds of the disclosure may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present disclosure can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester," and "prodrug", is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.

[0053] The present disclosure also embraces isotopically-labelled compounds of the present disclosure which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ^{2}H (or D), ^{3}H, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F, and ^{36}Cl, respectively.

[0054] Certain isotopically-labelled compounds of Formula (I) *(e.g.,* those labeled with ^{3}H and ^{14}C) are useful in compound and/or substrate tissue distribution assays. Tritiated (*i.e.,* ^{3}H) and carbon-14 (*i.e.,* ^{14}C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (*i.e.,* ^{2}H) may afford certain therapeutic advantages resulting from greater metabolic stability (*e.g.,* increased *in vivo* half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of Formula (I) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.


[0055] The compounds of Formula (I) may form salts which are also within the scope of this disclosure. Reference to a compound of the Formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated.

[0056] The present disclosure relates to compounds which are modulators of one or more bromodomains of the CBP/p300 family. In one embodiment, the compounds of the present disclosure are inhibitors of one or more bromodomains of the CBP/p300 family.

Compounds of the Disclosure

[0057] The present disclosure relates to compounds, or pharmaceutically acceptable salts or isomers thereof, capable of modulating CBP/p300 family bromodomains which are useful for the treatment of diseases and disorders associated with modulation of CBP/p300 family bromodomains. The disclosure further relates to compounds, or pharmaceutically acceptable salts or isomers thereof, which are useful for inhibiting CBP/p300 family bromodomains.

[0058] One aspect of the present disclosure describes compounds of Formula (I):



(I),

or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer thereof,
wherein:

R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OR^5, -$N(R^5)_2$, or -NHR^5;

R^2 is -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^6;

R^3 is -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^7;

R^4 and $R^{4'}$ are each independently -H, halogen, -OH, -CN, or -NH_2;

each R^5 is independently -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^6 and R^7 are each independently, at each occurrence, -C_1-C_6alkyl, -C_3-C_8cycloalkyl, - C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, -SR^8, -OR^8, -$(CH_2)_n$-OR^8, -NHR^8, -NR^8R^9, -$S(O)_2NR^8R^9$, -$S(O)_2R^{8'}$, - $C(O)R^{8'}$, -$C(O)OR^8$, -$C(O)NR^8R^9$, -$NR^8C(O)R^{9'}$, -$NR^8S(O)_2R^{9'}$, -$S(O)R^{8'}$, -$S(O)NR^8R^9$, or -$NR^8S(O)R^{9'}$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10};

wherein any two R^6 or any two R^7, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^6 or any two R^7, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^8 and R^9 are each independently, at each occurrence, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and R^9 may combine with the atom to which they are both attached to form a -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl,

spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10} or R^{11};

$R^{8'}$ and $R^{9'}$ are each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and $R^{9'}$ may combine with the atom to which they are both attached to form a -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10} or R^{11};

R^{10} and R^{11} are each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -N(C_1-C_6alkyl)$_2$, -S(O)$_2$NH(C_1-C_6alkyl), -S(O)$_2$N(C_1-C_6alkyl)$_2$, -S(O)$_2$$C_1$-$C_6$alkyl, -C(O)$C_1$-$C_6$alkyl, -C(O)$NH_2$, -C(O)NH($C_1$-$C_6$alkyl), -C(O)N($C_1$-$C_6$alkyl)$_2$, -C(O)O$C_1$-$C_6$alkyl, -N($C_1$-$C_6$alkyl)S$O_2$$C_1$-$C_6$alkyl, -S(O)($C_1$-$C_6$alkyl), -S(O)N($C_1$-$C_6$alkyl)$_2$, or -N($C_1$-$C_6$alkyl)S(O)($C_1$-$C_6$alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};

wherein any two R^{10} or any two R^{11}, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} or any two R^{11}, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -N(C_1-C_6alkyl)$_2$, -S(O)$_2$NH(C_1-C_6alkyl), -S(O)$_2$N(C_1-C_6alkyl)$_2$, -S(O)$_2$$C_1$-$C_6$alkyl, -C(O)$C_1$-$C_6$alkyl, -C(O)$NH_2$, -C(O)NH($C_1$-$C_6$alkyl), -C(O)N($C_1$-$C_6$alkyl)$_2$, -C(O)O$C_1$-$C_6$alkyl, -N($C_1$-$C_6$alkyl)S$O_2$$C_1$-$C_6$alkyl, -S(O)($C_1$-$C_6$alkyl), -S(O)N($C_1$-$C_6$alkyl)$_2$, or -N($C_1$-$C_6$alkyl)S(O)($C_1$-$C_6$alkyl); and

n is an integer from 1 to 4.

[0059] Another aspect of the present disclosure is the provision of pharmaceutical

compositions comprising therapeutically effective amounts of at least one compound of Formula (I).

[0060] An aspect of the present disclosure concerns compounds which are, or can be, inhibitors of one or more bromodomains of the CBP/p300 family (e.g., compounds of Formula (I)).

[0061] An aspect of the present disclosure concerns the use of an inhibitor of CBP/p300 family bromodomains (e.g., a compound of Formula (I)) for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors (e.g., solid tumors).

[0062] An aspect of the present disclosure concerns the use of an inhibitor of CBP/p300 family bromodomains (e.g., a compound of Formula (I)) for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer. In some embodiments, the cancer is a hematological cancer such as leukemia (e.g., acute myeloid leukemia).

[0063] An aspect of the present disclosure concerns the use of an inhibitor of CBP/p300 family bromodomains (e.g., a compound of Formula (I)) for use in the treatment, prevention, inhibition or elimination of cancer.

[0064] In some embodiments, compounds of the disclosure are of Formula (I), or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer thereof thereof, wherein:

R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, or -OR^5;

R^2 is -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^6, and wherein a -C_1-C_6alkyl group may have one or more methylene units replaced by - NR^6-, -O- or -S-;

R^3 is -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^7;

R^4 and $R^{4'}$ are each independently -H, halogen, -OH, -CN, or -NH_2;

R^5 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^6 and R^7 are each independently, at each occurrence, -H, -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen,

oxo, -CN, -SR^8, -OR^8, -$(CH_2)_n$-OR^8, -NHR^8, -NR^8R^9, - $S(O)_2NR^8R^9$, -$S(O)_2R^{8'}$, -$C(O)R^{8'}$, -$C(O)OR^8$, -$C(O)NR^8R^9$, -$NR^8C(O)R^{9'}$, -$NR^8S(O)_2R^{9'}$, -$S(O)R^{8'}$, -$S(O)NR^8R^9$, or -$NR^8S(O)R^{9'}$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10};

wherein any two R^6 or any two R^7, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^6 or any two R^7, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^8 and R^9 are each independently, at each occurrence, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and R^9 may combine with the atom to which they are both attached to form a -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10} or R^{11};

$R^{8'}$ and $R^{9'}$ are each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and $R^{9'}$ may combine with the atom to which they are both attached to form a -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10} or R^{11};

R^{10} and R^{11} are each independently, at each occurrence, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, - $S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, - $C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or

more -R^{12};


wherein any two R^{10} or any two R^{11}, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} or any two R^{11}, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^{12} is independently, at each occurrence, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl); and

n is an integer from 1 to 4.


[0065] In some embodiments, compounds of the disclosure have the Formula (I-a):



(I-a),

or a pharmaceutically acceptable salt thereof, wherein Ring A represents a -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl and wherein each of R^1, R^2, R^4, $R^{4'}$, and R^7 is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.


[0066] In some embodiments, compounds of the disclosure have the Formula (I-b):




(I-b),

or a pharmaceutically acceptable salt thereof, wherein Ring B represents a -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, or aryl and wherein each of R^1, R^3, R^4, $R^{4'}$, and R^6 is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.

[0067] In some embodiments, compounds of the disclosure have the Formula (I-c):






(I-c),

or a pharmaceutically acceptable salt thereof, wherein m is an integer from 1 to 4 and wherein each of R^1, R^2, R^4, $R^{4'}$, and R^7 is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.


[0068] In the present invention the compounds of the invention may be a compound of Formula (I-d):



(I-d),

or a pharmaceutically acceptable salt thereof, wherein Ring B represents -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, or heteroaryl, and wherein p is an integer from 1 to 2 and wherein each of R^1, R^3, R^4, $R^{4'}$, and R^{10} is as defined for Formula (I-d) in the enclosed claims. In some embodiments, Ring B is -C_3-C_8cycloalkyl. In some embodiments, Ring B is -C_4-C_8cycloalkenyl. In some embodiments, Ring B is aryl. In some embodiments, Ring B is heterocyclyl. In some embodiments, Ring B is heteroaryl.

[0069] In the present invention the compounds of the invention may be a compound of Formula (I-e):




(I-e),

or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2 and wherein each of R^6 and R^7 is as defined for formula (I-e)in the enclosed claims.

[0070] In some embodiments (e.g., embodiments of Formula I-e), p is 1. In some embodiments (e.g., embodiments of Formula I-e), p is 2. In some embodiments (e.g., embodiments of Formula I-e), R^7 is -$S(O)_2NR^8R^9$, -$C(O)OR^8$, -$C(O)NR^8R^9$, or -$S(O)NR^8R^9$. In some embodiments (e.g., embodiments of Formula I-e), R^7 is -$S(O)_2NH_2$, -C(O)OH, -$C(O)NH_2$, or -$S(O)NH_2$. In some embodiments (e.g., embodiments of Formula I-e), R^7 is -C(O)OH. In some embodiments (e.g., embodiments of Formula I-e), R^7 is -$S(O)_2NH_2$. In some embodiments (e.g., embodiments of Formula I-e), R^7 is -$C(O)NH_2$. In some embodiments

(e.g., embodiments of Formula I-e), R^7 is - $S(O)NH_2$. In some embodiments (e.g., embodiments of Formula I-e), R^6 is aryl or heteroaryl, wherein each aryl or heteroaryl is optionally substituted with one or more R^{10}.

[0071] In some embodiments, compounds of the disclosure have the Formula (I-f):




(I-f),

or pharmaceutically acceptable salt thereof, wherein Ring B is -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, or heteroaryl; and L is a C_1-C_6 alkylene chain optionally subsitituted with one or more R^6 or L is a C_1-C_6 alkylene chain optionally substituted with one or more R^6 , and wherein at least one methylene unit of L is replaced by -NR^6-, -O- or -S-; and wherein each of R^1, R^3, R^4, $R^{4'}$, R^6 and R^{10} is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination. In some embodiments, Ring B is -C_3-C_8cycloalkyl. In some embodiments, Ring B is -C_4-C_8cycloalkenyl. In some emodiments, Ring B is aryl. In some embodiments, Ring B is heterocyclyl. In some embodiments Ring B is heteroaryl. In some embodiments, L is a C_1-C_6 alkylene chain optionally substituted with one or more R^6. In some embodiments, L is a C_1-C_2 alkylene chain optionally substituted with one or more R^6. In some embodiments, L is a C_1-C_6 alkylene chain optionally substituted with one or more R^6, and wherein at least one methylene unit is replaced by -NR^6-, -O- or -S-. In some embodiments, L is a C_1-C_6 alkylene chain optionally substituted with one or more R^6, and wherein at least one methylene unit of L is replaced by -NR^6. In some embodiments, L is a C_1-C_6 alkylene chain optionally substituted with one or more R^6, and wherein at least one methylene unit of L is replaced by -O-. In some embodiments, L is a C_1-C_6 alkylene chain optionally substituted with one or more R^6, and wherein at least one methylene unit of L is replaced by -S-. In some embodiments (e.g., embodiments of Formula I-f), L is a C_1-C_2 alkylene chain optionally substituted with R^6 wherein R^6 is -CH_3, -$S(O)_2NH_2$, -C(O)OH, -$C(O)NH_2$, or -$S(O)NH_2$. In some embodiments (e.g., embodiments of Formula I-f), L is a C_1-C_2 alkylene chain optionally substituted with R^6 wherein R^6 is -CH_3. In some embodiments (e.g., embodiments of Formula I-f), L is a C_1-C_2 alkylene chain optionally substituted with R^6 wherein R^6 is -$S(O)_2NH_2$. In some embodiments (e.g., embodiments of Formula I-f), L is a C_1-C_2 alkylene chain optionally substituted with R^6 wherein R^6 is -C(O)OH. In some embodiments (e.g., embodiments of Formula I-f), L is a C_1-C_2 alkylene

chain optionally substituted with R^6 wherein R^6 is $-C(O)NH_2$. In some embodiments (e.g., embodiments of Formula I-f), L is a C_1-C_2 alkylene chain optionally substituted with R^6 wherein R^6 is $-S(O)NH_2$. In some embodiments (e.g., embodiments of Formula I-f), L is $-CH_2CH(C(O)OH)-*$, wherein "*" denotes the point of attachment to Ring B. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, or $-OR^5$; L is $-C_1$-C_6alkyl, where L is optionally substituted with one or more R^6; Ring B is $-C_3$-C_8cycloalkyl, heterocyclyl, heteroaryl, or aryl; and R^3 is -H, $-C_1$-C_6alkyl, or $-C_3$-C_8cycloalkyl, wherein each alkyl or cycloalkyl, is optionally substituted with one or more R^7; R^5 is methyl; R^7 is $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, -CN, $-OR^8$, $-NHR^8$, $-NR^8R^9$, -C(O)OH, $-C(O)NR^8R^9$, $-S(O)CH_3$, or $-S(O)NR^8R^9$; and R^8 or R^9 is -H or $-C_1$-C_6alkyl. In some embodiments R^6 is -C(O)OH. In some embodiments, R^3 is $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R^3 is cyclopentyl, cyclohexyl, 3-pyranyl, or 4-pyranyl. In some embodiments, R^3 is cyclopentyl, cyclohexyl or 3-pyranyl. In some embodiments, L is an C_1-C_6 alkylene chain optionally substituted with one or more R^6, and wherein at least one methylene unit is replaced by $-NR^6$-, -O- or -S-; and R^3 is $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, or heteroaryl, wherein each $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^7; and R^6 is independently, at each occurrence, -H, $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, $-SR^8$, $-OR^8$, $-(CH_2)_n-OR^8$, $-NHR^8$, $-NR^8R^9$, $-S(O)_2NR^8R^9$, $-S(O)_2R^{8'}$, $-C(O)R^{8'}$, $-C(O)NR^8R^9$, $-NR^8C(O)R^{9'}$, $-NR^8S(O)_2R^{9'}$, $-S(O)R^{8'}$, $-S(O)NR^8R^9$, or $-NR^8S(O)R^{9'}$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}, wherein R^{10} is -H, $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, halogen, $-NO_2$, -CN, $-NH_2$, $-OC_1$-C_6alkyl, $-NHC_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)_2$, $-S(O)_2NH(C_1$-C_6alkyl), $-S(O)_2N(C_1$-C_6alkyl$)_2$, $-S(O)_2C_1$-C_6alkyl, $-C(O)C_1$-C_6alkyl, $-C(O)NH_2$, $-C(O)NH(C_1$-C_6alkyl), $-C(O)N(C_1$-C_6alkyl$)_2$, $-C(O)OC_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, $-S(O)(C_1$-C_6alkyl), $-S(O)N(C_1$-C_6alkyl$)_2$, or $-N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more $-R^{12}$. In some embodiments, L is a C_1-C_6 alkylene chain, $-OCH_2$-, $-CH_2O$-, $-NR^6CH_2$-, or $-CH_2NR^6$-; and R^6 is H, $-C_1$-C_6alkyl, $-C_3$-C_6cycloalkyl or $-C(O)NR^8R^9$. In some embodiments, R^3 is cyclopentyl or cyclohexyl, wherein each cyclopentyl or cyclohexyl is optionally substituted with R^7. In some embodidments, R^3 is cyclopentyl or cyclohexyl, wherein each cyclopentyl or cyclohexyl is optionally substituted with R^7, wherein R^7 is -OH, halogen, oxo, -CN, -SH, -OH, $-NH_2$, $-S(O)_2NH_2$, -C(O)OH, or $-C(O)NH_2$.


[0072] In some embodiments, compounds of the disclosure have the Formula (I-g)



(I-g),

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^3, R^4, $R^{4'}$, R^6, Ring B and R^{10} is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.


[0073] In some embodiments, compounds of the disclosure have the Formula (I-h)



(I-h),

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^4, $R^{4'}$, R^6, and R^7 is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.


[0074] In some embodiments, compounds of the disclosure have the Formula (I-h')



(I-h'),

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^4, $R^{4'}$, R^6, and R^7 is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.


[0075] In some embodiments, compounds of the disclosure have the Formula (I-h'')



(I-h'')

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^4, $R^{4'}$, R^6, and R^7 is as defined with respect to Formula (I) above and described in classes and subclasses herein, both singly and in combination.

[0076] In some embodiments, compounds of the disclosure have the Formula (I-i):



(I-i),

or a pharmaceutically acceptable salt thereof,
wherein,

R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, $-OR^5$, $-N(R^5)_2$, or $-NHR^5$;

R^5 is $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl;

each R^6 is -OH, halogen, oxo, $-C_1$-C_6alkyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, $-NO_2$, -CN, $-NH_2$, $-(CH_2)_n$-OR^8, $-C(O)R^{8'}$, $-C(O)OR^8$, or $-C(O)NR^8R^9$, $-NHC_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)_2$, $-S(O)_2NH(C_1$-C_6alkyl), $-S(O)_2N(C_1$-C_6alkyl$)_2$, $-S(O)_2C_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, $-S(O)(C_1$-C_6alkyl), $-S(O)N(C_1$-C_6alkyl$)_2$, or $-N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10};

$R^{6'}$ is H or $-C_1$-C_6alkyl;

R^7 is independently, at each occurrence, -H, halogen, -OH, -CN, $-OC_1$-C_6alkyl, $-NH_2$, $-NHC_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)_2$, $-S(O)_2NH(C_1$-C_6alkyl), $-S(O)_2N(C_1$-C_6alkyl$)_2$, $-S(O)_2C_1$-C_6alkyl, $-S(O)_2OH$, $-C(O)C_1$-C_6alkyl, $-C(O)NH_2$, $-C(O)NH(C_1$-C_6alkyl), $-C(O)N(C_1$-C_6alkyl$)_2$, -C(O)OH, $-C(O)OC_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, $-S(O)(C_1$-C_6alkyl), $-S(O)N(C_1$-C_6alkyl$)_2$, $-S(O)_2NH_2$, $-N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl) or tetrazole;

R^8 and R^9 are each independently, at each occurrence, -H, $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10}; or

R^8 and R^9 may combine with the atom to which they are both attached to form a

spiroheterocyclyl, heterocyclyl, or heteroaryl, wherein the formed spiroheterocyclyl, heterocyclyl,or heteroaryl is optionally substituted with one or more R^{10};

$R^{8'}$ is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10}; or

R^{10} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -N(C_1-C_6alkyl)$_2$, -S(O)$_2$NH(C_1-C_6alkyl), -S(O)$_2$N(C_1-C_6alkyl)$_2$, -S(O)$_2$$C_1$-$C_6$alkyl, -C(O)$C_1$-$C_6$alkyl, - C(O)$NH_2$, -C(O)NH($C_1$-$C_6$alkyl), -NHC(O)$C_1$-$C_6$alkyl,-C(O)N($C_1$-$C_6$alkyl)$_2$, -C(O)O$C_1$-$C_6$alkyl, -N($C_1$-$C_6$alkyl)S$O_2$$C_1$-$C_6$alkyl, -S(O)($C_1$-$C_6$alkyl), -S(O)N($C_1$-$C_6$alkyl)$_2$, or -N($C_1$-$C_6$alkyl)S(O)($C_1$-$C_6$alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};

wherein any two R^{10} when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;


R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -N(C_1-C_6alkyl)$_2$, -S(O)$_2$NH(C_1-C_6alkyl), - S(O)$_2$N(C_1-C_6alkyl)$_2$, -S(O)$_2$$C_1$-$C_6$alkyl, -C(O)$C_1$-$C_6$alkyl, -C(O)$NH_2$, -C(O)NH($C_1$-$C_6$alkyl), - C(O)N($C_1$-$C_6$alkyl)$_2$, -C(O)O$C_1$-$C_6$alkyl, -N($C_1$-$C_6$alkyl)S$O_2$$C_1$-$C_6$alkyl, -S(O)($C_1$-$C_6$alkyl), -S(O)N($C_1$-$C_6$alkyl)$_2$, or -N($C_1$-$C_6$alkyl)S(O)($C_1$-$C_6$alkyl); and


m is an integer from 0 to 5;

n is an integer from 1 to 4; and

q is an integer from 0 to 4.

[0077] In some embodiments, compounds of the disclosure have the Formula (I-j):





(I-j),

or a pharmaceutically acceptable salt thereof,
wherein:

R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OR^5, -$N(R^5)_2$, or -NHR^5;

R^5 is independently, at each occurrence, -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^6 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, halogen, oxo, -$(CH_2)_n$-OR^8, -$C(O)R^{8'}$, -$C(O)OR^8$, or -$C(O)NR^8R^9$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10};

R^8 and R^9 are each independently, at each occurrence, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and R^9 may combine with the atom to which they are both attached to form a spiroheterocyclyl, heterocyclyl, or heteroaryl, wherein the formed spiroheterocyclyl, heterocyclyl,or heteroaryl is optionally substituted with one or more R^{10} or R^{11};

$R^{8'}$ is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11};

R^{10} is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, - $C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, - $N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};

wherein any two R^{10} when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), - $S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), - $C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl); and

n is an integer from 1 to 4.

[0078] In some embodiments, for compounds of Formula (I-j) or a pharmaceutically acceptable salt thereof:

R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OR^5, -$N(R^5)_2$, or -NHR^5;

R^5 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^6 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, halogen, oxo, -$(CH_2)_n$-OR^8, -$C(O)R^{8'}$, -$C(O)OR^8$, or -$C(O)NR^8R^9$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10};

R^8 and R^9 are each independently, at each occurrence, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^8 and R^9 may combine with the atom to which they are both attached to form a spiroheterocyclyl, heterocyclyl, or heteroaryl, wherein the formed spiroheterocyclyl, heterocyclyl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11};

$R^{8'}$ is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}; or

R^{10} is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, - $C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, - $N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};


wherein any two R^{10} when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), - $S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), - $C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl); and

n is an integer from 1 to 4.

[0079] In some embodiments, compounds of the disclosure have the Formula (I-k):



(I-k),

or a pharmaceutically acceptable salt thereof,
wherein,

R^1 is -OR^5;

R^5 is -C_1-C_6alkyl;

R^6 is -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, wherein each cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{10};


R^7 is -H, halogen, -OH, -CN, -OC_1-C_6alkyl, -NH_2, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$S(O)_2OH$, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -C(O)OH, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH_2$, -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl) or tetrazole;

R^{10} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, - $C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$NHC(O)C_1$-C_6alkyl, -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};

each R^{12} is independently halogen;

m is an integer from 0 to 5.

[0080] In some embodiments, compounds of the disclosure have the Formula (I-l):



(I-l),

or a pharmaceutically acceptable salt thereof,
wherein,

R^1 is -OR^5;

R^5 is -C_1-C_6alkyl;

R^6 is -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,

heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{10};

R^7 is independently, at each occurrence, -H, halogen, -OH, -CN, -OC_1-C_6alkyl, -NH_2, - NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$S(O)_2OH$, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$,

-C(O)OH, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH_2$, -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl) or tetrazole;


R^{10} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, - $C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$NHC(O)C_1$-C_6alkyl, -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};

each R^{12} is independently halogen;

m is an integer from 0 to 5; and

r is an integer from 0 to 5.

[0081] In some embodiments, compounds of the disclosure have the Formula (I-m)



(I-m),

or a pharmaceutically acceptable salt, thereof,
wherein:

R^1 is -OR^5;

R^5 is -C_1-C_6alkyl;

R^6 is phenyl optionally substituted with one or more R^{10};

R^{10} is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -

NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, - $C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, - $N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12};


wherein any two R^{10} when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;

wherein any two R^{10} when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;

R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), - $S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), - $C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl); and

n is an integer from 1 to 4.

[0082] In some embodiments, compounds of the disclosure have the Formula (I-n)



(I-n),

or a pharmaceutically acceptable salt thereof,
wherein:

R^1 is -OR^5;

R^5 is -C_1-C_3alkyl;

R^6 is phenyl optionally substituted with one or more R^{10};

R^{10} is independently, at each occurrence halogen, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, - Oaryl, or -Oheteroaryl, wherein each alkyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one or more -R^{12};

R^{12} is independently halogen.

[0083] In some embodiments, for compounds of Formula (I-n), or a pharmaceutically acceptable salt thereof:

R^1 is $-OR^5$;

R^5 is $-C_1$-C_3alkyl;

R^6 is phenyl optionally substituted with one or more R^{10};

R^{10} is independently, at each occurrence halogen, $-OC_1$-C_6alkyl, $-OC_3$-C_6cycloalkyl, - Oaryl, or -Oheteroaryl, wherein each alkyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one or more $-R^{12}$;

R^{12} is halogen.

[0084] It will be appreciated that throughout the present disclosure, unless otherwise indicated, reference to a compound of Formula (I) is intended to also include formulae (I-a), (I-b) , (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-h'), (I-h''), (I-i), (I-j), (I-k), (I-1), (I-m), and (I-n) and compound species of such formulae disclosed herein.

[0085] In some embodiments, R_1 is $-OCR^5$.

[0086] Compounds of the present disclosure can be compounds wherein R^1 is $-C_1$-C_6alkyl, -C_2-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, $-OR^5$, $-N(R^5)_2$, or $-NHR^5$. Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$. Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$ and R^5 is methyl.

[0087] Compounds of the present disclosure can be compounds wherein R^5 is $-C_1$-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl. Compounds of the present disclosure can be compounds wherein R^5 is $-C_1$-C_6alkyl. Compounds of the present disclosure can be compounds wherein R^5 is $-C_1$-C_3alkyl. Compounds of the present disclosure can be compounds wherein R^5 is methyl.

[0088] Compounds of the present disclosure can be compounds wherein R^6 is $-C_1$-C_6alkyl, -

C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, halogen, oxo, -$(CH_2)_n$-OR^8, -$C(O)R^{8'}$, -$C(O)OR^8$, or -$C(O)NR^8R^9$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}. Compounds of the present disclosure can be compounds wherein R^6 is -C_3-C_8cycloalkyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}. Compounds of the present disclosure can be compounds wherein R^6 is aryl optionally substituted with one or more R^{10}. Compounds of the present disclosure can be compounds wherein R^6 is phenyl optionally substituted with one or more R^{10}. Compounds of the present disclosure can be compounds wherein R^6 is phenyl substituted with one R^{10}. Compounds of the present disclosure can be compounds wherein R^6 is phenyl substituted with two R^{10}.

[0089] Compounds of the present disclosure can be compounds wherein R^{10} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, -Oaryl, -Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12}. Compounds of the present disclosure can be compounds wherein R^{10} is independently, at each occurrence, -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, CN, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, or -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$ wherein each alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12}. Compounds of the present disclosure can be compounds wherein R^{10} is independently, at each occurrence, -C_1-C_6alkyl, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, or halogen wherein each alkyl, or cycloalkyl, is optionally substituted with one or more -R^{12}. Compounds of the present disclosure can be compounds wherein R^{10} is independently, at each occurrence, -OC_1-C_6alkyl, or halogen wherein each alkyl is optionally substituted with one or more -R^{12}.

[0090] Compounds of the present disclosure can be compounds wherein R^{12} is independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-Cscycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl). Compounds of the present disclosure can be compounds

wherein R^{12} is independently, at each occurrence, halogen. Compounds of the present disclosure can be compounds wherein R^{12} is fluoro. Compounds of the present disclosure can be compounds wherein R^{12} is chloro.

[0091] Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$; R^5 is $-C_1$-C_6alkyl; R^6 is $-C_3$-C_8cycloalkyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}; R^{10} is independently, at each occurrence, - C_1-C_6alkyl, $-OC_1$-C_6alkyl, $-OC_3$-C_6cycloalkyl, or halogen wherein each alkyl, or cycloalkyl, is optionally substituted with one or more $-R^{12}$ and $-R^{12}$ is halogen.

[0092] Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$; R^5 is $-C_1$-C_3alkyl; R^6 is aryl optionally substituted with one or more R^{10}; R^{10} is independently, at each occurrence, $-C_1$-C_6alkyl, $-OC_1$-C_6alkyl, $-OC_3$-C_6cycloalkyl, or halogen wherein each alkyl, or cycloalkyl, is optionally substituted with one or more $-R^{12}$ and $-R^{12}$ is halogen.

[0093] Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$; R^5 is $-C_1$-C_3alkyl; R^6 is aryl substituted with one R^{10}; R^{10} is $-C_1$-C_6alkyl, $-OC_1$-C_6alkyl, $-OC_3$-C_6cycloalkyl, or halogen wherein each alkyl, or cycloalkyl, is optionally substituted with one or more $-R^{12}$ and $-R^{12}$ is halogen.

[0094] Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$; R^5 is $-C_1$-C_3alkyl; R^6 is aryl substituted with two R^{10}; R^{10} is independently, at each occurrence, $-OC_1$-C_6alkyl or halogen wherein each alkyl is optionally substituted with one or more $-R^{12}$ and $-R^{12}$ is halogen.

[0095] Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$; R^5 is methyl; R^6 is phenyl substituted with two R^{10}; R^{10} is independently, at each occurrence, $-OC_1$-C_6alkyl or halogen wherein each alkyl is optionally substituted with one or more $-R^{12}$ and $-R^{12}$ is halogen.

[0096] Compounds of the present disclosure can be compounds wherein R^1 is $-OR^5$; R^5 is methyl; and R^6 is phenyl.

[0097] Compounds of the present disclosure can be compounds wherein R^6 is aryl, optionally substituted with one or two R^{10}, wherein R^{10} is independently, at each occurrence, halogen or -

OC_1-C_6alkyl, wherein -OC_1-C_6alkyl is optionally substituted with halogen.

[0098] Compounds of the present disclosure can comprise aryl, wherein aryl can be ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. For example, aryl can include, but is not limited to, phenyl.

[0099] Compounds of the present disclosure can comprise heteroaryl, wherein heteroaryl is a group having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and/or having, in addition to carbon atoms, from one to five heteroatoms wherein the term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. For example, heteroaryl can include, but are is not limited to, pyridine, indole, benzapyrazole, benzoxale, furopyridine, or isoquinoline.

[0100] Compounds of the present disclosure can comprise heterocyclyl, wherein heterocyclyl is a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. For example, heterocyclyl can include, but are is not limited to, dihydrofuran, dihydrofuropyrine or dihydroisofuran.

[0101] In some embodiments, R^1 is -OR^5, -$N(R^5)_2$, -NHR^5, or -C_1-C_6alkyl. In some embodiments, R^1 is -OR^5 or -C_1-C_6alkyl. In some embodiments, R^5 of R^1 is -C_1-C_6alkyl. In some embodiments, R^1 is -OCH_3. In some embodiments, R^1 is -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, or aryl. In some embodiments, R^1 is -C_1-C_6alkyl. In some embodiments, R^1 is methyl, ethyl or propyl. In some embodiments, R^1 is methyl. In some embodiments, R^1 is -C_2-C_6alkenyl. In some embodiments, R^1 is aryl.

[0102] In some embodiments, R^2 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^6. In some embodiments, R^2 is -H. In some embodiments, R^2 is C_1-C_6alkyl optionally substituted with one or more R^6. In some embodiments, R^2 is aryl optionally substituted with one or more R^6. In some embodiments, R^2 is C_3-C_8cycloalkyl optionally substituted with one or more R^6. In some embodiments, R^2 is C_1-C_2alkyl substituted with aryl or heteroaryl, wherein each aryl or heteroaryl is optionally substituted with one or more R^{10}. In some embodiments R^2 is methyl optionally substituted with one or more R^6. In some embodiments R^2 is ethyl optionally substituted with one or more R^6. In some embodiments, R^2 is C_1-C_2alkyl substituted with aryl or heteroaryl, wherein each aryl or heteroaryl is optionally substituted with one or

more R^{10}, and wherein R^3 is cyclohexyl optionally substituted with one or more -C(O)OH.

[0103] In some embodiments, R^3 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^7. In some embodiments, R^3 or $R^{3'}$ is -H. In some embodiments, R^3 is -C_1-C_6alkyl. In some embodiments, R^3 is heterocyclyl optionally substituted with one or more R^7. In some embodiments, R^3 is heteroaryl optionally substituted with one or more R^7. In some embodiments, R^3 is spirocycloalkyl optionally substituted with one or more R^7. In some embodiments, R^3 is spiroheterocyclyl optionally substituted with one or more R^7. In some embodiments, R^3 is C_3-C_8cycloalkyl optionally substituted with one or more R^7. In some embodiments, R^3 is aryl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclohexyl optionally substituted with one or more -R^7. In some embodiments, R^3 is cyclohexyl optionally substituted with one or more -C(O)OH.

[0104] In some embodiments, R^3 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^7. In some embodiments, R^3 is -H. In some embodiments, R^3 is -C_1-C_6alkyl. In some embodiments, R^3 is heterocyclyl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclopropyl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclobutyl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclopentyl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclohexyl optionally substituted with one or more R^7. In some embodiments, R^3 is heteroaryl optionally substituted with one or more R^7. In some embodiments, R^3 is spirocycloalkyl optionally substituted with one or more R^7. In some embodiments, R^3 is spiroheterocyclyl optionally substituted with one or more R^7. In some embodiments, R^3 is C_3-C_8cycloalkyl optionally substituted with one or more R^7. In some embodiments, R^3 is aryl optionally substituted with one or more R^7. In some embodiments, R^3 is cyclohexyl optionally substituted with one or more -R^7. In some embodiments, R^3 is cyclohexyl optionally substituted with one or more - C(O)OH.

[0105] In some embodiments, R^4 and $R^{4'}$ are independently hydrogen, halogen, -OH, -CN, or -

NH_2. In some embodiments, R^4 and $R^{4'}$ are -H. In some embodiments, R^4 and $R^{4'}$ are halogen.

[0106] In some embodiments, R^5 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R^5 is -C_1-C_6alkyl. In some embodiments, R^5 is -C_1-C_3alkyl. In some embodiments, R^5 is methyl. In some embodiments, R^5 is ethyl.

[0107] In some embodiments, R^6 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, -SR^8, -OR^8, -$(CH_2)_n$-OR^8, -NHR^8, -NR^8R^9, -$S(O)_2NR^8R^9$, -$S(O)_2R^{8'}$, -$C(O)R^{8'}$, -$C(O)OR^8$, -$C(O)NR^8R^9$, -$NR^8C(O)R^{9'}$, -$NR^8S(O)_2R^{9'}$, -$S(O)R^{8'}$, -$S(O)NR^8R^9$, or -$NR^8S(O)R^9$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}. In some embodiments, R^6 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, or aryl. In some embodiments, R^6 is -C_1-C_6alkyl optionally substituted with one or more R^{10}. In some embodiments, R^6 is aryl optionally substituted with one or more R^{10}. In some embodiments, R^6 is heteroaryl optionally substituted with one or more R^{10}. In some embodiments, R^6 is -C(O)OH. In some embodiments, R^6 is halogen. In some embodiments, R^6 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, halogen, oxo, -$(CH_2)_n$-OR^8, - $C(O)R^{8'}$, -$C(O)OR^8$, or -$C(O)NR^8R^9$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}.

[0108] In some embodiments, R^7 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, -SR^8, -OR^8, -$(CH_2)_n$-OR^8, -NHR^8, -NR^8R^9, -$S(O)_2NR^8R^9$, -$S(O)_2R^{8'}$, -$C(O)R^{8'}$, -$C(O)OR^8$, -$C(O)NR^8R^9$, -$NR^8C(O)R^{9'}$, -$NR^8S(O)_2R^{9'}$, -$S(O)R^{8'}$, -$S(O)NR^8R^9$, or -$NR^8S(O)R^{9'}$, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^{10}. In some embodiments, R^7 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, or aryl. In some embodiments R^7 is -C_1-C_6alkyl optionally substituted with one or more R^{10}. In some embodiments, R^7 is aryl optionally substituted with one or more R^{10}. In some embodiments, R^7 is heteroaryl optionally substituted with one or more R^{10}. In some embodiments, R^7 is -C(O)OH. In some embodiments, R^7 is halogen.

[0109] In some embodiments, R^8 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or

more R^{10} or R^{11}. In some embodiments, R^8 is -H. In some embodiments, R^8 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, or aryl, wherein R^8 is optionally substituted with R^{10} or R^{11}. In some embodiments, R^8 is -C_1-C_6alkyl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^8 is aryl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^8 is heteroaryl optionally substituted with one or more R^{10} or R^{11}.

[0110] In some embodiments, $R^{8'}$ is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^8 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, or aryl, wherein $R^{8'}$ is optionally substituted with R^{10} or R^{11}. In some embodiments, $R^{8'}$ is -C_1-C_6alkyl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, $R^{8'}$ is aryl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, $R^{8'}$ is heteroaryl optionally substituted with one or more R^{10} or R^{11}.

[0111] In some embodiments, R^9 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^9 is -H. In some embodiments, R^9 is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, or aryl, wherein R^9 is optionally substituted with R^{10} or R^{11}. In some embodiments, R^9 is -C_1-C_6alkyl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^9 is aryl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^9 is heteroaryl optionally substituted with one or more R^{10} or R^{11}.

[0112] In some embodiments, $R^{9'}$ is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R^{10} or R^{11}. In some embodiments, $R^{9'}$ is -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, or aryl, wherein $R^{9'}$ is optionally substituted with R^{10} or R^{11}. In some embodiments, $R^{9'}$ is -C_1-C_6alkyl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, R^9 is aryl optionally substituted with one or more R^{10} or R^{11}. In some embodiments, $R^{9'}$ is heteroaryl optionally substituted with one or more R^{10} or R^{11}.

[0113] In some embodiments, R^{10} is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), - $S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), - $C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12}. In some embodiments, R^{10} is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, wherein R^{10} is substituted with R^{12}. In some embodiments, R^{10} is halogen. In some embodiments, R^{10} is each independently, at each occurrence, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, Oaryl, Oheteroaryl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, - $S(O)_2NH(C_1$-C_6ealkyl), - $S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, - C(O)NH(C_1-C_6elkyl), - $C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), - $S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12}; wherein any two R^{10} when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl; wherein any two R^{10} when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl. In some embodiments, R^{10} is each independently, at each occurrence halogen or -OC_1-C_6alkyl, -OC_3-C_6cycloalkyl, Oaryl, Oheteroaryl, wherein each alkyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one or more -R^{12}.

[0114] In some embodiments, R^{11} is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), - $S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), - $C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$, or -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more -R^{12}. In some embodiments, R^{11} is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, wherein R^{11} is substituted with R^{12}. In some embodiments, R^{11} is halogen.

[0115] In some embodiments, R^{12} is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, - CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), - $S(O)_2N(C_1$-

C_6alkyl)$_2$, -S(O)$_2$C$_1$-C$_6$alkyl, -C(O)C$_1$-C$_6$alkyl, -C(O)NH$_2$, -C(O)NH(C$_1$-C$_6$alkyl), - C(O)N(C$_1$-C$_6$alkyl)$_2$, -C(O)OC$_1$-C$_6$alkyl, -N(C$_1$-C$_6$alkyl)SO$_2$C$_1$-C$_6$alkyl, -S(O)(C$_1$-C$_6$alkyl), -S(O)N(C$_1$-C$_6$alkyl)$_2$, or -N(C$_1$-C$_6$alkyl)S(O)(C$_1$-C$_6$alkyl). In some embodiments, R^{12} is -H. In some embodiments, R^{12} is halogen.

[0116] In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.

[0117] In some embodiments R^1 is -C$_1$-C$_6$alkyl, -C$_3$-C$_8$cycloalkyl, or -OR^5; R^2 is -C$_1$-C$_6$alkyl, -C$_3$-C$_8$cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein each alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^6; R^3 is -H, -C$_1$-C$_6$alkyl, or -C$_3$-C$_8$cycloalkyl, wherein each alkyl, or cycloalkyl is optionally substituted with one or more R^7; R^5 is methyl; R^7 is-C$_1$-C$_6$alkyl, -C$_3$-C$_8$cycloalkyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, - CN, -OR^8, -NHR^8, -NR^{8}R^9, -C(O)OH, -C(O)NR^{8}R^9, -S(O)CH$_3$, or -S(O)NR^{8}R^9; and R^8 or R^9 is -H, or -C$_1$-C$_6$alkyl.

[0118] In some embodiments R^1 is -C$_1$-C$_6$alkyl, -C$_3$-C$_8$cycloalkyl, or -OR^5; and R^2 is (-CH$_2$)$_{1-2}$cycloalkyl, (-CH$_2$)$_{1-2}$heterocyclyl, (-CH$_2$)$_{1-2}$heteroaryl, or (-CH$_2$)$_{1-2}$aryl wherein each alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^6; and R^3 is (-CH$_2$)$_{1-2}$cycloalkyl, (-CH$_2$)$_{1-2}$heterocyclyl, (-CH$_2$)$_{1-2}$heteroaryl, or (-CH$_2$)$_{1-2}$aryl wherein each alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R^7; and R^5 is methyl; and R^7 is-C$_1$-C$_6$alkyl, -C$_3$-C$_8$cycloalkyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, -CN, -OR^8, -NHR^8, -NR^{8}R^9, -C(O)OH, -C(O)NR^{8}R^9, -S(O)CH$_3$, or -S(O)NR^{8}R^9; and R^8 or R^9 is -H, or -C$_1$-C$_6$alkyl.

[0119] In some embodiments, R^1 is -OR^5 and R^2 is alkyl. In some embodiments, R^1 is -OR^5 and R^2 is cycloalkyl. In some embodiments, R^1 is -OR^5 and R^2 is aryl. In some embodiments, R^1 is -OR^5 and R^2 is heteroaryl. In some embodiments, R^1 is -OR^5 and R^2 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -OR^5 and R^2 is alkyl substituted with heterocycloalkyl. In some embodiments, R^1 is -OR^5 and R^2 is alkyl substituted with aryl. In some embodiments, R^1 is -OR^5 and R^2 is alkyl substituted with heteroaryl.

[0120] In some embodiments, R^1 is -OR^5, R^2 is alkyl, and R^3 is alkyl. In some embodiments, R^1 is -OR^5, R^2 is cycloalkyl, and R^3 is alkyl. In some embodiments, R^1 is -OR^5, R^2 is aryl, and R^3 is alkyl. In some embodiments, R^1 is -OR^5, R^2 is heteroaryl, and R^3 is alkyl. In some embodiments, R^1 is -OR^5, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl. In some

embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, and R^3 is alkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl.

[0121] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, and R^3 is cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is cycloalkyl.

[0122] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, and R^3 is aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is aryl.

[0123] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, and R^3 is heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is heteroaryl.

[0124] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted

with aryl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl substituted with cycloalkyl.

[0125] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl substituted with aryl.

[0126] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl substituted with heteroaryl.

[0127] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, and R^4 and R^4 are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is-OR^5, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H.

[0128] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In

some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, and R^4 and R^4 are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, and R^4 and R^4 are -H.

[0129] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is-OR^5, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H.

[0130] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, and R^4 and R^4 are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H.

[0131] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and R^4 are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$,

R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H.

[0132] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H.

[0133] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and R^4 are -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is-OR^5, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are-H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H.

[0134] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH.

[0135] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -H and R^4 is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH.

[0136] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is-OR^5, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH.

[0137] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH.

[0138] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with

cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH.

[0139] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH.

[0140] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH.

[0141] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -OH

and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H.

[0142] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is-OR^5, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -OH and R^4 is -H.

[0143] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is-OR^5, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H.

[0144] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H.

[0145] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted

with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H.

[0146] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, Ri is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H.

[0147] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H.

[0148] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some

embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, R^4 is -H and R^4 is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0149] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -H and R^4 is $-NH_2$.

[0150] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0151] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some

embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0152] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and R^4 is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is - NH_2. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0153] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0154] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and R^4 is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2

is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is - NH_2. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0155] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0156] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is - OR^5, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0157] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is - OR^5, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some

embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0158] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0159] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is - H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0160] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and

$R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0161] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is - H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0162] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN.

[0163] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted

with aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN.

[0164] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN.

[0165] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN.

[0166] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN.

[0167] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -H

and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN.

[0168] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN.

[0169] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H.

[0170] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some

embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H.

[0171] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H.

[0172] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H.

[0173] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl,

R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H.

[0174] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is - CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H.

[0175] In some embodiments, R^1 is $-OR^5$, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is $-OR^5$, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H.

[0176] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl.

[0177] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is alkyl. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is cycloalkyl. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is aryl. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-

C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is alkyl substituted with heterocycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl and R^2 is alkyl substituted with heteroaryl.

[0178] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is alkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl.

[0179] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is cycloalkyl. In

some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is cycloalkyl.

[0180] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is aryl. In some embodiments, R^1 is -C_1-C_{6alkyl}, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is aryl.

[0181] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl,

-C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is heteroaryl.

[0182] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is alkyl substituted with cycloalkyl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-

C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl substituted with cycloalkyl.

[0183] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is alkyl substituted with aryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl substituted with aryl.

[0184] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl,

heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, and R^3 is alkyl substituted with heteroaryl. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, and R^3 is alkyl substituted with heteroaryl.

[0185] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, and R^4 and $R^{4'}$ are -H.

[0186] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is

cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, and R^4 and $R^{4'}$ are -H.

[0187] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-

C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, and R^4 and $R^{4'}$ are -H.

[0188] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, and R^4 and R^4 are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, and R^4 and $R^{4'}$ are -H.

[0189] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are - H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, - C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl,

heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, and R^4 and $R^{4'}$ are -H.

[0190] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, and R^4 and $R^{4'}$ are -H.

[0191] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with

heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are - H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, - C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, and R^4 and $R^{4'}$ are -H.

[0192] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with

heterocycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -OH.

[0193] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -OH.

[0194] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-

C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -OH.

[0195] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -OH.

[0196] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl,

-C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is - OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -OH.

[0197] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and R^4 is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is

-OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -OH.

[0198] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -OH.

[0199] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, R^4 is -OH and

$R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is - OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -OH and $R^{4'}$ is -H.

[0200] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl,

heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -OH and $R^{4'}$ is -H.

[0201] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -OH and R^4 is -H.

[0202] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -

C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -OH and $R^{4'}$ is -H.

[0203] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -OH and $R^{4'}$ is -H.

[0204] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl,

-C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -OH and $R^{4'}$ is -H.

[0205] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-

C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -OH and $R^{4'}$ is -H.

[0206] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2.

[0207] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-

C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -NH_2.

[0208] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is

aryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0209] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0210] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is - NH_2. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-

C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0211] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is $-NH_2$.

[0212] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl,

-C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is - NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -NH_2.

[0213] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is - NH_2 and $R^{4'}$ is -H. In some

embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -NH_2 and $R^{4'}$ is -H.

[0214] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -NH_2 and $R^{4'}$ is -H.

[0215] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is

aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0216] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-

C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0217] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0218] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is $-NH_2$ and $R^{4'}$ is -H. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-

C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -NH_2 and $R^{4'}$ is -H.

[0219] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -NH_2 and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-

C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is $-NH_2$ and $R^{4'}$ is -H.

[0220] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -H and $R^{4'}$ is -CN.

[0221] In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, - C_2-C_6alkenyl, - C_2-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is $-C_1$-C_6alkyl, $-C_2$-C_6alkenyl, $-C_2$-C_6alkynyl, $-C_3$-C_8cycloalkyl, $-C_4$-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -

CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -H and $R^{4'}$ is -CN.

[0222] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -H and $R^{4'}$ is -CN.

[0223] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is

heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -H and $R^{4'}$ is -CN.

[0224] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is - CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN. In

some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -H and $R^{4'}$ is -CN.

[0225] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -H and $R^{4'}$ is -CN.

[0226] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is - CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -

C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -H and $R^{4'}$ is -CN.

[0227] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl, R^4 is - CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl, R^4 is -CN and $R^{4'}$ is -H.

[0228] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is cycloalkyl, R^4 is -CN and $R^{4'}$ is -H.

[0229] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, - C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -

H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is aryl, R^4 is -CN and $R^{4'}$ is -H.

[0230] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, $R^2$is aryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is heteroaryl, R^4 is -CN and $R^{4'}$ is -H.

[0231] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-

C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, - C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with cycloalkyl, R^4 is -CN and $R^{4'}$ is -H.

[0232] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with aryl, R^4 is -CN and $R^{4'}$ is

-H.

[0233] In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, - C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is - H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, - C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and R^4 is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and R^4 is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with cycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heterocycloalkyl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with aryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H. In some embodiments, R^1 is -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocycloalkyl, heteroaryl, or aryl, R^2 is alkyl substituted with heteroaryl, R^3 is alkyl substituted with heteroaryl, R^4 is -CN and $R^{4'}$ is -H.

[0234] Compounds of the present disclosure can be compounds wherein R^6 is aryl, optionally substituted with one or two R^{10}, wherein R^{10} is independently, at each occurrence, halogen or -OC_1-C_6alkyl, wherein -OC_1-C_6alkyl is optionally substituted with halogen.

[0235] Compounds of the present disclosure can comprise aryl, wherein aryl can be ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. For example, aryl can include, but are is not limited to, phenyl.

[0236] Compounds of the present disclosure can comprise heteroaryl, wherein heteroaryl is a group having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and/or having, in addition to carbon atoms, from one to five

heteroatoms wherein the term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. For example, heteroaryl can include, but are is not limited to, pyridine, indole, benzapyrazole, benzoxale, furopyridine, or isoquinoline.

[0237] Compounds of the present disclosure can comprise heterocycl, wherein heterocyclyl is a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. For example, heterocyclyl can include, , but are is not limited to, dihydrofuran, dihydrofuropyrine or dihydroisofuran.

Method of Synthesizing the Compounds

[0238] The compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the examples given below.

[0239] The compounds of the present disclosure, *i.e.*, compounds of Formula (I), or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, prodrug, isomer, or tautomer thereof, may be prepared by organic synthesis such as those as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of Formula (I).

[0240] Those skilled in the art will recognize if a stereocenter exists in the compounds of Formula (I). Accordingly, unless otherwise indicated, the present disclosure includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).

[0241] The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.

Methods of Using the Disclosed Compounds

[0242] One aspect of the present disclosure relates to a compound of Formula (I) for use in medicine. Another aspect of the present disclosure relates to a method of modulating one or more of CBP/p300-family bromodomains, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I). Another aspect of the present disclosure relates to a method of inhibiting one or more of CBP/p300-family bromodomains, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I). In another aspect, the present disclosure relates to a method of inhibiting one or more of CBP/p300-family bromodomains, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula (I).

[0243] In another aspect, the ratio of inhibition of CBP (IC_{50} (μM gmean)) as compared to the inhibition of BRD4 (IC_{50} (μM gmean)) is determined. In some embodiments, the inhibition of CBP (IC_{50} (μM gmean)) is determined as outlined in Example 963. In some embodiments, the inhibition of BRD4 (IC_{50} (μM gmean)) is determined as outlined in Example 963. It will be appreciated that a positive ratio of inhibition for CBP vs. BRD4 indicates that a compound selectively inhibits CBP over BRIM. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 10:1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 20: 1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 50: 1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 100:1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 250:1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 500:1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 750:1. In some embodiments, the ratio of CBP IC_{50} to BRD4 IC_{50} is 1,000: 1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 2,500: 1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 5,000: 1. In some embodiments, a compound is characterized in that the ratio of CBP IC_{50} to BRD4 IC_{50} is 10,000:1. In some embodiments, a compound is characterized in that is has a BRD4 IC_{50} of greater than 0.01 μM. In some embodiments, a compound is characterized in that is has a BRD4 IC_{50} of greater than 0.1 μM. In some embodiments, a compound is characterized in that is has a BRD4 IC_{50} of greater than 1 μM.

[0244] Another aspect of the present disclosure relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with the inhibition of one or more of CBP/p300-family bromodomains, the method comprising administering a therapeutically effective amount of a compound of Formula (I). In one embodiment, the disease or disorder is selected from the group consisting of cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is cancer of the prostate including

castration-resistant prostate cancer, and breast cancer.

[0245] The present disclosure also relates to the use of an inhibitor of CBP/p300 family bromodomains for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of a disease or disorder mediated by CBP/p300 family bromodomains, wherein the medicament comprises a compound of Formula (I). In another aspect, the present disclosure relates to a method for the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder mediated by CBP/p300 family bromodomains, wherein the medicament comprises a compound of Formula (I). Another aspect of the present disclosure relates to a pharmaceutical composition for use in a method for treating a disease or disorder mediated by CBP/p300 family bromodomains, wherein the pharmaceutical composition comprises a compound of Formula (I). In yet another aspect, the present disclosure relates to a compound for use in a method for treating a disease or disorder mediated by CBP/p300 family bromodomains, wherein the compound comprises a compound of Formula (I).

[0246] The present disclosure also relates to the use of an inhibitor of CBP/p300 family bromodomains for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors, wherein the medicament comprises a compound of Formula (I). The present disclosure further relates to the use of an inhibitor of CBP/p300 family bromodomains for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer, wherein the medicament comprises a compound of Formula (I).

[0247] Another embodiment of the present disclosure relates to a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, prodrug, isomer, or tautomer thereof, or a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, prodrug, isomer, or tautomer thereof, and a pharmaceutically acceptable carrier which provides, upon administration to a human, a decrease in tumor burden and/or metastases.

[0248] The disclosure is directed to compounds as described herein and pharmaceutically acceptable salts, enantiomers, hydrates, solvates, prodrugs, isomers, or tautomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein, or pharmaceutically acceptable salts, enantiomers, hydrates, solvates, prodrugs, isomers, or tautomers thereof. The disclosure is directed to compounds as described herein and pharmaceutically acceptable salts thereof. The disclosure also includes pharmaceutical compositions comprising one or more compounds as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, pharmaceutical compositions reported herein can be provided in a unit dosage form container (e.g., in a vial or bag). In some embodiments, pharmaceutical compositions reported herein can be provided in an oral dosage form. In some embodiments, an oral dosage form of a compound of Formula (I) can be a capsule. In some embodiments, an oral dosage form of a compound of Formula (I) is a tablet. In some embodiments, an oral dosage form comprises

one or more fillers, disintigrants, lubricants, glidants, anti-adherents and/or anti-statics. In some embodiments, an oral dosage form is prepared via dry blending. In some embodiments, an oral dosage form is a tablet and is prepared via dry granulation.

[0249] The present disclosure also relates to a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, additive, or surfactant. The compounds or pharmaceutical compositions of the disclosure may be administered via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral administration. Depending on the intended mode of administration, the disclosed compounds or compositions can be in solid dosage form, such as, for example, tablets, or pills, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be administered using forms well known to those skilled in the pharmaceutical arts.

[0250] In one embodiment, the present disclosure relates to a method of preparing a pharmaceutical composition of the present disclosure by mixing at least one pharmaceutically acceptable compound of the present disclosure, and, optionally, one or more pharmaceutically acceptable carriers, additives, or excipients. Pharmaceutical compositions comprising a CBP Inhibitor can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume. The dosage forms of the present disclosure, may contain a mixture of one or more compounds of this disclosure, and may include additional materials known to those skilled in the art as pharmaceutical excipients. Stabilizing additives may be incorporated into the delivery agent solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution. The stabilizing additives may be employed at a concentration ranging from about 0.1 and 5% (W/V), preferably about 0.5% (W/V). Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine. In one embodiment, the stabilizing additives are gum acacia, gelatin and methyl cellulose.

[0251] Examples of pharmaceutical excipients and additives include, but are not limited to: acidifying agents (acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid); Aerosol propellants (butane, dichlorodifluoro-methane, dichlorotetrafluoroethane, isobutane, propane, trichloromonofluoromethane); Air displacements (carbon dioxide, nitrogen); Alcohol denaturants (denatonium benzoate, methyl isobutyl ketone, sucrose octaacetate); Alkalizing agents (strong ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine); Anticaking agents (see *glidant*); Antifoaming agents (dimethicone, simethicone); Antimicrobial preservatives (benzalkonium chloride, benzalkonium chloride solution, benzelthonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol,

dehydroacetic acid, ethylparaben, methylparaben, methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate, propylparaben, propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate sodium formaldehyde sulfoxylate sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherols excipient); Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid, lactic acid, phosphoric acid, potassium citrate, potassium metaphosphate, potassium phosphate monobasic, sodium acetate, sodium citrate, sodium lactate solution, dibasic sodium phosphate, monobasic sodium phosphate); Capsule lubricants (see *tablet and capsule lubricant*); Chelating agents (edetate disodium, ethylenediaminetetraacetic acid and salts, edetic acid); Coating agents (sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate methacrylic acid copolymer, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, zein); Colorants (caramel, red, yellow, black or blends, ferric oxide); Complexing agents (ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisic acid ethanolamide, oxyquinoline sulfate); Desiccants (calcium chloride, calcium sulfate, silicon dioxide); Emulsifying and/or solubilizing agents (acacia, cholesterol, diethanolamine (adjunct), glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, monoethanolamine (adjunct), oleic acid (adjunct), oleyl alcohol (stabilizer), poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 caster oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol diacetate, propylene glycol monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, trolamine, emulsifying wax); Filtering aids (powdered cellulose, purified siliceous earth); Flavors and perfumes (anethole, benzaldehyde, ethyl vanillin, menthol, methyl salicylate monosodium glutamate, orange flower oil, peppermint, peppermint oil, peppermint spirit, rose oil, stronger rose water, thymol, tolu balsam tincture, vanilla, vanilla tincture, vanillin); Glidants and/or anticaking agents (calcium silicate, magnesium silicate, colloidal silicon dioxide, talc); Humectants (glycerin, hexylene glycol, propylene glycol, sorbitol); Plasticizers (castor oil, diacetylated monoglycerides, diethyl phthalate glycerin, mono- and di-acetylated monoglycerides, polyethylene glycol, propylene glycol, triacetin, triethyl citrate); Polymers (e.g., cellulose acetate, alkyl celluloses, hydroxyalkylcelluloses, acrylic polymers and copolymers); Solvents (acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanut oil, polyethylene glycol, propylene carbonate, propylene glycol, sesame oil, water for injection, sterile water for injection, sterile water for irrigation, purified water); Sorbents (powdered cellulose, charcoal, purified siliceous earth); Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffening agents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, polyethylene excipient, stearyl alcohol, emulsifying wax, white wax, yellow wax); Suspending and/or viscosity-

increasing agents (acacia, agar, alginic acid, aluminum monostearate, bentonite, purified bentonite, magma bentonite, carbomer 934p, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carboxymethylcellulose sodium 12, carrageenan, microcrystalline and carboxymethylcellulose sodium cellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, methylcellulose, pectin, polyethylene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, silicon dioxide, colloidal silicon dioxide, sodium alginate, tragacanth, xanthan gum); Sweetening agents (aspartame, dextrates, dextrose, excipient dextrose, fructose, mannitol, saccharin, calcium saccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose, compressible sugar, confectioner's sugar, syrup); Tablet binders (acacia, alginic acid, sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, methylcellulose, polyethylene oxide, povidone, pregelatinized starch, syrup); Tablet and/or capsule diluents (calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, dextrin, dextrose excipient, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, compressible sugar, confectioner's sugar); Tablet disintegrants (alginic acid, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate starch, pregelatinized starch); Tablet and/or capsule lubricants (calcium stearate, glyceryl behenate, magnesium stearate, light mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, purified stearic acid, talc, hydrogenated vegetable oil, zinc stearate); Tonicity agent (dextrose, glycerin, mannitol, potassium chloride, sodium chloride); Vehicle: flavored and/or sweetened (aromatic elixir, compound benzaldehyde elixir, iso-alcoholic elixir, peppermint water, sorbitol solution, syrup, tolu balsam syrup); Vehicle: oleaginous (almond oil, corn oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, mineral oil, light mineral oil, myristyl alcohol, octyldodecanol, olive oil, peanut oil, persic oil, sesame oil, soybean oil, squalane); Vehicle: solid carrier (sugar spheres); Vehicle: sterile (bacteriostatic water for injection, bacteriostatic sodium chloride injection); Viscosity-increasing (see *suspending agent*); Water repelling agent (cyclomethicone, dimethicone, simethicone); and Wetting and/or solubilizing agent (benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40, hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether, polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol) may be used as excipients. This list is not meant to be exclusive, but instead merely representative of the classes of excipients and the particular excipients which may be used in dosage forms of the present disclosure.

[0252] Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a Compound of the Disclosure and a pharmaceutically acceptable carrier, such as a) a diluent, *e.g.*, purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose

and/or glycine; b) a lubricant, *e.g.*, silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, *e.g.*, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, *e.g.*, starches, agar, methyl cellulose, bentonite, xanthan gum, algic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.

[0253] For preparing pharmaceutical compositions from the compounds described in this disclosure inert, pharmaceutically acceptable carriers can be either solid or liquid. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, *e.g.*, magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.

[0254] Since the compounds of this disclosure are intended for use in pharmaceutical compositions a skilled artisan will understand that they can be provided in substantially pure forms for example, at least 60% pure, more suitably at least 75% pure, preferably at least 85% pure and most preferably at least 98% pure (w/w).

[0255] The pharmaceutical preparation may be in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, *e.g.*, an effective amount to achieve the desired purpose.

[0256] The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, from about 1 mg to about 500 mg, from about 1 mg to about 250 mg, or from about 1 mg to about 25 mg, according to the particular application.

[0257] The CBP Inhibitor Compounds provided herein are preferably administered in a therapeutically effective amount (e.g., an amount having a suitable favorable therapeutic index). The amount and frequency of administration of the compounds of the disclosure and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the medical condition being treated. The dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age,

weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

[0258] The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required. Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses.

[0259] The compounds of Formula (I) can form salts (e.g., pharmaceutically acceptable salts) which are also within the scope of this disclosure. Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated.

[0260] All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the disclosure and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the disclosure.

EXAMPLES

[0261] In the following examples those compounds falling within the scope of the claims are compounds of the invention and the remaining compounds are provided as reference examples.

[0262] Definitions used in the following Schemes and elsewhere herein are:

ACN acetonitrile

Ac_2O acetic anhydride

(+)BINAP (±)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalen

Boc tert-butoxycarbonyl

Brettphos Dicyclohexyl[3,6-dimethoxy-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine

Brettphos Pd G3 or 3rd generation BrettPhos precatalyst: Methanesulfonato(2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-

2-yl)palladium(II)

n-BuOH butanol

cm centimeter

DCE 1,2-dichloroethane

DCM dichloromethane or methylene chloride

D-CSA D-Camphorsulfonic acid

DEA diethylamine

DMC 2-Chloro-4,5-dihydro-1,3-dimethyl-1*H*-imidazolium chloride

DMP Dess-Martin periodinane, **1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1*H*)-one**

DMTMM 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride

DIEA N,N-diisopropylethylamine

DMAP 4-(dimethylamino)pyridine

DMF N,N-dimethylformamide

DMSO dimethylsulfoxide

DPPA diphenylphosphoryl azide

dppf bis(diphenylphosphino)ferrocene

EDC 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride

ES electrospray ionization

Et_3N triethylamine

EtOAc ethyl acetate

EtOH ethanol

FA formic acid

FCC flash column chromatography

h hours

HATU 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate

HCl hydrogen chloride

HOAc acetic acid

HPLC high performance liquid chromatography

$[Ir(COD)Cl]_2$ chloro(1,5-cyclooctadiene)iridium(I) dimer

$(i\text{-}Pr)_2NEt$ N,N-diisopropylethylamine

L liter

LC/MS liquid chromatography/mass spectrometry

LCMS liquid chromatography/mass spectrometry

LDA lithium diisopropylamine

LRMS low resolution mass spectrometry

K_2CO_3 potassium carbonate

KHMDS Potassium hexamethyldisilazide

mCPBA 3-Chloroperoxybenzoic acid

MeOH methanol

mL milliliter

mmol millimole

mg milligram

MHz megahertz

MS mass spectrometry

m/z mass/charge ratio

NBS N-bromosuccinimide

nm nanometer

NMM 4-methylmorpholine

NMR nuclear magnetic resonance

NH_4Cl ammonium chloride

$Pd_2(dba)_3$ tris(dibenzylideneacetone)dipalladium

Ph_3P triphenylphosphine

PhCHO benzaldehyde

PhMe toluene

ppm parts per million

rt room temperature

RT rentention time

(S)-(-)-MeO-BIPHEP (S)-(-)-2,2'-Bis(diphenylphosphino)-6,6'-dimethoxy-1,1'-biphenyl

SFC supercritical fluid chromatography

STAB sodium triacetoxyborohydride

TBS tert-Butyldimethylsilyl

TBDMS tert-Butyldimethylsilyl chloride

p-TSA para-toluenesulfonic anhydride

p-TsOH para-toluenesulfonic acid

TFA trifluoroacetic acid

TFAA trifluoroacetic anhydride

THF tetrahydrofuran

TMSCN trimethylsilyl cyanide

UV ultraviolet

XPhos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

ZnI_2 zinc iodide

Materials

[0263] Unless otherwise noted, all materials were obtained from commercial suppliers and were used without further purification. Anhydrous solvents were obtained from Sigma-Aldrich (Milwaukee, WI) and used directly. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere and all reactions utilizing microwave irraditation were run on a Biotage Initiator EXP EU instrument.

[0264] Unless otherwise noted, mass-triggered HPLC purification and/or purity and low resolution mass spectral data were measured using either: (1) Waters Acquity ultra performance liquid chromatography (UPLC) system (Waters Acquity UPLC with Sample Organizer and Waters Micromass ZQ Mass Spectrometer) with UV detection at 220 nm and a low resonance electrospray positive ion mode (ESI) (Column: Acquity UPLC BEH C18 1.7µm 2.1 X 50 mm; gradient: 5-100% Solvent B (95/5/0.09%: Acetonitrile/Water/Formic Acid) in Solvent A (95/5/0.1%: 10mM Ammonium Formate/Acetonitrile/Formic Acid) for 2.2 min then 100-5% Solvent B in Solvent A for 0.01 min then hold at 5% Solvent B in Solvent A for 0.29 min) or (2) Waters HT2790 Alliance high performance liquid chromatography (HPLC) system (Waters 996 PDA and Waters ZQ Single Quad Mass Spectrometer) with UV detection at 220 nm and 254 nm and a low resonance electrospray ionization (positive/negative) mode (ESI) (Column: XBridge Phenyl or C18, 5 µm 4.6x50 mm; gradient: 5-95% Solvent B (95% methanol/5% water with 0.1% Formic Acid) in Solvent A (95% water/5% methanol with 0.1% Formic Acid) for 2.5 min then hold at 95% Solvent B in Solvent A for 1 min (purity and low resolution MS only).


General Methods of Compound Preparation

[0265] Described herein are methods of synthesizing the compounds of the present disclosure. Compounds of the present disclosure can be synthesized according to the synthetic schemes provided below. Preparation of the starting material for Schemes 1 and 2 is described in "Preparation of Intermediates," see Intermediate 1. Preparation of the starting material for Schemes 3 and 4 can be found in Example 1, Part A of U.S. Patent No. 4,404,207.

[0266] Unless otherwise specified, the substituents R^2 and R^3 and of the following reaction schemes are as defined in the description and claims.


[0267] Scheme 1 provides methods useful for synthesizing compounds of Formula I.

Scheme 1




[0268] Scheme 2 provides methods useful for synthesizing compounds of Formula I.

Scheme 2




[0269] Alternatively, Scheme 3 provides methods useful for synthesizing certain compounds of Formula I.

Scheme 3



[0270] Alternatively, Scheme 4 provides methods useful for synthesizing certain compounds of Formula I.

Scheme 4




[0271] Unless otherwise specified, Ring B, R^1, R^6, R^7, R^{10}, m and q and of the following reaction schemes are as defined in the description and claims. The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes. For example, 6-fluoro-2-methylquinoline can be nitrated under acidic conditions to afford 6-fluoro-2-methyl-5-nitroquinoline. Asymmetric iridium-catalyzed hydrogenation of the quinoline gives (S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline. Carbamate formation and subsequent nucleophilic aromatic substitution yields a methyl 6-fluoro-2-methyl-5-nitroquinoline. Nitro

reduction, acylation and acid-mediated cyclization yields the methyl (S)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate core of Formula I-i.

[0272] Scheme 5 provides methods useful for synthesizing certain compounds of Formula I-i.


Scheme 5



Preparation of Intermediates

Intermediate 1: methyl (S)-5-amino-6-bromo-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate

[0273]



Step 1. **8-chloro-5-methoxy-2-methylquinoline hydrochloride**

[0274] Into a 5L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, 2-chloro-5-methoxyaniline (250 g, 1.59 mol) was dissolved in 1-butanol (1200 mL). Then hydrochloric acid (aq, 36.5%, 526.5 mL) and chloranil (456.5 g, 1.86 mol) were added. The resulting mixture was stirred for 1 h at 100°C under nitrogen atmosphere. Then a solution of (E)-but-2-enal (169 mL, 2.06 mol) in 1-butanol (300 mL) was added dropwise. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The oil bath was cooled to 70°C and tetrahydrofuran (1500mL) was added. Then the resulting mixture was stirred for 1 h at 70°C. The reaction mixture was cooled to 0°C and the solids were filtered. The solids were washed with tetrahydrofuran (3L) at 0°C. This afforded the title compound (300g, 77%) as a yellow solid. MS: (ES, *m/z*): 208, 210 $[M+H]^+$.

Step 2. **5-methoxy-2-methylquinoline**

[0275] Into a 1000-mL 3-necked round-bottom flask, 8-chloro-5-methoxy-2-methylquinoline hydrochloride (50 g, 204.82 mmol) was dissolved in methanol (300 mL). Then sodium hydroxide (3M, 205 mL) and 10% palladium on carbon (25 g) were added. Hydrogen (g) was charged into the reaction mixture. The reaction mixture was stirred under a hydrogen atmosphere for 3 h at room temperature. The reaction was vented to nitrogen and the solids were filtered out over celite. The filtered solution was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (28.5 g, 80%) as a yellow oil. MS: (ES, *m/z*): 174 $[M+H]^+$.

Step 3. **(2 S)-5-methoxy-2-m ethyl- 1,2,3,4-tetrahydroquinoline**

[0276] Into a 30-mL pressure tank reactor (50 atm), 5-methoxy-2-methylquinoline (4.0 g, 23.09 mmol) was dissolved in methanol (10 mL). Then Ru(OTf)(*η6*-hexamethylbenzene) ((*S*,*S*)-TsDPEN) ([*N*-[(1*S*,2,*S*)-2-(amino-κ*N*)-1,2-diphenylethyl]-4-methylbenzenesulfonamidato-κ*N*][(1,2,3,4,5,6-η)-1,2,3,4,5,6-hexamethylbenzene](1,1,1-trifluoromethanesulfonato-κ*O*)-ruthenium, prepared according to the procedure in J. Am. Chem. Soc. 2011, 133, 9878-9891 (150 mg, 0.23 mmol) was added. To the above hydrogen was introduced in. The resulting solution was stirred for 20 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:4). This afforded the title compound (3.0 g, 73%) as a yellow oil. MS: (ES, *m/z*): 178 $[M+H]^+$. *Step 4.* **methyl (S)-5-methoxy-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**

[0277] Into a 250-mL round-bottom flask, (2S)-5-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline

(18 g, 99.52 mmol) was dissolved in dichloromethane (100 mL). Then pyridine (23.6 g, 298.36 mmol) was added, followed by methyl carbonochloridate (9.4 g, 99.47 mmol). The resulting solution was stirred for 1 h at room temperature. The resulting solution was diluted with 100 mL of dichloromethane and washed with 3x200 mL of water. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:3). This afforded the title compound (21 g, 89%) as a yellow oil. MS: (ES, *m/z*): 236 $[M+H]^+$.

Step 5. **methyl (S)-5-hydroxy-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**

[0278] Into a 500-mL 3-necked round-bottom flask, methyl (2S)-5-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (21 g, 89.36 mmol) was dissolved in dichloromethane (150 mL). Then boron tribromide (150 mL, 0.15 mol, 1 M in CH_2Cl_2) was added. The resulting solution was stirred for 1 h at room temperature. The reaction was then quenched by the addition of 300 mL of water. The resulting mixture was extracted with 3x300 mL of dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (13.5 g, 68%) as a yellow solid. MS: (ES, *m/z*): 222 $[M+H]^+$.

Step 6. **methyl (S)-2-methyl-5-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroquinoline-1(2H)-carboxylate**

[0279] Into a 250-mL round-bottom flask, methyl (2S)-5-hydroxy-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (5 g, 18.08 mmol) was dissolved in dichloromethane (50 mL). Then pyridine (14.3 g, 180.78 mmol) and trifluoromethanesulfonic anhydride (10.2 g, 36.15 mmol) were added. The resulting solution was stirred for 1 h at room temperature. The resulting mixture was washed with 3x100 mL of water. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:3). This afforded the title compound (5.5 g, 86%) as a yellow oil. MS: (ES, *m/z*): 354 $[M+H]^+$.

Step 7. **methyl (S)-5-((diphenylmethylene)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**

[0280] Into a 500-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-2-methyl-5-[(trifluoromethane)sulfonyloxy]-1,2,3,4-tetrahydroquinoline -1-carboxylate (23.5 g, 65.18 mmol) was dissolved in toluene (100 mL). Then diphenylmethanimine (17.9 g, 97.78 mmol), tris(dibenzylideneacetone)dipalladium-chloroform

adduct (1.19 g, 1.30 mmol), (+/-)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (2.43 g, 3.90 mmol) and cesium carbonate (42.4 g, 130.13 mmol) were added. The resulting solution was stirred overnight at 100°C under nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:3). This afforded the title compound (33 g, 80%) as a yellow oil. MS: (ES, *m/z*): 385 $[M+H]^+$.

Step 8. **methyl (S)-5-amino-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**


[0281] Into a 500-mL round-bottom flask, methyl (2S)-5-[(diphenylmethylidene)amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (33 g, 85.93 mmol) was dissolved in methanol (200 mL). Then sodium acetate (17 g, 207.23 mmol) and hydroxylamine hydrochloride (12.3 g, 177.00 mmol) were added. The resulting solution was stirred for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (12.5 g, 66%) as a yellow solid. MS: (ES, *m/z*): 221 $[M+H]^+$.

Step 9. **methyl (S)-5-amino-6-bromo-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (Intermediate 1)**

[0282] Into a 100-mL 3-necked round-bottom flask, methyl (2S)-5-amino-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (1 g, 4.09 mmol) was dissolved in acetonitrile (20 mL). Then N-bromosuccinimide (730 mg, 4.10 mmol) was added. The resulting solution was stirred for 30 min at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (1.1 g, 90%) as a yellow solid. MS: (ES, *m/z*): 299, 301 $[M+H]^+$. H-NMR: (400 MHz, CD3OD, ppm): 7.19(d, *J*= 8.8 Hz, 1H), 6.84(d, *J*= 8.8 Hz, 1H), 4.73-4.69(m, 1H), 3.74(s, 3H), 2.64-2.57(m, 1H), 2.55-2.44(m, 1H), 2.12-2.05(m, 1H), 1.82-1.79(m, 1H), 1.17(d, *J*=6.9 Hz, 3H).

Intermediate 2: 3-phenylbutanoyl chloride

[0283]




Step 1

[0284] Into a 25-mL round-bottom flask, 3-phenylbutanoic acid (50 mg, 0.30 mmol) was dissolved in dichloromethane (5 mL). Then oxalyl chloride (2 mL) and one drop of N, N-dimethylformamide were added. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. This afforded the title compound (51mg, 90%) as yellow oil.

Intermediates 3 and 4: ethyl (trans)-4-amino-1-methylcyclohexane-1-carboxylate and ethyl (cis)-4-amino-1-methylcyclohexane-1-carboxylate

[0285]



***Step 1*. Synthesis of ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate.**

[0286] Into a 250-mL round-bottom flask, ethyl 4-oxocyclohexane-1-carboxylate (10 g, 58.75 mmol) was dissolved in toluene (100 mL). Then ethane-1,2-diol (14.60 g, 235.23 mmol) was added, followed by p-toluenesulfonic acid (1.02 g, 5.92 mmol). The resulting solution was stirred for 14 h at 100°C. After cooled to room temperature, the resulting solution was diluted with 100 mL of water. The resulting solution was extracted with 3x100 mL of ethyl acetate. The

organic layers were combined and washed with 3x100 mL of saturated sodium bicarbonate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (5:1).This afforded the title compound (3.0g, 23%) as a yellow oil. MS: (ES, *m/z*): 215 $[M+H]^+$.

Step 2. **Synthesis of ethyl 8-methyl-1,4-dioxaspiro[4.5]decane-8-carboxylate.**

[0287] Into a 250-mL 3-necked round-bottom flask, ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate (2.4 g, 11.20 mmol) was dissolved in tetrahydrofuran (100 mL). Then lithium diisopropylamide (2M in tetrahydrofuran, 8.4 mL, 16.77 mmol) was added dropwise. The mixture was stirred for 30 min at -78°C. To this was added iodomethane (2.38 g, 16.77 mmol). The resulting solution was stirred for 1 h at -78°C.The reaction was then quenched by the addition of 100 mL of ammonium chloride (aq, sat) and extracted with 3x100 ml of ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum.The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (1.8g, 69%) as a yellow oil. MS: (ES, m/z): 229 $[M+H]^+$.

Step 3. **Synthesis of ethyl 1-methyl-4-oxocyclohexane-1-carboxylate.**

[0288] Into a 100-mL round-bottom flask, ethyl 8-methyl-1,4-dioxaspiro[4.5]decane-8-carboxylate (2.3 g, 10.08 mmol) was dissolved in acetone (20 mL). Then sulfuric acid (1M, 20 mL) was added. The resulting solution was stirred for 14 h at room temperature. The resulting solution was diluted with 50 ml of water and extracted with 3x50 ml of ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (1.8g, crude) as a yellow oil. MS: (ES, m/z): 185 $[M+H]^+$.

Step 4. **Synthesis of ethyl (trans)-4-(benzylamino)-1-methylcyclohexane-1-carboxylate and ethyl (cis)-4-(benzylamino)-1-methylcyclohexane-1-carboxylate.**

[0289] Into a 100-mL round-bottom flask, ethyl 1-methyl-4-oxocyclohexane-1-carboxylate (1.7 g, 9.99 mmol) was dissolved in methanol (20 mL). Benzylamine (1.2 g, 11.20 mmol) and acetic acid (2.8 g, 46.63 mmol) were added, followed by sodium cyanoborohydride (2.9 g, 46.15 mmol). The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 30 mL of water and extracted with 3x30 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-SFC with the following conditions : Column,


Chiralpak AD-H, 2 X 25cm (5um); mobile phase, CO_2(80%), MeOH(2mM NH_3-MeOH)(20%); Flow rate: 40 mL/min; Detector, UV 220nm. This afforded the title compounds as follows: 280 mg (11%) of ethyl (trans)-4-(benzylamino)-1-methylcyclohexane-1-carboxylate(assumed stereochemistry, first eluting isomer, RT = 3.75min) as a yellow solid and 350 mg (13%) of ethyl (cis)-4-(benzylamino)-1-methylcyclohexane-1-carboxylate(assumed stereochemistry, second eluting isomer, RT =4.74 min) as a yellow solid. MS: (ES, m/z): 276 $[M+H]^+$.

Step S. **Synthesis of ethyl (trans)-4-amino-1-methylcyclohexane-1-carboxylate and ethyl (cis)-4-amino-1-methylcyclohexane-1-carboxylate.**

[0290] Into a 50-mL round-bottom flask, ethyl trans-4-(benzylamino)-1-methylcyclohexane-1-carboxylate (280 mg, 1.02 mmol) or ethyl cis-4-(benzylamino)-1-methylcyclohexane-1-carboxylate (280 mg, 1.02 mmol) was dissolved in methanol (10 mL). Palladium carbon (280 mg, 10%) was added. Hydrogen (g) was introduced into the reaction mixture. The resulting solution was stirred for 5 h at room temperature under hydrogen atmosphere. The solids were filtered out and the resulting mixture was concentrated under vacuum. This afforded the independent title compounds (75 mg, crude) as yellow oils. MS: (ES, m/z): 186 $[M+H]^+$.

Intermediate 5: 2-(3-fluoro-4-methoxyphenyl)acetaldehyde

[0291]



Step **1. Synthesis of 2-(3-fluoro-4-methoxyphenyl)ethan-1-ol.**


[0292] 2-(3-fluoro-4-methoxyphenyl)acetic acid (400 mg, 2.17 mmol) was dissolved in THF (4 mL). The reaction solution was cooled to 0°C. Lithium aluminium hydride (90.8 mg, 2.39 mmol) was added portionwise. The flask was then wrapped with aluminum foil and the resulting solution was stirred for 1 h at room temperature. The reaction was then quenched by the addition of 2 mL of water/ice. The resulting mixture was concentrated under vacuum. The solution was extracted with 2x10 mL of ethyl acetate and the organic layers were combined and evaporated. This afforded 290 mg (78%) of 2-(3-fluoro-4-methoxyphenyl)ethan-1-ol as colorless oil.

Step 2. **Synthesis of 2-(3-fluoro-4-methoxyphenyl)acetaldehyde.**

[0293] Into a 100-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-(3-fluoro-4-methoxyphenyl)ethan-1-ol (290 mg, 1.70 mmol) in dichloromethane (5 mL). The reaction was cooled to 0°C and Dess-Martin Periodinane (940 mg, 2.22 mmol, 1.30 equiv) was added. The flask was wrapped with aluminum foil and the resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (150 mg, 52%) as a colorless oil. MS: (ES, m/z): 169 $[M+H]^+$.

Intermediate 6: 3-(2H-1,2,3-triazol-2-yl)propanal

[0294]




Step1


***Step 1*. Synthesis of 2-(3-fluoro-4-methoxyphenyl)acetaldehyde.**

[0295] 1H-1,2,3-triazole (500 mg, 7.24 mmol) was dissolved in dichloromethane (15 mL) in a round bottom flask. Prop-2-enal (608 mg, 10.84 mmol) was added. The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (100 mg, 11%) as a yellow oil. MS: (ES, m/z): 126$[M+H]^+$.

Intermediate 7: 3-(2-methyl-1,3-oxazol-5-yl)propanal

[0296]





Step 1. **Synthesis of (2-methyl-1,3-oxazol-5-yl)methanol.**

[0297] Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, 2-methyl-1,3-oxazole-5-carboxylic acid (1.0 g, 7.86 mmol) was dissolved in tetrahydrofuran (10 mL). Then borane-tetrahydrofuran complex (31.6 mL, 330.2 mmol) was added dropwise with stirring at 0°C. The resulting solution was stirred for 30 min at 0°C. The resulting solution was allowed to react, with stirring, for an additional 2 h at room temperature. The reaction was then quenched by the addition of 20 mL of water and extracted with 3x40 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (1.43g, crude) as an off-white solid. MS: (ES, *m/z*): 114 $[M+H]^+$.

Step 2. **Synthesis of 2-methyl-1,3-oxazole-5-carbaldehyde.**

[0298] Into a 25-mL round-bottom flask, (2-methyl-1,3-oxazol-5-yl)methanol (1.43 g, 12.6 mmol) was dissolved in dichloromethane (10 mL). Then (1,1,1-triacetoxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one (6.97 g, 16.44 mmol) was added. The resulting solution was stirred for 30 min at 0°C. The resulting solution was allowed to react, with stirring, for an additional 2 h at room temperature. The reaction was then quenched by the addition of 20 mL of aqueous solution of sodium bicarbonate and 20 mL of aqueous solution of sodium bisulfite. The resulting solution was extracted with 3x30 mL of dichloromethane and the organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (677.3 mg, 48.4%) as an off-white solid. MS: (ES, *m/z*): 112 $[M+H]^+$.

Step 3. **Synthesis of ethyl (2E)-3-(2-methyl-1,3-oxazol-5-yl)prop-2-enoate.**

[0299] Into a 250-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, ethyl 2-(diethoxyphosphoryl)acetate (3.55 g, 15.9 mmol) was dissolved in tetrahydrofuran (20 mL). Then sodium hydride (3.29 g, 60% in oil, 137.3 mmol) in tetrahydrofuran (2 mL) was added dropwise with stirring at 0°C. The resulting mixture was stirred for 30 min at 0°C. To this was added a solution of 2-methyl-1,3-oxazole-5-carbaldehyde (677.3 mg, 6.10 mmol) in tetrahydrofuran (2 mL) dropwise with stirring at 0°C. The resulting solution was stirred for 1.5 h at 0°C. The reaction was then quenched by the addition of 40 mL of water and extracted with 3x80 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (145 mg, 13%) as a light yellow liquid. MS: (ES, *m/z*): 182 $[M+H]^+$.

Step 4. **Synthesis of ethyl 3-(2-methyl-1,3-oxazol-5-yl)propanoate.**

[0300] Into a 25-mL round-bottom flask, ethyl (2E)-3-(2-methyl-1,3-oxazol-5-yl)prop-2-enoate (145 mg, 0.80 mmol) was dissolved in methanol (5 mL). Then 10% palladium carbon (145 mg) was added. To the above hydrogen (g) was introduced in. The resulting solution was stirred for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This afforded the title compound (150 mg, crude) as a colorless oil. MS: (ES, *m/z*): 184 $[M+H]^+$.

Step 5. **Synthesis of 3-(2-methyl-1,3-oxazol-5-yl)propan-1-ol.**

[0301] Into a 25-mL 2-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, ethyl 3-(2-methyl-1,3-oxazol-5-yl)propanoate (134.2 mg, 0.73 mmol) was dissolved in diethyl ether (5 mL). Then LAH (33.4 mg, 0.88 mmol) was added in portions at 0°C. The resulting solution was stirred for 1 h at 0°C. The reaction was then quenched by the addition of 5 mL of aqueous potassium sodium tartrate and extracted with 3x10 mL of ether. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (122 mg, crude) as a colorless oil. MS: (ES, *m/z*): 142 $[M+H]^+$.


Step 6. **Synthesis of 3-(2-methyl-1,3-oxazol-5-yl)propanal.**

[0302] Into a 25-mL round-bottom flask, 3-(2-methyl-1,3-oxazol-5-yl)propan-1-ol (122 mg, 0.86 mmol) was dissolved in dichloromethane (5 mL). Then dimethyl phthalate (980 mg, 2.31 mmol) was added at 0°C. The resulting solution was stirred for 30 min at 0°C. The resulting solution was allowed to react, with stirring, for an additional 2 h at room temperature. The

resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (98.8 mg, 82%) as a yellow solid. MS: (ES, *m/z*): 140 $[M+H]^+$.

Intermediate 8: 3-(1-methyl-1H-pyrazol-4-yl)propanal


[0303]










[0304] Into a 20-mL 2-necked round-bottom flask, was placed 3-(1-methyl-1H-pyrazol-4-yl)propan-1-ol (140 mg, 1.00 mmol) in dichloromethane (5 mL). Dess-Martin reagent (551 mg, 1.30 mmol) was added portionwise and the resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound as a yellow oil (110 mg, 80%). MS: (ES, *m/z*): 139 $[M+H]^+$.

[0305] The following intermediates in **TABLE A** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Intermediate 8.


TABLE A


Intermediate Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
9	 3-(4-methyloxazol-2-yl)propanal	140
10	 3-(4-methyl-1H-pyrazol-1-yl)propanal	139
11	 3-(3-methyl-1H-pyrazol-1-yl)propanal	139
12	 3-(4-chloro-1H-pyrazol-1-yl)propanal	159

Intermediate Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
13	 3-(1H-pyrazol-1-yl)propanal	124
14	 3-(3-methoxyphenyl)propanal	164
15	 3 -(3 -fluorophenyl)propanal	152
16	 3-(3-fluoro-4-methoxyphenyl)propanal	169
17	 3-(2-oxopyridin-1(2H)-yl)propanal	151
18	 2-(2-oxopyridin-1(2H)-yl)acetaldehyde	137
19	 3-(2H-1,2,3-triazol-2-yl)propanal	125

Intermediate 20: 3-(5-methyloxazol-2-yl)propanal

[0306]





Step 1. **Synthesis of 4-(benzyloxy)-N-(prop-2-yn-1-yl)butanamide.**

[0307] Into a 100-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 4-(benzyloxy)butanoic acid (515 mg, 2.65 mmol) in DMF (5 mL). Prop-2-yn-1-amine (146 mg, 2.65 mmol), 1H-1,2,3-benzotriazol-1-ol (358 mg, 2.65 mmol), and EDC (508 mg, 2.65 mmol) were added. The flask was wrapped with aluminum foil and the resulting solution was stirred for 12 h at room temperature. The reaction was then quenched by the addition of 5 mL of water/ice. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The resulting mixture was concentrated under vacuum affording the title compound (460 mg, 75%) as a colorless oil. MS: (ES, *m/z*): 232 $[M+H]^+$.

Step 2. **Synthesis of 2-(3-(benzyloxy)propyl)-5-methyloxazole.**

[0308] Into a 100-mL round-bottom flask, was placed 4-(benzyloxy)-N-(prop-2-yn-1-yl)butanamide (460 mg, 1.99 mmol) in acetonitrile (10 mL). Goldtrichloride (30.05 mg, 0.1 mmol) was added and the resulting solution was stirred for 8 h at 50°C. The resulting mixture was concentrated under vacuum and the residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (280 mg, 61%) as a yellow oil. MS: (ES, *m/z*): 232 $[M+H]^+$.

Step 3. **Synthesis of 3-(5-methyloxazol-2-yl)propan-1-ol.**


[0309] Into a 50-mL round-bottom flask, was placed 2-[3-(benzyloxy)propyl]-5-methyl-1,3-oxazole (280 mg, 1.21 mmol) and 10% palladium on carbon (28 g) in methanol (5 mL). A balloon filled with hydrogen (g) was charged in and the suspension was stirred for 12 h at room temperature. The reaction was vented to nitrogen and the solids were filtered out over celite. The resulting solution was concentrated under vacuum affording the title compound (150 mg, 88%) as a white solid. MS: (ES, *m/z*): 142 $[M+H]^+$.

Step 4. **Synthesis of 3-(5-methyloxazol-2-yl)propanal.**

[0310] Into a 100-mL round-bottom flask, was placed 3-(5-methyl-1,3-oxazol-2-yl)propan-1-ol (150 mg, 1.06 mmol) in dichloromethane (5 mL). The reaction was cooled to 0°C and Dess-Martin reagent (586.4 mg, 1.38 mmol) was added. The resulting mixture was stirred for 1.5 h at room temperature and then concentrated under vacuum. This afforded the title compound (100 mg, 68%) as a white solid. MS: (ES, *m/z*): 140 $[M+H]^+$.

Intermediate 21: 3-(3-methylisoxazol-5-yl)propanal

[0311]



Step 1. **Synthesis of 3-(3-methyl-1,2-oxazol-5-yl)propan-1-ol.**

[0312] Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, 3,5-dimethyl-1,2-oxazole (2 g, 20.59 mmol) was dissolved in tetrahydrofuran (20 mL). Then n-butyllithium (10 M in hexanes, 8.25 mL, 87.58 mmol) was added dropwise. The resulting mixture was stirred at -78°C for 2 h. To this was added a solution of oxirane (2.72 g, 61.8 mmol) in tetrahydrofuran (5 mL). The resulting solution was stirred at - 78°C for 1 h. The resulting solution was diluted with 50 mL of ammonium chloride (aq.) and extracted with 3x50 mL of dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (1.47 g, crude) as an orange liquid. MS: (ES, *m/z*): 142 $[M+H]^+$.


Step 2. **Synthesis of 3-(3-methyl-1,2-oxazol-5-yl)propanal.**

[0313] Into a 25-mL round-bottom flask, 3-(3-methyl-1,2-oxazol-5-yl)propan-1-ol (500 mg, 3.54 mmol) was dissolved in dichloromethane (5 mL). Then Dess-Martin periodinane (1.95 g, 4.61 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The resulting solution was diluted with 50 mL of sodium bicarbonate and extracted with 3x50 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with

ethyl acetate/petroleum ether (1:1). This afforded the title compound (247 mg, 50%) as a light yellow liquid. MS: (ES, *m/z*): 140 $[M+H]^+$.

Intermediate 22: 3-(5-methyl-1,3,4-oxadiazol-2-yl)propanal

[0314]



Step 1. **Synthesis of N'-acetyl-4-(benzyloxy)butanehydrazide.**

[0315] Into a 250-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 4-(benzyloxy)butanoic acid (1.0 g, 5.15 mmol) in dichloromethane (10 mL). Acetohydrazide (724 mg, 9.77 mmol) was added followed by triethylamine (1.249 g, 12.34 mmol), 4-dimethylaminopyridine (1.25 g, 10.23 mmol) and EDC (1.98 g, 10.31 mmol). The resulting solution was stirred for 17 h at room temperature. The pH value of the solution was adjusted to 2 with hydrochloric acid (1N). The resulting solution was extracted with 2x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was concentrated under vacuum affording the title compound (1 g, 78%) as a white solid. MS: (ES, *m/z*): 251 $[M+H]^+$.

Step 2. **Synthesis of 2-(3-(benzyloxy)propyl)-5-methyl-1,3,4-oxadiazole.**

[0316] Into a 50-mL round-bottom flask, was placed N'-acetyl-4-(benzyloxy)butanehydrazide (300 mg, 1.20 mmol) in acetonitrile (5 mL). Phosphoroyl trichloride (5 mL) was added and the resulting solution was stirred for 2 h at 60°C. The resulting mixture was concentrated under vacuum and the residue was subjected to purification by FCC eluting with ethyl acetate. This afforded the title compound (180 mg, 65%) as a yellow oil. MS: (ES, *m/z*): 233 $[M+H]^+$.

Step 3. **Synthesis of 3-(5-methyl-1,3,4-oxadiazol-2-yl)propan-1-ol.**


[0317] Into a 50-mL round-bottom flask, was placed a suspension of 2-[3-(benzyloxy)propyl]-5-methyl-1,3,4-oxadiazole (180 mg, 0.77 mmol), and 10% palladium on carbon (18 mg) in methanol (5 mL). A balloon filled with hydrogen (g) was charged in and the reaction mixture was stirred for 24 h at room temperature. The reaction was vented to nitrogen and the solids were filtered out over celilte. The filtered solution was concentrated in vacuo and the residue was subjected to purification by FCC eluting with ethyl acetate. This afforded the title compound (100 mg, 91%) as a white solid. MS: (ES, *m/z*): 143 $[M+H]^+$.

Step 4. **Synthesis of 3-(5-methyl-1,3,4-oxadiazol-2-yl)propanal.**

[0318] Into a 100-mL 3-necked round-bottom flask, was placed 3-(5-methyl-1,3,4-oxadiazol-2-yl)propan-1-ol (100 mg, 0.70 mmol) in dichloromethane (5 mL). Dess-Martin periodinane reagent (388 mg, 0.91 mmol) was added and the resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was dissolved in 5 mL of ethyl acetate. The solids were filtered out over celite and the filtered solution was concentrated in vacuo. The residue was subjected to purification by FCC eluting with ethyl acetate. This afforded the title compound (80 mg, 81%) as a yellow oil. MS: (ES, *m/z*): 141 $[M+H]^+$.

Intermediate 23: 3-(5-methyl-1,3,4-oxadiazol-2-yl)propanal

[0319]



Step 1. **Methyl (2E)-3-(1-methyl-1H-pyrazol-3-yl)prop-2-enoate.**

[0320] Into a 50-mL vial purged and maintained with an inert atmosphere of nitrogen, 3-iodo-

1-methyl-1H-pyrazole (500 mg, 2.40 mmol) was dissolved in acetonitrile (10 mL). Then methyl prop-2-enoate (2.07 g, 24.03 mmol), palladium diacetate (108 mg, 0.48 mmol), tri-ortho-tolylphosphine (292 mg, 0.96 mmol) and triethylamine (1.216 g, 12.02 mmol) were added. The resulting solution was stirred for 2 h at 80°C under nitrogen atmosphere. The reaction mixture was cooled and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (130 mg, 33%) as a yellow oil. MS: (ES, *m/z*): 167[M+H]$^+$.

Step 2. **Methyl 3-(1-methyl-1H-pyrazol-3-yl)propanoate.**

[0321] Into a 50-mL round-bottom flask, methyl (2E)-3-(1-methyl-1H-pyrazol-3-yl)prop-2-enoate (130 mg, 0.78 mmol) was dissolved in methanol (10mL). Then 10% palladium on carbon (80 mg, 0.75 mmo) was added. Hydrogen (g) was charged into the reaction mixture. The resulting solution was stirred for 1 h at room temperature under hydrogen atmosphere. The reaction was vented to nitrogen and the solids were filtered out and the resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (120 mg, 91%) as an off-white oil. MS: (ES, *m/z*): 169 [M+H]$^+$.

Step 3. **3-(1-Methyl-1H-pyrazol-3-yl)propan-1-ol.**

[0322] Into a 25-mL round-bottom flask, methyl 3-(1-methyl-1H-pyrazol-3-yl)propanoate (150 mg, 0.89 mmol) was dissolved in tetrahydrofuran (10 mL) Then lithium aluminium hydride (40 mg, 1.05 mmol) was added. The resulting solution was stirred for 1 h at room temperature. The reaction was then quenched by addition of water (20 mL). The resulting solution was extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (120 mg, 96%) as an off-white oil. MS: (ES, *m/z*): 141 [M+H]$^+$.


Step 4. **3-(1-methyl-1H-pyrazol-3-yl)propanal.**

[0323] Into a 50-mL round-bottom flask, 3-(1-methyl-1H-pyrazol-3-yl)propan-1-ol (120 mg, 0.86 mmol) was dissolved in dichloromethane (10 mL). Then Dess-Martin periodinane (472 mg, 1.11 mmol) was added in portions. The resulting solution was stirred for 2 h at 0 °C in a water/ice bath. The reaction was then quenched by addition of water (20 mL). The resulting solution was extracted with 3x20 mL of dichloromethane. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title

compound (100 mg, 85%) as an off-white oil. MS: (ES, *m/z*): 139[M+H]$^+$.

Intermediate 24: 3-((tert-butyldimethylsilyl)oxy)-2-phenylpropanal

[0324]



***Step 1*. Synthesis of 3-[(tert-butyldimethylsilyl)oxy]-2-phenylpropan-1-ol.**


[0325] Into a 100-mL round-bottom flask, 2-phenylpropane-1,3-diol (2.5 g, 16.43 mmol) was dissolved in dichloromethane (30 mL). Then tert-butyldimethylsilyl chloride (2.6 g, 17.25 mmol) and 4-dimethylaminopyridine (20 mg, 0.16 mmol) were added, followed by triethylamine (2.7 mL, 19.42 mmol). The mixture was stirred for 12 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (2 g, 46%) as a yellow oil. MS : (ES, *m/z*): 267 [M+H]$^+$.


***Step 2*. Synthesis of 3-[(tert-butyldimethylsilyl)oxy]-2-phenylpropanal.**

[0326] Into a 50-mL round-bottom flask, 3-[(tert-butyldimethylsilyl)oxy]-2-phenylpropan-1-ol (1 g, 3.75 mmol) was dissolved in dichloromethane (20 mL) and cooled down to 0 °C. Then Dess-Martin periodinane (2 g, 4.72 mmol) was added. The mixture was stirred for 8 h at room temperature. Then water was added. The mixture was extracted with 2x50 mL of dichloromethane. The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:4). This afforded the title compound (800 mg, 81%) as a yellow oil. MS: (ES, *m/z*): 265 [M+H]$^+$.

Intermediate 25 and 26: methyl (cis)-4-amino-2,2-dimethylcyclohexane-1-carboxylate and methyl (trans)-4-amino-2,2-dimethylcyclohexane-1-carboxylate

[0327]





Step 1. **Synthesis of cis-methyl 4-(benzylamino)-2,2-dimethylcyclohexanecarboxylic acid and trans-methyl 4-(benzylamino)-2,2-dimethylcyclohexanecarboxylic acid.**


[0328] Into a 100-mL round-bottom flask, methyl 2,2-dimethyl-4-oxocyclohexane-1-carboxylate (1 g, 5.43 mmol) was dissolved in methanol (20 mL). Then phenylmethanamine (1.61 g, 10.86 mmol) was added. The resulting solution was stirred for 1 h at room temperature. Then sodium cyanoborohydride (1.37 g, 21.72 mmol) was added, followed by glacial acetic acid (980 mg, 16.33 mmol). The resulting solution was stirred for 8 h at room temperature. The solids were filtered out and the resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 um, 19 mm x 150 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (20.0% to 40.0% ACN over 7 min); UV Detector: 254 nm. This result in 890 mg (60%) of the product as a yellow oil. The product was then purified by Chiral Prep-HPLC with the following conditions: Column: CHIRALPAK IF, 2*25cm, 5um; Mobile Phase, A: hexanes and B: EtOH (30% EtOH over 11.5 min); UV Detector: 254 nm; RT1:6.97 and RT2:7.25.This afforded the title compounds 380 mg of cis-methyl 4-(benzylamino)-2,2-dimethylcyclohexanecarboxylic acid as a yellow oil and 200 mg of trans-methyl 4-(benzylamino)-2,2-dimethylcyclohexanecarboxylic acid as a yellow oil. MS: (ES, *m/z*): 262 $[M+H]^+$.


Step 2. **Synthesis of methyl (cis)-4-amino-2,2-dimethylcyclohexane-1-carboxylate and methyl (trans)-4-amino-2,2-dimethylcyclohexane-1-carboxylate.**

[0329] Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl 4-(benzylamino)-2,2-dimethylcyclohexane-1-carboxylate (380 mg, 1.38 mmol) was dissolved in methanol (14 mL). Then palladium on carbon (76 mg, 10%) was added, followed by acetic acid (0.7 mL). Hydrogen (g) was charged into the reaction mixture and the resulting solution was stirred under a hydrogen atmosphere for 8 h at room temperature. The reaction was vented to nitrogen and the solids were filtered out over celite. The filtered solution was concentrated under vacuum. This afforded the title compound (203 mg, crude) as a yellow oil, which could be used without further purification. MS : (ES, *m/z*): 186 $[M+H]^+$.

Intermediate 27: 2-methyl-3-phenylpropanal

[0330]





Step 1. **Synthesis of 2-methyl-3-phenylpropan-1-ol.**


[0331] Into a 250-mL round-bottom flask, 2-methyl-3-phenylpropanoic acid (3.0 g, 18.3 mmol) was dissolved in tetrahydrofuran (30 mL). Then boron trifluoride tetrahydrofuran complex (27 mL, 282.1 mmol) was added dropwise with stirring at 0°C. The resulting solution was stirred for 2 h at room temperature. The reaction was then quenched by addition of 30 mL of water and extracted with 3x50 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (2.0 g, 70%) as a yellow oil. MS: (ES, *m/z*): 151 $[M+H]^+$.

Step 2. **Synthesis of 2-methyl-3-phenylpropanal.**

[0332] Into a 250-mL round-bottom flask, 2-methyl-3-phenylpropan-1-ol (2.0 g, 13.3 mmol) was dissolved in dichloromethane (50 mL). Then Dess-Martin periodinane reagent (11.3 g, 26.6 mmol) was added. The resulting solution was stirred for 5 h at room temperature. The reaction was then quenched by addition of 100 mL of saturated sodium bicarbonate solution and extracted with 3x50 mL of dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:4). This afforded the title compound (1.0 g, 49%) as a yellow oil. MS: (ES, *m/z*): 149 $[M+H]^+$.

Intermediate 28: 2-(3-isopropoxyphenyl)acetaldehyde

[0333]



Step 1. **Synthesis of propan-2-yl 2-[3-(propan-2-yloxy)phenyl]acetate.**

[0334] Into a 250-mL round-bottom flask, 2-(3-hydroxyphenyl)acetic acid (2 g, 13. 15mmol) was dissolved in N,N-dimethylformamide (50 mL). Then potassium carbonate (5.45 g,

39.43mmol) was added, followed by 2-iodopropane (6.71 g, 39.47mmol). The resulting solution was stirred for 5 h at 60°C. The reaction mixture was cooled to room temperature and diluted with 100 mL of water. The resulting solution was extracted with 3x100 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (1.7 g, crude) as a yellow oil. MS: (ES, *m/z*): 237 $[M+H]^+$.

Step 2. **Synthesis of 2-[3-(propan-2-yloxy)phenyl]ethan-1-ol.**


[0335] Into a 50-mL round-bottom flask, propan-2-yl 2-[3-(propan-2-yloxy)phenyl]acetate (1.5 g, 4.44mmol) was dissolved in tetrahydrofuran (10 mL). Then lithium aluminum hydride (362 mg, 9.54mmol) wa added in portions. The resulting solution was stirred for 2 h at room temperature. The reaction was then quenched by the addition of 20 mL of potassium sodium tartrate (aq) and extracted with 3x30 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (0.9 g, 75%) as a yellow oil. MS: (ES, m/z): 181 $[M+H]^+$.

Step 3. **Synthesis of 2-(3-isopropoxyphenyl)acetaldehyde.**

[0336] Into a 50-mL round-bottom flask, 2-[3-(propan-2-yloxy)phenyl]ethan-1-ol (150 mg, 0.83mmol) was dissolved in chloroform (10 mL). Then Dess-Martin periodinane (530 mg, 1.25mmol) was added. The resulting solution was stirred for 2 h at room temperature. The solids were filtered out and the filtrate was diluted with 30 mL of sodium bicarbonate(aq). The resulting solution was extracted with 3x30 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (75 mg, 48%) as a yellow oil. MS: (ES, m/z): 179 $[M+H]^+$.

Intermediate 29: 3-aminocyclohexane-1-carbonitrile hydrochloride

[0337]



Step 1. **Synthesis of tert-butyl N-(3-cyanocyclohexyl)carbamate.**


[0338] Into a 50-mL round-bottom flask, tert-butyl N-(3-carbamoylcyclohexyl)carbamate (2.0 g, 8.25 mmol) was dissolved in dichloromethane (20 mL). Then trifluoroacetic anhydride (3.8 g, 18.09 mmol) and triethylamine (1.8 g, 17.79 mmol) were added. The resulting solution was stirred for 3 h at -10°C in an ice/salt bath. The resulting mixture was washed with 3x20 mL of water. The organic layer was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (1.27 g, 69%) as a white solid. MS: (ES, *m/z*): 225 $[M+H]^+$.

Step 2. **Synthesis of 3-aminocyclohexane-1-carbonitrile hydrochloride.**

[0339] Into a 50-mL round-bottom flask, tert-butyl N-3-cyanocyclohexyl carbamate (500 mg, 2.01 mmol) was dissolved in 1, 4-dioxane. Then 4 N hydrochloric acid (2 mL) was added. The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was washed with 3x10 mL of petroleum ether. The solids were collected by filtration. This afforded the title compound (258 mg, 70%) as a white solid. MS: (ES, *m/z*): 125 $[M+H]^+$.

Intermediate 30: (3R,6S)-6-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-3-amine

[0340]



Step 1. **Synthesis of [(2R,3S)-3-(acetyloxy)-3,6-dihydro-2H-pyran-2-yl]methyl acetate.**

[0341] Into a 2-L 3-necked round-bottom flask, [(2R,3S,4R)-3,4-bis(acetyloxy)-3,4-dihydro-2H-pyran-2-yl]methyl acetate (100 g, 367.31 mmol) was dissolved in dichloromethane (500 mL). Then triethylsilane (43 g, 369.81 mmol) and $BF_3 \cdot Et_2O$ (68 g, 479.12 mmol) were added. The resulting solution was stirred for 2 h at room temperature. The reaction was then quenched by the addition of 100 mL of sodium bicarbonate. The mixture was washed with water (3x200 mL) and brine (200 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:3). This afforded the title compound (72 g, 92%) as a yellow oil. MS: (ES, *m/z*): 215 $[M+H]^+$.

Step 2. **Synthesis of (2R,3S)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-ol.**

[0342] Into a 1-L round-bottom flask, [(2R,3S)-3-(acetyloxy)-3,6-dihydro-2H-pyran-2-yl]methyl acetate (36 g, 168.06 mmol) was dissolved in methanol (200 mL). Then t-BuOK (1.3 g, 11.59 mmol) was added. The resulting solution was stirred for 1 h at room temperature. Then the mixture was neutralized by Dowex (H+ Form). The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with dichloromethane/methanol (10:1). This afforded the title compound (19 g, 87%) as a yellow oil. MS: (ES, *m/z*): 131 $[M+H]^+$.

Step 3. **Synthesis of (2R,3S)-2-[[(tert-butyldimethylsilyl)oxy]methyl]-3,6-dihydro-2H-pyran-3-ol.**

[0343] Into a 1000-mL 3-necked round-bottom flask, (2R,3S)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-ol (19 g, 145.99 mmol) was dissolved in pyridine (200 mL). Then TBSCl (21.9 g, 145.30 mmol) was added. The resulting solution was stirred for 12 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:10). This afforded the title compound (28.4 g, 80%) as a light yellow oil. MS: (ES, *m/z*): 245 $[M+H]^+$.

Step 4. **Synthesis of (2R,3S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3,6-dihydro-2H-pyran-3-yl 2,2,2-trichloroacetimidate.**

[0344] Into a 1000-mL 3-necked round-bottom flask, (2R,3S)-2-[[(tert-butyldimethylsilyl)oxy]methyl]-3,6-dihydro-2H-pyran-3-ol (33 g, 135.02 mmol) was dissolved in dichloromethane (500 mL). Then DBU (26.7 g, 175.38 mmol) and Cl3CCN (25.2 g, 175.38

mmol) were added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:10). This afforded the title compound (42 g, 80%) as a yellow oil. MS: (ES, *m/z*): 388, 390, 392 $[M+H]^+$.

Step 5. **Synthesis of N-[(3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]-3,6-dihydro-2H-pyran-3-yl]-2,2,2-trichloroacetamide.**

[0345] Into a 1-L round-bottom flask, (2R,3S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3,6-dihydro-2H-pyran-3-yl 2,2,2-trichloroacetimidate (42 g, 108.03 mmol) was dissolved in 1,2-dichlorobenzene (300 mL). Then potassium carbonate (1.5 g, 10.85 mmol) was added. The resulting solution was stirred for 5 h at 180°C. The resulting mixture was cooled to room temperature and the solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (36 g, 86%) as a white solid. MS: (ES, *m/z*): 388, 390, 392 $[M+H]^+$,

Step 6. **Synthesis of (3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]-3,6-dihydro-2H-pyran-3-amine.**


[0346] Into a 100-mL round-bottom flask, N-[(3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]-3,6-dihydro-2H-pyran-3-yl]-2,2,2-trichloroacetamide (2.0 g, 5.14 mmol) was dissolved in i-propanol (10 mL). Then potassium hydroxide (868 mg, 15.47 mmol) was added. The resulting solution was stirred for 12 h at room temperature. The solids were filtered out. The residue was subjected to purification by FCC eluting with dichloromethane/methanol (10:1). This afforded the title compound (1 g, 80%) as a yellow oil. MS: (ES, *m/z*): 244 $[M+H]^+$.

Step 7. **Synthesis of (3R,6S)-6-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-3-amine.**

[0347] Into a 100-mL round-bottom flask, (3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]-3,6-dihydro-2H-pyran-3-amine (1 g, 4.11 mmol) was dissolved in methanol (10 mL). Then palladium on carbon (10%, 100 mg) was added. Hydrogen (g) was charged into the reaction mixture and the resulting mixture was stirred for 12 h at room temperature under hydrogen atmosphere. The reaction was vented to nitrogen and the solids were filtered out over celite. The filtered solution was concentrated under a vacuum and the residue was subjected to purification by FCC eluting with dichloromethane/methanol (10:1). This afforded the title compound (850 mg, 84%) as a yellow oil. MS: (ES, *m/z*): 246 $[M+H]^+$.

Intermediate 31: 1-thia-6-azaspiro[3.3]heptane 1,1-dioxide hydrochloride

[0348]



***Step 1*. Synthesis of tert-butyl 3-(2-oxoethylidene)azetidine-1-carboxylate.**

[0349] Into a 250-mL round-bottom flask, tert-butyl 3-oxoazetidine-1-carboxylate (11 g, 63.61 mmol) was dissolved in dichloromethane (150 mL). Then 2-(triphenyl-lambda5-phosphanylidene)acetaldehyde (24 g, 78.08 mmol) was added. The resulting solution was stirred for 6 h at 40°C. The reaction mixture was cooled to room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (11 g, 79%) as a yellow oil. MS: (ES, *m/z*): 198 $[M+H]^+$.

***Step 2*. Synthesis oftert-butyl 3-(acetylthio)-3-(2-oxoethyl)azetidine-1-carboxylate.**

[0350] Into a 250-mL round-bottom flask, tert-butyl 3-(2-oxoethylidene)azetidine-1-carboxylate (11 g, 55.77 mmol) was dissolved in tetrahydrofuran (100 mL). Then piperidine (0.39 mL, 3.90 mmol) and ethanethioic S-acid (6 mL, 83.65 mmol) were added. The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (11 g, 63%) of as a yellow oil. MS: (ES, *m/z*): 274

$[M+H]^+$.

Step 3. **Synthesis of tert-butyl 3-(2-hydroxyethyl)-3-sulfanylazetidine-1-carboxylate.**

[0351] Into a 500-mL 3-necked round-bottom flask, tert-butyl 3-(acetylsulfanyl)-3-(2-oxoethyl)azetidine-1-carboxylate (18 g, 65.85 mmol) was dissolved in ether (100 mL). Then $LiAlH_4$ (2.9 g, 76.41 mmol) was added. The resulting solution was stirred for 1 h at room temperature. The reaction was then quenched by the addition of 100 mL of sodium bicarbonate (sat.). The resulting solution was extracted with 3x100 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. This afforded the title compound (9 g, 59%) as a brown oil. MS: (ES, *m/z*): 234 $[M+H]^+$.

Step 4. **Synthesis of tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate.**

[0352] Into a 100-mL 3-necked round-bottom flask, tert-butyl 3-(2-hydroxyethyl)-3-sulfanylazetidine-1-carboxylate (500 mg, 2.14 mmol) was dissolved in toluene (4 mL). Then diethyl triphenylphosphonite (1 g, 2.84 mmol) was added. The resulting solution was stirred for 12 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:5). This afforded the title compound (250 mg, 49%) as a light yellow oil. MS: (ES, *m/z*): 216 $[M+H]^+$.

Step 5. **Synthesis of tert-butyl 1 -thia-6-azaspiro[3.3]heptane-6-carboxylate 1,1-dioxide.**

[0353] Into a 100-mL round-bottom flask, tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate (250 mg, 1.16 mmol) was dissolved in dichloromethane (10 mL). Then m-CPBA (400 mg, 2.32 mmol) was added. The resulting solution was stirred for 4 h at room temperature. The reaction was then quenched by the addition of 20 mL of sodium bicarbonate (sat.). The resulting solution was extracted with 3x100 mL of dichloromethane. Then the organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (200 mg, 70%) as a white solid. MS: (ES, *m/z*): 248 $[M+H]^+$.


Step 6. **Synthesis of 1-thia-6-azaspiro[3.3]heptane 1,1-dioxide hydrochloride.**

[0354] Into a 50-mL round-bottom flask, **tert-butyl 1** -thia-6-azaspiro[3.3]heptane-6-**carboxylate 1,1-dioxide** (50 mg, 0.20 mmol) was dissolved in HCl (1 M in dioxane) (2 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was

concentrated under vacuum. This afforded the title compound (20 mg, crude) as a white solid. MS: (ES, *m/z*): 148 $[M+H]^+$.

Intermediate 32: methyl 4-oxo-2-phenylbutanoate

[0355]



Step 1. **Synthesis of methyl 4,4-diethoxy-2-phenylbutanoate.**










[0356] Into a 500-mL 3-necked round-bottom flask, methyl 2-phenylacetate (15 g, 99.88 mmol) was dissolved in N,N-dimethylformamide (150 mL). Then KHMDS (527.56 mmol in 120 mL DMF) and 2-bromo-1,1-diethoxyethane (23.7 g, 120.26 mmol) were added. The resulting solution was stirred for 30 min at 45°C. The resulting mixture was cooled to room temperature and quenched by the addition of 300 mL of NH_4Cl (aq.). The resulting solution was extracted with 3x300 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:10). This afforded the title compound (19.25 g, 72%) as a yellow oil. MS: (ES, *m/z*): 267 $[M+H]^+$.


Step 2. **Synthesis of methyl 4-oxo-2-phenylbutanoate.**

[0357] Into a 500-mL 3-necked round-bottom flask, methyl 4,4-diethoxy-2-phenylbutanoate (19.25 g, 72.28 mmol) was dissolved in chloroform (20 mL). Then water (10 mL) and trifluoroacetic acid (96 mL, 1.29 mol) were added. The resulting solution was stirred for 2 h at room temperature. The reaction was then quenched by the addition of 100 mL of potassium carbonate. The resulting solution was extracted with 3x100 mL of dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. This afforded the title compound (12.5 g, 90%) as a yellow oil. MS: (ES, *m/z*): 193 $[M+H]^+$.

[0358] The following intermediates in **TABLE B** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Intermediate 32.


TABLE B

Intermediate Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
33	 methyl2-(3-fluorophenyl)-4-oxobutanoate	211
34	 methyl2-(4-fluorophenyl)-4-oxobutanoate	211
35	 methyl2-(3-chlorophenyl)-4-oxobutanoate	226
36	 methyl2-(4-chlorophenyl)-4-oxobutanoate	226
37	 methyl2-(2,3-difluorophenyl)-4-oxobutaneate	228
38	 methyl 4-oxo-2-m-tolyl)butanoate	207
39	 methyl 4-oxo-2-(p-tolyl)butanoate	207
40	 methyl 2-(3-fluoro-4-methoxyphenyl)-4-oxobutanoate	241
41	 methyl 2-(3-fluoro-4-methylphenyl)-4-	225

Intermediate Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	oxobutanoate	
42	 methyl 2-(3-chloro-4-methylphenyl)-4-oxobutanoate	240

Intermediate 43: tert-butyl ((trans)-4-(methylsulfonyl)cyclohexyl)carbamate

[0359]



***Step 1*. Synthesis of cis-4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate.**

[0360] A solution of cis-tert-butyl(4-hydroxycyclohexyl)carbamate (5.0 g, 23.22 mmol) and triethylamine (6.47 ml, 46.4 mmol) in dichloromethane (50 ml) was cooled to 0 °C. Mesyl chloride (2.71 ml, 34.8 mmol) was slowly added. The reaction mixture was allowed to stir at 0°C for 20 minutes. The reaction was then quenched with water (20 mL). The layers were allowed to separate and the organic layer was collected. The aqueous layer was washed with additional dichloromethane (2 x 5 mL). The organic layers were combined and washed with saturated ammonium chloride (10 mL), saturated sodium bicarbonate (10 mL) and brine (10 mL). The organic layer was then dried over sodium sulfate, filtered and concentrated to afford the title compound as a off-white solid. MS: (ES, *m/z*): 293 $[M+H]^+$.

***Step 2*. Synthesis of trans-4-((tert-butoxycarbonyl)amino)cyclohexyl) ethanethioate.**

[0361] thioacetic acid (2.57 ml, 35.8 mmol) was added to a stirred suspension of potassium tert-butoxide (4.02 g, 35.8 mmol) in DMF (50 mL) at 0 °C. The mixture was stirred for 5 mins and then a solution of cis-4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate (7.0 g, 23.86 mmol) in DMF (22.6 mL) was added. The mixture was heated to 80 °C for 4 hours and was then poured into a mixture of ethyl acetate (200 mL) and water (200 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (x2). The combined organic extracts were washed with 10% aqueous citric acid solution (200 mL), saturated sodium hydrogen carbonate solution (200 mL), and brine (200 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The crude product was subjected to purification by FCC (Biotage SNAP 340g; eluting with 10 - 30% EtOAc in hexanes) affording the title compound as a light orange solid. MS: (ES, *m/z*): 273 $[M+H]^+$.

Step 3. **Synthesis of tert-butyl-trans-4-(methylthio)cyclohexyl)carbamate.**

[0362] A stirred solution of trans-4-((tert-butoxycarbonyl)amino)cyclohexyl) ethanethioate (2.0g, 7.32 mmol) in MeOH (48 ml) was treated with sodium methoxide (1.04 g, 19.25 mmol) followed by iodomethane (0.449 ml, 7.22 mmol). The mixture was stirred at ambient temperature for 3 hours then diluted with ethyl acetate (200 mL) and water (200 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (100 mL x2). The combined organic extracts were washed with 10% aqueous citric acid solution (200 mL), saturated sodium hydrogen carbonate solution (200 mL), and brine (200 mL), dried over sodium sulphate, filtered and concentrated under vacuum to give crude product. The crude product was subjected to purification by FCC (Biotage SNAP 100g; eluting with 10 - 30% EtOAc in hexanes) affording the title compound as a white solid. MS: (ES, *m/z*): 246 $[M+H]^+$.

Step 4. **Synthesis of tert-butyl ((trans)-4-(methylsulfonyl)cyclohexyl)carbamate**


[0363] A solution of tert-butyl-trans-4-(methylthio)cyclohexyl)carbamate (1.0 g, 4.08 mmol) in MeOH (14 ml) was cooled to 0 °C and treated with a suspension of oxone (2.505 g, 4.08 mmol) in water (6 ml). The mixture was stirred at ambient temperature for 1 hour, then diluted with ethyl acetate (100 mL) and water (100 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (100 mL x 2). The combined organic extracts were washed with 10% aqueous citric acid solution (100 mL), saturated sodium hydrogen carbonate solution (100 mL), and brine (100 mL), dried over sodium sulphate, filtered and concentrated under vacuum to afford the crude product. The crude product was subjected to purification by FCC (Biotage SNAP 100g; eluting with 40 - 60% EtOAc in hexanes) affording the title compound as a white solid. MS: (ES, *m/z*): 278 $[M+H]^+$.

The disclosure is further illustrated by the following examples and synthesis schemes, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures

herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
The synthetic schemes are presented for the synthesis of certain compounds herein disclosed. The process and results for the assays testing BET family bromodomain inhibition and effects on a cancer cell line proliferation are also described.

Examples 1 and 2: methyl (S)-3,7-dimethyl-2-((R)-2-phenylpropyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-3,7-dimethyl-2-((S)-2-phenylpropyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f] quinoline-6-carboxylate

[0364]



Step 1. **methyl (2S)-6-bromo-2-methyl-5-(3-phenylbutanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0365] Into a 100-mL round-bottom flask, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate 1**) was dissolved in dichloromethane (8 mL). Then pyridine (132 mg, 1.67 mmol) was added, followed by the addition of a solution of 3-phenylbutanoyl chloride (73 mg, 0.40 mmol, **Intermediate 2**) in dichloromethane (2 mL) dropwise with stirring. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1/10-1/1). This

afforded the title compound (50 mg, 34%) as a white solid. MS: (ES, *m/z):* 445 $[M+H]^+$.

Step 2. **Methyl (2S)-6-amino-2-methyl-5-(3-phenylbutanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0366] Into a 8-mL vial, was placed a solution of methyl (2S)-6-bromo-2-methyl-5-(3-phenylbutanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate (50 mg, 0.11 mmol) in dimethylsulfoxide (2 mL). Next, cuprous iodide (20 mg, 0.11 mmol), L-proline (30 mg, 0.26 mmol) and sodium hydroxide (25 mg, 0.63 mmol) were added. The mixture was stirred for 1 minute before addition of ammonium hydroxide (2 mL, 28%, 51.36 mmol). The resulting solution was stirred for 2 h at 50°C. The resulting solution was cooled to room temperature and diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (30 mg, 70%) as colorless oil. MS: (ES, *m/z*): 382 $[M+H]^+$.

Step 3. **methyl (7S)-7-methyl-2-(2-phenylpropyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0367] Into a 50-mL round-bottom flask, methyl (2S)-6-amino-2-methyl-5-(3-phenylbutanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate (30 mg, 0.08 mmol) was dissolved in dimethylsulfoxide (2 mL). Next, acetic acid (2 mL) and 3 drops of sulfuric acid were added. The resulting solution was stirred for 12 h at 60°C. The resulting solution was cooled to room temperature and diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (25 mg, 87%) as colorless oil. MS: (ES, *m/z):* 364 $[M+H]^+$.

Step 4. **methyl (S)-3,7-dimethyl-2-((R)-2-phenylpropyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-3,7-dimethyl-2-((S)-2-phenylpropyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f] quinoline-6-carboxylate**

[0368] Into a 50-mL round-bottom flask, methyl (7S)-7-methyl-2-(2-phenylpropyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (45 mg, 0.12 mmol) was dissolved in tetrahydrofuran (5 mL). Then sodium hydride (12 mg, 0.25 mmol, 60%) was added, followed by the addition of iodomethane (35 mg, 0.25 mmol) dropwise with stirring. The resulting solution was stirred for 2 h at room temperature. The reaction was then quenched by the addition of 10 mL of water and concentrated. The crude product was purified by Flash-Prep-HPLC with the following conditions (IntelFlash-1): Column, C18 silica gel; mobile phase:


A: MeCN and B: water (containing 0.05% TFA) from 5% increasing to 40% within 30 min; UV Detector: 254 nm. The crude product was purified by Chiral-Prep-HPLC with the following conditions: Column, CHIRAL ART Cellulose-SB, 250x20mmI.D. ; mobile phase, A: hexanes and B: ethanol (hold 15.0% ethanol in 15 min); UV Detector: 254 nm. This afforded the title compounds as follows: 2.5 mg (5%) of methyl (7S)-3,7-dimethyl-2-[(2R)-2-phenylpropyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer) as a yellow oil and 3.5 mg (7%) of methyl (7S)-3,7-dimethyl-2-[(2S)-2-phenylpropyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer) as a yellow oil


First eluting isomer: ^{1}H-NMR ($CDCl_3$, 400 MHz) δ (ppm): 7.48-7.40(m, 1H), 7.27-7.13(m, 5H), 7.01(d, J=8.8 Hz, 1H), 4.81-4.77(m, 1H), 3.78(s, 3H), 3.40-3.35(m, 1H), 3.30-3.22(m, 5H), 3.06-3.00(m, 2H), 2.31-2.22(m. 1H), 1.76-1.68(m, 1H), 1.44(d, J=6.8 Hz, 3H), 1.17(d, J=6.8 Hz, 3H). MS: (ES, m/z): 378 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR ($CDCl_3$, 400 MHz) δ (ppm): 7.48-7.40(m, 1H), 7.27-7.17(m, 5H), 7.03(d, J=8.8 Hz, 1H), 4.81-4.77(m, 1H), 3.77(s, 3H), 3.41-3.38(m, 1H), 3.32-2.99 (m, 7H), 2.30-2.21(m. 1H), 1.75-1.71(m, 1H), 1.41(d, J=6.8 Hz, 3H), 1.17(d, J=6.4 Hz, 3H). MS: (ES, m/z): 378 $[M+H]^+$.

[0369] The following examples in **TABLE** 1 were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 1 and 2.


TABLE 1

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
3 and 4	 1st eluting isomer (3)	1st eluting isomer = 378	1st eluting isomer ^{1}H-NMR($CDCl_3$, 300 MHz) δ (*ppm*):
			7.43-7.41(m, 1H), 7.22-7.19(m, 3H), 7.09-7.06(m, 3H), 4.81-4.79(m, 1H), 3.82(s, 3H), 3.35-3.28(m, 6H), 3.08-3.01(m, 2H), 2.31-2.28(m, 1H), 1.75-1.45(m, 4H), 1.17(d, J=6.6Hz, 3H)
	2nd eluting isomer (4) methyl (7S)-3,7-dimethyl-2-(1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	2nd eluting isomer = 378	2nd eluting isomer ^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*):
			7.43-7.41(m, 1H), 7.23-7.21(m, 3H), 7.15-7.05(m, 3H), 4.81-4.78(m, 1H), 3.79(s, 3H), 3.44-3.29(m, 6H), 3.08-3.03(m, 2H), 2.31-2.28(m, 1H), 1.75-1.46(m, 4H), 1.20(d, J=6.6Hz, 3H)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
5 and 6	 1st eluting isomer (5)	1st eluting isomer = 364	1st eluting isomer ^{1}H-NMR($CDCl_3$, 400 MHz) δ (*ppm*):
			7.58-7.52(m, 1H), 7.34-7.30(m, 3H), 7.25-7.23(m, 2H), 7.10-7.05(m, 1H), 4.82-4.76(m, 1H), 4.56-4.51(m, 1H), 3.78(s, 3H), 3.48(s, 3H), 3.39-3.31(m, 1H), 3.09-3.35(m, 1H), 2.31-2.22(m, 1H), 1.91-1.89(m, 3H), 1.77-1.72(m, 1H), 1.25-1.16(m, 3H)
		2nd eluting isomer = 3 64	2nd eluting isomer ^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*):
	2nd eluting isomer (6)		7.45-7.40(m, 1H), 7.29-7.28(m, 2H), 7.22-7.17(m, 3H), 7.06(d, J=8.8Hz, 1H), 4.80-4.75(m, 1H), 4.40-4.37(m, 1H), 3.77(s, 3H), 3.43-4.31(m, 4H), 3.05-2.98(m, 1H), 2.34-2.26(m, 1H), 1.87-1.85(m, 3H), 1.72-1.67(m, 1H), 1.25-1.16(m, 3H)
	methyl (7S)-3,7-dimethyl-2-(1-phenylethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		

Example 7: methyl (S)-7-methyl-2-phenethyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0370]



Step 1. **Synthesis of methyl-(2S)-6-bromo-2-methyl-5-(3-phenylpropanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0371] Into a 50-mL round-bottom flask, methyl-(2S)-5,6-diamino-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.43 mmol, **Intermediate 1**) was dissolved in dichloromethane (10 mL). Pyridine (1 mL) was added, followed by 3-phenylpropanoyl chloride (169 mg, 1.00 mmol). The resulting solution was stirred for 12 h at 40 °C. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (100 mg, 55%) as a yellow solid. MS: (ES, m/z): 431,433 $[M+H]^+$.

Step 2. **Synthesis of methyl-(2S)-6-amino-2-methyl-5-(3-phenylpropanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0372] Into a 8-mL sealed tube, methyl-(2S)-6-bromo-2-methyl-5-(3-phenylpropanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate (20 mg, 0.05 mmol) was dissolved in dimethyl sulfoxide (2 mL). Then ammonium hydroxide (1 mL, 28%, 25.68 mmol), copper iodide (4 mg, 0.02 mmol), L-proline (3 mg, 0.03 mmol) and sodium hydroxide (12 mg, 0.3 mmol) were added successively. The resulting solution was stirred for 12 h at 40 °C. The resulting solution was diluted with 20 mL of water and extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting mixture was concentrated under vacuum. This afforded the title compound (10 mg, crude) as colorless oil. MS: (ES, *m/z):* 368 $[M+H]^+$.

Step 3. **Synthesis of methyl-(7S)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**





[0373] Into a 8-mL sealed tube, methyl-(2S)-6-amino-2-methyl-5-(3-phenylpropanamido)-1,2,3,4-tetrahydroquinoline-1-carboxylate (10 mg, 0.03 mmol) was dissolved in dimethyl sulfoxide (2 mL). Then acetic acid (1 mL) and sulfuric acid (0.1 mL) were added. The resulting solution was stirred for 12 h at 60°C. The resulting mixture was cooled to room temperature and diluted with water (10 mL). The resulting solution was extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified with the following condtions: Column: XBridge Prep C18 OBD Column, 5μm, 19x150mm; Mobile Phase, A: water (containing 0.05%TFA) and B: ACN(5% B to 56% ACN over 7 min); UV Detector: 254 nm. This afforded the title compound (2.8 mg, 29%) as a brown oil.





^{1}H-NMR ($CDCl_3$, 400 MHz) δ*(ppm)*: 7.70-7.68(m, 1H), 7.38-7.31(m, 1H), 7.29-7.20(m, 1H),

6.99-6.95(m, 4H), 4.80-4.78(m, 1H), 3.79(s, 3H), 3.23(br, 2H), 2.99-2.68(m, 4H), 2.12-2.04(m, 1H), 1.82-1.72(m, 1H), 1.08(d, J=6.4Hz, 3H). MS: (ES, *m/z*): 350 $[M+H]^+$.

[0374] The following examples in **TABLE** 2 were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 7.

TABLE 2


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
8	 methyl (S)-2-(3-fluoro4-methoxyphenethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	398	^{1}H-NMR(CD_3OD, 400 MHz) δ (*ppm*): 7.36(d, J=8.8Hz, 1H), 7.30-7.29(m, 1H), 6.99-6.91(m, 3H), 4.79-4.73(m, 1H), 3.83(s, 3H), 3.78(s, 3H), 3.17-3.06(m, 5H), 2.87-2.83(m, 1H), 2.28-2.21(m, 1H), 1.78-1.70(m, 1H), 1.15-1.13(m, 3H)
9	 methyl (S)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	336	^{1}H-NMR: ($CDCl_3$, 400 MHz) δ (*ppm*): 7.40-7.26(m,7H), 4.81-4.77(m, 1H), 4.29(s, 2H), 3.79(s, 3H), 3.13-3.05(m, 1H), 2.91-2.89(m, 1H), 2.28-2.19(m, 1H), 1.75-1.69(m, 1H), 1.14(d, J=6.8Hz, 3H)
10	 methyl(S)-3,7-dimethyl-2-phenethyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	364	^{1}H-NMR: ($CDCl_3$, 300 MHz) δ (*ppm*): 7.48(d, J=9.0Hz, 1H), 7.33-7.19(m, 5H), 7.08(d, J=9.0 Hz, 1H), 4.84-4.78(m, 1H), 3.81(s, 3H), 3.49(s, 3H), 3.35-3.14(m, 5H), 3.08-2.99(m, 1H), 2.31-2.24(m, 1H), 1.79-1.63(m, 1H), 1.16-1.13(m, 3H)
11		354	^{1}H-NMR: ($CDCl_3$, 400 MHz) δ (*ppm*): 7.84(d, J=9.2Hz, 1H), 7.50(s, 1H), 7.29-726(m, 1H), 7.20-7.17(m, 1H), 6.15(s, 1H), 4.84-4.77(m, 3H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl (S)-2-(2-(1H-pyrazol-1-yl)etliyl)-3,7-dimethyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		3.85-3.72(m, 5H), 3.49(s, 3H),3.19-3.05(m, 2H), 2.22-2.13 (m, 1H), 1.87-1.82(m, 1H), 1.13(d, J=6.8 Hz, 3H)
12	 methyl(S)-7-methyl-2-(2-(pyridin-2-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	351	^{1}H-NMR($CDCl_3$, 300 MHz) δ (*ppm*): 8.63-8.62(m, 1H), 7.70-7.67(m, 1H), 7.41-7.21(m, 4H), 4.84-4.78(m, 1H), 3.77(s, 3H),3.44-3.40(m, 2H), 3.33-3.29(m, 2H), 3.14-3.08(m, 1H), 2.97-2.88(m, 1H), 2.29-2.21(m, 1H), 1.79-1.70(m, 1H), 1.40(d, J=6.9 Hz, 3H)
13	 methyl (S)-3,7-dimethyl-2-(2-(pyridin-3-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	365	^{1}H-NMR: ($CDCl_3$, 400 MHz) δ (*ppm*): 8.52-8.47(m, 2H), 7.52-7.45 (m, 2H), 7.21-7.18(m, 1H), 7.08-7.06(m, 1H), 4.81-4.76(m, 1H), 3.78(s, 3H), 3.55(s, 3H), 3.29-3.17(m, 5H), 3.03-2.96(m, 1H), 2.31-2.22(m, 1H), 1.75-1.61(m, 1H), 1.15-1.12(m, 3H)
14	 methyl (S)-3,7-dimethyl-2-(2-(pyridin-4-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	365	^{1}H-NMR: ($CDCl_3$, 400MHz) δ (*ppm*): 8.72(s, 2H), 7.93(d, 1=9.2 Hz, 1H), 7.804(s, 2H), 7.30(d, J=9.2Hz, 1H), 4.86-4.82(m, 1H), 3.89(s, 3H), 3.82(s, 3H), 3.78-3.68(m, 2H), 3.47(s, 2H), 3.18-3.06(m,2H), 2.24-2.17(m, 1H), 1.88-1.85(m, 1H), 1.14(d, J=6.4 Hz, 3H)
15		381	^{1}H-NMR: ($CDCl_3$, 300 MHz) δ (*ppm*): 7.92(d, J=9.0Hz, 1H), 7.71-7.69(m, 1H), 7.48-7.42(m, 1H), 7.32(d, J=9.0 Hz, 1H), 6.63(d, J=9.0 Hz,

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl(S)-3,7-dimethyl-2-(2-(2-oxopyridin-l(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		1H), 6.33-6.31(m, 1H), 4.89-4.84(m, 1H), 4.53-4.48(m, 2H), 4.08(s, 3H), 3.84-3.78(m, 5H), 3.19-3.12(m, 2H), 2.25-2.18(m, 1H), 1.91-1.85(m, 1H), 1.19-1.15(m, 3H)

Example 16: (1R,3R)-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid

[0375]



Step 1. **methyl (S)-5-amino-6-(((1R,3R)-3-(methoxycarbonyl)cyclohexyl)amino)-2-methyl-3,4-dihydroquinoline-l(2H)-carboxylate**

[0376] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (1R,3R)-3-aminocyclohexane-1-carboxylate hydrochloride (130 mg, 0.67 mmol) was dissolved in dioxane (4 mL). Then methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate 1),** Brettphos (72 mg, 0.13 mmol), 3rd Generation Brettphos precatalyst (61 mg, 0.07 mmol) and sodium tert-butoxide (97 mg, 1.01 mmol) were added. The resulting solution was stirred for 1 h at 100°C

under nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (41.3 mg, 33%) as a dark green solid. MS: (ES, *m/z*): 376 $[M+H]^+$.

Step 2. **methyl (S)-2-benzyl-3-((IR,3R)-3-(methoxycarbonyl)cyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate**

[0377] Into a 25-mL round-bottom flask, methyl **methyl (S)-5-amino-6-(((1R,3R)-3-(methoxycarbonyl)cyclohexyl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate** (165.4 mg, 0.44 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (158.8 mg, 1.32 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (122.9 mg, 59%) as a yellow solid. MS: (ES, m/z): 476 $[M+H]^+$.





Step 3. **(1R,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid.**





[0378] Into a 25-mL round-bottom flask, methyl **methyl (S)-2-benzyl-3-((1R,3R)-3-(methoxycarbonyl)cyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate** (30 mg, 0.06 mmol) was dissolved in tetrahydrofuran (0.5 mL). Then water (0.5 mL) was added, followed by lithium hydroxide (7.0 mg, 0.29 mmol). The resulting solution was stirred for 3 h at 85°C. The pH value of the solution was adjusted to 5~6 with hydrochloric acid (1 mol/L). The resulting solution was extracted with ethyl acetate (3x20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 μm, 19 mm X 250 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (10.0% to 30.0% ACN over 10 min); UV Detector: 254nm. This afforded the title compound (15.2 mg, 52%) as a white solid.





^1H NMR (CD_3OD, 400 MHz) δ (ppm): 7.47 (d, J = 9.0 Hz, 1H), 7.39 (d, J = 8.9 Hz, 1H), 7.35-7.19 (m, 5H), 4.84-4.68 (m, 2H), 4.45-4.25 (m, 2H), 3.79 (s, 3H), 3.22-3.14 (m, 1H), 2.98-2.85 (m, 2H), 2.40-2.02 (m, 5H), 1.83-1.70 (m, 1H), 1.64-1.54 (m, 2H), 1.33-1.13 (m, 5H). MS: (ES, *m/z*): 462 $[M+H]^+$.





[0379] The following examples in **TABLE 3** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 16.




TABLE 3





Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
17	 (1S,3S)-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	462	^{1}H-NMR (CD_3OD, 400MHz)δ(*ppm*): 7.47 (d, J = 9.0 Hz, 1H), 7.39 (d, J=8.9 Hz, 1H), 7.35-7.19 (m, 5H), 4.84-4.68(m, 2H), 4.45-4.25 (m, 2H), 3.79 (s, 3H), 3.22-3.14(m, 1H), 2.98-2.85 (m, 2H), 2.40-2.02 (m, 5H), 1.83-1.70(m, 1H), 1.64-1.54 (m, 2H), 1.33-1.13 (m,5H)
18	 (1S,3R)-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	462	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.51-7.20 (m, 7H), 4.82-0.74 (m, 1H), 4.43 (s, 2H), 4.38-4.24 (m, 1H), 3.79 (s, 3H), 3.28-3.20 (m, 1H), 3.02-2.94 (m, 1H), 2.37-1.95 (m,5H), 1.94-1.67 (m, 3H), 1.50-1.28 (m, 3H), 1.17 (d, J = 6.7 Hz, 3H)
19	 (1R,3S)-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	462	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.51-7.20 (m, 7H), 4.82-0.74 (m, 1H), 4.43 (s, 2H), 4.38-4.25 (m, 1H), 3.79 (s, 3H), 3.28-3.18 (m, 1H), 3.02-2.92 (m, 1H), 2.38-1.95 (m,5H), 1.93-1.70 (m, 3H), 1.50-1.28 (m, 3H), 1.17 (d, J = 6.6 Hz, 3H)
20		434	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.51-7.20 (m, 7H), 4.82-0.74 (m, 1H), 4.43 (s, 2H), 4.38-4.25 (m,




Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	cis-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclobutane-1-carboxylic acid		1H), 3.79 (s, 3H), 3.28-3.18 (m, 1H), 3.02-2.92 (m, 1H), 2.38-1.95 (m,5H), 1.93-1.70 (m, 3H), 1.50-1.28 (m, 3H), 1.17 (d, *J* = 6.6 Hz, 3H)
21	 trans-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclobutane-1-carboxylic acid	434	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.89 (d, J = 9.0 Hz, 1H), 7.46 (d, J=9.0 Hz, 1H), 7.39-7.12 (m, 5H), 4.98-0.94 (m, 1H), 4.82-4.73 (m, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.31-2.79 (m, 5H), 2.52-2.19 (m, 3H), 1.86-1.69(m, 1H), 1.17 (d, J = 6.6 Hz, 3H)
22	 cis-4-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo [4,5 -f]quinolin-3-yl)cyclohexane-1-carboxylic acid	462	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.34-7.22 (m, 7H), 4.77-4.73 (m, 1H), 4.39(s, 2H),4.264.21(m, 1H), 3.76(s, 3H), 3.30-3.17 (m, 1H), 2.97-2.93 (m, 1H), 2.60(s, 1H),2.43-2.16(m, 5H),1.78-1.72(s, 1H),1.51-128(m, 4H),1.13(d, J=6.4Hz, 3H)
23	 trans-4-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	462	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.49-7.22 (m, 7H), 4.78-0.72 (m, 1H), 4.42 (s, 2H), 4.25-4.15 (m, 1H), 3.79 (s, 3H), 3.23-3.12 (m, 1H), 2.98-2.91 (m, 1H),2.37-3.07(m,4H),2.04-1.96 (m, 2H), 1.78-1.70 (m, 1H), 1.58-1.35 (m, 4H), 1.16 (d, J=6.7 Hz, 3H)
24		474	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.62 (d, J = 9.2 Hz, 1H), 7.56-7.36





Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 (S)-4-(2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo [4,5 -f]quinolin-3 -yl)bicyclo[2.2.1]heptane-1-carboxylic acid		(m, 1H), 7.42-7.16 (m, 3H), 7.07-6.98(m, 2H), 4.82-4.78 (m, 1H), 4.58 (s, 2H), 3.80 (s, 3H), 3.25-3.15(m, 1H), 3.00-2.90 (m, 1H), 2.70-2.48 (m,4H), 2.20-2.10 (m, 1H), 2.09-1.98 (m, 2H), 1.92-1.70 (m, 5H), 1.17 (d, J=6.7 Hz, 3H)
25	 trans-4-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)4-methylcyclohexane-1-caiboxylic acid	476	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.32-7.27 (m, 3H), 7.24-7.19 (m, 4H), 4.74-0.71 (m, 1H), 4.36 (s, 2H), 4.30-4.15(m, 1H), 3.73(s, 3H), 3.23-3.08 (m, 1H), 3.01-2.84(m, 1H), 2.36-2.08 (m, 5H), 1.81- 1.64 (m, 1H), 1.39-1.28 (m, 2H), 1.16- 1.05 (m,8H)
26	 cis-4-((S)-2-benzyl-6-(methoaycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)4-methy lcyclohexane-1-carboxylic acid	476	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 737-730 (m, 2H), 7.28-7.17 (m, 5H), 4.77-0.71 (m, 1H), 437 (s, 2H), 4.20-4.16(m, 1H), 3.74(s, 3H), 3.19-3.14 (m, 1H), 2.99-2.91(m, 1H), 2.31-2.18 (m, 3H), 1.76-1.62(m,5H), 1.41-1.20 (m, 5H), 1.12 (d, J = 6.9 Hz, 3H)
27	 trans-4-((S)-2-(4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	492	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.42-7.35 (m, 2H), 7.18 (d, *J* = 8.7 Hz, 2H), 6.89 (d, *J* = 8.7 Hz, 2H), 4.79-4.75 (m, 1H), 4.324.21 (m, 3H), 3.76-3.75 (m, 6H), 3.24-3.21 (m, 1H), 3.00-2.92 (m, 1H), 2.38-2.02 (m, 6H), 1.78-1.71 (m, 1H), 1.55-1.37 (m, 4H), 1.14 (d, *J* = 6.9 Hz, 3H)
28		510	^{1}H-NMR (DMSO-d6, 400 MHz) δ

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 trans-4-((S)-2-(3-fluoro4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid		(*ppm*): 7.46 (s, 1H),7.27 (d, J=6.9Hz,1H), 7.14-7.11 (m, 2H), 7.08-7.02 (m, 1H),4.67-4.62 (m, 1H), 4.28 (s, 3H), 3.78 (s, 3H), 3.66 (s, 3H), 3 . 10-3 . 02(m, 1H), 2.87-2.81 (m, 1H), 2.36-2.33 (m, 1H), 2.15-2.08 (m, 3H),1.95-1.91(m, 2H), 1.67-1.62 (m, 1H), 1.49-1.37 (m, 4H), 1.07 (d, J = 6.8 Hz, 3H)
29	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	476	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.83-7.82(m, 2H), 7.34-7.26(m, 3H), 7.22-7.19(m, 2H), 4.86-4.85(m, 1H), 4.43-4.36(m, 1H), 3.82(s, 3H), 3.66-3.61(m, 2H), 3.25-3.21(m, 2H), 3.06-2.99(m, 2H), 2.57-2.54(m, 1H), 2.30-2 . 13(m, 5H), 1.96-1.91(m, 1H), 1.63-1.56(m, 4H), 1.16(d, J= 6.9 Hz, 3H)
30	 cis-4-((S)-2-benzyl-6-(methoaycaiboiryl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)-1-methylcyclohexane-1-carboxylic acid	476	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.32-7.27 (m, 3H), 7.24-7.19(m, 4H), 4.74-4.71 (m, 1H), 4.36 (s, 2H), 4.30-4.15(m, 1H), 3.73(s, 3H), 3.23-3.08 (m, 1H), 3.01-2.84(m, 1H), 2.36-2.08 (m, 5H), 1.81-1.64 (m, 1H), 1.39-1.28 (m, 2H), 1.16- 1.05(m, 8H)
31		466	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.55-7.46 (m, 3H), 7.40-7.37(d, *J* = 9 Hz, 1H), 6.24 (s, 1H), 4.80-

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	trans-4-((S)-2-(2-(1H-pyrazol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid		4.71(m, 1H), 4.69-4.64(m, 2H), 4.24-4.15 (m, 1H), 3.78(s, 3H), 3.55-3.51(m, 2H), 3.19-3.13 (m, 1H), 2.99-2.89(m, 1H), 2.51-2.44 (m, 1H), 2.29-2.13 (s, 5H), 1.80-1.60 (m, 5H), 1.15-1.13 (d, *J* = 6.6 Hz, 3H)
32	 trans-4-((S)-2-(2-(2H-1,2,3-triazol-2-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo [4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	467	^{1}H-NMR($CDCl_3$, 400 MHz) δ (*ppm*): 7.83-7.81(m, 1H), 7.63-7.62(m, 2H), 7.43-7.37(m, 1H), 5.11-5.08(m, 2H), 4.84-4.82(m, 1H), 4.18-3.99(m, 3H), 3.81(s, 3H), 3.15-3.13(m, 2H), 2.48-2.43(m, 1H), 221-2 . 18(m, 5H), 1.90-1.86(m, 1H), 1.71 -1.59 (m, 4H), 1.16(d, J= 5.1 Hz, 3H)
33	 trans-4-((S)-6-(methoxycarbonyl)-7-metlyl-2-(2-(2-methyloxazol-5-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	481	^{1}H-NMR (CD_3OD, 400MHz) δ (*ppm*): 7.51 (d, J=9.0 Hz, 1H), 7.39 (d, J=8.9 Hz, 1H), 6.72 (s, 1H), 4.77-4.72(m, 1H), 4.32-4.23 (m, 1H), 3.78 (s, 3H),3.33-3.30(m, 2H), 3.23-3.09(m, 3H), 2.92-2.84 (m, 1H), 2.51-2.16 (m,9H), 1.88-1.82 (m, 2H), 1.72-1.62 (m, 3H), 1.14 (d, J = 6.6 Hz, 3H)
34	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(1-methyl-1H-pyrazol-4-yl)etlyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	480	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.50-7.47 (d, J = 9.0 Hz, 1H), 7.42-7.36 (m, 2H), 7.27 (s, 1H), 4.80-4.74(m, 1H),4.29 4.21 (m, 1H), 3.79(s, 3H), 3.76 (s, 3H), 321-3 . 18(m, 3H), 2.99-2.96 (m, 3H), 2.48-2.16 (m,6H), 1.68-1.66 (m, 5H), 1.13-1.11 (d, J = 6.6 Hz, 3H)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
35	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(5-methyloxazol-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	481	^{1}H-NMR (DMSO-d6, 400 MHz) δ (*ppm*): 7.52-7.49 (d, J = 92 Hz, 1H), 7.27-7.25 (d, J = 92 Hz, 1H), 6.70 (s, 1H), 4.65-4.61(m, 1H),4.34 (s, 1H), 3.66(s, 3H), 3.37-3.17 (m, 4H), 3.05-3.01 (m, 1H), 2.81-2.74 (m, 1H), 2.51-2.44 (m, 1H), 227-2.22 (m, 5H), 2.13-2.06 (m,3H), 1.86-1.80 (m, 2H), 1.65-1.57 (m, 3H), 1.05-1.04 (d, J = 6.4 Hz, 3H)
36	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(4-methy loxazol-2-yl)ethyl)-6,7,8,9-tetrahy dro-3 H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	481	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.47-7.33 (m, 2H), 6.05 (s, 1H), 4.77-4.65 (m, 1H), 4.26 (t, J = 12.5 Hz, 1H), 3.73 (s, 3H), 339-331 (m, 2H), 328-322 (m, 2H), 3.20-3.02 (m, 1H), 2.94-2.78 (m, 1H), 2.53-2.22 (m, 3H), 2,22-2.06 (m, 6H), 1.88-1.76 (m, 2H), 1.76-1.55 (m, 3H), 1.09 (d, J = 6.6 Hz, 3H)
37	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(3-methylisoxazol-5-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	481	^{1}H-NMR (CD_3OD, 400MHz) δ (*ppm*): 7.49-7.47 (m, 1H), 7.40 (d, J = 9.2 Hz, 1H), 6.10 (s, 1H), 4.7 8-4.70 (m, 1H), 4.36-4.25 (m, 1H), 3.79 (s, 3H), 3.43-3.34 (m, 2H), 3.25-3.21 (m, 2H), 3.23-3.10 (m, 1H), 2.91-2.83 (m, 1H), 2.50-2.40 (m, 1H), 2.39-2.15 (m, 8H), 1.88-1.58 (m, 5H), 1.14 (d, J = 6.8 Hz, 3H)
38		482	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.51 (d, J = 9.0 Hz,1H), 7.38 (d, J = 9.0 Hz,1H), 4.76-4.70 (m, 1H),


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(5-methyl-1,3,4-oxadiazol-2-yl)etlyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid		4.41 (s, 1H), 3.76 (s, 3H), 3.50-3.36 (m, 4H), 3.11-3.06 (m, 1H), 2.90-2.83 (m, 1H),2.49 (s, 3H), 2.43-2.18 (m,6H), 2.00-1.97 (m, 2H), 1.78-1.66 (m, 3H), 1.12(d, J=6.9 Hz, 3H)
39	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(4-methyl-1H-pyrazol-1-yl)etlyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	480	^{1}H-NMR (DMSO-d6, 400MHz) δ (*ppm*): 7.54 (s, 1H),7.51 (d, J = 9.2 Hz, 1H), 7.27-7.24(m, 2H), 4.66-4.62 (m, 1H), 4.53-4.49 (m,2H),4.19 (s, 1H), 3 . 66(s, 3H), 3.43-3.40 (m, 2H), 3.09-3.01 (m, 1H), 2.84-2.80 (m, 1H), 2.50-2.44 (m, 1H), 2.22-2.11 (m, 3H), 2.10-1.98 (m,5H), 1.75-1.57 (m, 5H), 1.06 (d, J = 6.8 Hz, 3H)
40	 trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(3-methyl-1H-pyrazol-1-yl)etlyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	480	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.47-735 (m, 3H), 5.97 (s, 1H), 4.77-4.73(m, 1H), 4.61-4.53 (m, 2H), 4.104.09 (ni, 1H), 3.76(s, 3H), 3.48-3.45(m, 2H), 3.20-3.12 (m, 1H), 2.96-2.89 (m, 1H), 2.42-2.39 (m, 1H), 2.26-2.10 (m,5H), 2.01(s, 3H), 1.75-1.59 (m, 5H), 1.12 (d, J = 6.8 Hz, 3H)
41	 trans-4-((S)-2-(2-(4-chloro-1H-pyrazol-1-yl)ethyl)-6-(methoxy carbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	500	^{1}H-NMR (DMSO-d6, 300MHz) δ (*ppm*): 8.08(s, 1H), 7.56-7.50(m, 2H), 7.29-7.26(d, J = 9.0 Hz, 1H), 4.66-0.57 (m, 3H), 4.28-4.20 (m,1H),3.67 (s, 3H), 3 . 18(s, 1H), 3.05-3.02 (m, 2H), 2.86-2.78 (m, 1H), 2.46-2.41 (m, 1H), 2.22-2.01 (m, 5H), 1.75-1.57 (m,5H), 1.07-1.05 (d, J = 6.6 Hz, 3H)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
42	 (trans)4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(3-methy1-1,2,4-oxadiazol-5-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	482	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.47 (d, J = 9.0 Hz, 1H), 7.34 (d, J = 8.9 Hz, 1H), 4.78-4.61 (m, 1H), 4.46-4.31 (m, 1H),3.73 (s, 3 H), 352-337 (m, 4H), 3.18-3.03 (m, 1H), 2.91-2.75 (m, 1H), 2.47-2.31 (m, 3H), 2.29 (s, 3H), 2.24-2.06 (m, 3H), 1.99-1.87 (m, 2H), 1.79-1.58 (m,3H), 1.08 (d, J = 6.6 Hz, 3H)
43	 (S)-4-(2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)benzoic acid	456	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 8.14 -8.11 (m, 2H), 7.41-7.39 (m, 1H), 7.33 - 7.30 (m, 2H), 7.16 -7.13 (m, 3H),6.95 -6.89 (m, 3H), 4.71-4.79 (m, 1H), 4.27 (s, 2H), 3.75(s, 3H), 3.31-3.29 (m, 1H), 3.08-2.94 (m, 1H), 236-224 (m, 1H), 1.82-1.74 (m, 1H), 1.17 (d, J = 6.6 Hz, 3H)
44	 (S)-3-(2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)benzoic acid	456	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 8.21-8.12 (m, 1H), 7.88-7.81 (m, 1H), 7.64-7.55 (t, J = 7.8 Hz, 1H), 7.48-7.37 (m, 2H), 7.23-7.07 (m, 3H), 6.99-6.85 (m, 3H), 4.85-0.76(m, 1H), 4.28 (s, 2H), 3.78 (s, 3H),3.31-3.22 (m, 1H), 3.07-2.95 (m, 1H), 236-224(m, 1H), 1.82-1.74(m, 1H), 1.17(d, J = 6.6 Hz, 3H)
45		480	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.51-7.48(m, 2H), 7.43-737(m, 1H), 6.10-6.09(m, 1H), 4.77-

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	(trans)4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(1-methyl-1H-pyrazol-3-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid		4.75(m, 1H), 4.35-4.30(m, 1H), 3.84(s, 3H), 3.78(s, 3H), 3.17-3.07(m, 5H), 2.95-2.89(m, 1H), 2.50-2 . 17(m, 6H), 1.79-1.70(m, 5H), 1.16 (d, J = 6.9Hz,3H)

Examples 46 and 47: methyl (7S)-2-[(IR)-2-hydroxy-l-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-[(1S)-2-hydroxy-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate

[0380]



***Step* 1. Synthesis of methyl (2S)-5-amino-2-methyl-6-[(oxan-4-yl)amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0381] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (300 mg, 1.00 mmol, **Intermediate 1**) was dissolved in toluene (20 mL). Then oxan-4-amine

(305 mg, 3.02 mmol), Brettphos (215 mg, 0.40 mmol), BrettPhos Pd G3 (182 mg, 0.20 mmol) and sodium tert-butoxide (289 mg, 3.01 mmol) were added. The resulting solution was stirred for 1 h at 110°C in the nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (200 mg, 62%) as a yellow oil. MS : (ES, *m/z):* 320 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-2-[2-[(tert-butyldimethylsilyl)oxy]-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0382] Into a 50-mL round-bottom flask, methyl (2S)-5-amino-2-methyl-6-[(oxan-4-yl)amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate (150 mg, 0.47 mmol) was dissolved in dichloromethane (10 mL) Then 3-[(tert-butyldimethylsilyl)oxy]-2-phenylpropanal (300 mg, 1.13 mmol, **Intermediate 24**) was added. The mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (150 mg, 57%) as a green oil. MS : (ES, m/z): 564 $[M+H]^+$.

Step 3. **Synthesis of methyl (7S)-2-[(IR)-2-hydroxy-l-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-[(1S)-2-hydroxy-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0383] Into a 25-mL round-bottom flask, methyl (7S)-2-[2-[(tert-butyldimethylsilyl)oxy]-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (150 mg, 0.27 mmol) was dissolved in tetrahydrofuran (5 mL). Then tetrabutylammonium fluoride (1 mL, 1M in THF) was added. The resulting solution was stirred for 30 min at 0°C. Then the resulting solution was allowed to react for 3 h at room temperature. The resulting solids were filtered out. The filtrate was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 um, 19 mm x 150 mm; mobile phase, A: Water (containing 10 mmol/L FA) and B: ACN (10.0% to 40.0% ACN over 7 min); UV Detector: 254 nm. This afforded the title compounds as follows: 2.9 mg (2%) of methyl (7S)-2-[(1R)-2-hydroxy-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer, RT = 5.2 min) as a white solid and 2.8 mg (2%) of methyl (7S)-2-[(1S)-2-hydroxy-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H, 8H, 9H-imidazo[4, 5-f] quinoline-6-carboxylate(assumed stereochemistry, second eluting isomer, RT = 6.1 min) as a white solid.


First eluting isomer (46): ^{1}H-NMR (300 MHz, Methanol-d_4) δ 7.49 - 7.21 (m, 7H), 4.82 - 4.70 (m, 1H), 4.68 - 4.58 (m, 1H), 4.58 - 4.42 (m, 2H), 4.23 -4.14 (m, 1H), 4.14 -4.04 (m, 1H), 3.90 -3.81 (m, 1H), 3.79 (s, 3H), 3.60 - 3.48 (m, 1H), 3.31 - 3.25 (m, 1H), 3.22 - 3.07 (m, 1H), 3.07 -

2.97 (m, 1H), 2.64 - 2.46 (m, 1H), 2.40 - 2.16 (m, 2H), 1.88 - 1.65 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 0.82 - 0.70 (m, 1H). MS : (ES, m/z): 450 $[M+H]^+$.

Second eluting isomer (47): ^{1}H-NMR (300 MHz, Methanol-d_4) δ 7.46 - 7.23 (m, 7H), 4.83 - 4.72 (m, 1H), 4.67 - 4.58 (m, 1H), 4.57 - 4.41 (m, 2H), 4.24 -4.14 (m, 1H), 4.14 -4.05 (m, 1H), 3.88 -3.76 (m, 4H), 3.60 - 3.47 (m, 1H), 3.42 - 3.36 (m, 1H), 3.22 - 3.07 (m, 1H), 3.07 - 2.92 (m, 1H), 2.68 - 2.51 (m, 1H), 2.38 - 2.15 (m, 2H), 1.88 - 1.68 (m, 2H), 1.19 (d, J = 6.6 Hz, 3H), 0.77 - 0.67 (m, 1H). MS : (ES, m/z): 450 $[M+H]^+$.

Examples 48 and 49: (1R,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid and (IS,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid

[0384]



***Step* 1. Synthesis of methyl (S)-5-amino-6-(((IS,4R)-4-(methoxycarbonyl)-3,3-dimethylcyclohexyl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**

[0385] Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (272 mg, 0.91 mmol, **Intermediate 1**) was dissolved in toluene (20 mL). Then cis-methyl 4-amino-2,2-dimethylcyclohexane-1-carboxylate (203 mg, 1.09 mmol, **Intermediate 25**),

BrettPhos Pd G3 (96 mg, 0.11 mmol), Brettphos (112 mg, 0.21 mmol) and sodium tert-butoxide (331 mg, 3.64 mmol) were added. The resulting solution was stirred for 1 h at 100°C under a nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (60 mg, 16%) as a yellow oil. MS : (ES, *m/z):* 404 $[M+H]^+$.

Step 2. **Synthesis of methyl (S)-2-benzyl-3-((1S,4R)-4-(methoxycarbonyl)-3,3-dimethylcyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0386] Into a 25-mL round-bottom flask, (S)-methyl 5-amino-6-(cis-4-(methoxycarbonyl)-3,3-dimethylcyclohexylamino)-2-methyl-3,4-dihydroquinoline-l(2H)-carboxylate (26 mg, 0.06 mmol) was dissolved in dichloromethane (4 mL). Then 2-phenylacetaldehyde (60 mg, 0.50 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The reaction mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (21 mg, 65%) as a yellow oil. MS: (ES, *m/z):* 504 $[M+H]^+$.

Step 3. **Synthesis of (1R,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid and (1S,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid.**

[0387] Into a 10-mL round-bottom flask, (S)-methyl 3-(cis-4-(methoxycarbonyl)-3,3-dimethylcyclohexyl)-7-methyl-2-phenyl-8,9-dihydro-3H-imidazo[4,5-f]quinoline-6(7H)-carboxylate (21 mg, 0.042 mmol) was dissolved in tetrahydrofuran (3 mL). Water (1 mL) was added, followed by lithium hydroxide (10 mg, 0.42 mmol). The resulting solution was stirred for 8 h at 85°C. The reaction mixture was cooled and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 um, 19 mm x 250 mm; mobile phase, A: Water (containing 10 mmol/L FA) and B: ACN (10.0% to 40.0% ACN over 19 min); UV Detector: 254 nm. This afforded the title compounds as follows: 1.2 mg (5.8%) of (1R,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H, 6H,7H, 8H, 9H-imidazo[4, 5-f] quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 15.35 min) as a white solid and 4.8 mg (24%) of (1S,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid (assumed stereochemistry, second eluting isomer, RT = 17.15 min) as a white solid.


First eluting isomer: ^{1}H-NMR (400 MHz, $CDCl_3$, *ppm*) δ 7.79 (d, *J* = 9.2 Hz, 1H), 7.44-7.30 (m, 4H), 7.24 - 7.17 (m, 2H), 4.94-4.79 (m, 1H), 4.79-4.56 (m, 2H), 4.56-4.41 (m, 1H), 3.82 (s,

3H), 3.33-3.31 (m, 2H), 2.37-2.26 (m, 1H), 2.26-1.99 (m, 3H), 1.96-1.81 (m, 2H), 1.81-1.60 (m, 2H), 1.37-1.24 (m, 1H), 1.16 (d, *J*= 6.4 Hz, 3H), 1.06 (s, 3H), 0.81 (s, 3H). MS: (ES, m/z): 490 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (400 MHz, $CDCl_3$, *ppm*) δ 7.81 (d, *J* = 8.8 Hz, 1H), 7.40 - 7.29 (m, 4H), 7.25 - 7.19 (m, 2H), 4.91 - 4.75 (m, 1H), 4.68 (s, 2H), 4.57 - 4.39 (m, 1H), 3.82 (s, 3H), 3.30 - 3.00 (m, 2H), 2.36 - 2.25 (m, 1H), 2.25 - 2.13 (m, 1H), 2.13 - 1.98 (m, 2H), 1.94 - 1.78 (m, 2H), 1.78 - 1.52 (m, 2H), 1.45 - 1.33 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H), 1.08 (s, 3H), 0.84 (s, 3H). MS: (ES, *m/z):* 490 $[M+H]^+$.

Examples 50 and 51: (1R,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid and (1S,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid

[0388]



***Step* 1. Synthesis of methyl (2S)-5-amino-6-[[trans-4-(methoxycarbonyl)-3,3-dimethylcyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0389] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (84 mg, 0.27 mmol, **Intermediate 1**) was dissolved in toluene (5 mL). Then trans-methyl 4-amino-2,2-dimethylcyclohexane-1-carboxylate (156 mg, 0.84 mmol, **Intermediate 26**), BrettPhos Pd G3 (51 mg, 0.06 mmol,), Brettphos (67 mg, 0.13 mmol), tert-butoxide (105 mg, 1.10 mmol). The resulting solution was stirred for 1 h at 100°C in the nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out. The filtrate was concentrated under

vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (55 mg, 48%) as a green oil. MS : (ES, *m/z):* 404 $[M+H]^+$.

Step 2. **Synthesis of (7S)-2-benzyl-3-[4-(methoxycarbonyl)-3,3-dimethylcyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0390] Into a 10-mL round-bottom flask, methyl (2S)-5-amino-6-[[trans-4-(methoxycarbonyl)-3,3-dimethylcyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (55 mg, 0.14 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (50 mg, 0.41 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The reaction mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (20 mg, 29 %) as a yellow oil. MS: (ES, *m/z*): 504 $[M+H]^+$.

Step 3. **Synthesis of (1R,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid and (1S,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-1-carboxylic acid.**


[0391] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-3-[4-(methoxycarbonyl)-3,3-dimethylcyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (10 mg, 0.02 mmol) was dissolved in tetrahydrofuran (2 mL) then water (1 mL) was added, followed by lithium hydroxide (4.6 mg, 0.19 mmol). The resulting solution was stirred for 2 h at 85°C. The reaction mixture was cooled and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 um, 19 mm x 250 mm; mobile phase, A: Water (containing 10 mmol/L FA) and B: ACN (10.0% to 40.0% ACN over 19 min); UV Detector: 254 nm. This afforded the title compounds as follows: 2 mg (21%) of (IR,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-l-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 14.7 min) as a white solid and 2 mg (21%) of (1S,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexane-l-carboxylic acid (assumed stereochemistry, second eluting isomer, RT = 15.6 min) as a white solid.

First eluting isomer: ^{1}H NMR (400 MHz, $CDCl_3$, ppm) δ 7.65 (d, *J* = 9.2 Hz, 1H), 7.43-7.33 (m, 1H), 7.31-7.27 (m, 1H), 7.24-7.15 (m, 4H), 4.86-4.75 (m, 1H), 4.52 (d, *J* = 16.4 Hz, 1H), 4.39-4.21 (m, 2H), 3.78 (s, 3H), 3.32-3.18 (m, 1H), 3.11-3.00 (m, 1H), 2.80-2.67 (m, 1H), 2.67-2.52 (m, 1H), 2.35-2.29 (m, 1H), 2.29-2.19 (m, 1H), 1.93-1.83 (m, 1H), 1.83-1.68 (m, 2H), 1.44-1.35 (m, 1H), 1.16 (d, *J* = 6.8 Hz, 3H), 0.99-0.92 (m, 4H), 0.75 (s, 3H). MS: (ES, *m/z):* 490 $[M+H]^+$.

Second eluting isomer: ^{1}H NMR (400 MHz, $CDCl_3$, ppm) δ 7.64 (d, *J* = 8.0 Hz, 1H), 7.43 (s, 1H), 7.32-7.27 (m, 1H), 7.24-7.15 (m, 4H), 4.85-4.73 (m, 1H), 4.51-4.32 (m, 2H), 4.31-4.22 (m, 1H), 3.79 (s, 3H), 3.33-3.20 (m, 1H), 3.15-3.00 (m, 1H), 2.78-2.65 (m, 1H), 2.55-2.38 (m, 1H), 2.33-2.17 (m, 2H), 1.83-1.60 (m, 3H), 1.16 (d, *J* = 6.8 Hz, 4H), 1.01-0.95 (m, 4H), 0.80 (s, 3H). MS: (ES, *m/z*): 490 $[M+H]^+$.

Examples 52 and 53: trans-6-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f|quinolin-3-yl)spiro[3.3]heptane-2-carboxylic acid and cis-6-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)spiro[3.3]heptane-2-carboxylic acid

[0392]



***Step* 1. methyl (2S)-5-amino-6-[[6-(methoxycarbonyl)spiro[3.3]heptan-2-yl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0393] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl 6-aminospiro[3.3]heptane-2-carboxylate hydrochloride (138 mg, 0.67 mmol) was dissolved in dioxane (4 mL). Then methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate 1),** Brettphos (72 mg, 0.13 mmol), 3rd Generation BrettPhos precatalyst (61 mg, 0.07 mmol) and sodium tert-butoxide (97 mg, 1.01 mmol) were added. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out.

The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (3:1). This afforded the title compound (76.2 mg, 59%) as an orange oil. MS: (ES, *m/z):* 388 $[M+H]^+$.

Step 2. **Synthesis of (7S)-2-benzyl-3-[6-(methoxycarbonyl)spiro[3.3]heptan-2-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0394] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-[[6-(methoxycarbonyl)spiro[3.3]heptan-2-yl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (76.2 mg, 0.20 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (70.9 mg, 0.59 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (43.6 mg, 45%) as an orange solid. MS: (ES, m/z): 488 $[M+H]^+$.

Step 3. **Synthesis of trans-6-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)spiro[3.3]heptane-2-carboxylic acid and cis-6-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)spiro[3.3]heptane-2-carboxylic acid.**

[0395] Into a 10-mL round-bottom flask, methyl (7S)-2-benzyl-3-[6-(methoxycarbonyl)spiro[3.3]heptan-2-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (43.6 mg, 0.09 mmol) was dissolved in tetrahydrofuran (1 mL). Then water (1 mL) was added, followed by lithium hydroxide (10.7 mg, 0.45 mmol). The resulting solution was stirred for 1 h at 85 °C. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 μm, 19 mm X 250 mm; mobile phase, A: Water (0.1% FA) and B: ACN (10.0% to 25.0% ACN over 24 min); UV Detector: 254 nm. This offered the title compounds as follows: 5.4 mg (13%) of cis-6-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)spiro[3.3]heptane-2-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 21.5 min) as a white solid and 4.5 mg (11%) of trans-6-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)spiro[3.3]heptane-2-carboxylic acid (assumed stereochemistry, second eluting isomer, RT = 23.0 min) as a white solid.


First eluting isomer: ^{1}H-NMR (300 MHz, CD_3OD, ppm): δ 7.42-7.37 (m, 2H), 7.38-7.22 (m, 3H), 7.19-7.12 (m, 2H), 4.86-4.72 (m, 2H), 4.39 (s, 2H), 3.80 (s, 3H), 3.21-3.10 (m, 1H), 3.10-2.75 (m, 4H), 2.45-2.20 (m, 7H), 1.83-1.70 (m, 1H), 1.16 (d, *J* = 6.6 Hz, 3H). MS: (ES, m/z): 474 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (300 MHz, CD_3OD, ppm): δ 7.44-7.39 (m, 2H), 7.38-7.22 (m, 3H), 7.19-7.12 (m, 2H), 4.78-4.72 (m, 2H), 4.39 (s, 2H), 3.80 (s, 3H), 3.21-3.12 (m, 1H),

3.09-2.88 (m, 2H), 2.83-2.76 (m, 2H), 2.44-2.20 (m, 7H), 1.77-1.70 (m, 1H), 1.17 (d, *J* = 6.7 Hz, 3H). MS: (ES, *m/z):* 474 $[M+H]^+$.

Examples 54 and 55: cis-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo [4,5-1] quinolin-3-yl)cyclopentane-l-carboxylic acid and trans-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclopentane-1-carboxylic acid

[0396]



***Step* 1. Synthesis of methyl (2S)-5-amino-6-[[3-(methoxycarbonyl)cyclopentyl]amino]-2-methyl-l,2,3,4-tetrahydroquinoline-l-carboxylate.**

[0397] Into a 8-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (300 mg, 1.00 mmol, **Intermediate 1**) was dissolved in dioxane (5 mL). Then methyl 3-aminocyclopentane-1-carboxylate hydrochloride (540 mg, 3.01 mmol), 3rd Generation Brettphos precatalyst (273 mg, 0.30 mmol), BrettPhos (323 mg, 0.60 mmol) and sodium tert-butoxide (385 mg, 4.01 mmol) were added. The resulting solution was stirred for 3 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled to room temperature and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (3:1). This afforded the title compound (130 mg, 36%) as a yellow oil. MS: (ES, *m/z):* 362 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-2-benzyl-3-[3-(methoxycarbonyl)cyclopentyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0398] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-[[3-(methoxycarbonyl)cyclopentyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (130 mg, 0.36 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (65 mg, 0.54 mmol) was added. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (120 mg, 72%) as a yellow oil. MS: (ES, m/z): 462 $[M+H]^+$.

Step 3. **Synthesis of cis-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclopentane-1-carboxylic acid and trans-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclopentane-1-carboxylic acid.**


[0399] Into a 25-mL round-bottom flask, was placed methyl (7S)-2-benzyl-3-[3-(methoxycarbonyl)cyclopentyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (142 mg, 0.31 mmol) dissolved in tetrahydrofuran (2 mL). Then water (2 mL) was added, followed by lithium hydroxide (37 mg, 1.55 mmol). The resulting solution was stirred for 2 h at 85°C. The reaction mixture was cooled and the resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100mm, 5 μm, 19 mm X 250 mm; mobile phase, A: Water (10 mmol/L NH_4HCO_3) and B: ACN (15.0% to 35.0% ACN over 7 min); UV Detector: 254 nm. This offered the title compounds as follows: 23.6 mg (17%) of cis-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclopentane-1-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 5.8 min) as a white solid and 29.2 mg (21%) of trans-3-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclopentane-1-carboxylic acid (assumed stereochemistry, second eluting isomer, RT = 6.7 min) as a white solid.

First eluting isomer: ^{1}H-NMR (300 MHz, CD_3OD, ppm): δ 7.56-7.17 (m, 7H), 4.89-4.73 (m, 2H), 4.44 (s, 2H), 3.79 (s, 3H), 3.30-3.18 (m, 1H), 3.01-2.90 (m, 1H), 2.89-2.78 (m, 1H), 2.52-2.07 (m, 4H), 2.02-1.70 (m, 4H), 1.17 (d, *J* = 6.7 Hz, 3H). MS: (ES, *m/z):* 448 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (300 MHz, CD_3OD, ppm): δ 7.56-7.17 (m, 7H), 4.92-4.72 (m, 2H), 4.43 (s, 2H), 3.79 (s, 3H), 3.27-3.19 (m, 1H), 3.03-2.93 (m, 1H), 2.87-2.78 (m, 1H), 2.59-2.41 (m, 1H), 2.37-2.12 (m, 3H), 2.02-1.90 (m, 2H), 1.82-1.68 (m, 2H), 1.17 (d, *J* = 6.7 Hz, 3H). MS: (ES, *m/z):* 448 $[M+H]^+$.

Examples 56 and 57: trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1R)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid and trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid

[0400]



***Step* 1. Synthesis of methyl (2S)-5-amino-2-methyl-6-[[trans-4-(methoxycarbonyl)cyclohexyl]amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0401] Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, trans-methyl-4-aminocyclohexane-1-carboxylate hydrochloride (259 mg, 1.34 mmol) were dissolved in dioxane (4 mL).Then methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (200 mg, 0.67 mmol, **Intermediate 1),** Brettphos (144.2 mg, 0.27 mmol), 3rd Generation BrettPhos precatalyst (121.6 mg, 0.13 mmol) and sodium tert-butoxide (193.4 mg, 2.01 mmol) was added successively. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (58.8 mg, 23%) as a green oil. MS: (ES, m/z): 376 $[M+H]^+$.

***Step 2.* Synthesis of methyl (7S)-7-methyl-2-(1-phenylethyl)-3-[trans-4-(methoxycarbonyl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0402] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-2-methyl-6-[[trans-4-(methoxycarbonyl)cyclohexyl]amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate (58.8 mg, 0.16 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylpropanal (126 mg, 0.94 mmol) was added. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (28.1 mg, 37%) as a yellow solid. MS: (ES, m/z): 490 $[M+H]^+$.

Step 3. **Synthesis of trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(IR)-l-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid and trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid.**

[0403] Into a 25-mL round-bottom flask, methyl (7S)-7-methyl-2-(1-phenylethyl)-3-[trans-4-(methoxycarbonyl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (25 mg, 0.05 mmol) was dissolved in tetrahydrofuran (3 mL). Then water (3 mL) was added, followed by lithium hydroxide (6.1 mg, 0.25 mmol). The resulting solution was stirred for 2 h at 85°C. The resulting mixture was cooled to room temperature and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 19 X150mm, 5μm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (18.0% to 38.0% ACN over 8 min); UV Detector: 254 nm. Then the product was purified by Chiral-Prep-HPLC with the following conditions: Column, CHIRAL ART Cellulose-SB, 2x25cm, 5μm; mobile phase, hexanes (1%TFA) and ethanol (hold 10.0% ethanol in 38 min); Detector, UV 254nm. This afforded the title compounds as follows: 1.4 mg (6%) of trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 25.83min) as a white solid and 2.9 mg (12%) of trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1R)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid (assumed stereochemistry, second eluting isomer, RT =32.76 min) as a white solid


First eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.36-7.26 (m, 3H), 7.26-7.14 (m, 4H), 4.82- 4.75 (m, 1H), 4.39-4.37 (m, 1H), 4.07-4.03 (m, 1H), 3.78 (s, 3H), 3.34-3.26 (m, 1H), 3.07-2.02 (m, 1H), 2.40-2.15 (m, 5H), 1.98-1.95 (m, 3H), 1.85 (d, *J* = 6.9 Hz, 3H), 1.77-1.69 (m, 2H), 1.55-1.42 (m, 1H), 1.17 (d, *J* = 6.6 Hz, 3H). MS: (ES, *m/z):* 476 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.37-7.29 (m, 1H), 7.28-7.26 (m, 2H), 7.24-7.17 (m, 4H), 4.81-4.75 (m, 1H), 4.44-4.41 (m, 1H), 4.06- 4.02 (m, 1H), 3.78 (s, 3H), 3.56-3.27 (m, 1H), 3.06-2.99 (m, 1H), 2.40-2.06 (m, 5H), 1.99-1.96 (m, 2H), 1.84 (d, *J* = 6.9 Hz, 3H), 1.79-1.70 (m, 3H), 1.49-1.42 (m, 1H), 1.20 (d, *J* = 6.6 Hz, 3H) . MS: (ES, *m/z):*

476 $[M+H]^+$.

Examples 58 and 59: methyl (S)-7-methyl-2-((R)-l-phenylethyl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-7-methyl-2-((S)-1-phenylethyl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0404]



Step 1. **Synthesis of methyl (2S)-5-amino-6-([1-[(tert-butoxy)carbonyl]piperidin-4-yl] amino)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0405] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, tert-butyl 4-aminopiperidine-1-carboxylate (402.7 mg, 2.01 mmol) was dissolved in toluene (4 mL). Methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (300 mg, 1.00 mmol, **Intermediate 1**), BrettPhos (216.2 mg, 0.40 mmol), 3rd Generation BrettPhos precatalyst (182.4 mg, 0.20 mmol) and sodium tert-butoxide (290 mg, 3.02 mmol) were added. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (197.1 mg, 47%) as a dark green solid. MS: (ES, m/z): 419 $[M+H]^+$.

Step 2. **Synthesis of tert-butyl 4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(IR)-l-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate and**

tert-butyl 4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(lS)-l-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate

[0406] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-([1-[(tert-butoxy)carbonyl]piperidin-4-yl]amino)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (197.1 mg, 0.47 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylpropanal (379.2 mg, 2.83 mmol) was added. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compounds as follows: 18.1 mg (7%) of tert-butyl 4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1R)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate as a yellow solid and15.6 mg (6%) of tert-butyl 4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate as a yellow solid. MS: (ES, m/z): 533 $[M+H]^+$.

Step 3. **Synthesis of methyl (S)-7-methyl-2-((R)-l-phenylethyl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-7-methyl-2-((S)-l-phenylethyl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate**


[0407] Into a 25-mL round-bottom flask, tert-butyl 4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1R)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate (18.1 mg, 0.03 mmol) was dissolved dichloromethane (5 mL). Then trifluoroacetic acid (1 mL) was added dropwise with stirring. The resulting solution was stirred for 1.5 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 19 mm X 250 mm; mobile phase, A: Water (10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 50.0% ACN over 7 min); UV Detector: 254 nm. This afforded the title compound (7.7 mg, 52%) as a white solid. ^{1}HNMR: (300 MHz, CD_3OD, ppm): δ 7.51 (d, *J* = 9.0 Hz, 1H), 7.41-7.19 (m, 6H), 4.78-4.69 (m, 1H), 4.64-4.58 (m, 1H), 4.38-4.26 (m, 1H), 3.79 (s, 3H), 3.40-3.35 (m, 1H), 3.17-3.12 (m, 1H), 2.98-2.88 (m, 2H), 2.68-2.58 (m, 1H), 2.48-2.20 (m, 3H), 2.19-2.04 (m, 1H), 1.80 (d, *J* = 7.3 Hz, 3H), 1.78-1.68 (m, 2H), 1.19 (d, *J* = 6.6 Hz, 3H), 0.82-0.74 (m, 1H). MS: (ES, *m/z):* 433 $[M+H]^+$.

[0408] Into a 25-mL round-bottom flask, tert-butyl 4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate (15.6 mg, 0.03 mmol) was dissolved dichloromethane (5 mL). Then trifluoroacetic acid (1 mL) was added dropwise with stirring. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 19

mm X 250 mm; mobile phase, A: Water (10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 50.0% ACN over 7 min); UV Detector: 254 nm. This afforded the title compounds (7.8 mg, 62%) as a white solid. ^{1}HNMR: (300 MHz, CD_3OD, ppm): δ 7.51 (d, *J* = 9.0 Hz, 1H), 7.41-7.19 (m, 6H), 4.78-4.72 (m, 1H), 4.64-4.58 (m, 1H), 4.38-4.26 (m, 1H), 3.79 (s, 3H), 3.40-3.35 (m, 1H), 3.17-3.12 (m, 1H), 2.98-2.88 (m, 2H), 2.68-2.58 (m, 1H), 2.48-2.20 (m, 3H), 2.19-2.04 (m, 1H), 1.80 (d, *J* = 7.3 Hz, 3H), 1.78-1.68 (m, 2H), 1.19 (d, *J* = 6.6 Hz, 3H), 0.82-0.74 (m, 1H). MS: (ES, *m/z*): 433 $[M+H]^+$.

Examples 60 and 61: cis-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-l-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid and trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid

[0409]



Step 1. **Synthesis of methyl (7S)-7-methyl-2-(1-phenylpropan-2-yl)-3-[trans-4-(methoxycarbonyl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0410] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-2-methyl-6-[[trans-4-(methoxycarbonyl)cyclohexyl]amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate (150 mg, 0.40 mmol) was dissolved in dichloromethane (5 mL). Then 2-methyl-3-phenylpropanal (178 mg, 1.20 mmol, **Intermediate 27**) was added. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (150 mg, 72%) as a yellow oil. MS: (ES, *m/z):* 504 $[M+H]^+$.

Step 2. **Synthesis of cis-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-l-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid and**

trans-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid.


[0411] Into a 50-mL round-bottom flask, methyl (7S)-7-methyl-2-(1-phenylpropan-2-yl)-3-[trans-4-(methoxycarbonyl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (150 mg, 0.30 mmol) was dissolved in tetrahydrofuran (5 mL). Water (5 mL) was added, followed by lithium hydroxide (36 mg, 1.50 mmol). The resulting solution was stirred for 1 h at 85 °C. The resulting mixture was cooled and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 5μm, 19X150mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (10.0% to 67.0% ACN over 5 min); UV Detector: 254 nm. The crude product was purified by Chiral-Prep-HPLC with the following conditions : Column, CHIRALPAK IE, 2×25cm,5μm; mobile phase, A: hexanes (0.1%FA) and B: ethanol (hold 35.0% ethanol in 10 min); UV Detector: 254nm. This afforded the title compounds as follows: 42.1 mg (28%) of trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(2R)-1-phenylpropan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid(assumed stereochemistry, first eluting isomer) as a white solid and 23.1 mg (15%) of trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(2S)-l-phenylpropan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-l-carboxylic acid(assumed stereochemistry,second eluting isomer) as a white solid.


First eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) δ(*ppm*): 7.37 (d, *J* = 9.0 Hz, 1H), 7.29 (d, *J* = 8.9 Hz, 1H), 7.22-6.98 (m, 5H), 4.80-4.67 (m, 1H), 4.08-3.97 (m, 1H), 3.77 (s, 3H), 3.68-3.54 (m, 1H), 3.24-2.87 (m, 4H), 2.43-1.88 (m, 6H), 1.79-1.50 (m, 6H), 1.39-1.07 (m, 4H), 0.59-0.56 (m, 1H). MS: (ES, *m/z):* 490 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) δ(*ppm*): 7.42-7.27 (m, 2H), 7.19-7.01 (m, 5H), 4.80-4.65 (m, 1H), 4.18- 4.03 (m, 1H), 3.75 (s, 3H), 3.68-3.53 (m, 1H), 3.28-3.04 (m, 3H), 3.00-2.84 (m, 1H), 2.46-1.90 (m, 6H), 1.83-1.57 (m, 3H), 1.51 (d, *J* = 6.8 Hz, 3H), 1.41-1.24 (m, 1H), 1.16 (d, *J* = 6.6 Hz, 3H), 0.75-0.72 (m, 1H). MS: (ES, *m/z*): 490 $[M+H]^+$.

Examples 62 and 63: (1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid and (1R,3S)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid

[0412]





***Step* 1. Synthesis of methyl (2S)-5-amino-6-[[cis-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0413] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl cis-3-aminocyclohexane-1-carboxylate hydrochloride (260 mg, 1.34 mmol) was dissolved in dioxane (4 mL). Then methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (200 mg, 0.66 mmol, **Intermediate 1),** Brettphos (144 mg, 0.26 mmol), Brettphos Pd G3 (122 mg, 0.14 mmol) and sodium tert-butoxide (194 mg, 2.02 mmol) were added. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled and the solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (125.5 mg, 50%) as a green oil. MS: (ES, m/z): 376 $[M+H]^+$.

***Step 2.* Synthesis of methyl (7S)-3-[cis-3-(methoxycarbonyl)cyclohexyl]-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0414] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-[[cis-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (125.5 mg, 0.33 mmol) was dissolved in dichloromethane (5 mL). Then 3-phenylpropanal (134.5 mg, 1.00 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (105.1 mg, 64%) as a green solid. MS: (ES, m/z): 490 $[M+H]^+$.

***Step 3.* Synthesis of (IS,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-**

tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid and (1R,3S)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid


[0415] Into a 25-mL round-bottom flask, methyl (7S)-3-[cis)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (105.1 mg, 0.21 mmol) was dissolved in tetrahydrofuran (2 mL). Then water (2 mL) was added, followed by lithium hydroxide (25.8 mg, 1.08 mmol). The resulting solution was stirred for 2 h at 85 °C. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 5μm, 19x150mm; mobile phase, A: water (10 mmol/L NH_4HCO_3) and B: ACN (20.0% to 45.0% ACN over 7 min); UV Detector: 254 nm. This afforded the title compounds as follow: 22.7 mg (22%) of Synthesis of (lS,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 4.8 min) as a white solid and 22.7 mg (22%) of (1R,3S)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid (assumed stereochemistry, second eluting isomer, RT = 5.9 min)as a white solid.


First eluting isomer: ^{1}H-NMR: (400 MHz, CD_3OD, ppm): δ 7.47-7.34 (m, 2H), 7.31-7.14 (m, 5H), 4.78-4.70 (m, 1H), 4.18-4.12 (m, 1H), 3.79 (s, 3H), 3.26-3.23 (m, 2H), 3.20-3.09 (m, 3H), 2.94-2.87 (m, 1H), 2.42-2.36 (m, 1H), 2.33-2.17 (m, 2H), 2.16-1.96 (m, 2H), 1.92-1.84 (m, 1H), 1.82-1.65 (m, 2H), 1.48-1.38 (m, 3H), 1.15 (d, *J* = 6.8 Hz, 3H). MS: (ES, *m/z*): 476 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR: (400 MHz, CD_3OD, ppm):8 7.48-7.33 (m, 2H), 7.31-7.13 (m, 5H), 4.78-4.70 (m, 1H), 4.17-4.10 (m, 1H), 3.78 (s, 3H), 3.25-3.22 (m, 2H), 3.26-3.07 (m, 3H), 2.95-2.87 (m, 1H), 2.46-2.35 (m, 1H), 2.34-2.19 (m, 2H), 2.12-1.96 (m, 2H), 1.94-1.88 (m, 1H), 1.76-1.66 (m, 1H), 1.57-1.40 (m, 4H), 1.15 (d, *J*= 6.8, 2.1 Hz, 3H).

Examples 64 and 65: (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid and (1S,3S)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid

[0416]





***Step* 1. Synthesis of methyl (2S)-5-amino-6-[[trans-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0417] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, trans-methyl-3-aminocyclohexane-1-carboxylate hydrochloride (260 mg, 1.34 mmol) was dissolved in dioxane (4 mL). Then methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (200 mg, 0.66 mmol, **Intermediate 1),** Brettphos (144 mg, 0.26 mmol), 3rd Generation BrettPhos precatalyst (122 mg, 0.14 mmol) and sodium tert-butoxide (194 mg, 2.02 mmol) were added. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (80 mg, 45%) as green oil. MS: (ES, m/z): 376 $[M+H]^+$.

***Step 2.* Synthesis of methyl (7S)-3-[trans-3-(methoxycarbonyl)cyclohexyl]-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0418] Into a 50-mL round-bottom flask, methyl (2S)-5-amino-6-[[trans-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (80 mg, 0.21 mmol) was dissolved in dichloromethane (5 mL). Then 3-phenylpropanal (57 mg, 0.42 mmol) was added. The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1).This afforded the title compound 75 mg (72%) as a yellow solid. MS: (ES, m/z): 490 [M+H]+.

***Step 3.* Synthesis of (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid and (1S,3S)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-**

f]quinolin-3-yl)cyclohexane-1-carboxylic acid.


[0419] Into a 50-mL round-bottom flask, methyl (7S)-3-[trans-3-(methoxycarbonyl)cyclohexyl]-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (75 mg, 0.15 mmol) was dissolved in tetrahydrofuran (2 mL). Water (2 mL) was added, followed by lithium hydroxide (18.3 mg, 0.76 mmol). The resulting solution was stirred for 2 h at 85 °C. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 μm, 19 mm X 250 mm; mobile phase, A: water (0.05% NH_4OH) and B: ACN (20.0% to 40.0% ACN over 12 min); UV Detector: 254 nm. This afforded the title compounds as follows: 2.6 mg (4%) of (1R,3R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid (assumed stereochemistry, first eluting isomer, RT = 8.9 min) as a white solid and 2.4 mg (3%) of (1S,3S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid (assumed stereochemistry, second eluting isomer, RT =11.2 min) as a white solid.


First eluting isomer: 1H NMR (Methanol-d4, 400 MHz) 6(ppm): 7.47-7.45(m, 1H), 7.36-7.33(m, 1H), 7.25-7.24(m, 4H), 7.19-7.16(m, 1H), 4.76-4.72(m, 1H), 4.64-4.59(m, 2H), 3.76(s, 3H), 3.26-3.11(m, 3H), 3.02-2.88(m, 3H), 2.33-2.20(m, 5H), 1.76-1.70(m, 3H), 1.48-1.48(m, 2H), 1.13(d, J=6.8 Hz, 3H). MS: (ES, m/z): 476 [M+H]+.

Second eluting isomer: 1H NMR (Methanol-d4, 400 MHz) 6(ppm): 7.49-7.47(m, 1H), 7.38-7.36(m, 1H), 7.26-7.25(m, 4H), 7.20-7.16(m, 1H), 4.77-4.68(m, 3H), 3.76(s, 3H), 3.26-3.11(m, 3H), 3.01-2.88(m, 3H), 2.37-2.20(m, 5H), 1.78-1.70(m, 3H), 1.57-1.51(m, 2H), 1.13(d, J=6.8 Hz, 3H). MS: (ES, m/z): 476 [M+H]+.

Example 66: methyl (S)-2-benzyl-3-((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0420]





Step 1. **Synthesis of methyl (2S)-5-amino-6-[[(3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]oxan-3-yl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0421] Into a 50-mL round-bottom flask, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (120 mg, 0.40 mmol, **Intermediate 1**) was dissolved in toluene (5 mL). Then (3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]oxan-3-amine (292 mg, 1.19 mmol, **Intermediate 30**), Brettphos (86 mg, 0.16 mmol, 0.40 equiv), 3rd Generation Brettphos precatalyst (72 mg, 0.08 mmol) and sodium tert-butoxide (76 mg, 0.79 mmol) were added. The resulting solution was stirred for 2 h at 110°C under nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (90 mg, 48%) as a brown oil. MS: (ES, *m/z):* 464 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-2-benzyl-3-[(3R,6S)-6-[[(tert-butyldimethylsilyl)oxy]methyl]oxan-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0422] Into a 50-mL round-bottom flask, methyl (2S)-5-amino-6-[[(3R,6S)-6-[[(tertbutyldimethylsilyl)oxy]methyl]oxan-3-yl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (90 mg, 0.19 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (23 mg, 0.19 mmol) was added. The resulting solution was stirred for 12 h at room temperature. The reaction mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (70 mg, 64%) as a light yellow solid. MS: (ES, *m/z):* 564 $[M+H]^+$.

Step 3. **Synthesis of (S)-methyl 2-benzyl-3-((3R,6S)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3-yl)-7-methyl-8,9-dihydro-3H-imidazo[4,5-f]quinoline-6(7H)-carboxylate.**

[0423] Into a 50-mL round-bottom flask, methyl (7S)-2-benzyl-3-[(3R,6S)-6-[[(tertbutyldimethylsilyl)oxy]methyl]oxan-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (30 mg, 0.05 mmol) was dissolved in tetrahydrofuran (3 mL). Then tetrabutylammonium fluoride (1 M in THF, 0.08 mL, 0.08 mmol) was added. The resulting



solution was stirred for 1 h at room temperature. The reaction mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). The crude product was purified by Prep-HPLC with the following conditions:




Column, XBridge C18 OBD Prep Column, 100 Å, 5 μm, 19 mm x 250 mm; mobile phase, A: Water (containing 0.05% TFA) and B: ACN (5.0% to 60.0% ACN over 30 min); UV Detector: 254 nm. This afforded the title compound (3.3 mg, 14%) as a yellow oil.

^{1}H-NMR: (CDCl3, 300 MHz) δ(*ppm*): 7.85-7.81(m, 1H), 7.41-7.29(m, 6H), 4.86-4.77(m, 2H), 4.61-4.51(m, 3H), 4.10-4.03(m, 1H), 3.84-3.81(m, 4H), 3.69-3.56(m, 3H), 3.18-3.15(m, 2H), 2.38-2.33(m, 1H), 2.20-2.14(m, 1H), 1.91-1.85(m, 1H), 1.79-1.75(m, 1H), 1.63-1.59(m, 1H), 1.46-1.42(m, 1H), 1.15(d, J=6.6 Hz, 3H). MS: (ES, m/z): 450 $[M+H]^+$.

[0424] The following examples in **TABLE 4** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 66.


TABLE 4

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
67	 methyl (S)-3-((1S,3R)-3-hydroxycyclohexyl)-7-methyl-2-((2-oxopyridin-1(2H)-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	451	^{1}H-NMR (DMSO-d6, 400 MHz)δ(*ppm*):
			7.66-7.64(m, 1H), 7.55-7.49(m, 2H), 7.45-7.43(m, 1H), 6.62-6.60(m, 1H), 6.42-638(m, 1H), 5.58-5.48(m, 2H), 4.75-4.66(m, 2H), 3.76(s, 3H), 3.70-3.66(m, 1H), 3.17-3.13(m, 1H), 2.94-2.90(m, 1H), 2.23-2.10(m, 3H), 2.0-1.88(m, 3H), 1.75-1.67(m, 2H), 1.42-1.39(m, 1H), 1.36-1.28(m, 1H), 1.13(d, J=6.8 Hz, 3H)
68	 methyl (S)-3-((1R,3S)-3-hydroxycyclohexyl)-7-methyl-2-((2-oxopyridin-l(2H)-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		^{1}H-NMR (DMSO-d6, 400 MHz) δ (*ppm*):
		451	7.66-7.64(m, 1H), 7.55-7.49(m, 2H), 7.45-7.43(m, 1H), 6.62-6.60(m, 1H), 6.42-638(m, 1H), 5.58-5.48(m, 2H), 4.75-4.66(m, 2H), 3.76(s, 3H), 3.70-3.66(m, 1H), 3.17-3.13(m, 1H), 2.94-2.90(m, 1H), 2.23-2.10(m, 3H), 2.0-1.88(m, 3H), 1.75-1.67(m, 2H), 1.42-1.39(m, 1H), 1.36-1.28(m, 1H), 1.13(d, J=6.8 Hz, 3H)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
69	 methyl (S)-3-((1R,3R)-3-hydroxycyclohexyl)-7-methyl-2-((2-oxopyridin-1(2H)-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	451	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.69-7.67(m, 1H), 7.56-7.49(m, 2H), 7.42-7.40(m, 1H), 6.59-6.57(m, 1H), 6.42-639(m, 1H), 5.68-5 . 64(m, 1H), 5.35-5.32(m, 1H), 4.98-4.85(m, 1H), 4.73-4.71(m, 1H), 4.28-4.26(m, 1H), 3.75(s, 3H), 3.13-3.11(m, 1H), 2.89-2.85(m, 1H), 2.52-2.50(m, 1H), 2.25-2.18(m, 2H), 1.98-1.82(m, 2H), 1.71-1.69(m, 2H), 1.68-1.64(m, 3H), 1.11(d, J=6.4 Hz, 3H)
70	 methyl (S)-3-((1S,3S)-3-hydroxycyclohexyl)-7-methyl-2-((2-oxopyridin-l(2H)-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	451	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.66-7.64(m, 1H), 7.55-7.49(m, 2H), 7.45-7.43(m, 1H), 6.62-6.60(m, 1H), 6.42-6.38(m, 1H), 5.58-5.47(m, 2H), 4.75-4.66(m, 2H), 3.76(s, 3H), 3.70-3.68(m, 1H), 3.17-3.13(m, 1H), 2.95-2.91(m, 1H), 2.22-2.11(m, 3H), 2.09-2.00(m, 2H), 1.87-1.75(m, 1H), 1.73-7.64(m, 2H), 1.52-1.37(m, 2H), 1.12(d, J=6.8 Hz, 3H)
71	 methyl (S)-3-((trans)4-tydroxycyclohexyl)-7-methyl-2-((2-oxopyridin-1(2H)-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quinoline-6-carboxylate	451	^{1}H-NMR ($CDCl_3$, 300MHz) *δ* (*ppm*): 7.47-7.44(m,2H), 7.34-7.27(m, 2H), 6.64-6.61(m, 1H), 6.16-6.11(m, 1H), 5.67-5.62(m, 1H), 5.45-5.40(m, 1H), 4.81-4.79(m, 1H), 4.68-4.65(m, 1H), 3.77-3.72(m,4H), 3.21-3.12(m, 1H), 3.05-3.01(m, 1H), 2.25-2.17(m, 3H), 2.11-2.05(m, 2H), 1.76-1.72(m, 2H), 1.60-1.49(m, 3H), 1.17(d, J=6.9Hz, 3H)

Example 72: (2S,5R)-5-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)tetrahydro-2H-pyran-2-carboxylic acid

[0425]




***Step* 1. Synthesis of (2S,5R)-5-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)tetrahydro-2H-pyran-2-carboxylic acid.**

[0426] Into a 50-mL round-bottom flask, was placed methyl (7S)-2-benzyl-3-[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (20 mg, 0.04 mmol, 1.00 equiv), water (1.5 mL), CH_3CN (1 mL), dichloromethane (1 mL), $NaIO_4$ (47 mg, 0.22 mmol, 4.94 equiv), and $RuCl_3.H_2O$ (5 g, 22.18 mmol) was added at 0°C. The resulting solution was stirred for 12 h at room temperature. The solids were filtered out. The product was purified with the following conditions: Column: XBridge Shield RP18 OBD Column, 5um, 19x150mm; Mobile Phase A:Water (0.1%FA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B in 7 min; 254 nm; RT: 6.5 min. This resulted in 1.3 mg (6%) of (2S,5R)-5-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]oxane-2-carboxylic acid as a yellow solid. ^{1}H-NMR: (300 MHz, $CDCl_3$, *ppm*): 7.47-7.45(m, 1H), 7.27-7.18(m, 6H), 4.84-4.80(m, 1H), 4.54-4.49(m, 1H), 4.37-4.27(m, 2H), 4.12-4.05(m, 2H), 3.94-3.92(m, 1H), 3.80(s, 1H), 3.25-3.20(m, 1H), 3.10-3.08(m, 1H), 2.37-2.32(m, 2H), 1.78-1.76(m, 1H), 1.61-1.53(m, 2H), 1.44-1.42(m, 1H), 1.18-1.16(m, 3H). MS: (ES, *m/z):* 464 $[M+H]^+$.

Example 73: methyl (S)-2-benzyl-3-((3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0427]




***Step* 1. Synthesis of methyl (S)-2-benzyl-3-((3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate**

[0428] Into a 50-mL round-bottom flask, was placed (2S,5R)-5-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]oxane-2-carboxylic acid (20 mg, 0.04 mmol), N,N-dimethylformamide (2 mL), HATU (32 mg, 0.08 mmol), NMM (18 mg, 0.18 mmol), NH_4Cl (4 mg, 0.07 mmol). The resulting solution was stirred for 1 h at room temperature. The product was purified with the following conditions: Column: XBridge Shield RP18 OBD Column, 5um,19*150mm;Mobile Phase A:Water (10mmol/L NH_4HCO_3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 75% B in 7 min; 254 nm; RT: 6.5 min. This resulted in 1.5 mg (8%) of methyl (7S)-2-benzyl-3-[(3R,6S)-6-carbamoyloxan-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate as a white solid. ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.55-7.53(m, 1H), 7.46-7.45(m, 1H), 7.35-7.30(m, 2H), 7.24-7.22(m, 3H), 4.79-4.74(m, 1H), 4.47-4.43(m, 3H), 4.17-4.11(m, 1H), 4.06-4.02(m, 1H), 3.76-3.70(m, 4H), 3.23-3.15(m, 1H), 2.98-2.95(m, 1H), 2.54-2.46(m, 1H), 2.28-2.15(m, 2H), 1.78-1.61(m, 2H), 1.48-1.42(m, 1H), 1.13(d, J=6.6 Hz, 3H). MS: (ES, *m/z):* 463 $[M+H]^+$.

Example 74: methyl (7S)-2-benzyl-7-methyl-3-[trans-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate

[0429]






***Step* 1. Synthesis of methyl (7S)-2-benzyl-7-methyl-3-[trans-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f] quinoline-6-carboxylate.**

[0430] Into a 25-mL round-bottom flask, trans-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-l-carboxylic acid (30 mg, 0.07 mmol) was dissolved in methanol (3 mL). Then ammonium chloride (15.8 mg, 0.30 mmol), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl morpholinium chloride (61.6 mg, 0.22 mmol) and triethylamine (15 mg, 0.15 mmol) were added. The resulting solution was stirred for overnight at room temperature. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 μm, 19 mm x 250 mm; mobile phase, A: water (10 mmol/L NH_4HCO_3) and B: ACN (22.0% to 38.0% ACN over 10 min); UV Detector: 254 nm. This offered the title compound (10.9 mg, 32%) as a white solid.

^{1}H-NMR (CD_3OD, 300 MHz) 6(ppm): 7.50-7.21 (m, 7H), 4.79-4.72 (m, 1H), 4.43 (s, 2H), 4.37-4.21 (m, 1H), 3.79 (s, 3H), 3.33-3.15 (m, 1H), 2.99-2.90 (m, 1H), 2.39-2.14 (m, 4H), 1.92-1.82 (m, 2H), 1.80-1.70 (m, 1H), 1.59-1.40 (m, 4H), 1.17 (d, *J* = 6.7 Hz, 3H). MS: (ES, m/z): 461 $[M+H]^+$.


[0431] The following examples in **TABLE** 5 were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 74.

TABLE 5

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
75	 methyl (S)-2-benzyl-3-((cis)-4-carbamoylcyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	461	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.52 (d, J = 9.0 Hz, 1H), 7.41-7.22(m,6H), 4.81-4.73 (m, 1H), 4.41 (s, 2H), 4.36-4.25(m, 1H), 3.79 (s, 3H), 3.32-3.15 (m, 1H), 3.00-2.92 (m, 1H), 2.70-2.50 (m, 3H), 2.37-2.19(m, 1H), 2.12-2.02 (m, 2H), 1.86-1.71 (m, 1H), 1.60-1.47(m, 2H), 1.36-1.22 (m, 2H), 1.17 (d, J = 6.7 Hz, 3H)
76	 methyl (S)-3-((trans)-4-carbamoylcyclohexyl)-7-methyl-2-phenethyl-3,7,8,9-tetrahydo-6H-imidazo[4,5-f] quinoline-6-carboxylate	475	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.43-730(m,2H), 7.27-7.25(m, 2H), 7.21-7.17(m, 3H), 4.78-4.75(m, 1H), 4.15-4.11(m, 1H), 3.79(s, 3H), 3.16-3.10(m, 5H), 2.97-2.89(m, 1H), 2.39-2.20(m, 4H), 1.99-1.95(m, 2H), 1.62-1.58(m, 5H), 1.16(d, J= 6.9 Hz, 3H
77	 methyl (S)-3-((cis)-4-carbamoylcyclohexyl)-7-methyl-2-phenethyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	475	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.52-7.49(m, 1H), 7.33-7.25(m, 3H), 7.20-7.17(m, 3H), 4.79-4.73(m, 1H), 4.22-4.15(m, 1H), 3.78(s, 3H), 3.34-3.09(m, 5H), 2.92-2.88(m, 1H), 2.64-2.60(m, 3H), 2.26-2.11(m, 3H), 1.77-1.70(m, 3H), 1.41-1.29(m,2H), 1.16(d, J= 6.9 Hz, 3H)

Example 78: methyl (S)-3-(azetidin-3-yl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0432]



Step 1. **Synthesis of methyl (2S)-5-amino-6-([1-[(tert-butoxy)carbonyl]azetidin-3-yl]amino)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0433] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate 1**) was dissolved in toluene (3 mL). Then tert-butyl 3-aminoazetidine-1-carboxylate (173.2 mg, 1.01 mmol), Brettphos (36 mg, 0.07 mmol), 3rd Generation BrettPhos precatalyst (60.8 mg, 0.07 mmol) and sodium tert-butoxide (96.6 mg, 1.01 mmol) were added. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled to room temperature and the solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (58 mg, 44%) as a brown solid. MS: (ES, *m/z*): 391 $[M+H]^+$.

Step 2. **Synthesis of tert-butyl 3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl] azetidine-1-carboxylate.**

[0434] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-([1-[(tert-



butoxy)carbonyl]azetidin-3-yl]amino)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (58 mg, 0.15 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (107 mg, 0.89 mmol) was added. The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (43.3 mg, 59%) as a yellow oil. MS: (ES, m/z): 491 $[M+H]^+$.





Step 3. **Synthesis of methyl (S)-3-(azetidin-3-yl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**





[0435] Into a 25-mL round-bottom flask, tert-butyl 3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]azetidine-1-carboxylate (43.3 mg, 0.09 mmol) was dissolved in dichloromethane (5 mL). Then trifluoroacetic acid (1.5 mL) was added. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 A, 5 um, 19 mm x 250 mm; mobile phase, A: Waters(containing 10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 45.0% ACN over 7 min); UV Detector: 254 nm. This afforded the title compounds (6 mg, 17%) of as a white solid. ^{1}H-NMR (CD_3OD, 400 MHz) δ(ppm): 7.84 (d, J = 9.0 Hz, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.37-7.21 (m, 3H), 7.19-7.12 (m, 2H), 5.45-5.35 (m, 1H), 4.82-4.76 (m, 1H), 4.45-4.22 (m, 4H), 3.81 (s, 3H), 3.72-3.64 (m, 2H), 3.28-3.49 (m, 1H), 3.02-2.94 (m, 1H), 2.32-2.24 (m, 1H), 1.85-1.75 (m, 1H), 1.18 (d, J = 6.7 Hz, 3H). MS: (ES, *m/z*): 391 $[M+H]^+$.






[0436] The following examples in **TABLE 6** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 78.





TABLE 6




Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
79	 methyl (S)-2-benzyl-7-methyl-3-((S)-pyirrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	405	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.49-7.18 (m, 7H), 5.04-4.99 (m, 1H),4.79-0.74 (m, 1H),4.46 (s, 2H),3.79 (s, 3H), 3.32-3.12 (m, 3H), 3.07-2.91 (m, 3H), 2.35-2.12 (m,2H), 1.92-1.86 (m, 1H), 1.78-1.71(m, 1H), 1.17 (d, J=6.7 Hz, 3H)
80		405	^{1}H-NMR (CD_3OD,300 MHz) δ (*ppm*): 7.49-7.17 (m, 7H), 5.05-0.95 (m,




Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-2-benzyl-7-methyl-3-((S)-pyirrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		1H), 4.80-4.74 (m, 1H), 4.46 (s, 2H),3.80 (s, 3H), 3.33-3.16(m, 2H), 3.14-2.83 (m, 4H),2.38-2.13 (m, 2H), 2.04-1.86 (m, 1H), 1.8 6-1.6 9 (m, 1H), 1.17 (d, J=6.7 Hz,3H)
81	 methyl (S)-7-methyl-2-phenethyl-3-(2-azaspiro [3.3] heptan-6-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	445	^{1}H-NMR (CD_3OD,300MHz) δ (*ppm*): 7.44-7.11 (m, 7H), 4.78-4.62 (m, 2H),3 . 82-3.74 (m, 6H), 3.29-2.88 (m, 9H), 2.62-2.50(m,2H), 228-220 (m, 1H), 1.74-1.70 (m, 1H), 1.15 (d, J = 6.7 Hz, 3H)
82	 methyl (S)-2-benzyl-7-methyl-3--(3-azaspiro [5.5] undecan-9-y 1)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	445	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.39-7.36(m, 1H), 7.35-7.30(m, 1H), 7.30-7.18(m, 5H), 4.81-4.77(m, 1H), 4.41-4.27(m, 2H), 4.03-3.99(m, 1H), 3.78(s, 3H), 3.27-3.21(m, 1H), 3.09-3.02(m, 1H), 2.89-2.83(m, 4H), 2.28-2.19(m, 3H), 1.82-1.68(m, 5H), 1.37-1.35(m, 3H), 1.18-1.16(m, 4H), 1.04-0.96(m, 2H)
83	 methyl(7S)-2-benzyl-3-(8-azabicyclo[3.2.1] octan-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	445	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.38 (d, J = 8.8 Hz, 1H), 7.35-7.13 (m, 6H), 4.82-4.77 (m, 1H), 4.70-4.60 (m, 1H), 444-4.28 (m, 2H), 3.79 (s, 3H), 3.70-3.61 (m, 2H), 3.29-3.22 (m, 1H), 3.07-3.02 (m, 1H),2.28-2.20(m, 1H), 2.11-2.04(m, 1H), 2.00-1.72 (m,9H), 1.17(d, J = 6.8 Hz, 3H)
84		431	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.56-7.42 (m, 2H), 7.41-7.18(m, 5H), 4.84-4.72 (m, 2H), 4.52-4.36





Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methy1(7S)-2-benzyl-3-(7-azabicyclo[2.2.1heptan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		(m, 2H), 3.84-3 . 78(m,4H), 3.30-3.18 (m, 1H), 3.10-2.93 (m,2H), 2.50-2.40 (m, 1H), 2.32-2.20 (m, 1H), 2.14-1.94(m,2H), 1.85-1.65 (m, 3H), 1.50-1.40(m, 1H), 1.18-1.12 (m,3H) .
85	 methyl (7S)-2-benzyl-3-(2-azabicyclo[2.2.1]heptan-7-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate	431	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.47 (d, J= 1.4 Hz, 2H), 7.40-7.20(m,3H), 7.20-7.10 (m, 2H), 4.82-4.76(m, 1H), 4.52(d, J= 2.3 Hz, 2H), 4.19-4.08(m,2H),3.80 (s, 3H),3.31-3.13 (m, 2H), 3.07-2.94 (m, 2H), 2.72-2.68(m, 1H), 2.35-2.17 (m, 1H), 1.82-1.50(m,5H), 1.18-1.14 (m, 3 H)
86	 methyl (S)-2-benzyl-7-methyl-3-(((R)-piperidin-3-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate	433	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.35 (d, J = 8.7 Hz, 1H), 7.31-7.19 (m, 5H), 7.11 (d, J = 8.7 Hz, 1H), 4.89-3.71 (m, 1H), 4.43-428 (m, 2H), 3.89-3.67 (m, 5H), 3.27-3.22(m, 1H), 3.08-2.81 (m, 3H), 2.60-2.57 (m, 1H), 233-223 (m, 2H), 1.94-1.61 (m, 5H), 1.42-128 (m, 1H), 1.19-1.11 (m, 4H)
87	 methyl (S)-2-benzyl-7-methyl-3 -(((S)-piperidin-3-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate	433	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.84 (d, J=9.2Hz, 1H), 7.62(d, J=9.2Hz, 1H),7.45-7.42(m, 2H), 7.39-7.34(m, 3H), 4.87-4.83(m, 1H), 4.63-4.61 (m,2H), 4.36(d, J=7.6Hz, 2H), 3.82(s, 3H), 3.33-3.32(m, 1H), 3.25-3.22(m, 2H), 3.14-2.98(m, 1H), 2.89-2.77(m, 2H), 2.32-2.25(m, 2H), 1.94-1.85(m,2H), 1.74-1.71 (m, 1H), 1.61-1.57(m, 1H), 1.37-1.33(m, 1H), 1.18(d, J=6.8Hz, 3H)
88		433	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.46 (d, J = 8.8 Hz, 1H), 7.34 -




Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-2-benzyl-7-methyl-3-(((S)-piperidin-2-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		7.18 (m, 6H), 4.86 - 4.79 (m, 1H), 4.43 (q, J = 15.9 Hz, 2H), 3.91 - 3.88 (m, 2H), 3.81 (s, 3H), 3.33-3.30(m, 1H), 3.11 - 2.93 (m, 2H), 2.76-2.73 (m, 1H), 2.46-2.21 (m, 2H), 1.82- 1.73 (m, 2H), 1.59 - 1.41 (m, 3H), 1.21 (d, J = 6.6 Hz, 5H)
89	 methyl (S)-2-benzyl-7-methyl-3 -(((R)-piperidin-2-yl)methyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	433	^{1}H-NMR($CDCl_3$, 300MHz) δ (*ppm*): 7.32(d, J=9.0Hz, 1H), 7.30-7.16(m, 6H), 4.83-4.77(m, 1H), 4.39(s, 2H),3.81(d, J=6.6 Hz, 2H), 3.78(s, 3H), 3 .31-3.22(m, 1H), 3.08-2.92(m, 2H), 2.66-2.64(m, 1H), 2.38-2.23 (m, 2H), 1.79-1.70(m, 2H), 1.56-1.52(m, 2H), 1.46-1.38(m, 1H), 1.24-1.16(m, 5H)
90	 methyl (S)-2-benzyl-7-methyl-3 -(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	419	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.54 (d, J=9.0 Hz, 1H), 7.46-7.20(m, 6H), 4.84-4.78 (m, 1H, 4.42-4.30 (m, 3H), 3.79(s, 3H), 3.29-3.19 (m, 1H), 3.14-2.91 (m,3H), 2.59-2.48 (m, 2H), 2.38-2.20 (m, 3H), 1.80-1.72(m, 1H), 1.45-1.35 (m, 2H), 1.17 (d, J=6.7 Hz, 3H)
91	 methyl (S)-2-benzyl-7-methyl-3-((R)-piperidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate	419	^{1}H-NMR ($CDCl_3$, 400MHz) δ (*ppm*): 7.39 (d, J= 8.8 Hz,1H), 7.30-7.17 (m, 6H), 4.82-4.78(m, 1H), 4.46-4.24(m,3H), 378 (s, 3H), 3.32-3.02 (m, 4H), 2.92-2.85 (m, 1H), 2.63-2.58 (m, 1H), 2.30-2.11(m, 2H). 1.75-1.73 (m, 2H), 1.43-1.38 (m, 2H), 1.17(d, J=68 Hz, 3H)
92		419	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.55-7.20 (m, 7H), 4.82-4.78 (m, 1H), 4.52-4.31 (m, 3H), 3.79 (s,


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-2-benzyl-7-methyl-3-((S)-piperidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate		3H),3.36-3.34(m, 1H), 3.28-3.15 (m, 1H), 3.01-2.92 (m, 2H), 2.87-2.80(m, 1H), 2.68-2.58 (m, 1H), 2.30-2.12 (m,2H), 1.81-1.71 (m, 2H), 1.48-1.40 (m, 2H), 1.17(d, J = 6.6 Hz, 3H)
93	 methyl(S)-2-benzyl-7-methyl-3-(piperidin-4-ylmethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	433	^{1}H-NMR ($CDCl_3$, 400MHz) δ (*ppm*): 7.43 (d, J=8.4Hz,1H), 7.31-7.19 (m, 5H), 7.06(d, J=8.8Hz, 1H), 4.83-4.78(m, 1H), 4.41-4.29 (m, 2H), 3.80 (d, J=8Hz, 5H), 3.31-3.01 (m,4H), 2.47-2.23 (m, 3H), 1.77-1.72 (m, 6H), 1.60(s, 3H)
94	 methyl(7S)-2-benzyl-3-(7-azabicyclo[2.2.1] heptan-2-yl)-7-methyl-3,7,8,9-tetraydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	431	^{1}H-NMR ($CDCl_3$, 400MHz) δ (*ppm*): 7.43 (d, J= 8.4 Hz, 1H), 7.31-7.19 (m, 4H), 7.06(d, J = 8.8 Hz, 2H), 4.83-4.78 (m, 1H), 4.57-429 (m, 3H), 3.80-3.69 (m, 6H), 3 .25-2.90 (m, 4H), 2.51-2.23 (m, 4H), 1.76-1.71 (m, 1H), 1.17(d, J = 6.8 Hz, 3H)
95	 methyl(S)-2-benzyl-7-methyl-3-(7-azaspiro[3.5]nonan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	459	^{1}H-NMR ($CDCl_3$, 400MHz) δ (*ppm*): 7.33 (d, J=2 Hz,2H), 7.32-7.24 (m, 3H), 7.14(d, J = 8.8 Hz,2H), 4.83-4.68(m,2H),4.37 (d, J = 6 Hz, 2H), 3.82(s, 3H), 3.30-3.03 (m,2H), 2.81-2.53 (m, 6H), 2.30-2.01 (m, 3H), 1.82-1.53 (m,6H), 1.20(d, J = 8.8 Hz,3H)
96		459	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.36 (d, J=8.9 Hz, 1H), 7.30-7.28(m, 1H),7.27-7.26 (m, 1H), 7.25-7.17(m,3H), 7.06(d, J=8.9

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl (S)-2-benzyl-7-methyl-3-(2-azaspiro[3.5] nonan-7-yl)-3 ,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		Hz, 1H), 4.81-4.79(m, 1H), 4.41-4.27(m, 2H), 4.10-3.92 (m, 1H), 3.78(s, 3H), 3.55(s, 2H), 3.37 (s, 2H), 3.35-3.19 (m, 1H), 3.12-2.96 (m, 1H), 2.35-2.19 (m, 1H), 2.19-1.93 (m, 4H), 1.83-1.67 (m, 1H), 1.53-1.42 (m, 1H), 1.39-1.20(m,3H), 1.17(d, J = 6.7 Hz, 3H)
97	 methyl (S)-3-(azetidin-3-ylmethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	405	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.40(d, J=8.7Hz, 1H), 7.31-7.11(m, 6H), 4.82-4.76(m, 1H), 4.36(d, J=6.0Hz, 2H),4.20(d, J=7.2 Hz, 2H), 3.77(s, 3 H), 3.61-3.53 (m, 2H), 3.34-3.21(m, 3H), 3.07-2.92(m, 2H), 2.28-2.20(m, 1H), 1.78-1.70(m, 1H), 1.17(d, J=6.9Hz, 3H)
98	 methyl(7S)-2-benzyl-7-methyl-3-(octahydrocyclopenta[c]pyrrol-5-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	445	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.47-7.40(m, 1H), 7.37-7.32(m, 1H), 7.30-7.27(m, 1H), 7.26-7.24(m, 2H), 7.17-7.15(m, 2H), 4.84-4.78(m, 1H), 4.50-4.44(m, 1H), 4.39-4.32(m, 2H), 3.80(s, 3H), 3.30-3.20(m, 3H), 3.15-3.01(m, 3H), 2.75-2.70(m,2H), 2.32-2.12(m, 3H), 1.92-1.90(m, 1H), 1.80-1.72(m, 2H), 1.20(d, J=6.6Hz, 3H)
99		489	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.43 (d, J =8.8 Hz, 1H), 7.26-7 . 13 (m, 2H), 6.77-6.73 (m, 1H), 6.63-6.60(m, 2H), 4.83-4.77 (m, 1H), 4.61-4.45 (m, 2H), 4.34-

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl (S)-2-(3-isopropoxybenzyl)-7-methyl-3-(2-azaspiro [3.3] heptan-6-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		4.22(m,2H), 3.95 (d, J = 15.4 Hz, 4H), 3.79(s, 3H), 3.30-3.19(m, 1H), 3.07-2.97 (m, 3H), 2.59-2.49(m,2H),2.31-2.20 (m, 1H), 1.79-1.69 (m, 1H), 1.29-1.24(m,6H), 1.17 (d, J = 6.6 Hz, 3H)
100	 methyl(S)-2-(3-methoxyphenethyl)-7-methyl-3-(2-azaspiro[3.3]heptan-6-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	475	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.40-7.28(m, 1H), 7.24-7.21 (m, 2H), 6.81-6.73(m, 3H), 4.83-4.78(m, 1H), 4.59-4.54(m, 1H), 3.81-3.76(m, 9H), 3.25-3.19(m, 5H), 3.17-2.95(m, 3H), 2.69-2.58(m,3H), 2.31-2.23(m, 1H), 1.77-1.71(m, 1H), 1.18(d, J=6.9Hz, 3H)
101	 methyl(S)-2-(3-isopropoxyphenethyl)-7-methyl-3-(2-azaspiro[3.3]heptan-6-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	503	^{1}H-NMR ($CDCl_3$, 300MHz) δ(*ppm*): 7.39 (d, J=8.9 Hz, 1H), 7.26-7.16(m,2H),6.77-6.69 (m, 3H), 4.80 - 4.78(m, 1H), 4.57 - 4.43 (m, 2H), 3.85- 3.83 (m, 3H), 3.79(s, 3H), 3.23 - 2.95 (m, 9H), 2.66-2.60 (m, 2H), 2.26-2.24(m, 1H), 1.75-1.71 (m, 1H), 1.30-1.25 (m,6H), 1.16 (d, J = 6.7 Hz, 3H)
102	 methyl(S)-2-(3-fluorobenzyl)-7-methyl-3-(pipendin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	437	' H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.57 (d, J = 9.0 Hz, 1H), 7.48-7.29 (m, 2H), 7.14-6.95 (m, 3H), 4.85-4.73 (m, 1H), 4.49-4.29(m, 3H), 3.80(s, 3H),3.33-2.91 (m, 4H), 2.62-2.54(m, 2H), 2.47-2.19(m, 3H), 1.87-1.70 (m, 1H), 1.50-1.42 (m, 2H), 1.17(d, J = 6.6 Hz, 3H)
103		467	^{1}H-NMR ($CDCl_3$, 300MHz) δ


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-2-(3-fluoro-4-methoxybenzyl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxy late		(*ppm*): 7.52-7.41 (m, 2H), 6.94-6.85 (m, 3H), 4.83-4.77 (m, 1H), 4.35-4.23 (m, 3H), 3.85 (s, 3H), 3.79(s, 3H), 3.39 (d, J = 10.6 Hz, 2H), 3.34-3.16(m, 1H), 3.11-2.95 (m, 1H), 2.78-2.65 (m, 4H), 2.30-2.23 (m, 1H), 1.79-1.72 (m, 1H), 1.66-1.51 (m,2H), 1.18 (d, J=6.7Hz, 3H)
104	 methyl(S)-7-methyl-2-phenethyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quinoline-6-carboxylate	433	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.52 (d, J = 9.0 Hz, 1H), 7.41-7.13 (m,6H), 4.86-4.69 (m, 1H), 4.3 0-4.18 (m, 1H), 3.79 (s, 3H), 3.33-3.07 (m, 7H), 2.98-2.88 (m, 1H), 2.76-2.57 (m, 2H), 2.44-2.18 (m, 3H), 1.83-1.67 (m, 1H), 1.51-1.29 (m, 2H), 1.16(d, J = 6.7 Hz, 3H)
105	 methyl (S)-2-benzyl-7-methyl-3-{2-methyl-2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	473	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.38-7.36(m, 1H), 7.32-7.30(m, 2H), 7.25-7.21(m, 4H), 4.77-4.43 (m, 1H), 4.39-4.38(m, 2H), 4.21-4.15(m, 1H), 3.76(s, 3H),3.24-3.16(m,3H),3.03-2.99(m, 2H), 2.97-2.91(m, 1H), 2.37(s, 3H), 2.27-2.20(m, 1H), 2.11-2.01(m, 2H), 1.97-1.94(m, 2H), 1.78-1.72(m, 1H), 1.44-1.37(m, 4H), 1.14(d, J=5.1 Hz, 3H)
106		449	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.63 (d, J=9.1 Hz, 1H), 7.39-7.17(m,6H),4.80-4.68 (m, 1H), 4.42(s, 3H), 3.75 (s, 3H), 3.27-

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl (S)-2-benzyl-3-((3S,4R)-3-methoxypiperidin-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate		3.13 (m, 1H), 3.12-2.99 (m, 2H), 2.98-2.83 (m,4H), 2.82-2.68 (m, 1H), 2.65(s, 1H), 2.60-2.34(m, 2H), 2.32-2.14 (m, 1H), 1.82-1.65 (m, 1H), 1.36 (d, J = 12.4 Hz, 1H), 1.10(d, J = 6.6 Hz, 3H)
107	 methyl (S)-2-(4-methoxybenzyl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	449	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.5 4-7.52 (d, J = 8.0 Hz, 1H), 7.41-7.39 (d, J = 8.8 Hz, 1H), 7.20-7.18 (d, J = 8.4 Hz, 2H), 6.91-6.89 (d, J = 8.8 Hz, 2H), 4.81-4.76 (m, 1H), 4.40-4.36 (m, 3H), 3.79-3.77 (m, 6H), 3.34-3.21 (m, 1H), 3.21-3.02 (m, 2H), 3.00-2.96 (m, 1H), 2.58-2.57 (m, 2H), 2.37-2.25 (m, 3H), 1.80-1.75 (m, 1H), 1.48-1.40 (m, 2H), 1.17-1.16 (d, J = 6.4 Hz, 3H)
108	 methyl (S)-2-(4-niethoxybenzyl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6 -carboxylate	489	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.41-7.38 (d, J=9Hz, 1H), 7.30-7.16 (m, 3H), 6.92-6.88 (m, 2H), 4.81-4.75 (m, 1H), 4.33 (s, 2H),4.28-4.20(m, 1H), 3.79-3.73(m, 6H), 3.63 (s, 2H), 3.42 (s, 2H),3.28-3.17(m, 1H), 3.02-2.92 (m, 1H) ,2.33-2.24 (m, 1H), 2.16-2.09 (m, 4H), 1.82-1.74 (m, 1H), 1.51-1.42 (m, 4H), 1.15-1.13 (d, J = 6.6 Hz, 3H)
109	 methyl (S)-2-(2-(1H-pyiazol-1-yl)ethyl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	463	^{1}H-NMR (CD_3OD, 400MHz) δ (*ppm*): 7.52-7.48(m,2H), 7.37-7.34(m, 1H), 7.26-7.24(m, 1H), 6.21-6.20(m, 1H), 4.76-4.73(m, 1H), 4.65-4.62(m, 2H), 4.25-4.16(m, 1H), 3.87-3.85(m, 2H), 3.75(s, 3H), 3.63-3.57(m, 2H), 3.51-3.47(m, 2H), 3.15-3.11(m, 1H), 2.93-2.89(m, 1H), 2.25-2.13(m, 5H), 1.74-1.57(m, 5H), 1.12(d, J=6.8Hz, 3H)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
110	 methyl (S)-2-(3-methoxybenzyl)-7-methyl-3-(2-azaspiro[3.3]heptan-6-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	461	^{1}H-NMR (CD_3OD, 400MHz) δ (*ppm*): 7.44-7.40 (m, 2H), 7.26-7.22 (m, 1H), 6.84-6.69(m,3H), 4.90-0.76 (m, 2H), 4.36 (s, 2H), 3.93-3.91(m, 1H), 3.80-3.76(m, 9H),3.23-3.21(m, 1H),3.19-2.93 (m, 3H), 2.54-2.24 (m, 3H), 1.81-1.74 (m, 1H), 1.16(d, J=6.8Hz,3H)

Examples 111 and 112: methyl (S)-2-benzyl-7-methyl-3-((S)-7-azaspiro[3.5]nonan-1-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-2-benzyl-7-methyl-3-((R)-7-azaspiro[3.5]nonan-1-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0437]



Step 1. **Synthesis of methyl (2S)-5-amino-6-([7-[(tert-butoxy)carbonyl]-7-azaspiro[3.5]nonan-1-yl]amino)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0438] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of

nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate 1**) was dissolved in toluene (4 mL). Then tert-butyl 1-amino-7-azaspiro[3.5]nonane-7-carboxylate (242 mg, 1.01 mmol), Brettphos (36 mg, 0.07 mmol), 3rd Generation BrettPhos precatalyst (60.8 mg, 0.07 mmol) and sodium tert-butoxide (48.3 mg, 0.50 mmol) were added. The resulting solution was stirred for 1 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled to room temperature and the solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (52.8 mg, 34%) as a brown solid. MS: (ES, *m/z*): 459 $[M+H]^+$.

Step 2. **Synthesis of tert-butyl 1-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-7-azaspiro[3.5] nonane-7-carboxylate.**

[0439] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-([7-[(tert-butoxy)carbonyl]-7-azaspiro[3.5]nonan-1-yl]amino)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (52.8 mg, 0.12 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (83 mg, 0.69 mmol) was added. The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (25 mg, 39%) as a yellow oil. MS: (ES, m/z): 559 $[M+H]^+$.

Step 3. **Synthesis of methyl (S)-2-benzyl-7-methyl-3-((S)-7-azaspiro[3.5]nonan-1-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-2-benzyl-7-methyl-3-((R)-7-azaspiro[3.5]nonan-1-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0440] Into a 25-mL round-bottom flask, tert-butyl 1-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-7-azaspiro[3.5]nonane-7-carboxylate (25 mg, 0.04 mmol) was dissolved in dichloromethane (5 mL). Then trifluoroacetic acid (1 mL) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 um, 19 mm x 250 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 40.0% ACN over 8 min); UV Detector: 254 nm. This afforded the title compounds as follows: 2.4 mg (12%) of methyl (7S)-3-[(1R)-7-azaspiro[3.5]nonan-1-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer, RT = 5.8 min) as a white solid and 1.7 mg (8%) of methyl (7S)-3-[(1S)-7-azaspiro[3.5]nonan-1-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer, RT = 7.1 min) as a white solid.


First eluting isomer: ^{1}H-NMR (CD_3OD, 400 MHz) δ(*ppm*): 7.69 (d, J = 9.0 Hz, 1H), 7.48 (d, J


= 9.0 Hz, 1H), 7.39-7.23 (m, 3H), 7.21-7.14 (m, 2H), 4.82-4.78 (m, 1H), 4.68-4.62 (m, 1H), 4.50-4.32 (m, 2H), 3.80 (s, 3H), 3.28-3.06 (m, 2H), 3.02-2.96 (m, 1H), 2.88-2.81 (m, 1H), 2.77-2.55 (m, 3H), 2.40-2.15 (m, 3H), 1.89-1.66 (m, 4H), 1.48-1.40 (m, 1H), 1.18 (d, J = 6.7 Hz, 3H), 1.09-1.02 (m, 1H). MS: (ES, m/z): 459 $[M+H]^+$.


Second eluting isomer: ^{1}H-NMR (CD_3OD, 400 MHz) δ(*ppm*): 7.70 (d, J = 9.0 Hz, 1H), 7.48 (d, J = 9.0 Hz, 1H), 7.39-7.23 (m, 3H), 7.22-7.15 (m, 2H), 4.82-4.77 (m, 1H), 4.72-4.68 (m, 1H), 4.48-4.32 (m, 2H), 3.81 (s, 3H), 3.25-3.08 (m, 2H), 3.02-2.94 (m, 1H), 2.90-2.82 (m, 1H), 2.80-2.60 (m, 3H), 2.42-2.30 (m, 1H), 2.28-2.16 (m, 2H), 1.94-1.88 (m, 1H), 1.87-1.67 (m, 3H), 1.45-1.38 (m, 1H), 1.17 (d, J = 6.7 Hz, 3H), 1.12-1.08 (m, 1H). MS: (ES, *m/z*): 459 $[M+H]^+$.


[0441] The following examples in **TABLE** 7 were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 111 and 112.


TABLE 7


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
113 and 114	 1st eluting isomer (113)	1st eluting isomer=447	1st eluting isomer ^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.41-7.12 (m, 7H), 4.82-4.75 (m, 1H), 4.39-4.37 (m, 1H), 4.07-4.03 (m, 1H), 3.98-3.85 (m, 1H),3.78 (s, 3H), 3.34-3.26 (m, 2H), 3.07-2.92 (m,2H), 2.75-2.01 (m, 4H), 1.98-1.95 (m, 1H), 1.85-1.73 (m, 1H), 1.55-1.42 (m, 4H), 1.17 (d, J = 6.6 Hz, 3H), 1. 12-0.88 (m, 2H)
	2nd eluting isomer(114) methyl (7S)-2-benzyl-7-methyl-3-(1-(piperidin-4-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-	2nd eluting isomer=447	2nd eluting isomer^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.37 (d, J = 8.4 Hz, 1H), 7.28-7.26 (m, 1H), 7.24-7.17 (m, 5H), 4.81-4.75 (m, 1H), 4.44-4.41 (m, 1H), 4.21-4.12 (m, 1H), 4.01-3.88 (m, 1H), 3.78 (s, 3H), 3.56-3.27 (m, 2H), 3.06-2.99 (m, 2H), 2.72-2.06 (m,5H), 1.99-1.96 (m, 2H), 1.48-1.29 (m, 3H), 1.20 (d, J = 6.6 Hz, 3H), 1.11-0.85

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	carboxylate		(m, 2H)
115, 116, 117 and 118	 1st eluting isomer (115)	1st eluting isomer=447	1st eluting isomer ^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*):
			9.42 (s, 1H),7.74 (d, J = 8.9 Hz, 1H), 7.57-7.51 (m, 1H), 752-723 (m, 5H), 4.94 (s, 1H), 4.93-4.74 (m, 2H), 4.45 (s, 1H), 3.81 (s, 3H),3.35-2.90 (m, 4H), 2.66 (s, 3H), 2.02-1.53 (m, 3H), 1.44 (s, 2H), 1.21 (s, 3H), 1.14(d, J = 6.6 Hz, 3H)
			2nd eluting isomer ^{1}H-NMR (CD_3, 300 MHz) δ (*ppm*):
			7.38 (d, J = 8.8 Hz, 1H), 7.33-7.28 (m,2H),7.26-7.20 (m, 4H), 4.82-4.80 (m, 1H), 4.404.22 (m, 2H), 4.10-3.98 (m, 1H), 3.78 (s, 3H),3.35-3.17 (m, 1H), 3.14-2.98 (m, 1H), 2.89 (d, J = 12.0 Hz, 1H), 2.48-2.37 (m, 2H), 2.34-2.16 (m, 2H), 2.00(d, J = 13.1 Hz, 1H), 1.82-1.71 (m,3H), 1.44 (s, 1H), 1.26 (d, J = 6.9 Hz, 3H), 1.19 (d, J = 6.7 Hz, 3H),1.09-0.85 (m, 1H)
		2nd eluting isomer=447	
		3rd eluting isomer = 447	3rd eluting isomer ^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*):
	2nd elutingisomer(116)		7.42 (d, J = 8.9 Hz, 1H), 7.32-7.27 (m, 2H),7.26-7.20 (m, 4H), 4.83-4.79 (m, 1H), 4.32 (s, 2H), 4.05-3.91 (m, 1H), 3.80 (s, 3H),3.41-3.19 (m, 2H), 3.16-2.98 (m,2H), 2.53-2.17 (m, 4H), 1.81-1.74 (m, 1H), 1.50-1.38 (m, 2H),1.29 (d, J = 6.9 Hz, 3H), 1.18 (d, J = 6.7 Hz, 3H), 1.15-1.04 (m, 1H), 0.38-0.25 (m, 1H)
	3rd eluting isomer (117)		
	4th eluting isomer (118)	4th eluting isomer = 447	
	methyl (7S)-2-benzyl-7-methyl-3-(1-(piperidin-3-yl)ethyl)-3,7,8,9 - tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		4th eluting isomer ^{1}H-NMR ($CDCl_3$, 300 MHz) δ *(ppm):*

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			7.42 (d, J = 8.9 Hz, 1H), 7.33-7.27 (m,2H),7.25-7.19 (m, 4H), 4.82-4.78 (m, 1H), 4.41-4.22 (m, 2H), 4.06-3.93 (m, 1H), 3.79 (s, 3H),3.54 (d, J = 11.4 Hz, 1H), 3.39-3.17 (m, 2H), 3.14-2.98 (m, 1H), 2.81-2.53 (m,2H), 2.44 (t,J = 11.9 Hz, 1H), 2.35 - 217 (m, 1H), 1.85-1.68 (m, 1H), 1.64 (s, 2H), 1.28-1.22 (m, 3H), 1.25-1.16 (m, 4H),0.50 (s, 1H)
119, 120, 121 and 122	 1^{st} eluting isomer (119)	1^{st} eluting isomer = 433	1^{st} eluting isomer ^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*):
			7.46-7.34 (m, 2H), 7.33-7.27 (m,2H),7.26-7.17 (m, 3H), 4.85-4.76 (m, 1H), 4.52-4.38(m, 1H), 4.36-4.21 (m, 1H), 3.85-3.65 (m, 4H), 3.34-3.18(m,2H), 3.18-3.01 (m, 2H), 2.64-2.53 (m, 1H), 2.51-2.40(m, 1H),2.36-2.16 (m,3H), 1.82-1.71 (m, 1H), 1.30-1.22(m, 1H), 1.15-1.20 (m,3H), 1.06-0.80 (m, 1H), 0.45-0.34(m,3H)
			2^{nd} eluting isomer^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*):
		2^{nd} eluting isomer = 433	7.56-7.52 (m, 2H), 7.39-7.26(m,2H),7.25-7.20 (m, 3H), 4.85-4.75 (m, 1H), 4.58-4.48(m, 1H),427-0.17 (m, 1H), 3.85-3.72 (m, 4H), 3.34-3.21 (m,2H), 3.18-3.01 (m, 2H), 2.66-2.52 (m, 1H), 2.45-2.22(m,4H), 1.82-1.71 (m, 1H), 1.39-1.00 (m, 5H), 0.62-0.48(m,3H)
	2^{nd} eluting isomer (120)	3^{rd} eluting	3^{rd} eluting isomer ^{1}H-NMR

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		isomer = 433	($CDCl_3$, 400 MHz) δ (*ppm*):
	3rd eluting isomer (121)		7.46-7.26 (m, 4H), 7.25-7 . 16(m, 3H), 4.86 -4.75 (m, 1H), 4.47-4.25 (m, 3H), 3.78 (s, 3H), 3.41-3.20 (m, 2H),3.12-3.01 (m, 1H), 2.93-2.73 (m,3H), 2.60 (t,J = 12.0 Hz, 1H), 2.32-2.19 (m, 1H), 1.82-1.72(m, 1H), 1.69-1.50 (m, 2H), 1.37-1.26 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 7.2 Hz, 3H)
	4th eluting isomer (122)	4th eluting isomer = 433	
	methyl(7S)-2-benzyl-7-methyl-3-(3-methylpiperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		4th eluting isomer ^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*):
			7.44-7.17 (m, 7H), 4.88-4.79(m, 1H), 4.50-4.31 (m, 3H), 3.81 (s, 3H), 3.36-3.20 (m, 2H), 3.19-3.02 (m, 1H,2.97-2.70 (m, 3H), 2.58-2.42 (m, 1H), 2.36-2.17 (m, 1H), 1.87-1.78 (m, 3H), 1.59-1.49 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H), 1.11 (d, J=72 Hz, 3H) .
123, 124, 125 and 126			1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.55 (d, J = 9.0 Hz, 1H), 7.46-7.20 (m,6H), 4.82-4.72 (m, 1H), 4.65-4.42 (m, 3H), 3.80 (s, 3H), 3.30-3.18 (m, 1H), 3.02-2.82 (m, 3H), 2.58-2.48(m, 1H), 2.40-2.20 (m, 2H), 1.82-1.74 (m, 1H), 1.62-1.52(m, 1H), 1.32-1.13 (m, 5H), 1.00 (d, J = 7.1 Hz, 3H)
			2nd eluting isomer^{1}H-NMR (CD_3OD,300 MHz) δ (*ppm*):
		1st eluting isomer = 433	7.55 (d, J = 9.0 Hz, 1H), 7.46-7.20 (m,6H), 4.82-4.72 (m, 1H), 4.65-4.42(m, 3H), 3.80 (s, 3H), 3.30-3.18 (m,


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1H), 3.02-2.82 (m, 3H), 2.52-2.22(m,3H), 1.82-1.74 (m, 1H), 1.62-1.52 (m, 1H), 1.32-1.13 (m,5H), 1.00(d, J = 7.1 Hz, 3H)
		2nd eluting isomer = 433	
		3rd eluting isomer = 433	3rd eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
	1st eluting isomer (123)	4th eluting isomer = 433	7.55 (d, J = 9.0 Hz, 1H), 7.46-7.20(m,6H), 4.82-4.72 (m, 1H), 4.65-4.42(m, 3H), 3.80 (s, 3H), 3.30-3.18 (m, 1H), 3.02-2.92 (m, 2H), 2.64-2.52 (m, 2H), 2.32-2.12 (m, 2H), 2.00-1.72 (m,2H), 1.45-1.30 (m,2H), 1.26-1.13 (m, 3H), 1.08 (d, J = 6.3 Hz, 3H)
	2nd eluting isomer (124)		
	3rd eluting isomer (125)		
	4th eluting isomer (126)		
	methyl (7S)-2-benzyl-7-methyl-3-(2-methylpiperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxyla3e		4th eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.55 (d, J = 9.0 Hz, 1H), 7.46-7.20 (m,6H), 4.82-4.72 (m, 1H), 4.65-4.42(m, 3H), 3.80 (s, 3H), 3.30-3.18 (m, 1H), 3.02-2.92 (m, 2H), 2.64-2.52(m,2H),2.32-2.12 (m, 2H), 2.00-1.72 (m,2H), 1.45-1.30 (m,2H), 1.26-1.13 (m, 3H), 1.08 (d, J=63 Hz, 3H)
127 and 128	 1st eluting isomer (127)		1st eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
		1st eluting isomer = 445	7.58-7.45 (m, 2H), 7.38-7.15 (m, 5H), 5.03-4.89 (m, 1H), 4.84-4.74 (m, 1H), 4.43 (s, 2H), 3.80 (s, 3H), 3 . 29-3.12 (m, 5H), 3.02-2.92 (m,3H), 2.39-2.21 (m,3H), 2.17-2.12 (m, 2H), 1.79-1.72 (m, 1H), 1.17(d, J = 6.6 Hz, 3H)
		2nd eluting	2nd elut ing isomer ^{1}H-NMR

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		isomer = 445	(CD_3OD, 400 MHz) δ (*ppm*):
	2nd eluting isomer (128)		7.55-7.44 (m, 2H), 7.38-7.15 (m, 5H), 5.02-4.92(m, 1H), 4.82-4.78 (m, 1H), 4.43 (s, 2H), 3.80(s, 3H), 3.30-3.15 (m, 5H), 3.04-2.88(m, 3H),2.34-2.17 (m, 3H), 2.08-2.02(m, 2H), 1.79-1.72 (m, 1H), 1.17 (d, J = 6.6 Hz, 3H)
	methyl(S)-2-benzyl-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxy late		
129, 130, 131 and 132	 1st eluting isomer (129)	1st eluting isomer = 445	1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.50-7.19 (m, 7H), 4.81-4.77 (m, 1H), 4.53-4.33 (m, 3H), 3.80 (s, 3 H), 3 . 29-3.12 (m, 3H), 3.08-2.93 (m,2H), 2.80-2.72 (m, 2H), 2.45-2.00(m, 5H), 1.82-1.72 (m, 2H), 1.18 (d, J =3.0 Hz, 1H)
			2nd elut ing isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
		2nd eluting isomer = 445	7.30-7.10(m, 7H), 4.69-4.62 (m, 1H), 4.35-4.20 (m, 3H), 3.68 (s, 3H),3 .52-3 . 48(m, 2H), 3.15-3.02 (m, 2H), 2.92-2.84 (m, 2H), 2.65-2.60 (m, 1H), 2.30-1.92 (m, 5H), 1.70-1.60 (m, 2H), 1.05 (d, J = 4.0 Hz, 3H)
		3rd eluting isomer = 445	3rd eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
	2nd eluting isomer (130)		7.62 (d, J=9.1 Hz, 1H), 7.50-7.17 (m, 6H), 4.86-4.75 (m, 1H), 4.48-4.46 (m, 2H), 3.80(s, 3H), 3.28-2.78(m, 5H), 2.69-2.52 (m, 3H), 2.50-2.38 (m, 2H), 2.30-2.22 (m, 1H), 2.00-
	3rd eluting isomer (131)	4th eluting isomer = 445	

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	4^{th} eluting isomer (132)		1.90 (m, 1H), 1.85-1.69(m,3H), 1.19 (d, J=6.6 Hz, 3H)
	methyl (7S)-2-benzyl-7-methyl-3-(octahydrocyclopenta[c]pyrrol-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		4^{th} elutingisomer ^{1}H-NMR (CD_3OD, 300 MHz) δ(*ppm*):
			7.65-7.18 (m, 7H), 4.85-4.78 (m,2H), 4.48-4.46 (m, 2H), 3.79 (s, 3H), 3.27-3.15 (m, 2H), 3.10-2.60 (m, 5H),2.48-2.40 (m, 2H), 2.32-2.20(m, 1H), 2.04-1.92 (m, 1H), 1.86-1.68 (m, 3H), 1.15(d, J=4.50 Hz, 3H)

Examples 133 and 134: (2R)-3-[(7S)-6-(methoxycarbonyl)-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropanoic acid and (2S)-3-[(7S)-6-(methoxycarbonyl)-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropanoic acid

[0442]



***Step* 1. Synthesis of methyl (S)-5-amino-6-(benzylamino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate.**

[0443] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (250 mg, 1.66 mmol, **Intermediate 1**) was dissolved in toluene (20 mL). Then benzyl amine (375 mg, 3.5 mmol), Brettphos (144 mg, 0.26 mmol), 3rd Generation BrettPhos precatalyst (122 mg, 0.14 mmol) and sodium tert-butoxide (483 mg, 5.0 mmol) were added. The resulting solution was stirred for 1 h at 110°C under nitrogen atmosphere. The reaction mixture was cooled to room temperature and the solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (352 mg, 65%) as a yellow solid. MS: (ES, *m/z):* 325 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-3-benzyl-2-(3-ethoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0444] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-(benzylamino)-2-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylate (350 mg, 0.86 mmol) was dissolved in dichloromethane (10 mL). Then ethyl 4-oxo-2-phenylbutanoate (281 mg, 1.29 mmol, **Intermediate 32**) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:2). This afforded the title compound (210 mg, 48%) as a yellow solid. MS: (ES, *m/z*): 512 $[M+H]^+$.

Step 3. **Synthesis of methyl (7S)-2-(3-ethoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0445] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (7S)-3-benzyl-2-(3-ethoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (100 mg, 0.19 mmol) was dissolved in methanol (5 mL). Then palladium on carbon (10%, 50 mg) was added and hydrogen (g) was charged into the reaction mixture. The reaction mixture was stirred overnight at room temperature. The reaction was vented to nitrogen and the solids were filtered out over celite. The filtrate was concentrated under vacuum. This afforded the title compound (80 mg, 98%) as a yellow oil. MS: (ES, *m/z*): 422 $[M+H]^+$.

Step 4. **Synthesis of methyl (7S)-2-[(2R)-3-ethoxy-3-oxo-2-phenylpropyl]-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-[(2S)-3-ethoxy-3-oxo-2-phenylpropyl]-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0446] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (7S)-2-(3-ethoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (70 mg, 0.16 mmol) was dissolved in N,N-dimethylformamide (2 mL) and then cesium carbonate (107 mg, 0.32 mmol) were added. This was followed by the addition of methyl iodide (22.8 mg, 0.16 mmol) dropwise with stirring. The resulting solution was stirred for 1h at rt (20°C). The resulting solution was diluted with 20 mL of water and extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). The crude product was purified by Chiral-Prep-HPLC with the following conditions (Prep-HPLC): Column, (R, R) WHELK-01 5/100 Kromasil, 25cm x 21.1mm; mobile phase: A: Hex (0.1% DEA) and B: ethanol (hold 30.0% ethanol in 38 min); UV Detector: 254 nm. This afforded the title compounds as follows: 30 mg (43%) of methyl (7S)-2-[(2R)-3-ethoxy-3-oxo-2-phenylpropyl]-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate as a yellow oil (assumed stereochemistry, first eluting isomer) and 30 mg (43%) of (7S)-2-[(2S)-3-ethoxy-3-oxo-2-phenylpropyl]-3,7-dimethyl-3 H,6H,7H, 8H,9H-imidazo[4, 5-f] quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer) as a yellow oil. MS: (ES, *m/z*): 436 $[M+H]^+$.

Step 5A. **Synthesis of (2R)-3-[(7S)-6-(methoxycarbonyl)-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropanoic acid.**

[0447] Into a 50-mL round-bottom flask, methyl (7S)-2-[(2R)-3-ethoxy-3-oxo-2-phenylpropyl]-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (30 mg, 0.07 mmol) was dissolved in tetrahydrofuran (2 mL). Then a solution of lithium hydroxide (8.2 mg, 0.34 mmol) in water (2 mL) was added. The resulting solution was stirred overnight at 85°C in an oil bath. The reaction mixture was cooled to room temperature and the solids were filtered out. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5μm, 19x150mm; mobile phase: A: water (containing 0.05%TFA) and B: ACN (25.0% to ACN 45.0% over 7 min); UV Detector: 254nm. This afforded the title compound (3.9 mg, 14%) as a white solid.
1H-NMR ($CDCl_3$, 400 MHz) δ(ppm): 7.85-7.90(m, 1H), 7.33-7.22(m, 4H), 7.20-7.16(m, 2H), 4.84-4.80(m, 1H), 4.67-4.63(m, 1H), 3.88(s, 3H), 3.68(s, 3H), 3.56-3.49(m, 1H), 3.21-3.16(m, 2H), 3.03-2.94(m, 1H), 2.17-2.11(m, 1H), 1.84-1.79(m, 1H), 1.12(d, J=6.8Hz, 3H). MS: (ES, m/z): 408 [M+H]+.


Step 5B. **Synthesis of (2S)-3-[(7S)-6-(methoxycarbonyl)-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo [4,5-f]quinolin-2-yl]-2-phenylpropanoic acid.**

[0448] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of

nitrogen, methyl (7S)-2-[(2S)-3-ethoxy-3-oxo-2-phenylpropyl]-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (30 mg, 0.07 mmol) was dissolved in tetrahydrofuran (2 mL), and then a solution of lithium hydroxide (8.2 mg, 0.34 mmol) in water (2 mL) was added. The resulting solution was stirred overnight at 85°C in an oil bath. The reaction mixture was cooled to rt (20°C). The solids were filtered out. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, Sum, 19x150mm; mobile phase: A: Water (containing 0.05%TFA) and B: ACN (25.0% ACN up to 45.0% in 7 min); UV Detector: 254/220nm. This afforded the title compound (3.8 mg, 14%) as a white solid. 1H-NMR ($CDCl_3$, 400 MHz) δ(ppm): 7.88-7.92(m, 1H), 7.52-7.33(m, 5H), 7.28-7.25(m, 1H), 4.90-4.81(m, 2H),4.00-3.93(m, 1H), 3.86-3.63(m, 6H), 3.34-3.26(m, 1H), 3.12-3.05(m, 2H), 2.13-2.10(m, 1H), 1.80-1.73(m, 1H), 1.12-1.05(m, 3H). MS: (ES, m/z): 408 [M+H]+.

Examples 135 and 136: (S)-3-((S)-6-(methoxycarbonyl)-3,7-dimethyl-6,7,8,9-tetrahydro-3H-imidazo [4,5-f]quinolin-2-yl)-2-phenylpropanoic acid and (R)-3-((S)-6-(methoxycarbonyl)-3,7-dimethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid

[0449]



***Step 1*. Synthesis of methyl (S)-5,6-diamino-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate.**

[0450] Into a 50-mL round-bottom flask, methyl (S)-5-amino-6-(benzylamino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (160 mg, 0.49 mmol) was dissolved in methanol (25 mL). Then 10% palladium on carbon (20 mg) was added. Hydrogen (g) was charged into the

reaction mixture and the reaction was stirred under a hydrogen atmosphere for 3 h at room temperature. The solids were filtered out over celite and the filtered solution was concentrated under vacuum affording the title compound (112 mg, 97%) as a yellow oil. MS: (ES, *m/z*): 236 $[M+H]^+$.

Step 2. **Synthesis of methyl-(2S)-5-amino-6-(4-methoxy-4-oxo-3-phenylbutanamido)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0451] Into a 50-mL round-bottom flask, methyl-(2S)-5,6-diamino-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (110 mg, 0.47 mmol) was dissolved in N,N-dimethylformamide (3 mL). Then 4-methoxy-4-oxo-3-phenylbutanoic acid (97 mg, 0.47 mmol), diisopropylethylamine (182 mg, 1.41 mmol) and O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (268 mg, 0.70 mmol) were added, successively. The resulting solution was stirred for 1 h at room temperature. The resulting solution was diluted with 20 mL of water and extracted with 3x30 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (40 mg, 20%) as a light yellow oil. MS: (ES, m/z): 426 $[M+H]^+$

Step 3. **Synthesis of methyl-(7S)-2-(3-methoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0452] Into a 50-mL round-bottom flask, methyl-(2S)-5-amino-6-(4-methoxy-4-oxo-3-phenylbutanamido)-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (40 mg, 0.09 mmol) was dissolved in dimethyl sulfoxide (2 mL). Then acetic acid (2 mL) and sulfuric acid (0.01 mL) were added. The resulting solution was stirred for 2 h at 60°C. The resulting solution was cooled to room temperature and diluted with 50 mL of water. The mixture was extracted with 3x50 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (20 mg, 52%) as a light yellow oil. MS: (ES, m/z): 408 $[M+H]^+$

Step 4. **Synthesis of (S)-3-((S)-6-(methoxycarbonyl)-3,7-dimethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid and (R)-3-((S)-6-(methoxycarbonyl)-3,7-dimethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid.**

[0453] Into a 50-mL round-bottom flask, methyl-(7S)-2-(3-methoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (20 mg, 0.05 mmol) was dissolved in tetrahydrofuran (2 mL). Then water (2 mL) was added, followed by lithium hydroxide (7 mg, 0.29 mmol). The resulting solution was stirred for 12 h at 85°C. The resulting


mixture was cooled to room temperature and concentrated under vacuum. The pH value of the solution was adjusted to 3 with hydrogen chloride (1 mol/L). The resulting solution was extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 Å, 5 μm, 19 mm x 250 mm; mobile phase, A: water (containing 0.05% TFA) and B: ACN (5.0% to 60% ACN over 30 min); UV Detector: 254nm. Then the product was purified by Chiral-HPLC with the following conditions: Column: (R,R)-WHELK-O1-Kromasil, 5cm x 25cm (5μm); Mobile Phase, A: Hexanes (containing 0.1%DEA) and B: EtOH (hold 40% EtOH in 38 min); UV Detector: 254 nm. This afforded the title compounds as follows: 3.3 mg (17%) of 3-[(7S)-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2R-phenylpropanoic acid (assumed stereochemistry, first eluting isomer, RT=21.72) as a white solid and 2.4 mg (12%) of 3-[(7S)-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2R-phenylpropanoic acid (assumed stereochemistry, second eluting isomer, RT=29.57) as white solid.


First eluting isomer: ^{1}H-NMR: (CD_3OD, 300 MHz) δ(*ppm*): 7.40-7.18(m, 7H), 4.80-4.75(m, 1H), 4.15-4.10(m, 1H), 3.77(s, 3H), 3.61-3.58(m, 1H), 2.85-2.75(m, 1H), 2.25-2.20(m, 2H), 1.75-1.70(m, 2H), 1.14-1.12(m, 3H). MS: (ES, m/z): 394 $[M+H]^+$

Second eluting isomer: ^{1}H-NMR: (CD_3OD, 300 MHz) δ(*ppm*): 7.39-7.20(m, 7H), 4.80-4.75(m, 1H), 4.15-4.10(m, 1H), 3.77(s, 3H), 3.65-3.60 (m, 1H), 3.30-3.25(m, 1H), 2.85-2.75(m, 1H), 2.22-2.18(m, 1H), 1.75-1.70(m, 2H), 1.13-1.11(d, J=6.0 Hz, 3H). MS: (ES, m/z): 394 $[M+H]^+$

Examples 137 and 138: (R)-3-((S)-3-(2-(dimethylamino)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid and (S)-3-((S)-3-(2-(dimethylamino)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid

[0454]





***Step* 1. Synthesis of methyl (2S)-5-amino-6-[[2-(dimethylamino) ethyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0455] Into a 8-mL sealed tube purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (200 mg, 0.67 mmol, **Intermediate 1**) was dissolved in toluene (3 mL). Then (2-aminoethyl) dimethylamine (589.3 mg, 6.69 mmol), 3rd Generation BrettPhos precatalyst (121.2 mg, 0.13 mmol), sodium tert-butoxide (96.4 mg, 1.00 mmol) and Brettphos (143.5 mg, 0.27 mmol) were added. The resulting solution was stirred for 2 h at 110 °C under nitrogen atmosphere. The resulting mixture was cooled to room temperature and concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with the following conditions: Column, C18 silica gel; mobile phase, A: water (containing 0.5% TFA) and B: ACN (5.0% to 40.0% ACN over 30 min); UV Detector: 254 nm. This afforded the title compound (150 mg, 73%) as a yellow oil. MS: (ES, *m/z*): 307[M+H]$^+$.

***Step 2.* Synthesis of methyl (7S)-3-[2-(dimethylamino)ethyl]-2-(3-ethoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0456] Into a 8-mL sealed tube, methyl (2S)-5-amino-6-[[2-(dimethylamino)ethyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (150 mg, 0.47 mmol) was dissolved in dichloromethane (2 mL). Then ethyl 4-oxo-2-phenylbutanoate (151.4 mg, 0.70 mmol, **Intermediate 32**) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with the following conditions: Column, C18 silica gel; mobile phase, A: water (containing 0.5% TFA) and B: ACN (5.0% to 60.0% ACN over 30 min); UV Detector: 254 nm. This afforded the title compound (150 mg, 65%) as yellow oil. MS: (ES, *m/z*): 493[M+H]$^+$.

***Step 3.* Synthesis of (R)-3-((S)-3-(2-(dimethylamino)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid and (S)-3-((S)-3-(2-(dimethylamino)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo [4,5-f]quinolin-2-yl)-2-phenylpropanoic acid.**


[0457] Into a 50-mL round-bottom flask, methyl (7S)-3-[2-(dimethylamino)ethyl]-2-(3-ethoxy-3-oxo-2-phenylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (130 mg, 0.25 mmol) was dissolved in tetrahydrofuran (2 mL). Then water (2 mL) was added, followed by lithium hydroxide (31.6 mg, 1.27 mmol). The resulting solution was stirred overnight at 85°C. The reaction mixture was cooled to room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 19x150mm, 5μm; mobile phase: A: water (containing 0.05% TFA) and B: ACN (8.0% to 48.0% ACN over 12 min); UV Detector: 254nm. The crude product was purified by Chiral-Prep-HPLC with the following conditions: Column, (R, R)WHELK-01 5/100 Kromasil, 25cmx21.1mm; mobile phase: A: hexanes (containing 0.1% TFA) and B: ethanol (hold 30.0% ethanol in 38 min); UV Detector: 254nm. This afforded the title compounds as follows: 15.1 mg (13%) of (2R)-3-[(7S)-3-[2-(dimethylamino)ethyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropanoic acid (assumed stereochemistry, first eluting isomer, RT = 18.6 min) as a white solid and 17.8 mg (15%) of (2S)-3-[(7S)-3-[2-(dimethylamino)ethyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropanoic acid (assumed stereochemistry, second eluting isomer, RT = 26.4 min) as a white solid.


First eluting isomer: ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(ppm): 7.86-7.84(m, 1H), 7.63-7.59(m, 1H), 7.28-7.19(m, 5H), 4.91-4.65(m, 4H), 3.84-3.78(m, 4H), 3.65-3.36(m, 3H), 3.02-2.89(m, 8H), 2.10-2.03(m, 1H), 1.77-1.70(m, 1H), 1.12(d, J=6.6 Hz, 3H). MS: (ES, m/z): 465[M+H]$^+$.

Second eluting isomer: ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(ppm): 7.86-7.83(m, 1H), 7.52-7.48(m, 1H), 7.28-7.19(m, 5H), 4.83-4.68(m, 4H), 3.95-3.82(m, 4H), 3.50-3.45(m, 2H), 3.14-3.08(m, 1H), 2.98-2.96(m, 2H), 2.85-2.75(m, 6H), 2.14-2.12(m, 1H), 1.78-1.73(m, 1H), 1.09(d, J=6.9 Hz, 3H). MS: (ES, m/z): 465[M+H]$^+$.

Examples 139 and 140: (S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid and (R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid

[0458]





Step 1. **Synthesis of methyl-(2S)-5-amino-2-methyl-6-[(oxan-4-yl)amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0459] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl-(2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (150 mg, 0.50 mmol, **Intermediate 1**) was dissolved in toluene (5 mL). Then oxan-4-amine (150 mg, 1.48 mmol), Brettphos (54 mg, 0.10 mmol), 3rd Generation BrettPhos precatalyst (45 mg, 0.05 mmol) and sodium tert-butoxide (100 mg, 1.04 mmol) were added successively. The resulting solution was stirred for 2 h at 110°C in the nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (110 mg, 69%) as a green oil. MS: (ES, m/z): 420$[M+H]^+$

Step 2. **Synthesis of methyl-(7S)-2-(3-methoxy-3-oxo-2-phenylpropyl)-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo [4,5-f]quinoline-6-carboxylate.**

[0460] Into a 100-mL round-bottom flask, methyl-(2S)-5-amino-2-methyl-6-[(oxan-4-yl)amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate (160 mg, 0.50 mmol) was dissolved in dichloromethane (10 mL). Then methyl-4-oxo-2-phenylbutanoate (192 mg, 1.00 mmol, **Intermediate 32**) was added. The resulting solution was stirred for 12 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC with ethyl acetate/petroleum ether (2:1). This afforded the title compound (120 mg, 49%) as a yellow oil. MS: (ES, m/z): 492$[M+H]^+$

Step 3. **Synthesis of (S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid and (R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo [4,5-f]quinolin-2-yl)-2-phenylpropanoic acid.**


[0461] Into a 25-mL round-bottom flask, methyl-(7S)-2-(3-methoxy-3-oxo-2-phenylpropyl)-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (120 mg, 0.24 mmol) was dissolved in tetrahydrofuran (8 mL). Then lithium hydroxide (31 mg, 1.29 mmol) dissolved in water (2 mL) was added dropwise. The resulting solution was stirred for 12 h at 85°C. After cooled to room temperature, the resulting mixture was concentrated under vacuum. The product was purified with the following conditions: Column: XSelect CSH Prep C18 OBD Column, 19x250mm, 5um; Mobile Phases, A:Water (containing 0.05%TFA) and B: ACN (15% to 45% ACN over 7 min); UV Detector: 254/220 nm. The products was seperated with the following conditions: Column: Phenomenex Lux 5u Cellulose-4£¬AXIA Packed, 2.12x25cm,5um;Mobile Phases, A: Hexanes (containing 0.1%TFA) and B: EtOH (30% EtOH over 25 min); UV Detector: 254/220 nm; This afforded the title compounds as follows: 6.6 mg (6%) of 3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2R-phenylpropanoic acid (assumed stereochemistry, first eluting isomer, RT=14.37 min) as a light yellow solid and 8.7 mg (7%) of 3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2S-phenylpropanoic acid (assumed stereochemistry, first eluting isomer, RT=18.48 min) as a light yellow solid.


First eluting isomer: ^{1}H-NMR: (CD_3OD, 400 MHz) δ (ppm): 7.82-7.74(m, 2H), 7.41-7.32(m, 5H), 4.85-4.82(m, 2H), 4.28-4.22(m, 1H), 4.14-4.10(m, 1H), 4.03-3.98(m, 2H), 3.79(s, 3H), 3.74-3.64(m, 2H), 3.49-3.48(m, 1H), 3.06-3.04(m, 1H), 2.96-2.95(m, 1H), 2.61-2.55(m, 1H), 2.45-2.35(m, 1H), 2.21-2.15(m, 1H), 1.98-1.90(m, 2H), 1.16(d, J=6.8 Hz, 4H). MS: (ES, m/z): 478$[M+H]^+$


Second eluting isomer: ^{1}H-NMR: (CD_3OD, 400 MHz) δ (*ppm*): 7.78-7.73(m, 2H), 7.39-7.31(m, 5H), 4.87-4.80(m, 2H), 4.28-4.24(m, 1H), 4.12-4.09(m, 1H), 4.03-3.97(m, 2H), 3.79(s, 3H), 3.74-3.64(m, 2H), 3.48-3.47(m, 1H), 3.03-2.98 (m, 2H), 2.55-2.35(m, 2H), 2.21-2.19(m, 1H), 1.98-1.85(m, 2H), 1.14-1.11(m, 4H). MS: (ES, *m/z*): 478$[M+H]^+$



[0462] The following examples in **TABLE 8** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 139 and 140.



TABLE 8


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
141 and 142		1st eluting isomer = 518	1st eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz)δ (*ppm*):
			7.36 - 7.13 (m, 7H), 4.74 - 4.72 (m, 1H), 4.60(s, 2H), 4.39 (s, 2H), 4.18- 4.14 (m, 2H), 3.76(s, 3H), 3.68


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			- 3.62 (m, 1H), 3.38 - 3.31 (m, 1H), 3.13-3.10(m, 1H),2.93 - 2.89 (m, 1H), 2.33 - 1.97(m, 5H), 1.76-1.69(m, 3H), 1.57-1.45 (m, 1H), 1.13-1.06(m,4H)
		2nd eluting isomer = 518	2nd eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz)δ (*ppm*):
	1st eluting isomer (141)		7.39 - 7.12(m, 7H), 4.74-4.71 (m, 1H), 4.60 (d, J=3.3 Hz, 2H), 4.42 - 4.36 (m, 2H), 4.26-4.18(m, 2H), 3.76 (s, 3H), 3.70-3.62 (m, 1H), 3.36(d, J = 7.8 Hz, 1H), 3.18-3.11 (m, 1H), 291-285 (m, 1H), 2.28 - 2.12(m, 3H), 2.31-1.92 (m, 5H), 1.74-1.53 (m, 1H), 1.10-1.01(m,4H)
	2nd elutingisomer(142)		
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-(2-oxaspiro[3.5]nonan-7-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
143 and 144	 1st eluting isomer (143)	1st eluting isomer = 554	1st eluting isomer ^{1}H-NMR(DMSO-d6, 300 MHz) δ (*ppm*):
			7.44-7.19 (m, 7H), 4.664.61 (m, 1H), 4.37 (s, 1H), 4.12-407 (m, 1H), 3.67-3.45 (m, 6H), 3.21-3.14(m, 1H), 3.08-2.95 (m, 4H), 2.85-2.76 (m, 1H), 2.25-2.18(m, 2H),2.16-209 (m, 2H), 2.08-1.96(m, 1H), 1.76-1.47 (m, 3H), 1.36-125 (m, 1H), 1.17(d, J = 6.6 Hz, 3H)
		2nd eluting isomer = 554	2nd eluting isomer^{1}H-NMR(DMSO-d6, 300 MHz)δ(*ppm*):


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	2nd elutingisomer(144)		7.46-7.31 (m, 3H), 7.29-7.20(m, 4H), 4.66-4.60(m, 1H), 4.51-4.43 (m, 1H), 4.12-4.08(m, 1H), 3.67-3.59 (m, 4H), 3.13-2.96(m, 6H), 2.75-2.82(m, 1H), 2.30-1.97 (m, 6H), 1.77-1.53(m, 4H), 1.08-1.06(d, J = 6.6 Hz, 3H)
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-((trans)-4-(methylsulfonyl)cyclohexyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
145 and 146	 1st eluting isomer (145)	1st eluting isomer = 507	1st elutingisomer ^{1}H-NMR($CDCl_3$, 400 MHz) δ (*ppm*):
			7.58-7.52(m, 1H), 7.35-7.30(m, 5H), 7.14-7.10(m, 1H), 4.77-4.74(m, 1H), 4.61-4.58(m, 1H), 4.29-4.23(m, 1H), 4.11-4.02(m, 1H), 3.82(s, 3H), 3.80-3.79(m, 1H), 3. 76-3.61(m, 4H), 3.39-335(m, 1H), 3.11-3.05(m, 1H), 2.96-2.90(m, 1H), 2.63-2.49(m,6H), 2.15-2.09(m, 1H), 1.71-1.63(m, 1H), 1.12-1.08(m, 3H)
		2nd eluting isomer = 507	2nd eluting isomer ^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*):
	2nd elutingisomer(146)		7.60-7.52(m, 1H), 7.40-7.31(m, 5H), 7.16-7.11(m, 1H), 4.77-4.75(m, 1H), 4.64-4.61(m, 1H), 4.30-4.28(m, 1H), 4.08-4.04(m, 1H), 3.82(s, 3H), 3.80-3.79(m, 1H), 3.76-3.62(m, 4H), 3.39-335(m, 1H), 3.14-
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-(2-morpholinoethyl)-6,7,8,9-tetratydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoicacid		


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			3.06(m, 1H), 2.97-2.93(m, 1H), 2.64-2.50(m, 6H), 2.21-2.11(m, 1H), 1.68-1.65(m, 1H), 1.12-1.08(m, 3H)
147 and 148	 1st eluting isomer (147)	1st eluting isomer = 504	1st elutingisomer ^{1}H-NMR(CF_3CO_2D, 300MHz) δ(*ppm*):
			7.86 (d, J=9.0 Hz, 1H), 7.44-7.26 (m, 4H), 7.26-7.13 (m, 3H), 6.78(s, 1H), 4.98-4.77 (m, 1H), 4.45- 4.35(m, 1H), 4.32-4.07(m, 2H), 4.04-3.84(m, 4H),3.81-3.56(m,3H), 3.25-3.07(m, 2H), 3.07-2.81(m, 2H), 2.37-2.20(m, 1H), 2.09-1.90(m, 2H), 1.89-1.70(m, 3H), 1.70-1.43(m, 3H), 1.15(d, J
		2nd eluting isomer = 504	= 6.9 Hz, 3H) 2nd eluting isomer ^{1}H-NMR($CDCl_3$, 300 MHz) δ*(ppm):*
	2nd elutingisomer(148)		7.48-7.33 (m, 3H), 7.26-7.09(m,3H),6.99 (d, J=8.1 Hz, 1H), 4.72(d, J = 8.1Hz, 1H), 4.41 (s, 1H), 4.12-3.80 (m, 2H), 3.73 (s, 3H),3.66-3.50(m, 1H), 3.23-2.75(m,5H), 2.50-2.00(m, 3H), 1.82-1.18(m, 7H), 1.11(d, J = 6.3 Hz, 4H)
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-(2-(piperidin-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
149 and 150		1st eluting isomer = 491	1st eluting isomer ^{1}H-NMR (DMSO-d6, 300 MHz) δ (*ppm*):
			7.41 (d, J = 7.1 Hz,


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			2H), 7.32-7.12(m,5H), 4.63-4.59 (m, 1H), 4.14-4.07 (m, 2H), 3.88-3.82(m, 1H), 3.67-3.55(m, 4H), 3.09-2.89(m, 4H),2.83-2.72(m, 1H), 2.45-2.40 (m, 1H), 2.17-2.09 (m, 1H), 2.04-1.70(m, 1H), 1.62-1.44(m, 3H), 1.32-1.20 (m,3H), 1.05 (d, J = 6.6 Hz, 3H)
		2nd eluting isomer = 491	2nd eluting isomer ^{1}H-NMR(DMSO-d6, 300 MHz)δ (*ppm*):
	1st eluting isomer (149)		7.41 (d, J = 7.1 Hz, 2H), 7.34-7.13(m, 5H), 4.67-4.59 (m, 1H), 4.18-4.08 (m, 2H), 3.93-3.87(m, 1H), 3.68-3.50 (m, 4H), 3.11-2.92 (m, 4H), 2.81-2.72(m, 1H), 2.40-2.00(m, 3H), 1.61-1.41 (m, 3H), 1.40-1.10(m,3H), 1.05(d, J = 6.6 Hz, 3H)
	2nd eluting isomer(150)		
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-(piperidin-4-ylmethyl)6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
151 and 152	 1st eluting isomer (151)	1st eluting isomer = 506	1st eluting isomer ^{1}H-NMR (CD_3OD, 300MHz) δ(*ppm*):
			7.45-7.14 (m, 7H), 4.76-4.68(m, 1H),427-0.02 (m, 2H), 3.76 (s, 3H), 3.70-3.61(m, 1H), 3.41-3.26(m, 5H),3.19-3.14 (m, 1H), 2.91-2.79(m, 1H), 2.37-1.99 (m, 5H), 1.89-1.81 (m, 1H), 1.79-1.58(m, 1H), 1.51-1.15(m, 2H), 1.10 (d, J = 6.6 Hz, 3H), 1.01-0.90


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			(m, 1H)
		2nd eluting isomer = 506	2nd eluting isomer ^{1}H-NMR(CD_3OD, 300 MHz)δ(*ppm*):
	2nd eluting isomer(152)		7.48-7.11 (m, 7H), 4.76-4.69(m, 1H), 430-0.16 (m, 1H), 4.09-4.02 (m, 1H), 3.76(s, 3H), 3.68-3.62(m, 1H),3.38-3 29 (m, 5H), 3.16 (m, 1H), 2.87(m, 1H), 2.36-2.02 (m, 5H), 1.89-1.81 (m, 1H), 1.72-1.61(m, 1H), 1.43-1.18 (m, 2H), 1.12 (d, J = 6.7 Hz, 3H), 1.11-1.03(m, 1H)
	3-((S)-6-(methoxycarbonyl)-3-((trans)-4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
153 and 154	 1st eluting isomer (153)	1st eluting isomer = 501	1st eluting isomer ^{1}H-NMR (CD_3OD, 400MHz) δ(*ppm*):
			7.39-7.35(m, 3H), 7.35-7.25(m, 3H), 7.25-7.21(m, 1H), 4.88-4.73 (m, 1H), 4.26-4.21 (m, 1H), 4.07-4.04 (m, 1H), 3.78(s, 3H), 3.70-3.65(m, 1H), 3.51-3.39(m, 2H), 3.33-3.14 (m, 1H),2.95-2.91 (m, 1H), 2.91-2.77(m, 1H),2.28-222 (m, 3H), 2.22-2.11 (m,2H), 1.98-1.90(m, 1H), 1.74-1.71 (m, 1H), 1.63-1.60(m,1H), 1.12(d, J = 6.7 Hz, 3H), 1.01 (s, 1H)
		2nd eluting isomer = 501	2nd eluting isomer ^{1}H-NMR(CD_3OD, 400 MHz)δ(*ppm*):
	2nd eluting isomer(154)		7.43-7.22 (m, 7H), 4.91-4.73(m, 1H), 4.30-0.06 (m, 1H),


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	3-((S)-3-((trans)4-cyanocyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		4.04-4.02 (m, 1H), 3.78(s, 3H), 3.72-3.66(m, 1H),3.38-3.33 (m, 1H), 3.18-3.16(m, 1H), 2.97-2.81(m, 2H),2.31-2.15 (m, 5H), 2.13-1.87(m,2H), 1.87-1.62(m, 2H), 1.15 (d, J = 6.6 Hz, 3H), 1.16-1.14 (m, 1H)
155 and 156		1st eluting isomer = 478	1st eluting isomer ^{1}H-NMR (CD_3OD, 400MHz) δ(*ppm*):
			7.53-7.48 (m, 1H), 7.37-7.22(m, 6H), 4.76-0.71 (m, 1H), 4.48-4.42 (m, 1H), 4.22-4.16(m, 1H),4.06-3.87 (m, 2H), 3.79 (s, 3H), 3.70-3.66(m, 1H), 3.55-3.49(m, 1H), 3.38-3.34 (m, 1H), 3.21-3.12(m, 2H), 2.93-2.87(m, 1H), 2.52-2.45 (m, 1H), 2.31-2.18 (m, 1H), 2.09-2.01 (m, 1H), 1.89-1.80 (m, 2H), 1.73-1.65(m, 1H), 1.12(d, J = 6.4 Hz, 3H)
		2nd eluting isomer = 478	2nd eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
	1st eluting isomer (155)		7.49 (d, J = 9.0 Hz, 1H), 7.47-7.34(m, 3H),7.33-7.31 (m, 2H), 7.24-7.20(m, 1H), 4.78-4.75 (m, 1H), 4.43-4.32 (m, 1H), 4.21-4.16 (m,
	2nd eluting isomer(156)		



Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		1H), 4.06(t, J = 10.8 Hz, 1H), 4.03-3.88 (m, 2H), 3.78 (s, 3H), 3.76-3.63(m, 1H), 3.54-3.49 (m, 1H), 3.44-3.35 (m, 1H), 3.19-3.12 (m, 1H),2.93-2.82 (m, 1H), 2.43-2.18 (m, 2H), 1.74-1.61 (m,3H), 1.33-1.17 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H)
157 and 158	 1st eluting isomer (157)	1st eluting isomer = 478	1st eluting isomer ^{1}H-NMR(CD_3OD, 300 MHz) δ(*ppm*): 7.80-7.70 (m, 2H), 7.32-7.21 (m, 5H), 4.60-4.73 (m, 1H), 421 (t, J = 15.0 Hz, 1H), 3.97-3.83 (m,3H), 3.70 (s, 3H), 3.64-3.48 (m, 2H), 3.35-3.25 (m, 1H),3.02-2.81 (m, 2H), 2.58-2.38 (m, 1H), 2.20-2.05 (m,2H), 1.98-1.75 (m, 3H), 1.21 (m, 1H), 1.05 (d, J = 6.9 Hz, 3H)
		2nd eluting isomer = 478	2nd eluting isomer ^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*):
	2nd eluting isomer(158)		7.80-7.70 (m, 2H), 7.32-7.21 (m,5H), 4.62-4.50 (m, 1H), 420 (t, J = 15.0 Hz, 1H), 3.93 (d, J= 9.0 Hz, 2H), 3.92-3.83 (m, 2H), 3.71 (s, 3H), 3.69-3.48 (m, 2H), 2.98-2.86(m,2H), 2.38-2.08 (m, 2H), 1.88-1.60 (m,3H), 1.32-1.20 (m, 2H),
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-(piperidin-4-ylmethyl)-6,7,8,9-tetrahy dro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoicacid		



Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1.04 (d, J = 33 Hz, 3H)
159, 160, 161 and 162	 1^{st} elutingisomer (159)	1^{st} eluting isomer = 506	1^{st} eluting isomer ^{1}H-NMR(CD_3OD, 400 MHz) δ(*ppm*):
			7.45-7.26 (m, 7H), 4.76-4.74(m, 1H), 4.30-4.22 (m, 2H), 3.76(s, 3H), 3.71-3.66(m, 1H), 3.43-330(m,3H), 3.15-3.12 (m, 1H), 2.92-2.87(m, 1H), 2.22-2.17 (m, 2H), 1.98-1.72 (m, 5H), 1.57-1.54(m, 2H), 1.13-1.09 (m, 5H)
			2^{nd} eluting isomer ^{1}H-NMR(CD_3OD, 400 MHz)δ(*ppm*):
			7.43-7.25 (m, 7H), 4.76-4.73 (m, 1H), 4.25-4.22 (m, 2H), 3.76(s, 3H), 3.66-3.64 (m, 1H), 3.43-3.29(m,3H),3.13-3.11 (m, 1H), 2.94-2.90(m, 1H), 2.22-2.17 (m, 2H), 1.98-1.72 (m, 5H), 1.57-1.54(m, 2H), 1.12-0.96 (m, 5H)
		2^{nd} eluting isomer = 506	
		3^{rd} eluting isomer = 506	3^{rd} eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
	2^{nd} elutingisomer(160)		7.45-7.24 (m, 7H), 4.76-4.74(m, 1H), 4.30-4.22 (m, 2H), 3.76 (s, 3H), 3.71-3.66(m, 1H), 3.43-3.30(m, 3H), 3.15-3.12 (m, 1H), 2.92-2.87(m, 1H), 222-221 (m, 1H), 2.04-1.72 (m, 7H), 1.41-1.38(m,
	3^{rd} eluting isomer (161)	4^{th} eluting isomer = 506	
	4^{th} eluting isomer (162)		


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1H), 1.12-1.07 (m, 5H)
	3-((S)-3-((cis)-3-(hydroxymethyl)cyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		4th eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.46- 7.25 (m, 7H), 4.76-4.74(m, 1H), 4.30-4.22 (m, 2H), 3.76 (s, 3H), 3.71-3.66(m, 1H), 3.43-3.30(m, 3H), 3.15-3.12 (m, 1H), 2.92-2.87 (m, 1H), 222-221 (m, 1H), 2.04-1.72 (m, 7H), 1.41-1.38(m, 1H), 1.20-1.09 (m,5H)
163, 164, 165 and 166	 1st elutingisomer (163)	1st eluting isomer = 506	1st eluting isomer ^{1}H-NMR(CD_3OD, 400 MHz) δ(*ppm*):
			7.45-7.26 (m, 7H), 4.76-4.74(m, 1H), 4.30-4.22 (m, 2H), 3.76(s,3H), 3.71-3.66(m, 1H), 3.43-3.30(m, 3H), 3.15-3.12 (m, 1H), 2.92-2.87 (m, 1H), 2.22-2.17 (m, 2H), 1.98-1.72 (m, 5H), 1.57-1.54(m, 2H), 1.13-1.09 (m, 5H)
			2nd eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz)δ*(ppm):*
			7.43-7.25 (m, 7H), 4.76-4.73 (m, 1H), 4.25-4.22 (m, 2H), 3.76(s, 3H), 3.66-3.64(m, 1H), 3.43-329(m,3H), 3.13-3.11 (m, 1H), 2.94-2.90(m, 1H), 2.22-2.17 (m, 2H), 1.98-1.72 (m, 5H), 1.57-1.54(m, 2H), 1.12-0.96 (m,
		2nd eluting	


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		isomer = 506	5H)
		3rd eluting isomer = 506	3rd eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
	2nd elutingisomer(164)		
	3rd eluting isomer (165)		7.45-7.24 (m, 7H), 4.76-4.74 (m, 1H), 4.30-4.22 (m, 2H), 3.76 (s, 3H), 3.71-3.66(m, 1H), 3.43-3.30(m, 3H), 3.15-3.12 (m, 1H), 2.92-2.87 (m, 1H), 222-221 (m, 1H), 2.04-1.72 (m, 7H), 1.41-1.38(m, 1H), 1.12-1.07 (m, 5H)
	4th eluting isomer (166)	4th eluting isomer = 506	
	3-((S)-3-((trans)-3-(hydroxymethyl)cyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		4th eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.46- 7.25 (m, 7H), 4.76-4.74 (m, 1H), 4.30-4.22 (m, 2H), 3.76 (s, 3H), 3.71-3.66(m, 1H), 3.43-3.30(m, 3H), 3.15-3.12 (m, 1H), 2.92-2.87 (m, 1H), 2.22-2.21 (m, 1H), 2.04-1.72 (m, 7H), 1.41-1.38(m, 1H), 1.20-1.09 (m,5H)
167 and 168	 1st eluting isomer (167)	1st eluting isomer = 524 2nd	1st eluting isomer ^{1}H-NMR(CD_3OD, 300 MHz) δ (*ppm*):
			7.43-7.36 (m, 2H), 7.32-7.20(m, 1H), 7.15-7.02 (m, 2H), 7.00-6.99 (m, 1H), 476-473 (m, 1H), 4.344.23 (m, 2H), 3.70-3.67 (m, 4H), 3.40-3.32(m, 4H), 3.13-3.07 (m, 1H), 293-287 (m, 1H), 2.32-2.13 (m,5H),



Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1.96 (d, J = 12.6 Hz, 1H), 1.76-1.69 (m, 1H), 156-1.19 (m, 3H), 1.12(d, J = 6.6
			Hz, 3H) 2nd eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz)δ(*ppm*):
		eluting isomer = 524	7.41-7.34 (m, 2H), 7.34-724(m, 1H), 7.24-7.16 (m, 1H), 7.16-7.14 (m, 1H), 7.00-6.96(m, 1H), 4.77-4.72 (m, 1H), 4.34 (s, 1H), 4.14 (s, 1H), 3.77 (s, 3H), 3.77-3.65 (m, 1H), 3.41-3.31 (s, 5H), 3.16-3.13 (m, 1H), 2.91-2.85 (m, 1H), 2.40-2.13 (m, 5H), 1.98-1.94(m, 1H), 1.76-1.69 (m, 1H), 1.50-1.46 (m, 1H), 1.34-1.26 (m, 2H), 1.13 (d, J= 6.7 Hz, 3H)
	2nd elutingisomer(168)		
	2-(3-fluorophenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)-4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid		
169 and 170	 1st eluting isomer (169)	1st eluting isomer = 524	1st eluting isomer ^{1}H-NMR(DMSO-d6, 400 MHz)δ(*ppm*):
			7.40-7.07 (m, 6H), 4.64-4.59(m, 1H), 4.28-4.14 (m, 2H), 3.65 (s, 3H),3.58-3.52(m, 1H), 3.34(s, 4H), 3.16-3.11 (m, 1H), 3.04-2.96 (m, 1H), 2.81-2.67 (m, 1H), 2.14-2.01 (m, 5H), 1.86-1.83 (m, 1H), 1.62-1.57(m, 1H), 1.36-1.23 (m, 3H), 1.04-1.03 (m, 3H)
		2nd eluting	2nd eluting isomer ^{1}H-


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		isomer = 524	NMR(DMSO-d6, 400 MHz)δ(*ppm*):
			7.46-7.10 (m, 6H), 4.64-4.59(m, 1H), 4.36-4.17 (m, 2H), 3.65 (s, 3H), 3.65-3.57 (m, 1H), 3.34 (s, 4H), 3.16-3.11 (m, 1H), 304-296 (m, 1H), 281-267 (m, 1H), 2.14-2.01 (m, 5H), 1.86-1.83 (m, 1H), 1.62-1.23 (m,4H), 1.05-1.04 (m, 3H)
	2nd eluting isomer(170)		
	2-(4-fluorophenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-y)propanoic acid		
171 and 172	 1st eluting isomer (171)	1st eluting isomer = 539	1st eluting isomer ^{1}H-NMR($CDCl_3$, 300 MHz) δ (*ppm*):
			7.47-7.42 (m, 1H), 7.39-7.32(m, 1H), 7.22 (s, 3H), 4.74-472 (m, 1H), 4.35-410(m, 2H), 3.76(s, 3H),3.70-3.60 (m, 1H), 3.35-3.31 (m, 5H), 3.30-2.93 (m, 2H), 2.26-2.18 (m,5H), 2.16-1.90(m, 1H), 1.80-1.12 (m,4H), 1.10(d, J= 6.6 Hz, 3H)
		2nd eluting isomer = 539	2nd eluting isomer ^{1}H-NMR($CDCl_3$, 300 MHz) δ (*ppm*):
	2nd eluting isomer(172)		748-722 (m, 6H), 4.74-4.72(m, 1H), 4.40-4.11 (m, 2H), 3.76-3.65 (m, 4H), 3.40-3.32(m, 5H), 3.31-2.80 (m, 2H), 228-215 (m,5H), 1.89-1.30 (m,5H), 1.28(d, J=672 Hz, 3H)
	2-(3-chlorophenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid		
173 and 174		1st eluting isomer = 539	1st eluting isomer ^{1}H-NMR($CDCl_3$, 300 MHz) δ (*ppm*):


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 1st eluting isomer (173)		7.41-7.25 (m, 6H), 4.74-4.72(m, 1H), 4.30-4.05 (m, 2H), 3.76 (s, 3H), 3.70-3.60(m, 1H), 3.40-3.30 (m, 5H), 3.20-2.92 (m, 2H), 2.25-2.16 (m, 5H), 1.90-1.29 (m, 5H), 1.10(d, J = 6.6Hz, 3H)
		2nd eluting isomer = 539	2nd eluting isomer ^{1}H-NMR($CDCl_3$, 300 MHz) δ (*ppm*):
			736-723 (m, 6H), 4.80-4.70(m, 1H), 4.40-4.95 (m, 2H), 3.75 (s, 3H), 3.70-3.60(m, 1H), 3.40-3.30 (m, 5H), 3.29-2.80 (m,2H),2.40-2.05 (m, 5H), 1.98-1.45(m, 2H), 1.50-1.11 (m, 6H)
	2nd elutingisomer(174)		
	2-(4-chlorophenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid		
175 and 176	 1st eluting isomer (175)	1st eluting isomer = 542	1st eluting isomer ^{1}H-NMR(CD_3OD, 400 MHz) δ (*ppm*):
			7.47 (d, J = 9.0 Hz, 1H), 7.42-7.37 (m, 2H), 7.24-7.14 (m, 2H), 4.79-4.71 (m, 1H), 4.444.28(m, 1H), 4.28-4.22 (m, 1H), 3.76-3.70 (m, 4H), 3.49-3.35 (m, 4H), 3.17-3.09 (m, 1H), 3.09-3.00(m, 1H), 2.94-2.87 (m, 1H), 2.38-2.18 (m, 5H), 2.01-1.92 (m, 1H), 1.77-1.69(m, 1H), 1.55-1.38 (m, 3H), 1.11(d, J = 6.7 Hz, 3H)
		2nd eluting isomer = 542	2nd eluting isomer ^{1}H-NMR(CD_3OD,


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			400MHz) δ (*ppm*):
			7.47 (d, J = 9.0 Hz, 1H), 7.42-7.37 (m,2H), 7.24-7.14 (m, 2H), 4.79-4.71 (m, 1H), 4.444.28(m, 1H), 4.28-4.22 (m, 1H), 3.76-3.70 (m, 4H), 3.49-3.35(m,5H), 3.17-3.09 (m, 1H), 294-287 (m, 1H), 2.38-2.18(m, 5H), 2.01-1.96 (m, 1H), 1.77-1.69 (m, 111), 1.55-1.38(m, 3H), 1.11 (d, J= 6.7 Hz, 3H)
	2^{nd} eluting isomer(176)		
	2-(3,4-difluorophenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid		
177 and 178	 1^{st} eluting isomer(177)	1^{st} eluting isomer = 520	1^{st} eluting isomer ^{1}H-NMR(CD_3OD, 400 MHz) δ (*ppm*):
			7.83-7.75 (m, 2H), 7.27-7.12(m,4H), 4.814.80 (m, 1H), 4.58-4.50 (m, 1H), 4.20-4.17 (m, 1H), 3.99-3.94 (m, 1H), 3.80 (s, 3H), 3.74-3.68(m, 1H), 3.49-3.33 (m, 4H), 3.17-2.91 (m, 2H), 2.44-2.02(m,9H), 1.97-1.82 (m, 1H), 1.54-1.44 (m, 1H), 1.38-1.22(m, 2H), 1.16(d, J=6.7Hz, 3H)
		2^{nd} eluting isomer = 520	2^{nd} eluting isomer ^{1}H-NMR(CD_3OD, 300MHz) δ (*ppm*):
			7.83-7.75 (m, 2H), 7.27-7.12(m, 4H), 4.81-4.80 (m, 1H), 4.58-4.50 (m, 1H), 4.20-4.17 (m, 1H), 3.99-3.94 (m, 1H), 3.80 (s, 3H), 3.74-3.68(m, 1H), 3.49-


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	2nd eluting isomer(178)		3.33 (m, 4H), 3.17-2.91 (m, 2H), 2.44-2.02(m,9H), 1.97-1.82 (m, 1H), 1.54-1.44 (m, 1H), 1.38-1.22(m,2H), 1.16(d, J = 6.7 Hz, 3H)
	3-((S)-6-(methoxycarbonyl)-3-((trans)-4-met hoxycyclohexyl)-7-niethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(m-tolyl)propanoic acid		
179 and 180	 1st eluting isomer (179)	1st eluting isomer = 520	1st eluting isomer ^{1}H-NMR(CD_3OD, 300 MHz) δ (*ppm*):
			7.36-7.27 (m, 2H), 7.26-7 . 18 (m, 2H), 7.07-7.02 (m, 2H), 4.82-4.68 (m, 1H), 4.11-4.03 (m, 1H), 4.02-3.92 (m, 1H), 3.77 (s, 3H), 3.68-3.52(m, 1H), 3.43-334 (m, 4H), 3.21-3.04 (m, 1H), 2.99-2.80(m, 1H), 2.33-1.99 (m, 8H), 1.97-1.82 (m, 1H), 1.79-1.62(m, 1H), 1.49-1.04 (m, 6H), 0.98-0.81 (m, 1H)
		2nd eluting isomer = 520	2nd eluting isomer ^{1}H-NMR(CD_3OD, 300MHz)δ (*ppm*):
			7.41-7.27 (m, 2H), 7.26-717(m,2H), 711-701 (m, 2H), 4.79-4.62 (m, 1H), 4.23-4.06(m, 1H), 4.02-3.89 (m, 1H), 3.75 (s, 3H), 3.75-3.56(m, 1H), 3.41-3.33 (m, 4H),3.24-3.09 (m, 1H), 2.93-2.77 (m, 1H), 2.36-1.99 (m, 8H), 1.95-1.82 (m, 1H), 1.79-1.61 (m, 1H), 1.52-1.07 (m, 6H), 1.06-0.93 (m, 1H)
	2nd eluting isomer(180)		
	3-((S)-6-(methoxycarbonyl)-3-((trans)-4-methoxycyclohexyl)-7-mettyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid		



Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
181 and 182	 1st eluting isomer (181)	1st eluting isomer = 554	1st eluting isomer ^{1}H-NMR(CD_3OD, 300MHz)δ(*ppm*):
			7.50-7.29 (m, 2H), 7.22(d, 1H), 7.06-6.89 (m, 2H), 4.81-4.68 (m, 1H), 4.27-4.21 (m, 1H), 4.00 (t, J= 7.5 Hz, 1H), 3.81 (S, 3H), 3.78 (S, 3H),3.70-3.56 (m, 1H), 3.48-3.34(m, 5H), 3.23-3.06 (m, 1H), 2.99-2.83 (m, 1H), 2.34-2.09 (m, 5H), 1.93-1.85 (m, 1H), 1.79-1.62(m, 1H), 1.52-1.22 (m, 2H), 1.20-1.07 (m, 4H)
		2nd eluting isomer = 554	2nd eluting isomer ^{1}H-NMR (CD_3OD, 300MHz)δ(*ppm*):
			7.47-7.32 (m, 2H), 7.25 (d, J = 12.2 Hz, 1H), 7.10-6.91 (m, 2H), 4.81-4.68 (m, 1H), 4.324.26(m, 1H), 4.05-3.96 (m, 1H), 3.80(S, 3H), 3.78(S, 3H), 3 . 72-3.58 (m, 1H), 3.48-3.34 (m, 5H), 325-308 (m, 1H), 2.95-2.79(m, 1H), 2.38-2.10 (m, 5H), 1.93-1.85 (m, 1H), 1.78-1.65(m, 1H), 1.54-1.20 (m, 3H), 1.14 (d, J= 6.6 Hz, 3H)
	2nd eluting isomer(182)		
	2-(3-fluoro-4-methoxyphenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)-4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid		
183 and 184		1st eluting isomer = 538	1st eluting isomer ^{1}H-NMR(CD_3OD, 300MHz) δ (*ppm*):
			7.45-7.28 (m, 2H), 7.14-7.08(m, 2H),


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 1st eluting isomer (183)		7.00-6.97 (m, 1H), 4.73-4.71 (m, 1H), 4.24-4.10(m, 1H), 4.07-4.04 (m, 1H), 3.77 (s, 3H), 3.64-3.61 (m, 1H), 3 . 40-3.32(m, 5H), 3 . 23-3.07 (m, 1H), 2.96-2.88(m, 1H), 2.34-2.07 (m, 8H), 1.93 (d, J = 12.5 Hz, 1H), 1.79-1.62(m, 1H), 1.53-1.17 (m, 3H), 1.11 (d, J = 6.7 Hz, 3H)
		2nd eluting isomer = 538	2nd eluting isomer ^{1}H-NMR(CD_3OD, 300MHz) δ (*ppm*):
	2nd eluting isomer(184)		7.37-7.31 (m, 2H), 7.16-7.01 (m, 2H), 7.00-6.96 (m, 1H), 4.90 (s, 1H),4.26-4.10(m, 1H), 4.01-3.95 (m, 1H), 3.76 (s, 3H), 3 . 70-3.61 (m, 1H), 3.42-3.35 (m,5H), 3.16-3.04 (m, 1H), 2.93-2.80 (m, 1H), 2.38-2.07(m, 8H), 1.95-1.85 (m, 1H), 1.73-1.67 (m, 1H), 1.48-1.35 (m, 1H), 1.32-1.18 (m, 2H), 1.13 (d, J = 6.7 Hz, 3H)
	2-(3-fluoro-4-methylphenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)-4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoicacid		
185 and 186	 1st eluting isomer (185)	1st eluting isomer = 553	1st eluting isomer ^{1}H-NMR(CD_3OD, 400MHz) δ (*ppm*):
			7.83-7.75 (m, 2H), 7.27-7.12(m, 4H), 4.81-4.80 (m, 1H), 4.58-4.50 (m, 1H), 4.20-4.17(m, 1H), 3.99-3.94 (m, 1H), 3.80 (s, 3H), 3.74-3.68(m, 1H), 3.49-


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			3.33 (m, 4H), 3 . 17-2.91 (m, 2H), 2.44-2.02(m,9H), 1.97-1.82 (m, 1H), 1.54-1.44 (m, 1H), 1.38-1.22 (m, 2H), 1.16(d, J=6.7Hz, 3H)
		2nd eluting isomer = 553	2nd eluting isomer ^{1}H-NMR(CD_3OD, 300MHz) δ (*ppm*):
			7.83-7.75 (m, 2H), 7.27-7.12(m, 4H), 4.81-4.80 (m, 1H), 4.58-4.50 (m, 1H), 4.20-4.17(m, 1H), 3.99-3.94 (m, 1H), 3.80 (s, 3H), 3.74-3.68(m, 1H), 3 .49-3.33 (m, 4H), 3 . 17-2.91 (m, 2H), 2.44-2.02(m,9H), 1.97-1.82 (m, 1H), 1.54-1.44 (m, 1H), 1.38-1.22 (m, 2H), 1.16(d, J = 6.7 Hz, 3H)
	2nd eluting isomer(186)		
	2-(3-chloro-4-methylphenyl)-3-((S)-6-(methoxycarbonyl)-3-((trans)-4-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoicacid		
187 and 188	 1st eluting isomer(179)	1st eluting isomer = 461	1st eluting isomer ^{1}H-NMR(CD_3OD, 300MHz) δ (*ppm*):
			7.36-7.27 (m, 2H), 7.26-7.18(m, 2H), 7.07-7.02 (m, 2H), 4.82-4.68 (m, 1H), 4.11-4.03 (m, 1H), 4.02-3.92 (m, 1H), 3.77 (s, 3H), 3.68-3.52(m, 1H), 3.43-3.34(m, 4H), 3.21-3.04 (m, 1H), 2.99-2.80(m, 1H), 2.33-1.99 (m, 8H), 1.97-1.82 (m, 1H), 1.79-1.62(m, 1H), 1.49-1.04 (m, 6H), 0.98-0.81 (m, 1H)
		2nd eluting	2nd eluting isomer ^{1}H-


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		isomer = 461	NMR (CD_3OD, 300MHz) δ (*ppm*):
			7.41-7.27 (m, 2H), 7.26-7.17 (m, 2H), 7.11-7.01 (m, 2H), 4.79-4.62 (m, 1H), 4.23-4.06(m, 1H), 4.02-3.89 (m, 1H), 3.75 (s, 3H), 3.75-3.56(m, 1H), 3.41-3.33 (m, 4H), 3.24-3.09 (m, 1H), 2.93-2.77 (m, 1H), 2.36-1.99 (m, 8H), 1.95-1.82 (m, 1H), 1.79-1.61(m, 1H), 1.52-1.07 (m, 6H), 1.06-0.93 (m, 1H)
	2nd eluting isomer(180)		
	3-((S)-3-cyclopertyl-6-(methoxycaibonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
189 and 190	 1st eluting isomer (189)	1st eluting isomer = 489	1st eluting isomer ^{1}H-NMR(CD_3OD, 300MHz) δ (*ppm*):
			7.50-7.29 (m, 2H), 7.22(d, 1H), 7.06-6.89 (m, 2H), 4.81-4.68 (m, 1H), 4.27-4.21 (m, 1H), 4.00(t, J = 7.5 Hz, 1H), 3.81 (S, 3H), 3.78 (S, 3H), 3.70-3.56 (m, 1H), 3.48-3.34(m, 5H), 3 .23-3.06 (m, 1H), 2.99-2.83 (m, 1H), 2.34-2.09 (m, 5H), 1.93-1.85 (m, 1H), 1.79-1.62(m, 1H), 1.52-1.22 (m, 2H), 1.20-1.07 (m, 4H)
		2nd eluting isomer = 489	2nd eluting isomer ^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*):
	2nd eluting isomer(190)		7.47-7.32 (m, 2H), 7.25 (d, J= 12.2 Hz, 1H), 7.10-6.91 (m, 2H), 4.81-4.68 (m, 1H), 4.32-4.26(m,
	3-((S)-3-cycloheptyl-6-		


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	(methoxycaibonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		1H), 4.05-3.96 (m, 1H), 3.80 (S, 3H), 3.78 (S, 3H), 3.72-3.58 (m, 1H), 3.48-3.34 (m, 5H), 3.25-3.08 (m, 1H), 2.95-2.79(m, 1H),2.38-2.10 (m, 5H), 1.93-1.85 (m, 1H), 1.78-1.65(m, 1H), 1.54-1.20 (m, 3H), 1.14 (d, J = 6.6 Hz, 3H)
191 and 192	 1st eluting isomer (191)	1st eluting isomer = 540	1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.58-7.49 (m, 3H), 7.39-6.90 (m, 7H), 6.78 (d, J=9 Hz, 1H), 4.81-4.67 (m, 1H),4.29-4.01 (m, 1H), 3.75(s, 3H), 3.63-3.44 (m, 1H), 3.27-3.10 (m, 2H), 3.02-2.89 (m, 1H), 236-215(m, 1H), 1.81-1.61 (m, 1H), 1.49-1.04 (m, 1H), 1.17-1.04 (d, J=6.6 Hz, 3H)
		2nd eluting isomer = 540	2nd eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.66-7.49 (m, 3H), 7.32 (d, J = 9 Hz, 1H), 7.26-6.99 (m, 7H), 6.80 (d, J= 9 Hz, 1H), 4.83-4.67 (m, 1H), 4.12-3.98 (m, 1H), 3.74 (s, 3H), 3.63-3.49 (m, 1H), 3.27-3.11 (m, 2H), 3.01-2.79 (m, 1H), 2.34-2.16(m, 1H), 1.83-1.61 (m, 1H), 1.19 (d, J= 6.6 Hz, 3H)
	2nd eluting isomer(192)		
	3-((S)-6-(methoxycarbonyl)-7-methyl-3-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		



Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
193 and 194	 1st elutingisomer(193)	1st eluting isomer = 447	1st eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.83-7.75 (m, 2H), 727-7.12 (m,4H), 4.81-0.80 (m, 1H), 4.58-4.50 (m, 1H), 4.20-4.17 (m, 1H),3.99-3.94 (m, 1H), 3.80 (s, 3H),3.74-3.68 (m, 1H), 3.49-3.33 (m, 4H),3.17-2.91 (m, 2H), 2.44-2.02(m,9H), 1.97-1.82 (m, 1H), 1.54-1.44 (m, 1H), 1.38-1.22(m,2H), 1.16 (d, J = 6.7 Hz, 3H)
		2nd eluting isomer = 447	2nd eluting isomer^1 H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.83-7.75 (m, 2H), 727-7.12 (m,4H), 4.81-0.80 (m, 1H), 4.58-4.50 (m, 1H), 4.20-4.17 (m, 1H),3.99-3.94 (m, 1H), 3.80 (s, 3H),3.74-3.68 (m, 1H), 3.49-3.33 (m, 4H),3.17-2.91 (m, 2H), 2.44-2.02(m,9H), 1.97-1.82 (m, 1H), 1.54-1.44 (m, 1H), 1.38-1.22 (m, 2H), 1.16 (d, J = 6.7 Hz, 3H)
	2nd elutingisomer(194)		
	3-((S)-3-cyclobutyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
195 and 196	 1st eluting isomer (195)	1st eluting isomer = 463	1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.36-7.27 (m, 2H), 7.26-7.18 (m,2H),7.07-7.02 (m, 2H), 4.82-4.68 (m, 1H), 4.11-4.03 (m,


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1H), 4.02-3.92 (m, 1H), 3.77 (s, 3H),3.68-3.52 (m, 1H), 3.43-3.34 (m, 4H),3.21-3.04 (m, 1H), 2.99-2.80 (m, 1H), 2.33-1.99 (m, 8H), 1.97-1.82 (m, 1H), 1.79-1.62(m, 1H), 1.49-1.04 (m, 6H), 0.98-0.81 (m, 1H)
		2nd eluting isomer = 463	2nd eluting isomer^1 H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.41-7.27 (m, 2H), 7.26-7.17 (m, 2H), 7.11-7.01 (m, 2H), 4.79-4.62 (m, 1H), 4.23-4.06 (m, 1H),4.02-3.89 (m, 1H), 3.75 (s, 3H),3.75-3.56 (m, 1H), 3.41-3.33 (m, 4H), 3.24-3.09 (m, 1H), 2.93-2.77(m, 1H), 2.36-1.99 (m, 8H), 1.95-1.82 (m, 1H), 1.79-1.61(m, 1H), 1.52-1.07 (m, 6H), 1.06-0.93 (m, 1H)
	2nd elutingisomer(196)		
	3-((S)-6-(methoxycaibonyl)-7-methyl-3-(pentan-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoicacid		
197 and 198	 1st eluting isomer(197)	1st eluting isomer = 449	1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.50-7.29 (m, 2H), 7.22(d, 1H), 7.06-6.89 (m, 2H), 4.81-4.68 (m, 1H), 4.27-4.21 (m, 1H), 400 (t, J = 7.5 Hz, 1H), 3.81 (S, 3H), 3.78 (S, 3H),3.70-3.56 (m, 1H), 3.48-3.34 (m, 5H), 3.23-3.06 (m, 1H), 2.99-2.83 (m,

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1H), 2.34-2.09 (m, 5H), 1.93-1.85 (m, 1H), 1.79-1.62 (m, 1H), 1.52-1.22 (m, 2H), 1.20-1.07 (m, 4H)
		2^{nd} eluting isomer = 449	2^{nd} eluting isomer^1 H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.47-7.32 (m, 2H), 7.25(d, J = 12.2Hz, 1H), 7.10-6.91 (m, 2H), 4.81-4.68 (m, 1H), 4.32-4.26 (m, 1H), 4.05-3.96 (m, 1H), 3.80 (S, 3H), 3.78 (S, 3H), 3.72-3.58 (m, 1H), 3.48-3.34 (m, 5H), 325-308 (m, 1H), 2.95-2.79 (m, 1H), 2.38-2.10 (m, 5H), 1.93-1.85 (m, 1H), 1.78-1.65 (m, 1H), 1.54-1.20 (m, 3H), 1.14 (d, J = 6.6 Hz, 3H)
	2^{nd} eluting isomer(198)		
	3-((S)-3-(tert-butyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
199 and 200	 1^{st} eluting isomer(199)	1^{st} eluting isomer = 492	1^{st} eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.82-7.74(m, 2H), 7.39-7.33(m, 5H), 4.55-4.52(m, 1H), 4.24-4.21(m, 1H), 4.01-3.95(m, 1H), 3.79-3.69(m, 5H), 3.04-3.00(m, 1H), 2.96-2.93(m, 1H), 2.42-2.38(m, 1H), 2.25-2.21(m, 2H), 2.19-2.10 (m, 1H), 2.04-1.98(m, 2H), 1.92-1.87(m, 1H), 1.60-1.56(m, 1H), 1.43-1.39(m, 1H), 1.28-1.22(m, 2H), 1.16(d, J=6.4Hz, 3H)


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		2^{nd} eluting isomer = 492	2^{nd} eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.39-7.23(m, 7H), 4.75-4.71(m, 1H), 4.19-4.17(m, 2H), 3.75(s, 3H), 3.70-3.64(m, 2H), 3.39-3.36(m, 1H),3.13-3.11(m, 1H), 2.93-2.89(m, 1H), 2.28-2.14(m, 3H),2.08-2.05(m, 1H), 1.95-1.87(m, 2H), 1.73-1.69(m, 1H), 1.58-1.53(m, 1H), 1.33-1.29(m, 1H), 1.11(d, J= 6.8Hz, 3H), 1.00-0.95(m, 1H)
	2^{nd} eluting isomer(200)		
	3-((S)-3-((trans)-4-hydroxycyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
201 and 202	 1^{st} eluting isomer (201)	1^{st} eluting isomer = 492	1^{st} eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.86-7.80(m, 2H), 7.45-7.32(m, 5H), 5.17-5.11(m, 1H), 4.34-4.31(m, 2H), 4.01-3.95(m, 1H), 3.80(s,3H),3.60-3.55(m, 1H), 3.04-2.90(m, 2H), 2.54-2.41(m, 2H), 2.24-2.18(m, 1H), 2.09-1.97(m,3H), 1.91-1.71(m, 4H), 1.30-1.28(m, 1H), 1.15(d, J=6.4Hz, 3H)
		2^{nd} eluting isomer = 492	2^{nd} eluting isomer^1 H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.79-7.73(m,2H), 7.38-7.31(m, 5H), 4.81-4.76(m, 1H),4.29-4.20(m, 2H), 3.93-3.90(m, 1H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	2nd eluting isomer(202)		3.81-3.75(m, 4H), 2.99-2.96(m, 2H), 2.43-2.42(m, 1H), 2.23-2.04(m, 3H), 1.90-1.78(m, 3H), 1.68-1.61(m, 2H), 1.30-1.28(m, 1H), 1.13-1.06(m, 4H)
	3-((S)-3-((1R,3R)-3-hydroxycyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
203 and 204	 1st eluting isomer (203)	1st eluting isomer = 492	1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.42-7.30(m,4H), 7.28-7.24(m, 3H), 4.76-4.71(m, 1H), 4.32-430(m, 1H), 4 16-4 15(m, 1H),3.75(s,3H),3.71-3.65(m, 1H), 3.57-3.56(m, 1H), 3.35-3.33(m, 1H),3.16-3.12(m, 1H), 2.90-2.86(m, 1H), 2.24-2.19(m, 1H), 2.11-1.99(m, 3H), 1.97-1.85(m, 2H), 1.74-1.69(m, 1H), 1.52-1.49(m, 2H), 1.33-130(m, 1H), 1.13(d, J=6.4Hz, 3H)
		2nd eluting isomer = 492	2nd eluting isomer^1 H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
	2nd eluting isomer(204)		7.43- 7.24(m,7H), 4.76-4.72(m, 1H), 4.28-4.25(m, 2H), 3.76-3.67(m, 5H), 3.39-3.33(m, 1H), 3.14-3 . 12(m, 1H), 2.94-2.90(m, 1H), 2.23-1.95(m, 5H), 1.78-1.71(m, 2H), 1.35-1.28(m, 2H), 1.12(d, J=6.4Hz, 3H), 1.03-1.00(m, 1H)
	3-((S)-3-((1R,3S)-3-hydroxycyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
205 and 206	 1st eluting isomer (205)	1st eluting isomer = 492	1st eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.41-7.24(m, 7H), 4.75-4.71(m, 1H), 4.25-4.16(m, 2H), 3.75(s,3H),3.69-3.65(m, 1H), 3.54-3.52(m, 1H),3.35-333(m, 1H), 3.13-3.09(m, 1H), 2.93-2.89(m, 1H),2.23-222(m, 1H), 2.06-1.97(m, 3H), 1.91-1.85(m, 2H), 1.73-1.68(m, 1H), 1.51-1.29(m, 3H), 1.11(d, J=6.4Hz, 3H)
		2nd eluting isomer = 492	2nd eluting isomer^1 H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.41-7.24(m, 7H), 4.75-4.71(m, 1H), 4.25-4.16(m, 2H), 3.75(s,3H),3.69-3.65(m, 1H), 3.54-3.52(m, 1H),3.35-333(m, 1H), 3.13-3.09(m, 1H),2.93-2.89(m, 1H),2.23-222(m, 1H), 2.06-1.97(m, 3H), 1.91-1.85(m, 2H), 1.73-1.68(m, 1H), 1.51-1.29(m, 3H), 1.11(d, J=6.4Hz, 3H
	2nd eluting isomer(206)		
	3-((S)-3-((1S,3R)-3-hydroxycyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
207 and 208	 1st eluting isomer(207)	1st eluting isomer = 476	1st eluting isomer ^{1}H-NMR (CD_3OD, 400MHz) δ (*ppm*):
			7.85- 7.75 (m, 2H), 7.37-7.32 (m, 5H), 4.86- 4.82(m, 1H), 4.50 - 4.40 (m, 1H), 4.24- 4.20 (m, 1H), 3.99- 3.93 (m, 1H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			3.80 (s, 3H), 3.74 - 3.70 (m,1H), 2.99-2.97 (m, 2H), 2.26-220 (m, 2H), 2.14 - 2.12 (m, 1H), 2.02 -1.83 (m, 4H), 1.78-1.76 (m, 1H), 1.52-1.42 (m, 1H), 1.45 -1.30 (m, 2H), 1.20-1.12 (m, 4H)
		2nd eluting isomer = 476	2nd eluting isomer ^{1}H-NMR(CD_3OD, 400MHz) δ (*ppm*):
			.83 -7.79 (m, 2H), 7.38-7.32 (m,5H),4.86-4.82 (m, 1H), 4.50 - 4.40 (m, 1H), 4.24-4.20 (m, 1H), 3.99-3.93 (m, 1H), 3.80 (s, 3H), 3.74 - 3.70 (m, 1H), 3.04-2.93 (m, 2H), 2.26-220 (m, 2H), 2.14- 2.12 (m, 1H), 2.02 -1.83 (m, 4H), 1.78-1.76 (m, 1H), 1.52- 1.42 (m, 1H),1.45 - 1.30 (m, 2H), 1.17-1.14 (m, 4H)
	2nd eluting isomer(208)		
	3-((S)-3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		
209, 210, 211 and 212	 1st eluting isomer(209)	1st eluting isomer = 501	1st eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.88-7.71 (m, 2H), 7.49-7.27 (m, 5H), 4.63-4.42 (m, 1H), 4.36-4.18 (m, 1H), 4.02-3.91 (m, 1H),3.83 (s, 3H), 3.80-3.62 (m, 1H), 311-296 (m, 2H), 2.82-2.69(m, 1H), 2.40-2.21 (m, 3H), 2.21-2.09 (m, 1H), 2.09-1.98 (m, 2H), 1.98-1.86(m, 1H),


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			1.86-1.61 (m, 2H), 1.38-1.27 (m, 1H), 1.22-1.11 (m,4H)
			2nd eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.91-7.73 (m, 2H), 7.49-7.27 (m, 5H), 4 .71-4.42 (m, 1H), 4.29-4.12 (m, 1H), 4.11-3.92 (m, 1H), 3.82-3.66 (m, 4H), 3.12-2.93 (m, 2H), 2.83-2.59 (m, 1H), 2.37-1.50 (m, 9H) 1.32-1.25 (m,2H),1.18 (d, J = 6.6 Hz, 3H)
		2nd elutingisomer = 501	3rd eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
		3rd elutingisomer = 501	7.51-7.40 (m, 1H), 7.40-7.31 (m,3H),7.28-7.19 (m, 2H), 7.19-7.06 (m, 1H), 4.81-4.68 (m, 1H), 4.41-4.23 (m, 1H),4.11-3.99 (m, 1H), 3.77 (s, 3H), 3.70-3.59 (m, 1H), 3.29-3.20 (m, 1H), 3.20-3.06 (m, 1H), 3.02-2.84 (m, 2H), 2.42-231 (m, 1H), 2.31-2.15 (m, 2H), 2.15-2.02 (m, 2H), 1.93-1.82(m, 1H),1.74-1.62 (m, 2H), 1.51-1.39 (m, 1H), 1.19-1.04 (m, 4H)
	2nd eluting isomer(210)	4th elutingisomer = 501	
	3rd eluting isomer (211)		
	4th eluting isomer (212)		
	3-((S)-3-((cis)-3-cyanocyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		4th eluting isomer ^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*):
			7.50-7.18 (m, 7H), 4.79-4.61 (m, 1H),


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			4.49-4.31 (m, 1H), 4.19-4.03 (m, 1H), 3.78 (s, 3H), 3.72-3.57 (m, 1H), 3. 27-3.09 (m, 2H), 3.02-2.80 (m, 2H), 2.55-2.33 (m, 1H), 2.33-2.04 (m, 4H), 1.96-1.79 (m, 1H), 1.79-153 (m, 2H), 1.53-1.31 (m, 1H), 1.25-1.01 (m, 4H)
213, 214, 215 and 216	 1st eluting isomer(213)	1st eluting isomer = 501 2nd eluting	1st eluting isomer ^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*):
			7.82-7.66 (m, 2H), 7.49-7.21 (m,5H),4.83-4.78 (m, 1H), 4.38-4.24 (m, 1H), 4.93-3.78(m,4H),3.73-3.58 (m, 1H), 3.46-3.35 (m, 2H), 3.16-2.81(m, 2H), 2.61-1.77 (m, 9H), 1.71-1.53 (m,1H),1.16(d, J=6.6 Hz, 3H)
			2nd eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.81-7.67 (m, 2H), 7.50-7.29 (m, 5H), 4.88-4.79 (m, 1H), 4.71-4.46 (m, 1H), 4.34-4.19(m, 1H),3.99-3.87 (m, 1H), 3.79 (s,3H), 3.63-3.47 (m, 1H), 3.47-3 37 (m, 1H), 3.11-2.94 (m, 2H), 2.62-2.42 (m, 1H), 2.42-2.14 (m, 3H), 2.02-1.61 (m, 5H), 1.26-1.04 (m, 4H)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		isomer = 501 3rd eluting isomer = 501	3rd eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.51-7.21 (m, 7H), 4.81-4.61 (m, 1H) 4.39-4.22 (m, 1H), 4.13-4.01 (m, 1H), 3.76 (s, 3H), 3.71-3.55 (m, 1H), 3.44-3.33 (m, 1H), 3.24-3.07 (m, 1H), 3.02-2.81 (m, 2H), 2.52-2.13 (m, 3H), 2.09-1.91 (m, 2H), 1.83-1.71 (m,3H), 1.62-1.43 (m, 1H), 1.14-1.11 (m, 4H)
	2nd eluting isomer(214)	4th eluting isomer = 501	
	3rd eluting isomer (215)		
	4th eluting isomer (216)		
	3-((S)-3-((trans)-3-cyanocyclohexyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid		4th eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*):
			7.43-7.25 (m, 7H), 4.79-4.68 (m, 1H), 4.46-4.32 (m, 1H), 4.26-4.07 (m, 1H), 3.82-3.61 (m,4H), 3.43-3.32 (m, 1H), 3.23-3.06 (m, 1H),2.96-2.83 (m, 2H), 2.54-2.3 8 (m, 1H), 2.33-2.04 (m, 4H), 1.99-1.83 (m, 1H), 1.83-1.54 (m, 2H), 1.44-1.31 (m, 1H), 1.24-0.98 (m, 4H)

Example 217: methyl (S)-2-benzyl-3-(2-(1,1-dioxidothiomorpholino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0463]





Step 1. **Synthesis of methyl (2S)-5-amino-6-[(2,2-dimethoxyethyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0464] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (500 mg, 1.67 mmol, **Intermediate 1**) was dissolved in toluene (10 mL). Then 2,2-dimethoxyethan-1-amine (1.09 g, 10.37 mmol), sodium tert-butoxide (480 mg, 4.99 mmol), 3rd Generation BrettPhos precatalyst (150 mg, 0.17 mmol) and BrettPhos (180 mg, 0.34 mmo) were added successively. The resulting solution was stirred for 2 h at 110°C under nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (3:1). This afforded the title compound (530 mg, 98%) as a brown oil. MS: (ES, *m/z*): 324 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-2-benzyl-3-(2,2-dimethoxyethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0465] Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-[(2,2-dimethoxyethyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (530 mg, 1.64 mmol) was dissolved in toluene (15 mL). Then 2-phenylacetaldehyde (423 mg, 3.52 mmol) was added. The resulting solution was stirred for 14 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (520 mg, 75%) as a yellow oil. MS: (ES, m/z): 424 $[M+H]^+$.

Step 3. **Synthesis of methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0466] Into a 100-mL round-bottom flask, methyl (7S)-2-benzyl-3-(2,2-dimethoxyethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (520 mg, 1.23 mmol) was dissolved in tetrahydrofuran (4 mL). Then hydrochloric acid (4 M, 8 mL) was added. The resulting solution was stirred for 3 h at 60°C. The reaction mixture was cooled to room temperature. The resulting solution was diluted with 40 mL of water and extracted with 2x90 mL of ethyl acetate and the organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (450 mg, crude) as a yellow solid. MS: (ES, m/z): 396 $[M+ H_2O]^+$.

Step 4. **Synthesis of methyl (S)-2-benzyl-3-(2-(1,1-dioxidothiomorpholino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**





[0467] Into a 50-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (80 mg, 0.21 mmol) was dissolved in methanol (6 mL). Then thiomorpholine 1,1-dioxide (143 mg, 1.06 mmol) and acetic acid (127 mg, 2.11 mmol) were added. The mixture was stirred at room temperature for 30 min. To the mixture was added sodium cyanoborohydride (134 mg, 2.13 mmol) at 0°C. The resulting solution was stirred for 12 h at room temperature. Then water (20mL) was added slowly. The resulting solution was extracted with 2x60 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 μm, 19 mm × 250 mm; mobile phase, A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 40.0% ACN over 10 min); UV Detector: 254 nm. This afforded the title compound (31 mg, 29%) as a white solid.





^{1}H-NMR (DMSO-d_6, 400 MHz) δ(*ppm*): 7.36-7.20 (m, 7H), 4.69-4.59 (m, 1H), 4.33 (s, 2H), 4.24-4.13 (m, 2H), 3.66 (s, 3H), 3.12-2.94 (m, 5H), 2.90-2.76 (m, 5H), 2.61-2.51 (m, 2H), 2.20-2.06 (m, 1H), 1.66-1.56 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H). MS: (ES, *m/z):* 497 $[M+H]^+$.




[0468] The following examples in **TABLE 9** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 217.





TABLE 9


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
218		461	^{1}H-NMR (DMSO-d6, 400 MHz) δ (*ppm*):

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-3-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		7.35-7.19 (m, 7H), 4.69-4.59 (m, 1H), 4.52 (s, 4H), 428 (s, 2H), 4.043.94 (m, 2H), 3.66(s, 3H), 3.16 (s, 4H), 310-299 (m, 1H), 280 (dt, J = 16.8, 6.0 Hz, 1H), 2.48-2.42 (m, 2H), 2.18-2.08 (m, 1H), 1.65-1.56 (m, 1H), 1.05 (d, J = 6.4 Hz, 3H)
219	 methyl (S)-3-(2-(1-oxa-6-azaspiro[3.3]heptan-6 -yl)ethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	461	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.43 (d, J = 8.8 Hz, 1H), 7.3 6-7.16 (m, 5H), 7.07 (d, J = 8.8Hz, 1H), 4.88-4.71 (m, 1H), 447 (t, J=7.5 Hz, 2H), 4.42-4.32(m, 2H), 3.90 (t, J=72 Hz, 2H), 3.78 (s, 3H), 3.50 (s, 2H), 3.36-3.19 (m, 1H), 311-294 (m, 3H), 2.80 (t, J= 7.5 Hz, 2H), 2.64-2.42 (m, 2H), 2.37-2.19 (m, 1H), 1.82-1.65 (m, 1H), 1.17 (d, J=6.6 Hz, 3H)
220	 methyl (S)-2-benzyl-3-(2-(1,1-dioxido-1-thia-6-azaspiro[3.3]heptan-6-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	509	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.90-7.85(m, 1H), 7.68-7.65(m, 1H), 7.45-7.30(m, 5H), 4.88(s, 3H), 4.69(s, 2H), 4.47-4.43(m, 2H), 4.00-3.98(m, 4H), 3.80(s, 3H), 3.12-2.93(m, 4H), 2.27-2.20(m, 3H), 1.89-1.86(m, 1H), 1.16(d, J=6.4Hz, 3H)
221	 methyl (S)-3-(2-(2-oxa-6-azaspiro[3.4]octan-6-yl)ethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	475	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.44 (d, J = 8.8 Hz, 1H), 7.32-7.27 (m, 2H), 7.26-7.21 (m, 3H),7.09 (d, J =8.8 Hz, 1H), 4.81-4.79 (m, 1H), 4.59 (t, J =5.2 Hz, 4H), 4.55-4.29 (m, 2H), 4.03 (t, J = 7.5 Hz, 2H), 3.78 (s, 3H), 3.28-3.23 (m, 1H), 3.12-2.95 (m, 1H), 2.68 (s, 2H), 2.57-2.19 (m, 5H), 2.07 (t, J =

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
			7.0 Hz, 2H), 1.77-1.71 (m, 1H), 1.17 (d, J =6.6 Hz, 3H)
222	 methyl (S)-3-(2-(1-oxa-7-azaspiro[3.5]nonan-7-yl)ethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	489	^{1}H-NMR (DMSO-d6, 400 MHz) δ (*ppm*): 7.48 (d, J=8.6 Hz, 1H), 7.35-7.28(m,2H), 7.28-720 (m, 4H), 4.69-4.59(m, 1H), 4.38-4.28 (m, 4H), 420-407 (m, 2H), 3.66 (s, 3H), 3.12-2.99 (m, 1H), 2.84-2.75 (m, 1H), 2.46-2.35 (m,2H), 2.34-2.22 (m, 4H), 2.21-2.07 (m, 3H), 1.77-1.55 (m, 5H), 1.05 (d, J = 6.8 Hz, 3H)
223	 methyl (S)-3-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)ethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	489	^{1}H-NMR (DMSO-d6, 400 MHz) δ (*ppm*): 7.35-7.19 (m, 7H), 4.69-4.59 (m, 1H),4.31 (s, 2H), 4.23 (s, 3H), 4.19-0.10 (m, 3H), 3.66 (s, 3H), 3.10-3.00 (m, 1H), 2.80-2.75 (m, 1H), 2.35-2.09 (m, 7H), 1.75-1.55 (m,5H), 1.05(d, J = 6.4Hz,3H)
224	 methyl(S)-2-benzyl-7 -methyl-3-(2-(piperazin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	448	^{1}H-NMR ($CDCl_3$, 300MHz) *δ* (*ppm*): 7.43 (d, J =8.7 Hz, 1H), 7.32-7.26 (m, 2H), 7.26-7.19 (m, 3H), 7.09 (d, J = 8.8Hz, 1H), 4.83-4.77 (m, 1H), 4.45-4.33 (m, 2H), 403 (t, J = 72 Hz, 2H), 378 (s, 3H), 3.31-3.23(m, 1H), 3.07-2.98(m, 1H), 2.88 (t,J = 4.9 Hz, 4H), 2.42-2.22 (m, 8H), 1.77-1.70 (m, 1H), 1.17 (d, J = 6.6Hz, 3H)
225	 methyl(S)-2-benzyl-7-methyl-3-	462	^{1}H-NMR ($CDCl_3$, 300MHz) *δ* (*ppm*): 7.43 (d, J = 8.8Hz, 1H), 7.39-7.27 (m, 2H), 7.24-7.13 (m, 3H), 7.09 (d, J = 8.8Hz, 1H), 4.83-4.79 (m, 1H), 4.51-4.29


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	(2-(4-methylpipeiazin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		(m, 2H), 4.02(t, J = 7.2 Hz, 2H), 3.78(s, 3H), 3.31-3.23 (m, 1H), 3.08-3.00 (m, 1H), 2.46-2.22 (m, 14H), 1.79-1.68 (m, 1H), 1.17 (d,J =6.7Hz, 3H)
226	 methyl (S)-2-(2-(1H-pyiazol-1-yl)ethyl)-7-methyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	453	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.55 (d, J = 9 Hz, 1H), 7.24(s, 1H), 7.26-7.21 (m, 1H), 7.06 (d, J = 8.7 Hz, 1H), 6.19-6.00 (m, 1H), 4.82-4.77 (m, 1H), 4. 76-4.65 (m, 2H),4.01-3.88 (m, 2H), 3.88-3.73 (m, 3H), 3.73-3.61 (m, 4H), 3.50-3.41 (m, 2H), 3.32-3.13 (m, 1H), 3.11-2.89 (m, 1H), 2.57-2.49 (m, 2H), 2.49-2.39 (m, 4H), 2.35-2.19 (m, 1H), 1.79-1.64 (m, 1H), 1.16 (d, J = 6.6Hz, 3H)
227	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(4-methylpipemzin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	466	^{1}H-NMR ($CDCl_3$, 300MHz) *δ* (*ppm*): 7.52 (d, J = 1.8 Hz, 1H), 7.43 (d, J = 8.9 Hz, 1H), 7.25-7.18 (m, 1H), 7.06 (d, J = 8.8 Hz, 1H), 6.13(t, J =2.1 Hz, 1H), 4.85-4.66(m, 3H), 3.89 (t, J = 6.7 Hz, 2H), 3.78 (s, 3H), 3.51-3.36 (m, 2H), 3.32-3.15 (m, 1H), 3.08-2.91 (m, 1H), 2.66-2.13 (m, 14H), 1.81-1.64 (m, 1H), 1.16 (d, J = 6.6 Hz, 3H)
228	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	465	^{1}H-NMR($CDCl_3$, 400 MHz) *δ* (*ppm*): 7.55 (s, 1H), 7.45 (d, J = 8.8 Hz, 1H), 729(s, 1H), 7.06 (d, J=8.8 Hz, 1H), 6.16 (s, 1H), 4.89-4.58 (m, 7H), 388-369 (m, 5H), 3.50-3.38 (m, 2H), 3.31-3.14 (m, 5H), 3.07-2.96 (m, 1H), 2.69-2.51 (m, 2H), 239-226 (m, 1H), 1.82-1.69 (m, 1H), 1.18(d, J =6.8 Hz, 3H)
229		479	^{1}H-NMR($CDCl_3$, 300MHz) δ

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3-(2-(piperazin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-i]quinoline-6-carboxylate		(*ppm*): 7.42-7.40(m, 2H), 7.35-7.29(m, 1H), 7.09(d, J=8.7 Hz, 1H), 6.56(d, J=9.0Hz, 1H), 6.08-6.05 (m, 1H), 4.80-4.78(m, 1H), 4.46-4.38(m, 2H), 4.22-4.18(m, 2H), 3.78(s, 3H), 3.4 4-3.3 7(m, 2H), 3.21-3.16(m, 1H), 3.01-2.96(m, 1H), 2.90-2.86(m, 4H), 2.64-2.60(m, 2H), 2.50-2.48(m,4H), 2.27-2.25(m, 1H), 1.76-1.68(m, 1H), 1.15(d,J=6.6Hz,3H)
230	 methyl (S)-7-methyl-3-(2-(4-methylpiperazin-1-yl)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	493	^{1}H-NMR($CDCl_3$, 300MHz) δ (*ppm*): 7.43-7.40(m, 2H), 7.34-7.28(m, 1H), 7.09(d, J=8.7 Hz, 1H), 6.58(d, J=9.0Hz, 1H), 6.09-6.04(m, 1H), 4.80-4.78(m, 1H), 4.48-4.39(m, 2H), 4.18-4.15(m, 2H), 3.78(s, 3H), 3.43-3.37(m, 2H), 3.22-3.18(m, 1H), 3.01-2.96(m, 1H), 2.64-2.52(m, 6H), 2.42-2.23(m, 8H), 1.76-1.71(m, 1H), 1.15(d, J=6.9 Hz, 3H)
231	 methyl (S)-3-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	492	^{1}H-NMR($CDCl_3$, 300MHz) δ (*ppm*): 7.42-7.40(m, 2H), 7.35-7.29(m, 1H), 7.08(d, J=9.0 Hz, 1H), 6.57(d, J=8.7Hz, 1H), 6.08-6.05(m, 1H), 4.80-4.78(m, 1H), 4.66(s, 4H), 4.46-4.38(m, 2H), 4.07-4.02(m, 2H), 3.78(s, 3H), 3.41-3.34(m, 2H), 3.29-3.18(m, 5H), 3.01-2.96(m, 1H), 2.69-2.65(m, 2H), 2.30-2.20(m, 1H), 1.77-1.71(m, 1H), 1.15(d, J=6.6 Hz, 3H)
232		439	^{1}H-NMR($CDCl_3$, 400MHz) δ (*ppm*): 7.73-7.61 (m, 1H), 7.60-7.48 (m, 2H), 7.41-7.29(m, 1H), 6.32-6.30 (m, 1H), 5.78 (s, 2H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl (S)-2-(2-(1H-pyiazol-1-yl)ethyl)-7-methyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		4.94-4.78 (m, 1H), 4.69-4.36 (m, 2H), 3.93-3.67 (m, 7H), 3.39-3.14 (m, 1H), 3.09-2.96 (m, 1H), 2.80-2.45 (m, 6H), 2.36-2.17 (m, 1H), 1.82-1.66 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H)
233	 methyl (S)-7-methyl-3-(2-morpholinoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	466	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.71 (d, J = 6.8 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.34-7.28(m, 1H), 7.19(d, J = 8.4Hz, 1H), 6.57 (d, J = 8.8 Hz, 1H), 6.18 (td, J = 6.8, 1.2Hz, 1H), 5.55 (d, J = 14.8 Hz, 1H), 5.49(d, J = 14.8 Hz, 1H), 4.83 - 4.74 (m, 1H), 4.58 - 4.36 (m, 2H), 3.77 (s, 3H), 3.71 (s, 4H),3.27 - 3.16 (m, 1H), 3.01 (d, J = 17.2,5.6Hz, 1H), 2.70 - 2.40(m, 6H),2.30 - 2.19 (m, 1H), 1.77 - 1.68 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H)

Examples 234 and 235: methyl (7S)-2-benzyl-7-methyl-3-[2-[(4S)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-benzyl-7-methyl-3-[2-[(4R)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f] quinoline-6-carboxylate

[0469]



***Step 1*. Synthesis of methyl (7S)-2-benzyl-7-methyl-3-[2-[(4S)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-benzyl-7-methyl-3-[2-[(4R)-1-oxa-6-azaspiro[3.4]octan-6-**

yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate..


[0470] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (100 mg, 0.26mmol) was dissolved in methanol (5 mL). Then 1-oxa-6-azaspiro[3.4]octane (89.9 mg, 0.79mmol) and acetic acid (79.6 mg, 1.33mmol) were added. The mixture was stirred for 30 min at room temperature. To the mixture was added sodium cyanoborohydride (167.1 mg, 2.66mmol) at 0°C. The resulting solution was stirred for 14 h at room temperature. The resulting solution was diluted with 10 mL of water and extracted with 3x10 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 19 X150mm 5μm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (30.0% to 55.0% ACN over 7 min); UV Detector: 254 nm. The product was purified by Chiral-Prep-HPLC with the following conditions: Column, CHIRAL ART Cellulose-SB, 2x25cm,5μm; mobile phase, Hexane and ethanol (hold 30.0% ethanol in 34 min); UV Detector: 220/254nm. This afforded the title compounds as follows: 9.7 mg (8%) of methyl (7S)-2-benzyl-7-methyl-3-[2-[(4S)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer, RT = 21.50min) as a white solid and 12.7 mg (10%) of methyl (7S)-2-benzyl-7-methyl-3-[2-[(4R)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer, RT = 22.71min) as a white solid

First eluting isomer: ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.44 (d, *J* = 8.7 Hz, 1H), 7.33-7.28 (m, 2H), 7.27 -7.23 (m, 3H),7.12 (d, *J* = 8.8 Hz, 1H), 4.83-4.77 (m, 1H), 4.49-4.40 (m, 4H), 4.05 (s, 2H), 3.78 (s, 3H), 3.28-3.23 (m, 1H), 3.06-2.92 (m, 1H), 2.90 (d, *J* = 10.6 Hz, 1H), 2.69-1.91 (m, 10H), 1.77-1.70 (m, 1H), 1.17 (d, *J* = 6.7 Hz, 3H). MS: (ES, *m/z):* 475 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.50 (s, 1H), 7.35 (d, *J* = 5.0 Hz, 4H), 7.34-7.26 (m, 2H), 4.83-4.78 (m, 1H), 4.51-4.42 (m, 6H), 3.79 (s, 4H), 3.38-3.20 (m, 1H), 3.12-3.00 (m, 1H), 2.75-2.62 (m, 6H), 2.50-1.66 (m, 5H), 1.17 (d, *J* = 6.7 Hz, 3H). MS: (ES, *m/z):* 475 $[M+H]^+$.

Examples 236, 237 and 238: methyl (S)-2-benzyl-3-(2-((2S,6R)-2,6-dimethylmorpholino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate, methyl (S)-2-benzyl-3-(2-((2R,6R)-2,6-dimethylmorpholino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate, and methyl (S)-2-benzyl-3-(2-((2S,6S)-2,6-dimethylmorpholino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0471]



Step 1. **Synthesis of methyl (7S)-2-benzyl-3-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-benzyl-3-[2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (7S)-2-benzyl-3-[2-[(2S,6S)-2,6-dimethylmorpholin-4-yl] ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo [4,5-f]quinoline-6-carboxylate.**

[0472] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (70 mg, 0.19 mmol) was dissolved in methanol (5 mL). Then 2,6-dimethylmorpholine (128 mg, 1.11 mmol) and acetic acid (67 mg, 1.12 mmol) were added. The mixture was stirred at room temperature for 30 min again. To the mixture was added sodium cyanoborohydride (70 mg, 1.11 mmol). The resulting solution was stirred for 12 h at room temperature. Water (10ml) was added and the resulting solution was extracted with 2x60 mL of ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 μm, 19 mm × 250 mm; mobile phase A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (30.0% to 45.0% ACN over 10 min); UV Detector: 254 nm. The crude product was purified by Prep-SFC with the following conditions: Column, CHIRALCEL OJ-H, 2x25cm, 5μm; mobile phase, CO_2 (90%), EtOH (2mM NH_3/MeOH) (10%) and echo (0%); UV Detector: 220nm. This afforded the title compounds as follows: 6.0mg (7%) of methyl (7S)-2-benzyl-3-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl] ethyl]-7-methyl-3H,6H,7H, 8H, 9H-imidazo[4, 5-f] quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer) as a white solid and 3.4mg (4%) of methyl (7S)-2-benzyl-3-[2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer, RT = 2.25 min) as a white solid and 3.9mg (4%) of methyl (7S)-2-benzyl-3-[2-[(2S,6S)-2,6-dimethylmorpholin-4-yl]ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, third eluting isomer, RT = 2.60 min) as a white solid.

First eluting isomer: ^{1}H-NMR ($CDCl_3$, 400 MHz) δ(*ppm*): 7.45 (d, *J* = 8.0 Hz, 1H), 7.32-7.27 (m, 2H), 7.26-7.16 (m, 3H), 7.10 (d, *J* = 8.8 Hz, 1H), 4.80 (h, *J* = 6.0 Hz, 1H), 4.47-4.33 (m, 2H), 4.03 (s, 2H), 3.78 (s, 3H), 3.63 (s, 2H), 3.34-3,23 (m, 1H), 3.04-2.98 (m, 1H), 2.54 (t, *J* = 11.6 Hz, 2H), 2.43-2.34 (m, 1H), 2.34-2.21 (m, 2H), 1.80-1.62 (m, 3H), 1.17 (d, *J* = 6.8 Hz,


3H), 1.15-1.11 (m, 6H). MS: (ES, *m/z):* 477 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR ($CDCl_3$, 400 MHz) δ(*ppm*): 7.55-7.41 (m, 1H), 7.33-7.27 (m, 2H), 7.26-7.18 (m, 3H), 7.11 (d, *J* = 8.4 Hz, 1H), 4.85-4.75 (m, 1H), 4.43 (s, 2H), 4.10-3.90 (m, 4H), 3.78 (s, 3H), 3.34-3.23 (m, 1H), 3.13-2.99 (m, 1H), 2.40-2.20 (m, 5H), 2.06-1.96 (m, 2H), 1.80-1.70 (m, 1H), 1.23-1.13 (m, 9H). MS: (ES, *m/z):* 477 $[M+H]^+$.

Third eluting isomer: ^{1}H-NMR ($CDCl_3$, 400 MHz) *δ*(*ppm*): 7.55-7.41 (m, 1H), 7.33-7.27 (m, 2H), 7.26-7.17 (m, 3H), 7.11 (d, *J* = 6.8 Hz, 1H), 4.87-4.74 (m, 1H), 4.43 (s, 2H), 4.11-3.91 (m, 4H), 3.78 (s, 3H), 3.35-3.23 (m, 1H), 3.13-2.98 (m, 1H), 2.46-2.17 (m, 5H), 2.04-1.94 (m, 2H), 1.82-1.69 (m, 1H), 1.22-1.12 (m, 9H). MS: (ES, *m/z):* 477 $[M+H]^+$.

Example 239: methyl (7S)-2-benzyl-3-[2-(2,2-dioxo-2lambda6-thia-6-azaspiro[3.3]heptan-6-yl)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate

[0473]



Step 1. **Synthesis of methyl (7S)-2-benzyl-7-methyl-3-(2-[2-thia-6-azaspiro[3.3]heptan-6-yl]ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**


[0474] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (50 mg, 0.13 mmol) was dissolved in methanol (5 mL). Then 2-thia-6-azaspiro[3.3]heptane oxalic acid salt (68 mg, 0.33 mmol) and sodium cyanoborohydride (13 mg, 0.21 mmol) were added. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with dichloromethane/methanol (10:1). This afforded the title compound (40 mg, 63%) as a white solid. MS: (ES, *m/z):* 477 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-2-benzyl-3-[2-(2,2-dioxo-2lambda6-thia-6-azaspiro[3.3]heptan-6-yl)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0475] Into a 8-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(2-[2-thia-6-azaspiro[3.3]heptan-6-yl]ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (38 mg, 0.08 mmol) was dissolved in dichloromethane (4 mL). Then 3-chloroperoxybenzoic acid (55 mg, 0.32 mmol) was added. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 Å, 5 μm, 19 mm × 250 mm; mobile phase, A: water (10mmol/L NH4HCO3) and B: ACN (20.0% to 40.0% ACN over 8 min); UV Detector: 254nm. This afforded the title compound (4.3 mg, 11%) as an off-white solid.
H-NMR: ($CDCl_3$, 400 MHz, *ppm*): 7.55 (d, J = 8.6 Hz, 1H), 7.40 - 7.21 (m, 6H), 4.81-4.58 (m, 1H), 4.75 - 4.45 (m, 4H), 4.18 - 3.68 (m, 8H), 3.57 - 3.19 (m, 5H), 3.15 - 3.02 (m, 2H), 2.29-2.25 (m, 1H), 1.94 - 1.79 (m, 1H), 1.20 (d, J = 6.8 Hz, 3H). MS: (ES, *m/z):* 509 $[M+H]^+$.

Example 240: methyl (S)-3-(2-(4-acetylpiperazin-1-yl)ethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0476]




[0477] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-[2-(piperazin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (30 mg, 0.07mmol) was dissolved in dichloromethane (2 mL). Then pyridine (16 mg, 0.20mmol) was added, followed by of acetyl chloride (10.5 mg, 0.13mmol). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 A, 5 um, 19 mm × 250 mm; mobile phase A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 45.0% ACN over 8 min); UV Detector: 254 nm. This afforded the title compound (8.8 mg, 26%) as a white solid. ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.48 (d, J = 8.6 Hz, 1H), 7.33-7.28 (m, 2H), 7.24-7.20 (m, 3H), 7.09 (d, J = 8.8 Hz, 1H), 4.83-4.77 (m, 1H), 4.43-4.41 (m, 2H), 4.05 (t, J = 7.0 Hz, 2H), 3.79 (s, 3H), 3.58 (t, J = 5.4 Hz, 2H), 3.40 (t, J = 5.1 Hz, 2H), 3.39-3.23 (m, 1H), 3.21-3.03 (m, 1H), 2.44-2.22 (m, 7H), 2.07 (s, 3H), 1.78-1.72 (m, 1H), 1.17 (d, J = 6.7 Hz, 3H). MS: (ES, *m/z):* 490 $[M+H]^+$.

Example 241: methyl (S)-2-benzyl-7-methyl-3-(2-(4-(methylsulfonyl)piperazin-1-

yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate


[0478]



[0479] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-[2-(piperazin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (30 mg, 0.07mmol) was added in dichloromethane (2 mL). Then triethylamine (20 mg, 0.20mmol) was added, followed by methylsulfonyl chloride (15.3 mg, 0.1mmol). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 5 um, 19 mm × 250 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 45.0% ACN over 8 min); UV Detector: 254 nm. This afforded the title compound (17.3 mg, 48%) as a white solid. ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.50-7.47 (m, 1H), 7.33-7.28 (m, 3H), 7.25-7.20 (m, 2H), 7.08 (d, J = 8.8 Hz, 1H), 4.83-4.77 (m, 1H), 4.41 (s, 2H), 4.04 (t, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.32-3.23 (m, 1H), 3.23 -3.16 (m, 4H), 3.16-3.03 (m, 1H), 2.77 (s, 3H), 2.47-2.36 (m, 6H), 2.36-2.22 (m, 1H), 1.79-1.72 (m, 1H), 1.17 (d, J = 6.7 Hz, 3H). MS: (ES, *m/z):* 526 $[M+H]^+$.

Example 242: methyl-(7S)-3-[2-(dimethylamino)ethyl]-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate

[0480]






[0481] Into a 25-mL round-bottom flask, methyl-(7S)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (30 mg, 0.09 mmol) was dissolved in tetrahydrofuran (3 mL). Then sodium hydride (60%, 10 mg, 0.25 mmol) was added. The mixture was stirred for 10 minutes at room temperature. Then (2-



bromoethyl)dimethylamine (26 mg, 0.17 mmol) was added. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was diluted with 10 mL of water and extracted with 3×10 mL of ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified with the following conditions: Column: XBridge Prep C18 OBD Column 19*150mm, 5μm; Mobile Phase, A: water (containing 10mmol/L NH_4HCO_3) and B: ACN (31% to 61% ACN over 8 min). UV Detector: 254 nm. This afforded the title compound (4.1 mg, 11%) as a brown oil.

^{1}H-NMR: ($CDCl_3$, 300 MHz) δ (*ppm*): 7.46(d, J=9.0 Hz, 1H), 7.33-7.13(m, 5H), 7.10(d, J=8.7 Hz, 1H), 4.84-4.78(m, 1H), 4.06-4.02(m, 2H), 3.78(s, 3H), 3.29-3.18(m, 5H), 3.08-2.99(m, 1H), 2.56-2.42(m, 2H), 2.25-2.23(m, 7H), 1.78-1.73(m, 1H), 1.15-1.10(m, 3H). MS: (ES, m/z): 421$[M+H]^+$

[0482] The following examples in **TABLE 10** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 242.


TABLE 10

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
243	 methyl(S)-2-benzyl-7-methyl-3-(3-(methylsulfonyl)propyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quinoline-6-carboxylate	456	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.52-7.48(m, 1H), 7.33-7.23(m, 5H), 7.12(d, J=8.8 Hz, 1H), 4.83-4.78(m, 1H), 4.42-4.38(m, 2H),4.19-4.17(m, 2H), 3.78(s, 3H), 3.33-3.25(m, 1H),3.09-305(m, 1H), 2.72-2.67(m, 5H), 2.29-2.23(m, 1H), 2.06-1.96(m,2H), 1.78-1.77(m, 1H), 1.18-1.15(m, 3H)
244	 methyl(S)-7-methyl-3-(3-(methylsulfonyl)propyl)-2-phenethyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	470	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.47(d, J=8.8Hz, 1H), 7.29-7.27(m, 2H), 7.23-7.19(m, 3H), 7.11(d, J=8.8Hz, 1H), 4.81-4.77(m, 1H), 4.13-4.09(m, 2H), 3.79(s, 3H),3.29-3.15(m, 5H), 3.16-3.00(m, 1H), 2.92-2.87(m, 5H), 2.29-2.19(m, 3H), 1.75-1.70(m, 1H), 1.17-1.13(m, 3H)
245		463	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.50(d, J=8.7 Hz, 1H), 7.34-7.20(m, 5H), 7.11(d, J=8.7 Hz,

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl(S)-7-methyl-3-(2-moipholinoethyl)-2-phenethyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		1H), 4.84-4.78(m, 1H), 4.03-3.99(m, 2H), 3.81(s, 3H), 3.70-3.67(m, 4H), 3.33-3.21(m, 5H), 3.08-3.03(m, 1H), 2.58-2.50(m, 2H), 2.46-2.43(m, 4H), 2.29-2.25(m, 1H), 1.79-1.73(m, 1H), 1.18(d, J=6.6 Hz, 3H).
246	 methyl (S)-2-benzyl-3-(2-(dimethylamino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	407	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*): 7.46(d, J=8.7 Hz, 1H), 7.34-7.24(m, 5H), 7.14(d, J=8.7 Hz, 1H), 4.85-4.79(m, 1H), 4.47-4.33(m, 2H), 4.13-4.08(m, 2H), 3.80(s, 3H), 3.35-3.24(m, 1H), 3.15-3.01(m, 2H), 2.43-2.20(m,BH), 1.75-1.68(m, 1H), 1.19 (d, J=6.8Hz, 3H)

Example 247: methyl (S)-2-cyclopropyl-7-methyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0483]



***Step 1*. Synthesis of methyl (2S)-5-amino-2-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0484] Into a 8-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate 1**) and 2-(morpholin-4-yl)ethan-1-amine (435 mg, 3.34 mmol,) were dissolved in toluene (5 mL) and then BrettPhos (60 mg, 0.11 mmol), sodium tert-butoxide (50 mg, 0.52 mmol) and 3rd Generation BrettPhos precatalyst (60 mg, 0.07 mmol) were added. The resulting solution was stirred for 3 h at 100°C under nitrogen atmosphere.

The reaction mixture was cooled and the resulting solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with dichloromethane/methanol (10:1). This afforded the title compound (130 mg (crude)) as a yellow solid. MS: (ES, *m/z*): 349[M+H]$^+$.



Step 2. **Synthesis of methyl (S)-2-cyclopropyl-7-methyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**





[0485] Into a 8-mL round-bottom flask, methyl (2S)-5-amino-2-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-1,2,3,4-tetrahydroquinoline-1-carboxylate (40 mg, 0.11 mmol) was dissolved in toluene (2 mL). Then cyclopropanecarbaldehyde (12 mg, 0.17 mmol) was added. The resulting solution was stirred for 2 days at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 Å, 5 μm, 19 mm × 250 mm; mobile phase: A: water (containing 0.05% NH_4OH) and B: ACN (25.0% ACN up to 50.0% in 8 min); UV Detector: 254nm. This afforded the title compound (10.8 mg, 24%) as a yellow solid.




^{1}H-NMR ($CDCl_3$, 400 MHz) δ(*ppm*): 7.42 (d, J = 8.8 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 4.76-4.72 (m, 1H), 4.36-4.32 (m, 2H), 3.77-3.70 (m, 7H), 3.23-3.16 (m, 1H), 2.94-2.74 (m, 1H), 2.76 (t, J = 7.1 Hz, 2H), 2.58-2.48 (m, 4H), 2.26-2.20 (m, 1H), 2.05-2.00 (m, 1H), 1.69-1.61 (m, 1H), 1.24 (s, 2H), 1.14-1.09 (m, 5H). MS: (ES, *m/z*): 399[M+H]$^+$.





[0486] The following examples in **TABLE 11** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 247.




TABLE 11

Example Number	Structure and Compound Name	LRMS *m/z* [M+H]$^+$	^{1}HNMR
248	 methyl (S)-2,7-dimethyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	373	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.46 (s, 1H),7.10 (d, J=8.4 Hz, 1H), 4.81-4.78 (m, 1H), 4.19 (t, J = 6.8 Hz, 2H), 3.79 (s, 3H), 3.69 (t, J = 4.8 Hz, 4H), 3.27-3.18 (m, 1H), 3.01-2.97 (m, 1H), 2.69-2.66 (m, 5H), 2.54-2.45 (m, 4H), 2.29-222 (m, 1H), 1.74-1.69 (m, 1H), 1.14 (d, J = 6.7 Hz, 3H)
249		415	^{1}H-NMR (CD_3OD, 300MHz) δ (*ppm*): 7.40 (d, J=9 Hz, 1H),7.29 (d, J=9 Hz, 1H), 4.73 (q, J=6.6 Hz, 1H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl(S)-2-(tert-butyl)-7-methyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6 caibo xylate		4.60-4.55 (m, 2H), 3.79-3 . 74(m, 7H), 3.34-3.29 (m, 1H), 2.90-2.78 (m, 3H), 2.65-2.62 (m, 4H), 2.30-2.27 (m, 1H), 1.69-1.62 (m, 10H), 1.14 (d, J = 6.6 Hz, 3H)
250	 methyl(S)-7-methyl-3-(2-moipholinoethyl)-2-phenyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate	435	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.92 (d, J = 8.8 Hz, 1H), 7.77(s, 2H), 7.66-7.54(m, 3H), 7.50 (d, J = 8.8 Hz, 1H), 4.85-4.75 (m, 3H), 3.84 (s, 3H), 3.79 (d, J = 7.6Hz, 4H), 3.18-3.14 (m, 3H), 3.08-2.96 (m, 1H), 2.96-2.74 (m, 4H), 2.17-2.16 (m, 1H), 1.85-1.82(m, 1H), 1.15 (d, J = 6.8 Hz, 3H)
251	 methyl(S)-2-(2-cyclopropylethyl)-7-methyl-3-(2-morpholinoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	427	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.51(d, J=8.7 Hz, 1H), 7.15(d, J=8.7 Hz, 1H), 4.82-4.76(m, 1H), 4.28-4.23(m, 2H), 3.80(s, 3H), 3.75-3.72(m, 4H), 3.24-2.19(m, 1H), 3.10-2.98(m, 3H), 2.76-2.71(m, 2H), 2.56-2.53(m, 4H), 2.29-2.21(m, 1H) 1.83-1.70(m, 3H), 1.15 (d,J=6.6 Hz, 1H), 0.83-0.78(m, 1H), 0.52-0.46(m, 2H), 1.15-1.10(m, 2H)
252	 methyl (S)-3-benzyl-7-methyl-2-(trifluoromethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate	404	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.72 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 8.8 Hz, 1H), 7.34-7.26 (m, 3H), 6.88(d, J = 6.8 Hz, 1H), 5.77-5.65 (m, 2H), 4.66-4.61 (m, 1H), 3.76 (s, 3H), 2.94-2.87 (m, 1H), 2.64-2.57 (m, 1H), 2.09-2.01 (m, 1H), 1.36-1.27 (m, 1H), 1.03 (d, J = 6.4 Hz, 3H)
253		482	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.46 (d, J = 8.9 Hz, 1H), 7.41-7.25(m, 6H), 4.78-4.72 (m, 1H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl(S)-2-benzyl-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		4.42 (s, 2H), 4.06 (d, J = 7.1 Hz, 2H), 3.79 (s,3H),3.23-3.16(m, 1H), 3.03-2.77(m, 5H), 2.27-2.21 (m, 1H), 1.93-1.69(m, 6H), 1.16(d, J = 6.6 Hz, 3H)
254	 methyl (S)-2-benzyl-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	468	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.45 (d, J=8.4 Hz, 1H), 7.31-7.19 (m, 4H), 7.21(d, J = 8.8 Hz, 2H), 4.834.80(m, 1H), 4.47-4.28 (m, 3H), 3.79 (s, 3H), 3 30-323 (m, 1H), 3.10-2.84 (m, 7H), 2.30-2.28(m, 1H) ,1.80-1.58(m, 3H), 1.18(d, J = 8.8 Hz,3H)
255	 methyl(S)-2-benzyl-3-((trans)-4-cyanocyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	443	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.44-7.41 (d,J=13.6Hz,1H),7.39-7.28(m, 6H), 4.79-4.77 (m, 1H), 4.43 (s, 2H), 4.30(s, 1H), 3.79(s, 3H),3.23-3.19 (m, 1H), 3.00-2.96 (m, 1H) ,2.79-2.78 (m, 1H), 2.30-2.21 (m, 5H), 1.80-1.75 (m, 1H),1.61-1.47 (m, 4H) ,1.17-1.15 (d, J=6.4Hz,3H)
256	 methyl(S)-2-benzyl-3-((cis)4-cyanocyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	443	^{1}H-NMR ($CDCl_3$, 400 MHz) δ (*ppm*): 7.49-7.46 (m, 2H), 7.36-7.32 (m, 2H), 7.28-7.26 (m, 3H), 4.80-4.78 (m, 1H), 4.43 (s, 2H), 4.33 (s, 1H), 3.80 (s, 3H), 3.34-3.32 (m, 1H), 3.30-3.24(m, 1H), 3.12-2.97 (m, 1H), 2.48-2.41 (m, 2H), 2.40-2.29 (m, 1H), 2.05-2.01 (m, 2H), 1.81-1.76 (m, 1H),1.69-1.63 (m, 2H), 1.55-1.52 (m, 2H), 1.18-1.17 (d, J = 6.4Hz, 3H)
257		433	^{1}H-NMR ($CDCl_3$, 300MHz) δ (*ppm*):


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl (S)-2-benzyl-7-methyl-3-(1-methylpiperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		7.41-7.33(m, 2H), 7.30-7.29(m, 2H), 7.25-7.21(m, 3H), 4.84-4.79(m, 1H), 4.45-4.31(m, 2H), 4.07-4.01(m, 1H), 3.80(s, 3H), 3.35-3.24(m, 1H), 3.11-3.01(m, 1H), 2.91-2.87(m, 2H), 2.47-2.43(m, 2H), 2.34-2.25(m,4H), 1.93-1.71(m, 3H), 1.47-1.44(m, 1H), 1.34-1.30(m, 1H), 1.21(d, J=6.9 Hz, 3H)
258	 methyl (S)-2-benzyl-7-methyl-3 -(2-methyl-2-azaspiro [3.3]heptan-6-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	444	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.41-7.32(m, 1H), 7.27-7.22(m, 4H), 7.12-7.09(m, 2H), 4.85-4.79(m, 1H), 4.61-4.55(m, 1H), 4.41-4.29(m 2H), 3.81(s, 3H), 3.46-3.22(m,5H), 3.09-2.93(m, 3H), 2.49-2.22(m,6H), 1.79-1.73(m, 1H), 1.21(d, J = 6.6 Hz, 3H)
259	 methyl (S)-7-methyl-2-((2-oxopyridin-1(2H)-yl)methyl)-3-(tetrahydro-2H-pyran-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	437	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 7.75-7.73(m, 1H), 7.57-7.53(m, 2H), 7.48-7.46(m, 1H), 6.63-6.61(m, 1H), 6.45-6.41(m, 1H), 5.63-5.51(m, 2H), 5.01-4.95(m, 1H), 4.77-4.75(m, 1H), 4.14-4.08(m,2H), 3.78(s, 3H), 3.64-3.58(m, 2H), 3.18-3.16(m, 1H), 2.96-2.92(m, 1H), 2.59-2.52(m, 2H), 2,26-2,23(m, 1H), 1.76-1.68(m, 3H), 1.14(d, J= 6.4 Hz, 3H)
260	 methyl (S)-7-methyl-2-((2-oxopyridin-1(2H)-yl)methyl)-3-((S)-tetrahydro-2H-pyran-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-	437	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.75-7.72(m, 1H), 7.62-7.59(m, 2H), 7.47(d, J=9.0 Hz, 1H), 6.63(d, J=8.7 Hz, I H), 6.44 -6.43 (m, 1H), 5 . 68-5.62(m, 1H), 5.47-5.42(m, 1H), 4.75-4.70(m, 2H), 4.20-4.10(m, 1H), 4.01-3.95(m, 1H), 4.90-3.85(m, 1H), 3.78(s, 3H), 3.65-3.55(m, 1H), 3.21-

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	f]quinoline-6-carboxylate		3.12(m, 1H), 2.98-2.87(m, 1H), 2.55-2.45(m, 1H), 2.25-2.18(m, 1H), 1.95-1.85(m, 3H), 1.80-1.70(m, 1H), 1.13(d, J=6.6Hz, 3H)
261	 methy l(S)-7-methyl-3-(3-(methylsulfonyl)propyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	487	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.51-7.46(m,2H), 7.41-735(m, 1H), 7.22(d, J=9 Hz, 1H), 6.59(d, J=9 Hz, 1H),6.19-6.14(m, 1H), 4.84 - 4.80 (m, 1H), 4.45 -4.3 8(m, 4H), 3.81 (s, 3 H), 3,46-3.39(m,2H), 3,24-2.21(m, 1H), 3.18-3.03(m, 3H), 298(s, 3H), 241-2.25(m, 3H), 1.79-1.73(m, 1H), 1.19(d, J=6.6 Hz, 3H)
262	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	472	^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.56-7.54 (m, 2H), 7.44(s, 2H), 625-623 (m, 1H), 4.80-4.64 (m, 4H), 3.79(s, 3H), 3.63-3.39(m,4H), 3.28-3.10 (m, 3H), 3.08-2.86 (m, 3H), 2.35-2.17 (m, 1H), 2.02-1.94 (m, 2H), 1.80-1.70 (m, 1H), 1.15 (d, J=6.7 Hz, 3H)
263	 methyl (S)-2-benzyl-3-cyclohexyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-flquinoline-6-carboxylate	418	^{1}H-NMR (CD_3OD 300MHz) δ (*ppm*): 7.45-7.22 (m, 7H), 4.78-4.73 (m, 1H), 4.38 (s, 2H), 4.21-4.17 (m, 1H), 3.76 (s, 3H), 3.23-3.16 (m, 1H), 2.99-2.93 (m, 1H), 2.28-2.22 (m, 1H), 2.14-2.06 (m, 2H), 1.79-1.66 (m, 4H), 1.50-1.44 (m, 2H), 128-122 (m, 3H), 1.12 (d, 3H, J=6.8Hz)

Examples 264 and 265: methyl (S)-2-benzyl-3-((S)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-2-benzyl-3-((R)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-

6H-imidazo [4,5-f]quinoline-6-carboxylate

[0487]



***Step* 1. Synthesis of methyl (2S)-5-amino-6-((1,1-dioxidotetrahydro-2H-thiopyran-3-yl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate.**

[0488] Into a 10-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (100 mg, 0.33 mmol, **Intermediate** 1) was dissolved in toluene (3 mL). Then 3-aminotetrahydro-2H-thiopyran 1,1-dioxide hydrochloride (186 mg, 1.00 mmol), BrettPhos (36 mg, 0.07 mmol), 3rd Generation BrettPhos precatalyst (61 mg, 0.07 mmol) and sodium tert-butoxide (97 mg, 1.01 mmol) were added. The resulting solution was stirred for 2 h at 100°C under nitrogen atmosphere. The reaction mixture was cooled to room temperature and the solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (54.9 mg, 45%) as a yellow solid. MS: (ES, *m/z):* 368 $[M+H]^+$.

***Step 2.* Synthesis of methyl (S)-2-benzyl-3-((S)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-2-benzyl-3-((R)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0489] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-((1,1-dioxidotetrahydro-2H-thiopyran-3-yl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (54.9 mg, 0.15 mmol) was dissolved in dichloromethane (5 mL). Then 2-phenylacetaldehyde (80.7 mg, 0.67 mmol) was added. The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 5μm, 19x150mm; mobile phase, A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (30.0% to 60.0% over 7 min); UV Detector: 254 nm. The crude product was purified by Chiral-Prep-HPLC with the following conditions (Prep-HPLC): Column, CHIRAL ART Cellulose-SB, 2x25cm, 5um; mobile phase, hexanes and ethanol (hold 40.0% ethanol in 30 min); UV Detector: 254 nm. This afforded the


title compounds as follows: 8.9 mg (13%) of methyl (7S)-2-benzyl-3-[(3R)-1,1-dioxo-1lambda6-thian-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer, RT = 20.61 min) as a white solid and 9.0 mg (13%) of methyl (7S)-2-benzyl-3-[(3S)-1,1-dioxo-1lambda6-thian-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer, RT = 23.64 min)as a white solid.



First eluting isomer: ^{1}H-NMR (CD_3OD, 400 MHz) *δ(ppm):* 7.56 (d, J = 9.0 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 7.41-7.24 (m, 5H), 4.91-4.72 (m, 2H), 4.50 (d, J = 16.0 Hz, 1H), 4.39 (d, J = 15.9 Hz, 1H), 3.91 (t, J = 12.8 Hz, 1H), 3.79 (s, 3H), 3.28-3.16 (m, 2H), 3.11-2.94 (m, 3H), 2.43-2.21 (m, 2H), 2.07-2.01 (m, 1H), 1.78-1.68 (m, 2H), 1.47-1.42 (m, 1H), 1.16 (d, J = 6.6 Hz, 3H). MS: (ES, *m/z):* 468 $[M+H]^+$.





Second eluting isomer: ^{1}H-NMR (CD_3OD, 400 MHz) *δ(ppm):* 7.56 (d, J = 9.0 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 7.41-7.24 (m, 5H), 4.92-4.73 (m, 2H), 4.51 (d, J = 15.9 Hz, 1H), 4.40 (d, J = 16.0 Hz, 1H), 3.95 (t, J = 12.8 Hz, 1H), 3.79 (s, 3H), 3.32-3.17 (m, 2H), 3.10-2.93 (m, 3H), 2.40-2.21 (m, 2H), 2.06-1.98 (m, 1H), 1.85-1.67 (m, 2H), 1.43-1.38 (m, 1H), 1.17 (d, J = 6.6 Hz, 3H). MS: (ES, *m/z):* 468 $[M+H]^+$.


[0490] The following examples in **TABLE 12** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 264 and 265.

TABLE 12

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
266 and 267	 1^{st} eluting isomer(177)	1^{st} eluting isomer = 472	1^{st} eluting isomer ^{1}H-NMR (CD_3OD, 300 MHz) δ (*ppm*): 7.61-7.49 (m, 3H), 7.44 (d, J = 9.0 Hz, 1H), 6.22-6.20 (m, 1H), 4.85-4.63 (m, 4H),3.96-3.88 (m, 1H), 3.79 (s, 3H), 3.54-3.48 (m, 2H), 3.38-3.36 (m, 1H), 3.22-3.04 (m, 3H), 296-288 (m, 1H), 2.50-2.32 (m, 1H),2.34-1.97 (m, 3H), 1.83-1.66 (m, 2H), 1.14 (d, J = 6.6 Hz, 3H)
		2^{nd}	2^{nd} eluting isomer ^{1}H-NMR


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
		eluting isomer = 472	(CD_3OD, 400 MHz) δ*(ppm):*
	2nd eluting isomer(178)		7.61-7.49 (m, 3H), 7.44 (d, J = 9.0 Hz, 1H), 6.22-6.18 (m, 1H), 4.85-4.63 (m, 4H),3.98-3.88 (m, 1H), 3.79 (s, 3H), 3.55-3.48 (m, 2H), 3.39-3.32 (m, 1H), 3.28-3.07 (m, 3H), 2.97-2.87 (m, 1H), 2.54-2.36(m, 1H), 2.35-1.98(m, 3H), 1.80-1.64 (m, 2H), 1.15 (d, J = 6.6 Hz, 3H)
	met hy 1 (7S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo [4,5-f] quinoline-6-carbo xylate		
268 and 269	 1st eluting isomer(179)	1st eluting isomer =473	1st elutingisomer ^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*):
			7.56-7.53(m,3H), 7.19(d, J=9 Hz, 1H), 5.11-5.07(m, 2H), 4.92-4.75(m,2H), 3.80-3.79(m, 4H), 3.76-3.66(m, 2H), 3.24-3.13(m, 3H), 3.10-2.99(m, 2H), 2.40-2 . 15(m, 4H), 2.02-1.98(m, 1H), 1.80-1.71(m, 1H), 1.15(d, J=6.6 Hz,3H)
		2nd eluting isomer =473	2nd elutingisomer^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*):
	2nd eluting isomer(180)		7.53-7.52(m,2H), 7.50-7.48(m, 1H), 7 . 18(d, J=9 Hz, 1H), 511-504(m,2H), 4.88-4.76(m, 2H), 3.82-3.73(m, 4H), 3.67-3.62(m, 2H), 3.22-3.09(m, 3H), 3.05-2.96(m, 2H), 2.28-2.15(m, 4H), 2.08-2.04(m, 1H), 1.77-1.70(m, 1H), 1.15(d, J=6.9 Hz, 3H)
	methyl (7S)-2-(2-(2H-1,2,3-triazol-2-yl)ethyl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		
270	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(3-(methylsulfonyl)propyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quino line-6-carboxylate	460	^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*):
			7.50-7.49 (m, 2H), 7.28-7.26(m, 1H), 7 . 15(d, J=9.0 Hz, 1H), 6.12-6.11(m, 1H), 4.81-4.77(m, 3H), 4.13-4.09(m, 2H), 3.78(s, 3H), 3.51-3.50(m, 2H), 3.27-3.19(m, 1H), 3.06-3.00(m, 1H), 2.92-2.89(m, 5H), 2.29-2 . 14(m, 3H), 1.80-1.72(m, 1H), 1.15(d, J=6.6Hz, 3H)
271		446	^{1}H-NMR ($CDCl_3$, 300 MHz)

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(methylsulfonyl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quinoline-6-carboxylate		δ(*ppm*): 7.52-7.51 (m, 2H), 7.27-7.26(m, 1H), 7.13(d, J=8.7 Hz, 1H), 6.14-6.12(m, 1H), 4.82-4.76(m, 3H), 4.40-4.35(m, 2H), 3.79(s, 3H), 3.54-3.48(m, 2H), 3.28-3.17(m, 3H), 3.04-2.97(m, 1H), 2.74(s, 3H), 2.30-2.19(m, 1H), 1.79-1.70(m, 1H), 1.15(d, J=6.6Hz, 3H)
272	 methyl (S)-7-methyl-3-(2-morpholinoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6 caiboxylate	480	^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.48-7.41 (m, 2H), 7.36-7.30(m, 1H), 7.12(d, J=9.0Hz, 1H), 6.56(d, J=9.0Hz, 1H), 6.11-6.07(m, 1H), 4.83-0.77(m, 1H), 4.48-4.36(m,2H), 4.23-4.18(m, 2H), 3.78(s, 3H), 3.65-3.63(m, 4H), 3.44-3.42(m, 2H), 3.22-3.17(m, 1H), 3.05-2.97(m, 1H), 2.65-2.61(m, 2H), 2.48-2.45(m, 4H), 2.27-222(m, 1H), 1.77-1.70(m, 1H), 1.15(d, J=6.6Hz, 3H)
273	 methyl(S)-7-methyl-3-(2-(methylsulfonyl)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	473	^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.52-7.43(m, 1H), 7.41-7.35(m, 2H), 7.23-7.20(m, 1H), 6.60-6.57(d, J=9 Hz, 1H), 6.20-6.15(m, 1H), 4.83-0.73(m, 3H), 4.41-4.33(m,2H), 3.81(s, 3H), 3.58-3.53(m, 2H),3.48-3.42(m, 2H), 322-3.18(m, 1H), 3.03-2.97(m, 4H), 2.31-227(m, 1H), 1.78-1.71(m, 1H), 1.18(d, J=6.6Hz, 3H)
274		450	^{1}H-NMR ($CDCl_3$, 300 MHz) δ(*ppm*): 7.52-7.51 (m, 2H), 7.27-7.26(m, 1H), 7.13(d, J=8.7Hz, 1H), 6.14-6.12(m, 1H), 4.82-4.76(m, 3H),

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$	^{1}HNMR
	methyl (S)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3-((R)-tetrahydro-2H-pyran-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-caiboxylate		4.40-4.35(m, 2H), 3.79(s, 3H), 3.54-3.48(m, 2H), 3.28-3.17(m, 3H),3.04-2.97(m, 1H), 2.74(s, 3H),2.30-2.19(m, 1H), 1.79-1.70(m, 1H), 1.15(d, J=6.6Hz, 3H)
275	 methyl (S)-2-(2-(2H-1,2,3-triazol-2-yl)ethyl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	473	^{1}H-NMR (CD_3OD, 300MHz)δ(*ppm*): 7.69(s, 2H), 7.42-7.38(m, 2H), 5.01-4.96 (m, 2H),4.87-4.70(m, 2H), 3.79 (s, 3H), 3.70-3.63(m,2H),3.59-3.43 (m, 2H), 3.28-2.81 (m, 6H), 2.26-2.10 (m, 3H), 1.81-1.64 (m, 1H), 1.13 (d, J = 6.7 Hz, 3H)

Examples 276: methyl (S)-3-((R)-1-(1H-tetrazol-5-yl)piperidin-3-yl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f] quinoline-6-carboxylate

[0491]



***Step* 1. Synthesis of methyl (2S)-5-amino-6-[[(3R)-1-[(tert-butoxy)carbonyl]piperidin-3-yl] amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0492] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (400 mg, 1.34 mmol, **Intermediate 1)** was dissolved in dioxane (10 mL). Then tert-butyl (3R)-3-aminopiperidine-1-carboxylate (800 mg, 3.99 mmol), BrettPhos (288 mg, 0.54 mmol), BrettPhos Pd 3rd generation precatalyst (243 mg, 0.27 mmol) and sodium tert-butoxide (386 mg, 4.02 mmol) were added. The resulting solution was stirred for 2 h at 100°C in the nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (300 mg, 54%) as a green solid. MS: (ES, m/z): 420 $[M+H]^+$.

***Step 2.* Synthesis of tert-butyl (3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl] piperidine-1-carboxylate.**

[0493] Into a 50-mL round-bottom flask, methyl (2S)-5-amino-6-[[(3R)-1-[(tert-butoxy)carbonyl]piperidin-3-yl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (300 mg, 0.72 mmol) was dissolved in dichloromethane (10 mL). Then 2-phenylacetaldehyde (258 mg, 2.15 mmol) was added. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (200 mg, 54%) as a green solid. MS: (ES, m/z): 519 $[M+H]^+$.

***Step 3.* Synthesis of methyl (7S)-2-benzyl-7-methyl-3-[(3R)-piperidin-3-ylJ-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0494] Into a 10-mL round-bottom flask, tert-butyl (3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]piperidine-1-carboxylate (200 mg, 0.39 mmol) was dissolved in dichloromethane (3 mL). Then trifluoroacetic acid (1 mL) was added. The flask was wrapped with aluminum foil and the resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. After addition of water, the pH value of the mixture was adjusted to 8-9 with sodium bicarbonate. The resulting solution was extracted with 2x10 mL of dichloromethane. The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (3:1). This afforded the title compound (140 mg, 87%) as a green

solid. MS : (ES, *m/z):* 419 $[M+H]^+$.

Step 4. **Synthesis of methyl (7S)-3-[(3R)-1-[(2H-1,2,3-benzotriazol-2-yl)carboximidoyl]piperidin-3-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0495] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-[(3R)-piperidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (50 mg, 0.12 mmol) was dissolved in dichloromethane (5 mL). Then 2-[(2H-1,2,3-benzotriazol-2-yl)carboximidoyl]-2H-1,2,3-benzotriazole (31.45 mg, 0.12 mmol)was added. The resulting solution was stirred for 3 days at room temperature. The resulting mixture was concentrated under vacuum and this afforded the title compound (60 mg, crude) as green crude oil, which could be used into next step without further purification. MS: (ES, m/z): 563 $[M+H]^+$.



Step S. **Synthesis of methyl (7S)-2-benzyl-7-methyl-3-[(3R)-1-(1H-1,2,3,4-tetrazol-5-yl)piperidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0496] Into a 25-mL round-bottom flask, methyl (7S)-3-[(3R)-1-[(2H-1,2,3-benzotriazol-2-yl)carboximidoyl]piperidin-3-yl]-2-benzyl-7-methyl-3H,6H,7H, 8H, 9H-imidazo[4, 5-f] quinoline-6-carboxylate (60 mg, 0.11 mmol) was dissolved in dichloromethane (5 mL). Then sodium azide (7.62 mg, 0.12 mmol) was added, followed by acetic acid (0.1 mL). The resulting solution was stirred for 1 day at room temperature. The resulting mixture was concentrated under vacuum. After addition of water, the pH value of the reaction mixture was adjusted to 9-10 with sodium bicarbonate. The resulting solution was extracted with 2x5 mL of dichloromethane. The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 um, 19 mm x 150 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (30.0% to 50.0% ACN over 7 min); UV Detector: 254 nm. This afforded the title compound (9.3 mg, 18%) of as a white solid.

^{1}H-NMR: (300 MHz,CD_3CD, *ppm*): 7.57-7.54 (d, *J*=9Hz, 1H), 7.46-7.43 (d, *J*=9Hz, 1H), 7.18-7.30 (m, 5H), 4.86-4.80 (m ,1H), 4.47-4.45 (m, 3H), 3.82-3.76(m, 6H),3.30-3.11 (m, 2H), 3.05-2.96 (m, 1H) ,2.43-2.23 (m, 2H) , 1.85-1.73 (m, 2H), 1.61-1.46 (m, 2H), 1.18-1.16 (d, J=6.6Hz,3H). MS : (ES, *m/z):* 487 $[M+H]^+$.


[0497] The following examples in **TABLE 13** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 276.


TABLE 13

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$	^{1}HNMR
277	 methyl (S)-3-((S)-1-(1H-tetrazol-5-yl)piperidin-3-yl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	487	^{1}H-NMR (CD_3OD, 300 MHz) δ(*ppm*): 7.57-7.54 (d, J=9Hz, 1H), 7.46-7.43 (d, J=9Hz 1H), 7.18-7.30 (m, 5H), 4.83-4.77(m,1H), 4.52-4.40 (m, 3H), 3.92-3.79(m,6H),3.29-3.15(m, 2H), 3.04-2.95 (m, 1H) ,2.35-2.23 (m, 2H), 1.85-1.76 (m, 2H), 1.57-1.48(m, 2H), 1.19-1.17 (d, J=6.9Hz,3H)
278	 methyl (S)-3-(1-(1H-tetrazol-5-yl)piperidin-4-yl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	487	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 738-721 (m, 7H), 4.78-4.74(m, 1H), 4.55-4.42 (m, 3H), 3.97-3.93 (m, 2H), 3.75 (s, 3H), 3.26-3.16 (m, 1H), 3.03-2.92 (m, 3H), 2.48-2.40 (m, 2H), 2.26-2.21 (m, 1H), 1.81-1.70 (m, 1H), 1.55-1.42(m,2H),1.13 (d, J = 6.8 Hz, 3H).

Examples 279 and 280: methyl (S)-3-((1R,3S)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-3-((1S,3R)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.

[0498]





***Step* 1. Synthesis of methyl (S)-5-amino-6-(((cis)-3-cyanocyclohexyl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**

[0499] Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed cis-3-aminocyclohexane-1-carbonitrile hydrochloride (714 mg, 4.00 mmol, **Intermediate 29),** NaOtBu (642 mg, 6.35 mmol), methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (443 mg, 1.33 mmol, **Intermediate 1),** Brettphos (539 mg, 0.95 mmol), and BrettPhos Pd 3rd generation precatalyst (269.5 mg, 0.28 mmol) in dioxane (10 mL). The resulting suspension was stirred for 2 h at 100°C in an oil bath. The reaction mixture was cooled to room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to FCC eluting with ethyl acetate/petroleum ether (1/1). This afforded the title compound (250 mg, 47%) as a green solid. MS : (ES, *m/z):* 343 $[M+H]^+$.

***Step 2.* Synthesis of methyl (S)-2-benzyl-3-((cis)-3-cyanocyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate**

[0500] Into a 50-mL round-bottom flask, was placed methyl (S)-5-amino-6-(((cis)-3-cyanocyclohexyl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (250 mg, 0.66 mmol), and 2-phenylacetaldehyde (263 mg, 2.08 mmol) in dichloromethane (5 mL). The resulting solution was stirred overnight at rt. The resulting mixture was concentrated under vacuum. The residue was subjected to FCC eluting with ethyl acetate/petroleum ether (2/1). This afforded the title compound (256 mg, 79%) as a light yellow solid. MS: (ES, *m/z):* 443 $[M+H]^+$.

***Step 3.* Synthesis of methyl (S)-3-((1R,3S)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-3-((1S,3R)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0501] Into a 20-mL sealed tube, was placed methyl (7S)-2-benzyl-3-(3-cyanocyclohexyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (256.0 mg, 0.52 mmol), sodium azide (213mg, 3.12 mmol) and NH_4Cl (175mg, 3.12 mmol) in N,N-dimethylformamide (8 mL). The final reaction mixture was irradiated with microwave radiation for 3 h at 140°C. The

reaction mixture was cooled to room temperature. The reaction was then quenched by the addition of 10 mL of saturated sodium bicarbonate. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The crude products were purified by Prep-HPLC with the following conditions: Column, XSelect CSH Prep C18 OBD Column, 19X250mm,5um; mobile phase, Water (10mmol/L NH_4HCO_3) and ACN (2.0% ACN up to 40.0% in 14 min); Detector, UV 254 nm.


[0502] This afforded the title compounds as follows: 22.6 mg (9%) of methyl (S)-3-((1R,3S)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer)as a white solid, and 47.0 mg (18%) of methyl (S)-3-((1S,3R)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer) as a white solid.


First eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) *δ(ppm):* 7.63-7.49 (m,1H) , 7.49-7.34 (m,1H), 7.34-7.16 (m,5H), 4.86-4.68 (m,1H), 4.57-4.32 (m,3H), 3.77 (s,3H), 3.28-2.89 (m,3H), 2.64-2.33 (m,1H), 2.33-1.39 (m,9H), 1.15 (d,*J* = 6.6 Hz, 3H).MS: (ES, *m/z):* 486 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) *δ(ppm):* 7.63-7.49 (m,1H), 7.48-7.36 (m,1H), 7.36-7.16 (m,5H), 4.83-4.70 (m,1H), 4.57-4.38 (m,3H), 3.76 (s,3H), 3.20-2.89 (m,3H), 2.63-2.47 (m,1H), 2.32-1.99 (m,3H), 1.99-1.82 (m,2H), 1.82-1.40 (m,4H), 1.16 (d,*J* = 6.6 Hz, 3H). MS: (ES, m/z): 486 $[M+H]^+$.

Examples 281 and 282: methyl (S)-3-((1R,3R)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-3-((1S,3S)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.

[0503]





***Step* 1. Synthesis of methyl (S)-5-amino-6-(((trans)-3-cyanocyclohexyl)amino)-2-methyl-3,4-dihydroquinoline-1(2H)-carboxylate**

[0504] Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed (trans)-3-aminocyclohexane-1-carbonitrile (134 mg, 1.03 mmol), NaOtBu (130 mg, 1.29 mmol), methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylate (100 mg, 0.30 mmol, **Intermediate 1),** Brettphos (72 mg, 0.13 mmol), and BrettPhos Pd G3 precatalyst (60 mg, 0.06 mmol) in dioxane (5 mL). The resulting solution was stirred for 1 h at 100°C in an oil bath. The reaction mixture was cooled to room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (60 mg, 47%) as a dark green solid. MS : (ES, *m/z):* 343 $[M+H]^+$.

***Step 2.* Synthesis of methyl (S)-2-benzyl-3-((trans)-3-cyanocyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate**

[0505] Into a 25-mL round-bottom flask, was placed methyl (2S)-5-amino-6-[[(trans)-3-cyanocyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (60 mg, 0.15 mmol), and 2-phenylacetaldehyde (63 mg, 0.50 mmol) in dichloromethane (2 mL). The resulting solution was stirred for 1 h at rt. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (0%-40%). This afforded the title compound (50 mg, 68%) as a yellow oil. MS: (ES, *m/z):* 443 $[M+H]^+$.

***Step 3.* Synthesis of methyl (S)-3-((1R,3R)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate and methyl (S)-3-((1S,3S)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0506] Into a 20-mL sealed tube, was placed methyl (S)-2-benzyl-3-((trans)-3-cyanocyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (256.0 mg, 0.52 mmol), NH_4Cl (175mg, 3.12 mmol) and NaN_3 (213mg, 3.12 mmol) in N,N-dimethylformamide (8 mL). The final reaction mixture was irradiated with microwave radiation

for 3 h at 140°C. The reaction mixture was cooled to room temperature. The reaction was then quenched by the addition of 10 mL of saturated sodium bicarbonate. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate and concentrated under vacuum. The crude products were purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100Å, 10 um, 19 mm X 250 mm; mobile phase, Water (10mmol/L NH_4HCO_3) and ACN (20.0% ACN up to 40.0% in 7 min); Detector, UV 254/220nm.


[0507] This afforded the title compounds as follows: 9.8 mg (19%) of methyl (S)-3-((1R,3R)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, first eluting isomer) as a white solid, 2.1 mg (4%) of methyl (S)-3-((1S,3S)-3-(1H-tetrazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (assumed stereochemistry, second eluting isomer) as a white solid.


First eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) δ(*ppm*)*:* 7.57-7.44 (m,1H), 7.42-7.31 (m,1H), 7.19-7.04 (m,3H), 7.01-7.6.82 (m,2H), 4.81-4.72 (m,1H), 4.62-4.43 (m,1H), 4.41-4.19 (m,2H), 3.77 (s,3H) , 3.59-2.46 (m,1H), 3.27-3.13 (m,1H), 3.04-2.88 (m,1H), 2.71-2.42 (m,2H), 2.42-2.03 (m,3H), 1.97-1.63 (m,2H) , 1.62-1.44 (m, 1H), 1.32-1.22(m,1H), 1.15 (d,J = 6.9 Hz, 3H), 1.04-0.91 (m,1H).MS: (ES, *m/z):* 486 $[M+H]^+$.

Second eluting isomer: ^{1}H-NMR (CD_3OD, 300 MHz) *δ*(*ppm*)*:* 7.53-7.41 (m, 1H), 7.41-7.29 (m,1H), 7.18-7.03 (m,3H), 6.99-6.82 (m,2H), 4.82-4.67 (m,1H), 4.62-4.41 (m,1H), 4.41-4.18 (m,2H), 3.77 (s,3H) ,3.58-2.47 (m, 1H), 3.25-3.13 (m,1H), 3.01-2.87 (m,1H), 2.76-2.42 (m,2H), 2.42-2.94 (m,3H), 1.87-1.68 (m,2H), 1.57-1.41 (m,1H), 1.37-1.22(m, 1H), 1.16 (d,J = 6.9 Hz, 3H), 1.03-0.89 (m,1H). MS: (ES, *m/z):* 486 $[M+H]^+$.

[0508] The following examples in **TABLE 14** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Examples 281 and 282.


TABLE 14

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$	^{1}HNMR
283	 methyl (S)-3-((trans)4-(1H-teriazol-5-yl)cyclohexyl)-2-benzyl-7-methyl-3,7,8,9-	486	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (*ppm*): 7.60-7.56 (d, J=9Hz, 1H), 7.32-7.22 (m, 6H), 4.86-4.80 (m,1H), 4.47-4.31 (m, 2H), 4.40-4.10(m, 1H), 3.88(s, 3H),3.32-3.22 (m, 1H), 3.10-2.95 (m, 2H) ,2.28-2.07 (m,

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$	^{1}HNMR
	tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate		6H), 1.78-1.69 (m, 4H), 1.22-1.19 (d, J=6.6Hz,3H)
284	 methyl(S)-3-((cis)-4(11H-tetrazol-5-yl)cyclohexyl)-24benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	486	^{1}H-NMR (CD_3OD, 400 MHz) δ (*ppm*): 735-723 (m, 6H), 7.19-7.17(d, J=9.2 Hz, 1H), 4.77-4.72 (m,1H), 4.41-4.38 (m,3H), 3.75(s, 3H), 3.31-3.30 (m, 1H), 3.21-3.15 (m, 1H), 2.97-2.91 (m, 1H),2.45-2.41 (m, 2H), 2.26-2.21 (m, 3H), 1.88-1.71 (m,3H), 1.40-1.28 (m, 2H), 1.13-1.12 (d, J=9.2Hz, 3H)

Example 285: (S)-2-(2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)acetic acid

[0509]




[0510] Into a 50-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (60 mg, 0.16 mmol) was dissolved in tetrahydrofuran (2 mL). Then sodium dihydrogen orthophosphate (191 mg, 1.59 mmol), dimethyl sulfoxide (3 mL) and water (2 mL) were added, followed by a solution of sodium chlorite (143 mg, 1.26 mmol, 80%) in water (1 mL) dropwise. The resulting solution was stirred for 12 h at room temperature. The resulting solution was diluted with 20 mL of water and extracted with 2 x 30 mL of ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered and concentrated under vacuum. The crude product was purified with the following conditions: Column, XBridge Prep C18 OBD Column, 100 Å, 5 μm, 19 mm x 250 mm; Mobile Phase, A: water (containing 0.1% FA) and B: ACN (20% to 37% ACN over 8 min); UV Detector: 254nm. This afforded the title compound (5.7 mg, 9%) as a white solid. ^{1}H-NMR (DMSO-d6, 400 MHz,) 6(ppm): 13.14 (s, 1H), 7.33-7.24 (m, 5H), 7.24-7.16 (m, 2H), 4.98

(d, J = 2.4 Hz, 2H), 4.66-4.62 (m, J = 6.0 Hz, 1H), 4.24 (s, 2H), 3.66 (s, 3H), 3.11-3.01 (m, 1H), 2.84-2.77 (m, 1H), 2.20-2.09 (m, 1H), 1.66-1.56 (m, 1H), 1.06 (d, J = 7.2 Hz, 3H). MS: (ES, m/z): 394 $[M+H]^+$.

Example 286: methyl (S)-3-(2-amino-2-oxoethyl)-2-benzyl-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate


[0511]



[0512] Into a 100-mL round-bottom flask, ammonium chloride (90 mg, 1.68 mmol) was dissolved in methanol (20 mL). Then triethylamine (72 mg, 0.71 mmol), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl morpholinium chloride (351 mg, 1.27 mmol) and 2-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H, 6H, 7H, 8H, 9H-imidazo[4, 5-f]quinolin-3-yl]acetic acid (130 mg, 0.33 mmol) were added. The resulting solution was stirred for 16 h at room temperature. The resulting solution was diluted with 100 mL of water and extracted with 3x50 mL of dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 Å, 5 μm, 19 mm X 250 mm; mobile phase, A: water (10 mmol/L NH_4HCO_3) and B: ACN (30.0% to 60.0% ACN over 8 min); UV Detector: 254nm. This afforded the title compound (8.6 mg, 7%) as a white solid. ^1H NMR (300 MHz, DMSO-d_6) δ 7.68 (s, 1H), 7.36-7.17 (m, 7H), 7.13 (d, *J*=9.0 Hz, 1H), 4.73 (s, 2H), 4.69-4.56 (m, 1H), 4.19(s, 2H), 3.64 (s, 3H), 3.11-2.96(m, 1H), 2.84-2.67 (m, 1H), 2.21-2.04 (m, 1H), 1.65-1.52 (m, 1H), 1.04 (d, J = 6.6 Hz, 3H). MS: (ES, *m/z):* 393 $[M+H]^+$.

Example 287: methyl (S)-2-benzyl-3-(2-hydroxyethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo [4,5-f] quinoline-6-carboxylate


[0513]



[0514] Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (7S)-2-benzyl-7-methyl-3-(2-oxoethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (100 mg, 0.26 mmol) was dissolved in tetrahydrofuran (5 mL). Then sodium borohydride (11 mg, 0.30 mmol) was added. The resulting solution was stirred for 2 h at 0 °C in a water/ice bath. The resulting solution was diluted with 50 mL of water and extracted with 3x50 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 19 x 150mm 5μm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (5.0 % to 55.0 % ACN over 7 min); UV Detector: 254nm. This afforded the title compound (3.1 mg , 3%) as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) *δ(ppm):* 7.45-7.42 (m, 1H), 7.34-7.22 (m, 3H), 7.22-7.15 (m, 2H), 7.13-7.11 (m, 1H), 4.82-4.76 (m, 1H), 4.42-4.31 (m, 2H), 4.12-4.08(m, 2H), 3.78-3.72 (m, 5H), 3.29-3.18 (m, 1H), 3.03-2.93 (m, 1H), 2.39-2.32 (s, 1H), 2.30-2.20 (m, 1H), 1.77-1.75 (m, 1H), 1.15 (d, *J*=6.6 Hz, 3H). MS: (ES, m/z): 380 $[M+H]^+$.

Example 288: (S)-3-(2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)propanoic acid

[0515]



***Step* 1. Synthesis of methyl (2S)-5-amino-6-[(3,3-diethoxypropyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate.**

[0516] Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, methyl (2S)-5-amino-6-bromo-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (300 mg, 1.00mmol, **Intermediate 1)** was dissolved in toluene (5 mL). Then 3,3-diethoxypropan-1-amine (885 mg, 6.01mmol), 3rd Generation BrettPhos precatalyst (91 mg, 0.10mmol), BrettPhos (108 mg, 0.20mmol) and sodium tert-butoxide (289 mg, 3.01mmol) were added successively. The resulting solution was stirred for 2 h at 110°C under nitrogen atmosphere. The reaction mixture was cooled and the resulting solids were filtered out. The filtrate was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (2:1). This afforded the title compound (240 mg, 62%) as a yellow oil. MS: (ES, m/z): 366 $[M+H]^+$.

Step 2. **Synthesis of methyl (7S)-2-benzyl-3-(3,3-diethoxypropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0517] Into a 25-mL round-bottom flask, methyl (2S)-5-amino-6-[(3,3-diethoxypropyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (240 mg, 0.66mmol) was dissolved in toluene (3 mL). Then 2-phenylacetaldehyde (158 mg, 1.32mmol) was added. The resulting solution was stirred for 14 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was subjected to purification by FCC eluting with ethyl acetate/petroleum ether (1:1). This afforded the title compound (220 mg, 72%) as a yellow oil. MS: (ES, m/z): 466 $[M+H]^+$.

Step 3. **Synthesis of methyl (7S)-2-benzyl-7-methyl-3-(3-oxopropyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0518] Into a 25-mL round-bottom flask, methyl (7S)-2-benzyl-3-(3,3-diethoxypropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (220 mg, 0.47mmol) was dissolved in tetrahydrofuran (3 mL). Then hydrochloric acid (aq, 4 M, 6 mL) was added. The resulting solution was stirred for 3 h at 60°C. After cooled to room temperature, water was added. The resulting solution was extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This afforded the title compound (140 mg, crude) as a yellow oil. MS: (ES, m/z): 392 $[M+H]^+$.


Step 4. **Synthesis of (S)-3-(2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)propanoic acid.**

[0519] Into a 10-mL round-bottom flask, methyl (7S)-2-benzyl-7-methyl-3-(3-oxopropyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (50 mg, 0.13mmol) was

dissolved in tetrahydrofuran (1 mL). Then sodium chlorite (57.5 mg, 0.64mmol), sodium dihydrogen orthophosphate (76 mg, 0.63mmol), dimethyl sulfoxide (1 mL) and water(1 mL) were added successively. The resulting solution was stirred for 2 h at room temperature. The resulting solution was added 20ml of water and extracted with 3x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 100 Å, 5 μm, 19 mm x 250 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (20.0% to 40.0% ACN over 8 min); UV Detector: 254 nm. This afforded the title compound (5.4 mg, 10%) as a white solid. ^{1}H-NMR ($CDCl_3$, 300 MHz) *δ(ppm):* 7.51 (d, J=8.1 Hz, 1H), 7.19-7.11 (m, 6H), 4.82-4.76 (m, 1H), 4.53-4.48 (m, 2H), 4.35-4.17 (s, 2H), 3.77 (s, 3H), 3.22-3.14 (m, 1H), 3.02-2.96 (m, 1H), 2.63-2.59 (m, 2H), 2.21-2.19 (m, 1H), 1.76-1.70 (m, 1H), 1.13 (d, J=6.3Hz, 3H). MS: (ES, *m/z*): 408 $[M+H]^+$.

Example 289: methyl (7S)-2-benzyl-3-(2-carbamoylethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo [4,5-1] quinoline-6-carboxylate

[0520]




[0521] Into a 10-mL round-bottom flask, 3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]propanoic acid (50 mg, 0.12mmol) was dissolved in methanol (2 mL). Then ammonium chloride (53.5 mg, 1.00mmol), triethylamine (10 mg, 0.10mmol) and 4-(4,6-dmethoxy-1,3,5-triazine-2-yl)-4-methyl morpholinium chloride (43.6 mg, 0.16mmol) were added successively. The resulting solution was stirred for 12 h at room temperature. The solids were filtered out and the filtrate was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions (2#-Analyse HPLC-SHIMADZU): Column, XBridge C18 OBD Prep Column, 100Å, 5 um, 19 mm x 250 mm; mobile phase, A: Water (containing 10 mmol/L NH_4HCO_3) and B: ACN (30.0% to 45.0% ACN over 8 min); UV Detector: 254 nm. This afforded the title compound (2.4 mg, 5%) as a white solid. ^{1}H-NMR ($CDCl_3$, 300 MHz) *δ(ppm):* 7.46 (d, J=9.0 Hz, 1H), 7.33-7.29 (m, 4H), 7.24-7.22 (m, 1H), 7.12 (d, J=8.7 Hz, 1H), 5.19-5.12 (m, 2H), 4.82-4.77 (m, 1H), 4.50-4.29 (m, 4H), 3.78 (s, 3H), 3.31-3.22 (m, 1H), 3.09-2.99 (m, 1H), 2.32-2.17 (m, 3H), 1.79-1.71 (m, 1H), 1.16 (d, J=6.6 Hz, 3H). MS: (ES, *m/z):* 407 $[M+H]^+$.

Example 290: methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1-methyl-1H-

pyrazol-3-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0522]



***Step* 1. Synthesis of methyl (*S*)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quinoline-6-carboxylate**

[0523] To a solution of methyl (*S*)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2,2-dimethoxyethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (726 mg, 1.698 mmol) in THF (4.2 mL), was added HCl aqueous solution (4 M, 4.2 mL, 16.98 mmol). The mixture was heated at 60 °C for 4h. After being cooled to rt, The mixture was basified with saturated sodium bicarbonate, and extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated. 680.2 mg of methyl (*S*)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate was obtained (1.78 mmol, 105% yield). MS (ES, *m/z):* 400 ($M+H_2O+1$) and 414 (M+MeOH+1). The crude product was used for next step without further purification.





***Step 2.* Synthesis of methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1-methyl-1H-pyrazol-3-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate**






[0524] To a solution of methyl (*S*)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (0.2 M in 1,4-dioxane with 10% HOAc, 100 µL, 0.02 mmol), was added (1-methyl-1H-pyrazol-3-yl)methanamine (1 M 1,4-dioxane, 200 µL, 0.2 mmol). The resulting mixture was put on a shaker at rt for 30 min before a solution of sodium triacetoxyborohydride (0.2 M in 1,2-DCE, 200 µL, 0.04 mmol) was added. The mixture was then put on a shaker at rt for 20 h. The mixture was diluted with ethyl acetate (0.8 mL) and 1N NaOH in brine (0.45 mL). the organic layer was separated. The aqueous layer was extracted with ethyl acetate (0.8 mL) one more time. The combined organic layers were dried down and the residue was purified by HPLC: Water Autopurification MS-directed HPLC prep fraction collection with the following conditions Column, Waters XBridge OBD C18, 5um,






19x50mm; flow rate 20ml/min; mobile phase, water with 0.1% ammonium hydroxide (A) and methanol with 0.1% ammonium hydroxide (B) running the following gradient 0 to 2 mins (15%B), 2 to 6 mins (15-100%B); Detector ZQ Mass Detector in electrospray ionization mode. This provided 6.1 mg of methyl (*S*)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1-methyl-1H-pyrazol-3-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (12.8 µmol, 64% yield) was obtained. MS (ESI, pos. ion) m/z: 477 (M + 1).






[0525] The following examples in **TABLE 15** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 290.






TABLE 15






Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
291	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((isoxazol-5-ylmethyl)amino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	464
292	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-((oxazol-5 -ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-catboxylate	464
293	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1 methyl-1H-pyrazol-4-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	477
294	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-((pyridin-3 -	474






Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
295	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)amino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	495
296	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2- hydroxyethyl)(methyl)amino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	441
297	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2((2-(dimethylamino)-2-oxoethyl)(methyl)amino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	482
298	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-hydroxypiperidin-1yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	467
299	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-	481







Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	(hydroxymethyl)piperidin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
300	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-((2-oxo-2-(pyrrolidin-1-yl)ethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	494
301	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(methyl(tetrahydro-2H-pyran-4-yl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	481
302	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)7-methyl-3-(2-(methyl((S)-tetrahydrofuran-3-yl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	467
303	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((S)-3-carbamoylpyrrolidin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	480
304	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2-hydroxy-2-	469







Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	methylpropyl)(methyl)amino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
305	 methyl(S)-2-(2-(1H-pyrazol-yl)ethyl)-7-methyl-3-(-(oxetan-3-ylamino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	439
306	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2-cyanoethyl)amino)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	436
307	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methy1-3-(2-((2-(2-oxoimidazolidin-1-yl)ethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	495
308	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-cyanopiperidin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	476
309	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((R)-3-	494


Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	acetamidopyrrolidin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
310	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((S)-3-acetamidopyrrolidin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6carboxylate	494
311	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-isopropylpipeiazin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro -6H-imidazo[4,5-f]quinoline-6carboxylate	494
312	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-cyclopropylpiperazin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6carboxylate	492
313	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	496
314	 methyl (S)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3-(2-	502

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	((pyrimidin-4-ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6-carboxylate	
315	 methyl (S)-7-methyl-3-(2-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	504
316	 methyl (S)-7-methyl-3-(2-(((1-methyl-1H-pyrazol-3-yl)methyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	504
317	 methyl (S)-7-methyl-3-(2-(((1-methyl-1H-1,2,4-triazol-5-yl)methyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	505
318	 methyl (S)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3-(2-((pyridin-3-ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	501
319		494

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	methyl (S)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3-(2-((((R)-tetrahydrofuran-2-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
320	 methyl (S)-3-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)amino)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	436
321	 methyl (S)-3-(2-(((R)-1-hydroxypropan-2-yl)amino)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6 -carboxylate	495
322	 methyl (S)-3-(2-((2-(dimethylamino)-2-oxoethyl)(methyl)amino)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	476
323	 methyl (S)- 3-(2-(4-(hydroxymethyl)piperidin-1-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6 -carboxylate	494
324		521


Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	 methyl(S)-3-(2-((2-(dimethylamino)2-oxoethyl)amino)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
325	 methyl (S)-7-methyl-3-(2-(methyl(tetrahydro-2H-pyian-4-yl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
326	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-cyclopropylpiperazin-1-yl)ethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	494
327	 methyl(S)-3-(2-((S)-3-carbamoylpyrrolidin-1-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	507
328	 methyl(S)-3-(2-((S)-3-carbamoylpyrrolidin-1-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	494
329		505

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	 methyl (S)-7-methyl-3-(2-(((3-methylisoxazol-5-yl)methyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
330	 methyl (S)-3-(2-((2-cyanoethyl)amino)ethyl)-7-methyl-2-(2-(2-oxopyridin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	494
331	 methyl (S)-3-(2-((isoxazol-5-ylmethyl)amino)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-y1)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6carboxylate	494
332	 methyl (S)-3-(2-(4-cyanopiperidin-1-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	466
333	 methyl(S)-3-(2-((R)-3-acetamidopyrrolidin-1-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	521
334		521

Example Number	Structure and Compound Name	LRMS m/z $[M+H]^+$
	 methyl (S)-3-(2-((S)-3-acetamidopyrrolidin-1-yl)ethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	

Example 335: methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((S)-3-acetamidopyrrolidin-1-yl)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate

[0526]








***Step* 1. Synthesis of methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((S)-3-acetamidopyrrolidin-1-yl)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo [4,5-f]quinoline-6-carboxylate**






[0527] To a solution of (S)-2-(2-(2-(1H-pyrazol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)acetic acid (0.2 M 1,4-dioxane with 10% DIEA, 100 µL, 0.02 mmol), was added a solution of (*S*)-N-(pyrrolidin-3-yl)acetamide (0.2 M in 1,4-dioxane, 120 µL, 0.024 mmol) and 2 a solution of DMC (0.2 M 1,2-DCE, 120 µL, 0.024 mmol). The resulting mixture was put on a shaker at rt for 20 h. The mixture was then diluted with ethyl acetate (0.8 mL) and brine (0.45 mL). The organic layer was separated and the aqueous layer was extratced with ethyl acetate. The combined organic layers were dried down and the residue was purified by HPLC: Water Autopurification MS-directed HPLC prep fraction collection with the following conditions Column, Waters XBridge OBD C18, 5um, 19x50mm; flow rate 20ml/min; mobile phase, water with 0.1% ammonium hydroxide (A) and methanol with 0.1% ammonium hydroxide (B) running the following gradient: 0 to 2 mins (15%B), 2 to 6 mins (15-100%B); Detector ZQ Mass Detector in electrospray ionization mode. This provided 3.4 mg of methyl (*S*)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((*S*)-3-acetamidopyrrolidin-1-yl)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate (6.70 µmol, 34% yield) was






obtained. MS (ESI, pos. ion) m/z: 508 (M + 1).






[0528] The following examples in **TABLE 16** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 335.






TABLE 16






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
336	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((pyrimidin-4-ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	489
337	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((pyrimidin-2-ylmethyl)amino)ethyl1)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	489
338	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((2-(pyridin-2-yl)ethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	502
339	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(((2-hydroxypyridin-4-yl)methyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	504
340		478






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-((oxazol-2-ylmethyl)amino-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
341	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((pyridin 4-ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	488
342	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-((oxazol-5 -ylmethyl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	478
343	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro -6H-imidazo[4,5-f]quinoline-6-carboxylate	506
344	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	491
345		491






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1-methyl-1H-pyrazol-3-yl)methyl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
346	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((pyridin-3-ylmethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6carboxylate	488
347	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((((R)-tetrahydrofuran-2-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	481
348	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	509
349	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(((R)-1-hydroxypropan-2yl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	455
350		455






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2-hydroxymethyl) (methyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
351	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2-(dimethylamino)-2-oxoethyl)(methyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6-carboxylate	496
352	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	481
353	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-(hydroxymethyl)piperidin-1-yl)-2 -oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6-carboxylate	495
354	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2-(dimethy	482





Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	lamino)-2-oxoethyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
355	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((2-oxo-2-(pyrrolidin-1-yl)ethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
356	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(methyl(tetrahydro-2H-pyran-4-yl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	495
357	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	495
358	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((tetrahydro-2H-pyran-4-yl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	481
359		481






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(methyl((S)-tetrahydrofuran-3-yl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
360	 methyl(S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((S)-3-carbamoylpyrrolidin-1-yl)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	494
361	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6-carboxylate	483
362	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(((1-hydroxycyclobutyl)methyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline -6-carboxylate	481
363	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((3-methylisoxazol-5-yl)methyl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	492
364		481






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((3-methyloxetan-3 yl)roethyl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
365	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-2-(oxetan-3-ylamino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	453
366	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((cyanomethyl)amino)-2-oxoethyl)-7-methy 1-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	436
367	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((isoxazol-5-ylmethyl)amino)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	478
368	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-oxo-2-((2-(2-oxoimidazolidin-1-yl)ethyl)amino)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	478
369		489






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-(4-cyanopiperidin-1-y1)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
370	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-3-(2-((R)-3-acetamidopyrrolidin-1-yl)-2-oxoethyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
371	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(((1-methyl-1H-1,2,4-triazol-5-yl)methyl)amino)-2-oxoethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	492
372	 methyl (S)-7-methyl-3-(2-(((1-methyl-1H-1,2,4-triazol-5-yl)methyl)amino)-2-oxoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	519
373	 methyl (S)-7-methyl-3-(2-oxo-2-((pyrimidin-4-	516






Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	ylmethyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]qumoline-6-carboxylate	
374	 methyl (S)-7-methyl-3-(2-oxo-2-((2-(pyridm-2-yl)ethyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]qumoline-6-carboxylate	529
375	 methyl (S)-7-methyl-3-(2-oxo-2-((pyridin-3-ylmethyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	515
376	 methyl (S)-7-methyl-3-(2-oxo-2-((((R)-tetrahydrofuran-2-yl)methyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
377	 methyl (S)-3-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6)-[-imidazo[4,5-f]quinoline-6-carboxylate	536
378		482



Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	mmethyl (S)-3-(2-(((R)-1-hydroxypropan-2-yl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6)-[-imidazo[4,5-f]quinoline-6-carboxylate	
379	 methyl(S)-3-(2-((2-hydroxyethyl)(methyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	482
380	 methyl (S)-3-(2-((2-(dimethylamino)-2-oxoethyl)(methyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	523
381	 methyl (S)-3-(2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
382	 methyl (S)-3-(2-((2-(dimethylamino)-2-oxoethyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	509
383		535

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl (S)-7-methyl-3-(2-oxo-2-((2-oxo-2-(pyrrolidin-1-yl)ethyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
384	 methyl (S)-7-methyl-3-(2-(methyl(tetrahydro-2H-pyian-4-yl)amino)-2-oxoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	522
385	 methyl (S)-7-methyl-3-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	522
386	 methyl (S)-7-methyl-3-(2-oxo-2-((tetrahydro-2H-pyran-4-yl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
387	 methyl(S)-7-methyl-3-(2-(methyl((S)-tetrahydrofuran-3-yl)amino)-2-oxoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-	508

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
388	 methyl(S)-3-(2-((S)-3-carbamoylpyrrolidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	521
389	 methyl(S)-3-(2-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	510
390	 methyl(S)-3-(2-(((1-hydroxycyclobutyl)methyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	508
391	 methyl (S)-7-methyl-3-(2-(((3-methylisoxazol-5-yl)methyl)amino)-2-oxoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	519
392		508


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 mmethyl (S)-7-methyl-3-(2-(((3-methyloxetan-3-yl)methyl)amino)-2-oxoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
393	 methyl(S)-7-methyl-3-(2-(oxetan-3-ylamino)-2-oxoethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	480
394	 methyl(S)-3-(2-((cyanomethyl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	463
395	 methyl (S)-7-methyl-3-(2-oxo-2-((2-(2-oxoimidazolidin-1-yl)ethyl)amino)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	536
396	 methyl (S)-3-(2-(4-cyanopiperidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	517
397		535


Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	 methyl (S)-3-(2-((R)-3-acetamidopyrrolidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	
398	 methyl (S)-3-(2-((S)-3-acetamidopyrrolidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	535
399	 methyl(S)-3-(2-((S)-3-hydroxypyrrolidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	494
400	 methyl (S)-7-methyl-3-(2-oxo-2-(3-oxopiperazin-1-yl)ethyl)-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	507
401	 methyl(S)-3-(2-(3,3-difluoropyrrolidin-1-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-	514

Example Number	Structure and Compound Name	LRMS *m/z* $[M+H]^+$
	imidazo[4,5-f]quinoline-6-carboxylate	
402	 methyl (S)-3-(2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	530
403	 methyl (S)-3-(2-((1H-pyrazol-5-yl)amino)-2-oxoethyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	490

Example 413 and 501: (1R,3R)-3-[(7S)-2-[(R)-(4-chlorophenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid; and (1R,3R)-3-[(7S)-2-[(S)-(4-chlorophenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid

[0529]





***Step* 1. 6-fluoro-2-methyl-5-nitroquinoline**

[0530] A solution of trifluoromethanesulfonic acid (82.0 mL, 0.923 mol) in HNO_3 (19.6 mL, 0.437 mol) was stirred for 20 min at 0 °C. This was followed by the addition of 6-fluoro-2-methylquinoline (50.0 g, 0.310 mol) in dichloromethane (300 mL) at 0 °C. The resulting mixture was stirred for 15 hours at room temperature (25 °C). The reaction mixture was diluted with water (300 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with dichloromethane (3 x 300 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with 1:4 ethyl acetate/petroleum ether) to afford 6-fluoro-2-methyl-5-nitroquinoline as a light yellow solid (60.0 g, 94%). LCMS (ES, *m/z*): 207 $[M+H]^+$

***Step 2.* (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline**

[0531] A solution of (S)-(-)-MeO-BIPHEP (1.03 g, 1.77 mmol), chloro(1,5-cyclooctadiene)iridium(I) dimer (538 mg, 0.80 mmol) in toluene (100 mL) was stirred for 30 min at room temperature (25 °C) under an atmosphere of nitrogen. This was followed by the addition of I_2 (410 mg, 1.62 mmol), and 6-fluoro-2-methyl-5-nitroquinoline (33.0 g, 0.160 mol) in toluene (100 mL). The resulting mixture was stirred for 20 h at room temperature (25 °C) under hydrogen (50 atm). The resulting mixture was concentrated under vacuum and purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford the crude product (35.0 g). The crude product was dissolved in ethyl acetate (230 mL), followed by the addition of D-Camphorsulfonic acid (36.9 g, 0.158 mol). The resulting solution was stirred for 1 h at 60 °C and then cooled to room temperature. The solids were collected by filtration, and rinsed with ethyl acetate (120 mL). The solids were dissolved in water (50 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with ethyl acetate (3 x 120 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline as a red solid (25.5 g, 76%). LCMS (ES, *m/z):* 211 $[M+H]^+$

***Step 3.* methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0532] A solution of (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline (25.3 g, 0.120 mol), pyridine (39.0 mL, 0.484 mol), and methyl carbonochloridate (18.7 mL, 0.242 mol) in dichloromethane (150 mL) was stirred for 3 h at room temperature (25 °C). The reaction was washed with 1N hydrogen chloride (aq., 2 x 70 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate as a yellow solid (29.8 g, 92%). LCMS (ES, *m/z*): 269 $[M+H]^+$

Step 4. **methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0533] A solution of methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate (29.6 g, 0.110 mol), pyridine (29.6 mL, 0.368 mol), potassium carbonate (30.5 g, 0.220 mol), and methyl (1R,3R)-3-aminocyclohexane-1-carboxylate (25.6 g, 162.84 mmol) in DMSO (270 mL) was stirred for 15 h at 90 °C and then cooled to room temperature. The reaction was quenched by the addition of water (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate as a red oil (32 g, 72%). LCMS (ES, *m/z*): 406 $[M+H]^+$

Step S. **methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0534] A solution of methyl **(2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate** (31.0 g, 76.46 mmol), NH_4Cl (24.3 g, 454.28 mmol), and Fe (powder, 64.3 g, 1.15 mol) in tetrahydrofuran (300 mL), ethanol (300 mL), water (100 mL) was stirred for 1 h at 80 °C and then cooled to room temperature. The solids were filtered out by filtration. The resulting solution was diluted with water (300 mL) and extracted with ethyl acetate (3 x 400 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford methyl (2S)-5-((R)-2-hydroxy-2-phenylacetamido)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as a dark green solid (27.5 g, 92%). LCMS (ES, *m/z*): 376 $[M+H]^+$

Step **6. methyl (2S)-5-[2-(4-chlorophenyl)-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-**

carboxylate

[0535] A solution of 2-(4-chlorophenyl)-2-hydroxyacetic acid (112 mg, 0.60 mmol), HATU (304 mg, 0.80 mmol), methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (150 mg, 0.40 mmol), and DIEA (155 mg, 1.20 mmol) in N,N-dimethylformamide (2 mL) was stirred for 15 h at room temperature (25 °C). The resulting solution was diluted with water (30 mL), and extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (2 x 25 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (2S)-5-[2-(4-chlorophenyl)-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as yellow oil (70.0 mg, 32%). LCMS (ES, *m/z):* 544 $[M+H]^+$.

Step 7. **methyl (7S)-2-[(4-chlorophenyl)(hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate**

[0536] A solution of methyl (2S)-5-[2-(4-chlorophenyl)-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (60.0 mg, 0.11 mmol) in AcOH (2 mL) was stirred for 15 h at 40 °C and then cooled to room temperature. The reaction mixture was diluted with water (10 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with ethyl acetate (3 x 15 mL). The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (7S)-2-[(4-chlorophenyl)(hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate as yellow oil (46.0 mg, 79%). LCMS (ES, *m/z):* 526 $[M+H]^+$.

Step 8. **(1R,3R)-3-[(7S)-2-[(R)-(4-chlorophenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid; and (1R,3R)-3-[(7S)-2-[(S)-(4-chlorophenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid**

[0537] A solution of methyl (7S)-2-[(4-chlorophenyl)(hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (50.0 mg, 0.10 mmol), and LiOH (11.4 mg, 0.48 mmol) in tetrahydrofuran (1 mL) and water (1 mL) was stirred for 15 h at 25 °C. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC (Column: XBridge Shield RP18 OBD Column, 5um, 19 x 150 mm; Mobile Phase, A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (10% to

37% over 12 min); Detector: UV 254 nm). The product fractions were lyophilized to afford (1R,3R)-3-[(7S)-2-[(R)-(4-chlorophenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (10.5 mg, 43%); and (1R,3R)-3-[(7S)-2-[(S)-(4-chlorophenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (7.0 mg, 29%). The absolute stereochemisties are unknown and therefore are left undefined in Table 17.


First eluting isomer (413): ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49 (d, *J* = 9.0 Hz, 1H), 7.42-7.33 (m, 5H), 6.19 (s, 1H), 4.92-4.90 (m, 1H), 4.82-4.72 (m, 1H), 3.79 (s, 3H), 3.34-3.20 (m, 1H), 3.02-2.94 (m, 1H), 2.90-2.87 (m, 1H), 2.36-2.09 (m, 4H), 1.99-1.96 (m, 1H), 1.80-1.42 (m, 5H), 1.16 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z):* 512 $[M+H]^+$.


Second eluting isomer (501): ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.33 (m, 6H), 6.22 (s, 1H), 4.84-4.73 (m, 2H), 3.78 (s, 3H), 3.27-3.16 (m, 1H), 3.04-2.92 (m, 1H), 2.90-2.88 (m, 1H), 2.46-2.35 (m, 2H), 2.30-2.22 (m, 1H), 2.15-2.02 (m, 2H), 1.82-1.71 (m, 1H), 1.63-1.55 (m, 2H), 1.40-1.28 (m, 1H), 1.15 (d, *J* = 6.6 Hz, 4H). LCMS (ES, *m/z):* 512 $[M+H]^+$.

Examples 424 and 660: (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid (424); (1R,3R)-3-[(7S)-2-[(S)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid (660)

Synthesis of intermediate 2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetic acid

[0538]





Step 1. 2-(5-fluoro-2-methoxyphenyl)-2-[(trimethylsilyl)oxy]acetonitrile

[0539] A solution of ZnI_2 (1.6 mg, 0.01 mmol), 5-fluoro-2-methoxybenzaldehyde (1.54 g, 9.99 mmol) in trimethylsilanecarbonitrile (1.5 mL, 11.25 mmol) was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford 2-(5-fluoro-2-methoxyphenyl)-2-[(trimethylsilyl)oxy]acetonitrile as a white solid (2.0 g, 79%).

Step 2. 2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetic acid

[0540] A solution of 2-(5-fluoro-2-methoxyphenyl)-2-[(trimethylsilyl)oxy]acetonitrile (1.50 g, 5.92 mmol) in hydrogen chloride (10 mL, 12M). The resulting solution was stirred for 1 h at 25 °C, and then stirred for 2 h at 70 °C. The reaction mixture was cooled and concentrated under vacuum. The crude product was purified by reverse phase chromatography (Column: C18; Mobile phase, A: water (containing 0.05% TFA) and B: ACN (5% to 20% over 30 min); Detector, UV 254 nm) to afford 2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetic acid as a white solid (1.10 g, 93%).

***Step 3.* 6-fluoro-2-methyl-5-nitroquinoline**

[0541] A solution of trifluoromethanesulfonic acid (82.0 mL, 0.923 mol) in HNO_3 (19.6 mL, 0.437 mol) was stirred for 20 min at 0 °C. This was followed by the addition of 6-fluoro-2-methylquinoline (50.0 g, 0.310 mol) in dichloromethane (300 mL) at 0 °C. The resulting mixture was stirred for 15 h at room temperature (25 °C). The reaction mixture was diluted with water

(300 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with dichloromethane (3 x 300 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with 1:4 ethyl acetate/petroleum ether) to afford 6-fluoro-2-methyl-5-nitroquinoline as a light yellow solid (60.0 g, 94%). LCMS (ES, *m/z):* 207 $[M+H]^+$

Step 4. **(2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline**

[0542] A solution of (S)-(-)-MeO-BIPHEP (1.03 g, 1.77 mmol), chloro(1,5-cyclooctadiene)iridium(I) dimer (538 mg, 0.80 mmol) in toluene (100 mL) was stirred for 30 min at room temperature (25 °C) under an atmosphere of nitrogen. This was followed by the addition of I_2 (410 mg, 1.62 mmol), 6-fluoro-2-methyl-5-nitroquinoline (33.0 g, 0.160 mol) in toluene (100 mL). The resulting mixture was stirred for 20 h at room temperature (25 °C) under hydrogen (50 atm). The resulting mixture was concentrated under vacuum and purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford the crude product (35.0 g). The crude product was dissolved in ethyl acetate (230 mL), followed by the addition of D-Camphorsulfonic acid (36.9 g, 0.158 mol). The resulting solution was stirred for 1 h at 60 °C and then cooled to room temperature. The solids were collected by filtration, and rinsed with ethyl acetate (120 mL). The solids were dissolved in water (50 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with ethyl acetate (3 x 120 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline as a red solid (25.5 g, 76%). LCMS (ES, *m/z*): 211 $[M+H]^+$

Step S. **methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0543] A solution of (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline (25.3 g, 0.120 mol), pyridine (39.0 mL, 0.484 mol), methyl carbonochloridate (18.7 mL, 0.242 mol) in dichloromethane (150 mL) was stirred for 3 h at room temperature (25 °C). The reaction was washed with 1M hydrochorlic acid (2 x 70 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate as a yellow solid (29.8 g, 92%). LCMS (ES, *m/z):* 269 $[M+H]^+$

Step **6. methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0544] A solution of methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate (29.6 g, 0.110 mol), pyridine (29.6 mL, 0.368 mol), potassium carbonate (30.5 g, 0.220 mol), methyl (1R,3R)-3-aminocyclohexane-1-carboxylate (25.6 g, 162.84 mmol) in DMSO (270 mL) was stirred for 15 h at 90 °C and then cooled to room temperature. The reaction was quenched by the addition of water (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate as a red oil (32 g, 72%). LCMS (ES, *m/z*): 406 $[M+H]^+$

***Step* 7. methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0545] A solution of methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate (31.0 g, 76.46 mmol), NH_4Cl (24.3 g, 454.28 mmol), Fe (64.3 g, 1.15 mol) in tetrahydrofuran (300 mL), ethanol (300 mL), water (100 mL) was stirred for 1 h at 80 °C and then cooled to room temperature. The solids were filtered out by filtration. The resulting solution was diluted with water (300 mL) and extracted with ethyl acetate (3 x 400 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as a dark green solid (27.5 g, 96%). LCMS (ES, *m/z*): 376 $[M+H]^+$

***Step 8.* methyl (2S)-5-[2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0546] A solution of 2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetic acid (240 mg, 1.20 mmol), HATU (228 mg, 0.60 mmol), methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (150 mg, 0.40 mmol), and DIEA (0.19 mL, 1.20 mmol) in N,N-dimethylformamide (10 mL) was stirred for 1 h at 25 °C. The resulting solution was diluted with H_2O (10 mL). The resulting solution was extracted with ethyl acetate (3x15 mL) and the organic layers combined. The resulting mixture was washed with brine (2x20 mL). The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 3:2 ethyl acetate/petroleum ether) to afford methyl (2S)-5-[2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as a yellow solid (180 mg, 81%). LCMS (ES, *m/z):* 558 $[M+H]^+$

Step 9. **methyl (7S)-2-[(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate.**

[0547] A solution of methyl (2S)-5-[2-(5-fluoro-2-methoxyphenyl)-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (180 mg, 0.32 mmol) in AcOH (8 mL) was stirred for overnight at 60 °C. The reaction mixture was cooled and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (7S)-2-[(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate as a yellow solid (120 mg, 69%). LCMS (ES, *m/z*): 540 $[M+H]^+$

Step 10. **(1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid; (1R,3R)-3-[(7S)-2-[(S)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid**

[0548] A solution of methyl (7S)-2-[(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (120 mg, 0.22 mmol), and LiOH (16 mg, 0.67 mmol) in tetrahydrofuran (2.0 mL), methanol (2.0 mL) and water (2.0 mL) was stirred overnight at 25 °C. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC (Column, XBridge Prep C18 OBD Column, 19x150 mm, 5um; Mobile phase, A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (15.0% to 29.0% over 14 min); Detector, UV 220/254nm). The product was separated by Chiral-Prep-HPLC (Column, CHIRALPAK IE, 2x25cm, 5 um; Mobile phase, A: Hex (containing 0.1%FA) and B: ethanol (hold 50.0% ethanol over 12 min); Detector, UV 220/254 nm). The product fractions were concentrated to afford (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (23.6 mg, 20%); and (1R,3R)-3-[(7S)-2-[(S)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (23.8 mg, 2%). Enantiomeric excess was determined via HPLC: Column: CHIRALPAK IE-3, Column size :0.46 x 5 cm; 3 μm; Mobile phase: Hex (0.1% FA) : EtOH = 50 : 50, Flow: 1.0 ml/min. For clarity, the absolute chemistry of each of compounds 424 and 660 was not included in table 17 however is shown in the scheme above.

First eluting isomer (424): ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.47 (m, 1H), 7.47-7.31 (m, 1H), 7.21-7.09 (m, 1H), 7.09-6.89 (m, 2H), 6.53(s, 1H), 4.81-4.61(m, 2H), 3.85(s, 3H), 3.78(s, 3H), 3.31-3.18(m, 1H), 3.06-2.82 (m, 2H), 2.57-2.41 (m, 1H), 2.41-2.31 (m, 1H), 2.31-


2.09 (m, 3H), 1.83-1.58 (m, 3H), 1.49-1.21 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 526 $[M+H]^+$.


Second eluting isomer (660): ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.69-7.44 (m, 2H), 7.44-7.29 (m, 1H), 7.12-6.99 (m, 1H), 6.98-6.82 (m, 1H), 6.37(s, 1H), 5.03-4.91(m, 1H), 4.81-4.69(m, 1H), 3.78(s, 3H), 3.61(s, 3H), 3.22-3.04(m, 1H), 3.02-2.87 (m, 2H), 2.54-2.41 (m, 1H), 2.41-2.27 (m, 1H), 2.27-2.08 (m, 3H), 1.82-1.58 (m, 3H), 1.58-1.41 (m, 2H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z):* 526 $[M+H]^+$.


Examples 452 and 515: (1R,3R)-3-[(7S)-2-[(S)-[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid (515), (1R,3R)-3-[(7S)-2-[(R)-[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid (452)

Synthesis of intermediate 2-(2-(difluoromethoxy)-5-fluorophenyl)-2-hydroxyacetic acid

[0549]







515 452

Step 1. **2-(difluoromethoxy)-5-fluorobenzaldehyde**

[0550] A solution of 5-fluoro-2-hydroxybenzaldehyde (2.0 g, 14.3 mmol), diethyl (bromodifluoromethyl)phosphonate (5.69 g, 21.3 mmol), potassium hydroxide (16.0 g, 285 mmol) in MeCN (100 mL) and water(50 mL) was stirred for 1 h at -30 °C. The reaction mixture was diluted with water (20 mL). The resulting solution was extracted with ethyl acetate (3x100 mL) and the organic layers combined and dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford 2-(difluoromethoxy)-5-fluorobenzaldehyde as a yellow solid (1.46 g, 54%) . LCMS (ES, m/z): 191 $[M+H]^+$

Step 2. **2-[2-(difluoromethoxy)-5-fluorophenyl]-2-[(trimethylsilyl)oxy]acetonitrile**

[0551] A solution of 2-(difluoromethoxy)-5-fluorobenzaldehyde (1.46 g, 7.68 mmol), TMSCN (760 mg, 7.66 mmol), ZnI_2 (50 mg, 0.16 mmol) in dichloromethane (3 mL) was stirred for 2 h at room temperature (25°C). The resulting mixture was concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford 2-[2-(difluoromethoxy)-5-fluorophenyl]-2-[(trimethylsilyl)oxy]acetonitrile as a yellow solid (800 mg, 36%) . LCMS (ES, m/z):290 $[M+H]^+$

Step 3. **2-[2-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetic acid**

[0552] A solution of 2-[2-(difluoromethoxy)-5-fluorophenyl]-2-[(trimethylsilyl)oxy]acetonitrile (800 mg, 2.77 mmol), 1,4-dioxane (2.0 mL), hydrogen chloride (1.0 mL, 12M) in water (2 mL) was stirred for 12 h at 70 °C and then cooled to room temperature. The resulting solution was concentrated under vacuum. The crude product was purified by reverse phase column chromatography (water (containing 0.05%TFA)/MeCN) to afford 2-[2-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetic acid (400 mg, 61%). LCMS (ES, m/z): 237 $[M+H]^+$

Step 4. **methyl (2S)-5-[2-[2-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl] amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0553] A solution of methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (prepared as in the scheme above for Expample 424 and 660) (200 mg, 0.53 mmol), 2-[2-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetic acid (220 mg, 0.93 mmol), DMTMM (350 mg, 1.26 mmol) in dichloromethane (5

mL) was stirred for 1 h room temperature (25 °C). The resulting solution was concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (2S)-5-[2-[2-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as a yellow solid (70.0 mg, 22%). LCMS (ES, m/z): 594 $[M+H]^+$

Step 5. **methyl (7S)-2-[[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate**

[0554] A solution of methyl (2S)-5-[2-[2-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetamido]-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (70.0 mg, 0.12 mmol) in glacial acetic acid (2.0 mL) was stirred for overnight at 40 °C and then cooled to room temperature. The resulting solution was concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:2 ethyl acetate/petroleum ether) to afford methyl (7S)-2-[[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate as a yellow solid (50.0 mg, 74%). LCMS (ES, m/z): 576 $[M+H]^+$

Step **6. (1R,3R)-3-[(7S)-2-[(S)-[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid; (1R,3R)-3-[(7S)-2-[(R)-[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid**

[0555] A solution of methyl (7S)-2-[[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (50.0 mg, 0.09 mmol), LiOH (10.0 mg, 0.42 mmol) in tetrahydrofuran (2.0 mL) and water (2.0 mL) was stirred for overnight at room temperature (25 °C). The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC (Column, XBridge Shield RP18 OBD Column, 30x150 mm, 5 um; Mobile phase, A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (25.0% to 35.0% over 8 min); Detector, UV 254/220 nm). The product fractions were concentrated to afford (1R,3R)-3-[(7S)-2-[(S)-[2-(difluoromethoxy)-5-fluorophenyl] (hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H, 6H,7H, 8H,9H-imidazo[4, 5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (4.50 mg, 9%), and (1R,3R)-3-[(7S)-2-[(R)-[2-(difluoromethoxy)-5-fluorophenyl](hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (4.30 mg, 9%). Enantiomeric excess was determined via HPLC: Column: CHIRALPAK IE-3, Column size :0.46 x 5 cm; 3 μm; Co-Solvent: IPA (20 mM NH_3) Gradient (B%) : 10% to 50%


in 4.0min, hold 2.0 min at 50%. For clarity, the absolute chemistry of each of compounds 452 and 515 was not included in table 17 however is shown in the scheme above.

First eluting isomer (515): ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63-7.61 (m, 1H), 7.53 (d, *J* = 8.8 Hz, 1H), 7.41(d, *J* = 9.2Hz, 1H) 7.20-7.13 (m, 2H), 6.67-6.30 (m, 2H), 4.98-4.95 (m, 1H), 4.76-4.71 (m, 1H), 3.78 (s, 3H), 3.15-2.86 (m, 3H), 2.46-2.20 (m, 5H), 1.81-1.53 (m, 5H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z):* 562 $[M+H]^+$.

Second eluting isomer (452): ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.53 (m, 1H), 7.47-7.42 (m, 2H), 7.40-7.12 (m, 2H), 6.85-6.44 (m, 2H), 4.94-4.91 (m, 1H), 4.76-4.71 (m, 1H), 3.78 (s, 3H), 3.22-2.84 (m, 3H), 2.46-2.23 (m, 5H), 1.84-1.61 (m, 5H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 562 $[M+H]^+$; >99.99% ee.

Example 462: (1R,3R)-3-[(7S)-2-[(R)-hydroxy(phenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid

[0556]



***Step 1*. 6-fluoro-2-methyl-5-nitroquinoline**

[0557] A solution of trifluoromethanesulfonic acid (82.0 mL, 0.923 mol) in HNO_3 (19.6 mL, 0.437 mol) was stirred for 20 min at 0 °C. This was followed by the addition of 6-fluoro-2-methylquinoline (50.0 g, 0.310 mol) in dichloromethane (300 mL) at 0 °C. The resulting mixture was stirred for 15 h at room temperature (25 °C). The reaction mixture was diluted with water (300 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with dichloromethane (3 x 300 mL). The combined organic layers weree dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with 1:4 ethyl acetate/petroleum ether) to afford 6-fluoro-2-methyl-5-nitroquinoline as a light yellow solid (60.0 g, 94%). LCMS (ES, *m/z):* 207 $[M+H]^+$

Step 2. **(2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline**

[0558] A solution of (S)-(-)-MeO-BIPHEP (1.03 g, 1.77 mmol), chloro(1,5-cyclooctadiene)iridium(I) dimer (538 mg, 0.80 mmol) in toluene (100 mL) was stirred for 30 min at room temperature (25 °C) under an atmosphere of nitrogen. This was followed by the addition of I_2 (410 mg, 1.62 mmol), 6-fluoro-2-methyl-5-nitroquinoline (33.0 g, 0.160 mol) in toluene (100 mL). The resulting mixture was stirred for 20 h at room temperature (25 °C) under hydrogen (50 atm). The resulting mixture was concentrated under vacuum and purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford the crude product (35.0 g). The crude product was dissolved in ethyl acetate (230 mL), followed by the addition of D-Camphorsulfonic acid (36.9 g, 0.158 mol). The resulting solution was stirred for 1 h at 60 °C and then cooled to room temperature. The solids were collected by filtration, and rinsed with ethyl acetate (120 mL). The solids were dissolved in water (50 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with ethyl acetate (3 x 120 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline as a red solid (25.5 g, 76%). LCMS (ES, *m/z):* 211 $[M+H]^+$

Step 3. **methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0559] A solution of (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline (25.3 g, 0.120 mol), pyridine (39.0 mL, 0.484 mol), methyl carbonochloridate (18.7 mL, 0.242 mol) in dichloromethane (150 mL) was stirred for 3 h at room temperature (25 °C). The reaction was washed with 1M hydrogen chloride (2 x 70 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate as a yellow solid (29.8 g, 92%). LCMS (ES, *m/z):* 269 $[M+H]^+$

Step 4. **methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-**

1,2,3,4-tetrahydroquinoline-1-carboxylate

[0560] A solution of methyl (2S)-6-fluoro-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate (29.6 g, 0.110 mol), pyridine (29.6 mL, 0.368 mol), potassium carbonate (30.5 g, 0.220 mol), methyl (1R,3R)-3-aminocyclohexane-1-carboxylate (25.6 g, 162.84 mmol) in DMSO (270 mL) was stirred for 15 h at 90 °C and then cooled to room temperature. The reaction was quenched by the addition of water (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate as a red oil (32 g, 72%). LCMS (ES, *m/z*): 406 $[M+H]^+$

Step S. **methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0561] A solution of (2S)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-5-nitro-1,2,3,4-tetrahydroquinoline-1-carboxylate (31.0 g, 76.46 mmol), NH_4Cl (24.3 g, 454.28 mmol), Fe (64.3 g, 1.15 mol) in tetrahydrofuran (300 mL), ethanol (300 mL), water (100 mL) was stirred for 1 h at 80 °C and then cooled to room temperature. The solids were filtered out by filtration. The resulting solution was diluted with water (300 mL) and extracted with ethyl acetate (3 x 400 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as a dark green solid (27.5 g, 92%). LCMS (ES, *m/z*): 376 $[M+H]^+$

Step 6. **methyl (2S)-5-((R)-2-hydroxy-2-phenylacetamido)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate**

[0562] A solution of (R)-2-hydroxy-2-phenylacetic acid (972 mg, 6.39 mmol), HATU (1.20 g, 3.16 mmol), methyl (2S)-5-amino-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (800 mg, 2.13 mmol), DIEA (1.08 mL, 6.20 mmol) in N,N-dimethylformamide (10 mL) was stirred for 5 h at room temperature (25 °C). The resulting solution was diluted with water (30 mL), and extracted with ethyl acetate (3 x 50 mL). The organic layers were combined and washed with brine (2 x 25 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (2S)-5-((R)-2-hydroxy-2-phenylacetamido)-6-

[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate as a colorless oil (600 mg, 55%). LCMS (ES, *m/z):* 510 $[M+H]^+$

***Step* 7. methyl (7S)-2-[(R)-hydroxy(phenyl)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate**

[0563] A solution of methyl (2S)-5-((R)-2-hydroxy-2-phenylacetamido)-6-[[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]amino]-2-methyl-1,2,3,4-tetrahydroquinoline-1-carboxylate (600 mg, 1.18 mmol) in glacial acetic acid (5 mL, 98%) was stirred for overnight at 40 °C and then cooled to room temperature. The reaction mixture was diluted with water (10 mL). The pH value of the solution was adjusted to 8 with sodium bicarbonate (saturated aqueous solution). The resulting solution was extracted with ethyl acetate (3 x 15 mL). The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude product was purified by silica gel chromatography (eluting with 1:1 ethyl acetate/petroleum ether) to afford methyl (7S)-2-[(R)-hydroxy(phenyl)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate(400 mg, 69%) as a colorless oil. LCMS (ES, *m/z*): 492 $[M+H]^+$




***Step 8.* (1R,3R)-3-[(7S)-2-[(R)-hydroxy(phenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-fJquinolin-3-yl]cyclohexane-1-carboxylic acid**



[0564] A solution of methyl (7S)-2-[(R)-hydroxy(phenyl)methyl]-3-[(1R,3R)-3-(methoxycarbonyl)cyclohexyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinoline-6-carboxylate (400 mg, 0.81 mmol), LiOH (100 mg, 4.17 mmol) in tetrahydrofuran (5 mL) and water (2 mL) was stirred for overnight at room temperature (25 °C). The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC (Column: XBridge Shield RP18 OBD Column, 5um, 19 x 150 mm; Mobile Phase, A: water (containing 10 mmol/L NH_4HCO_3) and B: ACN (3% to 30% over 21 min); Detector: UV 254 nm). The product fractions were lyophilized to afford (1R,3R)-3-[(7S)-2-[(R)-hydroxy(phenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid as a white solid (83.7 mg, 22%). Enantiomeric excess was determined via HPLC: Column: CHIRALPAK IE-3, Column size :0.46 x 5 cm; 3 μm; Mobile phase: Hex (0.1%FA) : EtOH = 85:15, Flow :1.0ml/min. For clarity, the absolute chemistry was not included in table 17 however is shown here instead. ^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.28 (m, 7H), 6.12(s, 1H), 4.84-4.74(m, 2H), 3.79(s, 3H), 3.33-3.25(m, 1H), 3.03-2.96 (m, 1H), 2.86-2.82 (m, 1H), 2.38-2.25 (m, 2H), 2.25-2.07 (m, 3H), 1.79-1.72 (m, 1H), 1.64-1.57 (m, 2H), 1.40-1.29 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z):* 478 $[M+H]^+$; 99.13% ee.




[0565] The following examples in **TABLE 17** were prepared using standard chemical




manipulations and procedures similar to those used for the preparation of previous Examples.

TABLE 17

Example Number	Structure and Compound Name	LRMS *m/z* [M+H]	^{1}H NMR
404[1]	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-flquinolin-2-yl)-2-phenylpropanoic acid 2nd eluting isomer	506	^{1}HNMR (CD_3OD, 300 MHz) δ (*ppm*): 7.31-7.05 (m, 7H), 4.70-4.61 (m, 1H), 4.18-3.89 (m, 2H), 3.67 (s, 3H), 3.66-3.51 (m, 1H), 3.38-3.31 (m, 1H), 3.28 (s, 3H), 3.15-2.98 (m, 1H), 2.88-2.76(m, 1H), 2.24-1.95 (m, 3H), 1.92-1.80 (m, 3H), 1.75-1.54 (m, 2H), 1.28-1.11 (m, 2H), 1.01 (d, *J* = 6.6 Hz, 3H), 0.86-0.81 (m, 1H).
405[2]	 3-((7S)-2-(1-(3,4-difluorophenyl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	526	^{1}HNMR (CD_3OD, 400 MHz) δ (*ppm*): 7.41 (d, *J* = 9.2 Hz, 1H), 7.29 (d, *J* =8.8 Hz, 1H), 7.06-7.01 (m, 2H), 6.84-6.86 (m, 1H), 4.73-4.64 (m, 2H), 3.76 (s, 3H), 3.70-3.64 (m, 1H), 3.31-3.14 (m, 2H), 3.08-3.04 (m, 1H), 2.95-2.80(m, 2H), 2.28-2.19 (m, 5H), 1.72-1.47 (m, 7H), 1.12 (d, *J* = 6.8 Hz, 3H), 1.09-0.92 (m, 1H).
406[2]		490	^{1}HNMR (CD_3OD, 400 MHz) δ (*ppm*): 7.37 (d, *J* = 9.2 Hz, 1H), 7.27 (d, *J* =8.8 Hz, 1H), 7.17-7.10

Example Number	Structure and Compound Name	LRMS *m/z* [M+H]	^{1}H NMR
	3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer		(m, 3H), 7.03 (d, *J* =6.8 Hz, 2H), 4.88-4.72 (m, 1H), 4.48-4.35 (m, 1H), 3.77 (s, 3H), 3.70-3.61 (m, 1H), 3.33-3.21 (m, 1H), 3.18-3.01 (m, 2H), 2.98-2.86(m, 2H), 2.31-1.95 (m, 5H), 1.75-1.53 (m, 6H), 1.35-1.28 (m, 1H), 1.12 (d, *J* = 6.4 Hz, 3H), 0.90-0.81 (m, 1H).
407[1]	 (7S)-2-(3-fluoro-4-methylphenyl)-3-(6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5- f]quinolin-2-yl)propanoic acid 2nd eluting isomer	510	^{1}HNMR (CD_3OD, 300 MHz) δ (*ppm*): 7.60 (d, *J* = 9.0 Hz, 1H), 7.49 (d, *J* =9.0 Hz, 1H), 7.22 (t, *J* =7.8 Hz, 1H), 7.13 (d, *J* =7.2 Hz, 1H), 7.05 (d, *J* =9.0 Hz, 1H), 4.88-4.77 (m, 1H), 4.65-4.60 (m, 1H), 4.33-4.28 (m, 1H), 3.96-3.80 (m, 3H), 3.77 (s, 3H), 3.75-3.72 (m, 1H), 3.58-3.34 (m, 2H), 3.24-3.09 (m, 2H), 2.51-2.20(m, 5H), 1.83-1.74 (m, 3H), 1.44-1.35 (m, 1H), 1.14 (d, *J* = 6.6 Hz, 3H).
408[2]	 (1S,4R)-4-((S)-2-(4-(difluoromethoxy)-3-fluorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-flquinolin-3-yl)cyclohexane-1-carboxylic acid	546	^{1}HNMR (CD_3OD, 400 MHz) δ (*ppm*): 7.47 (d, *J* = 8.8 Hz, 1H), 7.40 (d, *J* =9.2 Hz, 1H), 7.26 (t, *J* =8.0 Hz, 1H), 7.18 (d, *J* =6.4 Hz, 1H), 7.08 (d, *J* =8.4 Hz, 1H), 6.99-6.87 (t, 1H), 4.87-4.74 (m, 1H), 4.41 (s, 2H),

Example Number	Structure and Compound Name	LRMS *m/z* [M+H]	^{1}H NMR
			4.24-4.20 (m, 1H), 3.77 (s, 3H), 3.20-3.16 (m, 1H), 2.99-2.93 (m, 1H), 2.42-2.20(m, 4H), 2.08-2.05 (m, 2H), 1.77-1.72 (m, 1H), 1.58-1.46 (m, 4H), 1.14 (d, *J* = 6.8 Hz, 3H).
409[2]	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenoxycyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5- f]quinolin-3-yl)cyclohexane-1-carboxylic acid	504	^{1}HNMR (CD_3OD, 400 MHz) δ (*ppm*): 7.49 (d, *J* = 9.2 Hz, 1H), 7.39 (d, *J* =8.8 Hz, 1H), 7.24-7.19 (m, 4H), 6.90-6.82 (m, 1H), 5.48-5.40 (m, 1H), 4.74-4.69 (m, 1H), 3.77 (s, 3H), 3.28-2.92 (m, 3H), 2.58-2.29 (m, 5H), 1.84-1.59 (m, 6H), 1.43-1.30 (m, 3H), 1.13 (d, *J* = 6.4 Hz, 3H).
410[2]	 3-((7S)-2-((5-chloro-6-methoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	527	^{1}HNMR (CD_3OD, 400 MHz) δ (*ppm*): 7.68 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* =8.8 Hz, 1H), 7.42 (d, *J* =9.2 Hz, 1H), 6.85 (d, *J* =8.0 Hz, 1H), 4.91-4.76 (m, 3H), 4.52-4.45 (m, 1H), 3.92 (s, 3H), 3.79 (s, 3H), 3.24-3.16 (m, 1H), 2.98-2.92 (m, 2H), 2.41-2.19 (m, 5H), 1.78-1.61 (m, 3H), 1.48-1.29 (m, 2H), 1.15 (d, *J* = 6.8 Hz, 3H),
411[2]		492	^{1}HNMR (CD_3OD, 400 MHz) δ (*ppm*): 7.50 (d, *J* = 9.2 Hz, 1H), 7.41 (d, *J* =9.2

Example Number	Structure and Compound Name	LRMS *m/z* [M+H]	^{1}H NMR
	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5- f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer		Hz, 1H), 7.22-7.18 (m, 2H), 6.99-6.88 (m, 3H), 5.87-5.83 (m, 1H), 5.33-5.28 (m, 1H), 4.79-4.75 (m, 1H), 3.78 (s, 3H), 3.20-2.94 (m, 3H), 2.51-2.09 (m, 5H), 1.94 (d, *J* = 6.8 Hz, 3H), 1.76-1.58 (m, 4H), 1.37-1.29 (m, 1H), 1.14 (d, *J* = 6.4 Hz, 3H).
412[2]	 (1S,4R)-4-((S)-2-(3-fluoro-4-isopropoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	538	^{1}HNMR (CD_3OD, 400 MHz) δ *(ppm):* 7.44 (d, *J* = 8.8 Hz, 1H), 7.38 (d, *J* =9.2 Hz, 1H), 7.07-6.89 (m, 3H), 4.78-4.74 (m, 1H), 4.56.4.53 (m, 1H), 4.32 (s, 2H), 4.25-4.21 (m, 1H), 3.77 (s, 3H), 3.31-3.16 (m, 1H), 2.99-2.93 (m, 1H), 2.41-2.17(m, 4H), 2.07-2.03 (m, 2H), 1.77-1.73 (m, 1H), 1.55-1.43 (m, 4H), 1.28 (d, *J* = 6.0 Hz, 6H), 1.14 (d, *J* = 6.8 Hz, 3H).
413	 3-((7S)-2-((4-chlorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1- carboxylic acid 1st eluting isomer	512	^{1}HNMR (CD_3OD, 400 MHz) δ (ppm): 7.49 (d, *J* = 9.0 Hz, 1H), 7.42-7.33 (m, 5H), 6.19 (s, 1H), 4.92-4.90 (m, 1H), 4.82-4.72 (m, 1H), 3.79 (s, 3H), 3.34-3.20 (m, 1H), 3.02-2.94 (m, 1H), 2.90-2.87 (m, 1H), 2.36-2.09 (m, 4H), 1.99-1.96 (m, 1H), 1.80-1.42 (m, 5H), 1.16




Example Number	Structure and Compound Name	LRMS *m/z* [M+H]	^{1}H NMR
			(d, *J* = 6.6 Hz, 3H).







[1] Prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 139.





[2] Prepared using standard chemical manipulations and procedures similar to those used for the preparation of Example 16.


The following examples in **TABLE 18** were prepared using standard chemical manipulations and procedures similar to those used for the preparation of previous Examples.



TABLE 18





Example Number	Structure and Compound Name	^{1}H NMR, LCMS
414	 3-((7S)-2-((3-fluoro-4-methylphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.53-7.38 (m, 2H), 7.22-7.19 (m, 1H), 7.09-7.04 (m, 2H), 6.16 (s, 1H), 4.86-4.70 (m, 2H), 3.79 (s, 3H), 3.30-3.21 (m, 1H), 3.01-2.92 (m, 1H), 2.88-2.84 (m, 1H), 2.43-2.23 (m, 5H), 2.15-2.04 (m, 2H), 2.01-1.97 (m, 1H), 1.81-1.60 (m, 3H), 1.56-1.38 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 510 $[M+H]^+$.
415	 3-((7S)-2-((3-fluoro-4-methylphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.61-7.52 (m, 2H), 7.33-7.18 (m, 2H), 7.11-7.09 (m, 1H), 6.26 (s, 1H), 5.02-4.99 (m, 1H), 4.80-4.79 (m, 1H), 3.80 (s, 3H), 3.21-3.16 (m, 1H), 3.08-2.90 (m, 2H), 2.49-2.41 (m, 1H), 2.35-2.22 (m, 5H), 2.14-2.03 (m, 2H), 1.81-1.79 (m, 1H), 1.63-1.58 (m, 2H), 1.45-1.30 (m, 1H), 1.21-1.18 (m, 1H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 510 $[M+H]^+$.
416	 3-((7S)-2-((3-chloro-4-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.71-7.54 (m, 2H), 7.54-7.42 (m, 1H), 7.42-7.29 (m, 1H), 7.19-6.97 (m, 1H), 6.20(s, 1H), 4.99-4.89(m, 1H), 4.82-4.74(m, 1H), 3.98(s, 3H), 3.89(s, 3H), 3.29-3.19(m, 1H), 3.11-2.93 (m, 2H), 2.48-2.22 (m, 2H), 2.22-2.08 (m, 3H), 1.91-1.69 (m, 3H), 1.38-1.24 (m, 2H), 1.18 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 542 $[M+H]^+$
		







417	 3-((7S)-2-((3-fluoro-5-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51-7.42 (m, 2H), 6.94 (s, 1H), 6.79-6.72 (m, 1H), 6.55-6.62 (m, 1H), 6.19 (s, 1H), 5.03-4.90 (m, 1H), 4.84-4.70 (m, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.28-3.10 (m, 1H), 3.05-2.95 (m, 2H), 2.52-2.43 (m, 2H), 2.38-2.27 (m, 1H), 2.17-1.96 (m, 2H), 1.81-1.66 (m, 1H), 1.64-1.58 (m, 2H), 1.43-1.30 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H), 1.02-0.98 (m, 1H). LCMS (ES, m/z): 526 $[M+H]^+$.
418	 3-((7S)-2-((3-fluoro-5-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.37 (m, 2H), 6.80 (s, 1H), 6.77-6.72 (m, 1H), 6.66-6.59 (m, 1H), 6.15 (s, 1H), 4.85-4.70 (m, 2H), 3.80 (s, 6H), 3.28-3.19 (m, 1H), 3.05-2.95 (m, 1H), 2.91-2.87 (m, 1H), 2.42-2.03 (m, 5H), 1.81-1.60 (m, 3H), 1.56-1.38 (m, 2H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 526 $[M+H]^+$.
419	 3-((7S)-2-((2,3-dihydrobenzofuran-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48–7.38 (m, 2H), 7.25 (s, 1H), 7.15 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.11 (s, 1H), 4.81–4.74 (m, 2H), 4.53 (t, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.29–3.25 (m, 1H), 3.19–3.14 (m, 2H), 3.03–2.91 (m, 2H), 2.36–2.25 (m, 2H), 2.15–2.07 (m, 3H), 1.77–1.60 (m, 3H), 1.35–1.25 (m, 2H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 520 $[M+H]^+$.
420	 3-((7S)-2-((3-fluoro-4-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53-7.39 (m, 2H), 7.17-7.05 (m, 3H), 6.14 (s, 1H), 4.89-4.67 (m, 2H), 3.86 (s, 3H), 3.79 (s, 3H), 3.32-3.21 (m, 1H), 3.04-2.93 (m, 1H), 2.91-2.89 (s, 1H), 2.40-2.22 (m, 2H), 2.22-2.10 (m, 2H), 2.10-2.05 (m, 1H), 1.81-1.60 (m, 3H), 1.52-1.40 (m, 2H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 526 $[M+H]^+$.
421	 3-((7S)-2-((3-chloro-5-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.42 (m, 2H), 7.00-6.89 (m, 3H), 6.13 (s, 1H), 4.85-4.73 (m, 2H), 3.81 (s, 3H), 3.79 (s, 3H), 3.33-3.22 (m, 1H), 3.04-2.90 (m, 2H), 2.42-2.22 (m, 2H), 2.16-2.07 (m, 3H), 1.78-1.54 (m, 3H), 1.48-1.32 (m, 2H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 542 $[M+H]^+$.
		





422	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-ylamino)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.96-7.95 (m, 1H), 7.54-7.43 (m, 2H), 7.33 (d, J=8.8 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 6.63-6.56 (m, 1H), 5.56-5.39 (m, 1H), 4.79-4.64 (m, 1H), 3.76 (s, 3H), 3.28-3.17 (m, 1H), 2.96-2.79 (m, 2H), 2.47-2.14 (m, 5H), 1.92-1.81 (m, 3H), 1.81-1.61 (m, 3H), 1.41-1.19 (m, 3H), 1.11 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 504 $[M+H]^+$.
423	 3-((7S)-2-((3-chlorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.30 (m, 6H), 6.22 (s, 1H), 4.92-4.90 (m, 1H), 4.78-4.74 (m, 1H), 3.78 (m, 3H), 3.33-3.24 (m, 1H), 3.01-2.82 (m, 2H), 2.34-2.14 (m, 5H), 1.76-1.38 (m, 5H), 1.16 (d, *J* =6.4 Hz, 3H). LCMS (ES, m/z): 512 $[M+H]^+$.
424	 3-((7S)-2-((5-fluoro-2-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.47 (m, 1H), 7.47-7.31 (m, 1H), 7.21-7.09 (m, 1H), 7.09-6.89 (m, 2H), 6.53(s, 1H), 4.81-4.61(m, 2H), 3.85(s, 3H), 3.78(s, 3H), 3.31-3.18(m, 1H), 3.06-2.82 (m, 2H), 2.57-2.41 (m, 1H), 2.41-2.31 (m, 1H), 2.31-2.09 (m, 3H), 1.83-1.58 (m, 3H), 1.49-1.21 (m, 2H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 526 $[M+H]^+$
425	 3-((7S)-2-(1-hydroxy-1-phenylpropan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.42-7.28 (m, 2H), 7.22-7.10 (m, 5H), 5.08 (d, *J* = 9.2 Hz, 1H), 4.79-4.75 (m, 1H), 4.39-4.35 (m, 1H), 3.78 (s, 3H), 3.65-.3.53 (m, 1H), 3.26-3.20 (m, 1H), 3.05-2.96 (m, 2H), 2.42-2.20 (m, 1H), 2.20-1.92 (m, 4H), 1.79-1.70 (m, 1H), 1.70-1.50 (m, 5H), 1.40-1.35 (m, 1H), 1.14 (d, *J* = 6.8 Hz, 3H), 0.58-0.56 (m, 1H). LCMS (ES, *m/z*): 506 [M+H]



426	 3-((7S)-2-((7-chloro-2,3-dihydrobenzofuran-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.51 (m, 2H), 7.23-7.13 (m, 2H), 6.10 (s, 1H), 4.85-4.70 (m, 2H), 4.63 (t, *J* = 8.4 Hz, 2H), 3.79 (s, 3H), 3.31-3.19 (m, 3H), 3.04-2.88 (m, 2H), 2.43-2.21 (m, 2H), 2.20-2.05 (m, 3H), 1.80-1.59 (m, 3H), 1.45-1.30 (m, 2H), 1.16 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 554 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51-7.41



427	 3-((7S)-2-((7-fluoro-2,3-dihydrobenzofuran-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	(m, 1H), 7.41-7.29 (m, 1H), 7.24-7.13 (m, 1H), 7.11-6.94 (m, 1H), 6.19(s, 1H), 4.95-4.91(m, 1H), 4.81-4.71(m, 1H), 4.63 (t, *J* = 8.8 Hz, 2H), 3.78(s, 3H), 3.32-3.18(m, 3H), 3.08-2.91 (m, 1H), 2.82-2.67 (m, 1H), 2.39-2.18 (m, 4H), 2.16-1.98 (m, 1H), 1.82-1.68 (m, 1H), 1.68-1.50 (m, 2H), 1.50-1.38 (m, 1H), 1.16 (d, *J*=6.8 Hz, 3H), 1.14-1.06 (m, 1H). LCMS (ES, *m/z*): 538 $[M+H]^-$
428	 3-((7S)-2-((2,3-difluoro-6-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.44 (m, 1H), 7.44-7.34 (m, 1H), 7.31-7.19 (m, 1H), 6.96-6.78 (m, 1H), 6.57(s, 1H), 4.81-4.66(m, 1H), 4.52-4.29(m, 1H), 3.87(s, 3H), 3.79(s, 3H), 3.33-3.21(m, 1H), 3.08-2.84 (m, 2H), 2.59-2.41 (m, 1H), 2.39-2.22 (m, 2H), 2.22-2.12 (m, 1H), 2.12-1.96 (m, 1H), 1.82-1.68 (m, 1H), 1.69-1.52 (m, 2H),1.24-1.07 (m, 4H), 1.24-0.99 (m, 1H). LCMS (ES, *m/z*): 544 $[M+H]^+$




429	 3-((7S)-2-((5-fluoro-1H-indazol-7-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.06 (s, 1H), 7.56-7.50 (m, 1H), 7.48 – 7.39 (m, 2H), 7.16 – 7.08 (m, 1H), 6.59 (s, 1H), 5.06 – 4.95 (m, 1H), 4.82 – 4.73 (m, 1H), 3.79 (s, 3H), 3.31 – 3.22 (m, 1H), 3.05 – 2.92 (m, 2H), 2.47 – 2.10 (m, 5H), 1.82 – 1.64 (m, 3H), 1.5-1.28 (m, 2H), 1.17 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 536 $[M+H]^+$.
430	 3-((7S)-2-((2-chloro-4-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.74 (d, *J* = 9.2 Hz, 1H), 7.52 (d, *J* = 8.8 Hz, 1H), 7.41 (d, *J* = 8.8 Hz, 1H), 6.99-6.97 (m, 2H), 6.40 (s, 1H), 4.85-4.81 (m, 1H), 4.74-4.71 (m, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.20-3.13(m, 1H), 2.95-2.90 (m, 1H), 2.89-2.85 (m, 1H), 2.47-2.45 (m, 1H), 2.30-2.17 (m, 4H), 1.75-1.64 (m, 4H), 1.54-1.45 (m, 1H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 542 $[M+H]^-$.
431	 3-((7S)-2-((2-chloro-4-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.59 (d, *J* = 9.2 Hz, 1H), 7.41 (d, *J* = 9.2 Hz, 1H), 7.24 (d, *J* = 8.8 Hz, 1H), 7.02 (s, 1H), 6.84 (d, *J* = 8.8 Hz, 1H), 6.50 (s, 1H), 4.77-4.72 (m, 1H), 4.54-4.53 (m, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.29-3.23(m, 1H), 2.98-2.91 (m, 2H), 2.47-2.45 (m, 1H), 2.36-2.33 (m, 1H), 2.28-2.17 (m, 2H), 2.08-2.03 (m, 1H), 1.72-1.65 (m, 3H), 1.37-1.21 (m, 1H), 1.21-1.18 (m, 1H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 542 $[M+H]^+$.
		^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.51 (d, *J* = 9.0 Hz, 1H), 7.44 (d, *J* = 9.0 Hz, 1H), 7.40-7.31


432	 3-((7S)-2-((3,4-difluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	(m, 1H), 7.23-7.18 (m, 1H), 7.15-7.11 (m, 1H), 6.18 (s, 1H), 4.93-4.91 (m, 1H), 4.80-4.76 (m, 1H), 3.79 (s, 3H), 3.26-3.21 (m, 1H), 3.01-2.94 (m, 1H), 2.86-2.84 (m, 1H), 2.41-2.09 (m, 4H), 1.92-1.89 (m, 1H), 1.78-1.48 (m, 5H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^+$.
433	 3-((7S)-2-((3-chloro-5-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62-7.51 (m, 2H), 7.12-7.07 (m, 1H), 7.03-6.97 (m, 1H), 6.86-6.80 (m, 1H), 6.20 (s, 1H), 5.03-4.92 (m, 1H), 4.78 (m, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 3.24-3.22 (m, 1H), 3.06-2.96 (m, 2H), 2.53-2.36 (m, 2H), 2.32-2.28 (m, 1H), 2.14-2.12 (m, 1H), 2.04-2.00 (m, 1H), 1.83-1.71 (m, 1H), 1.61-1.52 (m, 2H), 1.40-1.31 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H), 1.05-0.97 (m, 1H). LCMS (ES, m/z): 542 $[M+H]^+$.
434	 3-((7S)-2-((5-fluoro-1H-indol-7-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.87-7.74 (m, 2H), 7.43-7.30 (m, 2H), 7.02-6.92 (m, 1H), 6.76 (s, 1H), 6.59-6.52 (m, 1H), 4.86-4.71 (m, 2H), 3.82 (s, 3H), 3.29-3.09 (m, 2H), 3.06-2.97 (m, 1H), 2.47-2.36 (m, 2H), 2.35-2.24 (m, 1H), 2.16-2.08 (m, 1H), 2.05-1.85 (m, 2H), 1.74-1.60 (m, 1H), 1.59-1.45 (m, 1H), 1.20 (d, J = 6.8 Hz, 3H), 0.93-0.77 (m, 1H), 0.75-0.61 (m, 1H). LCMS (ES, *m/z*): 535 $[M+H]^+$.
435	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.21- 8.01 (m, 1H), 7.79 - 7.62 (m, 1H), 7.56 -7.44 (m, 1H), 7.44 -7.33 (m, 1H), 7.33- 7.16 (m, 1H), 7.03- 6.88 (m, 1H), 5.52-5.31 (m, 1H), 4.81- 4.61 (m, 1H), 3.76 (s, 3H), 3.31 - 3.12 (m, 1H), 3.02 - 2.87 (m, 2H), 2.59 - 2.41 (m, 1H), 2.35 - 2.12 (m, 4H), 2.04 - 1.92(m, 1H), 1.91 -1.59 (m, 6H), 1.47 - 1.31 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 505 $[M+H]^+$.
436	 3-((7S)-2-(2-(4-chloro-1H-pyrazol-1-yl)-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.87 (s, 1H), 7.57 (d, J = 8.8 Hz, 1H), 7.52-7.38 (m, 2H), 5.51-5.44 (m, 1H), 5.36-5.25 (m, 1H), 5.03-4.92 (m, 1H), 4.82-4.71 (m, 1H), 4.60-4.52 (m, 1H), 3.79 (s, 3H), 3.24-3.11 (m, 1H), 3.09-2.86 (m, 2H), 2.49-2.19 (m, 4H), 1.96-1.85 (m, 2H), 1.80-1.60 (m, 3H), 1.36-1.29 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 516 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.64-7.39 (m, 3H), 7.39-7.21 (m, 1H), 7.16-6.89 (m, 1H),





437	 3-((7S)-2-((3-chloro-4-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	6.17(s, 1H), 5.05-4.91(m, 1H), 4.82-4.68(m, 1H), 3.87(s, 3H), 3.78(s, 3H), 3.29-3.12(m, 1H), 3.02-2.89 (m, 2H), 2.51-2.21 (m, 3H), 2.19-1.93 (m, 2H), 1.84-1.71 (m, 1H), 1.69-1.54 (m, 2H), 1.51-1.36 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H),1.10-0.97 (m, 1H). LCMS (ES, m/z): 542 $[M+H]^-$
438	 3-((7S)-2-((3-fluoro-4-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.40 (m, 2H), 7.32-7.24 (m, 1H), 7.16-7.10 (m, 1H), 7.08-7.00 (m, 1H), 6.17 (s, 1H), 4.98-4.90 (m, 1H), 4.82-4.71 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.30-3.17 (m, 1H), 3.04-2.94 (m, 2H), 2.50-2.29 (m, 2H), 2.27-2.18 (m, 1H), 2.13-1.95 (m, 2H), 1.80-1.68 (m, 1H), 1.61-1.54 (m, 2H), 1.44-1.27 (m, 1H), 1.15 (d, J = 6.8, 3H), 1.09-1.06 (m, 1H). LCMS (ES, m/z): 526 $[M+H]^+$.
439	 3-((7S)-2-(acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.50 (m, 1H), 7.43-7.40 (m, 1H), 7.40-7.37 (m, 2H), 7.32-7.30 (m, 3H), 6.89 (s, 1H), 4.81-4.78 (m, 1H), 4.52-4.48 (m, 1H), 3.79 (s, 3H), 3.30-3.18 (m, 1H), 3.10-2.94 (m, 1H), 2.40-2.20 (m, 2H), 2.18 -2.09 (m, 6H), 1.82-1.76 (m, 1H), 1.72-1.67 (m, 2H), 1.43-1.35 (m, 1H), 1.32-1.29 (m, 1H), 1.16 (d, J = 6.7 Hz, 3H), 1.12-1.03 (m, 1H). LCMS (ES, m/z): 519 $[M+H]^+$.
440	 3-((7S)-2-((2,3-dihydrobenzofuran-7-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.83 (s, 2H), 7.30 (d, J = 6.8 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 6.93 (t, J = 7.6 Hz, 1H), 6.42 (s, 1H), 4.85-4.62 (m, 3H), 4.53-4.41 (m, 1H), 3.833 (s, 3H), 3.27-2.98 (m, 5H), 2.53-2.35 (m, 2H), 2.34-2.09 (m, 3H), 1.92-1.85 (m, 1H), 1.75-1.62 (m, 2H), 1.22-1.01 (m, 5H). LCMS (ES, m/z): 520 $[M+H]^+$

441	 methyl (7S)-2-(1-(3,4-difluorophenyl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.30 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.10-6.96 (m, 2H), 6.83-6.73 (m, 1H), 4.82-4.68 (m, 1H), 4.21-4.05 (m, 1H), 3.82-3.69 (m, 5H), 3.62-3.49 (m, 3H), 3.30-3.12 (m, 2H), 3.11-3.02 (m, 1H), 2.99-2.87 (m, 1H), 2.35-2.01 (m, 5H), 1.76-1.64 (m, 3H), 1.57-1.45 (m, 4H), 1.12 (d, J = 6.8 Hz, 3H), 0.92-0.71 (m, 1H). LCMS (ES, m/z): 523 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.59-7.47 (m, 1H), 7.47-7.32 (m, 2H), 7.12-6.99 (m, 1H), 7.09-6.93 (m, 1H), 6.51(s, 1H), 4.82-4.57(m, 2H), 3.87(s, 3H), 3.78(s, 3H), 3.32-3.18(m, 1H), 3.05-





442	3-((7S)-2-((5-chloro-2-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	2.79 (m, 2H), 2.57-2.41 (m, 1H), 2.41-2.31 (m, 1H), 2.31-2.05 (m, 3H), 1.82-1.67 (m, 3H), 1.52-1.22 (m, 2H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 542 $[M+H]^+$
443	 3-((7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.81-7.75 (m, 3H), 7.34(s, 1H), 4.87-4.72(m, 2H), 4.71-4.62(m, 2H), 4.30-4.15(m, 1H), 3.79(s, 3H), 3.18-2.96 (m, 3H), 2.45-2.20 (m, 5H), 1.95-1.70 (m, 3H), 1.65-1.60 (m, 1H), 1.62 (d, J = 6.8 Hz, 3H), 1.55-1.40 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^+$.
444	 3-((7S)-2-((2-(difluoromethyl)-5-fluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86-7.83 (m, 3H), 7.51-7.34 (m, 2H), 7.29-7.23 (m, 1H), 6.64-6.62 (m, 1H), 4.89-4.76 (m, 3H), 3.83(s, 3H), 3.27-3.02(m, 3H), 2.48-2.14(m, 5H), 1.90-1.85 (m, 1H), 1.76-1.69 (m, 2H), 1.27-1.15 (m, 5H). LCMS (ES, m/z): 546 $[M+H]^+$.


445	 3-((7S)-2-((5-fluoro-2-isopropoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.52 (m, 1H), 7.45-7.40 (m, 1H), 7.31-7.29 (m, 1H), 7.08-6.90 (m, 2H), 6.38 (s, 1H), 4.86-4.75 (m, 2H), 4.62-4.50 (m, 1H), 3.79 (s, 3H), 3.30 – 3.17 (m, 1H), 2.95 – 2.86 (m, 2H),2.48- 2.44 (m, 1H), 2.32-2.24 (m, 4H), 1.80 – 1.50 (m, 5H), 1.18 (d, J = 6.0 Hz, 3H), 1.13 (d, J = 6.4 Hz, 3H), 1.03 (d, J = 6.0 Hz, 3H). LCMS (ES, m/z): 554 $[M+H]^+$.
446	 2-(3-fluoro-4-methylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD3OD, 400 MHz) δ (ppm): 7.56-7.54(m, 1H), 7.44-7.41(m, 1H), 7.20-7.04(m, 3H), 4.80-4.70(m, 1H), 4.65-4.50(m, 1H), 4.35-4.25(m, 1H), 4.05-3.95(m, 2H), 3.80-3.50(m, 5H), 3.40-3.10(m, 3H), 2.98-2.85(m, 1H),2.55-2.15(m, 6H), 1.95-1.65(m, 3H), 1.12(d, J=6.8Hz, 3H). LCMS (ES, m/z): 510 $[M+H]^+$
447	 3-((7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.78 (d, J = 9.2 Hz, 1H), 7.59 (d, J = 9.2 Hz, 1H), 7.49-7.32 (m, 1H), 7.30-7.16 (m, 2H), 5.30-5.14 (m, 1H), 4.84-4.74 (m, 1H), 4.34-4.25 (m, 1H), 4.02-3.90 (m, 1H), 3.82 (s, 3H), 3.62-3.49 (m, 1H), 3.13-2.92 (m, 2H), 2.41-2.32 (m, 1H), 2.28-2.02 (m, 5H),




	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3,4-difluorophenyl)propanoic acid 2nd eluting isomer	2.02-1.95 (m, 1H), 1.95-1.82 (m, 3H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
448	 3-((7S)-2-((5-fluoro-1H-indol-7-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.87-7.76 (m, 2H), 7.42 (s, 1H), 7.32-7.22 (m, 1H), 6.85-6.74 (m, 2H), 6.54-6.51 (m, 1H), 5.27-5.16 (m, 1H), 4.85-4.76 (m, 1H), 3.82 (s, 3H), 3.20-3.03 (m, 2H), 3.02-2.93 (m, 1H), 2.54-2.33 (m, 2H), 2.32-2.20 (m, 1H), 2.14-1.86 (m, 3H), 1.70-1.56 (m, 1H), 1.55-1.44 (m, 1H), 1.19 (d, *J* = 6.8 Hz, 3H), 1.05-0.81 (m, 2H). LCMS (ES, *m/z*): 535 $[M+H]^+$.



449	 3-((7S)-2-((2,5-difluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.50 (m, 1H), 7.43-7.41 (m, 1H), 7.36-7.32 (m, 1H), 7.14-7.08 (m, 2H), 6.42 (s, 1H), 4.87-4.72(m, 2H), 3.78 (s, 3H),3..33-3.20 (m, 1H), 2.96-2.88 (m, 2H), 2.47-2.2.42 (m, 1H), 2.32-2.12 (m, 4H), 1.80-1.67 (m, 3H), 1.59-1.48 (m, 2H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$
450	 (1S,4R)-4-((S)-2-(1-(1H-indazol-1-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.22 (s, 1H), 7.99 – 7.90 (m, 1H), 7.82 – 7.73 (m, 1H), 7.71 – 7.62 (m, 1H), 7.51 – 7.37 (m, 2H), 7.23 – 7.12 (m, 1H), 5.40-5.25 (m, 1H), 4.73 – 4.62 (m, 1H), 3.67 (s, 3H), 3.18 – 3.02 (m, 1H), 3.02 – 2.86 (m, 1H), 2.58-2.50 (m, 1H), 2.24 – 1.88 (m, 9H), 1.80 – 1.68 (m, 1H), 1.66 – 1.44 (m, 3H), 1.38 – 1.29 (m, 1H), 1.05 (d, J=6.6, 3H). LCMS (ES, m/z): 528 $[M+H]^-$.
451	 3-((7S)-2-(hydroxy(2-methylbenzo[d]oxazol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.68 (s, 1H), 7.50 (d, *J* = 8.4 Hz, 1H), 7.49–7.40 (m, 3H), 6.32 (s, 1H), 4.89–4.74 (m, 2H), 3.79 (s, 3H), 3.29–3.25 (m, 1H), 3.04–2.98 (m, 1H), 2.85-2.83 (m, 1H), 2.64 (s, 3H), 2.35–2.31 (m, 2H), 2.29–2.26 (m, 2H), 2.13–1.97 (m, 1H), 1.78–1.74 (m, 1H), 1.67–1.61 (m, 2H), 1.44–1.20 (m, 2H), 1.17 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 533 $[M+H]^-$.
452	 3-((7S)-2-((2-(difluoromethoxy)-5-fluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54 (d, *J* = 8.8 Hz, 1H), 7.47-7.42 (m, 2H), 7.40-7.12 (m, 2H), 6.85-6.45 (m, 1H), 6.44 (s, 1H), 4.94-4.91 (m, 1H), 4.76-4.71 (m, 1H), 3.78 (s, 3H), 3.22-2.84 (m, 3H), 2.46-2.23 (m, 5H), 1.84-1.61 (m, 5H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 562 $[M+H]^+$.



	3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	





453	 3-((7S)-2-(2-hydroxy-1-phenylpropan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55 (d, J=8.8 Hz, 1H), 7.38 (d, J=8.8 Hz, 1H), 7.28-7.15 (m, 5H), 5.73-5.54 (m, 1H), 4.78-7.64 (m, 1H), 3.80 (s, 3H), 3.51-3.33 (m, 2H), 3.28-3.17 (m, 2H), 3.02-2.83 (m, 2H), 2.64-2.52 (m, 1H), 2.45-2.21 (m, 4H), 1.91-1.80(m, 2H), 1.75-1.62 (m, 5H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.
454	 3-((7S)-2-(2-cyclopentyl-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55 (d, J = 9.2 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 5.27-5.12 (m, 2H), 4.80-4.76 (m, 1H), 3.79 (s, 3H), 3.23–3.16 (m, 1H), 3.08-2.88 (m, 2H), 2.58-2.53 (m, 1H), 2.39–2.19 (m, 5H), 1.98–1.88 (m, 4H), 1.75–1.66 (m, 6H), 1.53-1.48 (m, 2H), 1.33–1.18 (m, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 484 $[M+H]^+$.
455	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 4th eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm):7.46-7.38(m, 2H), 7.30-7.25(m, 5H), 4.75-4.74(m, 1H), 4.50-4.46(m, 1H), 4.26-4.25(m, 1H), 3.76-3.74(m, 4H), 3.69-3.63(m, 1H), 3.41-3.35(m, 4H), 3.11-3.09(m, 1H), 2.94-2.90(m, 1H), 2.27-2.09(m, 3H), 2.00-1.96(m, 1H), 1.75-1.72(m, 1H), 1.61-1.48(m, 3H), 1.29-1.25(m, 1H), 1.11(d, J=6.8 Hz, 3H), 1.07-1.05(m, 1H). LCMS (ES, m/z): 506 [M+H]+.
456	 2-(4-chlorophenyl)-3-((7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.52 (m, 1H), 7.48-7.39 (m, 5H), 5.05-4.91 (m, 1H), 4.85-4.72 (m, 1H), 4.35-4.20 (m, 1H), 3.85-3.73 (m, 4H), 3.44-3.35 (m, 1H), 3.15-3.02 (m, 1H), 2.98-2.85 (m, 1H), 2.31-1.95 (m, 6H), 1.90-1.68 (m, 4H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 496 $[M+H]^+$.


457	 4-((7S)-2-(1-(3-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm):7.53 - 7.38 (m,1H), 7.38 -7.23 (m, 2H), 6.03 (s, 1H), 4.83 - 4.68 (m, 1H), 4.68 - 4.51 (m, 1H), 4.51 - 4.36 (m, 1H), 4.36 - 4.17 (m, 1H), 4.03 - 3.88 (m, 1H), 3.76 (s, 3H), 3.27 - 3.09 (m, 1H), 3.01 - 2.82 (m, 1H), 2.59 - 2.07 (m, 6H), 1.99 - 1.59 (m, 4H), 1.59 - 1.39 (m, 4H), 1.14 - 1.12 (d, J =6.6 Hz, 3H). LCMS:(ES, m/z): 514 $[M+H]^-$.





	yl)cyclohexane-1-carboxylic acid 1st eluting isomer	
458	 3-((7S)-2-(benzo[d]oxazol-5-yl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.49 (s, 1H), 7.85-7.77 (m, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.59-7.51 (m, 1H), 7.50-7.45 (m, 1H), 7.44-7.37 (m, 1H), 6.35 (s, 1H), 4.88-4.83 (m, 1H), 4.81-4.73 (m, 1H), 3.79 (s, 3H), 3.30-3.24 (m, 1H), 3.07-2.93 (m, 1H), 2.86-2.77 (m, 1H), 2.41-2.23 (m, 2H), 2.21-2.05 (m, 2H), 2.03-1.90 (m, 1H), 1.83-1.71 (m, 1H), 1.70-1.53 (m, 2H), 1.52-1.29 (m, 2H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 519 $[M+H]^+$.
459	 3-((7S)-2-(1-(3-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.93-7.66 (m, 2H), 7.66-7.46 (m, 1H), 6.17 (s, 1H), 4.83-4.72 (m, 1H), 4.72-4.53 (m, 2H), 4.33-4.09 (m, 1H), 3.80 (s, 3H), 3.18-2.88 (m, 3H), 2.59-2.13 (m, 5H), 1.99-1.66 (m, 4H), 1.63 (d, J =7.2 Hz, 3H), 1.59-1.40 (m, 1H), 1.34-1.23(m, 1H), 1.15 (d, J =6.6 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^+$.
460	 3-((7S)-2-((2,3-dihydrobenzofuran-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.4-7.33(m, 2H), 7.34 (s, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.18 (s, 1H), 4.94–4.88 (m, 1H), 4.79–4.75 (m, 1H), 4.53 (t, J = 8.4 Hz, 2H), 3.78 (s, 3H), 3.25–3.15 (m, 3H), 3.01–2.92 (m, 2H), 2.43–2.30 (m, 3H), 2.28–1.98 (m, 2H), 1.78–1.73 (m, 1H), 1.64-1.58 (m, 2H), 1.40–1.31 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H), 1.07–1.04 (m, 1H). LCMS (ES, m/z): 520 $[M+H]^+$.

461	 3-((7S)-2-((7-chloro-2,3-dihydrobenzofuran-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.42 (m, 2H), 7.29 (s, 1H), 7.22 (s, 1H), 6.18 (s, 1H), 5.08-4.93 (m, 1H), 4.83-4.71 (m, 1H), 4.63 (t, J = 8.4 Hz, 2H), 3.79 (s, 3H), 3.30-3.12 (m, 3H), 3.04-2.90 (m, 2H), 2.51-2.38 (m, 1H), 2.39- 2.20 (m, 2H), 2.16-1.98 (m, 2H), 1.82-1.71 (m, 1H), 1.70-1.62 (m, 2H), 1.54-1.39 (m, 1H), 1.16(d, J = 6.4 Hz, 3H), 1.14-1.09 (m, 1H). LCMS (ES, m/z): 554 $[M+H]^+$.
462	 3-((7S)-2-(hydroxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51-7.25 (m, 7H), 6.20 (s, 1H), 4.98-4.72 (m, 2H), 3.79(s, 3H), 3.33-3.25(m, 1H), 3.06-2.81 (m, 2H), 2.41-2.20 (m, 2H), 2.18-2.05 (m, 3H), 1.81-1.72 (m, 1H), 1.70-1.53 (m, 2H), 1.48-1.25 (m, 2H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 478 $[M+H]^+$.





463	 (1R,3R)-3-((S)-2-(5-fluoro-2-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.68-7.66 (m, 2H), 7.10-6.96 (m, 3H), 4.85-4.75 (m, 2H), 4.54-4.38 (m, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.16-3.12 (m, 1H), 3.06-2.94 (m, 2H), 2.44-2.39 (m, 1H), 2.34-2.11 (m, 4H), 1.84-1.65 (m, 3H), 1.33-1.25 (m, 2H), 1.17 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 510 $[M+H]^+$
464	 3-((7S)-2-((3-fluoro-2,6-dimethoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49-7.41 (m, 2H), 7.17-7.12 (m, 1H), 6.77-6.74 (m, 1H), 6.55(s, 1H), 4.86-4.76(m, 1H), 4.38-4.34(m, 1H),3.84(s, 3H), 3.79(s, 3H), 3.53(s, 3H), 3.33-325(m, 1H), 3.05-2.98(m, 1H), 2.94-2.92 (m, 1H), 2.50-2.48 (m, 1H), 2.31-2.18(m, 3H), 2.02-1.93(m, 1H), 1.79-1.75 (m, 1H), 1.61-1.58 (m, 2H), 1.18-1.16 (m, 4H), 0.99-0.96 (m, 1H). LCMS (ES, *m/z*): 556 $[M+H]^-$



465	 (1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.46 (s, 1H), 8.89 (s, 2H) 8.86 (s, 1H), 7.78 (d, J = 3.6 Hz, 1H), 5.13-5.02 (m, 1H), 4.97 (d, *J* = 6.8 Hz, 2H), 4.87-4.81 (m, 1H), 3.84 (s, 3H), 3.33-2.99 (m, 3H), 2.45-2.15 (m, 5H), 1.88-1.70 (m, 4H), 1.43-1.28 (m, 1H), 1.19 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 503 $[M+H]^-$.
466	 4-((7S)-2-(1-(3-fluoro-4-methoxyphenyl)-2-methylpropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD3OD, 300 MHz) δ (ppm): 7.53-7.41(m, 2H),7.18-7.06(m, 3H),4.85-4.70(m, 1H), 4.60-4.50(m, 1H), 4.12-4.00(m, 1H), 3.85(s, 3H), 3.78 (s, 3H), 3.12-2.75(m, 2H), 2.55-1.65(m, 9H), 1.60-1.45(m, 1H),1.40-1.25(m, 1H),1.18(d, *J*=6.9Hz, 3H), 1.18-1.10(m, 4H), 0.93(d, *J*=6.6Hz, 3H). LCMS (ES, m/z): 552$[M+H]^+$
467	 3-((7S)-2-(hydroxy(1-methyl-1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61(s, 1H), 7.45-7.38 (m, 3H), 7.38-7.32 (m, 1H), 7.17-7.15 (m, 1H), 6.42(s, 1H), 6.41(s, 1H), 4.91- 4.75 (m, 2H), 3.79 (s, 3H), 3.78 (s, 3H), 3.31-3.22 (m, 1H), 3.11-3.00 (m, 1H), 2.91-2.85 (m, 1H), 2.45-2.31 (m, 2H), 2.28-2.21 (m, 1H), 2.12-2.00 (m, 1H), 1.99-1.80 (m, 1H), 1.79-1.70 (m, 1H), 1.62-1.40 (m, 2H), 1.17 (d, *J* = 6.4 Hz, 3H), 1.12-1.09 (m, 1H), 0.92-0.89 (m, 1H). LCMS (ES, *m/z*): 531 $[M+H]^+$.
		




468	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.85-7.76 (m, 4H), 7.56-7.53 (m, 1H), 7.49-7.43 (m, 3H), 7.37-7.34 (m, 1H), 4.87-4.72 (m, 1H), 4.60-4.56 (m, 1H), 4.50-4.45 (m, 1H), 3.94-3.70 (m, 6H), 3.51-3.50 (m, 1H), 3.45-3.38 (m, 1H), 3.22-3.11 (m, 2H), 2.94 (m, 1H), 2.60-2.05 (m, 3H), 2.00-1.71 (m, 3H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^-$




469	 3-((7S)-2-(1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50-7.48 (m, 1H), 7.41-7.37 (m, 1H), 7.307-7.01 (m, 5H), 5.65-5.50 (m, 1H), 5.05-4.96 (m, 1H), 4.80-4.69 (m, 1H), 3.79 (s, 3H), 3.50-3.35 (m, 1H), 3.30-3.15 (m, 2H), 2.99-2.82 (m, 2H), 2.35-2.22 (m, 4H), 1.94-1.80 (m, 6H), 1.79-1.60 (m, 3H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 533 $[M+H]^-$.
470	 3-((7S)-2-(hydroxy(4-methoxyphenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 7.49-7.45 (m, 1H), 7.32-7.27 (m, 3H), 6.89-6.86 (m, 2H), 6.50-6.20 (m, 1H), 6.03 (s, 1H), 4.86-4.79 (m, 1H), 4.67-4.62 (m, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 3.08-3.01 (m, 1H), 2.88-2.82 (m, 2H), 2.34-2.29 (m, 1H), 2.18-2.10 (m, 2H), 1.95-1.88 (m, 2H), 1.66-1.61 (m, 1H), 1.58-1.48 (m, 2H), 1.26-1.22 (m, 1H), 1.06 (d, J = 6.8 Hz, 3H), 1.94-0.90 (m, 1H). LCMS (ES, m/z): 508 $[M+H]^+$.
471	 (1R,3R)-3-((S)-2-(3-fluoro-4-methylbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 8.8 Hz, 1H), 7.19-7.10 (m, 1H), 6.97-6.87 (m, 2H), 4.81-4.62 (m, 2H), 4.42-4.23 (m, 2H), 3.76 (s, 3H), 3.25-3.10 (m, 1H), 3.02-2.88 (m, 2H), 2.37-2.06 (m, 8H), 1.81-1.59 (m, 3H), 1.34-1.20 (m, 2H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 494 $[M+H]^+$.
472	 3-((7S)-2-(hydroxy(3-methoxyphenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50-7.40(m, 2H), 7.27-7.08 (m, 2H), 6.94-6.84(m, 2H), 6.23(s, 1H), 4.91-4.88(m, 1H), 3.79 (s, 6H), 3.34-2.96 (m, 2H), 2.78-2.68 (m, 1H), 2.36-2.05 (m, 5H), 1.78-1.55 (m, 3H), 1.31-1.15 (m, 6H). LCMS (ES, *m/z*): 508 $[M+H]^+$.


		





473	 3-((7S)-2-(methoxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53-7.24 (m, 7H), 5.80 (s, 1H), 4.80 – 4.72 (m, 2H), 3.79 (s, 3H), 3.52 (s, 3H),3.32-3.25 (m, 1H), 3.05-2.86 (m, 2H), 2.38-2.19 (m, 2H), 2.18 – 2.02 (m, 3H), 1.78-1.55 (m, 3H), 1.52-1.30 (m, 2H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 492 $[M+H]^+$.
474	 3-((7S)-2-((7-fluoro-2,3-dihydrobenzofuran-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.46 (m, 1H), 7.46-7.37 (m, 1H), 7.17-7.01 (m, 2H), 6.15(s, 1H), 5.03-4.92(m, 1H), 4.83-4.71(m, 1H), 4.63 (t, *J* = 8.4 Hz, 2H), 3.78(s, 3H), 3.31-3.18(m, 3H), 3.02-2.83 (m, 2H), 2.52-2.31 (m, 2H), 2.31-2.21 (m, 1H), 2.16-2.08 (m, 1H), 2.08-1.98 (m, 1H), 1.84-1.69 (m, 1H), 1.69-1.51 (m, 2H), 1.47-1.33 (m, 1H), 1.15 (d, *J*=6.8 Hz, 3H), 1.12-1.04 (m, 1H). LCMS (ES, *m/z*): 538 $[M+H]^-$
475	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 6th eluting isomer	1H-NMR (CD3OD, 400 MHz) δ (ppm): 7.49-7.47(m, 1H), 7.40-7.37(m, 3H), 7.34-7.25(m, 3H), 4.77-4.71(m, 2H), 4.32-4.30(m, 1H), 3.76-3.66 (m, 5H), 3.39(s, 3H), 3.27-3.22(m, 1H), 3.13-3.10(m, 1H), 2.92-2.87(m, 1H), 2.38-2.21(m, 3H), 2.08-2.04(m, 1H), 1.96-1.86(m, 3H), 1.74-1.69(m, 2H), 1.55-1.50(m, 1H), 1.12(d, *J*=6.8 Hz, 3H). LCMS (ES, m/z): 506 [M+H]+.
476	 (1R,3R)-3-((S)-2-((6-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.15-8.12 (m, 1H), 7.75-7.71 (m, 1H), 7.58-7.55 (m, 2H), 7.47-7.44 (m, 1H), 6.71-6.69 (m, 1H), 6.10-6.06 (m, 1H), 5.70-5.66 (m, 1H), 5.15-5.06(m, 1H), 4.78-4.74(m, 1H), 3.78(s, 3H), 3.22-3.14(m, 1H), 2.98-2.90 (m, 2H), 2.43-2.37 (m, 1H), 2.32-2.20 (m, 4H), 1.74-1.68 (m, 3H), 1.54-1.46 (m, 2H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 527 $[M+H]^+$.

477	 4-((7S)-2-(1-(3-fluoro-4-methoxyphenyl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50-7.30 (m, 2H), 7.12-6.93 (m, 3H), 4.80-4.70 (m, 1H), 4.64-4.53 (m, 1H), 4.32-4.20 (m, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.04-2.89 (m, 1H), 2.49-2.23 (m, 3H), 2.23-2.05 (m, 2H), 1.97 (s, 1H), 1.92-1.65 (m, 5H), 1.64-1.52 (m, 1H), 1.38-1.23 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 1H), 1.12-1.08 (m, 1H). LCMS (ES, *m/z*): 524 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.09 (s,





478	 3-((7S)-2-((5-fluoro-1H-indazol-7-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	1H), 7.52-7.50 (m, 1H), 7.49-7.40 (m, 2H), 7.24-7.20 (m, 1H), 6.63(s, 1H), 5.20-5.08 (m,1H), 5.85-5.75 (m, 1H), 3.80 (s, 3H), 3.28-3.15 (m, 1H), 3.04-2.91 (m, 2H), 2.48-2.41 (m, 2H), 2.34 -2.25 (m, 1H), 2.15-1.95 (m, 2H), 1.80-1.45(m, 3H) , 1.14 (d, J = 6.4 Hz, 3H) , 1.10-1.00 (m, 1H), 0.98-0.88 (m, 1H). LCMS (ES, m/z): 536 $[M+H]^-$.
479	 3-((7S)-2-((3,4-difluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.54-7.38 (m, 3H), 7.22-7.14 (m, 2H), 6.20 (s, 1H), 4.96-4.93 (m, 1H), 4.79-4.74 (m, 1H), 3.78 (s, 3H), 3.24-3.18 (m, 1H), 3.01-2.94 (m, 2H), 2.50-2.21 (m, 3H), 2.17-1.97 (m, 2H), 1.78-1.72 (m, 1H), 1.63-1.55 (m, 2H), 1.49-1.31 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H), 1.09-1.04 (m, 1H). LCMS (ES, m/z): 514 $[M+H]^+$.
480	 3-((7S)-2-(hydroxy(1H-indazol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.87 (s, 1H), 7.53 (s, 1H), 7.51-7.37 (m, 4H), 6.33 (s, 1H), 4.94-4.89 (m, 1H), 4.79-4.74 (m, 1H), 3.78 (s, 3H), 3.32-3.27(m, 1H), 3.04-2.98 (m, 1H), 2.97-2.84 (m, 1H), 2.33-2.25 (m, 2H), 2.15-1.95 (m, 3H), 1.78-1.72 (m, 1H), 1.62-1.54 (m, 2H), 1.31-1.24 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H), 1.15-1.13 (m, 1H). LCMS (ES, *m/z*): 518 $[M+H]^+$.


481	 (1R,3R)-3-((S)-2-(3-fluoro-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48-7.38(m, 2H), 7.04-7.01(m, 3H), 4.86-4.67(m, 2H), 4.40-4.15(m, 2H), 3.85(s, 3H), 3.76(s, 3H), 3.30-3.10(m, 1H), 2.99-2.89(m, 2H), 2.48-2.05(m, 5H),1.85-1.65(m, 3H) , 1.40-1.20(m, 2H) , 1.13(d, J=6.4 Hz, 3H)LCMS (ES, m/z): 510 $[M+H]^+$.
482	 3-((7S)-2-((2-cyclopropoxy-5-fluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.70-7.65 (m, 2H), 7.39-7.29 (m, 2H), 7.17-7.11 (m, 1H), 6.36 (s, 1H), 4.87-4.79 (m, 2H), 3.82 (s, 3H), 3.73-3.71 (m, 1H), 3.33-2.99 (m, 3H), 2.46-2.18 (m, 5H), 1.83-1.68 (m, 3H), 1.46-1.22 (m, 2H), 1.17 (d, J = 6.8 Hz, 3H), 0.70-0.63(m, 2H), 0.43-0.36 (m, 2H). LCMS (ES, *m/z*): 552 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.35 (S, 1H), 8.16 (d, J = 4.8 Hz, 1H), 7.54-7.52 (m, 2H), 7.46-7.43 (m, 1H), 7.37-7.34 (m, 1H), 6.02-5.96




483	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-3-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	7.40-7.45 (m, 1H), 7.37-7.34 (m, 1H), 6.02-5.90 (m, 1H), 4.84-4.64(m, 2H), 3.79(s, 3H), 3.25-3.11(m, 1H), 2.96-2.81 (m, 1H), 2.60-2.10 (m, 6H), 2.09-2.01 (m, 1H), 1.91 (d, J = 6.8 Hz, 3H), 1.79-1.53 (m, 4H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 493 $[M+H]^+$.
484	 (1R,3R)-3-((S)-2-(1-(6-(difluoromethoxy)pyridin-3-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.05 (s, 1H), 7.77-7.63 (m, 1H), 7.55-7.27 (m, 3H), 6.92 (d, J = 8.4 Hz, 1H), 5.12-4.95 (m, 1H), 4.81-4.68 (m, 1H), 3.79 (s, 3H), 3.29-3.15 (m, 1H), 3.04-2.86 (m, 2H), 2.49-2.34 (m, 1H), 2.33-2.25 (m, 1H), 2.24-2.13 (m, 3H), 1.97-1.80 (m, 2H), 1.78-1.61 (m, 3H), 1.59-1.50 (m, 1H), 1.46-1.28 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 555 $[M+H]^+$.



485	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.44 (d, J = 9.0 Hz, 1H), 7.33 (d, J = 9.0 Hz, 1H), 7.16 (s, 1H), 5.93 – 5.62 (m, 1H), 4.78 – 4.66 (m, 1H), 4.62 – 4.34 (m, 3H), 3.97 – 3.84 (m, 1H), 3.76 (s, 3H), 3.28 – 3.14 (m, 1H), 3.02 – 2.73 (m, 2H), 2.37 – 2.05 (m, 8H), 1.89 – 1.59 (m, 3H), 1.59 – 1.39 (m, 5H), 1.13 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 494 $[M+H]^-$
486	 3-((7S)-2-(1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.56 (m, 1H), 7.43-7.41 (m, 1H), 5.32-5.30 (m, 1H), 5.15-5.13 (m, 1H), 4.78-4.76 (m, 1H), 3.78 (s, 3H), 3.32-3.31 (m, 1H), 3.20-3.11 (m, 1H), 2.96-2.90 (m, 2H), 2.51-2.48 (m, 1H), 2.48-2.36 (m, 2H), 2.36-2.27 (m, 2H), 2.08-2.04 (m, 1H), 1.93-1.86 (m, 2H), 1.72-1.61 (m, 9H), 1.56-1.51 (m, 1H), 1.38-1.25 (m, 5H), 1.14 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
487	 (1S,4r)-4-((S)-2-(1-(2H-indazol-2-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.67 (s, 1H), 7.76 – 7.63 (m, 2H), 7.62 – 7.54 (m, 1H), 7.54 – 7.46 (m, 1H), 7.32 – 7.21 (m, 1H), 7.11 – 7.00 (m, 1H), 5.09 – 4.96 (m, 1H), 4.74 – 4.60 (m, 1H), 3.69 (s, 3H), 3.18 – 3.01 (m, 1H), 2.99 – 2.84 (m, 1H), 2.47 (s, 1H), 2.22 – 2.07 (m, 5H), 2.03 – 1.92 (m, 4H), 1.80 – 1.64 (m, 1H), 1.59 – 1.36 (m, 4H), 1.05 (d, J=6.3, 3H). LCMS (ES, m/z): 528 $[M+H]^+$.
488	 3-((7S)-2-((3,5-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63–7.47 (m, 2H), 7.12 (d, J = 6.8 Hz, 3H), 6.90-6.87 (m, 1H), 6.26 (s, 1H), 5.04 – 4.93 (m, 1H), 4.81-4.78 (m, 1H), 3.79 (s, 3H), 3.24-3.15 (m, 1H), 3.02-2.98 (m, 2H), 2.52-2.06 (m, 5H), 1.81-1.59 (m, 3H)



	3-((7S)-2-((3,5-difluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	(m, 2H), 2.32-2.06 (m, 5H), 1.81-1.59 (m, 5H), 1.52-1.42 (m, 1H), 1.22-1.17 (m, 1H) , 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^+$.




489	 (1R,3R)-3-((S)-2-(4-chlorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 (d, *J* = 8.8 Hz, 1H), 7.38 (d, *J* = 9.2 Hz, 1H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 4.81-4.62(m, 2H), 4.45-4.22(m, 2H), 3.79(s, 3H), 3.28-3.12(m, 1H), 3.00-2.86 (m, 2H), 2.35-2.10 (m, 5H), 1.81-1.61 (m, 3H), 1.33-1.20 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 496 $[M+H]^+$.
490	 2-(3-fluorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.48-7.24(m, 3H), 7.19-6.95(m, 3H), 4.74-4.55(m, 2H), 4.20-3.95(m, 3H), 3.76-3.55(m, 5H), 3.40-3.00(m, 2H), 2.92-2.85(m, 1H), 2.55-2.05(m, 3H), 1.87-1.68(m, 4H), 1.10(d, *J* =6.9Hz, 3H). LCMS (ES, m/z): 496 $[M+H]^+$
491	 3-((7S)-2-(cycloheptyl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.65-7.49 (m, 1H),7.48-7.23 (m, 1H),5.33-5.12(m, 1H), 4.82-4.58(m, 2H), 3.78(s, 3H), 3.28-3.12 (m, 1H), 3.04-2.86 (m, 2H), 2.59-2.41 (m, 2H), 2.41-2.19 (m, 5H), 2.02-1.82 (m, 2H), 1.82-1.53 (m, 9H), 1.53-1.41 (m, 3H), 1.25-1.11 (m, 5H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
492	 3-((7S)-2-(1-(4-(difluoromethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.75 (s, 1H), 7.62 (s, 1H), 7.44-7.33 (m, 2H), 6.85 - 6.48 (m, 1H), 4.79 - 4.46 (m, 4H), 4.12 - 3.86 (m, 1H), 3.76 (s, 3H), 3.28 - 3.12 (m, 1H), 3.02 - 2.84 (m, 2H), 2.44 - 2.11 (m, 5H), 1.88 - 1.62 (m, 3H), 1.59 - 1.40 (m, 5H),1.13 - 1.11 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 530 $[M+H]^+$.


493	 3-((7S)-2-((3,5-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.67–7.45 (m, 2H), 7.02 (d, *J* = 6.4 Hz, 3H), 6.94-6.91 (m, 1H), 6.23 (s, 1H), 4.93-4.92 (m, 1H), 4.81-4.79 (m, 1H), 3.80 (s, 3H), 3.28–3.18 (m, 1H), 3.01-2.88 (m, 2H), 2.42-2.12 (m, 4H), 2.03-1.99 (m, 1H),





	difluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1.83-1.63 (m, 4H), 1.52-1.42 (m, 1H), 1.17 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^+$.
494	 (1S,4r)-4-((S)-2-((1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 – 7.24 (m, 4H), 7.20 (d, *J* = 3.2 Hz, 1H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.37 (s, 1H), 4.77 – 4.67 (m, 1H), 4.44 (s, 2H), 4.40 – 4.25 (m, 1H), 3.76 (s, 3H), 3.27 – 3.15 (m, 1H), 3.02 – 2.88 (m, 1H), 2.42 – 2.21 (m, 2H), 2.21 – 2.01 (m, 2H), 2.01 – 1.85 (m, 2H), 1.81 – 1.68 (m, 1H), 1.48 – 1.29 (m, 4H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 501 $[M+H]^+$
495	 2-(4-chlorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, *J* = 8.8 Hz, 1H), 7.43-7.27 (m, 5H), 4.80-4.67 (m, 1H), 4.60-4.49 (m, 1H), 4.35-4.26 (m, 1H), 4.09-3.91 (m, 2H), 3.76 (s, 3H), 3.74-3.65 (m, 1H), 3.61-3.50 (m, 1H), 3.42-3.35 (m, 1H), 3.29-3.23 (m, 1H), 3.20-3.07 (m, 1H), 2.95-2.83 (m, 1H), 2.56-2.41 (m, 1H), 2.29-2.16 (m, 1H), 2.16-2.04 (m, 1H), 1.98-1.80 (m, 2H), 1.78-1.65 (m, 1H), 1.11 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 512 $[M+H]^+$.
496	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46-7.41 (m, 2H), 7.30-7.26 (m, 2H), 7.06-7.02 (m, 2H), 6.95-6.91 (m, 1H), 5.89-5.86 (m, 1H), 5.02-4.93 (m, 1H), 4.80-4.76 (m, 1H), 3.79 (s, 3H), 3.29-3.23 (m, 1H), 2.94-2.90 (m, 2H), 2.50-2.48 (m, 1H), 2.37-2.18 (m, 4H), 1.90-1.69 (m, 7H), 1.50 (m, 1H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.





497	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52 (d, *J* = 9.0 Hz, 1H), 7.41 (d, *J* = 9.3 Hz, 1H), 7.23 (d, *J* = 8.4 Hz, 2H), 7.16 (d, *J* = 8.1 Hz, 2H), 4.86-4.74 (m , 1H), 4.28-4.23(m , 2H) , 4.06-3.93(m, 3H), 3.79 (s , 3H), 3.72-3.65 (m, 1H), 3.68-3.62 (m, 1H), 3.60-3.50 (m, 1H),3.45-3.32 (m, 1H), 2.99-2.92 (m, 1H), 2.32-2.21 (m , 5H), 1.78-1.72 (m, 3H), 1.23-1.12 (m, 4H). LCMS (ES, *m/z*): 492 $[M+H]^+$.
498	 (1R,3R)-3-((S)-2-((3-chlorophenyl)(methyl)amino)-6-	LCMS (ES, *m/z*): 511 $[M+H]^+$


	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	
499	 3-((7S)-2-(benzo[d]oxazol-5-yl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.49 (s, 1H), 7.99 (s, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.54-7.45 (m, 2H), 7.44-7.37 (m, 1H), 6.38 (s, 1H), 5.05-4.93 (m, 1H), 4.83-4.71 (m, 1H), 3.79 (s, 3H), 3.30-3.14 (m, 1H), 3.07-2.95 (m, 1H), 2.94-2.86 (m, 1H), 2.49-2.33 (m, 2H), 2.32-2.22 (m, 1H), 2.15-2.03 (m, 1H), 2.02-1.90 (m, 1H), 1.83-1.68 (m, 1H), 1.65-1.44 (m, 2H), 1.31-1.20 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H), 0.97-0.86 (m, 1H). LCMS (ES, *m/z*): 519 $[M+H]^+$.
500	 (1R,3R)-3-((S)-2-((1H-indol-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.47 (d, J = 9.0 Hz, 1H), 7.45 – 7.30 (m, 2H), 7.27 (d, J = 8.3 Hz, 1H), 7.10 – 6.86 (m, 2H), 6.20 (s, 1H), 5.00 – 4.88 (m, 1H), 4.81 – 4.65 (m, 1H), 4.57 – 4.47 (m, 2H), 3.76 (s, 3H), 3.24 – 3.09 (m, 1H), 3.02 – 2.84 (m, 2H), 2.37 – 2.06 (m, 5H), 1.83 – 1.53 (m, 3H), 1.52 – 1.40 (m, 1H), 1.40 – 1.22 (m, 1H), 1.13 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 501 $[M+H]^+$




501	 3-((7S)-2-((4-chlorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.33 (m, 6H), 6.22 (s, 1H), 4.84-4.73 (m, 2H), 3.78 (s, 3H), 3.27-3.16 (m, 1H), 3.04-2.92 (m, 1H), 2.90-2.88 (m, 1H), 2.46-2.35 (m, 2H), 2.30-2.22 (m, 1H), 2.15-2.02 (m, 2H), 1.82-1.71 (m, 1H), 1.63-1.55 (m, 2H), 1.40-1.28 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H), 1.14-1.01(m, 1H). LCMS (ES, *m/z*): 512 $[M+H]^+$.
502	 (1R,3R)-3-((S)-2-(3,4-difluorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 9.2 Hz, 1H), 7.23-7.18 (m, 2H), 7.05-7.02 (m, 1H), 4.78-4.65(m, 2H), 4.40-4.22(m, 2H), 3.79(s, 3H), 3.26-3.15(m, 1H), 3.03-2.96 (m, 2H), 2.38-2.12 (m, 5H), 1.79-1.62 (m, 3H), 1.41-1.23 (m, 2H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
503	 3-((7S)-2-(1-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50 (d, J = 9.2 Hz, 1H), 7.39 (d, J = 8.8 Hz, 1H), 7.28-7.15 (m, 5H), 5.40-5-31 (m, 1H), 5.06-4.98 (m, 1H), 4.80-4.76 (m, 1H), 3.82 (s, 3H), 3.56-3.40 (m, 1H), 3.29-3.24 (m, 1H), 3.22-3.12 (m, 1H), 3.04-2.84 (m, 2H), 2.46-2.32 (m, 2H), 2.32-2.15 (m, 3H), 1.80-1.65 (m, 3H), 1.53-1.38 (m, 2H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^-$



	2nd eluting isomer	
504	 4-((7S)-2-(1-(4-(difluoromethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm):7.82 - 7.53 (m, 2H), 7.51 - 7.36 (m, 1H), 7.36 - 7.22 (m, 1H), 6.93 - 6.39 (m, 1H), 4.79 - 4.59 (m, 2H), 4.59 - 4.43 (m, 1H), 4.40 - 4.09 (m, 1H), 4.05 - 3.85 (m, 1H), 3.76 (s, 3H), 3.26 - 3.10 (m, 1H), 3.10 - 2.83 (m, 1H), 2.61 - 2.41 (m, 1H), 2.35 - 2.08 (m, 4H), 1.96 - 1.79 (m,1H), 1.79 - 1.53 (m, 3H), 1.49 - 1.36 (m, 4H), 1.32 - 1.22 (m, 1H), 1.13 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 530 $[M+H]^+$



505	 3-((7S)-2-(2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86-7.68 (m, 2H), 7.50 – 7.26 (m, 5H), 5.07 – 4.94 (m, 2H), 4.88 – 4.80 (m, 1H), 4.56 – 4.47 (m, 1H), 4.29 – 4.20 (m, 1H), 3.83 (s, 3H), 3.29 – 3.02 (m, 3H), 2.46 – 2.37 (m, 2H), 2.34 – 2.14 (m, 3H), 1.96 – 1.84 (m, 1H), 1.83 – 1.66 (m, 2H), 1.23 – 1.07 (m, 5H). LCMS (ES, m/z): 492 $[M+H]^+$.
506	 2-(3-chlorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52-7.38(m, 3H), 7.32-7.28(m, 3H), 4.77-4.59(m, 2H), 4.23-3.98(m, 6H), 3.78-3.45(m, 2H), 3.35-2.89(m, 4H), 2.52-2.48(m, 1H), 2.25-2.16(m, 2H), 1.90-1.43(m, 3H), 1.14(d, J=6.6 Hz, 3H). LCMS (ES, m/z): 512 $[M+H]^-$
507	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((1-methyl-1H-indol-5-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49-7.38 (m, 3H), 7.37-7.30 (m, 1H), 7.14 (d, J = 3.2 Hz, 1H), 7.11-7.03 (m, 1H), 6.38 (d, J = 3.2 Hz, 1H), 4.83-4.69 (m, 1H), 4.47 (s, 2H), 4.41-4.27 (m, 1H), 3.78 (s, 6H), 3.31-3.18 (m, 1H), 3.08-2.92 (m, 1H), 2.41-2.23 (m, 2H), 2.20-2.04 (m, 2H), 2.02-1.88 (m, 2H), 1.84-1.69 (m, 1H), 1.50-1.32 (m, 4H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 515 [M+H]+.
508	 (1S,4R)-4-((S)-2-(3-chloro-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.43-7.37(m, 3H),7.27-7.17(m, 2H),4.86-4.77(m, 1H), 4.35-4.25(m, 3H), 3.84(s, 3H), 3.76(s, 3H), 3.25-2.85(m, 2H), 2.69(s, 1H),2.45-2.03(m, 6H), 1.78-1.71(m, 1H),1.54-1.45(m, 3H),1.14(d, J=6.6Hz, 3H). LCMS (ES, m/z): 526 $[M+H]^+$





509	 (1R,3R)-3-((S)-2-(3,4-difluorophenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.48 (m, 1H), 7.44-7.37 (m, 1H), 7.33-7.23 (m, 1H), 7.23-7.08 (m, 2H), 4.82-4.71 (m, 2H), 3.79 (s, 3H), 3.32-3.10 (m, 4H), 3.09-2.85 (m, 3H), 2.41-2.17 (m, 5H), 1.91-1.82 (m, 1H), 1.81-1.67 (m, 3H), 1.63-1.48 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 512 $[M+H]^+$.
510	 (4-fluorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50 (d, J = 8.8 Hz, 1H), 7.43-7.32 (m, 3H), 7.07-6.96 (m, 2H), 4.80-4.66 (m, 1H), 4.59-4.46 (m, 1H), 4.29-4.16 (m, 1H), 4.04-3.91 (m, 2H), 3.76 (s, 3H), 3.72-3.61 (m, 1H), 3.61-3.47 (m, 1H), 3.31-3.22 (m, 2H), 3.20-3.07 (m, 1H), 2.95-2.83 (m, 1H), 2.54-2.37 (m, 1H), 2.27-2.17 (m, 1H), 2.15-2.02 (m, 1H), 2.00-1.78 (m, 2H), 1.78-1.63 (m, 1H), 1.10 (d, J = 6.7, 2.0 Hz, 3H). LCMS (ES, *m/z*): 496 $[M+H]^+$.
511	 3-((7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3-fluoro-4-methylphenyl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.44 (d, J = 8.8 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.18 – 6.98 (m, 3H), 5.05 – 4.90 (m, 1H), 4.85 – 4.72 (m, 1H), 4.28-4.21 (m, 1H), 3.77 (s, 3H), 3.73 – 3.65 (m, 1H), 3.42 – 3.33 (m, 1H), 3.18-3.10 (m, 1H), 2.92 – 2.85 (m, 1H), 2.31 – 2.12 (m, 6H), 2.11 – 1.92 (m, 3H), 1.90 – 1.67 (m, 4H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 491 $[M+H]^+$.
512	 (1R,3R)-3-((S)-2-(3-chloro-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (*d6*-DMSO, 400 MHz) δ (ppm): 7.90–7.84 (m, 1H), 7.69–7.62 (m, 1H), 7.00 (s, 2H), 6.93 (s, 1H), 4.91–4.81 (m, 1H), 4.78–4.68 (m, 1H), 4.68–4.60 (m, 1H), 4.39–4.31 (m, 1H), 3.77 (s, 3H), 3.71 (s, 3H), 3.05–2.93 (m, 3H), 2.36–2.24 (m, 1H), 2.24–2.05 (m, 3H), 2.04–1.96 (m, 1H), 1.86–1.65 (m, 3H), 1.40–1.33 (m, 1H), 1.27–1.13 (m, 1H), 1.09 (d, J=6.4 Hz, 3H).LCMS (ES, m/z): 526 $[M+H]^+$.






513	 3-((7S)-2-(methoxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.30 (m, 7H), 5.84 (s, 1H), 4.80 – 4.72 (m, 2H), 3.79 (s, 3H), 3.55 (s, 3H), 3.32-3.21 (m, 1H), 3.08-2.90 (m, 2H), 2.64-2.35 (m, 3H), 2.13–2.05 (m, 1H), 1.98-1.73 (m, 2H), 1.61-1.45 (m, 2H), 1.35-1.21 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H), 0.85-0.77 (m, 1H),. LCMS (ES, m/z): 492 $[M+H]^+$.




514	 3-((7S)-2-(2-cyclopentylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 9.2 Hz, 1H), 4.83-4.65 (m, 2H), 3.79 (s, 3H), 3.23-3.09 (m, 1H), 3.09-2.95 (m, 3H), 2.95-2.79 (m, 1H), 2.51-2.33 (m, 2H), 2.33-2.15 (m, 3H), 1.99-1.82 (m, 6H), 1.82-1.49 (m, 8H), 1.29-1.25 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 468 $[M+H]^+$.
515	 3-((7S)-2-((2-(difluoromethoxy)-5-fluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62 (d, J = 9.2 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.41(d, J = 9.2Hz, 1H) 7.20-7.13 (m, 2H), 6.67-6.30 (m, 2H), 4.98-4.95 (m, 1H), 4.76-4.71 (m, 1H), 3.78 (s, 3H), 3.15-2.86 (m, 3H), 2.46-2.20 (m, 5H), 1.81-1.53 (m, 5H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 562 $[M+H]^+$.
516	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47 (t, J = 8.0 Hz, 1H), 7.35 (d, J =8.8 Hz, 1H), 7.28-7.16 (m, 3H), 7.16-7.03 (m, 3H), 6.91-6.59 (m, 3H), 4.81-4.68 (m, 1H), 4.35-4.24 (m, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 3.59-3.48 (m, 1H), 3.29-3.13 (m, 2H), 3.07-2.91 (m, 1H), 2.33-2.21 (m, 1H), 1.79-1.66 (m, 1H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 500 $[M+H]^+$.



517	 4-((7S)-2-(1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.81-7.75 (m, 2H), 7.27-7.26 (m, 3H), 7.19-7.15 (m, 2H), 5.72-5.66 (m, 1H), 4.84-4.83 (m, 1H), 4.42-4.37 (m, 1H), 3.82 (s, 3H), 3.62-3.60 (m, 1H), 3.33-3.27 (m, 1H), 3.12-3.09 (m, 2H), 2.52-2.49 (m, 1H), 2.26-2.02 (m, 4H), 2.00 (s, 3H), 1.95-1.88 (m, 3H), 1.69-1.65 (m, 1H), 1.45-1.37 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H), 0.38-0.36 (m, 1H).LCMS (ES, m/z): 533 $[M+H]^+$.
518	 (1S,4R)-4-((S)-2-((5-chloro-6-methoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.72 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 9.2 Hz, 1H), 7.41-7.39 (d, J = 9.2 Hz, 1H), 6.90 (d, J = 7.6 Hz,1H), 4.72-4.74(m, 1H), 4.50-4.39 (m, 3H), 3.95 (s, 3 H), 3.79(s, 3H), 3.26-3.15 (m, 1H), 3.03-2.96 (m, 1H), 2.49-2.40 (m, 1H), 2.38-2.25 (m, 3H), 2.15-2.07 (m, 2H), 1.80-1.36 (m, 3H), 1.61-1.45 (m, 2H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 527,529 $[M+H]^+$.
		



519	 (1R,3R)-3-((S)-2-((3-fluorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 496 $[M+H]^+$.
520	 methyl 2-((7S)-1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53 (s, 1H), 7.46 (s, 1H), 7.42-7.34 (m, 2H), 5.18-5.00 (m, 1H), 4.83-4.70 (m, 1H), 4.70-4.57 (m, 1H), 4.57-4.43 (m, 1H), 4.03-3.86 (m, 1H), 3.79 (s, 3H), 3.43-3.35 (m, 2H), 3.26-3.11 (m, 3H), 3.04-2.88 (m, 1H), 2.37-2.18 (m, 2H), 2.18-2.01 (m, 1H), 1.82-1.64 (m, 1H), 1.44 (d, *J* = 6.9 Hz, 3H), 1.15 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 457 $[M+H]^+$.




521	 (S)-2-(2-(3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)ethyl)benzoic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.87 – 7.81 (m, 1H), 7.55 – 7.48 (m, 1H), 7.47 – 7.40 (m, 1H), 7.40 – 7.32 (m, 1H), 7.32 – 7.21 (m, 2H), 4.82 – 4.73 (m, 1H), 4.57 – 4.46 (m, 1H), 3.79 (s, 3H), 3.49 – 3.38 (m, 4H), 3.23 – 3.10 (m, 1H), 3.00 – 2.88 (m, 1H), 2.32 – 2.14 (m, 3H), 1.96 – 1.88 (m, 2H), 1.84 – 1.71 (m, 3H), 1.70 – 1.55 (m, 3H), 1.46 – 1.36 (m, 1H), 1.14 (d, *J*=6.8 Hz, 3H).LCMS (ES, m/z): 476 $[M+H]^+$.
522	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((Z)-1-phenoxyprop-1-en-1-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, *J* = 9.2 Hz, 1H), 7.40 (d, *J* = 8.8 Hz, 1H), 7.25-7.21 (m, 2H), 7.15-7.12 (m, 2H), 6.97-6.93 (m, 1H), 6.07-6.05 (m, 1H), 5.15-5.02 (m, 1H), 4.77-4.74 (m, 1H), 3.77 (s, 3H), 3.18-3.15 (m, 1H), 3.03-2.92 (m, 1H), 2.47-2.36 (m, 1H), 2.26-2.20 (m, 4H), 1.93 (d, *J* = 6.8 Hz, 3H), 1.85-1.81 (m, 1H), 1.76-1.60 (m, 5H), 1.12 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 504 $[M+H]^+$.
523	 3-((7S)-2-((3-chlorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51-7.30 (m, 6H), 6.24 (s, 1H), 4.93-4.74 (m, 2H), 3.78 (s, 3H), 3.33-3.17 (m, 1H), 3.01-2.94 (m, 1H), 2.82 (m, 1H), 2.37-2.35 (m, 2H), 2.29-2.24 (m, 2H), 2.08-2.05 (m, 1H), 1.77-1.72 (m, 1H), 1.60-1.54 (m, 2H), 1.34-1.30 (m, 1H), 1.15 (d, *J* = 6.8 Hz, 3H), 1.14-1.05 (m, 1H). LCMS (ES, m/z): 512 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.59-7.45 (m, 5H), 7.39 (d, *J* = 8.8 Hz, 1H), 6.92-6.56 (m, 1H), 4.82-4.68 (m, 1H), 4.48-4.29 (m, 2H), 4.10-


524	 2-(4-(difluoromethyl)phenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	3.89 (m, 3H), 3.83-3.68 (m, 4H), 3.62-3.47 (m, 1H), 3.45-3.34 (m, 1H), 3.21-3.06 (m, 1H), 3.00-2.86 (m, 1H), 2.45-2.31 (m, 1H), 2.30-2.15 (m, 1H), 1.83-1.62 (m, 3H), 1.28-1.17 (m, 1H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.
525	 3-((7S)-2-(acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48-7.46 (m, 1H), 7.42-7.39 (m, 6H), 6.56 (s, 1H), 4.81-4.79 (m, 1H), 4.75-4.60 (m, 1H), 3.79 (s, 3H), 3.31-3.29 (m, 1H), 3.03-2.93 (m, 2H), 2.40-2.31 (m,3H), 2.15-2.01 (m, 5H), 1.82- 1.74 (m, 1H), 1.65-1.60 (m, 2H), 1.18-1.08 (m, 4H), 1.02-0.91 (m, 1H). LCMS (ES, m/z): 519$[M+H]^+$.
526	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.51-7.37 (m, 2H), 7.17 (d, J = 2.1 Hz, 1H), 5.88 (s, 1H), 4.81 – 4.68 (m, 1H), 4.57 – 4.34 (m, 2H), 4.34 – 4.18 (m, 1H), 4.05 – 3.88 (m, 1H), 3.76 (s, 3H), 3.24 – 3.11 (m, 1H), 3.01 – 2.85 (m, 1H), 2.62 – 2.38 (m, 1H), 2.38 – 2.08 (m, 8H), 1.95 – 1.79 (m, 1H), 1.79 – 1.55 (m, 3H), 1.55 – 1.40 (m, 3H), 1.35 – 1.27 (m, 1H), 1.12 (d, J = 6.6 Hz, 3H).LCMS (ES, *m/z*): 494 $[M+H]^+$
527	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47 (d, J=9.2 Hz, 1H), 7.36 (d, J=9.2 Hz, 1H), 7.25-7.23 (m, 4H), 7.21-7.13 (m, 1H), 4.81-4.57 (m, 2H), 3.77 (s, 3H), 3.33-3.12 (m, 4H), 3.06-2.81 (m, 3H), 2.41-2.14 (m, 5H), 1.83-1.65 (m, 3H), 1.52-1.39 (m, 2H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 476 $[M+H]^+$.
528	 (1R,3R)-3-((S)-2-((S)-hydroxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.40 (m, 4H), 7.30-7.28 (m, 3H), 6.12(s, 1H), 4.95-4.90 (m,1H), 4.84-4.79(m, 1H), 3.79(s, 3H), 3.33-3.25(m, 1H), 3.03-2.82 (m, 2H), 2.49-2.30 (m, 2H), 2.29-2.21 (m, 1H), 2.12-2.07 (m, 1H), 1.99-1.90 (m, 1H), 1.85-1.79 (m, 1H), 1.64-1.49 (m, 2H), 1.40-1.29 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H), 0.95-0.89 (m, 1H). LCMS (ES, *m/z*): 478 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.55-7.40 (m, 2H), 7.30-7.26 (m, 2H), 7.05 (d, J = 7.5 Hz, 2H), 7.00-6.95 (m, 1H), 5.91-5.88 (m, 1H), 4.85-4.77 (m, 2H), 3.78 (s, 3H), 3.27-3.14 (m, 1H),





529	 (1R,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	2.97-2.90 (m, 1H), 2.55-2.30 (m, 2H), 2.30-2.17 (m, 3H), 2.17-2.08 (m, 1H), 2.04-1.91 (m, 1H), 1.87-1.80 (m, 3H), 1.76-170 (m, 1H), 1.62-1.40 (m, 3H), 1.13 (d, J = 6.9 Hz, 1H). LCMS (ES, m/z): 492 $[M+H]^+$.
530	 (1R,3R)-3-((S)-2-(1-(6-cyclopropylpyrazin-2-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	8.30 (s, 1H), 7.69 (s, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.47 (d, J = 9.2 Hz, 1H), 4.84-4.74(m, 2H), 3.79(s, 3H), 3.23-3.15(m, 1H), 3.03-2.86 (m, 2H), 2.56-2.42 (m, 1H), 2.52-2.05 (m, 6H), 1.79-1.63 (m, 7H), 1.35-1.24 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H), 1.07-1.05 (m, 4H). LCMS (ES, m/z): 530 $[M+H]^+$.
531	 3-((7S)-2-(1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm):7.57-7.55 (m, 1H), 7.44-7.42 (m, 1H), 5.14-5.04 (m, 2H), 4.79-4.75 (m, 1H), 3.78 (s, 3H), 3.44-3.40 (m, 1H), 3.24-3.20 (m, 1H), 2.95-2.88 (m, 2H), 2.54-2.48 (m, 1H), 2.38-2.25 (m, 4H), 1.95-1.87 (m, 4H), 1.87-1.73 (m, 5H), 1.69-1.67 (m, 3H), 1.55-1.51 (m, 1H), 1.41-1.19 (m, 5H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 498 $[M+H]^+$.
532	 (1S,4R)-4-((S)-2-(3,5-difluoro-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.50-7.35 (m, 2H), 7.05-6.71 (m, 2H), 4.78-4.74 (m, 1H), 4.37 (s, 2H), 4.27-4.19 (m, 1H), 3.94 (s, 3H), 3.79 (s, 3H), 3.22-3.16 (m, 1H), 2.98-2.90 (m, 1H), 2.59-2.46 (m, 1H), 2.36-2.19 (m, 3H), 2.12-1.92 (m, 2H), 1.85–1.69 (m, 1H), 1.55-1.44 (m, 4H), 1.16 (d, J = 6.9 Hz, 3H).LCMS (ES, m/z): 528 $[M+H]^+$.

533	 (1R,3R)-3-((S)-2-(4-(difluoromethoxy)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (*d6*-DMSO, 400 MHz) δ (ppm): 12.60 (br, 1H), 7.91–7.84 (m, 1H), 7.69–7.62 (m, 1H), 7.43–7.38 (m, 2H), 7.32–7.05 (m, 3H), 4.85–4.65 (m, 3H), 4.43–4.36 (m, 1H), 3.71 (s, 3H), 3.07–2.91 (m, 3H), 2.35–2.25 (m, 1H), 2.22–2.08 (m, 3H), 2.04–1.96 (m, 1H), 1.82–1.66 (m, 3H), 1.49–1.41 (m, 1H), 1.29–1.21 (m, 1H), 1.09 (d, J=6.4Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^+$.
534	 (1R,3R)-3-((7S)-2-(1-hydroxy-1-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.84-7.80 (m, 2H), 7.58-7.56 (m, 2H), 7.48-7.43 (m, 3H), 4.86-4.82(m, 1H), 4.69-4.65(m, 1H), 3.82(s, 3H), 3.26-3.08(m, 3H), 3.03-2.98 (m, 1H), 2.65-2.45 (m, 2H), 2.52-1.82 (m, 5H), 1.69-1.62 (m, 1H), 1.52-1.48 (m, 1H), 1.20 (d, J = 6.4 Hz, 3H), 1.01





	(1R,3R)-3-((S)-2-(1-hydroxy-1-phenylpropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(t, *J* = 7.2 Hz, 3H), 0.88-0.79 (m, 2H). LCMS (ES, *m/z*): 506 $[M+H]^+$.
535	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((3-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 507 $[M+H]^+$.
536	 3-((7S)-6-(methoxycarbonyl)-3-(4-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.30 (d, *J* = 8.7 Hz, 1H), 7.21-7.06 (m, 9H), 6.77 (d, *J* = 8.7 Hz, 1H), 4.86-4.71 (m, 1H), 4.30-4.20 (m, 1H), 3.89 (s, 3H), 3.75 (s, 3H), 3.55-3.42 (m, 1H), 3.32-2.82 (m, 3H), 2.32-2.21 (m, 1H), 1.75-1.58 (m, 1H), 1.12 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^+$.


537	 3-((7S)-2-((3,5-difluoro-2-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.63 (d, *J* = 8.8 Hz, 1H), 7.55 (d, *J* = 9.2 Hz, 1H), 7.21-7.19 (m, 1H), 7.08-7.04 (m, 1H), 6.46 (s, 1H), 4.94-4.92 (m, 1H), 4.80-4.78 (m, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.27-3.21 (m, 1H), 3.05 – 2.89 (m, 2H), 2.51-2.41 (m, 1H), 2.38 – 2.15 (m, 4H), 1.80-1.69 (m, 3H), 1.52-1.43 (m, 2H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 544 $[M+H]^+$.
538	 3-((7S)-2-(hydroxy(3-methoxyphenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st cluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.24(m, 3H), 7.04-6.86 (m, 3H), 6.21(s, 1H), 4.87-4.73(m, 1H), 3.77 (s, 6H), 3.33-3.32 (m, 1H), 3.00-2.77 (m, 2H), 2.29-2.05 (m, 5H), 1.75-1.31 (m, 5H), 1.79-1.45 (m, 4H). LCMS (ES, *m/z*): 508 $[M+H]^+$.
539	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.47(d, *J*=9.0Hz, 1H), 7.34(d, *J*=9.0Hz, 1H), 7.20(d, *J*=8.1Hz, 2H), 7.08(d, *J*=7.8Hz, 2H),4.84-4.70(m, 1H), 4.44-4.42(m, 1H), 4.17-4.12(m, 1H), 3.95-3.88(m, 2H), 3.76(s, 3H),3.67-3.52(m, 2H), 3.34-3.08(m, 3H), 2.93-2.87(m, 1H),2.44-2.08(m, 6H), 1.95-1.65(m, 3H), 1.10(d, *J*=6.6Hz, 3H). LCMS (ES, m/z): 492 $[M+H]^+$




	f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 1st eluting isomer	(ES, m/z): 492 [M+H]+
540	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.11-8.09 (m, 1H), 7.84 (s, 2H), 7.81-7.73 (m, 1H), 7.09-7.02 (m, 1H), 7.02-6.95 (m, 1H), 5.28-5.13 (m, 1H), 3.83 (m, 3H), 3.40-3.30 (m, 1H), 3.25-3.10 (m, 1H), 3.10-2.99 (m, 1H), 2.70-2.56 (m, 1H), 2.54-2.36 (m, 2H), 2.36-2.20 (m, 3H), 2.09-1.83 (m, 5H), 1.83-1.67 (m, 4H), 1.22-1.10 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 505 $[M+H]^+$.



541	 (1R,3R)-3-((S)-2-(3-fluoro-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 6.70-6.68 (m, 1H), 6.67-6.51 (m, 2H), 4.82-4.72 (m, 1H), 4.50-4.31 (m, 2H), 3.76 (s, 3H), 3.74 (s, 3H), 3.28-3.12 (m, 1H), 3.04-2.92 (m, 1H), 2.78-2.76 (m, 1H), 2.40-2.21 (m, 4H), 2.21-2.02 (m, 1H), 1.83-1.69 (m, 1H), 1.69-1.50 (m, 2H), 1.48-1.20 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 510 $[M+H]^+$.
542	 3-((7S)-2-(1-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48-7.45 (m, 1H), 7.44-7.29 (m, 5H), 7.28-7.21 (m, 1H), 4.81-4.66 (m, 2H), 3.78 (s, 3H), 3.41-3.33 (m, 1H), 3.05-2.92 (m, 1H), 2.78-2.71 (m, 1H), 2.43-2.22 (m, 2H), 2.11 (s, 3H), 2.10-1.95 (m, 2H), 1.79-1.71 (m, 2H), 1.65-1.30 (m, 4H), 1.17 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 492 $[M+H]^+$.
543	 (1S,4R)-4-((S)-2-(4-(dimethylamino)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H NMR (CD_3OD, 300 MHz) δ (ppm): 7.88-7.81 (m, 2H), 7.22 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 4.89-4.87 (m, 1H), 4.62-4.54 (m, 3H), 3.82 (s, 3H), 3.09-3.00 (m, 2H), 2.98 (s, 6H), 2.54-2.50 (m, 1H), 2.35-2.21 (m, 3H), 2.17-2.13 (m, 2H), 1.98-1.92 (m, 1H), 1.64-1.52 (m, 4H), 1.19 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 505 $[M+H]^+$.
544	 (1S,4R)-4-((S)-2-(4-(difluoromethoxy)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 – 7.36 (m, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 7.03 – 6.51 (m, 1H), 4.81 – 4.67 (m, 1H), 4.41 (s, 2H), 4.31 – 4.15 (m, 1H), 3.78 (s, 3H), 3.27 – 3.10 (m, 1H), 3.03 – 2.87 (m, 1H), 2.47 – 2.32 (m, 1H), 2.32 – 2.15 (m, 3H), 2.15 – 1.97 (m, 2H), 1.84 – 1.66 (m, 1H), 1.64 – 1.37 (m, 4H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^+$



	3-yl)cyclohexane-1-carboxylic acid	




545	 3-((7S)-2-(1-hydroxy-1-phenylpropan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62-7.42 (m, 4H), 7.34-7.01 (m, 3H), 5.22 (d, J = 7.2 Hz, 1H), 4.88-4.70 (m, 2H), 3.78 (s, 3H), 3.70-3.51 (m, 1H), 3.23-3.15 (m, 1H), 3.01-2.94 (m, 2H), 2.45-2.15 (m, 4H), 1.92-1.51 (m, 6H), 1.47 (d, J = 6.8 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$
546	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((6-methoxypyridin-2-yl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.56-7.47(m, 3H), 6.81(d, J=7.5 Hz, 1H), 6.61(d, J=8.4Hz, 1H),4.78-4.72(m, 3H), 4.44(s, 1H), 3.81(3, 3H), 3.76(s, 3H), 3.25-3.15(m, 1H), 2.99-2.85(m, 2H), 2.45-2.15(m, 5H),1.80-1.55(m, 3H), 1.35-1.25(m, 2H), 1.13(d, J=6.6Hz, 3H). LCMS (ES, m/z): 493 $[M+H]^+$.
547	 (1R,3R)-3-((S)-2-(2-cyclohexylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, J = 9.2 Hz, 1H), 7.38 (d, J = 9.2 Hz, 1H), 4.78-4.74 (m, 2H), 3.79 (s, 3H), 3.16-3.14 (m, 1H), 3.03-2.92 (m, 4H), 2.45-2.42 (m, 2H), 2.29-2.24 (m, 2H), 1.94-1.89 (m, 4H), 1.77-1.59 (m, 8H), 1.40-1.25 (m, 5H), 1.14 (d, J = 6.4 Hz, 3H), 1.08-1.02 (m, 2H). LCMS (ES, m/z): 482 $[M+H]^+$.
548	 3-((7S)-2-(2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62 – 7.50 (m, 2H), 7.42 – 7.24 (m, 5H), 5.21 – 5.13 (m, 1H), 4.83-4.70 (m, 2H), 3.80 (s, 3H), 3.51 (d, J = 7.2 Hz, 2H), 3.17 – 3.05 (m, 1H), 3.02 – 2.89 (m, 2H), 2.31 – 2.14 (m, 5H), 1.86 – 1.67 (m, 3H), 1.51 – 1.40 (m, 1H), 1.32 – 1.24 (m, 1H), 1.14 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 492 $[M+H]^+$.


549	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-methylbenzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.45-7.35(m, 2H), 7.12-7.08(m, 4H), 4.86-4.60(m, 2H), 4.39-4.23(m, 2H), 3.76(s, 3H), 3.30-3.10(m, 1H), 2.99-2.86(m, 2H), 2.40-2.00(m, 8H),1.80-1.52(m, 3H) , 1.35-1.12(m, 5H) LCMS (ES, m/z): 476 $[M+H]^+$.





550	 (1R,3R)-3-((S)-2-(3-fluoro-4-methylphenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.05-7.13 (m, 1H), 7.00-6.90 (m, 2H), 4.62-4.77 (m, 2H), 3.77 (s, 3H), 3.27-3.09 (m, 4H), 3.04-2.84 (m, 3H), 2.38-2.17 (m, 8H), 1.83-1.62 (m, 3H), 1.61-1.43 (m, 2H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 508 $[M+H]^+$.
551	 4-((7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.94-7.79 (m, 3H), 7.40 (s, 1H), 4.75-4.61 (m, 2H), 4.61–4.43 (m, 1H), 4.43-4.28 (m, 1H), 3.83 (s, 3H), 3.19–3.01 (m, 2H), 2.69-2.54 (m, 1H), 2.46–2.17 (m, 5H), 2.12-1.99 (m, 1H),1.99-1.86 (m,1H),1.86-1.71 (m,1H), 1.71-1.51 (m, 5H), 1.38-1.24 (m,1H),1.18 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^+$.
552	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.54 (s, 1H), 8.45(s, 1H), 8.38 (d, J = 2.4 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.35 (d, J = 9.2 Hz, 1H), 4.84-4.74(m, 1H), 4.50-4.35(m, 1H), 4.01-3.85(m, 1H), 3.79(s, 3H), 3.60-3.45(m, 1H), 3.25-3.11(m, 2H), 2.96-2.81 (m, 1H), 2.60-2.49 (m, 1H), 2.46-2.11 (m, 5H), 2.01-1.85 (m, 1H), 1.79-1.61 (m, 3H), 1.61-1.51 (m, 1H), 1.50 (d, J = 6.8 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 492 $[M+H]^-$.


553	 (1S,4R)-4-((S)-2-(2,3-difluoro-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 9.2 Hz, 1H), 6.92 – 6.76 (m, 2H), 4.78 – 4.67 (m, 1H), 4.37 (s, 2H), 4.29 – 4.15 (m, 1H), 3.86 (s, 3H), 3.76 (s, 3H), 3.21 – 3.10 (m, 1H), 2.98 – 2.80 (m, 1H), 2.53 – 2.38 (m, 1H), 2.38 – 2.19 (m, 3H), 2.19 – 2.04 (m, 2H), 1.78 – 1.59 (m, 3H), 1.59 – 1.38 (m, 2H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^+$
554	 3-((7S)-2-(1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.01 (m, 7H), 5.65-5.50 (m, 1H), 4.84-4.74 (m, 1H), 4.51-4.35 (m, 1H), 3.79 (s, 3H), 3.50-3.15 (m, 3H), 3.03-2.82 (m, 2H), 2.41-2.22 (m, 2H), 2.20-1.95 (m, 6H), 1.81-1.70 (m, 1H), 1.69-1.55 (m, 2H), 1.35-1.20 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H), 0.70-0.60 (m, 1H). LCMS (ES, m/z): 533 $[M+H]^-$.





555	 (S)-2-((3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methyl)benzoic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.02(d, *J*=7.6Hz, 1H), 7.54-7.36(m, 4H), 7.12(d, *J*=7.6Hz, 1H) 4.88-4.76(m, 3H), 4.39-4.33(m, 1H), 3.78(s, 3H), 3.21-2.84(m, 2H), 2.28-2.13(m, 3H), 1.83-1.56(m, 6H), 1.39-1.21(m, 3H), 1.16 (d, *J*=6.8Hz, 3H). LCMS (ES, m/z): 462 $[M+H]^+$
556	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5,6,7,8-tetrahydroquinoxalin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.34 (s, 1H), 7.53-7.50 (m, 1H), 7.31-7.28 (m, 1H), 4.78-4.58 (m, 2H), 4.50-4.32 (m, 2H), 3.69 (s, 3H), 3.05-2.96 (m, 1H), 2.87-2.75 (m, 6H), 2.31-2.10 (m, 3H), 2.09-2.03 (m, 2H), 1.75-1.58 (m, 4H), 1.749-1.70 (m, 4H), 1.45-1.30 (m, 1H), 1.11 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 518 $[M+H]^+$.



557	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.57 (d, *J* = 8.8 Hz, 1H), 7.43 (d, *J* = 9.2 Hz, 1H), 5.28–5.16 (m, 2H), 4.77–4.76 (m, 1H), 3.94–3.92 (m, 1H), 3.87–3.84 (m, 1H), 3.79 (s, 3H), 3.60–3.58 (m, 1H), 3.46–3.37 (m, 2H), 3.16–3.14 (m, 1H), 3.02-3.00 (m, 1H), 2.95–2.90 (m, 1H), 2.55–2.53 (m, 1H), 2.39–2.36 (m, 2H), 2.30–2.24 (m, 2H), 2.09–2.06 (m, 1H), 1.92–1.90 (m, 2H), 1.78–1.52 (m, 9H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^-$
558	 4-((7S)-2-(1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.56 (m, 1H), 7.43-7.41 (m, 1H), 5.19-5.16 (m, 1H), 5.05-5.00 (m, 1H), 4.78-4.76 (m, 1H), 3.79 (s, 3H), 3.42-3.38 (m, 1H), 3.21-3.05 (m, 1H), 2.93-2.89 (m, 1H), 2.64 -2.54 (m, 1H), 2.53-2.37 (m, 2H), 2.29-2.25 (m, 3H), 2.15-2.90 (m, 3H), 1.75-1.60 (m, 5H), 1.65 (d, *J* = 8.0 Hz, 3H), 1.57-1.51 (m, 1H), 1.42-1.35 (m, 2H), 1.36-1.21 (m, 4H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, m/z): 498 $[M+H]^-$.
559	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58 (d, *J* = 9.2 Hz, 1H), 7.40 (d, *J* = 9.2 Hz, 1H), 4.89-4.81 (m, 1H), 4.85-4.81 (m, 1H), 3.96-3.89 (m, 1H), 3.88-3.80 (m, 1H), 3.79 (s, 3H), 3.48 (m, 1H), 3.17 (m, 3H), 3.01-2.92 (m, 2H), 2.52-2.32 (m, 2H), 2.32-2.18 (m, 3H), 1.99-1.87 (m, 3H), 1.79-1.69 (m, 2H), 1.69-1.62 (m, 2H), 1.59-1.45 (m, 3H), 1.40-1.29 (m, 1H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.29 (m, 2H), 7.19-7.06 (m, 1H), 7.07-6.94 (m, 2H)



560	 (1S,4R)-4-((S)-2-(2-(3-fluoro-4-methoxyphenyl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(m, 2H), 7.19-7.00 (m, 1H), 7.07-6.94 (m, 2H), 4.81-4.67 (m, 1H), 4.03-3.92 (m, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 3.33-3.25 (m, 1H), 3.01-2.89 (m, 1H), 2.41-2.26 (m, 2H), 2.26-2.12 (m, 2H), 2.06-1.92 (m, 2H), 1.84 (s, 6H), 1.76-1.62 (m, 1H), 1.51-1.41 (m, 2H), 1.26-1.03 (m, 5H). LCMS (ES, *m/z*): 538 $[M+H]^+$.




561	 (1S,4R)-4-((S)-2-(5-fluoro-2-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49-7.40(m, 2H), 7.10-6.95(m, 2H), 6.80-6.70(m, 1H), 4.80-4.70(m, 1H), 4.35(s, 2H), 4.30-4.15(m, 1H), 3.95(s, 3H), 3.75(s, 3H), 3.25-2.85(m, 2H), 2.45-2.05(m, 6H),1.80-1.30(m, 5H), 1.14(d, J=6.8Hz, 3H). LCMS (ES, *m/z*): 510 $[M+H]^+$.
562	 (1R,3R)-3-((S)-2-((6-cyclopropoxypyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.26 (s, 1H), 7.88 (s, 2H), 7.80 – 7.72 (m, 1H), 7.01 – 6.95 (m, 1H), 5.14 – 5.03 (m, 1H), 4.90 – 4.83 (m, 1H), 4.72 – 4.55 (m, 2H), 4.20 – 4.11 (m, 1H), 3.83 (s, 3H), 3.17 – 2.99 (m, 3H), 2.50 – 2.39 (m, 1H), 2.37 – 2.17 (m, 4H), 1.99 – 1.88 (m, 1H), 1.88 – 1.75 (m, 2H), 1.68 – 1.60 (m, 1H), 1.50 – 1.35 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 3H), 0.87 – 0.79 (m, 2H), 0.79 – 0.67 (m, 2H). LCMS (ES, m/z): 519 $[M+H]^+$.
563	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.34 (m, 2H), 7.25-7.07 (m, 4H), 4.83-4.62 (m, 2H), 4.32-4.21 (m, 1H), 4.18-4.07 (m, 1H), 4.06-3.90 (m, 2H), 3.88-3.70 (m, 4H), 3.70-3.54 (m, 1H), 3.26-3.10 (m, 2H), 3.02-2.89 (m, 1H), 2.81-2.61 (m, 1H), 2.36-2.18 (m, 4H), 1.80-1.71 (m, 1H), 1.67-1.55 (m, 1H), 1.13 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.
564	 3-((7S)-2-((2-(difluoromethyl)-5-fluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.89-7.83 (m, 2H), 7.77-7.72 (m, 1H), 7.53-7.50 (m, 1H), 7.34-7.31 (m, 1H), 7.21-6.93 (m, 1H), 6.74-6.72 (m, 1H), 4.95-4.93 (m, 1H), 4.85-4.81 (m, 2H), 3.83 (s, 3H), 3.19-3.12(m, 1H), 3.02-2.95 (m, 2H), 2.50-2.48 (m, 1H), 2.30-2.16(m, 4H), 1.89-1.73 (m, 4H), 1.50-1.42 (m, 1H), 1.16 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 546 $[M+H]^+$.


		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.82 (s, 1H), 7.52 (d, *J* = 8.4 Hz, 1H), 7.48–7.40 (m, 3H), 6.35 (s, 1H), 4.96–4.89 (m, 1H), 4.79–4.75 (m,





565	 3-((7S)-2-(hydroxy(2-methylbenzo[d]oxazol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1H), 3.78 (s, 3H), 3.30–3.24 (m, 1H), 3.22–3.01 (m, 1H), 3.00–2.91 (m, 1H), 2.64 (s, 3H), 2.43–2.42 (m, 2H), 2.40–2.25 (m, 1H), 2.09–2.00 (m, 1H), 1.99–1.96 (m, 1H), 1.78–1.73 (m, 1H), 1.56–1.47 (m, 2H), 1.32–1.26 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H), 0.95–0.92 (m, 1H). LCMS (ES, *m/z*): 533 $[M+H]^+$.
566	 3-((7S)-2-(furo[2,3-c]pyridin-5-yl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.72 (s, 1H), 8.02 – 7.95 (m, 2H), 7.55 – 7.45 (m, 1H), 7.45 – 7.38 (m, 1H), 6.99 (s, 1H), 6.38 (s, 1H), 5.06 – 4.96 (m, 1H), 4.81 – 4.72 (m, 1H), 3.78 (s, 3H), 3.30 – 3.18 (m, 1H), 2.99 – 2.87 (m, 1H), 2.84 – 2.80 (m, 1H), 2.43 – 2.31 (m, 1H), 2.29 – 2.20 (m, 2H), 2.18 – 2.11 (m, 1H), 2.08 – 2.00 (m, 1H), 1.83 – 1.67 (m, 3H), 1.67 – 1.50 (m, 2H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 519 $[M+H]^+$.
567	 methyl 3-((7S)-azepan-4-yl)-7-methyl-2-(1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.38-7.21 (m, 2H), 7.18-7.04 (m, 3H), 7.04-6.96 (m, 2H), 4.78-4.65 (m, 1H), 4.38-4.33 (m, 1H), 3.77 (s, 3H), 3.63-3.51(m, 1H), 3.29-3.19 (m, 1H), 3.19-2.89 (m, 6H), 2.90-2.74 (m, 1H), 2.35-2.16 (m, 3H), 1.98-1.92 (m, 1H), 1.77-1.56 (m, 2H), 1.54 (d, J = 6.8 Hz, 3H), 1.41-1.34 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H), 0.77-0.69 (m, 1H). LCMS (ES, *m/z*): 461 $[M+H]^+$.
568	 (1R,3R)-3-((S)-2-(4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.43 (d, J = 9.2 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.16 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 9.2 Hz, 2H), 4.81-4.63 (m, 2H), 4.40-4.19 (m, 2H), 3.82-3.70 (m, 6H), 3.26-3.12 (m, 1H), 3.02-2.85 (m, 2H), 2.37-1.98 (m, 5H), 1.80-1.69 (m, 1H), 1.68-1.55 (m, 2H), 1.37-1.09 (m, 5H). LCMS (ES, *m/z*): 492 $[M+H]^-$.

569	 4-((7S)-2-(1-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.47 (d, J = 9.2 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.26-7.17 (m, 5H), 5.29 (t, J = 7.2 Hz, 1H), 4.78-4.76 (m, 1H), 4.60-4.55 (m, 1H), 3.78 (s, 3H), 3.34-3.32 (m, 2H), 3.20-3.17 (m, 1H), 2.96-2.92 (m, 1H), 2.51-2.46 (m, 1H), 2.30-2.19(m, 4H), 2.16-2.05 (m, 1H), 1.97-1.95 (m, 1H), 1.72-1.32 (m, 4H), 1.13 (d, J = 6.8 Hz, 3H).LCMS (ES, *m/z*): 492 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, J = 9.2 Hz, 1H), 7.39 (d, J = 9.2 Hz, 1H), 4.81-4.68 (m, 2H), 3.78 (s, 3H), 3.20-3.16 (m, 1H), 3.09-2.98





570	 (1R,3R)-3-((S)-2-(2-cyclobutylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(m, 1H), 2.90-2.84 (m, 3H), 2.42-2.34 (m, 3H), 2.32-2.18 (m, 3H), 2.14 -2.05 (m, 2H), 1.93-1.82 (m, 6H), 1.82-1.58 (m, 5H), 1.17-1.10 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 454 $[M+H]^+$.
571	 (1R,3R)-3-((S)-2-(benzyl(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.21 (m, 7H), 4.81-4.63 (m, 1H), 4.59-4.41 (m, 1H), 4.41-4.21 (m, 1H), 4.22-4.04 (m, 1H), 3.78(s, 2H), 3.22-3.09(m, 1H), 3.04-2.92 (m, 1H), 2.92-2.74 (m, 3H), 2.59-2.41 (m, 1H), 2.40-2.00 (m, 4H), 1.91-1.51 (m, 5H), 1.42-1.32 (m, 2H), 1.15(d, J = 6.0 Hz, 3H). LCMS (ES, *m/z*): 491 $[M+H]^-$
572	 3-((7S)-2-((2,5-difluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.68-7.64 (m, 1H), 7.53-7.50 (m, 1H), 7.43-7.40 (m, 1H), 7.08-7.05 (m, 2H), 6.39 (s, 1H), 5.01-4.95 (m, 1H), 4.87-4.72 (m, 1H), 3.81 (s, 3H), 3.31-3.13(m, 1H), 2.97-2.96 (m, 1H), 2.94-2.86 (m, 1H), 2.50-2.46 (m, 1H), 2.44-2.32 (m, 1H), 2.28-2.17 (m, 3H), 1.74-1.60 (m, 3H), 1.53-1.15 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H) . LCMS (ES, *m/z*): 514 $[M+H]^+$


573	 (1S,4R)-4-((S)-2-((3-chlorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 511 $[M+H]^+$
574	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenoxycyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.27-7.14 (m, 4H), 6.92-6.90 (m, 1H), 5.15-5.04 (m, 1H), 4.73-4.50 (m, 1H), 3.77 (s, 3H), 3.23-3.15 (m, 1H), 2.94-2.85 (m, 1H), 2.60-2.49 (m, 1H), 2.41-2.18 (m, 5H), 1.89-1.70 (m, 2H), 1.86-1.65 (m, 5H), 1.54-1.46 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H) LCMS (ES, m/z): 504 $[M+H]^+$.
575	 (1R,3R)-3-((S)-2-(cyclohexylmethyl)	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, J=8.8 Hz, 1H), 7.39 (d, J=8.8 Hz, 1H), 4.76-4.73 (m, 2H), 3.72 (s, 3H), 3.22-3.17 (m, 1H), 3.21-3.13 (m, 1H), 2.94-2.86 (m, 3H), 2.47-2.40 (m, 2H), 2.27-2.25 (m, 3H), 1.94-1.89 (m, 3H), 1.76-1.62




	(1R,3R)-3-((S)-2-(cyclohexylmethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(m, 8H), 1.48-1.29 (m, 4H), 1.17-1.02 (m, 4H). LCMS (ES, *m/z*): 468 $[M+H]^+$.
576	 methyl (7S)-7-methyl-2-(1-phenylpropan-2-yl)-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate. 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.26 (d, J = 9.0 Hz, 1H), 7.15-7.10 (m, 4H), 7.03-7.01 (m, 2H), 4.85-4.71 (m, 1H), 3.76-3.62 (m, 7H), 3.43 (s, 2H), 3.32-3.08 (m, 4H), 2.35-1.66 (m, 8H), 1.58 (d, J = 6.6 Hz, 3H), 1.45-1.30 (m, 1H), 1.12 (d, J = 6.6 Hz, 3H), 0.60-0.40 (m, 1H).LCMS (ES, m/z): 487 [M+H]+.



577	 (1R,3R)-3-((S)-2-((1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.51-7.41 (m, 3H), 7.41-7.29 (m, 1H), 7.24-7.13 (m, 1H), 7.11-6.94 (m, 1H), 6.19(s, 1H), 4.81-4.71(m, 2H), 4.71-4.57(m, 2H), 3.78 (s, 3H), 3.32-3.18 (m, 1H), 3.08-2.91 (m, 1H), 2.82-2.67 (m, 1H), 2.39-2.18 (m, 3H), 2.16-1.98 (m, 1H), 1.82-1.68 (m, 1H), 1.68-1.60 (m, 1H), 1.50-1.38 (m, 2H),1.21-1.02 (m, 4H), 0.97-0.94 (m, 1H). LCMS (ES, *m/z*): 501 $[M+H]^+$
578	 3-((7S)-2-((2,3-dihydrobenzofuran-7-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.45 (m, 2H), 7.41-7.36 (m, 1H), 7.17 (d, J = 7.2 Hz, 1H), 6.90 (t, J = 7.6 Hz, 1H), 6.28 (s, 1H), 4.85-4.70 (m, 2H), 4.53-4.38 (m, 2H), 3.78 (s, 3H), 3.33-3.12 (m, 3H), 2.98-2.85 (m, 2H), 2.48-2.37 (m, 1H), 2.31-2.21 (m, 2H), 2.15-1.92 (m, 2H), 1.78-1.53 (m, 3H), 1.49-1.28 (m, 2H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 520 $[M+H]^+$
579	 (1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.43 (s, 1H), 8.42 (s, 1H), 7.80 (d, J = 2.8 Hz, 1H), 7.52-7.46 (m, 2H), 6.72-6.10 (m, 2H), 5.62 (d, J = 9.2 Hz, 1H), 4.99-4.91 (m, 1H), 4.76-4.59 (m, 1H), 3.78 (s, 3H), 3.20 (m, 1H), 2.97 (m, 2H), 2.43-2.31 (m, 2H), 2.30-2.02 (m, 3H), 1.82-1.75 (m, 1H), 1.72-1.60 (m, 2H), 1.21-1.02 (m, 5H). LCMS (ES, *m/z*): 503 $[M+H]^+$
580	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-1-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.32-8.23 (m, 1H), 7.93-7.85 (m, 2H), 7.58 (d, J = 6.6 Hz, 1H), 7.46-7.40 (m, 4H), 7.35-7.22 (m, 1H), 5.12-5.08 (m, 1H), 4.77-4.74 (m, 1H), 4.45-4.37 (m, 1H), 3.97-3.77 (m, 3H), 3.78 (s, 3H), 3.52-3.48 (m, 2H), 3.20-3.18 (m, 1H), 3.04-2.88 (m, 2H), 2.45-2.25 (m, 2H), 2.12-1.98 (m, 1H), 1.79 (m, 3H), 1.14 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^+$



	1]quinolin-2-yl)-2-(naphthalen-1-yl)propanoic acid 1st eluting isomer	[M+H]+




581	 (1S,4R)-4-((S)-2-(4-(dimethylamino)-3-fluorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.89-7.86(m, 2H), 7.85-7.07(m, 3H), 4.75-4.50(m, 4H), 3.80(s, 3H), 3.25-3.30(m, 2H), 2.85(s, 6H), 2.60-2.10(m, 6H), 2.00-1.45(m, 5H), 1.19(d, *J*=6.6Hz, 3H). LCMS (ES, m/z): 523 $[M+H]^+$
582	 4-((7S)-2-(2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.43-7.41 (m, 1H), 7.36-7.33 (m, 3H), 7.31-7.24 (m, 3H), 4.87-4.73 (m, 1H), 4.58-4.53(m, 1H), 4.45-4.40 (m ,1H), 4.22-4.14 (m, 2H), 3.76 (s, 3H), 3.30-3.26 (m, 1H), 2.99-2.95 (m, 1H), 2.39-2.29 (m, 3H), 2.28-2.13 (m, 1H), 2.12-1.85 (m, 3H), 1.78-1.68 (m, 1H), 1.67-1.55 (m, 1H), 1.16-1.13 (m, 4H), 1.00-0.91 (m, 1H). LCMS (ES, *m/z*): 492 $[M+H]^-$.
583	 3-((7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.84-7.80 (m, 2H), 7.66 (d, *J* = 2.0 Hz, 1H), 7.41 (d, *J* = 1.6 Hz, 1H), 6.25 (m, 1H), 4.86-4.67 (m, 3H), 4.26 (m, 1H), 3.80 (s, 3H), 3.17-2.99 (m, 3H), 2.31-2.22 (m, 5H), 1.89-1.85 (m, 3H), 1.68-1.54 (m, 4H), 1.48 (m, 1H), 1.36-1.25 (m,1H), 1.15 (d, *J* – 6.8 Hz, 3H). LCMS (ES, *m/z*): 480 $[M+H]^+$.
584	 2-(4-(difluoromethyl)phenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.48 (m, 5H), 7.39 (d, *J* = 8.8 Hz, 1H), 6.93-6.60 (m, 1H), 4.82-4.66 (m, 1H), 4.58-4.56 (m, 1H), 4.38-4.35 (m, 1H), 4.06-3.92 (m, 2H), 3.78-3.74 (m, 4H), 3.63-3.49 (m, 1H), 3.43-3.34 (m, 2H), 3.16-3.08 (m, 1H), 2.92-2.88 (m, 1H), 2.49-2.42 (m, 1H), 2.28-2.05 (m, 2H), 2.03-1.81 (m, 2H), 1.81-1.65 (m, 1H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.


585	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.51-8.35(m, 3H), 7.45 (d, *J* = 8.8 Hz, 1H), 7.34(d, *J* = 8.8 Hz, 1H), 4.77-4.72(m, 2H), 3.96-3.93(m, 1H), 3.77(s, 3H), 3.60-3.54(m, 1H), 3.33-3.20(m, 2H), 2.99-2.88 (m, 2H), 2.45-2.22 (m, 5H), 1.84-1.54 (m, 8H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.





	carboxylic acid 2nd eluting isomer	
586	 (1R,3R)-3-((S)-2-((6-(tert-butoxy)pyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.32 (s, 1H), 8.02 (s, 1H), 7.88 (s, 2H), 4.98-4.89 (m, 2H), 4.78-4.71 (m, 2H), 3.84 (s, 3H), 3.05-2.95 (m, 3H), 2.50-2.12 (m, 5H), 2.09-1.71 (m, 4H), 1.51–1.40 (m, 1H), 1.27 (s, 9H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 536 $[M+H]^+$
587	 3-((7S)-2-(hydroxy(isoquinolin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 9.16(s, 1H), 8.08-8.97 (m, 3H), 7.79-7.40 (m, 4H), 6.47(s, 1H), 5.12(s, 1H), 4.77-4.73 (m, 1H), 3.78(s, 3H), 3.34-3.20 (m, 1H), 2.93-2.82 (m, 2H), 2.38-2.15 (m, 5H), 1.76-1.54 (m, 5H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 529 $[M+H]^+$.
588	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(2-oxopiperidin-1-yl)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54-7.51 (m, 1H), 7.32-7.29 (m, 1H), 5.66-5.61 (m, 1H), 4.66-4.62 (m, 1H), 3.66 (s, 3H), 3.56-3.52 (m, 1H), 3.45-3.41 (m, 1H), 3.07-3.00(m, 1H), 2.99-2.77 (m, 2H), 2.39-2.34 (m, 1H), 2.24-2.20 (m, 1H), 2.20-2.11 (m, 5H), 1.68-1.51 (m, 11H), 1.35-1.15 (m, 2H), 1.09 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 509 $[M+H]^-$

589	 3-((7S)-2-(furo[2,3-c]pyridin-5-yl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.73 (s, 1H), 8.11 (s, 1H), 8.07 – 8.02 (m, 1H), 7.51 – 7.45-7.38 (m, 2H), 7.03 (s, 1H), 6.36 (s, 1H), 4.80 – 4.72 (m, 2H), 3.78 (s, 3H), 3.27 – 3.14 (m, 1H), 3.01 – 2.89 (m, 2H), 2.45 – 2.38 (m, 2H), 2.28 – 2.20 (m, 1H), 2.12 – 1.98 (m, 2H), 1.76-1.73 (m, 1H), 1.63 – 1.47 (m, 2H), 1.25-1.09 (m, 4H), 1.08-1.01 (m, 1H). LCMS (ES, m/z): 519 $[M+H]^+$.
590	 (1S,4R)-4-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.45-7.35 (m, 2H), 7.34-7.19 (m, 5H), 4.82-4.71 (m, 1H), 4.39 (s, 2H), 4.28-4.14 (m, 1H), 3.76 (s, 3H), 3.28-3.15 (m, 1H), 3.02-2.89 (m, 1H), 2.41-2.10 (m, 4H), 2.06-1.92 (m, 2H), 1.79-1.69 (m, 1H), 1.45-1.36 (m, 4H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 462 $[M+H]^+$





591	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(p-tolyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 491 $[M+H]^+$
592	 (1R,3R)-3-((S)-2-((4-chlorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 511 $[M+H]^+$



593	 (1R,3R)-3-((S)-2-((6-(difluoromethoxy)pyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.98-7.94 (m, 1H), 7.88-7.86 (s, 2H), 7.43-7.41 (m, 1H), 7.40-7.15 (m, 1H), 6.98-6.97 (m, 1H), 5.05-5.01 (m, 1H), 4.84-4.72 (m, 3H), 3.83 (s, 3H), 3.19-2.98 (m, 3H), 2.50-2.30 (m, 2H), 2.30-2.10 (m, 3H), 2.00-1.70 (m, 4H), 1.42-1.30 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*):529 $[M+H]^+$
594	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.41 (m, 2H), 7.37-7.31 (m, 5H), 4.81-4.66 (m, 2H), 4.41-4.27 (m, 1H), 4.22-4.11 (m, 1H), 4.10-4.02 (m, 1H), 4.01-3.93 (m, 1H), 3.91-3.76 (m, 4H), 3.71-3.59 (m, 1H), 3.42-3.34 (m, 1H), 3.23-3.14 (m, 1H), 3.04-2.89 (m, 1H), 2.87-2.63 (m, 1H), 2.34-2.17 (m, 1H), 1.86-1.66 (m, 2H), 1.14 (d, J = 6.0 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$.
595	 (1S,4R)-4-((S)-2-(3-fluoro-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.86 (s, 2H), 6.84 – 6.68 (m, 3H), 4.89 – 4.82 (m, 1H), 4.67 (s, 2H), 4.63 – 4.49 (m, 1H), 3.83 (s, 6H), 3.21 – 2.98 (m, 2H), 2.65 – 2.50 (m, 1H), 2.40 – 2.12 (m, 5H), 2.00 – 1.88 (m, 1H), 1.84 – 1.68 (m, 2H), 1.62 – 1.47 (m, 2H), 1.19 (d, J = 6.9 Hz, 3H). LCMS (ES, m/z): 510 $[M+H]^+$.
		




596	 3-((7S)-2-(2-(4,4-difluorocyclohexyl)-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.71-7.51 (m, 1H), 7.50-7.27 (m, 1H), 5.37-5.12(m, 2H), 4.82-4.71(m, 1H), 3.78(s, 3H), 3.24-3.09 (m, 1H), 3.03-2.88 (m, 2H), 2.59-2.41 (m, 1H), 2.41-2.13 (m, 5H), 2.11-1.91 (m, 5H), 1.91-1.61 (m, 8H), 1.42-1.32 (m, 2H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 534 $[M+H]^+$.




597	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 508 $[M+H]^+$
598	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(o-tolyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 491 $[M+H]^+$
599	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-3-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.35 (s, 1H), 8.16 (d, J = 4.4 Hz, 1H), 7.54-7.52 (m, 2H), 7.46-7.43 (m, 1H), 7.37-7.34 (m, 1H), 6.02-5.96 (m, 1H), 4.84-4.64(m, 2H), 3.79(s, 3H), 3.25-3.11(m, 1H), 3.08-2.86 (m, 1H), 2.60-2.10 (m, 6H), 2.09-2.01 (m, 1H), 1.87 (d, J = 6.4 Hz, 3H), 1.79-1.53 (m, 4H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 493 $[M+H]^+$.
600	 (1S,4R)-4-((S)-2-((1H-indol-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.44-7.26(m, 4H), 7.06-6.93(m, 2H), 6.22(s, 1H), 4.86-4.74(m, 1H), 4.53(s, 2H), 4.52-4.39(m, 1H), 3.75(s, 3H), 3.30-2.90(m, 2H), 2.55-1.95(m, 6H), 1.75-1.45(m, 5H), 1.14(d, J=6.6Hz, 3H). LCMS (ES, m/z): 501 $[M+H]^+$.


		





601	 (1R,3R)-3-((S)-2-(3-fluorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.55-7.26 (m, 3H), 7.09-6.96 (m, 3H), 4.81-4.65(m, 2H), 4.49-4.32(m, 2H), 3.79(s, 3H), 3.28-3.17(m, 1H), 3.03-2.96 (m, 2H), 2.45-2.10 (m, 5H), 1.81-1.68 (m, 3H), 1.33-1.20 (m, 2H), 1.16 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 480 $[M+H]^+$.
602	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.53 (m, 1H), 7.52-7.41 (m, 1H), 7.38-7.23 (m, 5H), 4.83-4.69 (m, 2H), 4.41-4.30 (m, 1H), 4.13-3.92 (m,2H), 3.91-3.76 (m, 4H), 3.75-3.62 (m, 1H), 3.25-3.10 (m, 3H), 3.02-2.76 (m, 2H), 2.74-2.57 (m, 1H), 2.31-2.16 (m, 1H), 1.78-1.68 (m, 1H), 1.14 (d, J = 5.6 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$.
603	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.57 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 5.17 –5.08 (m, 2H), 4.77–4.74 (m, 1H), 3.95–3.89 (m, 2H), 3.79 (s, 3H), 3.71–3.68 (m, 1H), 3.48–3.39 (m, 2H), 3.20–3.18 (m, 1H), 3.02-3.00 (m, 1H), 2.94–2.90 (m, 1H), 2.57–2.55 (m, 1H), 2.40–2.24 (m, 4H), 1.97–1.90 (m, 4H), 1.76–1.62 (m, 8H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^+$
604	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.53 – 8.46 (m, 1H), 8.18 – 8.09 (m, 2H), 7.50 (d, J = 9.2 Hz, 1H), 7.40 (d, J = 9.2 Hz, 1H), 5.46 – 5.36 (m, 1H), 4.79 – 4.70 (m, 1H), 3.77 (s, 3H), 3.28 – 3.18 (m, 1H), 3.00 (s, 1H), 2.96 – 2.87 (m, 1H), 2.53 – 2.41 (m, 1H), 2.32 – 2.19 (m, 4H), 1.87 (s, 1H), 1.80 – 1.60 (m, 7H), 1.58 – 1.47 (m, 1H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.

605	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.51-7.38 (m, 2H), 7.30-7.21 (m, 2H), 7.02 (d, J = 7.5 Hz, 2H), 6.95-6.80 (m, 1H), 5.88-5.70 (m, 1H), 4.85-4.70 (m, 2H), 3.78 (s, 3H), 3.23-3.10 (m, 1H), 3.00-2.85 (m, 1H), 2.55-2.30 (m, 2H), 2.30-2.15 (m, 3H), 2.19-2.03 (m, 1H), 2.03-1.97 (d, J = 12.9 Hz, 1H), 1.84 (d, J = 6.9 Hz, 3H), 1.80-1.76 (m, 1H), 1.70-1.50 (m, 3H), 1.13 (d, J = 6.3 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.74(s, 1H), 7.66-7.53 (m, 2H), 7.42 (d, J = 8.4 Hz, 1H),





606	 3-((7S)-2-(hydroxy(1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	7.29 (d, *J* = 3.2 Hz, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 6.51- 6.45 (m, 2H), 4.83- 4.67 (m, 2H), 3.80 (s, 3H), 3.31-3.22 (m, 1H), 3.11-3.00 (m, 1H), 2.36-1.78 (m, 7H), 1.62-1.54 (m, 1H), 1.39-1.25 (m, 3H), 1.19 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 517 $[M+H]^+$.
607	 3-((7S)-2-(1-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1H-NMR (CD3OD, 400 MHz) δ (ppm): 7.49-7.20 (m, 7H), 4.85-4.71 (m, 2H), 3.78 (s, 3H), 3.43-3.33 (m, 1H), 3.04-2.92 (m, 1H), 2.91-2.80 (m, 1H), 2.41-2.25 (m, 3H), 2.10-1.99 (m, 4H), 1.97-1.82 (m, 1H), 1.75-1.62 (m, 1H), 1.55-1.35 (m, 2H), 1.16 (d, *J* = 6.4 Hz, 3H), 1.11-0.95 (m, 1H), 0.78-0.62 (m, 1H). LCMS (ES, m/z): 492 $[M+H]^+$.
608	 3-((7S)-2-(hydroxy(1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86-7.69 (m, 3H), 7.48 (d, *J* = 8.4 Hz, 1H), 7.32 (d, *J* = 3.2 Hz, 1H), 7.17 (d, *J* = 7.6 Hz, 1H), 6.52-6.49 (m, 2H), 4.88-4.86 (m, 1H), 4.76-4.59 (m, 1H), 3.82 (s, 3H), 3.31-3.24 (m, 1H), 3.15-3.01 (m, 1H), 2.35-2.21 (m, 1H), 2.23-2.06 (m, 2H), 2.06-1.85 (m, 4H), 1.73-1.69 (m, 1H), 1.48-1.40 (m, 2H), 1.27-1.22 (m, 1H), 1.21 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 517 $[M+H]^+$.


609	 methyl 2-((7S)-1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 7.95 (s, 1H), 7.55 (s, 1H), 7.31-7.15 (m, 2H), 4.62-455 (m, 1H), 4.54-4.35 (m, 2H) , 4.30-4.15 (m, 1H), 3.85-3.70 (m, 2H), 3.65 (s, 3H), 3.45-3.35 (m, 2H), 3.35-3.25 (m, 2H), 3.12-3.01 (m, 1H), 2.85-2.75 (m, 1H), 2.20-2.01 (m, 4H), 2.00-1.91 (m, 1H), 1.75-1.50 (m, 4H), 1.48-1.32 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 3H), 1.06 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 511 $[M+H]^+$.
610	 3-((7S)-2-((5-chloropyridin-2-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.45 (s, 1H), 8.00-7.97 (m, 1H), 7.89-7.87 (m, 1H), 7.82-7.45 (m, 2H), 6.46 (s, 1H), 5.11-5.05 (m, 1H), 4.87-4.83 (m, 1H), 3.82(s, 3H), 3.18-3.12(m, 1H), 3.03-2.94 (m, 2H), 2.45-2.11 (m, 5H), 1.94-1.73 (m, 4H), 1.52-1.48 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 513 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.68 (s, 1H), 8.51 (s, 1H), 7.97 – 7.86 (m, 2H), 5.5.11–4.85 (m, 4H), 3.84 (s, 3H), 3.13 – 2.97 (m, 4H),




611	 (1R,3R)-3-((S)-2-((6-isopropylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	2.50 – 2.35 (m, 2H), 2.33 – 2.17 (m, 3H), 1.97 – 1.76 (m, 4H), 1.52 – 1.38 (m, 1H), 1.22 – 1.13 (m, 9H). LCMS (ES, m/z): 506 $[M+H]^+$.
612	 3-((7S)-2-(hydroxy(1H-indazol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.05 (s, 1H), 8.01 (s, 1H), 7.51-7.46 (m, 2H), 7.42-7.38 (m, 2H), 6.37 (s, 1H), 5.00-4.98 (m, 1H), 4.80-4.75 (m, 1H), 3.78 (s, 3H), 3.27-3.20(m, 1H), 3.02-2.98 (m, 1H), 2.89-2.84 (m, 1H), 2.38-2.36 (m, 2H), 2.31-2.25 (m, 1H), 2.11-1.97 (m, 2H), 1.79-1.76 (m, 1H), 1.56-1.41 (m, 2H), 1.20-1.16 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H), 0.99-0.96 (m, 1H). LCMS (ES, *m/z*): 518 $[M+H]^+$.



613	 (1S,4R)-4-((S)-2-((3-fluorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 495 $[M+H]^+$
614	 3-((7S)-2-((2-hydroxycyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.55 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 4.83–4.76 (m, 2H), 3.79 (s, 3H), 3.53 3.48 (m, 1H), 3.23 3.17 (m, 1H), 3.15–3.14 (m, 1H), 2.99–2.89 (m, 1H), 2.79–2.73 (m, 1H), 2.46–2.41 (m, 2H), 2.39–2.24 (m, 3H), 2.01–1.99 (m, 1H), 1.93–1.91 (m, 2H), 1.77–1.59 (m, 7H), 1.34–1.30 (m, 2H), 1.21–1.14 (m, 6H). LCMS (ES, *m/z*): 484 $[M+H]^+$
615	 3-((7S)-2-(cycloheptyl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.65-7.48 (m, 1H), 7.48-7.22 (m, 1H), 5.13-4.94(m, 1H), 4.82-4.67(m, 2H), 3.78(s, 3H), 3.29-3.12 (m, 1H), 3.08-2.82 (m, 2H), 2.61-2.19 (m, 6H), 2.19-2.01 (m, 1H), 2.01-1.82 (m, 2H), 1.82-1.46 (m, 12H), 1.42-1.32 (m, 2H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
616	 (1R,3R)-3-((S)-2-(3-chlorobenzyl)-6-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48-7.45(m, 1H), 7.40-7.38(m, 1H), 7.30-7.23(m, 3H), 7.18-7.17(m, 1H), 4.77-4.68(m, 2H), 4.44-4.40(m, 1H), 4.33-4.29(m, 1H), 3.76(s, 3H), 3.19-3.15(m, 1H), 2.98-2.94(m, 2H), 2.33-2.13(m, 5H), 1.76-1.64(m, 3H), 1.24-1.23(m, 2H), 1.13(d, J=6.8Hz,



	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	3H). LCMS (ES, *m/z*): 496 $[M+H]^+$.




617	 (1S,4R)-4-((S)-2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.93 (s, 1H), 7.56 – 7.33 (m, 3H), 5.22 – 5.03 (m, 1H), 4.81 – 4.65 (m, 1H), 3.76 (s, 3H), 3.26 – 3.07 (m, 1H), 3.02 – 2.87 (m, 1H), 2.56 – 2.37 (m, 1H), 2.37 – 2.07 (m, 5H), 1.96 – 1.86 (m, 2H), 1.78 – 1.52 (m, 7H), 1.11 (d, *J* = 6.9 Hz, 3H). LCMS (ES, *m/z*): 512 $[M+H]^+$
618	 3-((7S)-2-(2-hydroxy-1-phenylpropan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.60 (d, *J*=8.8 Hz, 1H), 7.40 (d, *J*=9.2 Hz, 1H), 7.24-7.15 (m, 3H), 7.22-7.16 (m, 2H), 5.85-5.77 (m, 1H), 4.78-7.65 (m, 1H), 3.79 (s, 3H), 3.45-3.33 (m, 2H), 3.22-3.01 (m, 2H), 2.88-2.64 (m, 2H), 2.57-2.49 (m, 1H), 2.45-2.20 (m, 3H), 2.11-2.01(m, 1H), 1.82-1.78 (m, 3H), 1.75 (s, 3H), 1.74-1.65 (m, 1H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 506 [M+H]+.
619	 (1R,3R)-3-((S)-2-((6-(difluoromethoxy)pyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.18 (s, 1H), 7.79-7.65 (m, 1H), 7.57-7.30 (m, 3H), 6.93 (d, *J* = 8.0 Hz, 1H), 4.84 -4.66 (m, 2H), 4.44-4.36 (m, 2H), 3.79 (s, 3H), 3.28-3.12 (m, 1H), 3.05-2.91 (m, 2H), 2.43-2.10 (m, 5H), 1.84-1.65 (m, 3H), 1.56-1.30 (m, 2H), 1.15 (d, *J* = 6.4 Hz, 1H). LCMS (ES, *m/z*): 529 $[M+H]^+$.
620	 2-(4-cyclopropylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49 (d, *J* = 9.2 Hz, 1H) , 7.38 (d, *J* = 9.2 Hz, 1H) , 7.17 (d, *J* = 8.0 Hz, 2H) , 7.00 (d, *J* = 8.0 Hz, 2H), 4.74-4.73 (m, 1H), 4.42-4.35(m , 1H) , 4.42-4.23 (m, 1H), 3.94-3.87 (m, 2H), 3.76(s, 3H), 3.73-3.50 (m, 2H), 3.35-3.30 (m, 1H), 3.29-3.03 (m, 2H), 2.93-2.88 (m, 1H), 2.52-2.31 (m, 1H), 2.30-2.19 (m, 1H), 2.14-2.01 (m, 1H), 1.98-1.80 (m, 3H), 1.80-1.70 (m,1H), 1.11 (d, *J* = 6.8 Hz, 3H) , 0.92-0.89 (m, 2H), 0.65-0.61 (m , 2H). LCMS (ES, *m/z*): 518$[M+H]^-$.


621	 (1R,3R)-3-((S)-2-(2-cyanobenzyl)-6-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.79 (d, *J* = 7.6 Hz, 1H), 7.64-7.43 (m, 4H), 7.15-7.13 (m, 1H), 4.83-4.61 (m, 4H), 3.79 (s, 3H), 3.28-2.92 (m, 3H), 2.41-2.17 (m, 5H), 1.79-1.66 (m, 4H), 1.47-1.37 (m, 1H), 1.16(d, *J* = 6.0 Hz, 3H). LCMS (ES, *m/z*): 487 $[M+H]^+$





	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	[illegible]
622	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(tetrahydro-2H-pyran-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.65-7.58 (m, 1H), 7.48-7.42 (m, 1H), 4.81-4.70 (m, 1H), 3.96-3.86 (m, 2H), 3.79 (s, 3H), 3.55-3.43 (m, 1H), 3.43-3.35 (m, 2H), 3.28-3.13 (m, 1H), 3.13-2.99 (m, 2H), 2.99-2.84 (m, 1H), 2.56-2.38 (m, 2H), 2.33-2.16 (m, 3H), 2.02-1.86 (m, 3H), 1.86-1.53 (m, 7H), 1.48 (d, *J* = 6.8 Hz, 3H), 1.40-1.20 (m, 2H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, m/z): 498 $[M+H]^+$.
623	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-oxo-1-(piperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.51 (d, *J* = 8.8 Hz, 1H), 7.39 (d, *J* = 9.2 Hz, 1H), 4.77–4.72 (m, 1H), 4.59–4.52 (m, 2H), 3.78 (s, 3H), 3.63–3.56 (m, 4H), 3.25–3.23 (m, 1H), 3.02-2.99 (m, 1H), 2.94–2.90 (m, 1H), 2.50–2.48 (m, 1H), 2.33–2.24 (m, 4H), 1.92–1.85 (m, 2H), 1.77–1.74 (m, 7H), 1.72–1.55 (m, 5H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 511 $[M+H]^+$
624	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-oxo-1-(piperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.52 (d, *J* = 8.8 Hz, 1H), 7.39 (d, *J* = 9.2 Hz, 1H), 4.83–4.72 (m, 2H), 4.56–4.52 (m, 1H), 3.79 (s, 3H), 3.68–3.60 (m, 1H), 3.56–3.45 (m, 3H), 3.23–3.17 (m, 1H), 3.01-2.98 (m, 1H), 2.95–2.89 (m, 1H), 2.50–2.48 (m, 1H), 2.36–2.24 (m, 4H), 1.89–1.86 (m, 2H), 1.77–1.44 (m, 11H), 1.28-1.23 (m, 1H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 511 $[M+H]^+$





625	 3-((7S)-2-(cyclohexyl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.60 – 7.53 (m, 1H), 7.45 – 7.39 (m, 1H), 5.07 – 4.97 (m, 1H), 4.80 – 4.69 (m, 2H), 3.79 (s, 3H), 3.27 – 3.15 (m, 1H), 3.01-2.86 (m, 2H), 2.53 – 2.13 (m, 6H), 2.08 – 2.00 (m, 1H), 1.96 – 1.80 (m, 3H), 1.80-1.73 (m, 5H), 1.35 – 1.22 (m, 4H), 1.21 – 1.12 (m, 5H). LCMS (ES, m/z): 484 $[M+H]^+$.
626	 methyl (7S)-2-(1-(3,4-difluorophenyl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49 (d, *J* = 9.2 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 1H), 7.15-7.00 (m, 2H), 6.90-6.81 (m, 1H), 4.79-4.65 (m, 1H), 4.49-4.31 (m, 1H), 3.79 (s, 3H), 3.69-3.57 (m, 1H), 3.33-3.05 (m, 5H), 3.00-2.88 (m, 1H), 2.88-2.75 (m, 1H), 2.76-2.65 (m, 1H), 2.48-2.23 (m, 3H), 1.81-1.65 (m, 2H), 1.51 (d, *J* = 6.8 Hz, 3H), 1.15 (d, *J* = 6.4 Hz, 3H), 1.10-0.96 (m, 1H). LCMS (ES, *m/z*): 483 $[M+H]^+$.



	carboxylate 1st eluting isomer	
627	 4-((7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm):7.84 - 7.74 (m, 2H), 7.64 (d, J = 2.0 Hz, 1H), 7.41 (s, 1H), 6.28-6.26 (m, 1H), 4.78 - 4.63 (m, 2H), 4.61 - 4.41 (m, 1H), 4.41 - 4.26 (m, 1H), 3.81 (s, 3H), 3.20 - 2.99 (m, 2H), 2.63 - 2.46 (m, 1H), 2.42 - 2.11 (m, 5H), 2.08 - 1.94 (m,1H), 1.94 - 1.82 (m,1H), 1.82 - 1.68 (m,1H), 1.68 - 1.42 (m, 5H), 1.32 - 1.21 (m,1H), 1.16 (d, J = 6.8 Hz, 3H). LCMS: (ES, m/z):480 $[M+H]^+$.
628	 (1R,3R)-3-((S)-2-(2-(4-chloro-1H-pyrazol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.95 – 7.81 (m, 3H), 7.39 (s, 1H), 4.87 – 4.67 (m, 3H), 3.86 – 3.71 (m, 5H), 3.12 – 2.91 (m, 3H), 2.53 – 2.36 (m, 3H), 2.36 – 2.15 (m, 2H), 2.01 – 1.79 (m, 4H), 1.69 – 1.51 (m, 1H), 1.17 (d, J = 6.9 Hz, 3H). LCMS (ES, m/z): 500 $[M+H]^+$.




629	 2-(4-(difluoromethyl)phenyl)-3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.45 (m, 5H), 7.40 (d, J = 9.2 Hz, 1H), 6.91-6.53 (m, 1H), 4.86-4.68 (m, 2H), 4.40-4.27 (m, 1H), 4.19-4.04 (m, 2H), 4.03-3.92 (m, 1H), 3.91-3.80 (m, 1H), 3.79 (s, 3H), 3.73-3.61 (m, 1H), 3.31-3.27 (m, 1H), 3.23-3.11 (m, 1H), 2.99-2.89 (m, 1H), 2.87-2.71 (m, 1H), 2.32-2.18 (m, 1H), 1.90-1.78 (m, 1H), 1.77-1.66 (m, 1H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 564 $[M+H]^+$.
630	 3-((7S)-2-((5-chloro-2-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86-7.73(m, 1H),7.58-7.48 (m, 1H), 7.48-7.34 (m, 1H), 7.34-7.23 (m, 1H), 6.99-6.84 (m, 1H), 6.37(s, 1H), 5.08-4.92(m, 1H), 4.81-4.61(m, 1H), 3.78(s, 3H), 3.64(s, 3H), 3.27-3.04 (m, 1H), 3.01-2.93 (m, 1H), 2.93-2.82 (m, 1H), 2.59-2.39 (m, 1H), 2.39-2.28(m, 1H), 2.28-2.07(m, 3H), 1.85-1.60 (m, 3H), 1.59-1.38 (m, 2H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 542 $[M+H]^+$
631	 3-((7S)-2-(hydroxy(isoquinolin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 9.17(s, 1H), 8.26-8.02 (m, 3H), 7.82-7.50 (m, 4H), 6.51(s, 1H), 5.08-4.75 (m, 2H), 3.78(s, 3H), 3.33-3.15 (m, 1H), 2.99-2.77 (m, 2H), 2.45-2.02 (m, 5H), 1.75-1.48 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H), 1.12-1.07(m, 2H). LCMS (ES, m/z): 529 $[M+H]^+$.




632	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 3rd eluting isomer	^{1}H-NMR (CD3OD, 400 MHz) δ (ppm): 7.51-7.47(m, 1H), 7.42-7.38(m, 3H), 7.34-7.25(m, 3H), 4.79-4.71(m, 2H), 4.32-4.30(m, 1H), 3.76 (s, 3H), 3.75-3.67 (m, 2H), 3.40(s, 3H), 3.27-3.22(m, 1H), 3.14-3.12(m, 1H), 2.90-2.86(m, 1H), 2.37-2.21(m, 3H), 2.09-2.05(m, 1H), 1.96-1.86(m, 3H), 1.75-1.69(m, 2H), 1.54-1.50(m, 1H), 1.12(d, *J*=6.8 Hz, 3H). LCMS (ES, m/z): 506 [M+H]+.



633	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenoxymethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.59-7.45 (m, 2H), 7.39-7.29 (m, 2H), 7.10 (m, 2H), 7.02 (m, 1H), 5.42 (s, 2H), 4.78 (m, 1H), 4.51 (m, 1H), 3.79 (s, 3H), 3.19 (m, 1H), 2.97 (m, 1H), 2.55-2.44 (m, 1H), 2.43-2.20 (m, 5H), 2.03 (m, 2H), 1.77 (m, 1H), 1.62 (m, 2H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 478 $[M+H]^+$.
634	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((6-oxo-7-azaspiro[3.5]nonan-7-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55 (d, *J* = 9.2 Hz, 1H), 7.44 (d, *J* = 8.8 Hz, 1H), 5.22-5.03 (m, 1H), 4.82-4.64 (m, 3H), 3.79 (s, 3H), 3.31-3.26 (m, 2H), 3.25-3.11 (m, 1H), 3.01-2.87 (m, 2H), 2.73-2.59 (m, 1H), 2.55-2.40 (m, 2H), 2.32-2.19 (m, 4H), 2.02-1.89 (m, 6H), 1.88-1.78 (m, 4H), 1.77-1.56 (m, 3H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 523 $[M+H]^+$.
635	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.92-7.81 (m, 2H), 5.13-5.02 (m, 1H), 4.89-4.81 (m, 1H), 3.96-3.88 (m, 2H), 3.83 (s, 3H), 3.52-3.35 (m, 2H), 3.32-3.25 (m, 1H), 3.15-2.90 (m, 3H), 2.52-2.45 (m, 2H), 2.38-2.26 (m, 3H), 2.24-2.06 (m, 1H), 2.00-1.80 (m, 5H), 1.72-1.45 (m, 5H), 1.18 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.
636	 3-((7S)-2-((2,3-dihydrofuro[2,3-c]pyridin-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.89 (s, 1H), 7.62-7.62 (m, 1H), 7.62-7.52 (m, 1H), 7.47-7.45 (m, 1H), 6.22 (s, 1H), 4.92-4.90 (m, 1H), 4.82-4.72 (m, 1H), 4.70-4.45 (m, 2H), 3.79 (s, 3H), 3.43-3.34 (m, 1H), 3.34-3.17 (m, 2H), 3.02-2.92 (m, 2H), 2.51-2.32 (m, 1H), 2.30-2.09 (m, 3H), 2.01-1.97 (m, 1H), 1.82-1.78 (m, 3H), 1.72-1.40 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 521 $[M+H]^+$.





637	 3-((7S)-2-(cyclohexyl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58 – 7.51 (m, 1H), 7.44 – 7.37 (m, 1H), 5.23 – 5.16 (m, 1H), 4.80 – 4.72 (m, 1H), 4.72 – 4.65 (m, 1H), 3.79 (s, 3H), 3.24 – 3.12 (m, 1H), 3.00- 2.85 (m, 2H), 2.53 (td, J = 13.2, 5.5 Hz, 1H), 2.37 – 2.20 (m, 6H), 2.01 – 1.93 (m, 1H), 1.90 – 1.63 (m, 7H), 1.52 – 1.41 (m, 1H), 1.36 – 1.18 (m, 2H), 1.17 – 0.97 (m, 6H). LCMS (ES, m/z): 484 $[M+H]^+$.
638	 3-((7S)-2-((2,3-difluoro-6-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62-7.51 (m, 1H), 7.49-7.34 (m, 1H), 7.31-7.11 (m, 1H), 6.91-6.78 (m, 1H), 6.58(s, 1H), 4.89-4.81(m, 1H), 4.78-4.66(m, 1H), 3.83(s, 3H), 3.78(s, 3H), 3.27-3.12(m, 1H), 3.01-2.89 (m, 1H), 2.89-2.76 (m, 1H), 2.54-2.41 (m, 1H), 2.41-2.27 (m, 1H), 2.27-2.12 (m, 3H), 2.12-2.02 (m, 1H),1.95-1.83 (m, 1H), 1.78-1.61 (m, 3H),1.14 (d, J = 6.4 Hz, 3H), LCMS (ES, m/z): 544 $[M+H]^+$.
639	 (1S,4R)-4-((S)-2-(4-acetamido-3-fluorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.88-7.84(m, 1H), 7.47-7.38(m, 2H), 7.08-7.04(m, 2H),4.80-4.50(m, 2H), 4.40(s, 2H), 4.35-4.15(m, 1H), 3.75(s, 3H), 3.25-3.10(m, 1H), 3.00-2.90(m, 1H), 2.50-2.00(m, 7H),1.75-1.40(m, 6H), 1.14(d, J=6.8Hz, 3H). LCMS (ES, m/z): 537 $[M+H]^+$.
640	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-methyl-1-phenylpropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 300 MHz) δ (ppm): 7.40-7.19 (m, 7H), 4.84-4.68 (m, 1H), 4.50-4.42 (m, 1H), 3.97 (d, J = 10.4 Hz, 1H), 3.74 (s, 3H), 3.31-3.25 (m, 1H), 3.05-2.88 (m, 2H), 2.41-2.25 (m, 3H), 2.25-1.91 (m, 6H), 1.72-1.64 (m, 1H), 1.14 (t, J = 6.3 Hz, 6H), 0.92-0.88 (m, 4H). LCMS (ES, m/z): 504 $[M+H]^+$.






641	 (1R,3R)-3-((S)-2-(3,4-dimethoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.43 (d, J = 9.2 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H), 6.96 (s, 1H), 6.94-6.76 (m, 2H), 4.97-4.88 (m, 1H), 4.80-4.68 (m, 1H), 4.37-4.25 (m, 2H), 3.83-3.71 (m, 9H), 3.26-3.14 (m, 1H), 3.00-2.88 (m, 1H), 2.76-2.74 (m, 1H), 2.34-2.13 (m, 4H), 2.10-1.93 (m, 1H), 1.78-1.67 (m, 1H), 1.61-1.45 (m, 2H), 1.42-1.25 (m, 1H), 1.18-1.03 (m, 4H). LCMS (ES, m/z): 522 $[M+H]^+$.
		^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.39




642	 (1R,3R)-3-((S)-2-((6-isopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58-7.39 (m, 3H), 6.82 (d, J = 7.2Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 5.20-5.17 (m, 1H), 4.81-4.77 (m, 2H), 4.45-4.42 (m, 2H), 3.79 (s, 3H), 3.24-3.16 (m, 1H), 2.97-2.92 (m, 2H), 2.36-2.19 (m, 5H), 1.78-1.71 (m, 3H), 1.42 (m, 2H), 1.22 (d, J = 6.0 Hz, 3H), 1.16 (t, J = 6.4 Hz, 6H). LCMS (ES, *m/z*): 521 $[M+H]^+$
643	 (1R,3R)-3-((S)-2-((4-chloro-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.88(s, 1H), 7.58-7.40(m, 3H), 5.90-5.75(m, 1H), 5.60-5.48(m, 1H), 4.80-4.65(m, 2H), 3.80(s, 3H), 3.25-2.75(m, 3H),2.40-2.10(m, 5H), 1.75-1.45(m, 5H), 1.12(d, J=6.6Hz, 3H) LCMS (ES, m/z):486 $[M+H]^+$.
644	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(m-tolyl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, *J* = 9.2 Hz, 1H), 7.36 (d, *J* = 8.8 Hz, 1H), 7.23-7.11 (m, 2H), 7.12-7.03 (m, 2H), 4.80-4.67 (m, 1H), 4.52-4.38 (m, 1H), 4.26-4.15 (m, 1H), 3.98-3.87 (m, 2H), 3.76 (s, 3H), 3.71-3.59 (m, 1H), 3.59-3.44 (m, 1H), 3.35-3.33 (m, 1H), 3.21-3.05 (m, 2H), 2.98-2.85 (m, 1H), 2.52-2.34 (m, 1H), 2.30 (s, 3H), 2.28-2.16 (m, 1H), 2.07-2.01 (m, 1H), 1.97-1.79 (m, 2H), 1.78-1.66 (m, 1H), 1.11 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.



645	 (1R,3R)-3-((S)-2-((6-chloropyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.62 (s, 1H), 8.53 (s, 1H), 7.53 (d, *J* = 9.3 Hz, 1H), 7.40 (d, *J* = 9.0 Hz, 1H), 4.87 (s, 1H), 4.75-4.73 (m, 1H), 3.76 (s, 3H), 3.31-3.29 (m, 1H), 2.92-2.86 (m, 2H), 2.33-2.20 (m, 6H), 1.75-1.69 (m, 6H), 1.13 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
646	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50-7.20 (m, 7H), 4.80-4.60 (m, 1H), 4.02-3.80 (m, 1H), 3.79 (s, 3H), 3.40-3.30 (m, 1H), 3.01-2.80 (m, 1H), 2.40-2.25 (m, 2H), 2.22-2.12 (m, 2H), 2.00-1.90 (m, 2H), 1.85 (s, 6H), 1.78-1.60 (m, 1H), 1.45-1.35 (m, 2H), 1.15 (d, *J* = 6.8 Hz, 3H), 1.12-0.97 (m, 2H). LCMS (ES, *m/z*): 490 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.58 – 7.50 (m, 3H), 7.43 – 7.32 (m, 3H), 7.32 – 7.24 (m, 1H), 5.25 – 5.18 (m, 1H), 5.05 – 4.94 (m, 1H), 4.82 –



647	 3-((7S)-2-(2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	4.71 (m, 1H), 3.79 (s, 3H), 3.50 – 3.40 (m, 1H), 3.30 – 3.23 (m, 1H), 3.23 – 3.14 (m, 1H), 2.99 – 2.88 (m, 2H), 2.41 – 2.32 (m, 2H), 2.31 – 2.18 (m, 3H), 1.97 – 1.84 (m, 2H), 1.81 – 1.70 (m, 2H), 1.69 – 1.56 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H).LCMS (ES, m/z): 492 $[M+H]^-$.
648	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52 (d, *J* = 9.0 Hz, 1H), 7.38 (d, *J* = 9.0 Hz,1H), 4.86-4.73 (m, 2H), 3.98-3.95 (m, 2H), 3.78 (m, 3H), 3.49-3.40 (m, 2H), 3.34-3.11 (m, 1H), 3.07-2.87 (m, 4H), 2.45-2.24 (m, 5H), 1.94-1.63 (m, 10H), 1.43-1.38 (m, 2H), 1.14 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 484 $[M+H]^+$.




649	 3-((7S)-2-((3,5-difluoro-2-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.90 (s, 2H), 7.42-7.38 (m, 1H), 7.15-7.10 (m, 1H), 6.51 (s, 1H), 5.09-5.02 (m, 1H), 4.88-4.86 (m, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 3.24-2.94 (m, 3H), 2.53-2.49 (m, 1H), 2.31-2.12 (m,4H), 1.92-1.89 (m, 1H), 1.81-1.71 (m, 2H), 1.56-1.37 (m, 2H), 1.19 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 544 $[M+H]^+$.
650	 (1R,3R)-3-((S)-2-(4-chlorophenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (ppm): 7.83-7.80 (m, 1H), 7.40-7.38 (m, 1H), 7.26-7.17 (m, 3H), 4.83-4.15 (m, 4H), 3.83 (s, 4H), 3.58-3.50 (m, 1H), 3.16 (s, 4H), 2.96 (s, 1H), 2.33-1.91 (m, 7H), 1.36-1.26 (m, 2H), 1.14 (d, *J* = 6.3 Hz, 3H). LCMS (ES, *m/z*): 510 $[M+H]^+$.
651	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.58-7.42 (m, 4H), 5.60-5.40 (m, 1H), 4.90-4.44 (m, 3H), 4.02-3.91 (m, 1H), 3.77 (s, 3H), 3.65-3.15 (m, 5H), 2.98-2.80 (m, 2H), 2.62-2.52 (m, 1H), 2.32-2.18 (m, 1H), 1.75-1.68 (m, 1H), 1.43 (d, *J*=6.9 Hz, 3H), 1.13 (d, *J*=6.6 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.
652		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.32-8.30 (m, 1H), 8.20-8.09 (m, 2H), 7.57 (d, *J* = 9.2 Hz, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.09 (t, *J* = 7.2 Hz, 1H), 5.46-5.30 (m, 1H), 4.81-4.70 (m, 1H), 3.95 (s,


652	(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(methyl(pyridin-2-yl)amino)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	3H), 3.78 (s, 3H), 3.27-3.09 (m, 2H), 3.02-2.89 (m, 1H), 2.56-2.19 (m, 4H), 2.13-1.42 (m, 10H), 1.10 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 518 $[M+H]^+$.
653	 4-((7S)-2-(1-(3-fluoro-4-methoxyphenyl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48-7.26 (m, 2H), 7.12-6.89 (m, 3H), 4.80-4.70 (m, 1H), 4.65-4.52 (d, J = 7.6 Hz, 1H), 4.32-4.21 (m, 1H), 3.85 (s, 3H), 3.79 (s, 3H), 3.12-2.91 (m, 1H), 2.49-2.19 (m, 3H), 2.20-2.00 (m, 2H), 2.00-1.89 (m, 1H), 1.88-1.62 (m, 5H), 1.61-1.47 (m, 1H), 1.45-1.27 (m, 2H), 1.17 (d, J = 6.4 Hz, 3H), 1.11-0.96 (m, 1H). LCMS (ES, m/z): 524 $[M+H]^+$.
654	 3-((7S)-2-((2,3-dihydrofuro[2,3-c]pyridin-5-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.05-7.93 (s, 1H), 7.64 (d, J = 4.0 Hz, 1H), 7.52-7.49 (m, 1H), 7.42-7.31 (m, 1H), 6.17 (s, 1H), 4.82-4.71 (m, 2H), 4.70-4.45 (m, 2H), 3.78 (s, 3H), 3.21 (m, 1H), 3.29-3.27 (m, 1H), 3.20-3.15 (m, 1H), 3.05-2.94 (m, 2H), 2.50-2.31 (m, 2H), 2.26-2.20 (m, 1H), 2.16-2.03 (m, 2H), 1.74-1.70 (m, 1H), 1.70-1.61 (m, 2H), 1.33 (m, 1H), 1.21-1.11 (m, 4H). LCMS (ES, m/z): 521 $[M+H]^+$.
655	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.51-7.39 (m, 1H), 7.39-7.24 (m, 2H), 7.19-7.01 (m, 1H), 4.81-4.63 (m, 1H), 4.63-4.48 (m, 1H), 4.43-4.38 (m, 1H), 4.24-4.18 (m, 1H),4.01-3.81 (m, 1H), 3.76 (s, 3H), 3.29-3.11 (m, 1H), 3.02-2.82 (m, 1H), 2.62-2.39 (m, 1H), 2.39-2.01 (m, 5H), 2.00-1.80 (m, 4H), 1.80-1.51 (m, 3H), 1.43 (d, J – 6.9 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H). LCMS: (ES, m/z):494 $[M+H]^+$.
656	 (1S,4R)-4-((S)-2-(3-chloro-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.87 (d, J = 9.3 Hz, 1H), 7.62 (d, J = 9.3 Hz, 1H), 7.11 (s, 1H), 7.05 – 6.97 (m, 2H), 4.78 – 4.51 (m, 4H), 3.77 (s, 3H), 3.71 (s, 3H), 3.14 – 2.87 (m, 2H), 2.61 – 2.53 (m, 1H), 2.29 – 2.07 (m, 3H), 2.04 – 1.95 (m, 2H), 1.86 – 1.74 (m, 1H), 1.65 – 1.41 (m, 4H), 1.09 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 526 $[M+H]^+$.
657		^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.55 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 4.81–4.76 (m, 2H), 3.79 (s, 3H), 3.58–3.53 (m, 1H), 3.33–3.23 (m, 2H), 3.17–3.14 (m, 1H), 2.94–2.89 (m, 1H), 2.74–2.68 (m, 1H), 2.49–2.30 (m, 2H), 2.28–





	3-((7S)-2-((2-hydroxycyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	2.24 (m, 3H), 2.02–1.92 (m, 1H), 1.79–1.76 (m, 3H), 1.75–1.73 (m, 3H), 1.64–1.62 (m, 3H), 1.41–1.21 (m, 3H), 1.16–1.12 (m, 4H). LCMS (ES, *m/z*): 484 [M+H]
658	 4-((7S)-2-(2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53-7.45 (m, 1H), 7.45-7.31 (m, 5H), 7.31-7.23 (m, 1H), 5.20-5.09 (m, 1H), 4.81-4.72 (m, 1H), 4.36-4.22 (m, 1H), 3.79 (s, 3H), 3.51-3.39 (m, 1H), 3.38-3.36 (m, 1H), 3.24-3.13 (m, 1H), 2.99-2.90 (m, 1H), 2.51-2.47 (m, 1H), 2.38-2.11 (m, 4H), 2.11-2.02 (m, 1H), 2.02-1.90 (m, 1H), 1.83-1.70 (m, 1H), 1.70-1.61 (m, 1H), 1.61-1.45 (m, 1H), 1.29-1.22 (m, 1H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.
659	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.48-7.39 (m, 2H), 7.36-7.30 (m, 2H), 6.95-7.02 (m, 1H), 6.87 (d, *J* = 7.8 Hz, 2H), 4.78-4.73(m, 1H), 4.17-4.07 (m, 1H), 3.80 (s, 3H), 3.47 (s, 3H), 3.20-3.12 (m, 1H), 2.94-2.87 (m, 1H), 2.42-2.26 (m, 4H), 2.23-2.06 (m, 2H), 1.81-1.70 (m, 3H), 1.38-1.31 (m, 2H), 1.17 (d, *J* =6.6 Hz, 3H). LCMS (ES, *m/z*): 477 $[M+H]^+$.
660	 3-((7S)-2-((5-fluoro-2-methoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.69-7.44 (m, 2H), 7.44-7.29 (m, 1H), 7.12-6.99 (m, 1H), 6.98-6.82 (m, 1H), 6.37(s, 1H), 5.03-4.91(m, 1H), 4.81-4.69(m, 1H), 3.78(s, 3H), 3.61(s, 3H), 3.22-3.04(m, 1H), 3.02-2.87 (m, 2H), 2.54-2.41 (m, 1H), 2.41-2.27 (m, 1H), 2.27-2.08 (m, 3H), 1.82-1.58 (m, 3H), 1.58-1.41 (m, 2H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 526 $[M+H]^+$





661	 (1S,4R)-4-((S)-2-(3-fluoro-2-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.85 (s, 2H), 7.28-7.16 (m, 3H), 4.90-4.89 (m, 1H), 4.68 (s, 2H), 4.56-4.54 (m, 1H), 3.87 (d, *J* = 2.7 Hz, 3H), 3.83 (s, 3H), 3.12-3.04 (m, 2H), 2.56-2.51 (m, 1H), 2.39-2.29 (m, 3H), 2.26-2.15 (m, 2H), 1.96-1.91 (m, 1H), 1.90-1.73 (m, 2H), 1.69-1.50 (m, 2H), 1.18 (d, *J* = 6.9 Hz, 3H). LCMS (ES, *m/z*): 510 $[M+H]^+$.
662	 3-((7S)-2-((5-fluoro-2-isopropoxyphenyl)(hydroxy)methyl)-6-	^{1}H NMR (CD_3OD,400 MHz) δ (ppm): δ 7.61 (m,1H), 7.52-7.42 (m, 2H), 7.05-6.98 (m, 1H), 6.90-6.85 (m, 1H), 6.32 (s, 1H), 4.96-4.85 (m, 1H), 4.81-4.76 (m, 1H), 4.49-4.43 (m, 1H), 3.79 (s, 3H), 3.20-3.16 (m, 1H), 2.98 – 2.85 (m, 2H), 2.51 – 2.35 (m, 2H), 2.29 – 2.07 (m, 3H), 1.78 – 1.60 (m, 3H), 1.50-1.39 (m, 2H), 1.18 (d, *J* = 6.8 Hz, 3H),


	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	1.12 (d, J = 6.0 Hz, 3H), 0.63 (d, J = 6.0 Hz, 3H). LCMS (ES, m/z): 554 $[M+H]^+$.
663	 (1R,3R)-3-((S)-2-((5-chloropyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.44 (s, 1H), 7.79 (d, *J* = 2.4 Hz, 1H), 7.54 (d, *J* = 2.4 Hz, 1H), 7.42 (d, *J* = 8.8 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 1H), 4.90-4.85(m, 1H), 4.80-4.75(m, 2H), 4.57-4.54(m, 1H), 3.79(s, 3H), 3.23-3.15(m, 1H), 2.98-2.92 (m, 2H), 2.41-2.28 (m, 5H), 1.65-1.80 (m, 4H), 1.46-1.43 (m, 1H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 497 $[M+H]^+$.
664	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-(2-oxopyrrolidin-1-yl)benzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.93 – 7.85 (m, 1H), 7.74 – 7.60 (m, 3H), 7.46 – 7.36 (m, 2H), 4.80 – 4.50 (m, 4H), 3.85 – 3.69 (m, 6H), 3.15-2.89 (m, 4H), 2.18 – 1.94 (m, 7H), 1.82 (s, 1H), 1.56 – 1.42 (m, 4H), 1.16 – 1.06 (m, 3H). LCMS (ES, m/z): 545 $[M+H]^+$.




665	 (1R,3R)-3-((S)-2-((6-cyclopropylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.56 (s, 1H), 8.50 (s, 1H), 7.94 – 7.83 (m, 2H), 4.99 (s, 2H), 4.87 – 4.76 (m, 2H), 3.84 (s, 3H), 3.14 – 2.99 (m, 3H), 2.48 – 2.34 (m, 2H), 2.31 – 2.18 (m, 3H), 2.17 – 2.08 (m, 1H), 1.95 – 1.75 (m, 4H), 1.52 – 1.40 (m, 1H), 1.7 (d, *J*=6.8 Hz, 3H), 1.03 – 0.95 (m, 2H), 0.78-1.72 (m, 2H). LCMS (ES, m/z): 504 $[M+H]^+$.
666	 3-((7S)-2-(1-(2-hydroxy-1H-indol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52-7.31 (m, 2H), 7.28-6.01 (m, 4H), 4.83-4.69 (m, 1H), 4.67-3.90 (m, 1H), 3.85-3.61 (m, 4H), 3.33-3.20 (m, 1H), 3.10-2.81 (m, 2H), 2.55-2.10 (m, 5H), 1.98-1.55 (m, 6H), 1.41-1.25 (m, 4H), 1.14 (d, *J* = 6.6 Hz, 3H). LCMS (ES, m/z): 531 $[M+H]^+$.
667	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51 (d, *J* = 9.2 Hz, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 4.81-4.68 (m, 2H), 4.02-3.91 (m, 1H), 3.78 (s, 3H), 3.55-3.38 (m, 2H), 3.26-3.10 (m, 2H), 3.07-2.93 (m, 2H), 2.52-2.34 (m, 2H), 2.33-2.15 (m, 3H), 2.12-1.89 (m, 3H), 1.88-1.79 (m, 2H), 1.78-1.63 (m, 4H), 1.62-1.45 (m, 3H), 1.42-1.25 (m, 2H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 484 $[M+H]^+$.



	yl)cyclohexane-1-carboxylic acid 1st eluting isomer	
668	 3-((7S)-2-(2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.88-7.80 (m, 2H), 7.48 – 7.34 (m, 5H), 5.16 – 5.00 (m, 2H), 4.87 – 4.82 (m, 1H), 4.80 – 4.70 (m, 1H), 4.55 – 4.47 (m, 1H), 3.83 (s, 3H), 3.22 – 2.97 (m, 3H), 2.54 – 2.42 (m, 1H), 2.32 – 2.13 (m, 4H), 1.99 – 1.87 (m, 1H), 1.82 – 1.68 (m, 2H), 1.49 – 1.39 (m, 1H), 1.34 – 1.23 (m, 1H), 1.18 (d, *J*=6.8H, 3H). LCMS (ES, m/z): 492 $[M+H]^+$.



669	 (1R,3R)-3-((S)-2-((5-chloropyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.56 (S, 1H), 8.50 (S, 1H), 7.55 (d, *J* = 9.0 Hz, 1H), 7.42 (d, *J* = 8.8 Hz, 1H), 4.89-4.68 (m, 4H), 3.78 (s, 3H), 3.24-3.09 (m, 1H), 2.97-2.80 (m, 2H), 2.45-2.13 (m, 5H), 1.86-1.60 (m, 4H), 1.60-1.41 (m, 1H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
670	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(N-methylphenylsulfonamido)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.95-7.75 (m, 2H), 7.75-7.71 (m, 1H), 7.78-7.72 (m,2H), 7.65-7.61 (m, 1H), 7.55-7.51 (m, 1H), 4.98-4.86 (m, 1H), 4.81-4.75 (m, 1H), 3.79(s, 3H), 3.32 (s, 3H), 3.13-2.96 (m, 2H), 2.89-2.79 (m, 1H), 2.51-2.48 (m, 1H), 2.45-2.20 (m, 4H) , 2.14-2.07 (m, 1H), 1.92-1.85 (m, 1H), 1.79-1.57 (m, 3H), 1.16 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 541 $[M+H]^-$.
671	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47 – 7.23 (m, 2H), 7.17 (s, 1H), 7.07 (s, 1H), 4.79 – 4.66 (m, 1H), 4.36 – 4.12 (m, 1H), 3.76 (s, 3H), 3.71 (s, 3H), 3.55 – 3.39 (m, 1H), 3.26 – 3.16 (m, 1H), 3.14 – 2.98 (m, 1H), 2.98 – 2.83 (m, 2H), 2.43 – 2.18 (m, 4H), 2.18 – 2.04 (m, 2H), 1.89 – 1.77 (m, 1H), 1.77 – 1.60 (m, 2H), 1.60 – 1.50 (m, 1H), 1.47 (d, *J* = 6.8 Hz, 3H), 1.19 – 1.03 (m, 4H). LCMS (ES, *m/z*): 494 $[M+H]^+$
672	 (1R,3R)-3-((S)-2-((1-cyclopropyl-1H-pyrazol-4-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61 (s, 1H), 7.48 (d, *J* = 9.2 Hz, 1H), 7.44-7.33 (m, 2H), 4.90-4.92 (m, 1H), 4.80-4.70 (m, 1H), 4.33-4.21 (m, 1H), 4.20-4.11 (m, 1H), 3.78 (s, 3H), 3.64-3.53 (m, 1H), 3.25-3.11 (m, 1H), 2.99-2.79 (m, 2H), 2.39-2.14 (m, 5H), 1.80-1.59 (m, 3H), 1.53-1.41 (m, 2H), 1.14 (d, *J* = 6.8 Hz, 3H), 1.06-0.94 (m, 4H). LCMS (ES, *m/z*): 492 $[M+H]^+$.





673	 4-((7S)-2-(1-(3-fluoro-4-methoxyphenyl)-2-methylpropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.50-7.38(m, 2H), 7.17-7.03(m, 3H), 4.85-4.72(m, 1H), 4.65-4.50(m, 1H), 4.12-4.00(m, 1H), 3.85(s, 3H), 3.80(s, 3H), 3.15-2.75(m, 2H), 2.55-1.70(m, 9H), 1.60-1.25(m, 2H), 1.17(d, *J*=6.6Hz, 3H), 1.11-1.08(m, 4H), 0.92(d, *J*=6.6Hz, 3H). LCMS (ES, m/z): 552 $[M+H]^-$
674	 3-((7S)-2-(2-cyclopentyl-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61 (d, *J* = 8.8 Hz, 1H), 7.48 (d, *J* = 9.2 Hz, 1H), 5.13-5.11 (m, 1H), 5.11-5.03 (m, 1H), 4.80-4.76 (m, 1H), 3.79 (s, 3H), 3.24 -2.88 (m, 3H), 2.56 2.18 (m, 5H), 2.12–1.94 (m, 4H), 1.90–1.69 (m, 7H), 1.55-1.52 (m, 2H), 1.33–1.26 (m, 3H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 484 $[M+H]^+$.
675	 (1R,3R)-3-((S)-2-(4-fluorobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.50 – 7.30 (m, 2H), 7.27 – 7.17 (m, 2H), 7.07 – 6.92 (m, 2H), 4.77 – 4.54 (m, 2H), 4.41 – 4.15 (m, 2H), 3.74 (s, 3H), 3.23 – 3.07 (m, 1H), 2.98 – 2.84 (m, 2H), 2.37 – 2.04 (m, 5H), 1.79 – 1.55 (m, 3H), 1.30 – 1.16 (m, 2H), 1.11 (d, *J* = 6.9 Hz, 3H). LCMS (ES, *m/z*): 480 $[M+H]^+$
676	 2-(3-(difluoromethyl)phenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.84-7.71 (m, 2H), 7.59-7.50 (m, 4H), 6.95-6.57 (m, 1H), 4.88-4.72 (m, 2H), 4.4-4.36 (m, 1H), 4.13-3.92 (m, 3H), 3.76 (s, 3H), 3.62-3.44 (m, 3H), 3.11-2.85 (m, 2H), 2.61-2.43 (m, 1H), 2.30-2.11 (m, 2H), 2.07-1.78 (m, 3H), 1.14 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.


677	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 508 $[M+H]^+$





678	 3-((7S)-2-((2-cyclopropoxy-5-fluorophenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.73-7.61 (m, 3H), 7.26-7.09 (m, 2H), 6.31 (s, 1H), 5.00-4.81 (m, 2H), 3.82 (s, 3H), 3.70-3.68 (m, 1H), 3.13-2.94 (m, 3H), 2.47-2.14 (m, 5H), 1.91-1.64 (m, 3H), 1.49-1.25 (m, 2H), 1.17 (d, J = 6.4 Hz, 3H), 0.59-0.55(m, 2H), 0.12-0.02 (m, 2H). LCMS (ES, *m/z*): 552 $[M+H]^+$.
679	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, J = 9.2 Hz, 1H), 7.38 (d, J = 9.2 Hz, 1H), 4.83-4.69 (m, 2H), 3.98-3.87 (m, 2H), 3.83-3.69 (m, 4H), 3.23-3.12 (m, 1H), 3.11-3.03 (m, 2H), 3.00-2.99 (m, 1H), 2.95-2.85 (m, 1H), 2.48-2.33 (m, 2H), 2.33-2.17 (m, 3H), 2.16-2.04 (m, 2H), 2.03-1.84 (m, 5H), 1.80-1.53 (m, 4H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.
680	 3-((7S)-3-(4-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.93 (d, J = 8.7 Hz, 2H), 7.45 – 7.31 (m, 3H), 7.27 – 7.14 (m, 3H), 7.13 – 7.01 (m, 2H), 6.87 (d, J = 90. Hz, 1H), 4.81-4.75 (m, 1H), 4.37 – 4.18 (m, 1H), 3.75 (s, 3H), 3.62 – 3.44 (m, 1H), 3.25 – 3.10 (m, 2H), 3.04 – 2.86 (m, 1H), 2.37 – 2.15 (m, 1H), 1.81 – 1.63 (m, 1H), 1.12 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 495 $[M+H]^+$


681	 (1R,3R)-3-((S)-2-((4-cyanophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 502 $[M+H]^+$
682	 3-((7S)-2-(hydroxy(4-methoxyphenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 7.48-7.45 (m, 1H), 7.31-7.24 (m, 3H), 6.89-6.86 (m, 2H), 6.21-6.16 (m, 1H), 5.97-5.96 (m, 1H), 4.83-4.75 (m, 1H), 4.68-4.63 (m, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 3.13-3.06 (m, 1H), 2.89-2.81 (m, 2H), 2.27-2.11 (m, 2H), 2.07-1.87 (m, 3H), 1.68-1.57 (m, 3H), 1.36-1.24 (m, 2H), 1.07 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 508 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.91-7.82





683	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 4th eluting isomer	(m, 2H), 5.09-5.05 (m, 1H), 4.35-4.29 (m, 1H), 4.90-4.07 (m, 1H), 3.82 (s, 3H), 3.61-3.58 (m, 1H), 3.53-3.47 (m, 1H), 3.41-3.36 (m, 2H), 3.15-3.04 (m, 3H), 2.57-2.54 (m, 1H), 2.46-2.40 (m, 2H), 2.37-2.20 (m, 4H), 2.04-2.01 (m, 2H), 1.92-1.89 (m, 3H), 1.81-1.78 (m, 3H), 1.70-1.59 (m, 4H) 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$
684	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, J = 9.0 Hz, 1H), 7.44 (d, J = 9.0 Hz, 1H), 7.32-7.18 (m, 3H), 7.17-7.10 (m, 1H), 5.39-5.23 (m, 1H), 4.80-4.67 (m, 2H), 4.66-4.58 (m, 3H), 4.56-4.46 (m, 1H), 3.88-3.64 (m, 4H), 3.26-3.13 (m, 1H), 3.03-2.92 (m, 1H), 2.91-2.84 (m, 1H), 2.48-2.34 (m, 1H), 2.33-2.09 (m, 4H), 1.82-1.60 (m, 4H), 1.58-1.44 (m, 1H), 1.23-1.10 (m, 3H). LCMS (ES, *m/z*): 531 $[M+H]^+$.



685	 4-((7S)-2-((R)-1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.54 (m, 1H), 7.45-7.41 (m, 1H), 5.18-5.16 (m, 1H), 5.02-4.96 (m, 1H), 4.77-4.74 (m, 1H), 3.79 (s, 3H), 3.42-3.40 (m, 1H), 3.21-3.18 (m, 1H), 2.92-2.88 (m, 1H), 2.62-2.58 (m, 1H), 2.53-2.39 (m, 2H), 2.31-2.25 (m, 3H), 2.07-1.96 (m, 3H), 1.81-1.69 (m, 5H), 1.62 (d, J = 8.0 Hz, 3H), 1.54-1.50 (m, 1H), 1.40-1.32 (m, 2H), 1.33-1.23 (m, 4H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 498 $[M+H]^+$.
686	 methyl (7S)-3-(azepan-4-yl)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46-7.32 (m, 4H), 4.84-4.71 (m, 1H), 4.70-4.55 (m, 2H), 4.55-4.44 (m, 1H), 4.05-3.91 (m, 1H), 3.79 (s, 3H), 3.52-3.36 (m, 3H), 3.30-3.16 (m, 2H), 3.04-2.91 (m, 1H), 2.70-2.60 (m, 1H), 2.51-2.37 (m, 1H), 2.34-2.04 (m, 3H), 2.03-1.86 (m, 1H), 1.82-1.67 (m, 1H), 1.65-1.51 (m, 1H), 1.47 (d, J = 7.2 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 485 $[M+H]^+$.
687	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-(trifluoromethyl)pyridazin-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 9.45 (s, 1H), 8.12(s, 1H), 7.56 (d, J = 9.2 Hz, 1H), 7.46 (d, J = 8.8 Hz, 1H), 4.84-4.74(m, 4H), 3.79(s, 3H), 3.33-3.25(m, 1H), 3.03-2.96 (m, 2H), 2.46-2.12 (m, 5H), 1.88-1.62 (m, 4H), 1.55-1.41 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 532 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 5.20–5.16 (m, 1H), 4.84–4.79 (m, 1H), 4.76–4.73 (m, 2H)



688	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-oxo-6-azaspiro[2.5]octan-6-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(m, 1H), 4.64–4.79 (m, 1H), 4.70–4.75 (m, 2H), 3.79 (s, 3H), 3.37–3.36 (m, 2H), 3.24–3.16 (m, 1H), 2.96–2.92 (m, 2H), 2.61-2.49 (m, 2H), 2.38–2.23 (m, 5H), 1.91–1.82 (m, 2H), 1.80–1.56 (m, 5H), 1.15 (d, J = 6.4 Hz, 3H), 0.47–0.41 (m, 4H). LCMS (ES, m/z): 509 $[M+H]^+$.




689	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 508 $[M+H]^+$
690	 (1R,3R)-3-((S)-2-(benzylamino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51-7.39 (m, 2H), 7.39-7.31 (m, 2H), 7.31-7.21 (m, 2H), 7.21-7.07 (m, 1H), 4.87(s, 2H), 4.64-4.46(m, 2H), 3.77(s, 3H), 3.19-3.03(m, 1H), 2.96-2.82 (m, 1H), 2.81-2.63 (m, 1H), 2.43-2.18 (m, 5H), 2.09-1.94 (m, 1H), 1.91-1.77 (m, 1H), 1.68-1.59 (m, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z):477 $[M+H]^+$
691	 (1S,4r)-4-((S)-2-((4-chlorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 511 $[M+H]^+$
692	 (1S,4r)-4-((S)-2-((cyclohexyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.60-7.51 (d, J = 8.8 Hz, 1H), 7.50-7.37 (d, J = 8.8 Hz, 1H), 4.87-4.69 (m, 3H), 4.65-4.48 (m, 1H), 3.79 (s, 3H), 3.58-3.48 (m, 1H), 3.23-3.07 (m, 1H), 3.00-2.88 (m, 1H), 2.56-2.48 (m, 1H), 2.47-2.32 (m, 2H), 2.32-2.16 (m, 3H), 2.12-1.88 (m, 4H), 1.81-1.61 (m, 5H), 1.59-1.48 (m, 1H), 1.46-1.23 (m, 5H), 1.21-1.03 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 484 $[M+H]^+$.


		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.10 (s, 1H), 7.99 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 5.21-5.19 (m, 1H), 4.86-4.72 (m,





693	 (1R,3R)-3-((S)-2-((6-isopropoxypyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	2H), 4.51-4.39 (m, 2H), 3.79 (s, 3H), 3.25-3.18 (m, 1H), 3.01-2.94 (m, 2H), 2.43-2.19 (m, 5H), 1.85-1.74 (m, 3H), 1.60 (m, 1H), 1.43 (m, 1H), 1.24-1.18 (m, 6H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 522 $[M+H]^+$
694	 (1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 477 $[M+H]^+$
695	 (1R,3R)-3-((S)-2-((6-cyclopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.93 – 7.83 (m, 2H), 7.81 – 7.73 (m, 1H), 7.19 (d, J = 7.6 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 5.01 (s, 2H), 4.83 – 4.69 (m, 2H), 3.83 (s, 4H), 3.13 – 2.95 (m, 3H), 2.43 – 2.17 (m, 5H), 1.97 – 1.87 (m, 1H), 1.87 – 1.68 (m, 3H), 1.46 – 1.35 (m, 1H), 1.17 (d, J = 6.4 Hz, 3H), 0.58 – 0.38 (m, 4H). LCMS (ES, m/z): 519 $[M+H]^+$.
696	 (1R,3R)-3-((S)-2-((4,4-dimethyl-2-oxopiperidin-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54-7.43(m, 2H), 5.15-5.05(m, 1H), 4.89-4.74(m, 3H), 3.79(s, 3H), 3.42-3.32(m, 2H), 3.19-3.15(m, 1H), 2.96-2.90(m, 2H), 2.46-2.18(m, 7H), 1.95-1.80 (m, 2H), 1.79-1.63(m, 5H), 1.15 (d, J=6.8 Hz, 3H), 1.07(s, 3H), 1.03(s, 3H). LCMS (ES, m/z): 511 $[M+H]^+$

697	 (1R,3R)-3-((S)-2-((5-(difluoromethoxy)pyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.41-8.35 (m, 2H), 7.60-7.58 (m, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 9.2 Hz, 1H), 7.18-6.73 (m, 1H), 4.86-4.70 (m, 2H), 4.56-4.41 (m, 2H), 3.79 (s, 3H), 3.27-3.13 (m, 1H), 3.04-2.90 (m, 2H), 2.42-2.09 (m, 5H), 1.86-1.62 (m, 3H), 1.56-1.29 (m, 2H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 529 $[M+H]^+$.
698		^{1}H-NMR (DMSO, 300 MHz) δ (ppm): 12.46 (br, 1H), 8.08 – 7.93 (m, 1H), 7.87 – 7.59 (m, 3H), 7.37 – 7.03 (m, 6H), 6.87 (d, J = 9.0 Hz, 1H), 4.70 – 4.51 (m, 1H), 4.38 – 4.17 (m, 1H), 3.62 (s, 3H), 3.49 – 3.37 (m, 1H), 3.17 – 2.93 (m, 2H), 2.93 –





	3-((7S)-3-(3-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 1st eluting isomer	2.75 (m, 1H), 2.22 – 2.04 (m, 1H), 1.76 – 1.48 (m, 1H), 1.04 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 495 $[M+H]^-$
699	 3-((7S)-2-((4,4-difluorocyclohexyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, *J* = 9.2 Hz, 1H), 7.42 (d, *J* = 9.2 Hz, 1H), 5.28-5.12 (m, 1H), 4.80-4.65 (m, 2H), 3.79(s, 3H), 3.23-3.15(m, 1H), 3.03-2.96 (m, 1H), 2.93-2.82 (m, 1H), 2.58-2.25 (m, 7H), 2.05-1.81 (m, 5H), 1.79-1.52 (m, 4H), 1.48-1.22 (m, 2H), 1.14 (d, *J* = 6.4 Hz, 3H), 1.13-1.09 (m, 1H). LCMS (ES, *m/z*): 520 $[M+H]^+$.
700	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.37 (m, 2H), 7.27-7.08 (m, 4H), 4.82-4.64 (m, 2H), 4.30-4.23 (m, 1H), 4.12-3.92 (m, 2H), 3.90-3.76 (m, 4H), 3.72-3.60 (m, 1H), 3.23-3.07 (m, 3H), 2.99-2.75 (m, 2H), 2.71-2.59 (m, 1H), 2.37-2.16 (m, 4H), 1.78-1.70 (m, 1H), 1.14 (d, *J* = 6.0 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.


701	 3-((7S)-2-(1,3-dihydroisobenzofuran-4-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62-7.42 (m, 2H), 7.42-7.33 (m, 1H), 7.32-7.16 (m, 1H), 7.06-6.87 (m, 1H), 6.57(s, 1H), 5.85-5.60(m, 1H), 5.36-5.14(m, 1H), 4.83-4.67(m, 3H), 4.41-4.19(m, 1H), 3.79(s, 3H), 3.31-3.16(m, 1H), 3.04-2.95 (m, 2H), 2.57-2.41 (m, 1H), 2.41-2.20 (m, 2H), 2.13-1.91 (m, 2H), 1.90-1.72 (m, 1H), 1.63-1.39 (m, 2H),1.31-1.11 (m, 4H),1.06-0.79 (m, 1H). LCMS (ES, *m/z*): 520 $[M+H]^+$
702	 (1R,3R)-3-((S)-2-((cyclohexyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.91-7.90 (m, 2H), 5.07-5.00 (m, 3H), 4.96-4.87 (m, 1H), 3.83 (s, 3H), 3.68-3.66 (m, 1H), 3.09-3.02 (m, 2H), 2.47-2.41 (m, 3H), 2.28-2.41(m, 2H), 2.08-1.90 (m, 5H), 1.89-1.78 (m, 3H), 1.74-1.33 (m, 8H), 1.17 (d, *J*=6.8, 3H).LCMS (ES, *m/z*): 484 $[M+H]^+$.
703	 (1S,4R)-4-((S)-2-(2-(4-chloro-1H-pyrazol-1-yl)ethoxy)-6-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.90 (s, 1H), 7.52 (s, 1H), 7.27-7.21 (m, 2H), 4.91-4.87 (m, 2H), 4.74–4.69 (m, 1H), 4.63-4.60 (m, 2H), 4.20–4.14 (m, 1H), 3.77 (s, 3H), 3.15–3.07 (m, 1H), 2.82–2.75 (m, 1H), 2.38–2.28 (m, 1H), 2.26–2.21 (m, 1H), 2.15-1.98 (m, 4H), 1.82-1.75 (m, 2H), 1.68–1.58 (m, 3H), 1.13 (d, *J* = 6.6 Hz, 3H).




	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 516 $[M+H]^+$
704	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(6-methylpyrazin-2-yl)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.27(s, 1H), 7.80(s, 1H), 7.58(d, *J*=8.8Hz, 1H), 7.48(d, *J*=8.8Hz, 1H), 4.79-4.76(m, 2H), 3.80(s, 3H), 3.33-2.90(m, 3H), 2.48-2.00(m, 8H), 1.99-1.37(m, 9H), 1.17(d, *J*=6.8Hz, 3H). LCMS (ES, m/z): 504 $[M+H]^+$



705	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, *J* = 9.2 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 4.82-4.69 (m, 2H), 4.07-3.94 (m, 1H), 3.93-3.84 (m, 1H), 3.83-3.70 (m, 4H), 3.23-3.08 (m, 2H), 3.07-2.97 (m, 2H), 2.95-2.85 (m, 1H), 2.51-2.34 (m, 2H), 2.33-2.19 (m, 3H), 2.15-2.02 (m, 2H), 2.01-1.84 (m, 5H), 1.81-1.55 (m, 4H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.
706	 (1S,4R)-4-((S)-2-(2-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.82 (d, *J*=7.6Hz, 1H), 7.62-7.40 (m, 4H), 7.26 (d, *J*=8.0 Hz, 1H), 4.80-4.70 (m, 1H), 4.65(s, 2H), 4.30-4.10 (m, 1H), 3.75(s, 3H), 3.25-3.10 (m, 1H), 2.98-2.85(m, 1H), 2.45-2.00(m, 6H), 1.75-1.40(m, 5H), 1.13(d, J=6.4Hz, 3H). LCMS (ES, *m/z*): 487 $[M+H]^+$.
707	 (1S,4R)-4-((S)-2-(3-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.75-7.63 (m, 2H), 7.63-7.37 (m, 4H), 4.84-4.69 (m, 1H), 4.49 (s, 2H), 4.32-4.18 (m, 1H), 3.79 (s, 3H), 3.29-3.12 (m, 1H), 3.04-2.91 (m, 1H), 2.51-2.36 (m, 1H), 2.34-2.16 (m, 3H), 2.15-2.00 (m, 2H), 1.85-1.69 (m, 1H), 1.63-1.41 (m, 4H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 487 $[M+H]^+$.
708	 4-((7S)-2-(hydroxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.28 (m, 7H), 6.25(s, 1H), 4.84-4.74(m, 1H), 4.68-4.54(m, 1H), 3.79(s, 3H), 3.33-3.18(m, 1H), 3.03-2.96 (m, 1H), 2.46-2.12 (m, 4H), 2.05-1.72 (m, 4H), 1.59-1.45 (m, 1H), 1.16 (d, *J* = 6.6 Hz, 3H), 1.14-1.02 (m, 1H), 0.99-0.87 (m, 1H). LCMS (ES, *m/z*): 478 $[M+H]^+$.



	1st eluting isomer	




709	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.59-7.40 (m, 4H), 5.60-5.40 (m, 1H), 4.92-4.42 (m, 3H), 4.02-3.88 (m, 1H), 3.75-3.35 (m, 6H), 3.32-3.15 (m, 2H), 3.30-2.91 (m, 2H), 2.32-2.24 (m, 2H), 1.73-1.68 (m, 1H), 1.40 (d, *J*=6.9 Hz, 3H), 1.12 (d, *J*=6.6 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.
710	 (1S,4R)-4-((S)-2-(1-((1H-pyrazol-1-yl)methyl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.44 (m, 3H), 7.37 (d, *J* = 8.8 Hz, 1H), 6.27-6.25 (m, 1H), 4.81-4.67 (m, 1H), 4.48-4.38 (m, 3H), 3.77 (s, 3H), 3.22-3.07 (m, 1H), 2.98-2.81 (m, 1H), 2.46-2.17 (m, 4H), 2.12-2.08 (m, 2H), 1.83-1.50 (m, 5H), 1.49-1.37 (m, 2H), 1.26-1.17 (m, 2H), 1.12 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^-$.
711	 (1R,3R)-3-((S)-2-((cyclopentyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.77-7.56 (m, 1H), 7.47-7.45 (m, 1H), 4.91-4.82 (m, 2H), 4.79-4.65 (m, 1H), 4.18-4.09 (m, 1H), 3.79 (s, 3H), 3.20-3.14 (m, 1H), 2.99-2.92 (m, 2H), 2.47-2.26 (m, 5H), 1.98-1.45 (m, 14H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.
712	 3-((7S)-2-(2-(4,4-difluorocyclohexyl)-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63-7.49 (m, 1H),7.46-7.28 (m, 1H),5.32-5.11(m, 1H), 5.11-4.97(m, 1H), 4.82-4.63(m, 1H), 3.78(s, 3H), 3.28-3.17 (m, 1H), 3.06-2.88 (m, 2H), 2.63-2.32 (m, 2H), 2.32-2.18 (m, 3H), 2.11-1.89 (m, 8H), 1.84-1.66 (m, 6H), 1.49-1.33 (m, 2H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 534 $[M+H]^+$.


713	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(tetrahydro-2H-pyran-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.98-7.78 (m, 2H), 5.14-5.12 (m, 1H), 4.01-3.88 (m, 2H), 3.88-3.69 (m, 4H), 3.50-3.38 (m, 2H), 3.30-3.20 (m, 1H), 3.21-3.06 (m, 2H), 3.06-2.93 (m, 1H), 2.67-2.40 (m, 2H), 2.40-2.18 (m, 3H), 2.12-1.93 (m, 3H), 1.93-1.73 (m, 4H), 1.67-1.61 (m, 3H), 1.56 (d, *J* = 6.8 Hz, 3H), 1.50-1.29 (m, 2H), 1.18 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 498 $[M+H]^+$.





	1st eluting isomer	
714	 (1S,4R)-4-((S)-2-((4-isopropyl-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61 – 7.30 (m, 4H), 5.76 – 5.53 (m, 2H), 4.83 – 4.69 (m, 1H), 4.53 – 4.30 (m, 1H), 3.79 (s, 3H), 3.27 – 3.13 (m, 1H), 3.04 – 2.93 (m, 1H), 2.93 – 2.78 (m, 1H), 2.59 – 2.38 (m, 1H), 2.31 – 1.99 (m, 5H), 1.87 – 1.71 (m, 1H), 1.71 – 1.47 (m, 4H), 1.20 (d, *J*=6.8 Hz, 6H), 1.15 (d, *J*=6.8 Hz, 6H). .LCMS (ES, *m/z*): 494 $[M+H]^-$
715	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylsulfonamido)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.01-7.95 (m, 2H), 7.59-7.52(m, 3H), 7.49-7.43 (m, 1H), 7.38-7.31 (m, 1H), 4.92-4.83 (m, 1H), 4.79-4.71 (m, 1H), 3.79 (s, 3H), 3.03-2.96 (m, 1H), 2.90-2.82 (m, 1H), 2.79-2.71 (m, 1H), 2.45-2.39 (m, 1H), 2.38-2.21 (m, 4H), 1.89-1.72 (m, 3H), 1.64-1.52 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 527 $[M+H]^+$.
716	 (1R,3R)-3-((S)-2-((6-cyclopropoxypyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.17(s, 1H), 8.09(s, 1H), 7.54(d, *J*=9.2Hz, 1H), 7.42(d, *J*=9.2Hz, 1H) 4.88-4.54(m, 3H), 4.23-4.21(m, 1H), 3.78(s, 3H), 3.19-2.92(m, 3H), 2.39-2.10(m, 6H), 1.81-1.69(m, 4H), 1.45-1.42(m, 1H), 1.15(d, *J*=6.4 Hz, 3H), 6.70-0.67(m, 4H). LCMS (ES, m/z): 520 $[M+H]^+$

717	 4-((7S)-2-(acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52-7.28 (m, 7H), 6.57 (s, 1H), 4.81-4.67 (m, 1H), 4.36-4.19 (m, 1H), 3.79 (s, 3H), 3.30-3.21 (m, 1H), 3.04-2.88 (m, 1H), 2.50-1.88 (m, 10H), 1.82-1.57 (m, 2H), 1.38-1.24 (m, 1H), 1.22-1.01 (m, 4H). LCMS (ES, m/z): 519 $[M+H]^-$
718	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(3-methylbenzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.51-7.41(m, 2H), 7.17-7.03(m, 4H), 4.77-4.69(m, 2H), 4.43-4.29(m, 2H), 3.76(s, 3H), 3.21-3.14(m, 1H), 2.99-2.92(m, 2H), 2.43-2.03(m, 8H), 1.77-1.57(m, 3H), 1.28-1.12(m, 5H). LCMS (ES, *m/z*): 476 $[M+H]^+$.





719	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((3-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 493 $[M+H]^+$
720	 3-((7S)-2-(1-(3,4-difluorophenyl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50-7.42 (d, *J* = 9.2 Hz, 1H), 7.36-7.26 (d, *J* = 8.8 Hz, 1H), 7.24-7.13 (m, 1H), 7.16-7.01 (m, 2H), 5.01-4.89 (m, 1H), 4.77-4.66 (m, 1H), 3.76 (s, 3H), 3.71-3.54 (m, 1H), 3.42-3.51 (m, 1H), 3.22-3.10 (m, 1H), 3.04-2.75 (m, 3H), 2.45-2.21 (m, 4H), 2.15-1.96 (m, 1H), 1.95-1.78 (m, 2H), 1.78-1.62 (m, 3H), 1.34 (d, *J* = 6.8 Hz, 3H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 526 $[M+H]^+$.



721	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, *J* = 9.2 Hz, 1H), 7.39 (d, *J* = 9.2 Hz, 1H), 4.82-4.69 (m, 2H), 4.02-3.91 (m, 1H), 3.78 (s, 3H), 3.51-3.39 (m, 1H), 3.24-3.14 (m, 1H), 3.13-3.01 (m, 2H), 3.01-2.98 (m, 1H), 2.94-2.84 (m, 1H), 2.52-2.34 (m, 2H), 2.34-2.17 (m, 3H), 2.10-1.82 (m, 5H), 1.79-1.63 (m, 4H), 1.62-1.45 (m, 3H), 1.43-1.25 (m, 2H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 484 $[M+H]^+$.
722	 3-((7S)-2-(1-(2-hydroxy-1H-indol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.62-7.39 (m, 2H), 7.23-7.11 (m, 1H), 6.95-6.23 (m, 3H), 4.83-4.71 (m, 1H), 4.45-3.98 (m, 1H), 3.85-3.63 (m, 4H), 3.33-3.15 (m, 1H), 2.93-2.75 (m, 2H), 2.61-2.12 (m, 5H), 2.10-1.55 (m, 6H), 1.41-1.30 (m, 4H), 1.25-1.12 (m, 3H). LCMS (ES, m/z): 531 $[M+H]^+$.
723	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-(((1R,4R)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.49-7.34(m, 2H), 4.88-4.72(m, 2H), 3.76(s, 3H), 3.32-3.00(m, 5H), 2.93-2.86(m, 4H), 2.42-2.06(m, 7H), 1.89-1.66(m, 8H), 1.32-1.11(m, 7H). LCMS (ES, m/z): 498 $[M+H]^-$.
		^{1}H NMR (400 MHz, CD_3OD) δ (ppm): 7.60 (d, *J* =



724	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	9.2 Hz, 1H), 7.45 (d, *J* = 8.8 Hz, 1H), 5.19–5.17(m, 1H), 4.96–4.93 (m, 1H), 4.88–4.76 (m, 1H), 3.96–3.93 (m, 1H), 3.89–3.87 (m, 1H), 3.79 (s, 3H), 3.64–3.62 (m, 1H), 3.47–3.38 (m, 2H), 3.16–3.14 (m, 1H), 2.94–2.90 (m, 1H), 2.54–2.41 (m, 3H), 2.27–2.24 (m, 3H), 2.06–1.97 (m, 3H), 1.81–1.76 (m, 1H), 1.74–1.55 (m, 8H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^+$




725	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-((1R)-(methylsulfinyl)(phenyl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 7.66-7.21 (m, 7H), 6.11-5.79 (m, 1H), 4.74-4.57 (m, 1H), 4.55-4.24 (m, 1H), 3.67 (d, *J* = 5.7 Hz, 3H), 3.21-3.00 (m, 1H), 2.97-2.82 (m, 1H), 2.65 (s, 1H), 2.45 (s, 2H), 2.39-2.09 (m, 3H), 2.09- 1.89 (m, 3H), 1.87-1.73 (m, 1H), 1.73-1.40 (m, 2H), 1.31-1.18 (m, 1H), 1.09 (d, *J* = 6.4 Hz, 3H), 0.89-0.73 (m, 1H). LCMS (ES, *m/z*): 524 $[M+H]^+$.
726	 3-((7S)-2-((4-cyanocyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, *J* = 8.8 Hz, 1H), 7.37 (d, *J* = 8.8 Hz, 1H), 4.81-4.75(m, 2H), 3.78 (s, 3H), 3.18-3.15 (m, 1H), 3.08-3.06 (m, 1H), 2.97-2.89 (m, 4H), 2.42-2.32 (m, 2H), 2.31-2.24 (m, 3H), 2.03-1.88 (m, 6H), 1.85-1.80 (m, 1H), 1.75-1.70 (m, 5H), 1.51-1.47 (m, 2H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 493 $[M+H]^-$.
727	 (1S,4r)-4-((S)-2-((3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 508 $[M+H]^+$
728	 2-(3-fluorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.47-7.19(m, 5H), 7.17-7.14(m, 1H), 4.74-4.47(m, 2H), 4.18-3.97(m, 4H), 3.75-3.45(m, 5H), 3.42-3.28(m, 2H), 2.89-2.84(m, 1H), 2.21-2.20(m, 2H), 1.76-1.67(m, 3H), 1.45-1.35(m, 1H),1.12(d, *J* =6.6Hz, 3H). LCMS (ES, *m/z*): 496 $[M+H]^+$.


		^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52 (d, *J* =





729	 4-((7S)-6-(methoxycarbonyl)-2-((4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	9.0 Hz, 1H), 7.38 (d, *J* = 9.0 Hz, 1H), 4.83-4.67 (m, 1H), 4.44-4.29 (m, 1H), 3.78 (s, 3H), 3.52-3.43 (m, 1H), 3.25-3.11 (m, 1H), 2.98-2.83 (m, 3H), 2.55-2.37 (m, 3H), 2.33-2.15 (m, 4H), 2.05-1.84 (m, 5H), 1.81-1.62 (m, 4H), 1.60-1.36 (m, 7H), 1.14 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
730	 3-((7S)-2-(2-(4-chloro-1H-pyrazol-1-yl)-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.85 (s, 1H), 7.55 (d, *J* = 8.8 Hz, 1H), 7.49-7.39 (m, 2H), 5.45-5.35 (m, 1H), 5.06-4.93 (m, 1H), 4.85-4.67 (m, 3H), 3.79 (s, 3H), 3.29-3.17 (m, 1H), 3.00-2.89 (m, 2H), 2.49-2.16 (m, 4H), 2.04-1.95 (m, 1H), 1.93-1.82 (m, 1H), 1.79-1.61 (m, 3H), 1.36-1.28 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 516 $[M+H]^+$.
731	 3-((7S)-2-((5-chloropyridin-2-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.46 (s, 1H), 8.05-8.01 (m, 1H), 7.95-7.89 (m, 1H), 7.88-7.80 (m, 2H), 6.53 (s, 1H), 5..2-4.88 (m, 1H), 4.85-4.80 (m, 1H), 3.83 (s, 3H), 3.18-2.95 (m, 3H), 2.53-2.10 (m, 5H), 2.02-1.62 (m, 4H), 1.59-1.45 (m, 1H), 1.18 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 513 $[M+H]^+$.
732	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54 – 7.48 (m, 1H), 7.42 – 7.35 (m, 1H), 4.80 – 4.67 (m, 1H), 4.50 – 4.45 (m, 1H), 4.41 – 4.31 (m, 1H), 3.78 (s, 3H), 3.75 – 3.56 (m, 2H), 3.56 – 3.40 (m, 2H), 3.30 – 3.19 (m, 1H), 3.01-2.97 – 2.86 (m, 2H), 2.56 – 2.44 (m, 1H), 2.34 – 2.21 (m, 4H), 2.13 – 2.00 (m, 2H), 1.97 – 1.83 (m, 4H), 1.82 – 1.62 (m, 5H), 1.56 – 1.42 (m, 1H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 497 $[M+H]^+$.

733	 (1S,4R)-4-((S)-2-((4-cyclopropyl-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86 – 7.81 (m, 2H), 7.68 (s, 1H), 7.38 (s, 1H), 5.96 – 5.82 (m, 2H), 4.90 – 4.82 (m, 1H), 4.70 – 4.57 (m, 1H), 3.82 (s, 3H), 3.19 – 3.07 (m, 1H), 3.07 – 2.96 (m, 1H), 2.61 – 2.51 (m, 1H), 2.40 – 2.14 (m, 5H), 1.97 – 1.85 (m, 1H), 1.82 – 1.72 (m, 2H), 1.71 – 1.53 (m, 3H), 1.17 (d, *J* = 6.4 Hz, 3H), 0.94 – 0.82 (m, 2H), 0.57 – 0.49 (m, 2H). LCMS (ES, m/z): 492 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.40-7.20 (m, 2H), 7.18-7.05 (m, 3H), 7.10-6.98 (m, 2H), 4.79-4.66 (m, 1H), 4.37-4.33 (m, 1H), 3.77 (s, 3H),





734	 methyl 3-((7S)-azepan-4-yl)-7-methyl-2-(1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	3.64-3.51 (m, 1H), 3.29-3.02 (m, 4H), 3.02-2.78 (m, 3H), 2.70-2.58 (m, 1H), 2.49-2.32 (m, 1H), 2.32-2.14 (m, 2H), 1.98-1.62 (m, 4H), 1.53 (d, J = 6.8 Hz, 3H), 1.12 (d, J = 6.4 Hz, 3H), 0.79-0.75 (m, 1H). LCMS (ES, m/z): 461 $[M+H]^+$.
735	 4-((7S)-2-(hydroxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47-7.28 (m, 7H), 6.25(s, 1H), 4.84-4.74(m, 1H), 4.68-4.54(m, 1H), 3.79(s, 3H), 3.33-3.18(m, 1H), 3.08-2.96 (m, 1H), 2.46-1.72 (m, 8H), 1.59-1.45 (m, 1H), 1.16 (d, J = 6.6 Hz, 3H), 1.14-1.05 (m, 1H), 1.01-0.87 (m, 1H). LCMS (ES, m/z): 478 $[M+H]^+$.
736	 methyl 2-((7S)-1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53 (s, 1H), 7.51-7.40(m, 3H), 5.08-4.94 (m, 1H), 4.82-4.71 (m, 1H), 4.66-4.52 (m, 1H), 4.52-4.38(m, 1H), 3.99-3.85 (m, 1H), 3.79 (s, 3H), 3.43-3.36 (m, 4H), 3.29-3.14 (m, 1H), 3.08-2.89 (m, 3H), 2.72-2.54 (m, 1H), 2.54-2.38 (m, 1H), 2.38-2.21 (m, 3H), 1.83-1.67 (m, 1H), 1.43 (d, J=6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 497 $[M+H]^+$.


737	 (1S,4R)-4-((S)-2-((4-chloro-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.82 (s, 1H), 7.54-7.43 (m, 3H), 5.73-5.63 (m, 2H), 4.78-4.75 (m, 1H), 4.59-4.55 (m, 1H), 3.76 (s, 3H), 3.18-3.13 (m, 1H), 2.99-2.93 (m, 1H), 2.51-2.45 (m, 1H), 2.32-2.20 (m, 3H), 2.13-2.09 (m, 2H), 1.77-1.71 (m, 2H), 1.67-1.58 (m, 3H), 1.12 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 486 $[M+H]^+$.
738	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-methylpyrazin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.48(s, 1H), 8.41(s, 1H), 7.53-7.38(m, 2H), 4.77-4.55(m, 4H), 3.75(s, 3H), 3.25-2.85(m, 3H), 2.50(s, 3H), 2.40-2.15(m, 5H), 1.80-1.45(m, 5H), 1.13(d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 478 $[M+H]^+$.
739	 (1R,3R)-3-((S)-2-((2,2-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57 (d, J = 8.8 Hz, 1H), 7.47 (d, J = 9.2 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.32-7.22 (m, 1H), 7.06-7.02 (m, 2H), 5.18-5.05 (m, 1H), 5.02-4.91 (m, 2H), 4.82-4.68 (m, 2H), 4.56-4.43 (m, 1H), 3.79 (s, 3H), 3.28-3.16




	(1R,3R)-3-((S)-2-((2,2-dioxidobenzo[c]isothiazol-1(3H)-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(m, 1H), 3.05-2.80 (m, 2H), 2.50-2.41 (m, 1H), 2.38-2.14 (m, 4H), 2.03-1.88 (m, 1H), 1.86-1.72 (m, 2H), 1.68-1.65 (m, 2H), 1.16 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 553 $[M+H]^+$.
740	 (1S,4R)-4-((S)-2-(3,4-dimethoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.49 – 7.30 (m, 2H), 6.97 – 6.84 (m, 2H), 6.82 – 6.69 (m, 1H), 4.80 – 4.68 (m, 1H), 4.37 – 4.24 (m, 3H), 3.82 – 3.71 (m, 9H), 3.27 – 3.11 (m, 1H), 3.02 – 2.86 (m, 1H), 2.50 – 2.31 (m, 1H), 2.31 – 2.12 (m, 3H), 2.12 – 1.97 (m, 2H), 1.81 – 1.66 (m, 1H), 1.60 – 1.31 (m, 4H), 1.14 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 522 $[M+H]^+$



741	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.57 (d, *J* = 9.0 Hz, 1H), 7.46 (d, *J* = 9.0 Hz, 1H), 5.01-4.89 (m, 2H), 4.83-4.67 (m, 2H), 4.03-3.85 (m, 2H), 3.84-3.68 (m, 4H), 3.58-3.43 (m, 2H), 3.27-3.09 (m, 1H), 3.06-2.89 (m, 2H), 2.56-2.15 (m, 5H), 2.09-1.86 (m, 4H), 1.82-1.49 (m, 5H), 1.14 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 486 $[M+H]^+$.
742	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.42(d, J = 8.8 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.29-7.27(m, 1H), 7.27-7.22 (s, 1H), 4.73-4.70 (m, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 3.55-3.53 (m, 1H), 3.30-3.21 (m, 1H), 3.05-3.02 (m, 1H), 3.00-2.86 (m, 2H), 2.86-2.77 (m, 1H), 2.29-2.19 (m, 6H), 1.88-1.50 (m, 7H), 1.15-1.12 (d, J = 6.8Hz, 3H). LCMS (ES, m/z): 494 [M+H]+.
743	 (S)-2-(2-(6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)ethyl)benzoic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86 (d, *J* = 7.8 Hz, 1H), 7.53 – 7.47 (m, 1H), 7.47 – 7.40 (m, 1H), 7.40 – 7.33 (m, 1H), 7.33 – 7.22 (m, 2H), 4.85 – 4.73 (m, 2H), 4.13 – 4.04 (m, 2H), 3.79 (s, 3H), 3.74 – 3.66 (m, 2H), 3.43 – 3.35 (m, 4H), 3.25 – 3.12 (m, 1H), 3.00 – 2.88 (m, 1H), 2.66 – 2.40 (m, 2H), 2.30 – 2.20 (m, 1H), 1.86 – 1.51 (m, 3H), 1.14 (d, *J* = 6.8 Hz, 3H).LCMS (ES, m/z): 478 $[M+H]^+$.
744	 (1S,4R)-4-((S)-2-(4-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.71(d, *J*=8.4Hz, 2H), 7.49-7.40(m, 4H), 4.85-4.70(m, 1H), 4.50(s, 2H), 4.30-4.10(m, 1H), 3.75(s, 3H), 3.25-3.10(m, 1H), 3.00-2.90(m, 1H), 2.45-2.00(m, 6H),1.75-1.35(m, 5H), 1.14(d, *J*=6.4Hz, 3H). LCMS (ES, *m/z*): 487 $[M+H]^+$.



	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	




745	 (1R,3R)-3-((S)-2-((5-chloro-6-methylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.50 (s, 1H), 7.96-7.84 (m, 2H), 5.05-4.95 (m, 2H), 4.87-4.77 (m, 2H), 3.83 (s, 3H), 3.14-2.94 (m, 3H), 2.53 (s, 3H), 2.50-2.37 (m, 2H), 2.35-2.17 (m, 3H), 2.05-1.79 (m, 4H), 1.60-1.39 (m, 1H), 1.23-1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 512 $[M+H]^-$.
746	 methyl 2-((7S)-1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(7-azaspiro[3.5]nonan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49-7.37(m, 4H), 4.82-4.70(m, 2H), 4.60-4.40(m, 2H), 3.88-3.80(m, 1H), 3.75(s, 3H), 3.25-3.15(m, 1H), 2.98-2.70(m, 5H), 2.60-2.38(m, 3H), 2.35-2.15(m, 2H), 1.80-1.75(m, 5H), 1.40(d, J=6.8Hz, 3H), 1.13(d, J=6.8Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$.
747	 3-((7S)-2-((4,4-difluorocyclohexyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 5.03-4.90 (m, 1H), 4.80-4.65 (m, 2H), 3.79(s, 3H), 3.23-3.15(m, 1H), 3.03-2.96 (m, 1H), 2.93-2.82 (m, 1H), 2.45-2.32 (m, 2H), 2.30-2.03 (m, 6H), 2.02-1.62 (m, 8H), 1.60-1.45 (m, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 520 $[M+H]^+$.
748	 (S)-2-((3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methoxy)benzoic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.04-7.92 (m, 1H),7.92-7.82 (m, 2H), 7.73-7.59 (m, 1H), 7.48-7.33 (m, 1H), 7.28-7.12 (m, 1H), 5.85(s, 2H), 4.87-4.85(m, 1H),4.75-4.51(m, 1H), 3.83(s, 3H), 3.28-3.01(m, 2H), 2.43-2.19 (m, 3H), 2.19-2.07 (m, 2H), 2.07-1.97 (m, 2H), 1.97-1.88 (m, 1H), 1.88-1.76 (m, 1H), 1.71-1.42 (m, 3H), 3 1.18 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 478 $[M+H]^+$


749	 3-((7S)-2-(1-hydroxy-1-(pyridin-2-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.52-8.50 (m, 1H), 8.00-7.92 (m, 1H), 7.90-7.62 (m, 3H), 7.60-7.31 (m, 1H), 4.852-4.76 (m, 2H), 3.83-3.72 (m, 3H), 3.30-3.21 (m, 1H), 3.07 (m, 1H), 2.87-2.84 (m, 1H), 2.47-2.39 (m, 1H), 2.35-2.28 (m, 4H), 2.18-2.02 (m, 2H), 2.00-1.85 (m, 2H), 1.85-1.67 (m, 2H), 1.59-1.52 (m, 1H), 1.20-1.11 (m,





	imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	4H). LCMS (ES, *m/z*): 495 $[M+H]^+$.
750	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.77-7.56(m, 3H), 7.44 (s, 1H), 6.22 (t, *J* = 2.4 Hz, 1H), 4.98-4.92(m, 1H), 4.84-4.80 (m, 1H), 4.67-4.62 (m, 2H), 4.13-4.01(m, 1H), 3.99-3.89 (m, 1H), 3.79(s, 3H), 3.50-3.30 (m, 1H), 3.19-2.99 (m, 3H), 2.80-2.45 (m, 2H), 2.35-2.01 (m, 4H), 1.90-1.75 (m, 1H), 1.57 (d, *J* = 7.2 Hz, 3H) , 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 486 $[M+H]^+$.
751	 3-((7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3,4-difluorophenyl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.74 (d, *J* = 8.8 Hz, 1H), 7.56 (d, *J* = 9.2 Hz, 1H), 7.47-7.38 (m, 1H), 7.35-7.20 (m, 2H), 5.25-5.16 (m, 1H), 4.87- 4.79 (m, 1H), 4.34-4.28 (m, 1H), 4.00-3.88 (m, 1H), 3.82 (s, 3H), 3.63-3.47 (m, 1H), 3.13-3.03 (m, 1H), 3.03-2.88 (m, 1H), 2.40-2.16 (m, 3H), 2.16-2.02 (m, 3H), 2.02-1.95 (m, 1H), 1.95-1.82 (m, 3H), 1.17 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.
752	 (1S,4R)-4-((S)-2-((cyclopentyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.55 (m, 1H), 7.47-7.45 (m, 1H), 4.88-4.75 (m, 3H), 4.56-4.50 (m, 1H), 4.14-4.10 (m, 1H), 3.79 (s, 3H), 3.21-3.12 (m, 1H), 2.97-2.90 (m, 1H), 2.58-2.52 (m, 1H), 2.42-2.36 (m, 2H), 2.28-2.20 (m, 3H), 2.06-2.03 (m, 2H), 1.80-1.61 (m, 11H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.

753	 (1R,3R)-3-((S)-2-(1-((1H-pyrazol-1-yl)methyl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.57-7.48 (m, 2H), 7.44-7.35 (m, 2H), 6.24-6.22 (m, 1H), 5.03-4.98 (m, 1H), 4.88-4.86 (m, 1H), 4.74-4.68 (m, 1H), 4.24-4.17 (m, 1H), 3.78 (s, 3H), 3.12-3.02 (m, 1H), 3.01-2.95 (m, 1H), 2.91-2.75 (m, 1H), 2.65-2.12 (m, 5H), 1.95-1.55 (m, 5H), 1.41-1.30 (m, 2H), 1.30-1.02 (m, 5H). LCMS (ES, *m/z*): 492 $[M+H]^+$.
754	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50 (d, *J* = 1.6 Hz, 1H), 7.38-7.36 (m, 3H), 6.13-6.12 (m, 1H), 4.80-4.60 (m, 3H), 4.55-4.45 (m, 1H), 4.02-3.89 (m, 1H), 3.79(s, 3H), 3.56-3.38(m, 2H), 3.28-2.99 (m, 3H), 2.95-2.81 (m, 3H), 2.31-2.11 (m, 2H), 1.65 -1.55 (m, 2H), 1.43 (d, *J* = 7.2 Hz, 3H), 1.13 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 486 $[M+H]^+$.





	2nd eluting isomer	
755	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(pyrazin-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.58-8.44(m, 3H), 7.52 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 9.2 Hz, 1H), 4.82-4.75(m, 3H), 3.78 (s, 3H), 3.51-3.42 (m, 3H), 3.32-2.12 (m, 1H), 2.29-2.86 (m, 2H), 2.41-2.23 (m, 5H), 1.89-1.65 (m, 5H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 478 $[M+H]^-$.
756	 2-(4-isopropylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.11 (s, 1H), 7.59-7.44 (m, 2H), 7.27 – 7.15 (m, 4H), 4.86 – 4.70 (m, 1H), 4.52 – 4.37 (m, 1H), 4.31 – 4.20 (m, 1H), 4.00 – 3.89 (m, 1H), 3.86 (s, 3H), 3.61 – 3.49 (m, 2H), 3.46 – 3.36 (m, 1H), 3.22 – 3.07 (m, 1H), 3.05–2.80 (m, 3H), 2.55 – 2.35 (m, 1H), 2.32 – 2.18 (m, 1H), 2.12-2.01 (m, 1H), 1.98 – 1.82 (m, 2H), 1.81 – 1.67 (m, 1H), 1.22 (d, J = 6.9 Hz, 6H), 1.14 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 520 $[M+H]^+$.



757	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 5th eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48-7.41(m, 2H), 7.32-7.25(m, 5H), 4.76-4.74(m, 1H), 4.53-4.50(m, 1H), 4.26-4.24(m, 1H), 3.76-3.71(m, 4H), 3.69-3.65(m, 1H), 3.42-3.31(m, 4H), 3.14-3.11(m, 1H), 2.90-2.86(m, 1H), 2.33-2.30(m, 1H), 2.22-2.09(m, 2H),2.01-1.96(m, 1H), 1.78-1.74(m, 1H), 1.64-1.50(m, 3H), 1.31-1.28(m, 1H), 1.14-1.12(m, 4H). LCMS (ES, m/z): 506 [M+H]+.
758	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.03 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 9.2 Hz, 1H), 7.51-7.43 (m, 2H), 7.38-7.36(m, 1H), 7.27 (d, J = 6.8 Hz, 1H), 5.54-5.49 (m, 1H), 4.87-4.84(m, 1H), 4.82-4.74(m, 2H), 3.79(s, 3H), 3.72-3.50(m, 2H), 3.23-3.05 (m, 2H), 3.03-2.96 (m, 3H), 2.48-2.25 (m, 5H), 1.80-1.59 (m, 5H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 531 $[M+H]^+$.
759	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.57 (d, J = 9.0 Hz, 1H), 7.47 (d, J = 9.3 Hz, 1H), 4.97-4.92 (m, 2H), 4.81-4.78 (m, 1H), 4.61-4.56 (m, 1H), 3.93-3.90 (m, 2H), 3.79 (s, 3H), 3.74-3.70 (m, 1H), 3.51-3.48 (m, 2H), 3.22-3.17 (m, 1H), 2.99-2.94 (m, 1H), 2.64-2.50 (m, 1H), 2.41-2.35 (m, 2H), 2.30-2.16 (m, 3H), 2.13-1.92 (m, 4H), 1.83-1.53 (m, 5H), 1.14 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 486 $[M+H]^+$.
	N.	




760	 3-((7S)-2-((4-cyanocyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 4.83-4.73(m, 2H), 3.78 (s, 3H), 3.21-3.15 (m, 1H), 3.14-3.12 (m, 1H), 2.92-2.89 (m, 4H), 2.60-2.55 (m, 1H), 2.42-2.39 (m, 2H), 2.32-2.22 (m, 3H), 2.12-2.05 (m, 2H), 2.02-1.96 (m, 2H), 1.90-1.84 (m, 3H), 1.78-1.55 (m, 6H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 493 $[M+H]^+$.




761	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 507 $[M+H]^+$
762	 3-((7S)-2-(cyclopentyl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56 (d, J = 9.2 Hz, 1H), 7.44 (d, J = 9.2 Hz, 1H), 3.31-5.26 (m, 1H), 4.78–4.76 (m, 2H), 3.79 (s, 3H), 3.17–3.14 (m, 1H), 3.01-2.98 (m, 1H), 2.94–2.84 (m, 2H), 2.53–2.52 (m, 1H), 2.37–2.25 (m, 4H), 2.23–2.08 (m, 1H), 1.77–1.56 (m, 10H), 1.36–1.25 (m, 1H), 1.23–1.20 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.
763	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.45 (d, J = 8.8 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.25-7.05 (m, 5H), 4.95-4.90 (m, 1H), 4.80-4.65 (m, 1H), 3.75 (s, 3H), 3.65-3.55 (m, 1H), 3.40-3.30 (m, 1H), 3.25–3.15 (m, 1H), 3.05-2.80 (m, 3H), 2.41-2.22 (m, 4H), 2.00-1.90 (m, 1H), 1.89–1.60 (m, 5H), 1.36 (d, J = 6.8 Hz, 3H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 490 $[M+H]^+$.
764	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57 – 7.50 (m, 1H), 7.43 – 7.36 (m, 1H), 4.79 – 4.70 (m, 2H), 4.46 – 4.36 (m, 1H), 3.78 (s, 3H), 3.70 – 3.60 (m, 1H), 3.58 – 3.41 (m, 2H), 3.29 – 3.13 (m, 2H), 2.99-2.85 (m, 2H), 2.55 – 2.43 (m, 1H), 2.41 – 2.19 (m, 4H), 2.02 – 1.80 (m, 6H), 1.80 – 1.58 (m, 6H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 497 $[M+H]^+$.


		





765	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.16-8.06 (m, 1H), 7.74-7.64 (m, 1H), 7.53 (d, J = 9.2 Hz, 1H), 7.41 (d, J = 9.2 Hz, 1H), 6.97 (t, J = 6.4 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.67-6.53 (m, 1H), 4.82-4.63 (m, 2H), 3.78 (s, 3H), 3.29-3.11 (m, 1H), 2.95-2.82 (m, 1H), 2.57-2.31 (m, 3H), 2.30-2.12 (m, 3H), 2.09-1.98 (m, 1H), 1.94-1.81 (m, 4H), 1.77-1.59 (m, 2H), 1.58-1.43 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 493 $[M+H]^+$.
766	 (1S,4R)-4-((S)-2-(2-cyclopentylethoxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.30 – 7.21 (m, 2H), 4.77 – 4.65 (m, 1H), 4.60 – 4.53 (m, 2H), 4.33 – 4.23 (m, 1H), 3.77 (s, 3H), 3.19 – 3.07 (m, 1H), 2.84 – 2.72 (m, 1H), 2.48 – 2.37 (m, 1H), 2.33 – 2.12 (m, 5H), 2.10 – 2.00 (m, 1H), 1.98 – 1.84 (m, 6H), 1.75 – 1.55 (m, 7H), 1.32 – 1.24 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H).LCMS (ES, m/z): 484$[M+H]^+$.
767	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(3-phenylpropoxy)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 – 7.25 (m, 6H), 7.24 – 7.18 (m, 1H), 4.78 – 4.67 (m, 1H), 4.63 – 4.55 (m, 2H), 4.37 – 4.26 (m, 1H), 3.78 (s, 3H), 3.19 – 3.04 (m, 2H), 2.92 – 2.80 (m, 2H), 2.52 – 2.41 (m, 1H), 2.31 – 2.18 (m, 6H), 2.06 – 1.95 (m, 2H), 1.85 – 1.77 (m, 1H), 1.74 – 1.61 (m, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.
768	 2-(3-chlorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.52-7.50(m, 2H), 7.41-7.38(m, 1H), 7.33-7.29(m, 3H) ,4.80-4.50(m, 2H), 4.25-3.89(m, 7H), 3.75-3.55(m, 2H), 3.40-2.83(m, 3H), 2.45-2.15(m, 2H), 1.85-1.45(m, 4H), 1.14(d, J=6.9 Hz, 3H). LCMS (ES, m/z): 512 $[M+H]^+$.

769	 (1S,4R)-4-((S)-2-((4-cyanophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 502 $[M+H]^+$
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.50





770	 3-((7S)-2-((3-fluoro-2,6-dimethoxyphenyl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	(m, 1H), 7.43-7.41 (m, 1H), 7.17-7.12 (m, 1H), 6.79-6.77(m, 1H), 6.54 (s, 1H), 4.87-4.70 (m, 2H), 3.83-3.50 (m, 9H), 3.33-3.16 (m, 1H), 2.93-2.82 (m, 2H), 2.51-2.46 (m, 1H), 2.35-2.32 (m, 1H), 2.22-2.20 (m, 3H), 2.05-2.02 (m, 1H), 1.92-1.88 (m, 1H), 1.70-1.68 (m, 3H) 1.44 (d, J = 4.0 Hz, 3H). LCMS (ES, m/z): 556 $[M+H]^+$
771	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53-7.40 (m, 4H), 6.18-6.12 (m, 1H), 5.55-5.38 (m, 1H), 4.80-4.50 (m, 3H), 3.98-3.85 (m, 1H), 3.75 (s, 3H), 3.54-3.15 (m, 5H), 2.98-2.75 (m, 2H), 2.62-2.48 (m, 1H), 2.29-2.15 (m, 1H), 1.75-1.68 (m, 1H), 1.43 (d, J – 6.9 Hz, 3H) ,1.12 (d, J – 6.6 Hz, 3H). LCMS (ES, m/z):472 $[M+H]^+$
772	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.86 (s, 2H), 7.70 (s, 1H), 7.42 (s, 1H), 6.33-6.28 (m, 1H), 5.80-5.55 (m, 1H), 4.92-4.65 (m, 2H), 4.32-4.15 (m, 1H), 3.82-3.75 (m, 4H), 3.55-3.38 (m, 2H), 3.38-2.98 (m, 4H), 2.88-2.65 (m, 1H), 2.35-2.15 (m, 2H), 1.98-1.78 (m, 1H), 1.61 (d, J = 7.2 Hz, 3H) ,1.22 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 472 $[M+H]^+$.


773	 2-(4-fluorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50 (d, J = 8.8 Hz, 1H), 7.45-7.33 (m, 3H), 7.10-6.98 (m, 2H), 4.80-4.67 (m, 1H), 4.54-4.39 (m, 1H), 4.30-4.17 (m, 1H), 4.12-4.02 (m, 1H), 4.02-3.92 (m, 2H), 3.76 (s, 3H), 3.73-3.63 (m, 1H), 3.61-3.50 (m, 1H), 3.30-3.24 (m, 1H), 3.22-3.09 (m, 1H), 2.94-2.83 (m, 1H), 2.45-2.30 (m, 1H), 2.26-2.12 (m, 1H), 1.81-1.66 (m, 3H), 1.46-1.41 (m, 1H), 1.10 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 496 $[M+H]^+$.
774	 3-((7S)-2-(cyclopentyl(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56 (d, J = 9.2 Hz, 1H), 7.41 (d, J = 9.2 Hz, 1H), 5.11-5.06 (m, 1H), 4.78–4.73 (m, 2H), 3.79 (s, 3H), 3.21–3.17 (m, 1H), 3.01-2.99 (m, 1H), 2.95–2.90 (m, 1H), 2.70–2.68 (m, 1H), 2.50–2.23 (m, 5H), 1.97–1.76 (m, 3H), 1.75–1.57 (m, 9H), 1.23-1.19 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.15-8.04 (m, 2H), 7.54-7.50 (m, 1H) 7.49-7.45 (m, 1H),7.31-7.30 (m, 1H), 4.78-4.71 (m, 2H), 4.69-




775	 (1R,3R)-3-((S)-2-((5-isopropoxypyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	4.60 (m, 1H), 4.49-4.31 (m, 2H), 3.79(s, 3H), 3.25-3.20 (m, 1H), 3.02-2.95 (m, 2H), 2.41-2.12 (m, 5H), 1.82-1.69 (m, 3H), 1.40-1.31 (m, 8H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 521 $[M+H]^+$
776	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-2-((3-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 493 $[M+H]^+$



777	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((6-(trifluoromethyl)pyridazin-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.25 – 8.15 (m, 2H), 7.98 – 7.88 (m, 2H), 4.98 – 4.82 (m, 4H), 3.84 (s, 3H), 3.16 – 2.98 (m, 2H), 2.95 (s, 1H), 2.49 – 2.34 (m, 2H), 2.32 – 2.14 (m, 3H), 2.09 – 2.03 (m, 1H), 2.00 – 1.86 (m, 2H), 1.86 – 1.75 (m, 1H), 1.54 – 1.40 (m, 1H), 1.20 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 532 $[M+H]^+$.
778	 (S)-2-((6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methyl)benzoic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.19 (d, J = 7.6 Hz, 1H), 7.83 (s, 2H), 7.71 – 7.63 (m, 1H), 7.61 – 7.53 (m, 1H), 7.46 (d, J = 7.6 Hz, 1H), 5.01 (s, 2H), 4.91-4.95 (m, 1H), 4.84 – 4.77 (m, 1H), 4.15 – 4.05 (m, 2H), 3.82 (s, 3H), 3.55 – 3.44 (m, 2H), 3.12 – 2.99 (m, 1H), 2.98 – 2.87 (m, 1H), 2.69 – 2.50 (m, 2H), 2.30 – 2.17 (m, 1H), 1.90 – 1.78 (m, 3H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 464 $[M+H]^-$.
779	 (1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-(methylsulfonyl)(phenyl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 12.48-11.85 (br, 1H), 7.85-7.71(m, 2H), 7.64 (d, J = 6.0 Hz, 1H), 7.48-7.32 (m, 4H), 6.59-6.41 (m, 1 H), 4.72-4.65 (m, 1H), 4.60-4.41 (m, 1H), 3.79 (s, 3H), 3.25(s, 3H), 3.23-3.12 (m, 1H), 3.02-2.91(m, 1H), 2.50-2.41 (m, 1H), 2.38-2.25 (m, 1H), 2.25-2.12 (m, 1H), 2.09-1.91 (m, 3H), 1.84-1.79 (m, 1H), 1.79-1.61 (m, 2H), 1.41-1.26 (m, 1H), 1.16 (d, J = 10.0 Hz, 3H). 1.01-0.95 (m, 1H). LCMS (ES, *m/z*): 540 $[M+H]^+$.
780		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.65-7.41 (m, 3H), 6.84-6.82 (m, 1H), 6.61-6.59 (m, 1H), 5.22-5.12 (m, 1H), 4.85-4.79 (m, 1H), 4.49-4.39(m, 3H), 3.81 (s, 3H), 3.21-3.19 (m, 1H), 2.98-2.94 (m, 1H), 2.47-2.44 (m, 1H), 2.35-2.17 (m,



	(1S,4R)-4-((S)-2-((6-isopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	3H), 2.17-2.08 (m, 2H), 1.17 (m, 1H), 1.62(m, 2H), 1.51-1.48 (m, 2H), 1.35-1.22 (m, 6H), 1.25-0.99 (m, 3H). LCMS (ES, *m/z*): 521 $[M+H]^+$




781	 3-((7S)-2-(1-hydroxy-1-(pyridin-2-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.45-8.43 (m, 1H), 8.15-7.90 (m, 2H), 7.84 (s, 2H), 7.43-7.41 (m, 1H), 5.15-5.04 (m, 1H), 4.84-4.72 (m, 1H), 3.83 (s, 3H), 3.24-3.20 (m, 1H), 3.17-3.05 (m, 1H), 2.95-2.92 (m, 1H), 2.53-2.50 (m, 1H), 2.43-2.41 (m, 1H), 2.37-2.31 (m, 1H), 2.22 (s, 3H), 2.13-1.99 (m, 2H), 1.88-1.82 (m, 1H), 1.75-1.50 (m, 2H), 1.23-1.10 (m, 4H), 0.99-0.71 (m, 1H). LCMS (ES, *m/z*): 493 $[M+H]^+$.
782	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.92 – 7.76 (m, 2H), 7.67 – 7.56 (m, 1H), 6.05 (s, 1H), 5.12 – 5.07 (m, 1H), 4.72 – 4.56 (m, 2H), 4.24 – 4.05 (m, 1H), 3.81 (s, 3H), 3.21 – 2.86 (m, 3H), 2.51 – 2.31 (m, 2H), 2.31 – 2.09 (m, 3H), 2.09 – 1.76 (m, 7H), 1.73 – 1.48 (m, 5H), 1.18 (d, *J* = 6.9 Hz, 3H). LCMS (ES, *m/z*): 494 $[M+H]^+$
783	 2-(3-fluoro-4-methylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.57-7.54(m, 1H), 7.46-7.43(m, 1H), 7.24-7.06(m, 3H), 4.85-4.75(m, 1H), 4.62-4.45(m, 1H), 4.35-4.25(m, 1H), 4.15-3.95(m, 3H), 3.80-3.55(m, 5H), 3.40-3.10(m, 2H), 2.98-2.85(m, 1H),2.45-2.15(m, 5H), 1.85-1.65(m, 3H), 1.50-1.40(m, 1H), 1.15(d, J=6.6Hz, 3H). LCMS (ES, m/z): 510$[M+H]^-$.
784	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54 (d, *J* = 9.2 Hz, 1H), 7.41 (d, *J* = 8.8 Hz, 1H), 4.79-4.75(m, 1H), 4.38-4.32 (m, 1H), 3.99-3.96 (m, 2H), 3.79 (s, 3H), 3.48-3.42 (m, 2H), 3.20-3.12 (m, 1H), 3.07-3.03 (m, 2H), 2.95-2.88 (m, 1H), 2.62-2.51 (m, 1H), 2.50-2.35 (m, 2H), 2.28-2.24 (m, 3H), 2.01-1.98 (m, 2H), 1.80-1.69 (m, 8H), 1.42-1.33 (m, 2H), 1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 484 $[M+H]^+$.


785	 2-(4-(difluoromethyl)phenyl)-3-((7S)-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.59-7.47 (m, 5H), 7.41 (d, *J* = 8.8 Hz, 1H), 6.91-6.56 (m, 1H), 4.86-4.67 (m, 2H), 4.42-4.32 (m, 1H), 4.16-4.04 (m, 1H), 4.03-3.93 (m, 1H), 3.92-3.81 (m, 1H), 3.78 (s, 3H), 3.76-3.66 (m, 1H), 3.32-3.26 (m, 2H), 3.23-3.11 (m, 1H), 2.98-2.78 (m, 2H), 2.75-





	3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 4th eluting isomer	2.63 (m, 1H), 2.31-2.18 (m, 1H), 1.79-1.66 (m, 1H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 564 $[M+H]^+$.
786	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49 (t, J = 8.0 Hz, 1H), 7.36 (d, J =8.8 Hz, 1H), 7.28-7.18 (m, 3H), 7.18-7.07 (m, 3H), 6.92-6.69 (m, 3H), 4.81-4.68 (m, 1H), 4.33-4.23 (m, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 3.59-3.47 (m, 1H), 3.31-3.16 (m, 2H), 3.00-2.88 (m, 1H), 2.33-2.18 (m, 1H), 1.81-1.67 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^+$.
787	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.44-7.35 (m, 3H), 7.34-7.28 (m, 3H), 7.04-6.94 (m, 1H), 4.79-4.68(m, 1H), 4.64-4.58(m, 1H), 3.78(s, 3H), 3.68(s, 3H), 3.18-3.05(m, 1H), 3.03-2.98 (m, 1H), 2.86-2.78 (m, 1H), 2.48-2.31 (m, 2H), 2.28-2.17 (m, 3H), 2.05-1.92 (m, 1H), 1.95-1.87 (m, 1H), 1.80-1.54 (m, 3H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 477 $[M+H]^+$.
788	 (1R,3R)-3-((S)-2-((3-chlorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 497 $[M+H]^+$





789	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, J = 9.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H),7.25-7.00 (m, 4H), 5.62-5.42 (m, 2H),4.91-4.68 (m, 2H), 3.77 (s, 3H), 3.33-2.79 (m, 7H), 2.46-2.19 (m, 5H), 1.91-1.63 (m, 5H), 1.12(d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 531 $[M+H]^+$.
790	 4-((7S)-2-(1-(3-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53 - 7.19 (m, 3H), 6.06 (s, 1H), 4.78 - 4.63 (m, 1H), 4.63 - 4.51 (m, 1H), 4.51 - 4.40 (m, 1H), 4.40 - 4.22 (m, 1H), 4.05 - 3.91 (m, 1H), 3.76 (s, 3H), 3.27 - 3.11 (m, 1H), 3.01 - 2.78 (m, 1H), 2.54 - 2.02 (m, 6H), 1.96 - 1.62 (m, 4H), 1.62 - 1.47 (m, 1H),1.42 - 1.40 (d, J = 6.9 Hz, 3H), 1.14 - 1.12 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$


	imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	LCMS (ES, m/z): 514 [M+H]+.
791	 3-((7S)-6-(methoxycarbonyl)-3-(3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 1st eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.30-7.19(m, 7H), 4.29-4.23(m, 1H), 4.04-4.00(m, 1H), 3.78(s, 3H), 3.65-3.60(m, 1H), 3.42-3.37(m, 1H), 3.35(s, 3H), 3.18-3.14(m, 2H), 2.91-2.88(m, 1H), 2.13-2.11(m, 1H), 2.07-2.05(m, 4H), 1.95-1.89(m, 2H), 1.86-1.82(m, 1H), 1.57-1.54(m, 1H), 1.33-1.30(m, 1H), 1.21-1.15 (m, 1H), 1.16(d, J=6.8 Hz, 3H). LCMS (ES, *m/z*): 506 $[M+H]^+$.
792	 (1S,4R)-4-((S)-2-(benzyloxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.47 (m, 2H), 7.47-7.32 (m, 3H), 7.29-7.19 (m, 2H), 5.56 (s, 2H), 4.75-4.65 (m, 1H), 4.33-4.22 (m, 1H), 3.75 (s, 3H), 3.20-3.06 (m, 1H), 2.83-2.73 (m, 1H), 2.37-2.04 (m, 6H), 1.92-1.80 (m, 2H), 1.71-1.52 (m, 3H), 1.12 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 478 $[M+H]^+$.




793	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.18-8.06 (m, 1H), 7.77-7.63 (t, *J* = 7.2 Hz, 1H), 7.52 (d, *J* = 9.2 Hz, 1H), 7.41 (d, *J* = 9.2 Hz, 1H), 6.96 (t, *J* = 6.0 Hz, 1H), 6.87 (d, *J* = 8.4 Hz, 1H), 6.68-6.54 (m, 1H), 4.80-4.64 (m, 2H), 3.78 (s, 3H), 3.26-3.11 (m, 1H), 2.99-2.85 (m, 1H), 2.56-2.44 (m, 1H), 2.43-2.30 (m, 2H), 2.28-2.11 (m, 3H), 2.08-1.96 (m, 1H), 1.90-1.76 (m, 4H), 1.75-1.57 (m, 2H), 1.56-1.39 (m, 1H), 1.12 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 493 $[M+H]^+$.
794	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1H NMR (400 MHz, CD_3OD) δ (ppm): 7.80 (d, *J* = 9.2 Hz, 1H), 7.74 (d, *J* = 9.2 Hz, 1H), 5.39–5.37 (m, 1H), 4.95-4.92 (m, 1H), 4.83–4.81 (m, 1H), 3.98–3.88 (m, 2H), 3.82 (s, 3H), 3.73–3.70 (m, 1H), 3.50–3.41 (m, 2H), 3.15–3.11(m, 1H), 3.00–2.95 (m, 1H), 2.64–2.51 (m, 1H), 2.48–2.45 (m, 2H), 2.31–2.24 (m, 3H), 2.13–2.06 (m, 3H), 1.86–1.83 (m, 2H), 1.76–1.58 (m, 7H), 1.16 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^+$
795	 (1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.43 (s, 1H), 7.71 (d, *J* = 3.6 Hz, 1H), 7.53 (d, *J* = 8.8 Hz, 1H), 7.42 (d, *J* = 8.8 Hz, 1H), 6.61 (d, *J* = 3.6 Hz, 1H), 4.89-4.87(m, 1H), 4.80-4.69 (m, 3H), 3.79(s, 3H), 3.24-3.17(m, 1H), 2.98-2.92 (m, 2H), 2.43-2.17 (m, 5H), 1.79-1.60 (m, 4H), 1.43-1.31 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 503 $[M+H]^+$.



	3-yl)cyclohexane-1-carboxylic acid	
796	 (1S,4R)-4-((S)-2-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 510 $[M+H]^+$



797	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-((methylsulfinyl)(phenyl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 7.67-7.25 (m, 7H), 6.12-5.79 (m, 1H), 4.75-4.58 (m, 1H), 4.47-4.28 (m, 1H), 3.67 (s, 3H), 3.20-3.04 (m, 1H), 2.98-2.78 (m, 1H), 2.62 (s, 1H), 2.45 (s, 2H), 2.41-2.22 (m, 2H), 2.20-2.08 (m, 1H), 2.08-1.86 (m, 3H), 1.85-1.74 (m, 1H), 1.74-1.54 (m, 2H), 1.29-1.14 (m, 1H), 1.09 (d, *J* = 6.8 Hz, 3H), 1.02-0.79 (m, 1H). LCMS (ES, *m/z*): 524 $[M+H]^+$.
798	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, *J* = 6.8 Hz, 1H), 7.43-7.40 (d, *J* = 6.8 Hz, 1H), 4.91-4.89 (m, 2H), 4.85-4.76 (m, 1H), 4.72-4.54 (m, 1H), 3.79-3.69 (m, 5H), 3.51-3.45 (m, 2H), 3.17-3.14 (m, 1H), 2.97-2.90 (m, 2H), 2.35-2.21 (m, 5H), 2.11-1.95 (m, 6H), 1.78-1.72 (m, 2H), 1.64-1.48 (m, 1H).1.14 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 483 [M+H]+
799	 (1R,3R)-3-((S)-2-((4-fluoro-3-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 511 $[M+H]^+$
800	 4-((7S)-2-(2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52-7.45 (m, 1H), 7.45-7.31 (m, 5H), 7.31-7.23 (m, 1H), 5.17-5.07 (m, 1H), 4.83-4.71 (m, 1H), 4.40-4.28 (m, 1H), 3.79 (s, 3H), 3.51-3.40 (m, 1H), 3.40-3.35 (m, 1H), 3.24-3.11 (m, 1H), 3.00- 2.86 (m, 1H), 2.52-2.45 (m, 1H), 2.42-2.13 (m, 4H), 2.13-2.03(m, 1H), 1.96-1.86 (m, 1H), 1.82-1.71 (m, 1H), 1.72-1.64 (m, 1H), 1.58-1.51 (m, 2H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.





801	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.54 (s, 1H), 8.45(s, 1H), 8.38 (d, J = 2.8 Hz, 1H), 7.45 (d, J = 9.2 Hz, 1H), 7.35 (d, J = 9.2 Hz, 1H), 4.84-4.74(m, 1H), 4.50-4.35(m, 1H), 4.01-3.85(m, 1H), 3.79(s, 3H), 3.60-3.45(m, 1H), 3.25-3.11(m, 2H), 2.96-2.81 (m, 1H), 2.60-2.49 (m, 1H), 2.46-2.11 (m, 5H), 2.01-1.85 (m, 1H), 1.79-1.61 (m, 3H), 1.61-1.51 (m, 1H), 1.50 (d, J = 6.8 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 492 $[M+H]^+$.
802	 (1R,3R)-3-((S)-2-((3-fluorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 481 $[M+H]^+$
803	 methyl (7S)-7-methyl-2-(1-phenylpropan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.45 (d, J = 8.8 Hz, 1H), 7.30 (d, J = 9.2 4.80-4.71 (m, 1H), 4.27-4.13 (m, 1H), 3.79 (s, 3H), 3.68-3.55 (m, 1H), 3.33-3.22 (m, 1H), 3.25-3.06 (m, 3H), 3.05-2.90 (m, 2H), 2.81-2.68 (m, 1H), 2.55-2.44 (m, 1H), 2.39-2.22 (m, 2H), 2.20-2.02 (m, 1H), 1.78-1.66 (m, 2H), 1.56 (d, J = 6.8 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H), 0.56-0.43 (m, 1H). LCMS (ES, m/z): 447 $[M+H]^+$.
804	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-3-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, J = 9.2 Hz, 1H), 7.39 (d, J = 9.2 Hz, 1H), 4.83-4.69 (m, 2H), 4.02-3.83 (m, 2H), 3.82-3.69 (m, 4H), 3.52-3.39 (m, 1H), 3.25-3.10 (m, 1H), 3.09-2.85 (m, 4H), 2.50-2.10 (m, 7H), 2.03-1.80 (m, 4H), 1.80-1.55 (m, 4H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.


805	 (1S,4R)-4-((S)-2-((4-fluorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 495 $[M+H]^+$





806	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61-7.48 (m, 1H),7.43-7.24 (m, 1H), 4.83-4.64(m, 2H), 3.97-3.82(m, 2H), 3.78 (s, 3H), 3.55-3.43 (m, 1H), 3.38-3.35 (m, 1H), 3.24-3.11 (m, 1H), 3.10-2.74 (m, 4H), 2.56-2.33 (m, 2H), 2.33-2.07 (m, 4H), 2.01-1.82 (m, 3H), 1.82-1.57 (m, 5H), 1.47-1.36 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.
807	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethoxy-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.40-7.30 (m, 4H), 7.29-7.22 (m, 2H), 7.21-7.19 (m, 1H), 4.82-4.78 (m, 2H), 4.70-4.59 (m, 1H), 4.21-4.09 (m, 1H), 3.76 (s, 3H), 3.20-3.15 (m, 2H), 3.12-3.05 (m, 1H), 2.81-2.78 (m, 1H), 2.42-2.19 (m, 2H), 2.13-2.04 (m, 4H), 1.81-1.72 (m, 2H), 1.75-1.45 (m, 3H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 492$[M+H]^+$.
808	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54-7.51 (m, 1H), 7.42-7.39 (m, 1H), 4.78-4.73 (m, 1H), 4.62 (m, 1H), 3.87-3.85 (m, 1H), 3.78-3.61 (m, 4H), 3.28-2.84 (m, 2H), 2.72-2.66 (m, 1H), 2.50-2.18 (m, 5H), 2.15-2.05 (m, 3H), 1.895 (m, 1H), 1.76-1.54 (m, 7H), 1.46 (d, J = 6.4 Hz, 3H) 1.35-1.29 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^-$.


809	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(p-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 477 $[M+H]^+$
810	 (1R,3R)-3-((S)-2-(2-(4-chloro-1H-pyrazol-1-yl)ethoxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.93 (s, 1H),7.51 (s, 1H),7.38-7.22(m, 1H), 7.22-7.06(m, 1H), 4.94-4.89(m, 1H),4.88-4.81(m, 1H),4.81-4.65(m, 1H),4.65-4.44(m, 3H), 3.76(s, 3H), 3.18-3.01(m, 1H), 2.98-2.83 (m, 1H), 2.83-2.63 (m, 1H), 2.38-2.12 (m, 3H), 2.12-1.93 (m, 2H), 1.87-1.71 (m, 2H), 1.71-1.51 (m, 3H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 516 $[M+H]^+$.
		




811	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.94 (s, 1H), 7.59 – 7.54 (m, 2H), 7.28 (d, *J*=8.7Hz, 1H), 5.15-4.98 (m, 1H), 4.70-4.40 (m, 3H), 3.98-3.81 (m, 1H), 3.67 (s, 3H), 3.31-2.76 (m, 6H), 2.28-1.95 (m, 3H), 1.68-1.55 (m, 1H), 1.23 (d, *J* = 6.9 Hz, 3H), 1.06 (d, *J* = 6.6 Hz, 3H). LCMS (ES, m/z): 457 $[M+H]^+$.
812	 4-((7S)-2-(2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.45-7.42 (m, 1H), 7.41-7.34 (m, 3H), 7.32-7.24 (m, 3H), 4.81-4.73 (m, 1H), 4.60-4.57 (m, 1H), 4.47-4.44 (m,1H), 4.43-4.17 (m, 2H), 3.76 (s, 3H), 3.30-3.27 (m, 1H), 2.98-2.93 (m, 1H), 2.40-2.28 (m, 3H), 2.27-2.13 (m, 1H), 2.00-1.96 (m, 2H), 1.94-1.83 (m, 1H), 1.80-1.73 (m, 1H), 1.71-1.57 (m, 1H), 1.17-1.13 (m, 4H), 0.98-0.90 (m, 1H). LCMS (ES, *m/z*): 492 $[M+H]^+$.



813	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.18 (d, *J* = 8.0 Hz, 2H), 7.78-7.75 (m, 1H), 7.69-7.64 (m, 4H), 5.49-5.48 (m, 1H), 4.80-4.76 (m, 1H), 3.79 (s, 3H), 3.23-3.16 (m, 1H), 3.06-2.99 (m, 2H), 2.52-2.48 (m, 1H), 2.25-2.17 (m, 4H), 1.81-1.62 (m, 4H), 1.48-1.45 (m, 1H), 1.13 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 512 $[M+H]^+$.
814	 (1R,3R)-3-((S)-2-(benzylsulfonyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.67 (s, 2H), 7.42-7.33 (m, 5H), 5.54-5.51 (m, 1H), 5.04-5.01 (m, 1H), 4.84-4.78 (m, 1H), 3.81 (s, 3H), 3.19-3.5 (m, 1H), 3.07-3.02 (m, 2H), 2.57-2.50 (m, 1H), 2.36-2.33 (m, 1H), 2.26-2.23 (m, 3H), 1.86-1.67 (m, 4H), 1.63-1.55 (m, 1H), 1.38-1.34 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 526 $[M+H]^+$.
815	 (1S,4R)-4-((S)-2-((3-chlorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 497 $[M+H]^+$
		



816	 (1R,3R)-3-((S)-2-((3,4-difluorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 500 $[M+H]^+$




817	 4-((7S)-2-(1-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, *J* = 9.2 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 7.27-7.23 (m, 2H), 7.20-7.17 (m, 3H), 5.29 (t, *J* = 7.2 Hz, 1H), 4.78-4.75 (m, 1H), 4.68-4.62 (m, 1H), 3.78 (s, 3H), 3.33-3.32(m, 2H), 3.23-3.21 (m, 1H), 2.93-2.89 (m, 1H), 2.50-2.48 (m, 1H), 2.40-2.30 (m, 1H), 2.27-2.20 (m, 3H), 2.16-2.09 (m, 1H), 1.97-1.92 (m, 1H), 1.75-1.70(m, 1H), 1.65-1.61 (m, 1H),1.56-1.51 (m, 2H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$
818	 (1S,3R)-3-((S)-2-(2-cyclobutylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51 (d, *J* = 8.8 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 1H), 4.79-4.71 (m, 1H), 4.46-4.35 (m, 1H), 3.78 (s, 3H), 3.22-3.15 (m, 1H), 2.95-2.87 (m, 3H), 2.62-2.58 (m, 1H), 2.50-2.35 (m, 3H), 2.35-2.22 (m, 1H), 2.20-2.03 (m, 5H), 2.01-1.88 (m, 5H), 1.80-1.52 (m, 5H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, m/z): 454 $[M+H]^+$.
819	 (1R,3R)-3-((S)-2-((3-cyanophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 488 $[M+H]^+$
820	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((4-methylpyrimidin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.52 (d, *J* = 4.2 Hz, 1H), 7.58 (d, *J* =9.0 Hz, 1H), 7.43 (d, *J* =9.0 Hz, 1H), 7.23 (d, *J* = 5.1 Hz, 1H), 4.88 - 4.49 (m,4H), 3.79 (s,3H), 3.28 - 3.09 (m, 1H), 2.99 - 2.81 (m, 2H), 2.48(s, 3H), 2.43 - 2.12 (m, 5H), 1.93 - 1.53 (m, 4H), 1.53 - 1.41 (m, 1H), 1.16 - 1.14 (d, *J* = 6.9 Hz, 3H). LCMS (ES, *m/z*):478 $|M+H|^+$


		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, *J* = 8.8 Hz, 1H), 7.41 (d, *J* = 8.8 Hz, 1H), 7.27-7.14 (m, 4H), 6.92-6.90 (m, 1H), 5.15-5.04 (m, 1H),





821	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((E)-1-phenoxyprop-1-en-1-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	4.73-4.50 (m, 1H), 3.77 (s, 3H), 3.23-3.15 (m, 1H), 2.94-2.85 (m, 1H), 2.60-2.49 (m, 1H), 2.41-2.18 (m, 5H), 1.89-1.70 (m, 2H), 1.86-1.65 (m, 5H), 1.54-1.46 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H) LCMS (ES, m/z): 504 $[M+H]^+$.
822	 3-((7S)-2-(1-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53 (d, J = 9.2Hz, 1H), 7.40 (d, J = 8.4Hz, 1H), 7.36- 7.14 (m, 5H), 5.32-5.27 (m, 1H), 5.08-4.98 (m, 1H), 4.82-4.68 (m, 1H), 3.79 (s, 3H), 3.45-3.41 (m, 1H), 3.25-3.21 (m, 2H), 3.01-2.95 (m, 2H), 2.41-2.18 (m, 4H), 2.16-2.02 (m, 1H), 1.98-1.82 (m, 2H), 1.78-1.59 (m, 3H), 1.15 (d, J = 6.4, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$
823	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.51 (s, 1H), 8.18-8.10 (m, 2H), 7.47-7.35 (m, 2H), 5.12-5.07 (m, 1H), 4.82-4.74 (m, 1H), 3.77 (s, 3H), 3.23-3.15 (m, 1H), 3.00-2.89 (m, 1H), 2.53-2.42 (m, 1H), 2.39-2.30 (m, 2H), 2.32-2.15 (m, 3H), 2.02-1.71 (m, 7H), 1.69-1.57 (m, 2H), 1.13 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 506 $[M+H]^+$.
824	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm):) 7.47 – 7.29 (m, 2H), 7.22 (d, J = 2.1 Hz, 1H), 5.90 (s, 1H), 4.79 – 4.65 (m, 1H), 4.59 – 4.47 (m, 1H), 4.46 – 4.34 (m, 1H), 4.34 – 4.18 (m, 1H), 4.00 – 3.82 (m, 1H), 3.76 (s, 3H), 3.26 – 3.16 (m, 1H), 2.98 – 2.83 (m, 1H), 2.58 – 2.38 (m, 1H), 2.38 – 2.03 (m, 8H), 1.93 – 1.80 (m, 1H), 1.80 – 1.56 (m, 3H), 1.49 – 1.35 (m, 4H), 1.14 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 494 $[M+H]^+$

825	 3-((7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.90(s, 1H), 7.87-7.75 (m, 2H), 7.31(s, 1H), 5.12-5.02(m, 1H), 4.87-4.72(m, 1H), 4.71 (d, J = 6.8 Hz, 2H), 4.30-4.15(m, 1H), 3.79(s, 3H), 3.18-2.96 (m, 3H), 2.45-2.30 (m, 2H), 2.29-2.18 (m, 2H), 2.14-1.99 (m, 2H), 1.95-1.70 (m, 3H), 1.65-1.60 (m, 1H), 1.57 (d, J = 6.8 Hz, 3H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$.
826	 3-((7S)-2-((1,3-dihydroisobenzofuran-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.64-7.52 (m, 1H), 7.52-7.41 (m, 1H), 7.41-7.31 (m, 1H), 7.31-7.19 (m, 1H), 7.07-6.91 (m, 1H), 6.60(s, 1H), 5.63-5.42(m, 1H), 5.42-5.26(m, 1H), 4.86-4.58(m, 4H), 3.79(s, 3H), 3.32-3.18(m, 1H), 3.04-2.92 (m, 1H), 2.84-2.61 (m, 1H), 2.44-2.21 (m, 3H), 2.13-





	4-yl)(hydroxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	1.93 (m, 2H), 1.91-1.72 (m, 3H), 1.72-1.43 (m, 2H), 1.18 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 520 $[M+H]^-$
827	 3-((7S)-2-(1-(3-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.11-7.46 (m, 3H), 6.20 (s, 1H), 5.28-5.01 (m, 1H), 4.79-4.48 (m, 2H), 4.30-4.01 (m, 1H), 3.80 (s, 3H), 3.22-2.87 (m, 3H), 2.64-2.31 (m, 2H), 2.31-2.11 (m, 3H), 2.11-1.79 (m, 4H), 1.73-1.48 (m, 4H), 1.32-1.23 (m, 1H), 1.16 (d, *J* –6.6 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$.
828	 (1R,3R)-3-((S)-2-((5-chloropyrimidin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.74 (s, 2H), 7.56 (d, *J* = 9.2 Hz, 1H), 7.42 (d, *J* = 8.8 Hz, 1H), 4.82-4.65 (m, 2H), 3.79 (s, 3H), 3.17 (m, 1H), 2.97-2.87 (m, 2H), 2.45-2.16 (m, 6H), 1.92-1.54 (m, 6H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 498 $[M+H]^+$.


829	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.55 (d, *J* = 9.0 Hz, 1H), 7.44 (d, *J* = 9.3 Hz, 1H), 7.25 (d, *J* = 8.4 Hz, 2H), 7.16 (d, *J* = 8.1 Hz, 2H), 4.86-4.80 (m, 1H), 4.78-4.54 (m , 1H) , 4.29-4.24 (m, 1H), 3.99-3.92 (m, 2H), 3.78-3.54 (m , 5H), 3.38-3.11 (m, 3H), 2.95-2.90 (m, 1H), 2.53-2.34 (m, 1H), 2.33-1.69 (m, 8H), 1.14(d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.
830	 (1R,3R)-3-((S)-2-((1H-indazol-6-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 503 $[M+H]^+$
831	 (1R,3R)-3-((S)-2-((4-chlorophenyl)amino)-6-	LCMS (ES, *m/z*): 497 $[M+H]^+$




	(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	
832	 4-((7S)-6-(methoxycarbonyl)-2-((-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53 (d, J = 9.0 Hz, 1H), 7.39 (d, J =9.0 Hz, 1H), 4.83-4.66 (m, 1H), 4.47-4.26 (m, 1H), 3.78 (s, 3H), 3.33-3.32 (m, 3H), 3.28-3.06 (m, 2H), 3.01-2.82 (m, 3H), 2.58-2.35 (m, 3H), 2.34-2.17 (m, 3H), 2.16-2.03 (m, 2H), 2.02-1.86 (m, 2H), 1.85-1.55 (m, 6H), 1.31-1.07 (m, 7H). LCMS (ES, *m/z*): 498 $[M+H]^+$.



833	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.34 (s, 1H), 8.15-8.10 (m, 2H), 7.61-7.40 (m, 2H), 6.59 (t, J = 6.4 Hz, 1H), 4.79-4.62 (m, 2H), 3.77 (s, 3H), 3.23-3.11 (m, 1H), 2.95-2.83 (m, 1H), 2.62-2.31 (m, 3H), 2.30-2.12 (m, 4H), 1.98-1.90 (m, 1H), 1.88 (d, J = 6.8 Hz, 3H), 1.78-1.51 (m, 3H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 494 [M+H]+.
834	 methyl (7S)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-(1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53-7.49 (m, 2H), 7.31 (s, 1H), 7.20 (s, 1H), 5.55-5.35 (m, 1H), 4.97 (s, 1H), 4.78-4.32 (m, 2H), 3.95-3.85 (m, 1H), 3.75-3.58 (m, 3H), 3.52-3.15 (m, 5H), 2.98-2.65 (m, 2H), 2.32-2.12 (m, 2H), 1.95 (s, 3H), 1.76-1.66 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 1.12 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 486 $[M+H]^-$.
835	 4-((7S)-2-(acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.54-7.29 (m, 7H), 6.57 (s, 1H), 4.82-4.69 (m, 1H), 4.35-4.18 (m, 1H), 3.79 (s, 3H), 3.30-3.19 (m, 1H), 3.04-2.90 (m, 1H), 2.52-1.85 (m, 10H), 1.85-1.54 (m, 2H), 1.40-1.25 (m, 1H), 1.18 (d, J = 6.6 Hz, 3H), 1.13-1.01 (m, 1H). LCMS (ES, m/z): 519 $[M+H]^+$
836	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.82-7.59 (m, 3H), 7.37 (s, 1H), 5.22-5.02 (m, 1H), 4.83-4.78 (m, 1H), 4.61 (d, J = 7.2 Hz, 2H), 4.24-3.97 (m, 1H), 3.80 (s, 3H), 3.57-3.44 (m, 2H), 3.42-3.32 (m, 2H) ,3.21-2.89 (m, 4H), 2.89-2.70 (m, 1H), 2.70-2.49 (m, 1H), 2.33-2.12 (m, 3H), 1.93-1.76 (m, 1H), 1.55 (d, J =6.9 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 497 $[M+H]^+$.



	1st eluting isomer	




837	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 494 $[M+H]^+$
838	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(p-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 478 $[M+H]^+$
839	 (1S,4R)-4-((S)-2-((2-chlorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 497 $[M+H]^+$
840	 methyl (S)-2-benzyl-3-((1R,3R)-3-(methoxycarbonyl)cyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51-7.38 (m, 2H), 7.34 - 7.26 (m, 2H), 7.23-7.19 (m, 3H), 4.81-4.63 (m, 2H), 4.62-4.38 (m, 2H), 3.77 (s, 3H), 3.74 (s, 3H), 3.25-3.13 (m, 1H), 3.02-3.86 (m, 2H), 2.55-2.03 (m, 5H), 1.79-1.53 (m, 3H), 1.30-1.15 (m, 2H), 1.13 (d, *J*=6.8, 3H). LCMS (ES, *m/z*): 476 $[M+H]^+$.


841	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63-7.46 (m, 1H),7.46-7.28 (m, 1H),4.86-4.68(m, 2H), 3.92-3.76(m, 5H), 3.58-3.39 (m, 1H),3.31-3.11 (m, 2H), 3.09-2.89 (m, 4H), 2.53-2.35 (m, 2H), 2.35-2.12 (m, 4H), 2.01-1.85 (m, 3H), 1.84-1.54 (m, 5H), 1.51-1.37 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.





	1st eluting isomer	
842	 methyl (7S)-3-(azepan-4-yl)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55 (s, 1H), 7.52-7.33 (m, 3H), 4.82-4.72 (m, 1H), 4.71-4.57 (m, 2H), 4.56-4.44 (m, 1H), 4.04-3.89 (m, 1H), 3.79 (s, 3H), 3.47-3.34 (m, 3H), 3.28-3.14 (m, 2H), 3.07-2.89 (m, 1H), 2.74-2.60 (m, 1H), 2.59-2.40 (m, 1H), 2.35-2.21 (m, 1H), 2.17-1.85 (m, 3H), 1.84-1.62 (m, 2H), 1.46 (d, J = 7.2 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 485 $[M+H]^+$.
843	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.43-7.37 (m, 3H), 7.32-7.26 (m, 3H), 6.99 (t, J = 7.6 Hz, 1H), 4.73-4.69 (m, 1H), 4.42-4.40 (m, 1H), 3.76 (s, 3H), 3.09-3.03 (m, 1H), 2.82-2.76 (m, 1H), 2.52-2.36 (m, 3H), 2.35-2.17 (m, 3H), 2.01-1.99 (m, 2H), 1.70-1.62 (m, 3H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 463M+H]$^+$.
844	 methyl (7S)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-(1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53-7.40 (m, 2H), 7.31 (s, 1H), 7.17 (s, 1H), 5.49-5.38 (m, 1H), 4.89-4.38 (m, 3H), 3.98-3.85 (m, 1H), 3.78 (s, 3H), 3.50-3.15 (m, 3H), 2.98-2.20 (m, 4H), 2.60-2.15 (m, 2H), 1.96 (s, 3H), 1.78-1.65 (m, 1H), 1.42 (d, J = 6.9 Hz, 3H) 1.12 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 486 $[M+H]^+$.

845	 2-(3-fluoro-4-methylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.61 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 9.0 Hz, 1H), 7.24-7.11 (m, 1H), 7.07-7.04 (m, 2H), 4.81-4.57 (m, 2H), 4.32-4.28 (m, 1H), 4.07-3.96 (m, 2H), 3.79 (s, 3H), 3.77-3.72 (m, 1H), 3.58-3.45 (m, 1H), 3.42-3.33 (m, 2H), 3.14-3.09 (m, 1H), 2.96-2.92 (m, 1H), 2.35-2.30 (m, 1H), 2.26-2.25 (m, 4H), 2.18-2.09 (m, 1H), 1.83-1.74 (m, 2H), 1.44-1.43 (m, 1H), 1.14 (d, J = 6.9 Hz, 3H). LCMS (ES, m/z): 510 $[M+H]^+$.
846	 (1R,3R)-3-((S)-2-((2-fluoro-4-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 511 $[M+H]^+$





847	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(m-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 477 $[M+H]^+$
848	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.51-8.35(m, 3H), 7.48 (d, *J* = 9.2 Hz, 1H), 7.35(d, *J* = 8.8 Hz, 1H), 4.87-4.71(m, 2H), 3.95-3.93(m, 1H), 3.78(s, 3H), 3.68-3.63(m, 1H), 3.34-3.18(m, 2H), 2.97-2.88 (m, 2H), 2.41-2.08 (m, 5H), 1.92-1.66 (m, 5H), 1.47 (d, *J* = 6.8 Hz, 3H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.



849	 3-((7S)-6-(methoxycarbonyl)-3-(4-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.32 (d, *J* = 9.0 Hz, 1H), 7.23-7.08 (m, 9H), 6.79 (d, *J* = 8.7 Hz, 1H), 4.85-4.70 (m, 1H), 4.45-4.25 (m, 1H), 3.89 (s, 3H), 3.75 (s, 3H), 3.55-3.42 (m, 1H), 3.32-2.85 (m, 3H), 2.32-2.21 (m, 1H), 1.75-1.58 (m, 1H), 1.14 (d, *J* = 6.9 Hz, 3H). LCMS (ES, *m/z*): 500 $[M+H]^+$.
850	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((6-methoxypyridin-3-yl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 494 $[M+H]^+$
851	 (1S,4R)-4-((S)-2-((2-fluoro-4-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 511 $[M+H]^+$
		^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.29-8.20



852	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-1-yl)propanoic acid 2nd eluting isomer	(m, 1H), 7.90-7.70 (m, 2H), 7.55-7.30 (m, 6H), 5.05-5.01 (m, 1H), 4.82-4.71 (m, 1H), 4.2-3.7 (m, 8H), 3.59-3.51 (m, 1H), 3.48-3.33 (m, 1H), 3.33-3.12 (m, 1H), 2.96-2.89 (m, 1H), 2.35-2.18 (m, 1H), 2.18-1.93 (m, 1H), 1.78-1.72 (m, 1H), 1.51-1.42 (m, 1H), 1.18-1.11 (m, 4H), 0.65 (m, 1H). LCMS (ES, m/z): 528 $[M+H]^+$




853	 (1S,4R)-4-((S)-2-((1H-indazol-6-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 503 $[M+H]^+$
854	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 493 $[M+H]^+$
855	 4-((7S)-2-(1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (CD_3OD, 400 MHz) δ (ppm): 7.83-7.74 (m, 2H), 7.29-7.27 (m, 3H), 7.18-7.17 (m, 2H), 5.67-5.63 (m, 1H), 4.86-4.84 (m, 1H), 4.50-4.42 (m, 1H), 3.81 (s, 3H), 3.64-3.60 (m, 1H), 3.28-3.27 (m, 1H), 3.18-3.16 (m, 1H), 3.01-2.95(m, 1H), 2.53-2.49 (m, 1H), 2.32-2.25 (m, 4H), 2.04-1.88 (m, 6H), 1.70-1.68 (m, 1H), 1.52-1.40 (m, 1H), 1.21 (d, J = 6.4 Hz, 3H), 0.50-0.48 (m, 1H). LCMS (ES, *m/z*): 533 $[M+H]^+$.
856	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yl)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.54 (s, 1H), 8.38 (s, 1H), 8.00 (s, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 4.84-4.74(m, 2H), 3.79(s, 3H), 3.33-3.15(m, 1H), 3.03-2.96 (m, 1H), 2.86-2.82 (m, 1H), 2.52-2.05 (m, 6H), 1.89-1.55 (m, 7H), 1.45-1.30 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 490 $[M+H]^+$.


		





857	 (1S,4R)-4-((S)-2-((4-cyanophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 488 $[M+H]^+$
858	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-(2-oxopyrrolidin-1-yl)benzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.60-7.54 (m, 2H), 7.45-7.40 (m, 1H), 7.37-7.30 (m, 3H), 4.78-4.39 (m, 6H), 3.89-3.80 (m, 1H), 3.76 (s, 3H), 3.30-3.20 (m, 1H), 3.12-2.80 (m, 1H), 2.75-2.68 (m, 2H), 2.29-2.09 (m, 7H), 1.77-1.48 (m, 3H), 1.31-1.28 (m, 1H), 1.20-1.12 (m, 4H). LCMS (ES, m/z): 545 [M+H]+.
859	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 493 $[M+H]^+$
860	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.77-7.66 (m, 2H), 7.58-7.56(m, 1H), 7.44 (s, 1H), 6.22-6.20 (m, 1H), 4.86-4.79(m, 2H), 4.67 (d, *J* = 7.2 Hz, 2H), 4.13-3.95(m, 2H), 3.79(s, 3H), 3.50-3.30 (m, 2H), 3.19-2.99 (m, 3H), 2.50-2.31 (m, 1H), 2.28-2.15 (m, 2H), 2.03-1.90 (m, 1H), 1.88-1.76 (m, 1H), 1.57 (d, *J* = 7.2 Hz, 3H), 1.56-1.47 (m, 1H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 486 [M+H]+.

861	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-methyl-1H-indazol-6-yl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 518 $[M+H]^+$
		^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.91 (s, 1H), 7.58 (s, 1H), 7.49-7.34 (m, 2H), 6.89 - 6.51 (m, 1H), 4.81- 4.61 (m, 3H), 4.61- 4.32 (m, 1H), 4.03 - 3.83 (m, 1H), 3.76 (s, 3H), 3.28 - 3.12 (m,





862	3-((7S)-2-(1-(4-(difluoromethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	4.05 - 3.85 (m, 1H), 3.70 (s, 3H), 3.28 - 3.12 (m, 1H), 3.02 - 2.79 (m, 2H), 2.49 - 2.17 (m, 4H), 2.17 - 2.03 (m, 1H), 1.96 - 1.81 (m, 2H), 1.80 - 1.54 (m, 3H), 1.38 - 1.35 (d, J = 6.9 Hz, 3H), 1.13 - 1.11 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 530 $[M+H]^+$.
863	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.50-7.35(m, 2H), 4.86-4.77(m, 2H), 3.94-3.90(m, 2H), 3.76(s, 3H), 3.45-3.60(m, 3H), 2.99-2.86(m, 4H), 2.45-2.18(m, 6H),1.91-1.45(m, 9H) ,1.12(d, J=6.6 Hz, 3H). LCMS (ES, m/z): 470 $[M+H]^+$.
864	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 4th eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 4.81-4.68 (m, 1H), 4.54-4.40 (m, 1H), 4.06-3.94 (m, 1H), 3.78 (s, 3H), 3.53-3.43 (m, 1H), 3.38-3.36 (m, 1H), 3.26-2.97 (m, 3H), 2.94-2.83 (m, 1H), 2.69-2.54 (m, 1H), 2.48-2.21 (m, 3H), 2.18-2.01 (m, 3H), 1.99-1.80 (m, 4H), 1.79-1.65 (m, 2H), 1.62-1.49 (m, 4H), 1.41-1.26 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 484 $[M+H]^+$.


865	 (1S,4R)-4-((S)-2-((4-chlorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 497 $[M+H]^+$
866	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(m-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 477 $[M+H]^+$
867	 3-((7S)-6-(methoxycarbonyl)-7-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.49-7.47 (m, 2H), 7.46 (d, J = 9.2Hz, 1H), 7.29-7.31 (s, 1H), 4.94-4.87 (m, 1H), 4.73-4.68 (m, 1H), 3.76-3.75(s, 6H), 3.55-3.54 (m, 1H), 3.14-3.30 (m, 2H), 2.92-2.79 (m, 3H), 2.30-2.24 (m, 4H), 2.23-2.08 (m, 1H), 1.93-1.80(m, 2H), 1.72-1.64 (m, 3H), 1.37-






	methyl-2-(1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1H), 1.95-1.80(m, 2H), 1.72-1.64 (m, 5H), 1.57-1.39 (d, *J* = 6.8 Hz, 3H), 1.12-1.34 (d, *J* = 6.8Hz, 3H). LCMS (ES, *m/z*): 494[M+H]$^+$.
868	 2-(3-(difluoromethyl)phenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.88-7.79 (m, 2H), 7.59-7.50 (m, 4H), 6.95-6.57 (m, 1H), 4.88-4.72 (m, 2H), 4.4-4.36 (m, 1H), 4.13-3.92 (m, 4H), 3.76 (s, 3H), 3.69-3.60 (m, 2H), 3.11-2.85 (m, 2H), 2.48-2.33 (m, 1H), 2.30-2.11 (m, 1H), 1.97-1.78 (m, 3H), 1.67-1.51 (m, 1H), 1.15 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 528 [M+H]$^+$.



869	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-methyl-1-phenylpropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H NMR (CD_3OD, 300 MHz) δ (ppm): 7.40-7.29 (m, 6H), 7.24-7.22 (m, 1H), 4.78-4.75 (m, 1H), 4.43-4.69 (m, 1H), 3.98 (d, *J* = 10.4 Hz, 1H), 3.75 (s, 3H), 3.35-2.28 (m, 1H), 2.96-2.85 (m, 2H), 2.40-2.24 (m, 3H), 2.24-1.65 (m, 6H), 1.39-1.36 (m, 1H), 1.17-1.13 (m, 6H), 0.95-0.88 (m, 4H). LCMS (ES, *m/z*): 504 [M+H]$^+$.
870	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.86-7.78 (m, 4H), 7.53-7.52 (m, 1H), 7.47-7.41 (m, 3H), 7.37-7.34 (m, 1H), 4.87-4.72 (m, 1H), 4.44-4.36 (m, 2H), 3.99-3.75 (m, 7H), 3.49-3.43 (m, 2H), 3.32-3.29 (m, 1H), 2.93-2.88 (m, 1H), 2.22-2.17 (m, 2H), 1.77-1.73 (m, 1H), 1.47-1.44 (m, 2H), 1.13 (d, *J* = 6.4 Hz, 3H), 1.0-0.9 (m, 1H). LCMS (ES, m/z): 528 [M+H]$^-$
871	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62-7.49 (m, 3H), 7.41-7.39 (m, 1H), 6.57-6.55 (m, 1H), 6.35-6.33 (m, 1H), 4.84-4.75 (m, 2H), 4.54-4.49 (m, 2H), 3.78 (s, 3H), 3.56-3.53 (m, 1H), 3.40-3.37 (m, 1H), 3.40-3.37 (m, 1H), 3.33-3.32 (m, 1H), 2.91-2.88(m, 1H), 2.39-2.20 (m, 5H), 1.89-1.64 (m, 5H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 493 [M+H]$^+$.
872	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.45(d, *J*=9Hz, 1H), 7.34(d, *J*=9Hz, 1H), 7.24(d, *J*=8.1Hz, 2H), 7.10(d, *J*–7.8Hz, 2H),4.84-4.70(m, 1H), 4.34-3.85(m, 5H), 3.75(s, 3H), 3.65-3.45(m, 2H), 3.35-3.07(m, 2H), 2.90-2.80(m, 1H),2.35-2.12(m, 5H), 1.75-1.60(m, 3H), 1.25-1.18(m, 1H), 1.12(d, *J*=6.6Hz, 3H)LCMS (ES, *m/z*): 492[M+H]$^+$.




	f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 2nd eluting isomer	


873	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethoxy-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.41-7.31 (m, 4H), 7.30-7.15 (m, 3H), 4.81-4.65(m, 3H), 4.30-4.16(m, 1H), 3.79(s, 3H), 3.18-3.01(m, 3H), 2.84-2.70 (m, 1H), 2.50-2.39 (m, 1H), 2.38-2.11 (m, 2H), 2.08-1.90 (m, 4H), 1.80-1.55 (m, 2H), 1.53-1.35 (m, 2H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 492 [M+H]+.
874	 (1R,3R)-3-((S)-2-benzoyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.13 (d, J = 7.2 Hz, 2H), 7.81-7.55 (m, 5H), 5.18-5.01(m, 1H), , 4.84-4.74 (m, 1H), 3.79 (s, 3H), 3.28-3.11 (m, 1H), 3.03-2.92 (m, 2H), 2.62-2.49 (m, 1H), 2.45-2.19 (m, 4H), 2.12-2.01 (m, 1H), 1.90-1.62 (m, 4H), 1.16 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 476 $[M+H]^+$.
875	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 493 $[M+H]^+$
876	 (1R,3R)-3-((S)-2-((4-fluorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 481 $[M+H]^+$





877	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.47 (m, 2H), 7.40 (s, 1H), 7.36 (d, J = 9.2 Hz, 1H), 4.81-4.69 (m, 1H), 4.66-4.56 (m, 1H), 4.53-4.36 (m, 2H), 4.01-3.88 (m, 1H), 3.77 (s, 3H), 3.26-3.12 (m, 3H), 3.01-2.88 (m, 1H), 2.88-2.70 (m, 2H), 2.48-2.34 (m, 2H), 2.33-2.19 (m, 1H), 1.85-1.78 (m, 1H), 1.76-1.63 (m, 1H), 1.50-1.38 (m, 4H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 471

	imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	[M+H]+.
878	 3-((7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): δ 7.89-7.75 (m, 3H), 7.34 (d, J = 1.6 Hz, 1H), 6.27 (t, J = 2.0 Hz, 1H), 5.13-5.02 (m, 1H), 4.85-4.69 (m, 2H), 4.21-4.19 (m, 1H), 3.80 (s, 3H), 3.19-3.06 (m, 1H), 3.04-2.91 (m, 2H), 2.42-2.32 (m, 2H), 2.30- 2.17 (m, 2H), 2.13-2.01 (m, 2H), 1.96-1.78 (m, 3H), 1.72-1.57 (m, 4H), 1.34-1.25 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 480 $[M+H]^+$.
879	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-methyl-1H-indazol-6-yl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 518 $[M+H]^+$
880	 (1S,4R)-4-((S)-2-((4-fluorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 481 $[M+H]^+$
881	 (1S,4R)-4-((S)-2-((3,4-difluorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 499 $[M+H]^+$
882	 (1S,4R)-4-((S)-2-(benzylsulfonyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.71-7.51 (m, 2H), 7.44-7.13 (m, 5H),4.94 (s, 2H), 4.85-4.72(m, 1H) , 3.81(s, 3H), 3.31-3.01(m, 3H), 2.51-1.76 (m, 7H), 1.71-1.31 (m, 4H), 1.18 (d, J = 6.9 Hz, 3H). LCMS (ES, m/z): 526 $[M+H]^+$.





883	 (1S,4R)-4-((S)-2-((3-fluorophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 482 $[M+H]^+$
884	 (1S,4r)-4-((S)-2-((3-cyanophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 488 $[M+H]^+$



885	 3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(m-tolyl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.48 (d, *J* = 9.2 Hz, 1H), 7.37 (d, *J* = 9.2 Hz, 1H), 7.23-7.15 (m, 2H), 7.14-7.05 (m, 2H), 4.80-4.69 (m, 1H), 4.47-4.32 (m, 1H), 4.26-4.14 (m, 1H), 4.08-4.37 (m, 1H), 3.98-3.90 (m, 2H), 3.76 (s, 3H), 3.71-3.59 (m, 1H), 3.60-3.44 (m, 1H), 3.35-3.33 (m, 1H), 3.23-3.12 (m, 1H), 2.97-2.81 (m, 1H), 2.37-2.14 (m, 5H), 1.80-1.66 (m, 3H), 1.27-1.22 (m, 1H), 1.13 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 492 $[M+H]^+$.
886	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 4th eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, *J* = 9.2 Hz, 1H), 7.41 (d, *J* = 9.2 Hz, 1H), 4.82-4.68 (m, 1H), 4.61-4.43 (m, 1H), 4.02-3.84 (m, 2H), 3.83-3.71 (m, 4H), 3.25-3.00 (m, 3H), 2.99-2.84 (m, 1H), 2.74-2.55 (m, 1H), 2.50-2.24 (m, 3H), 2.23-1.86 (m, 9H), 1.81-1.49 (m, 4H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.
887	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	1H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.34 (s, 1H), 8.20-8.12 (m, 2H), 7.58-7.39 (m, 2H), 6.59 (t, J = 6.8 Hz, 1H), 4.80-4.63 (m, 2H), 3.78 (s, 3H), 3.21-3.12 (m, 1H), 2.96-2.85 (m, 1H), 2.62-2.37 (m, 3H), 2.29-2.08 (m, 4H), 1.99-1.85 (m, 4H), 1.78-1.49 (m, 3H), 1.11 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 494 [M+H]+.




888	 2-(4-isopropylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.54 – 7.35 (m, 2H), 7.31 – 7.17 (m, 4H), 4.85 – 4.69 (m, 1H), 4.44 – 4.28 (m, 1H), 4.28 – 4.17 (m, 1H), 4.09 – 3.90 (m, 2H), 3.78 (s, 3H), 3.73 – 3.60 (m, 1H), 3.60 – 3.46 (m, 1H), 3.45 – 3.35 (m, 1H), 3.28 – 3.11 (m, 1H), 3.01 – 2.81 (m, 2H), 2.37 – 2.15 (m, 2H), 1.85 – 1.66 (m, 3H), 1.23 (d, J = 6.9 Hz, 6H), 1.16 (d, J = 6.6 Hz, 3H), 1.11 – 0.99 (m, 1H). LCMS (ES, m/z): 520 $[M+H]^+$.




889	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 4.80-4.68 (m, 1H), 4.57-4.42 (m, 1H), 4.03-3.93 (m, 1H), 3.79 (s, 3H), 3.56-3.44 (m, 1H), 3.38-3.35 (m, 1H), 3.26-2.98 (m, 3H), 2.97-2.83 (m, 1H), 2.73-2.52 (m, 1H), 2.45-2.03 (m, 6H), 2.00-1.81 (m, 4H), 1.77-1.53 (m, 6H), 1.40-1.26 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 484 $[M+H]^+$.
890	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(2-oxopiperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.02-7.72 (m, 2H), 5.16-4.97 (m, 1H), 4.81-4.76(m, 1H), 4.24-4.03(m, 1H), 3.82(s, 3H), 3.79-3.69(m, 1H),3.63-3.42(m, 4H), 3.13-3.04 (m, 1H), 3.04-2.91 (m, 2H), 2.59-2.39 (m, 3H), 2.39-2.19 (m, 4H), 2.19-2.05 (m, 1H), 2.03-1.78 (m, 7H), 1.72-1.56 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 497 $[M+H]^+$
891	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57-7.50 (m, 1H), 7.47-7.34 (m, 6H), 4.84-4.68 (m, 2H), 4.42-4.27 (m, 1H), 4.13-3.93 (m, 2H), 3.9-3.76 (m, 4H), 3.73-3.60 (m, 1H), 3.29-3.21 (m, 2H), 3.20-3.09 (m, 1H), 3.04-2.86 (m, 2H), 2.74-2.59 (m, 1H), 2.31-2.19 (m, 1H), 1.82-1.67 (m, 1H), 1.15 (d, J = 5.6 Hz, 3H). LCMS (ES, m/z): 514 $[M+H]^-$.
892	 (1R,3R)-3-((S)-2-((1-acetylpiperidin-4-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.54 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 9.0 Hz, 1H), 4.90-4.76 (m, 1H), 4.74-4.54 (m, 1H), 3.95-3.90 (m, 1H), 3.78 (s, 3H), 3.41-3.31 (m, 2H), 3.09-2.87 (m, 3H), 2.80-2.50 (m, 2H), 2.50-2.15 (m, 6H), 2.11 (d, J = 3.9 Hz, 3H), 1.98-1.69 (m, 8H), 1.42-1.38 (m, 2H), 1.14 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$


		





893	 2-(4-chlorophenyl)-3-((7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.50 – 7.42 (m, 1H), 7.40 – 7.30 (m, 5H), 5.08 – 4.90 (m, 1H), 4.80 – 4.70 (m, 1H), 4.35 – 4.20 (m, 1H), 3.80 (s, 3H), 3.78 – 3.70 (m, 1H), 3.40 – 3.32 (m, 1H), 3.18 – 3.05 (m, 1H), 2.92 – 2.86 (m, 1H), 2.40 – 2.16 (m, 3H), 2.12 – 1.95 (m, 3H), 1.90 – 1.65 (m, 4H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 496 $[M+H]^+$.
894	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 – 7.29 (m, 2H), 7.26 (s, 1H), 7.08 (s, 1H), 4.75 – 4.64 (m, 1H), 4.36 – 4.12 (m, 1H), 3.76 (s, 3H), 3.73 (s, 3H), 3.52 – 3.39 (m, 1H), 3.26 – 3.16 (m, 1H), 3.11 – 2.99 (m, 1H), 2.96 – 2.84 (m, 2H), 2.40 – 2.04 (m, 6H), 1.88 – 1.76 (m, 1H), 1.74 – 1.50 (m, 3H), 1.46 (d, *J* = 6.8 Hz, 3H), 1.32 – 1.17 (m, 1H), 1.14 (d, *J* = 6.4 Hz, 3H).LCMS (ES, *m/z*): 494 $[M+H]^+$
895	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 8.19-8.03 (m, 2H), 7.86-7.78 (m, 1H), 7.78-7.67 (m, 2H), 7.67-7.56 (m, 2H), 5.12-4.96(m, 1H) , 4.87-4.68(m, 1H), 3.79(s, 3H), 3.29-3.09(m, 1H), 3.09-2.81 (m, 1H), 2.62-2.43 (m, 1H), 2.38-2.03 (m, 5H), 1.89-1.70 (m, 1H),1.70-1.47 (m, 4H), 1.15 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 512 $[M+H]^+$.
896	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-oxo-2-(piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.93-7.86 (m, 2H), 4.95-4.92 (m, 2H), 4.62-4.59 (m, 1H), 3.83 (s, 3H), 3.72-3.65 (m, 3H), 3.55-3.53 (m, 1H), 3.08-2.99 (m, 3H), 2.43-2.38 (m, 3H), 2.28-2.24 (m, 2H), 2.126 (m, 1H), 1.97-1.56 (m, 11H), 1.17 (d, *J* = 6.8 Hz, 3H). LCMS (ES, m/z): 497 $[M+H]^+$

897	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.52 (d, *J* = 8.4 Hz, 1H), 7.40 (d, *J* = 8.8 Hz, 1H), 4.81-4.68 (m, 1H), 4.57-4.43 (m, 1H), 3.99-3.84 (m, 2H), 3.83-3.72 (m, 4H), 3.23-3.00 (m, 3H), 2.97-2.83 (m, 1H), 2.66-2.52 (m, 1H), 2.48-2.21 (m, 3H), 2.20-2.02 (m, 4H), 2.01-1.82 (m, 5H), 1.80-1.48 (m, 4H), 1.14 (d, *J* = 6.4 Hz, 3H). LCMS (ES, *m/z*): 470 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.92-7.88





898	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 3rd eluting isomer	(m, 2H), 5.19-5.14 (m, 1H), 4.33-4.26 (m, 1H), 3.99-3.97 (m, 1H), 3.83 (s, 3H), 3.73-3.63 (m, 2H), 3.45-3.42 (m, 1H), 3.25-2.90 (m, 4H), 2.52 -2.47 (m, 2H), 2.32-2.22 (m, 5H), 2.11-2.07 (m, 1H), 2.00-1.77 (m, 7H), 1.68-1.59 (m, 4H), 1.18 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$.
899	 (1S,4R)-4-((S)-2-((4-fluoro-3-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 511 $[M+H]^+$
900	 2-(4-chlorophenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51 (d, J = 9.2 Hz, 1H), 7.42-7.27 (m, 5H), 4.80-4.69 (m, 1H), 4.51-4.41 (m, 1H), 4.32-4.23 (m, 1H), 4.12-4.02 (m, 1H), 4.01-3.89 (m, 2H), 3.76 (s, 3H), 3.73-3.64 (m, 1H), 3.60-3.47 (m, 1H), 3.36-3.31 (m, 1H), 3.21-3.08 (m, 1H), 2.96-2.82 (m, 1H), 2.43-2.27 (m, 1H), 2.27-2.13 (m, 1H), 1.83-1.65 (m, 3H), 1.49-1.39 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 512 $[M+H]^+$.


901	 2-(4-(difluoromethyl)phenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.52 (m, 5H), 7.41 (d, J = 8.8 Hz, 1H), 6.92-6.59 (m, 1H), 4.82-4.68 (m, 1H), 4.51-4.25 (m, 2H), 4.15-3.91 (m, 3H), 3.78-3.74 (m, 4H), 3.58-3.56 (m, 1H), 3.39-3.37 (m, 1H), 3.25-3.08 (m, 1H), 2.96-2.87 (m, 1H), 2.40-2.13 (m, 2H), 1.75-1.69 (m, 3H), 1.32-1.28 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^+$.
902	 2-(4-(difluoromethyl)phenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.62-7.49 (m, 5H), 7.42 (d, J = 9.2 Hz, 1H), 6.96-6.59 (m, 1H), 4.83-4.70 (m, 1H), 4.69-4.52 (m, 1H), 4.47-4.35 (m, 1H), 4.07-3.88 (m, 2H), 3.87-3.70 (m, 4H), 3.65-3.54 (m, 1H), 3.50-3.41 (m, 1H), 3.40-3.34 (m, 1H), 3.24-3.10 (m, 1H), 2.99-2.85 (m, 1H), 2.61-2.44 (m, 1H), 2.29-2.19 (m, 1H), 2.17-2.07 (m, 1H), 2.04-1.82 (m, 2H), 1.82-1.66 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 528 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54-7.52 (m, 1H), 7.50-7.24 (m, 6H), 4.86-4.69 (m, 2H), 4.38-4.26 (m, 1H), 4.25-4.13 (m, 1H), 4.12-4.02 (m, 1H), 4.01-3.93 (m, 1H), 3.92-3.80 (m, 1H),




903	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 4th eluting isomer	3.18 (s, 3H), 3.13-3.08 (m, 1H), 3.01-2.96 (m, 1H), 3.25-3.13 (m, 1H), 3.02-2.88 (m, 1H), 2.87-2.66 (m, 1H), 2.33-2.14 (m, 1H), 1.96-1.82 (m, 1H), 1.80-1.68 (m, 1H), 1.16 (d, J = 6.0 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$.
904	 2-(4-cyclopropylphenyl)-3-((7S)-6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 (d, J = 8.8 Hz, 1H) , 7.38 (d, J = 9.2 Hz, 1H) , 7.20 (d, J = 8.0 Hz, 2H) , 7.02 (d, J = 6.8 Hz, 2H),4.76-4.71 (m, 1H), 4.33-4.31(m , 1H) , 4. 20-4.16 (m, 1H), 4.07-3.87 (m, 3H), 3.81(s, 3H), 3.71-3.69 (m, 1H), 3.69-3.46 (m, 1H), 3.45-3.29 (m, 1H), 3.25-3.11 (m, 1H), 2.91-2.87 (m, 1H), 2.27-2.20 (m, 2H), 1.86-1.84 (m, 1H), 1.73-1.67 (m, 3H), 1.14-1.12 (m, 4H) , 0.93-0.91 (m, 2H) , 0.63-0.621 (m, 2H) . LCMS (ES, *m/z*): 518$[M+H]^+$.



905	 3-((7S)-3-(3-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 2nd eluting isomer	^{1}H-NMR (DMSO, 300 MHz) δ (ppm): 12.43 (br, 1H), 8.08 – 7.91 (m, 2H), 7.89 – 7.68 (m, 2H), 7.37 – 7.16 (m, 6H), 6.89 (d, J = 8.7 Hz, 1H), 4.80 – 4.53 (m, 1H), 4.40 – 4.20 (m, 1H), 3.62 (s, 3H), 3.47 – 3.30 (m, 1H), 3.14 – 2.93 (m, 2H), 2.93 – 2.74 (m, 1H), 2.26 – 2.04 (m, 1H), 1.73 – 1.46 (m, 1H), 1.04 (d, J = 6.6 Hz, 3H). LCMS (ES, *m/z*): 495 $[M+H]^-$
906	 3-((7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3-fluoro-4-methylphenyl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.42 (d, J = 9.2 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.18 – 7.00 (m, 3H), 5.08 – 4.90 (m, 1H), 4.80 – 4.70 (m, 1H), 4.25 – 4.18 (m, 1H), 3.76 (s, 3H), 3.73 – 3.67 (m, 1H), 3.36 – 3.33 (m, 1H), 3.14 – 3.10 (m, 1H), 2.92 – 2.86 (m, 1H), 2.25 – 2.16 (m, 6H), 2.08 – 1.92 (m, 3H), 1.90 – 1.72 (m, 4H), 1.12 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 491 $[M+H]^+$.
907	 4-((7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.93-7.79 (m, 3H), 7.38 (s, 1H), 4.79-4.46 (m, 2H), 4.46-4.26 (m, 1H), 4.43-4.28 (m, 1H), 3.83 (s, 3H), 3.19-3.07 (m, 1H), 3.07-2.92 (m, 1H), 2.71-2.52 (m, 1H), 2.52-2.31 (m, 2H),2.31-2.14 (m, 3H), 2.12-1.99 (m, 1H), 1.99-1.84 (m,1H),1.84-1.72 (m,1H), 1.71-1.53 (m, 5H), 1.41-1.26 (m,1H),1.21 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 514 $[M+H]^+$.
908		^{1}H-NMR (CD_3OD, 400 MHz) δ(*ppm*): 7.47-7.43 (m, 2H), 7.40-7.34 (m, 2H), 7.28-7.25 (m, 3H), 4.71-4.67 (m, 1H), 4.46-4.34 (m, 1H), 3.76 (s, 3H), 3.03-2.97 (m, 1H), 2.75-2.69 (m, 1H), 2.43-2.21 (m, 3H), 2.20-2.16 (m, 3H), 2.07-1.99 (m, 2H),



	(1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-phenoxy-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	1.69-1.59 (m, 5H), 1.10 (d, J = 6.4 Hz, 3H). MS: (ES, m/z): 464 $[M+H]^+$.




909	 (1S,4R)-4-((S)-2-((3,5-dimethyl-1H-pyrazol-4-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 481 $[M+H]^+$
910	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.56 (s,1H), 7.49-7.36 (m,3H), 5.03-4.91 (m,1H), 4.82-4.69 (m,1H), 4.66-4.38 (m, 2H), 3.98-3.82 (m,1H), 3.79 (s,3H), 3.31-3.19 (m,1H), 3.19-3.12 (m,3H), 3.01-2.81 (m,3H), 2.64-2.53 (m,1H), 2.53-2.41 (m,1H), 2.37-2.20 (m,1H), 2.20-2.03 (m,2H), 1.83-1.62 (m,1H), 1.43 (d, J =6.9 Hz, 3H), 1.40-1.26 (m,1H), 1.16 (d, J = 6.6 Hz,3H). LCMS (ES, m/z): 497 $[M+H]^+$.
911	 (1S,4R)-4-((S)-2-((1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 526 $[M+H]^+$
912	 4-((7S)-2-(1-(4-(difluoromethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.75 (s, 1H), 7.64 (s, 1H), 7.54 - 7.23 (m, 2H), 6.97 - 6.38 (m, 1H), 4.79 - 4.61 (m, 2H), 4.61 - 4.41 (m, 1H), 4.41 - 4.13 (m, 1H), 4.07 - 3.89 (m, 1H), 3.76 (s, 3H), 3.28 - 3.11 (m, 1H), 3.07 - 2.82 (m, 1H), 2.57 - 2.41 (m, 1H), 2.32 - 2.08 (m, 4H), 1.92 - 1.52 (m,5H), 1.44 - 1.22 (m, 4H), 1.13 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 530 $[M+H]^+$


913	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.56-7.31 (m, 2H), 7.27-7.08 (m, 4H), 4.83-4.62 (m, 2H), 4.32-4.19 (m, 1H), 4.10-3.91 (m, 2H), 3.88-3.78 (m, 4H), 3.71-3.57 (m, 1H), 3.27-3.11 (m, 3H), 3.00-2.80 (m, 2H), 2.72-2.55 (m, 1H), 2.32 (s, 3H), 2.27-2.15 (m, 1H), 1.80-1.68 (m, 1H), 1.15 (d, J =





	methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 3rd eluting isomer	6.0 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.
914	 3-((7S)-3-(4-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.93 (d, *J* = 8.7 Hz, 2H), 7.52 – 7.33 (m, 3H), 7.28 – 7.04 (m, 5H), 6.88 (d, *J* = 8.7 Hz, 1H), 4.82 – 4.68 (m, 1H), 4.40 – 4.16 (m, 1H), 3.75 (s, 3H), 3.65 – 3.44 (m, 1H), 3.25 – 3.10 (m, 2H), 3.03 – 2.84 (m, 1H), 2.37 – 2.16 (m, 1H), 1.83 – 1.64 (m, 1H), 1.15 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 495 $[M+H]^+$
915	 (1S,4R)-4-((S)-2-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 481 $[M+H]^+$
916	 (1R,3R)-3-((S)-2-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 481 $[M+H]^+$





917	 4-((7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.97-7.79 (m, 2H), 7.69 (d, *J* = 2.4 Hz, 1H), 7.42 (d, *J* = 2.0 Hz, 1H), 6.29-6.27 (m, 1H), 4.76-4.62 (m, 2H), 4.58-4.39 (m, 1H), 4.39-4.21 (m, 1H), 3.80 (s, 3H), 3.23-3.07 (m, 1H), 3.07-2.85 (m,1H), 2.64-2.51 (m, 1H), 2.43-2.09 (m, 5H), 2.09-1.97 (m,1H), 1.97-1.83 (m,1H), 1.81-1.65 (m,1H), 1.65-1.42 (m, 5H), 1.32-1.21 (m,1H), 1.19 (d, *J* = 6.8 Hz, 3H). LCMS: (ES, *m/z*):480 $[M+H]^+$.
918	 4-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53-7.39 (m, 1H), 7.39-7.24 (m, 2H), 7.24-7.12 (m, 1H), 4.79-4.66 (m, 1H), 4.66-4.48 (m, 1H), 4.48-4.39 (m, 1H), 4.31-4.19 (m, 1H),4.01-3.81 (m, 1H), 3.76 (s, 3H), 3.29-3.08 (m, 1H), 3.02-2.82 (m, 1H), 2.64-2.41 (m, 1H), 2.41-2.01 (m, 5H),1.95 (s, 3H),1.94-1.79 (m,1H), 1.79-1.58 (m, 3H), 1.52-1.41 (m,1H),1.41 (d, *J* = 6.9 Hz, 3H), 1.15 (d, *J* = 6.9 Hz, 3H). LCMS: (ES, *m/z*):494 $[M+H]^+$


	yl)cyclohexane-1-carboxylic acid 1st eluting isomer	
919	 methyl (7S)-7-methyl-2-(1-phenylpropan-2-yl)-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	1H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.29 (d, J = 9.0 Hz, 1H), 7.19-7.14 (m, 4H), 7.13-7.05 (m, 2H), 4.85-4.71 (m, 1H), 3.75-3.52 (m, 7H), 3.42 (s, 2H), 3.32-2.80 (m, 4H), 2.26-1.65 (m, 8H), 1.62-1.50 (m, 4H), 1.15 (d, J = 6.6 Hz, 3H), 0.78-0.60 (m, 1H). LCMS (ES, *m/z*): 487 $[M+H]^+$.
920	 2-(4-(difluoromethyl)phenyl)-3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63-7.51 (m, 5H), 7.44 (d, J = 8.8 Hz, 1H), 6.92-6.58 (m, 1H), 4.88-4.84 (m, 1H), 4.83-4.69 (m, 1H), 4.48-4.36 (m, 1H), 4.16-4.06 (m, 1H), 4.04-3.95 (m, 1H), 3.94-3.82 (m, 1H), 3.79 (s, 3H), 3.76- 3.67 (m, 1H), 3.54-3.42 (m, 1H), 3.30-3.25 (m, 1H), 3.23-3.12 (m, 1H), 3.00-2.86 (m, 2H), 2.78-2.63 (m, 1H), 2.33-2.16 (m, 1H), 1.80-1.67 (m, 1H), 1.14 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 564 $[M+H]^+$.




921	 methyl (7S)-2-(1-(3,4-difluorophenyl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.32 (d, J = 8.8 Hz, 1H), 7.19 (d, J = 9.2 Hz, 1H), 7.1-6.99 (m, 2H), 6.93-6.82 (m, 1H), 4.82-4.68 (m, 1H), 4.32-4.11 (m, 1H), 3.80-3.72 (m, 3H), 3.72-3.65 (m, 2H), 3.62-3.47 (m, 3H), 3.31-3.13 (m, 2H), 3.12-3.01 (m, 1H), 2.96-2.84 (m, 1H), 2.35-1.97 (m, 5H), 1.82-1.65 (m, 3H), 1.61-1.44 (m, 4H), 1.14 (d, J = 6.8 Hz, 3H), 1.02-0.88 (m, 1H). LCMS (ES, *m/z*): 523 $[M+H]^+$.
922	 (1R,3R)-3-((S)-2-(cyclopentylcarbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.59-7.52 (m, 1H), 7.47-7.39 (m, 1H), 5.06-4.91 (m, 1H), 4.76-4.65 (m, 1H), 4.44-4.33(m, 1H), 3.80 (s, 3H), 3.39-3.19 (m, 1H), 3.02-2.65(m, 4H), 2.32-2.05(m, 5H), 1.92-1.77(m, 3H), 1.76-1.45 (m, 8H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, *m/z*): 483 $[M+H]^+$.
923	 (1R,3R)-3-((S)-2-(cyclopentyl(methyl)carbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46-7.38 (m, 2H), 5.24-5.19 (m, 1H), 4.75-4.69 (m, 1H), 4.68-4.20 (m, 1H), 3.79 (s, 3H), 3.33-3.11 (m, 4H), 2.92-2.56 (m, 4H), 2.23-2.13(m, 1H), 2.09-1.99 (m, 5H), 1.77-1.46 (m, 10H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 497 $[M+H]^+$.




924	 (1R,3R)-3-((S)-2-((2-chlorophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 511 $[M+H]^+$



925	 (1R,3R)-3-((S)-2-(cyclohexylcarbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55 (d, *J* = 9.6 Hz, 1H), 7.42 (d, *J* = 9.2 Hz, 1H), 5.02-4.89 (m, 1H), 4.72-4.70 (m, 1H), 4.02-3.98 (m, 1H), 3.79 (s, 3H), 3.26 (m, 1H), 2.98-2.96 (m, 1H), 2.91-2.71 (m, 3H), 2.29-2.12 (m, 3H), 2.14-2.10 (m, 2H), 2.09-1.80 (m, 3H), 1.80-1.62 (m, 4H), 1.60-1.25 (m, 6H), 1.15 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 497 $[M+H]^+$.
926	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.64 (s, 1H),7.64-7.55 (m, 1H), 7.52-7.44 (m, 2H), 5.58-5.45 (m, 1H), 4.90-4.42 (m, 3H), 4.02-3.89 (m, 1H), 3.77 (s, 3H), 3.72-3.40 (m, 3H), 3.34-3.18 (m, 2H), 2.98-2.72 (m, 2H), 2.39-2.20 (m, 2H), 1.73-1.67 (m, 1H), 1.40 (d, *J*=6.9 Hz, 3H), 1.13 (d, *J*=6.6 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.
927	 3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propanoic acid 4th eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.55-7.36 (m, 2H), 7.28-7.05 (m, 4H), 4.83-4.65 (m, 2H), 4.29-4.11 (m, 2H), 4.09-3.90 (m, 2H), 3.91-3.70 (m, 4H), 3.69-3.55 (m, 1H), 3.25-3.11 (m, 2H), 3.01-2.85 (m, 1H), 2.79-2.65 (m, 1H), 2.37-2.15 (m, 4H), 1.82-1.64 (m, 2H), 1.16 (d, *J* – 6.0 Hz, 3H). LCMS (ES, *m/z*): 528 $[M+H]^+$.
928	 methyl (7S)-7-methyl-2-(1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 (d, *J* = 8.8 Hz, 1H), 7.36 (d, *J* = 8.8 Hz, 1H), 7.15 (d, *J* = 3.2 Hz, 2H), 4.81 – 4.67 (m, 1H), 4.63 – 4.49 (m, 1H), 3.77 (s, 3H), 3.70 (s, 3H), 3.57 – 3.37 (m, 3H), 3.27 – 3.17 (m, 1H), 3.17 – 2.99 (m, 2H), 2.99 – 2.89 (m, 3H), 2.62 – 2.44 (m, 2H), 2.33 – 2.20 (m, 1H), 2.00 – 1.88 (m, 1H), 1.77 – 1.64 (m, 1H), 1.49 (d, *J* = 6.8 Hz, 3H), 1.17 – 1.04 (m, 4H).. LCMS (ES, *m/z*): 451 $[M+H]^+$





929	 3-((7S)-6-(methoxycarbonyl)-7-methyl-2-(1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.54-7.38 (m, 2H), 4.76-4.74 (m, 1H), 4.61 (m, 1H), 3.88-3.85 (m, 1H), 3.79-3.70 (m, 4H), 3.66-3.62 (m, 1H), 3.37-3.32 (m, 1H), 3.25-3.15 (m, 2H), 2.95-2.90 (m, 1H), 2.65 (m, 1H), 2.39-2.26 (m, 5H), 2.20-2.04 (m, 3H), 1.91-1.88 (m, 1H), 1.74-1.66 (m, 5H). 1.63-1.58 (m, 2H), 1.44 (d, J = 6.8 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$.
930	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.63-7.41 (m, 4H), 5.60-5.48 (m, 1H), 4.88 (s, 1H), 4.79-4.45 (m, 2H), 4.01-3.91 (m, 1H), 3.77 (s, 3H), 3.45 (d, J=9 Hz, 3H), 3.32-3.30 (m, 2H), 2.94-2.92 (m, 2H), 2.65-2.55 (m, 1H), 2.32-2.18 (m, 1H), 1.75-1.65 (m, 1H), 1.40 (d, J=6.9 Hz, 3H), 1.13 (d, J=6.6 Hz, 3H). LCMS (ES, m/z): 506 $[M+H]^+$.
931	 methyl (7S)-2-(1-(3,4-difluorophenyl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.51 (d, J = 8.8 Hz, 1H), 7.36 (d, J = 9.2 Hz, 1H), 7.16-7.02 (m, 2H), 6.95-6.88 (m, 1H), 4.81-4.65 (m, 1H), 4.49-4.31 (m, 1H), 3.79 (s, 3H), 3.69-3.57 (m, 1H), 3.33-3.05 (m, 5H), 3.00-2.88 (m, 1H), 2.88-2.75 (m, 1H), 2.76-2.65 (m, 1H), 2.53-2.23 (m, 3H), 1.81-1.65 (m, 2H), 1.51 (d, J = 6.8 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H), 1.00-0.83 (m, 1H). LCMS (ES, *m/z*): 483 $[M+H]^+$.
932	 methyl (7S)-3-(azepan-4-yl)-2-((S)-1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.57 (s, 1H), 7.52-7.32 (m, 3H), 4.82-4.68 (m, 1H), 4.70-4.54 (m, 2H), 4.53-4.45 (m, 1H), 4.05-3.88 (m, 1H), 3.78 (s, 3H), 3.30-3.20 (m, 1H), 3.19-3.00 (m, 3H), 2.98-2.87 (m, 2H), 2.57-2.35 (m, 2H), 2.35-2.19 (m, 1H), 2.07-2.01 (m, 1H), 1.98-1.87 (m, 1H), 1.85-1.67 (m, 2H), 1.63-1.48 (m, 1H), 1.45 (d, J = 6.8 Hz, 3H), 1.16 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 485 $[M+H]^+$.






933	 (1S,4R)-4-((S)-2-((3-fluoropyridin-4-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, *m/z*): 482 $[M+H]^+$
		




934	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)carbamoyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63-7.59 (m, 2H), 7.41-7.31 (m, 2H), 7.22-7.11 (m, 3H), 4.94 (m, 2H), 4.88-4.72 (m, 1H), 3.81 (s, 3H), 3.50 (s, 3H), 2.98-2.87 (m, 2H), 2.61-2.51 (m, 2H), 2.28-2.21 (m, 1H), 2.19-2.11 (m, 2H), 1.76-1.73 (m, 2H), 1.66-1.63 (m, 1H), 1.58-1.55 (m, 2H), 1.18 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 505 $[M+H]^+$.
935	 methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(piperazin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate	^{1}H-NMR ($CDCl_3$, 300 MHz) δ (ppm): 7.53 (s, 1H), 7.42 (d, J = 8.7 Hz, 1H), 7.24 (s, 1H), 7.06 (d, J = 8.7 Hz, 1H), 6.13 (t, J = 2.1 Hz, 1H), 4.85-4.76 (m, 1H), 4.72 (t, J = 6.6 Hz, 2H), 3.90 (t, J = 6.6 Hz, 2H), 3.78 (s, 3H), 3.45 (t, J = 6.6 Hz, 2H), 3.31-3.16 (m, 1H), 3.08-2.92 (m, 1H), 2.90-2.82 (m, 4H), 2.51 (t, J = 6.6 Hz, 2H), 2.48-2.41 (m, 4H), 2.31-2.20 (m, 1H), 1.78-1.63 (m, 1H), 1.16 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 452 $[M+H]^+$.
936	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (DMSO, 400 MHz) δ (ppm): 8.02 (s, 1H), 7.55 (s, 1H), 7.31-7.15 (m, 2H), 4.62-455 (m, 1H), 4.54-4.35 (m, 2H), 4.30-4.15 (m, 1H), 3.85-3.70 (m, 2H), 3.65 (s, 3H), 3.45-3.35 (m, 2H), 3.35-3.25 (m, 2H), 3.12-3.01 (m, 1H), 2.85-2.75 (m, 1H), 2.20-1.90 (m, 5H), 1.80-1.46 (m, 5H), 1.18 (d, J = 6.8 Hz, 3H), 1.06 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$.



937	 2-(4-(difluoromethyl)phenyl)-3-((7S)-3-(5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propanoic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.60-7.47 (m, 5H), 7.43 (d, J = 9.2 Hz, 1H), 6.90-6.56 (m, 1H), 4.88-4.81 (m, 1H), 4.80-4.71 (m, 1H), 4.38-4.28 (m, 1H), 4.25-4.14 (m, 1H), 4.13-4.07 (m, 1H), 4.03-3.93 (m, 1H), 3.94-3.80 (m, 1H), 3.78 (s, 3H), 3.73-3.63 (m, 1H), 3.32-3.26 (m, 1H), 3.24-3.12 (m, 1H), 2.98-2.87 (m, 1H), 2.86-2.70 (m, 1H), 2.34-2.17 (m, 1H), 2.00-1.89 (m, 1H), 1.84-1.69 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 564 $[M+H]^+$.
938	 methyl (7S)-3-(azepan-4-yl)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.63 (s, 1H), 7.51-7.34 (m, 3H), 4.82-4.73 (m, 1H), 4.72-4.59 (m, 2H), 4.58-4.44 (m, 1H), 4.05-3.88 (m, 1H), 3.79 (s, 3H), 3.55-3.34 (m, 3H), 3.30-3.16 (m, 2H), 3.01-2.87 (m, 1H), 2.75-2.59 (m, 1H), 2.54-2.42 (m, 1H), 2.36-2.23 (m, 1H), 2.21-1.95 (m, 3H), 1.88-1.67 (m, 2H), 1.44 (d, J = 6.8 Hz, 3H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z): 485 $[M+H]^+$.
		^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.53-7.46 (m, 2H), 4.98-4.89 (m, 1H), 4.78-4.73 (m, 2H)



939	 (1R,3R)-3-((S)-2-(cyclohexyl(methyl)carbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	(m, 2H), 4.58-4.49 (m, 1H), 4.70-4.75 (m, 2H), 3.80 (s, 3H), 3.27-3.21 (m, 1H), 3.15 (s, 3H), 3.05-2.92 (m, 1H), 2.92-2.70 (m, 3H), 2.30-2.15 (m, 3H), 1.98-1.81 (m, 5H), 1.80-1.52 (m, 7H), 1.52-1.40 (m, 2H), 1.31-1.20 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H). LCMS (ES, m/z):511 $[M+H]^+$.
940	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(7-azaspiro[3.5]nonan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61(s, 1H),7.54-7.51(m, 2H), 7.43(s, 1H), 5.05-4.95(m, 2H), 4.85-4.70(m, 1H), 4.58-4.45(m, 2H), 4.00-3.85(m, 1H), 3.75(s, 3H),3.25-3.10(m, 4H),2.98-2.88(m, 1H), 2.75-2.55(m, 3H), 2.30-2.15(m, 2H), 2.05-1.95(m, 4H), 1.80-1.70(m, 1H), 1.43(d, J=7.2Hz, 3H),1.14(d, J=6.8Hz, 3H). LCMS (ES, m/z): 511 $[M+H]^+$.




941	 (1R,3R)-3-((S)-2-((3-fluoropyridin-4-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 482 $[M+H]^+$
942	 methyl (7S)-3-(azepan-4-yl)-7-methyl-2-(1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.41-7.24 (m, 2H), 7.20-7.03 (m, 5H), 4.79-4.64 (m, 1H), 4.46-4.42 (m, 1H), 3.76 (s, 3H), 3.62-3.49 (m, 1H), 3.31-3.15 (m, 2H), 3.12-3.01 (m, 2H), 2.99-2.78 (m, 3H), 2.71-2.68 (m, 1H), 2.46-2.36 (m, 1H), 2.34-2.12 (m, 2H), 1.95-1.79 (m, 2H), 1.79-1.61 (m, 2H), 1.49 (d, J = 6.8 Hz, 3H), 1.16 (d, J = 6.8 Hz, 3H), 1.02-0.98 (m, 1H). LCMS (ES, m/z): 461 $[M+H]^+$.
943	 (1S,4R)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((2-methylpyridin-4-yl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	LCMS (ES, m/z): 478 $[M+H]^+$
		^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.56 (s, 1H), 7.43 (s, 1H), 7.42-7.36 (m, 2H), 5.16-5.05 (m, 1H), 4.80-4.70 (m, 1H), 4.70-4.59 (m, 1H), 4.55-4.44 (m, 1H), 4.05-3.89 (m, 1H), 3.79 (s, 3H), 3.45-3.35 (m, 1H), 3.29-3.07 (m


944	methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	[illegible], 4H), 3.01-2.87 (m, 1H), 2.41-2.20 (m, 3H), 1.80-1.64 (m, 1H), 1.41 (d, *J* = 6.9 Hz, 3H), 1.13 (d, *J* = 6.6 Hz, 3H). LCMS (ES, *m/z*): 457 $[M+H]^+$.
945	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 4th eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.77-7.56(m, 3H), 7.44 (s, 1H), 6.22 (t, *J* = 2.0 Hz, 1H), 4.99-4.92 (m, 1H), 4.83-4.79(m, 1H), 4.67 (d, *J* = 6.0 Hz, 2H), 4.13-4.01(m, 1H), 3.99-3.89 (m, 1H), 3.79(s, 3H), 3.50-3.30 (m, 1H), 3.19-2.99 (m, 3H), 2.80-2.45 (m, 2H), 2.35-2.01 (m, 4H), 1.90-1.75 (m, 1H), 1.57 (d, *J* = 6.8 Hz, 3H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 486 $[M+H]^+$.
946	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.61 (d, *J* = 2.0 Hz, 1H), 7.44 (d, *J* = 2.0 Hz, 1H), 7.40 (m, 2H), 6.14-6.13 (m, 1H), 4.80-4.60 (m, 3H), 4.55-4.45 (m, 1H), 4.02-3.89 (m, 1H), 3.79(s, 3H), 3.80-3.35 (m, 2H), 3.28-2.99 (m, 4H), 2.95-2.81 (m, 2H), 2.31-2.11 (m, 2H), 1.65 -1.55 (m, 2H), 1.43 (d, *J* = 7.2 Hz, 3H), 1.13 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 486 $[M+H]^+$.
947	 methyl (7S)-7-methyl-2-(1-phenylpropan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.46 (d, *J* = 8.8 Hz, 1H), 7.33 (d, *J* = 9.2 Hz, 1H), 7.19-7.06 (m, 5H), 4.81-4.68 (m, 1H), 4.31-4.20 (m, 1H), 3.78 (s, 3H), 3.70-3.56 (m, 1H), 3.28-3.20 (m, 1H), 3.20-3.02 (m, 3H), 3.02-2.88 (m, 2H), 2.80-2.71 (m, 1H), 2.59-2.47 (m, 1H), 2.41-2.30 (m, 1H), 2.30-2.21 (m, 1H), 2.21-1.99 (m, 1H), 1.81-1.68 (m, 2H), 1.53 (d, *J* = 6.8 Hz, 3H), 1.15 (d, *J* = 6.8 Hz, 3H), 0.70-0.56 (m, 1H). LCMS (ES, *m/z*): 447 $[M+H]^+$.
948	 (1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylcarbamoyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 8.02 (d, *J* = 8.4 Hz, 2H), 7.65-7.56 (m, 2H), 7.41-7.36 (m, 2H), 7.10-7.06 (m, 1H), 4.88 (m, 1H), 4.80-4.74 (m, 1H), 3.81 (s, 3H), 3.34-3.26 (m, 1H), 3.06-2.76 (m, 4H), 2.27-2.19 (m, 3H), 1.90-1.60 (m, 5H), 1.17 (d, *J* = 6.8 Hz, 3H). LCMS (ES, *m/z*): 491 $[M+H]^+$.
949		^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53-7.24 (m, 4H), 5.55-5.38 (m, 1H), 4.82-4.65 (m, 1H),4.55-4.28 (m, 2H), 4.13-3.75 (m, 4H), 3.50-3.20 (m, 5H), 3.18-2.78 (m, 2H), 2.62-2.48 (m, [illegible]



949	methyl (7S)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-(1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	1H), 2.28-2.16 (m, 1H), 2.06-2.00 (m, 1H), 1.98 (s, 2H), 1.75-1.58 (m, 1H), 1.41 (d, J = 6.9 Hz, 2H) ,1.32-1.26 (m, 1H) , 1.12 (d, J = 6.6 Hz, 2H). LCMS (ES, m/z): 486 $[M+H]^+$.
950	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD3OD, 300 MHz) δ (ppm): 8.28 – 7.93 (m, 1H), 7.62 – 7.32 (m, 3H), 5.10 – 4.99 (m, 1H), 4.81-4.62 (m, 2H), 4.53 – 4.45 (m, 1H), 4.05-3.86 (m, 1H), 3.75 (s, 3H), 3.65-3.52 (m, 3H), 3.26 – 2.83 (m, 3H), 2.31 – 1.97 (m, 3H), 1.71 – 1.56 (m, 1H), 1.43 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H). LCMS (ES, m/z): 457 [M+H]+.
951	 methyl (7S)-7-methyl-2-(1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.47 (d, J = 9.2 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.24 (s, 1H), 7.14 (s, 1H), 4.80 – 4.67 (m, 1H), 4.62 – 4.43 (m, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 3.55 – 3.45 (m, 1H), 3.43 – 3.33 (m, 2H), 3.28 – 3.20 (m, 1H), 3.13 – 2.97 (m, 2H), 2.97 – 2.84 (m, 3H), 2.67 – 2.35 (m, 2H), 2.35 – 2.16 (m, 1H), 1.94 – 1.84 (m, 1H), 1.76 – 1.65 (m, 1H), 1.47 (d, J = 6.8 Hz, 3H), 1.26 – 1.08 (m, 4H).LCMS (ES, *m/z*): 451 $[M+H]^+$
952	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.60 (s, 1H), 7.53 (d, J = 9.2 Hz, 1H), 7.43 (s, 1H), 7.36 (d, J = 9.2 Hz, 1H), 4.79-4.69 (m, 1H), 4.67-4.54 (m, 1H), 4.52-4.36 (m, 2H), 4.01-3.88 (m, 1H), 3.76 (s, 3H), 3.29-3.15 (m, 3H), 2.98-2.69 (m, 3H), 2.53-2.19 (m, 3H), 1.85-1.76 (m, 1H), 1.77-1.65 (m, 1H), 1.51-1.41 (m, 1H), 1.40 (d, J = 6.8 Hz, 3H), 1.13 (d, J = 6.4 Hz, 3H). LCMS (ES, *m/z*): 471 $[M+H]^+$.

953	 methyl (7S)-3-(azepan-4-yl)-7-methyl-2-(1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 3rd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.38-7.25 (m, 2H), 7.21-7.00 (m, 5H), 4.78-4.67 (m, 1H), 4.43-4.39 (m, 1H), 3.75 (s, 3H), 3.65-3.51 (m, 1H), 3.31-3.18 (m, 1H), 3.18-3.12 (m, 1H), 3.11-2.98 (m, 4H), 2.98-2.75 (m, 2H), 2.44-2.32 (m, 1H), 2.32-2.18 (m, 2H), 2.03-1.99 (m, 1H), 1.78-1.59 (m, 2H), 1.54 (d, J = 6.8 Hz, 3H), 1.50-1.35 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H), 0.91-0.86 (m, 1H). LCMS (ES, *m/z*): 461 $[M+H]^+$.
954	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.82-7.62 (m, 3H), 7.44 (s, 1H), 6.22 (t, J = 2.4 Hz, 1H), 4.86-4.67 (m, 4H), 4.13-3.95(m, 2H), 3.79(s, 3H), 3.50-3.30 (m, 2H), 3.19-2.99 (m, 3H), 2.50-2.31 (m, 1H), 2.28-2.15 (m, 2H), 2.03 -1.79 (m, 2H), 1.57 (d, J = 6.8 Hz, 3H), 1.56-1.47 (m, 1H), 1.13

	dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	(d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 486 $[M+H]^+$.
955	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.86 (s, 2H), 7.70 (s, 1H), 7.42 (s, 1H), 6.33-6.28 (m, 1H), 5.82-5.60 (m, 1H), 4.92-4.65 (m, 3H), 4.35-4.22 (m, 1H), 3.82-3.75 (m, 4H), 3.72-3.42 (m, 2H), 3.25-2.92 (m, 3H), 2.85-2.65 (m, 1H), 2.35-2.14 (m, 2H), 1.98-1.85 (m, 1H), 1.61 (d, J=7.2 Hz, 3H), 1.18 (d, J=6.6 Hz, 3H). LCMS (ES, m/z): 472 $[M+H]^+$.
956	 methyl (7S)-2-(1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 1st eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.53-7.40 (m, 4H), 6.19-6.17 (m, 1H), 5.55-5.38 (m, 1H), 4.80-4.45 (m, 3H), 3.98-3.85 (m, 1H), 3.75 (s, 3H), 3.54-3.10 (m, 5H), 2.95-2.78 (m, 2H), 2.62-2.48 (m, 1H), 2.28-2.15 (m, 1H), 1.75-1.68 (m, 1H), 1.43 (d, J = 6.9 Hz, 3H) , 1.13 (d, J=6.9 Hz, 3H). LCMS (ES, m/z): 472 $[M+H]^+$.

957	 3-((7S)-2-(1-(5-fluoro-2-methoxyphenyl)-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 2nd eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.24 (d, J = 8.8 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 6.93-6.84 (m, 2H), 6.66-6.62 (m, 1H), 4.74-4.61 (m, 1H), 4.52-4.39 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.05-2.99 (m, 1H), 2.85-2.70 (m, 2H), 2.69-2.58 (m, 1H), 2.55-2.45 (m, 1H), 2.41-2.32 (m, 1H), 2.31-2.20 (m, 1H), 2.18-2.07 (m, 1H), 1.86-1.60 (m, 7H), 1.52-1.35 (m, 1H), 1.06 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 540 $[M+H]^+$.
958	 methyl (7S)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-(1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-6-carboxylate 2nd eluting isomer	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.85 (s, 2H), 7.49 (s, 1H), 7.23 (s, 1H), 5.78-5.62 (m, 1H), 4.91-4.53 (m, 3H), 4.28-4.15 (m, 1H), 3.84-3.40 (m, 6H), 3.32-2.94 (m, 3H), 2.86-2.68 (m, 1H), 2.35-2.14 (m, 2H), 2.00 (s, 3H), 1.95-1.84 (m, 1H), 1.58 (d, J = 6.6 Hz, 3H) 1.28 (d, J = 6.6 Hz, 3H). LCMS (ES, m/z): 486 $[M+H]^+$.
959	 methyl (7S)-2-(1-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinoline-	^{1}H-NMR (CD_3OD, 300 MHz) δ (ppm): 7.56 (s, 1H), 7.52-7.32(m, 3H), 5.04-4.92 (m, 1H), 4.83-4.69 (m, 1H), 4.68-4.52 (m, 1H), 4.52-4.37(m, 1H), 4.01-3.82 (m, 1H), 3.79 (s, 3H), 3.31-3.15 (m, 2H), 3.15-3.09 (m, 2H), 3.09-2.82 (m, 4H), 2.72-2.56 (m, 1H), 2.56-2.38 (m, 1H), 2.37-2.21 (m, 1H), 2.18-1.98 (m, 2H), 1.85-1.68 (m, 1H), 1.42 (d, J =6.9 Hz, 3H), 1.17 (d, J = 6.9 Hz, 3H). LCMS (ES, m/z): 497 $[M+H]^+$.

	6-carboxylate 3rd eluting isomer	
960	 3-((7S)-2-(1-(5-fluoro-2-methoxyphenyl)-1-hydroxyethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 6.95-6.81 (m, 4H), 6.68-6.65 (m, 1H), 4.74-4.61(m, 1H), 4.52-4.39 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 2.95-2.60 (m, 4H), 2.49-2.35 (m, 1H), 2.21-2.05 (m, 3H), 1.96-1.85 (m, 2H), 1.80 (s, 3H), 1.72-1.55 (m, 3H), 0.95 (d, J = 6.8 Hz, 3H). LCMS (ES, m/z): 540 $[M+H]^+$.

961	 (1R,3R)-3-((S)-2-((2-chlorophenyl)carbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 9.06-9.04 (m, 1H), 7.71-7.63 (m, 2H), 7.51-7.48(m, 1H), 7.44-7.39(m, 1H), 7.10-7.05 (m, 1H), 5.07-5.01 (m, 1H), 4.88-4.76 (m, 1H), 3.82(s, 3H), 3.34-3.26(m, 1H), 3.09-2.76 (m, 4H), 2.28-2.20 (m, 3H), 1.91-1.60 (m, 5H), 1.17 (d, J = 6.8Hz, 3H). LCMS (ES, m/z): 525 $[M+H]^+$.
962	 3-((7S)-2-(hydroxy(1-methyl-1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexane-1-carboxylic acid 1st eluting isomer	^{1}H-NMR (CD_3OD, 400 MHz) δ (ppm): 7.75(s, 1H), 7.45-7.32 (m, 3H), 7.19-7.15 (m, 2H), 6.43(s, 1H), 6.42(s, 1H), 5.04- 4.91 (m, 1H), 4.80- 4.79 (m, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.31-3.22 (m, 1H), 3.11-3.00 (m, 1H), 2.91-2.85 (m, 1H), 2.45-2.31 (m, 2H), 2.28-2.21 (m, 1H), 2.12-2.00 (m, 1H), 1.91-1.70 (m, 2H), 1.55-1.30 (m, 2H), 1.25-1.18 (m, 1H), 1.16 (d, J = 6.8 Hz, 3H), 0.82-0.78 (m, 1H). LCMS (ES, m/z): 531 $[M+H]^+$.

Example 963: HTRF biochemical assay for CBP and BRD4 activity

[0566] The assay was performed in a final volume of 6 µL in assay buffer containing 50 mM Hepes (pH 7.5, (0.5M Hepes, pH 7.5 solution; Teknova H1575)), 0.5 mM GSH, 0.01% BGG (0.22 µM filtered, Sigma, G7516-25G), 0.005% BSA (0.22 µM filtered, EMD Millipore Cosporation, 126575) and 0.01% Triton X-100 (Sigma, T9284-10L). Nanoliter quantities of 10-point, 3-fold serial dilution in DMSO were pre-dispensed into 1536 assay plates (Corning, #3724BC) for a final test concentration of 33 µM to 1.7 nM, top to lowest dose, respectively. 3 µL of 2x Protein and 3 µL of 2 x Peptide Ligand were added to assay plates (pre-stamped with compound). Plates were incubated for varying times at room temperature prior to measuring the signal. TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) was measured on the PHERAstar (BMG, equipped with HTRF optic module [337/520/490]) or on the Envision (PerkinElmer, equipped with the TRF Laser unit, TRF dual mirror D400/D505 and

emission filters M520 and M495). Data were reported as percent inhibition compared with control wells based on the following equation: %inh = 1-((TR-FRET ratio - AveLow) / (AveHigh - AveLow)) where TR-FRET ratio = (Fluorescence at 520nm/Fluorescence at 490nm) * 10000), AveLow = average TR-FRET ratio of no enzyme control (n=32), and AveHigh= average TR-FRET ratio of DMSO control (n = 32). IC50 values were determined by curve fitting of the standard 4 parameter logistic fitting algorithm included in the Activity Base software package: IDBS XE Designer Model205. Data is fitted using the Levenburg Marquardt algorithm. For all assay formats data were reported as percent inhibition compared with control wells based on the following equation: %inh = 100*((FLU - AveLow) / (AveHigh - AveLow)) where FLU = measured Fluorescence, AveLow = average Fluorescence of no enzyme control (n=32), and AveHigh= average Fluorescence of DMSO control (n=32). IC50 values were determined by curve fitting of the standard 4 parameter logistic fitting algorithm included in the Activity Base software package: IDBS XE Designer Model205. Data is fitted using the Levenburg Marquardt algorithm. IC_{50} values are shown in Table 19, below. As set forth in Table 19 below, an IC_{50} value of greater than or equal to 0.001 μM and less than or equal to 0.01 μM is marked "++++"; a value greater than 0.01 μM and less than or equal to 0.1 μM is marked "+++"; a value greater than 0.1 μM and less than or equal to 1 μM is marked "++"; and a value greater than 1 μM and less than 1000 μM is marked "+." Compounds that were not tested in a particular assay are marked "NT."

Table 19 - IC_{50} Values

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
1	+	+
2	++	+
3	++	+
4	+	+
5	+	+
6	++	+
7	++	+
8	++	NT
9	+	+
10	+	+
11	+	+
12	+	+
13	+	+
14	+	+
15	+	+
16	++++	+
17	+++	+
18	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
19	+++	+
20	++	+
21	++	+
22	++	+
23	+++	+
24	+++	+
25	+++	+
26	++	+
27	++++	+
28	++++	+
29	+++	+
30	++	+
31	+++	+
32	++	+
33	++	+
34	++	+
35	++	+
36	+++	+
37	+++	+
38	++	+
39	+++	+
40	+++	+
41	+++	+
42	+++	+
43	+++	+
44	++	+
45	++	+
46	+++	+
47	++	+
48	++	+
49	++	+
50	++	+
51	++	+
52	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
53	+++	+
54	+++	+
55	++	+
56	+++	+
57	+++	+
58	++	+
59	++	+
60	++++	+
61	+++	+
62	+++	+
63	++	+
64	++++	+
65	+++	+
66	+++	+
67	++	+
68	++	++
69	+++	+
70	++	+
71	++	+
72	+++	+
73	+++	+
74	+++	+
75	+++	++
76	++++	++
77	+++	+
78	+	+
79	++	+
80	++	+
81	+++	+
82	+++	+
83	++	+
84	++	+
85	++	+
86	+	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
87	+	+
88	++	+
89	+	+
90	++	+
91	++	+
92	+++	++
93	++	+
94	+++	+
95	+++	+
96	+++	+
97	++	+
98	++	+
99	++	+
100	++	+
101	++	+
102	++	+
103	+++	+
104	++	+
105	+++	+
106	+	+
107	++	+
108	+++	+
109	+++	+
110	+++	+
111	+	+
112	++	+
113	++	+
114	+	+
115	+	+
116	++	+
117	+	+
118	++	+
119	++	+
120	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
121	++	+
122	++	+
123	++	+
124	++	+
125	++	+
126	++	+
127	+++	++
128	++	+
129	+++	+
130	++	+
131	+++	+
132	+	+
133	++	+
134	+	+
135	++	+
136	+	+
137	+	+
138	+++	+
139	++	+
140	++++	++
141	++++	+
142	+++	+
143	++++	+
144	+++	+
145	+++	+
146	++	+
147	++	+
148	++	+
149	+++	+
150	+	+
151	+++	+
152	+++	+
153	+++	+
154	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
155	++++	+
156	+++	+
157	++	+
158	++++	+
159	+++	+
160	++++	+
161	++++	+
162	+++	+
163	++++	+
164	++++	+
165	+++	+
166	+++	+
167	++++	+
168	+++	+
169	++++	+
170	+++	+
171	++++	+
172	+++	+
173	++++	+
174	+++	+
175	++++	+
176	++++	+
177	+++	+
178	++++	+
179	++++	+
180	+++	+
181	++++	+
182	+++	+
183	++++	+
184	+++	+
185	+++	+
186	++++	+
187	++++	+
188	+++	NT

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
189	++++	+
190	+++	+
191	++++	+
192	++	+
193	+++	+
194	+++	+
195	++	+
196	+++	+
197	++	+
198	+	+
199	+++	+
200	++++	+
201	+++	+
202	++++	+
203	+++	+
204	++++	+
205	+++	+
206	++	+
207	++++	+
208	+++	+
209	+++	+
210	+++	+
211	++++	+
212	+++	+
213	++++	+
214	++++	+
215	+++	+
216	++	+
217	++	+
218	++	+
219	++	+
220	++	+
221	++	+
222	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
223	+++	+
224	++	+
225	++	+
226	++	+
227	++	+
228	++	+
229	+	+
230	+	+
231	+	+
232	+	+
233	+	+
234	++	+
235	++	+
236	++	+
237	++	+
238	++	+
239	++	+
240	++	+
241	+++	+
242	++	+
243	++	+
244	+++	+
245	+++	+
246	++	+
247	+	+
248	+	+
249	+	+
250	+	+
251	+	+
252	+	++
253	++	+
254	+++	+
255	+++	+
256	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
257	+++	+
258	++	+
259	++	+
260	++	+
261	++	+
262	++	+
263	+++	+
264	+++	+
265	+++	+
266	++	+
267	++	+
268	++	+
269	++	+
270	++	+
271	+	+
272	++	+
273	++	+
274	++	+
275	++	+
276	+++	+
277	+++	+
278	+++	+
279	++	+
280	++++	+
281	++	+
282	++	+
283	++++	+
284	++	+
285	++	+
286	++	+
287	++	+
288	++	+
289	++	+
290	+	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
291	++	NT
292	++	+
293	+	+
294	++	+
295	+	+
296	+	+
297	+	+
298	++	+
299	++	+
300	+	+
301	++	+
302	++	+
303	++	+
304	++	+
305	++	+
306	+	+
307	+	+
308	++	+
309	++	+
310	++	+
311	+	+
312	++	+
313	++	+
314	++	+
315	+	+
316	+	+
317	++	+
318	++	+
319	+	+
320	++	+
321	+	+
322	++	+
323	++	+
324	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
325	++	+
326	++	+
327	++	+
328	+	+
329	++	+
330	+	+
331	+	+
332	++	+
333	++	+
334	+	+
335	++	+
336	+	+
337	++	+
338	+	+
339	++	+
340	++	+
341	++	+
342	++	+
343	+	+
344	++	+
345	++	+
346	++	+
347	++	+
348	++	+
349	+	+
350	++	+
351	++	+
352	++	+
353	++	+
354	+	+
355	+	+
356	++	+
357	++	+
358	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
359	++	+
360	++	+
361	++	+
362	++	+
363	++	+
364	++	+
365	++	+
366	++	+
367	++	+
368	+	+
369	++	+
370	++	+
371	++	+
372	++	+
373	+	+
374	++	+
375	+	+
376	++	+
377	+++	+
378	+	+
379	++	+
380	++	+
381	++	+
382	+	+
383	+++	+
384	++	+
385	++	+
386	+++	+
387	++	+
388	++++	+
389	++++	+
390	++	+
391	+	+
392	++++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
393	++	+
394	+++	+
395	++	+
396	++	+
397	++	+
398	++	+
399	+	+
400	++	+
401	++	+
402	++	+
403	+	+
404	++++	+
405	++++	+
406	++++	+
407	++++	+
408	++++	+
409	++++	++
410	++++	++
411	++++	++
412	++++	++
413	++++	++
414	++++	++
415	++++	++
416	++++	++
417	++++	++
418	++++	++
419	++++	++
420	++++	++
421	++++	++
422	++++	++
423	++++	++
424	++++	++
425	++++	++
426	++++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
427	++++	++
428	++++	++
429	++++	++
430	++++	++
431	++++	++
432	++++	+
433	++++	++
434	++++	++
435	++++	++
436	++++	++
437	++++	++
438	++++	++
439	++++	++
440	++++	++
441	++++	++
442	++++	++
443	++++	+
444	++++	++
445	++++	++
446	++++	+
447	++++	+
448	++++	++
449	++++	+
450	++++	++
451	++++	++
452	++++	++
453	++++	+++
454	++++	++
455	++++	+
456	++++	+
457	++++	++
458	++++	++
459	++++	+
460	++++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
461	++++	++
462	++++	+
463	++++	+
464	++++	++
465	++++	++
466	++++	+
467	++++	++
468	++++	+
469	++++	+++
470	++++	++
471	++++	+
472	++++	++
473	++++	++
474	++++	++
475	++++	+
476	++++	++
477	++++	+
478	++++	++
479	++++	+
480	++++	++
481	++++	+
482	++++	++
483	++++	++
484	++++	++
485	++++	+
486	++++	++
487	++++	++
488	++++	++
489	++++	+
490	++++	+
491	++++	++
492	++++	+
493	++++	++
494	++++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
495	++++	+
496	++++	++
497	++++	+
498	++++	++
499	++++	++
500	++++	++
501	++++	++
502	++++	+
503	++++	++
504	++++	+
505	++++	+
506	++++	+
507	++++	++
508	++++	+
509	++++	+
510	++++	+
511	++++	+
512	++++	+
513	++++	+
514	++++	+
515	++++	++
516	++++	+
517	++++	++
518	++++	++
519	++++	++
520	++++	++
521	++++	+
522	++++	+
523	++++	++
524	++++	+
525	++++	++
526	++++	+
527	++++	++
528	++++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
529	++++	+
530	++++	++
531	++++	++
532	++++	+
533	++++	+
534	++++	+
535	++++	++
536	++++	+
537	++++	++
538	++++	+
539	++++	+
540	++++	++
541	++++	+
542	++++	+
543	++++	++
544	++++	+
545	++++	++
546	++++	+
547	++++	++
548	++++	++
549	++++	+
550	++++	+
551	++++	+
552	++++	++
553	++++	+
554	++++	++
555	++++	+
556	++++	++
557	++++	++
558	++++	+
559	++++	+
560	++++	+
561	++++	+
562	++++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
563	++++	+
564	++++	+
565	++++	+
566	++++	++
567	++++	++
568	++++	+
569	++++	++
570	++++	++
571	++++	++
572	++++	+
573	++++	++
574	++++	+
575	++++	+
576	++++	++
577	++++	+
578	++++	+
579	++++	++
580	++++	+
581	++++	+
582	++++	+
583	++++	+
584	++++	+
585	++++	++
586	++++	++
587	++++	++
588	++++	+
589	++++	+
590	++++	+
591	++++	+
592	++++	++
593	++++	+
594	++++	+
595	++++	++
596	++++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
597	++++	+
598	++++	++
599	++++	++
600	+++	++
601	+++	+
602	+++	+
603	+++	+
604	+++	++
605	+++	++
606	+++	+++
607	+++	+
608	+++	+++
609	+++	++
610	+++	+
611	+++	+
612	+++	++
613	+++	+
614	+++	+
615	+++	+
616	+++	+
617	+++	+
618	+++	++
619	+++	+
620	+++	+
621	+++	+
622	+++	+
623	+++	++
624	+++	++
625	+++	+
626	+++	++
627	+++	+
628	+++	+
629	+++	+
630	+++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
631	+++	+
632	+++	+
633	+++	+
634	+++	+
635	+++	++
636	+++	+
637	+++	+
638	+++	+
639	+++	+
640	+++	++
641	+++	+
642	+++	++
643	+++	+
644	+++	+
645	+++	+
646	+++	+
647	+++	++
648	+++	+
649	+++	+
650	+++	+
651	+++	+
652	+++	++
653	+++	++
654	+++	+
655	+++	+
656	+++	+
657	+++	+
658	+++	++
659	+++	+
660	+++	+
661	+++	+
662	+++	++
663	+++	+
664	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
665	+++	+
666	+++	++
667	+++	++
668	+++	+
669	+++	+
670	+++	++
671	+++	+
672	+++	++
673	+++	+
674	+++	+
675	+++	+
676	+++	+
677	+++	++
678	+++	++
679	+++	+
680	+++	+
681	+++	+
682	+++	+
683	+++	++
684	+++	++
685	+++	++
686	+++	++
687	+++	+
688	+++	+
689	+++	++
690	+++	++
691	+++	+
692	+++	+
693	+++	++
694	+++	++
695	+++	+
696	+++	+
697	+++	+
698	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
699	+++	+
700	+++	+
701	+++	+
702	+++	+
703	+++	++
704	+++	+
705	+++	++
706	+++	+
707	+++	+
708	+++	+
709	+++	+
710	+++	+
711	+++	+
712	+++	+
713	+++	+
714	+++	+
715	+++	++
716	+++	++
717	+++	+
718	+++	+
719	+++	++
720	+++	+
721	+++	+
722	+++	++
723	+++	+
724	+++	+
725	+++	+
726	+++	+
727	+++	++
728	+++	+
729	+++	+
730	+++	+
731	+++	+
732	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
733	+++	+
734	+++	+
735	+++	+
736	+++	++
737	+++	+
738	+++	+
739	+++	++
740	+++	+
741	+++	+
742	+++	+
743	+++	+
744	+++	+
745	+++	+
746	+++	++
747	+++	+
748	+++	+
749	+++	+
750	+++	
751	+++	+
752	+++	+
753	+++	+
754	+++	+
755	+++	+
756	+++	+
757	+++	+
758	+++	+
759	+++	+
760	+++	+
761	+++	++
762	+++	+
763	+++	+
764	+++	+
765	+++	++
766	+++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
767	+++	++
768	+++	+
769	+++	+
770	+++	+
771	+++	+
772	+++	+
773	+++	+
774	+++	+
775	+++	+
776	+++	++
777	+++	+
778	+++	+
779	+++	+
780	+++	+
781	+++	+
782	+++	+
783	+++	+
784	+++	+
785	+++	+
786	+++	+
787	+++	+
788	+++	++
789	+++	+
790	+++	+
791	+++	+
792	+++	+
793	+++	+
794	+++	+
795	+++	+
796	+++	++
797	+++	+
798	+++	+
799	+++	++
800	+++	++

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
801	+++	+
802	+++	+
803	+++	+
804	+++	+
805	+++	+
806	+++	+
807	+++	+
808	+++	++
809	+++	++
810	+++	+
811	+++	+
812	+++	+
813	+++	+
814	+++	+
815	+++	++
816	+++	++
817	+++	++
818	+++	++
819	+++	++
820	+++	+
821	+++	+
822	+++	+
823	+++	+
824	+++	+
825	+++	
826	+++	++
827	+++	+
828	+++	+
829	+++	+
830	+++	++
831	+++	+
832	+++	+
833	+++	+
834	+++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
835	+++	+
836	+++	++
837	+++	+
838	+++	++
839	+++	++
840	+++	+
841	+++	+
842	+++	+
843	+++	+
844	+++	+
845	+++	+
846	+++	+
847	+++	++
848	+++	+
849	+++	+
850	+++	++
851	+++	+
852	+++	+
853	+++	++
854	++	++
855	++	+
856	++	+
857	++	++
858	++	+
859	++	++
860	++	+
861	++	++
862	++	+
863	++	+
864	++	+
865	++	++
866	++	++
867	++	+
868	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
869	++	+
870	++	+
871	++	+
872	++	+
873	++	++
874	++	++
875	++	++
876	++	+
877	++	+
878	++	+
879	++	+
880	++	+
881	++	++
882	++	+
883	++	++
884	++	++
885	++	+
886	++	++
887	++	+
888	++	+
889	++	++
890	++	++
891	++	+
892	++	+
893	++	+
894	++	+
895	++	+
896	++	+
897	++	+
898	++	+
899	++	++
900	++	+
901	++	+
902	++	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
903	++	+
904	++	+
905	++	+
906	++	+
907	++	+
908	++	+
909	++	+
910	++	+
911	++	+
912	++	+
913	++	+
914	++	+
915	++	+
916	++	+
917	++	+
918	++	+
919	++	+
920	++	+
921	++	+
922	++	+
923	++	+
924	++	+
925	++	+
926	++	+
927	++	+
928	++	+
929	++	+
930	++	+
931	++	+
932	+	+
933	+	+
934	+	+
935	+	+
936	+	+

Example No.	CBP IC_{50} (μM gmean)	BRD4 IC_{50} (μM gmean)
937	+	+
938	+	+
939	+	+
940	+	+
941	+	+
942	+	+
943	+	+
944	+	+
945	+	
946	+	+
947	+	+
948	+	+
949	+	+
950	+	+
951	+	+
952	+	+
953	+	+
954	+	
955	+	+
956	+	+
957	+	+
958	+	+
959	+	+
960	+	+
961	+	+
962	+	+++

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not

form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- US62559436 [0001]
- US62692593 [0001]
- WO2016086200A1 [0003]
- US4404207A [0265]

Non-patent literature cited in the description

- **T. W. GREENEP. G. M. WUTS**Protective Groups in Organic SynthesisWiley19990000 [0239]
- Remington's Pharmaceutical SciencesMack Publishing Co.19900000 [0253]
- J. Am. Chem. Soc., 2011, vol. 133, 9878-9891 [0276]

Patentkrav

1. Forbindelse med formel (I-d):



(I-d)

eller et farmaceutisk acceptabelt salt deraf, hvor:

Ring B repræsenterer -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl eller heteroaryl;

R^1 er -OR^5 eller -C_1-C_6alkyl;

R^3 er -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl, hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^7;

R^4 og $R^{4'}$ er hver uafhængigt -H, halogen, -OH, -CN eller -NH_2;

R^5 er -C_1-C_6alkyl, -C_3-C_8cycloalkyl, heterocyclyl, aryl eller heteroaryl;

R^7 er uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, -SR^8, -OR^8, -$(CH_2)_n$-OR^8, -NHR^8, -NR^8R^9, -$S(O)_2NR^8R^9$, -$S(O)_2R^{8'}$, -$C(O)R^{8'}$, -$C(O)OR^8$, -$C(O)NR^8R^9$, -$NR^8C(O)R^{9'}$, -$NR^8S(O)_2R^{9'}$, -$S(O)R^{8'}$, -$S(O)NR^8R^9$ eller -$NR^8S(O)R^{9'}$, hvor hver alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^{10};

hvor hvilke som helst to R^7, når de er på ikke-tilstødende atomer, kan kombineres for at danne en brodannende cycloalkyl eller heterocyclyl;

hvor hvilke som helst to R^7, når de er på tilstødende atomer, kan kombineres for at danne en cycloalkyl, heterocyclyl, aryl eller heteroaryl;

R^8 og R^9 er hver uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,

heterocyclyl, aryl eller heteroaryl er eventuelt substitueret med en eller flere R^{10} eller R^{11}; eller

R^8 og R^9 kan kombineres med atomet, til hvilket de er begge bundet, for at danne en -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl, hvor den dannede -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^{10} eller R^{11},

$R^{8'}$ og $R^{9'}$ er hver uafhængigt, ved hver forekomst, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl eller heteroaryl er eventuelt substitueret med en eller flere R^{10} eller R^{11}; eller

R^8 og $R^{9'}$ kan kombineres med atomet, til hvilket de er begge bundet, for at danne en -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl, hvor den dannede -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^{10} eller R^{11},

R^{10} og R^{11} er hver uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NOz, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$ eller -$N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl), hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere -R^{12};

hvor hvilke som helst to R^{10} eller hvilke som helst to R^{11}, når de er på ikke-tilstødende atomer, kan kombineres for at danne en brodannende cycloalkyl eller heterocyclyl;

hvor hvilke som helst to R^{10} eller hvilke som helst to R^{11}, når de er på tilstødende atomer, kan kombineres for at danne en cycloalkyl, heterocyclyl, aryl eller heteroaryl;

R^{12} er uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NOz, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$C(O)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$ eller
- $N(C_1$-C_6alkyl$)S(O)(C_1$-C_6alkyl);
n er et heltal fra 1 til 4; og
p er et heltal fra 1 til 2.

2. Forbindelsen ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor R^5 er -C_1-C_6alkyl.









3. Forbindelsen ifølge krav 1 eller krav 2 eller et farmaceutisk acceptabelt salt deraf, hvor R^1 er -OCH_3.








4. Forbindelsen ifølge et hvilket som helst af kravene 1-3 eller et farmaceutisk acceptabelt salt deraf, hvor R^3 er cyclopropyl, cyclobutyl, cyclopentyl eller cyclohexyl eventuelt substitueret med en eller flere -R^7.







5. Forbindelsen ifølge et hvilket som helst af kravene 1-4 eller et farmaceutisk acceptabelt salt deraf, hvor R^3 er cyclohexyl eventuelt substitueret med en eller flere -R^7.








6. Forbindelsen ifølge et hvilket som helst af kravene 1-5 eller et farmaceutisk acceptabelt salt deraf, hvor Ring B er aryl.








7. Forbindelsen ifølge krav 1 valgt fra gruppen bestående af:







Forbindelse Nr.	Struktur	Navn
7		methyl (7S)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
9		methyl (7S)-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
10		methyl (7S)-3,7-dimethyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
11		methyl (7S)-3,7-dimethyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
12		methyl (7S)-7-methyl-2-[2-(pyridin-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
13		methyl (7S)-3,7-dimethyl-2-[2-(pyridin-3-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
14		methyl (7S)-3,7-dimethyl-2-[2-(pyridin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
15		methyl (7S)-3,7-dimethyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
16		(1R,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
17		(1S,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
18		(1R,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
19		(1S,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
20		cis-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclobutan-1-carboxylsyre
21		trans-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclobutan-1-carboxylsyre
22		cis-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre








Forbindelse Nr.	Struktur	Navn
23		trans-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
24		4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]bicyclo[2.2.1]heptan-1-carboxylsyre
25		trans-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-1-methylcyclohexan-1-carboxylsyre
26		cis-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-1-methylcyclohexan-1-carboxylsyre
27		trans-4-[(7S)-6-(methoxycarbonyl)-2-[(4-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
28		trans-4-[(7S)-2-[(3-fluor-4-methoxyphenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
29		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
30		cis-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
31		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f] quinolin-3-yl]cyclohexan-1-carboxylsyre
32		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(2H-1,2,3-triazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f] quinolin-3-yl]cyclohexan-1-carboxylsyre
33		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(2-methyl-1,3-oxazol-5-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
34		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
35		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(5-methyl-1,3-oxazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre








Forbindelse Nr.	Struktur	Navn
36		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(4-methyl-1,3-oxazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
37		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(3-methyl-1,2-oxazol-5-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
38		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
39		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(4-methyl-1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
40		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
41		trans-4-[(7S)-2-[2-(4-chlor-1H-pyrazol-1-yl)ethyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
42		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre








Forbindelse Nr.	Struktur	Navn
43		4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]benzoesyre
44		3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]benzoesyre
45		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(1-methyl-1H-pyrazol-3-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
48		(1R,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexan-1-carboxylsyre
49		(1S,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexan-1-carboxylsyre
50		(1R,4R)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexan-1-carboxylsyre








Forbindelse Nr.	Struktur	Navn
51		(1S,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]-2,2-dimethylcyclohexan-1-carboxylsyre
52		trans-6-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]spiro[3.3]heptan-2-carboxylsyre
53		cis-6-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]spiro[3.3]heptan-2-carboxylsyre
54		cis-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclopentan-1-carboxylsyre
55		trans-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclopentan-1-carboxylsyre
62		(1R,3S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
63		(1S,3R)-3-[(7S)-6-(methoxycarbonyl)-7-methy1-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre








Forbindelse Nr.	Struktur	Navn
64		(1S,3S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
65		(1R,3R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
66		methyl (7S)-2-benzyl-3-[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
67		methyl (7S)-3-[(1S,3R)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
68		methyl (7S)-3-[(1R,3S)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
69		methyl (7S)-3-[(1R,3R)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
70		methyl (7S)-3-[(1S,3S)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
71		methyl (7S)-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3-[(1r,4r)-4-hydroxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
72		(2S,5R)-5-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]oxan-2-carboxylsyre
73		methyl (7S)-2-benzyl-3-[(3R,6S)-6-carbamoyloxan-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
74		methyl (7S)-2-benzyl-7-methyl-3-[(trans)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
75		methyl (7S)-2-benzyl-7-methyl-3-[(1s,4s)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
76		methyl (7S)-7-methyl-2-(2-phenylethyl)-3-[(trans)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
77		methyl (7S)-7-methyl-2-(2-phenylethyl)-3-[(cis)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
78		methyl (7S)-3-(azetidin-3-yl)-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
79		methyl (7S)-2-benzyl-7-methyl-3-[(3R)-pyrrolidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
80		methyl (7S)-2-benzyl-7-methyl-3-[(3S)-pyrrolidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
81		methyl (7S)-3-{2-azaspiro[3.3]heptan-6-yl}-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
82		methyl (7S)-3-{3-azaspiro[5.5]undecan-9-yl}-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
83		methyl (7S)-3-{8-azabicyclo[3.2.1]octan-3-yl}-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
84		methyl (7S)-3-[(1R,2S,4S)-7-azabicyclo[2.2.1]heptan-2-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
85		methyl (7S)-3-[(7R)-2-azabicyclo[2.2.1]heptan-7-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
86		methyl (7S)-2-benzyl-7-methyl-3-{[(3R)-piperidin-3-yl]methyl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
87		methyl (7S)-2-benzyl-7-methyl-3-{[(3S)-piperidin-3-yl]methyl}-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
88		methyl (7S)-2-benzyl-7-methyl-3-{[(2S)-piperidin-2-yl]methyl}-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
89		methyl (7S)-2-benzyl-7-methyl-3-{[(2R)-piperidin-2-yl]methyl}-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
90		methyl (7S)-2-benzyl-7-methyl-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
91		methyl (7S)-2-benzyl-7-methyl-3-[(3S)-piperidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
92		methyl (7S)-2-benzyl-7-methyl-3-[(3R)-piperidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
93		methyl (7S)-2-benzyl-7-methyl-3-[(piperidin-4-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
94		methyl (7S)-3-{2-azaspiro[3.3]heptan-6-yl}-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
95		methyl (7S)-3-{7-azaspiro[3.5]nonan-2-yl}-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
96		methyl (7S)-3-{2-azaspiro[3.5]nonan-7-yl}-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
97		methyl (7S)-3-[(azetidin-3-yl)methyl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
98		methyl (7S)-3-[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
99		methyl (7S)-3-{2-azaspiro[3.3]heptan-6-yl}-7-methyl-2-{[3-(propan-2-yloxy)phenyl]methyl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
100		methyl (7S)-3-{2-azaspiro[3.3]heptan-6-yl}-2-[2-(3-methoxyphenyl)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
101		methyl (7S)-3-{2-azaspiro[3.3]heptan-6-yl}-7-methyl-2-{2-[3-(propan-2-yloxy)phenyl]ethyl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
102		methyl (7S)-2-[(3-fluorphenyl)methyl]-7-methyl-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
104		methyl (7S)-7-methyl-2-(2-phenylethyl)-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
105		methyl (7S)-2-benzyl-7-methyl-3-{2-methyl-2-azaspiro[3.5]nonan-7-yl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
106		methyl (7S)-2-benzyl-3-[(3S,4R)-3-methoxypiperidin-4-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
107		methyl (7S)-2-[(4-methoxyphenyl)methyl]-7-methyl-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
108		methyl (7S)-3-{2-azaspiro[3.5]nonan-7-yl}-2-[(4-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
109		methyl (7S)-3-{2-azaspiro[3.5]nonan-7-yl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
110		methyl (7S)-3-{2-azaspiro[3.3]heptan-6-yl}-2-[(3-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
111		methyl (7S)-3-[(1S)-7-azaspiro[3.5]nonan-1-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
112		methyl (7S)-3-[(1R)-7-azaspiro[3.5]nonan-1-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
113		methyl (7S)-2-benzyl-7-methyl-3-[(1R)-1-(piperidin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
114		methyl (7S)-2-benzyl-7-methyl-3-[(1S)-1-(piperidin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
115		methyl (7S)-2-benzyl-7-methyl-3-[(1S)-1-[(3R)-piperidin-3-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
116		methyl (7S)-2-benzyl-7-methyl-3-[(1S)-1-[(3S)-piperidin-3-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
117		methyl (7S)-2-benzyl-7-methyl-3-[(1R)-1-[(3R)-piperidin-3-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
118		methyl (7S)-2-benzyl-7-methyl-3-[(1R)-1-[(3S)-piperidin-3-yl]ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
119		methyl (7S)-2-benzyl-7-methyl-3-[(3R,4S)-3-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat






Forbindelse Nr.	Struktur	Navn
120		methyl (7S)-2-benzyl-7-methyl-3-[(3S,4S)-3-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
121		methyl (7S)-2-benzyl-7-methyl-3-[(3R,4R)-3-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
122		methyl (7S)-2-benzyl-7-methyl-3-[(3S,4R)-3-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
123		methyl (7S)-2-benzyl-7-methyl-3-[(2S,4S)-2-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
124		methyl (7S)-2-benzyl-7-methyl-3-[(2R,4S)-2-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
125		methyl (7S)-2-benzyl-7-methyl-3-[(2S,4R)-2-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
126		methyl (7S)-2-benzyl-7-methyl-3-[(2R,4R)-2-methylpiperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
127		methyl (7S)-2-benzyl-7-methyl-3-[(2s,4r)-6-azaspiro[3.4]octan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
128		methyl (7S)-2-benzyl-7-methyl-3-[(2r,4s)-6-azaspiro[3.4]octan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
129		methyl (7S)-3-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
130		methyl (7S)-3-[(3aS,4R,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
131		methyl (7S)-3-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
132		methyl (7S)-3-[(3aS,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
217		methyl (7S)-2-benzyl-3-[2-(1,1-dioxo-1λ^6-thiomorpholin-4-yl)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
218		methyl (7S)-2-benzyl-7-methyl-3-(2-{2-oxa-6-azaspiro[3.3]heptan-6-yl}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
219		methyl (7S)-2-benzyl-7-methyl-3-(2-{1-oxa-6-azaspiro[3.3]heptan-6-yl}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
220		methyl (7S)-2-benzyl-3-(2-{1,1-dioxo-1λ^6-thia-6-azaspiro[3.3]heptan-6-yl}ethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
221		methyl (7S)-2-benzyl-7-methyl-3-(2-{2-oxa-6-azaspiro[3.4]octan-6-yl}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
222		methyl (7S)-2-benzyl-7-methyl-3-(2-{1-oxa-7-azaspiro[3.5]nonan-7-yl}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
223		methyl (7S)-2-benzyl-7-methyl-3-(2-{2-oxa-7-azaspiro[3.5]nonan-7-yl}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
224		methyl (7S)-2-benzyl-7-methyl-3-[2-(piperazin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
225		methyl (7S)-2-benzyl-7-methyl-3-[2-(4-methylpiperazin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
226		methyl (7S)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
227		methyl (7S)-7-methyl-3-[2-(4-methylpiperazin-1-yl)ethyl]-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
228		methyl (7S)-7-methyl-3-(2-{2-oxa-6-azaspiro[3.3]heptan-6-yl}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
229		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-[2-(piperazin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
230		methyl (7S)-7-methyl-3-[2-(4-methylpiperazin-1-yl)ethyl]-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
231		methyl (7S)-7-methyl-3-(2-{2-oxa-6-azaspiro[3.3]heptan-6-yl}ethyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
232		methyl (7S)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-2-[(1H-pyrazol-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
233		methyl (7S)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-2-[(2-oxo-1,2-dihydropyridin-1-yl)methy1]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
234		methyl (7S)-2-benzyl-7-methyl-3-{2-[(4S)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
235		methyl (7S)-2-benzyl-7-methyl-3-{2-[(4R)-1-oxa-6-azaspiro[3.4]octan-6-yl]ethyl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
236		methyl (7S)-2-benzyl-3-{2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl}-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
237		methyl (7S)-2-benzyl-3-{2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]ethyl}-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
238		methyl (7S)-2-benzyl-3-{2-[(2S,6S)-2,6-dimethylmorphofin-4-yl]ethyl}-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
239		methyl (7S)-2-benzyl-3-(2-{2,2-dioxo-λ^6-thia-6-azaspiro[3.3]heptan-6-yl}ethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
240		methyl (7S)-3-[2-(4-acetylpiperazin-1-yl)ethyl]-2-benzyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
241		methyl (7S)-2-benzyl-3-[2-(4-methansulfonylpiperazin-1-yl)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
242		methyl (7S)-3-[2-(dimethylamino)ethyl]-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
243		methyl (7S)-2-benzyl-3-(3-methansulfonylpropyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
244		methyl (7S)-3-(3-methansulfonylpropyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
245		methyl (7S)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
246		methyl (7S)-2-benzyl-3-[2-(dimethylamino)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
251		methyl (7S)-2-(2-cyclopropylethyl)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
253		methyl (7S)-2-benzyl-3-[(1,1-dioxo-1λ⁶-thian-4-yl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
254		methyl (7S)-2-benzyl-3-(1,1-dioxo-1λ⁶-thian-4-yl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
255		methyl (7S)-2-benzyl-7-methyl-3-[(trans)-4-cyanocyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
256		methyl (7S)-2-benzyl-7-methyl-3-[(cis)-4-cyanocyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
257		methyl (7S)-2-benzyl-7-methyl-3-(1-methylpiperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
258		methyl (7S)-2-benzyl-7-methyl-3-{2-methyl-2-azaspiro[3.3]heptan-6-yl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
259		methyl (7S)-7-methyl-3-(oxan-4-yl)-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
260		methyl (7S)-7-methyl-3-[(3S)-oxan-3-yl]-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
261		methyl (7S)-3-(3-methanesulfonylpropyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
262		methyl (7S)-3-(1,1-dioxo-1λ^6-thian-4-yl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
263		methyl (7S)-2-benzyl-3-cyclohexyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
264		methyl (7S)-2-benzyl-3-[(3R)-1,1-dioxo-λ^6-thian-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
265		methyl (7S)-2-benzyl-3-[(3S)-1,1-dioxo-λ⁶-thian-3-yl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
266		methyl (7S)-3-[(3S)-1,1-dioxo-λ⁶-thian-3-yl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
267		methyl (7S)-3-[(3R)-1,1-dioxo-1λ⁶-thian-3-yl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
268		methyl (7S)-3-[(3S)-1,1-dioxo-λ⁶-thian-3-yl]-7-methyl-2-[2-(2H-1,2,3-triazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
269		methyl (7S)-3-[(3R)-1,1-dioxo-1λ⁶-thian-3-yl]-7-methyl-2-[2-(2H-1,2,3-triazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
270		methyl (7S)-3-(3-methansulfonylpropyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
271		methyl (7S)-3-(2-methansulfonylethyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
272		methyl (7S)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
273		methyl (7S)-3-(2-methansulfonylethyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
274		methyl (7S)-7-methyl-3-[(3R)-oxan-3-yl]-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
275		methyl (7S)-3-(1,1-dioxo-1λ^6-thian-4-yl)-7-methyl-2-[2-(2H-1,2,3-triazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
276		methyl (7S)-2-benzyl-7-methyl-3-[(3S)-1-(1H-1,2,3,4-tetrazol-5-yl)piperidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
277		methyl (7S)-2-benzyl-7-methyl-3-[(3R)-1-(1H-1,2,3,4-tetrazol-5-yl)piperidin-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
278		methyl (7S)-2-benzyl-7-methyl-3-[1-(1H-1,2,3,4-tetrazol-5-yl)piperidin-4-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
279		methyl (7S)-2-benzyl-7-methyl-3-[(1R,3S)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
280		methyl (7S)-2-benzyl-7-methyl-3-[(1S,3R)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
281		methyl (7S)-2-benzyl-7-methyl-3-[(1R,3R)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
282		methyl (7S)-2-benzyl-7-methyl-3-[(1S,3S)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
283		methyl (7S)-2-benzyl-7-methyl-3-[(trans)-4-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
284		methyl (7S)-2-benzyl-7-methyl-3-[(cis)-4-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
285		2-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]eddikesyre
286		methyl (7S)-2-benzyl-3-(carbamoylmethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
287		methyl (7S)-2-benzyl-3-(2-hydroxyethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
288		3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]propionsyre
289		methyl (7S)-2-benzyl-3-(2-carbamoylethyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
290		methyl (7S)-7-methyl-3-(2-{[(1-methyl-1H-pyrazol-3-yl)methyl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
291		methyl (7S)-7-methyl-3-(2-{[(1,2-oxazol-5-yl)methyl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
292		methyl (7S)-7-methyl-3-(2-{[(1,3-oxazol-5-yl)methyl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
293		methyl (7S)-7-methyl-3-(2-{[(1-methyl-1H-pyrazol-4-yl)methyl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
294		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-(2-{[(pyridin-3-yl)methyl]amino}ethyl)-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
295		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-(2-{[(1r,4r)-4-(hydroxymethyl)cyclohexyl]amino}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
296		methyl (7S)-3-{2-[(2-hydroxyethyl)(methyl)amino]ethyl}- 7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
297		methyl (7S)-3-(2-{[(dimethylcarbamoyl)methyl](methyl)amino}ethyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
298		methyl (7S)-3-[2-(4-hydroxypiperidin- 1-yl)ethyl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
299		methyl (7S)-3-{2-[4-(hydroxymethyl)piperidin-1-yl]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
300		methyl (7S)-7-methyl-3-(2-{[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
301		methyl (7S)-7-methyl-3-{2-[methyl (oxan-4-yl)amino]ethyl}-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
302		methyl (7S)-7-methyl-3-(2-{methyl[(3S)-oxolan-3-yl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
303		methyl (7S)-3-{2-[(3S)-3-carbamoylpyrrolidin-1-yl]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
304		methyl (7S)-3-{2-[(2-hydroxy-2-methylpropyl)(methyl)amino]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
305		methyl (7S)-7-methyl-3-{2-[(oxetan-3-yl)amino]ethyl}-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
306		methyl (7S)-3-{2-[(2-cyanoethyl)amino]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
307		methyl (7S)-7-methyl-3-(2-{ [2-(2-oxoimidazolidin-1-yl)ethyl]amino}ethyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
308		methyl (7S)-3-[2-(4-cyanopiperidin-1-yl)ethyl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
309		methyl (7S)-3-{2-[(3R)-3-acetamidopyrrolidin-1-yl]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
310		methyl (7S)-3-{2-[(3S)-3-acetamidopyrrolidin-1-yl]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
311		methyl (7S)-7-methyl-3-{2-[4-(propan-2-yl)piperazin-1-yl]ethyl}-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
312		methyl (7S)-3-[2-(4-cyclopropylpiperazin-1-yl)ethyl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
313		methyl (7S)-3-{2-[4-(2-hydroxyethyl)piperazin-1-yl]ethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
314		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-(2-{[(pyrimidin-4-yl)methyl]amino}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
315		methyl (7S)-7-methyl-3-(2-{[(1-methyl-1H-pyrazol-4-yl)methyl]amino}ethyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
316		methyl (7S)-7-methyl-3-(2-{[(1-methyl-1H-pyrazol-3-yl)methyl]amino}ethyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat






Forbindelse Nr.	Struktur	Navn
317		methyl (7S)-7-methyl-3-(2-{[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]amino}ethyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
318		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-(2-{[(pyridin-3-yl)methyl]amino}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
319		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-[2-({[(2R)-oxolan-2-yl]methyl}amino)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
320		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-(2-{[(trans)-4-(hydroxymethyl)cyclohexyl] amino}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
321		methyl (7S)-3-(2-{ [(2R)-1-hydroxypropan-2-yl]amino}ethyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
322		methyl (7S)-3-[2-(4-hydroxypiperidin-1-yl)ethyl]-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
323		methyl (7S)-3-{2-[4-(hydroxymethyl)piperidin-1-yl]ethyl}- 7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
324		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-(2-{[2-oxo-2-(pyrrolidin-1- yl)ethyl]amino}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
325		methyl (7S)-7-methyl-3-{2-[methyl(oxan-4-yl)amino]ethyl}-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]- 3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
326		methyl (7S)-7-methyl-3-(2-{methyl[(3S)-oxolan-3-yl]amino}ethyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
327		methyl (7S)-3-{2-[(3S)-3-carbamoylpyrrolidin-1-yl]ethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]- 3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
328		methyl (7S)-3-(2-{[(1-hydroxycyclobutyl)methyl]amino}ethyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
329		methyl (7S)-7-methyl-3-(2-{[(3-methyl-1,2-oxazol-5-yl)methyl]amino}ethyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
330		methyl (7S)-3-{2-[(2-cyanoethyl)amino]ethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
331		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-(2-{[2-(2-oxoimidazolidin-1-yl)ethyl]amino}ethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
332		methyl (7S)-3-[2-(4-cyanopiperidin-1-yl)ethyl]-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
333		methyl (7S)-3-{2-[(3R)-3-acetamidopyrrolidin-1-yl]ethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]- 3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
334		methyl (7S)-3-{2-[(3S)-3-acetamidopyrrolidin-1-yl]ethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]- 3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
335		methyl (7S)-3-{2-[(3S)-3-acetamidopyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
336		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-({ [(pyrimidin-4-yl)methyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
337		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-({ [(pyrimidin-2-yl)methyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
338		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-({[2-(pyridin-2-yl)ethyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
339		methyl (7S)-3-({[(2-hydroxypyridin-4-yl)methyl]carbamoyl}methyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
340		methyl (7S)-7-methyl-3-({[(1,3-oxazol-2-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
341		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-({ [(pyridin-4-yl)methyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
342		methyl (7S)-7-methyl-3-({[(1,3-oxazol-5-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
343		methyl (7S)-3-({[(4,5-dimethyl-4H-1,2,4-triazol-3-yl)methyl]carbamoyl}methyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-flquinolin-6-carboxylat
344		methyl (7S)-7-methyl-3-({[(1-methyl-1H-pyrazol-4-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
345		methyl (7S)-7-methyl-3-({[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
346		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-({[(pyridin-3-yl)methyl]carbamoyl]methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat






Forbindelse Nr.	Struktur	Navn
347		methyl (7S)-7-methyl-3-[({ [(2R)-oxolan-2-yl]methyl}carbamoyl)methyl]-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
348		methyl (7S)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3-({ [(1r,4r)-4-(hydroxymethyl)cyclohexyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
349		methyl (7S)-3-({[(2R)-1-hydroxypropan-2-yl]carbamoyl}methyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
350		methyl (7S)-3-{[(2-hydroxyethyl)(methyl)carbamoyl]methyl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
351		methyl (7S)-3-({[(dimethylcarbamoyl)methyl](methyl)carbamoyl}methyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
352		methyl (7S)-3-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
353		methyl (7S)-3-{2-[4-(hydroxymethyl)piperidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]- 3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
354		methyl (7S)-3-({[(dimethylcarbamoyl)methyl]carbamoyl}methyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
355		methyl (7S)-7-methyl-3-({[2-oxo-2-(pyrrolidin-1-yl)ethyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
356		methyl (7S)-7-methyl-3-{[methyl(oxan-4-yl)carbamoyl]methyl}-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
357		methyl (7S)-7-methyl-3-({[(oxan-4-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
358		methyl (7S)-7-methyl-3-{[(oxan-4-yl)carbamoyl]methyl}-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
359		methyl (7S)-7-methyl-3-({methyl[(3S)-oxolan-3-yl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
360		methyl (7S)-3-{2-[(3S)-3-carbamoylpyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
361		methyl (7S)-3-{[(2-hydroxy-2-methylpropyl)(methyl)carbamoyl]methyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
362		methyl (7S)-3-({[(1-hydroxycyclobutyl)methyl]carbamoyl}methyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
363		methyl (7S)-7-methyl-3-({[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
364		methyl (7S)-7-methyl-3-({[(3-methyloxetan-3-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
365		methyl (7S)-7-methyl-3-{[(oxetan-3-yl)carbamoyl]methyl}-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
366		methyl (7S)-3-{[(cyanomethyl)carbamoyl]methyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
367		methyl (7S)-7-methyl-3-({[(1,2-oxazol-5-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
368		methyl (7S)-7-methyl-3-({[2-(2-oxoimidazolidin-1-yl)ethyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
369		methyl (7S)-3-[2-(4-cyanopiperidin-1-yl)-2-oxoethyl]-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
370		methyl (7S)-3-{2-[(3R)-3-acetamidopyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
371		methyl (7S)-7-methyl-3-({[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]carbamoyl}methyl)-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
372		methyl (7S)-7-methyl-3-({[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]carbamoyl}methyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo [4,5-f]quinolin-6-carboxylat
373		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-({[(pyrimidin-4-yl)methyl]carbamoyl]methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
374		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-({[2-(pyridin-2-yl)ethyl]carbamoyl]methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
375		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-({[(pyridin-3-yl)methyl]carbamoyl]methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
376		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-[({[(2R)-oxolan-2-yl]methyl}carbamoyl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
377		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-({[(1r,4r)-4-(hydroxymethyl)cyclohexyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
378		methyl (7S)-3-({[(2R)-1-hydroxypropan-2-yl]carbamoyl}methyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
379		methyl (7S)-3-{[(2-hydroxyethyl)(methyl)carbamoyl]methyl]-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
380		methyl (7S)-3-({[(dimethylcarbamoyl)methyl](methyl)carbamoyl}methyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]- 3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
381		methyl (7S)-3-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
382		methyl (7S)-3-({[(dimethylcarbamoyl)methyl]carbamoyl}methyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
383		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-({[2-oxo-2-(pyrrolidin-1-yl)ethyl]carbamoyl}methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
384		methyl (7S)-7-methyl-3-{[methyl(oxan-4-yl)carbamoyl]methyl}-2-[2-(2-oxo-1,2-dihydropyridin-1- yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
385		methyl (7S)-7-methyl-3-({[(oxan-4-yl)methyl]carbamoyl}methyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
386		methyl (7S)-7-methyl-3-{[(oxan-4-yl)carbamoyl]methyl}-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H, 8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
387		methyl (7S)-7-methyl-3-({methyl[(3S)-oxolan-3-yl]carbamoyl}methyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
388		methyl (7S)-3-{2-[(3S)-3-carbamoylpyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1- yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
389		methyl (7S)-3-{[(2-hydroxy-2-methylpropyl)(methyl)carbamoyl]methyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
390		methyl (7S)-3-({[(1-hydroxycyclobutyl)methyl]carbamoyl}methyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
391		methyl (7S)-7-methyl-3-({[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}methyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
392		methyl (7S)-7-methyl-3-({[(3-methyloxetan-3-yl)methyl]carbamoyl}methyl)-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H, 8H,9H-imidazo [4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
393		methyl (7S)-7-methyl-3-{[(oxetan-3-yl)carbamoyl]methyl}-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
394		methyl (7S)-3-{[(cyanomethyl)carbamoyl]methyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
395		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-({[2-(2-oxoimidazolidin-1-yl)ethyl]carbamoyl]methyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
396		methyl (7S)-3-[2-(4-cyanopiperidin-1-yl)-2-oxoethyl]-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
397		methyl (7S)-3-{2-[(3R)-3-acetamidopyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1- yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
398		methyl (7S)-3-{2-[(3S)-3-acetamidopyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1- yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
399		methyl (7S)-3-{2-[(3S)-3-hydroxypyrrolidin-1-yl]-2-oxoethyl}-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1- yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
400		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-[2-oxo-2-(3-oxopiperazin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
401		methyl (7S)-3-[2-(3,3-difluorpyrrolidin-1-yl)-2-oxoethyl]-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
402		methyl (7S)-3-(2-{5H,6H,7H,8H-imidazo[1,2-a]pyrazin-7-yl}-2-oxoethyl)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1- yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
403		methyl (7S)-7-methyl-2-[2-(2-oxo-1,2-dihydropyridin-1-yl)ethyl]-3-{[(1H-pyrazol-5-yl)carbamoyl]methyl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
465		(1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
476		(1R,3R)-3-((S)-2-((6-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
489		(1R,3R)-3-((S)-2-(4-chlorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
494		(1S,4r)-4-((S)-2-((1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
500		(1R,3R)-3-((S)-2-((1H-indol-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
507		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((1-methyl-1H-indol-5-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
514		(1R,3R)-3-((S)-2-(2-cyclopentylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
521		(S)-2-(2-(3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)ethyl)benzoesyre
527		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
533		(1R,3R)-3-((S)-2-(4-(difluormethoxy)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
543		(1S,4r)-4-((S)-2-(4-(dimethylamino)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
544		(1S,4r)-4-((S)-2-(4-(difluormethoxy)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
546		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((6-methoxypyridin-2-yl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
547		(1R,3R)-3-((S)-2-(2-cyclohexylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
549		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-methylbenzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
555		(S)-2-((3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methyl)benzoesyre
556		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5,6,7,8-tetrahydroquinoxalin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
559		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((R)-tetrahydro-2H-pyran-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
562		(1R,3R)-3-((S)-2-((6-cyclopropoxypyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
568		(1R,3R)-3-((S)-2-(4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
570		(1R,3R)-3-((S)-2-(2-cyclobutylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
575		(1R,3R)-3-((S)-2-(cyclohexylmethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
577		(1R,3R)-3-((S)-2-((1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
579		(1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
586		(1R,3R)-3-((S)-2-((6-(tert-butoxy)pyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
590		(1S,4r)-4-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
593		(1R,3R)-3-((S)-2-((6-(difluormethoxy)pyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
600		(1S,4r)-4-((S)-2-((1H-indol-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
601		(1R,3R)-3-((S)-2-(3-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
611		(1R,3R)-3-((S)-2-((6-isopropylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
614		(1R,3R)-3-((S)-2-(((1R,2S)-2-hydroxycyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
616		(1R,3R)-3-((S)-2-(3-chlorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
619		(1R,3R)-3-((S)-2-((6-(difluormethoxy)pyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
621		(1R,3R)-3-((S)-2-(2-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
628		(1R,3R)-3-((S)-2-(2-(4-chlor-1H-pyrazol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
634		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((6-oxo-7-azaspiro[3.5]nonan-7-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
635		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((S)-tetrahydro-2H-pyran-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
642		(1R,3R)-3-((S)-2-((6-isopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
643		(1R,3R)-3-((S)-2-((4-chlor-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
645		(1R,3R)-3-((S)-2-((6-chlorpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
648		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
650		(1R,3R)-3-((S)-2-(4-chlorphenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
657		(1R,3R)-3-((S)-2-(((1S,2R)-2-hydroxycyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
663		(1R,3R)-3-((S)-2-((5-chlorpyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
664		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-(2-oxopyrrolidin-1-yl)benzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
665		(1R,3R)-3-((S)-2-((6-cyclopropylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
667		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
669		(1R,3R)-3-((S)-2-((5-chlorpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
672		(1R,3R)-3-((S)-2-((1-cyclopropyl-1H-pyrazol-4-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
675		(1R,3R)-3-((S)-2-(4-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
679		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
684		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
687		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-(trifluormethyl)pyridazin-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
688		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-oxo-6-azaspiro[2.5]octan-6-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
693		(1R,3R)-3-((S)-2-((6-isopropoxypyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
695		(1R,3R)-3-((S)-2-((6-cyclopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
697		(1R,3R)-3-((S)-2-((5-(difluormethoxy)pyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
705		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
706		(1S,4r)-4-((S)-2-(2-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
707		(1S,4r)-4-((S)-2-(3-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
714		(1S,4r)-4-((S)-2-((4-isopropyl-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
716		(1R,3R)-3-((S)-2-((6-cyclopropoxypyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
718		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(3-methylbenzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
721		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
723		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-(((1r,4R)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
726		(1R,3R)-3-((S)-2-(((1r,4R)-4-cyanocyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
729		(1R,4r)-4-((S)-6-(methoxycarbonyl)-2-(((1r,4R)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre





Forbindelse Nr.	Struktur	Navn
733		(1S,4r)-4-((S)-2-((4-cyclopropyl-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
737		(1S,4r)-4-((S)-2-((4-chlor-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
738		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-methylpyrazin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
739		(1R,3R)-3-((S)-2-((2,2-dioxidobenzo[c]isothiazol-1(3H)-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
743		(S)-2-(2-(6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)ethyl)benzoesyre
744		(1S,4r)-4-((S)-2-(4-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
755		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(pyrazin-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
758		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
760		(1R,3R)-3-((S)-2-(((1s,4S)-4-cyanocyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
775		(1R,3R)-3-((S)-2-((5-isopropoxypyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
777		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((6-(trifluormethyl)pyridazin-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
778		(S)-2-((6-(methoxycarbonyl)-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methyl)benzoesyre

Forbindelse Nr.	Struktur	Navn
780		(1S,4r)-4-((S)-2-((6-isopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
784		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
789		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
795		(1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
804		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-3-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
806		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((S)-tetrahydro-2H-pyran-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre


Forbindelse Nr.	Struktur	Navn
818		(1S,3R)-3-((S)-2-(2-cyclobutylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
820		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((4-methylpyrimidin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
828		(1R,3R)-3-((S)-2-((5-chlorpyrimidin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
832		(1R,4r)-4-((S)-6-(methoxycarbonyl)-2-(((1s,4S)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
840		methyl (S)-2-benzyl-3-((1R,3R)-3-(methoxycarbonyl)cyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
841		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((R)-tetrahydro-2H-pyran-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre








Forbindelse Nr.	Struktur	Navn
858		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-(2-oxopyrrolidin-1-yl)benzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
863		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
864		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
871		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
886		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
889		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre


Forbindelse Nr.	Struktur	Navn
890		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(2-oxopiperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
892		(1R,3R)-3-((S)-2-((1-acetylpiperidin-4-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
897		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre og
935		methyl (S)-2-(2-(1H-pyrazol-1-yl)ethyl)-7-methyl-3-(2-(piperazin-1-yl)ethyl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat.

eller et farmaceutisk acceptabelt salt deraf.

8. Forbindelsen ifølge krav 1, valgt fra gruppen bestående af:


Forbindelse Nr.	Struktur	Navn
16		(1R,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
17		(1S,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
18		(1R,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
19		(1S,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
22		cis-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
23		trans-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
27		trans-4-[(7S)-6-(methoxycarbonyl)-2-[(4-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
48		(1R,4S)-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-

Forbindelse Nr.	Struktur	Navn
		3-yl]-2,2-dimethylcyclohexan-1-carboxylsyre og
263		methyl (7S)-2-benzyl-3-cyclohexyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat.

eller et farmaceutisk acceptabelt salt deraf.

9. Forbindelse med formel (I-e):



(I-e),

eller et farmaceutisk acceptabelt salt deraf, hvor:

R^6 og R^7 er hver uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, -OH, halogen, oxo, -CN, -SR^8, -OR^8, -$(CH_2)_n$-OR^8, -NHR^8, -NR^8R^9, -$S(O)_2NR^8R^9$, -$S(O)_2R^{8'}$, -$C(O)R^{8'}$, -$C(O)OR^8$, -$C(O)NR^8R^9$, -$NR^8C(O)R^{9'}$, -$NR^8S(O)_2R^{9'}$, -$S(O)R^{8'}$, -$S(O)NR^8R^9$ eller -$NR^8S(O)R^{9'}$, hvor hver alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^{10};

hvor hvilke som helst to R^6 eller hvilke som helst to R^7, når de er på ikke-tilstødende atomer, kan kombineres for at danne en brodannende cycloalkyl eller heterocyclyl;

hvor hvilke som helst to R^6 eller hvilke som helst to R^7, når de er på tilstødende atomer, kan kombineres for at danne en cycloalkyl, heterocyclyl, aryl eller heteroaryl;

R^8 og R^9 er hver uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,

heterocyclyl, aryl eller heteroaryl er eventuelt substitueret med en eller flere R^{10} eller R^{11}; eller

R^8 og R^9 kan kombineres med atomet, til hvilket de er begge bundet, for at danne en -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl, hvor den dannede -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^{10} eller R^{11};

$R^{8'}$ og $R^{9'}$ er hver uafhængigt, ved hver forekomst, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, aryl, heteroaryl, hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl eller heteroaryl er eventuelt substitueret med en eller flere R^{10} eller R^{11}; eller

R^8 og $R^{9'}$ kan kombineres med atomet, til hvilket de er begge bundet, for at danne en -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl, hvor den dannede -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere R^{10} eller R^{11};

R^{10} og R^{11} er hver uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH(C_1$-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -CCO)OC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$ eller -$N(C_1$-$C_b$alkyl$)S(O)(C_1$-$C_b$alkyl), hvor hver alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl eller aryl er eventuelt substitueret med en eller flere -R^{12};

hvor hvilke som helst to R^{10} eller hvilke som helst to R^{11}, når de er på ikke-tilstødende atomer, kan kombineres for at danne en brodannende cycloalkyl eller heterocyclyl;




hvor hvilke som helst to R^{10} eller hvilke som helst to R^{11}, når de er på tilstødende atomer, kan kombineres for at danne en cycloalkyl, heterocyclyl, aryl eller heteroaryl;






R^{12} er uafhængigt, ved hver forekomst, -H, -C_1-C_6alkyl, -C_2-C_6alkenyl, -C_2-C_6alkynyl, -C_3-C_8cycloalkyl, -C_4-C_8cycloalkenyl, heterocyclyl, heteroaryl, aryl, -OH, halogen, oxo, -NO_2, -CN, -NH_2, -OC_1-C_6alkyl, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$S(O)_2NH$(Ci-C_6alkyl), -$S(O)_2N(C_1$-C_6alkyl$)_2$, -$S(O)_2C_1$-C_6alkyl, -$C(O)C_1$-C_6alkyl, -$C(O)NH_2$, -$C(O)NH(C_1$-C_6alkyl), -$C(O)N(C_1$-C_6alkyl$)_2$, -$CCO)OC_1$-C_6alkyl, -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl, -$S(O)(C_1$-C_6alkyl), -$S(O)N(C_1$-C_6alkyl$)_2$ eller -$N(C_1$-C_6alkyl$)S(O)$ (C_1-C_6alkyl);
n er et heltal fra 1 til 4; og
p er 1 eller 2.







10. Forbindelsen ifølge krav 9 eller et farmaceutisk acceptabelt salt deraf, hvor p er 1.







11. Forbindelsen ifølge krav 9 eller krav 10 eller et farmaceutisk acceptabelt salt deraf, hvor R^7 er -C(O)OH.







12. Forbindelsen ifølge krav 7 valgt fra gruppen bestående af:







Forbindelse Nr.	Struktur	Navn
16		(1R,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
17		(1S,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
18		(1R,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-







Forbindelse Nr.	Struktur	Navn
		f]quinolin-3-yl]cyclohexan-1-carboxylsyre
19		(1S,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
22		cis-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
23		trans-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
27		trans-4-[(7S)-6-(methoxycarbonyl)-2-[(4-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
28		trans-4-[(7S)-2-[(3-fluor-4-methoxyphenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
29		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
30		cis-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
31		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
32		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(2H-1,2,3-triazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
33		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(2-methyl-1,3-oxazol-5-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
34		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
35		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(5-methyl-1,3-oxazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
36		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(4-methyl-1,3-oxazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
37		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(3-methyl-1,2-oxazol-5-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
38		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
39		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(4-methyl-1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
40		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(3-methyl-1H-pyrazol-1-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
41		trans-4-[(7S)-2-[2-(4-chlor-1H-pyrazol-1-yl)ethyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
42		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
45		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[2-(1-methyl-1H-pyrazol-3-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
62		(1R,3S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
63		(1S,3R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
64		(1S,3S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
65		(1R,3R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylethyl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
67		methyl (7S)-3-[(1S,3R)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
68		methyl (7S)-3-[(1R,3S)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
69		methyl (7S)-3-[(1R,3R)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
70		methyl (7S)-3-[(1S,3S)-3-hydroxycyclohexyl]-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
71		methyl (7S)-7-methyl-2-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]-3-[(1r,4r)-4-hydroxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
74		methyl (7S)-2-benzyl-7-methyl-3-[(trans)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
75		methyl (7S)-2-benzyl-7-methyl-3-[(1s,4s)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
76		methyl (7S)-7-methyl-2-(2-phenylethyl)-3-[(trans)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
77		methyl (7S)-7-methyl-2-(2-phenylethyl)-3-[(cis)-4-carbamoylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
255		methyl (7S)-2-benzyl-7-methyl-3-[(trans)-4-cyanocyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
256		methyl (7S)-2-benzyl-7-methyl-3-[(cis)-4-cyanocyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
263		methyl (7S)-2-benzyl-3-cyclohexyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
279		methyl (7S)-2-benzyl-7-methyl-3-[(1R,3S)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
280		methyl (7S)-2-benzyl-7-methyl-3-[(1S,3R)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
281		methyl (7S)-2-benzyl-7-methyl-3-[(1R,3R)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
282		methyl (7S)-2-benzyl-7-methyl-3-[(1S,3S)-3-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
283		methyl (7S)-2-benzyl-7-methyl-3-[(trans)-4-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
284		methyl (7S)-2-benzyl-7-methyl-3-[(cis)-4-(1H-1,2,3,4-tetrazol-5-yl)cyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
408		(1S,4r)-4-((S)-2-(4-(difluormethoxy)-3-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
410		(1R,3R)-3-((S)-2-((5-chlor-6-methoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
412		(1S,4R)-4-((S)-2-(3-fluor-4-isopropoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
463		(1R,3R)-3-((S)-2-(5-fluor-2-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
465		(1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre






Forbindelse Nr.	Struktur	Navn
471		(1R,3R)-3-((S)-2-(3-fluor-4-methylbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
476		(1R,3R)-3-((S)-2-((6-cyano-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
481		(1R,3R)-3-((S)-2-(3-fluor-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
489		(1R,3R)-3-((S)-2-(4-chlorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
494		(1S,4r)-4-((S)-2-((1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
500		(1R,3R)-3-((S)-2-((1H-indol-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
502		(1R,3R)-3-((S)-2-(3,4-difluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
507		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((1-methyl-1H-indol-5-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
508		(1S,4r)-4-((S)-2-(3-chlor-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
509		(1R,3R)-3-((S)-2-(3,4-difluorphenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
512		(1R,3R)-3-((S)-2-(3-chlor-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
514		(1R,3R)-3-((S)-2-(2-cyclopentylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
518		(1S,4r)-4-((S)-2-((5-chlor-6-methoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
521		(S)-2-(2-(3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)ethyl)benzoesyre
527		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
532		(1S,4r)-4-((S)-2-(3,5-difluor-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
533		(1R,3R)-3-((S)-2-(4-(difluormethoxy)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
541		(1R,3R)-3-((S)-2-(3-fluor-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
543		(1S,4r)-4-((S)-2-(4-(dimethylamino)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
544		(1S,4r)-4-((S)-2-(4-(difluormethoxy)benzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
546		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((6-methoxypyridin-2-yl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
547		(1R,3R)-3-((S)-2-(2-cyclohexylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
548		(1R,3R)-3-((S)-2-((S)-2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
549		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-methylbenzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
550		(1R,3R)-3-((S)-2-(3-fluor-4-methylphenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
553		(1S,4r)-4-((S)-2-(2,3-difluor-4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
555		(S)-2-((3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methyl)benzoesyre
556		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5,6,7,8-tetrahydroquinoxalin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
559		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((R)-tetrahydro-2H-pyran-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
561		(1S,4r)-4-((S)-2-(5-fluor-2-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-







Forbindelse Nr.	Struktur	Navn
		imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
562		(1R,3R)-3-((S)-2-((6-cyclopropoxypyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
568		(1R,3R)-3-((S)-2-(4-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
570		(1R,3R)-3-((S)-2-(2-cyclobutylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
575		(1R,3R)-3-((S)-2-(cyclohexylmethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
577		(1R,3R)-3-((S)-2-((1H-indol-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
579		(1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-5-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
581		(1S,4r)-4-((S)-2-(4-(dimethylamino)-3-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
586		(1R,3R)-3-((S)-2-((6-(tert-butoxy)pyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
590		(1S,4r)-4-((S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
593		(1R,3R)-3-((S)-2-((6-(difluormethoxy)pyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
595		(1S,4r)-4-((S)-2-(3-fluor-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
600		(1S,4r)-4-((S)-2-((1H-indol-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
601		(1R,3R)-3-((S)-2-(3-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
611		(1R,3R)-3-((S)-2-((6-isopropylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
614		(1R,3R)-3-((S)-2-(((1R,2S)-2-hydroxycyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
616		(1R,3R)-3-((S)-2-(3-chlorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
619		(1R,3R)-3-((S)-2-((6-(difluormethoxy)pyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre






Forbindelse Nr.	Struktur	Navn
621		(1R,3R)-3-((S)-2-(2-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
628		(1R,3R)-3-((S)-2-(2-(4-chlor-1H-pyrazol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
633		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenoxymethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
634		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((6-oxo-7-azaspiro[3.5]nonan-7-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
635		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((S)-tetrahydro-2H-pyran-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
639		(1S,4r)-4-((S)-2-(4-acetamido-3-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
641		(1R,3R)-3-((S)-2-(3,4-dimethoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
642		(1R,3R)-3-((S)-2-((6-isopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
643		(1R,3R)-3-((S)-2-((4-chlor-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
645		(1R,3R)-3-((S)-2-((6-chlorpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
647		(1R,3R)-3-((S)-2-((R)-2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
648		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre






Forbindelse Nr.	Struktur	Navn
650		(1R,3R)-3-((S)-2-(4-chlorphenethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
656		(1S,4r)-4-((S)-2-(3-chlor-5-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
657		(1R,3R)-3-((S)-2-(((1S,2R)-2-hydroxycyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
658		(1S,4r)-4-((S)-2-((S)-2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
661		(1S,4r)-4-((S)-2-(3-fluor-2-methoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
663		(1R,3R)-3-((S)-2-((5-chlorpyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
664		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-(2-oxopyrrolidin-1-yl)benzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
665		(1R,3R)-3-((S)-2-((6-cyclopropylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
667		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
669		(1R,3R)-3-((S)-2-((5-chlorpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
672		(1R,3R)-3-((S)-2-((1-cyclopropyl-1H-pyrazol-4-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
675		(1R,3R)-3-((S)-2-(4-fluorbenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
679		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
684		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo [4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
687		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-(trifluormethyl)pyridazin-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo [4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
688		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-oxo-6-azaspiro[2.5]octan-6-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
692		(1S,4r)-4-((S)-2-((cyclohexyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
693		(1R,3R)-3-((S)-2-((6-isopropoxypyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-







Forbindelse Nr.	Struktur	Navn
		tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
695		(1R,3R)-3-((S)-2-((6-cyclopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
696		(1R,3R)-3-((S)-2-((4,4-dimethyl-2-oxopiperidin-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
697		(1R,3R)-3-((S)-2-((5-(difluormethoxy)pyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
702		(1R,3R)-3-((S)-2-((cyclohexyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
705		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
706		(1S,4r)-4-((S)-2-(2-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
707		(1S,4r)-4-((S)-2-(3-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
711		(1R,3R)-3-((S)-2-((cyclopentyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
714		(1S,4r)-4-((S)-2-((4-isopropyl-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
716		(1R,3R)-3-((S)-2-((6-cyclopropoxypyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
718		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(3-methylbenzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
721		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
723		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-(((1r,4R)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
726		(1R,3R)-3-((S)-2-(((1r,4R)-4-cyanocyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
729		(1R,4r)-4-((S)-6-(methoxycarbonyl)-2-(((1r,4R)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
733		(1S,4r)-4-((S)-2-((4-cyclopropyl-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
737		(1S,4r)-4-((S)-2-((4-chlor-1H-pyrazol-1-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
738		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((5-methylpyrazin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
739		(1R,3R)-3-((S)-2-((2,2-dioxidobenzo[c]isothiazol-1(3H)-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
740		(1S,4r)-4-((S)-2-(3,4-dimethoxybenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
741		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
744		(1S,4r)-4-((S)-2-(4-cyanobenzyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre




Forbindelse Nr.	Struktur	Navn
745		(1R,3R)-3-((S)-2-((5-chlor-6-methylpyrazin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
748		(S)-2-((3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)methoxy)benzoesyre
752		(1S,4r)-4-((S)-2-((cyclopentyloxy)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
755		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(pyrazin-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
758		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
759		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
760		(1R,3R)-3-((S)-2-(((1s,4S)-4-cyanocyclohexyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
775		(1R,3R)-3-((S)-2-((5-isopropoxypyridin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
777		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((6-(trifluormethyl)pyridazin-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
780		(1S,4r)-4-((S)-2-((6-isopropoxypyridin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
784		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
789		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
795		(1R,3R)-3-((S)-2-((5H-pyrrolo[2,3-b]pyrazin-3-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
798		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
800		(1R,4r)-4-((S)-2-((R)-2-hydroxy-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
804		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-3-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
806		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((S)-tetrahydro-2H-pyran-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
818		(1S,3R)-3-((S)-2-(2-cyclobutylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre



Forbindelse Nr.	Struktur	Navn
820		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((4-methylpyrimidin-2-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
828		(1R,3R)-3-((S)-2-((5-chlorpyrimidin-2-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
832		(1R,4r)-4-((S)-6-(methoxycarbonyl)-2-(((1s,4S)-4-methoxycyclohexyl)methyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
840		methyl (S)-2-benzyl-3-((1R,3R)-3-(methoxycarbonyl)cyclohexyl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
841		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(((R)-tetrahydro-2H-pyran-3-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
858		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(4-(2-oxopyrrolidin-1-yl)benzyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre






Forbindelse Nr.	Struktur	Navn
863		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
864		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
871		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(2-oxopyridin-1(2H)-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
886		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
889		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((R)-tetrahydro-2H-pyran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
890		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-(2-oxopiperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre



Forbindelse Nr.	Struktur	Navn
892		(1R,3R)-3-((S)-2-((1-acetylpiperidin-4-yl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
896		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-oxo-2-(piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre, and
897		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-((S)-tetrahydrofuran-2-yl)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre.

eller et farmaceutisk acceptabelt salt deraf.

13. Forbindelse ifølge krav 7, valgt fra gruppen bestående af:


Forbindelse Nr.	Struktur	Navn
16		(1R,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
17		(1S,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
18		(1R,3S)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
19		(1S,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
22		cis-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
23		trans-4-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
27		trans-4-[(7S)-6-(methoxycarbonyl)-2-[(4-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
28		trans-4-[(7S)-2-[(3-fluor-4-methoxyphenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
263		methyl (7S)-2-benzyl-3-cyclohexyl-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat


eller et farmaceutisk acceptabelt salt deraf.

14. Forbindelsen ifølge krav 1 med den kemiske formel:




(1R,3R)-3-[(7S)-2-benzyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre, eller et farmaceutisk acceptabelt salt deraf.

15. Forbindelsen ifølge krav 1 med den kemiske formel:




trans-4-[(7S)-6-(methoxycarbonyl)-2-[(4-methoxyphenyl)methyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre, eller et farmaceutisk acceptabelt salt deraf.








16. Forbindelsen ifølge krav 9 med den kemiske formel:

















trans-4-[(7S)-2-[(3-fluor-4-methoxyphenyl)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre, eller et farmaceutisk acceptabelt salt deraf.








17. Forbindelse valgt fra gruppen bestående af:







Forbindelse Nr.	Struktur	Navn
1		methyl (7S)-3,7-dimethyl-2-[(2S)-2-phenylpropyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat








Forbindelse Nr.	Struktur	Navn
2		methyl (7S)-3,7-dimethyl-2-[(2R)-2-phenylpropyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
3		methyl (7S)-3,7-dimethyl-2-[(2R)-1-phenylpropan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
4		methyl (7S)-3,7-dimethyl-2-[(2S)-1-phenylpropan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
5		methyl (7S)-3,7-dimethyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
6		methyl (7S)-3,7-dimethyl-2-[(1R)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
8		methyl (7S)-2-[2-(3-fluor-4-methoxyphenyl)ethyl]-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
46		methyl (7S)-2-[(1R)-2-hydroxy-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
47		methyl (7S)-2-[(1S)-2-hydroxy-1-phenylethyl]-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
56		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1R)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
57		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(1S)-1-phenylethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexan-1-carboxylsyre
58		methyl (7S)-7-methyl-2-[(1R)-1-phenylethyl]-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
59		methyl (7S)-7-methyl-2-[(1S)-1-phenylethyl]-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
60		cis-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(2R)-1-phenylpropan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl] cyclohexan-1-carboxylsyre
61		trans-4-[(7S)-6-(methoxycarbonyl)-7-methyl-2-[(2S)-1-phenylpropan-2-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f] quinolin-3-yl] cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
103		methyl (7S)-2-[(3-fluor-4-methoxyphenyl)methyl]-7-methyl-3-(piperidin-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
133		(2R)-3-[(7S)-6-(methoxycarbonyl)-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
134		(2S)-3-[(7S)-6-(methoxycarbonyl)-3,7-dimethyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
135		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
136		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
137		(2R)-3-[(7S)-3-[2-(dimethylamino)ethyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
138		(2S)-3-[(7S)-3-[2-(dimethylamino)ethyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
139		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
140		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-(oxan-4-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
141		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-{2-oxaspiro[3.5]nonan-7-yl}-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
142		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-{2-oxaspiro [3.5] nonan-7-yl } -3H,6H,7H,8H,9H-imidazo [4,5-f]quinolin-2-yl]-2-phenylpropionsyre
143		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methansulfonylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
144		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methansulfonylcyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
145		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
146		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
147		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[2-(piperidin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
148		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[2-(piperidin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
149		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(piperidin-4-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
150		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(piperidin-4-yl)methyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
151		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
152		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
153		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-cyanocyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
154		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-cyanocyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
155		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(3S)-oxan-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
156		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(3S)-oxan-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
157		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(3R)-oxan-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
158		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(3R)-oxan-3-yl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre








Forbindelse Nr.	Struktur	Navn
159		(2R)-3-[(7S)-3-[(cis)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
160		(2S)-3-[(7S)-3-[(cis)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
161		(2R)-3-[(7S)-3-[(trans)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
162		(2S)-3-[(7S)-3-[(trans)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
163		(2R)-3-[(7S)-3-[(trans)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
164		(2S)-3-[(7S)-3-[(trans)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre








Forbindelse Nr.	Struktur	Navn
165		(2R)-3-[(7S)-3-[(trans)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
166		(2S)-3-[(7S)-3-[(trans)-3-(hydroxymethyl)cyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
167		(2R)-2-(3-fluorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
168		(2S)-2-(3-fluorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(1r,4r)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
169		(2R)-2-(4-fluorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
170		(2S)-2-(4-fluorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre







Forbindelse Nr.	Struktur	Navn
171		(2R)-2-(3-chlorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
172		(2S)-2-(3-chlorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
173		(2R)-2-(4-chlorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
174		(2S)-2-(4-chlorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
175		(2R)-2-(3,4-difluorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
176		(2S)-2-(3,4-difluorphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre






Forbindelse Nr.	Struktur	Navn
177		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-(3-methylphenyl)propionsyre
178		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-(3-methylphenyl)propionsyre
179		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-(4-methylphenyl)propionsyre
180		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-(4-methylphenyl)propionsyre
181		(2R)-2-(3-fluor-4-methoxyphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
182		(2S)-2-(3-fluor-4-methoxyphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre







Forbindelse Nr.	Struktur	Navn
183		(2R)-2-(3-fluor-4-methylphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
184		(2S)-2-(3-fluor-4-methylphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
185		(2R)-2-(3-chlor-4-methylphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
186		(2S)-2-(3-chlor-4-methylphenyl)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-methoxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]propionsyre
187		(2R)-3-[(7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
188		(2S)-3-[(7S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
189		(2R)-3-[(7S)-3-cycloheptyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
190		(2S)-3-[(7S)-3-cycloheptyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
191		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-phenyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
192		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-phenyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
193		(2R)-3-[(7S)-3-cyclobutyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
194		(2S)-3-[(7S)-3-cyclobutyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
195		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-(pentan-3-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
196		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-(pentan-3-yl)-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
197		(2R)-3-[(7S)-3-tert-butyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
198		(2S)-3-[(7S)-3-tert-butyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
199		(2R)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-hydroxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
200		(2S)-3-[(7S)-6-(methoxycarbonyl)-7-methyl-3-[(trans)-4-hydroxycyclohexyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
201		(2R)-3-[(7S)-3-[(1R,3R)-3-hydroxycyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
202		(2S)-3-[(7S)-3-[(1R,3R)-3-hydroxycyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
203		(2R)-3-[(7S)-3-[(IR,3S)-3-hydroxycyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
204		(2S)-3-[(7S)-3-[(1R,3S)-3-hydroxycyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
205		(2R)-3-[(7S)-3-[(IS,3R)-3-hydroxycyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
206		(2S)-3-[(7S)-3-[(1S,3R)-3-hydroxycyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
207		(2R)-3-[(7S)-3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
208		(2S)-3-[(7S)-3-cyclohexyl-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
209		(2S)-3-[(7S)-3-[(cis)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
210		(2R)-3-[(7S)-3-[(cis)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
211		(2S)-3-[(7S)-3-[(cis)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
212		(2R)-3-[(7S)-3-[(cis)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
213		(2S)-3-[(7S)-3-[(1R,3R)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
214		(2R)-3-[(7S)-3-[(1R,3R)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
215		(2S)-3-[(7S)-3-[(1S,3S)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
216		(2R)-3-[(7S)-3-[(1S,3S)-3-cyanocyclohexyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-2-yl]-2-phenylpropionsyre
247		methyl (7S)-2-cyclopropyl-7-methyl-3-[2-(morpholin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
248		methyl (7S)-2,7-dimethyl-3-[2-(morpholin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
249		methyl (7S)-2-tert-butyl-7-methyl-3-[2-(morpholin-4-yl)ethyl]-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
250		methyl (7S)-7-methyl-3-[2-(morpholin-4-yl)ethyl]-2-phenyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
252		methyl (7S)-1-benzyl-7-methyl-2-(trifluormethyl)-1H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-6-carboxylat
404		(S)-3-((S)-6-(methoxycarbonyl)-3-((1R,3S)-3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
405		(1R,3R)-3-((S)-2-((R)-1-(3,4-difluorphenyl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
406		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
407		(S)-2-(3-fluor-4-methylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((R)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre







Forbindelse Nr.	Struktur	Navn
409		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenoxycyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
411		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
422		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-ylamino)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
425		(1R,3R)-3-((S)-2-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
435		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
439		(1R,3R)-3-((S)-2-((R)-acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
441		methyl (S)-2-((R)-1-(3,4-difluorphenyl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
443		(1R,3R)-3-((S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
446		(R)-2-(3-fluor-4-methylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
447		(S)-3-((S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3,4-difluorphenyl)propionsyre
450		(1S,4r)-4-((S)-2-(1-(1H-indazol-1-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
455		(S)-3-((S)-6-(methoxycarbonyl)-3-((1R,3R)-3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
456		(S)-2-(4-chlorphenyl)-3-((S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
457		(1R,4r)-4-((S)-2-((R)-1-(3-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
459		(1R,3R)-3-((S)-2-((R)-1-(3-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
466		(1R,4r)-4-((S)-2-((R)-1-(3-fluor-4-methoxyphenyl)-2-methylpropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
468		(R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-2-yl)propionsyre
469		(1R,3R)-3-((S)-2-((S)-1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
473		(1R,3R)-3-((S)-2-((R)-methoxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
475		(S)-3-((S)-6-(methoxycarbonyl)-3-((1S,3S)-3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
477		(1R,4r)-4-((S)-2-((R)-1-(3-fluor-4-methoxyphenyl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
483		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(pyridin-3-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
484		(1R,3R)-3-((S)-2-(1-(6-(difluormethoxy)pyridin-3-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
485		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
486		(1R,3R)-3-((S)-2-((R)-1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
487		(1S,4r)-4-((S)-2-(1-(2H-indazol-2-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
490		(R)-2-(3-fluorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
492		(1R,3R)-3-((S)-2-((R)-1-(4-(difluormethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
495		(R)-2-(4-chlorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
496		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
497		(S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((R)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre
498		(1R,3R)-3-((S)-2-((3-chlorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
504		(1R,4r)-4-((S)-2-((R)-1-(4-(difluormethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
505		(1R,3R)-3-((S)-2-((S)-2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
506		(R)-2-(3-chlorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
510		(R)-2-(4-fluorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre







Forbindelse Nr.	Struktur	Navn
511		(S)-3-((S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3-fluor-4-methylphenyl)propionsyre
513		(1R,3R)-3-((S)-2-((S)-methoxy(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
516		(R)-3-((S)-6-(methoxycarbonyl)-3-(3-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
517		(1R,4r)-4-((S)-2-((R)-1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
519		(1R,3R)-3-((S)-2-((3-fluorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
520		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-((R)-pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
522		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((Z)-1-phenoxyprop-1-en-1-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
524		(R)-2-(4-(difluormethyl)phenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((R)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
525		(1R,3R)-3-((S)-2-((S)-acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
526		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
529		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
530		(1R,3R)-3-((S)-2-(1-(6-cyclopropylpyrazin-2-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
531		(1R,3R)-3-((S)-2-((S)-1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
535		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((3-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
536		(S)-3-((S)-6-(methoxycarbonyl)-3-(4-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
539		(R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre
540		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyridin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
545		(1R,3R)-3-((S)-2-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
551		(1S,4r)-4-((S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
552		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
554		(1R,3R)-3-((S)-2-((R)-1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
557		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
558		(1S,4r)-4-((S)-2-((S)-1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
560		(1S,4r)-4-((S)-2-(2-(3-fluor-4-methoxyphenyl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
563		(R)-3-((S)-3-((R)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre
567		methyl (S)-3-((S)-azepan-4-yl)-7-methyl-2-((R)-1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
571		(1R,3R)-3-((S)-2-(benzyl(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
573		(1S,4r)-4-((S)-2-((3-chlorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
574		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-phenoxycyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
576		methyl (S)-7-methyl-2-((R)-1-phenylpropan-2-yl)-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
580		(R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-1-yl)propionsyre
582		(1R,4r)-4-((S)-2-((R)-2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
583		(1R,3R)-3-((S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
584		(R)-2-(4-(difluormethyl)phenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
585		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
588		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(2-oxopiperidin-1-yl)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
591		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(p-tolyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
592		(1R,3R)-3-((S)-2-((4-chlorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
594		(R)-3-((S)-3-((R)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
597		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
598		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(o-tolyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
599		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(pyridin-3-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
602		(R)-3-((S)-3-((S)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
603		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
604		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
605		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-phenoxyethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
609		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
613		(1S,4r)-4-((S)-2-((3-fluorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
617		(1S,4r)-4-((S)-2-(1-(4-chlor-1H-pyrazol-1-yl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
620		(R)-2-(4-cyclopropylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
622		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(tetrahydro-2H-pyran-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f] quinolin-3-yl)cyclohexan-1-carboxylsyre
623		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
624		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-oxo-1-(piperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
626		methyl (S)-2-((R)-1-(3,4-difluorphenyl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
627		(1S,4r)-4-((S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
629		(R)-2-(4-(difluormethyl)phenyl)-3-((S)-3-((R)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
632		(R)-3-((S)-6-(methoxycarbonyl)-3-((1R,3R)-3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
640		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-2-methyl-1-phenylpropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
644		(R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(m-tolyl)propionsyre
646		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(2-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
651		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
652		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(methyl(pyridin-2-yl)amino)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
653		(1S,4r)-4-((S)-2-((S)-1-(3-fluor-4-methoxyphenyl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
655		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
659		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
666		(1R,3R)-3-((S)-2-((S)-1-(2-hydroxy-1H-indol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
668		(1R,3R)-3-((S)-2-((R)-2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
670		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(N-methylphenylsulfonamido)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
671		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(1-methyl- 1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
673		(1S,4r)-4-((S)-2-((S)-1-(3-fluor-4-methoxyphenyl)-2-methylpropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
676		(R)-2-(3-(difluormethyl)phenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
677		(1S,4r)-4-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
680		(R)-3-((S)-3-(4-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
681		(1R,3R)-3-((S)-2-((4-cyanophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
683		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
685		(1R,4r)-4-((S)-2-((R)-1-(cyclohexyloxy)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
686		methyl (S)-3-((S)-azepan-4-yl)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
689		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
690		(1R,3R)-3-((S)-2-(benzylamino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
691		(1S,4r)-4-((S)-2-((4-chlorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
694		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
698		(R)-3-((S)-3-(3-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
700		(R)-3-((S)-3-((S)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre
703		(1S,4r)-4-((S)-2-(2-(4-chlor-1H-pyrazol-1-yl)ethoxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
704		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(6-methylpyrazin-2-yl)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
709		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
710		(1S,4r)-4-((S)-2-(1-((1H-pyrazol-1-yl)methyl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
713		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(tetrahydro-2H-pyran-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
715		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylsulfonamido)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
717		(1R,4r)-4-((S)-2-((R)-acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
719		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((3-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
720		(1R,3R)-3-((S)-2-((S)-1-(3,4-difluorphenyl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
722		(1R,3R)-3-((S)-2-((R)-1-(2-hydroxy-1H-indol-1-yl)ethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
724		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo [4,5-f] quinolin-3-yl)cyclohexan-1-carboxylsyre
725		(1R,4r)-4-((7S)-6-(methoxycarbonyl)-7-methyl-2-((1R)-(methylsulfinyl)(phenyl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
727		(1S,4r)-4-((S)-2-((3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
728		(S)-2-(3-fluorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
732		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
734		methyl (S)-3-((S)-azepan-4-yl)-7-methyl-2-((S)-1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
736		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
742		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
746		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(7-azaspiro[3.5]nonan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
750		methyl (S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
751		(R)-3-((S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3,4-difluorphenyl)propionsyre
753		(1R,3R)-3-((S)-2-(1-((1H-pyrazol-1-yl)methyl)cyclopropyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
754		methyl (S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
756		(R)-2-(4-isopropylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
757		(R)-3-((S)-6-(methoxycarbonyl)-3-((1S,3S)-3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
761		(1S,4r)-4-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)(methyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
763		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-phenylpropan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
764		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
765		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(pyridin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
766		(1S,4r)-4-((S)-2-(2-cyclopentylethoxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
767		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(3-phenylpropoxy)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
768		(S)-2-(3-chlorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
769		(1S,4r)-4-((S)-2-((4-cyanophenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
771		methyl (S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
772		methyl (S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
773		(S)-2-(4-fluorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
776		(1S,4r)-4-((S)-6-(methoxycarbonyl)-2-((3-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
779		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-(methylsulfonyl)(phenyl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
782		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
783		(S)-2-(3-fluor-4-methylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
785		(S)-2-(4-(difluormethyl)phenyl)-3-((S)-3-((R)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
786		(S)-3-((S)-6-(methoxycarbonyl)-3-(3-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
787		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
788		(1R,3R)-3-((S)-2-((3-chlorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
790		(1S,4r)-4-((S)-2-((S)-1-(3-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
791		(R)-3-((S)-6-(methoxycarbonyl)-3-((1R,3S)-3-methoxycyclohexyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
792		(1S,4r)-4-((S)-2-(benzyloxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
793		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(pyridin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
794		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
796		(1S,4r)-4-((S)-2-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
797		(1R,4r)-4-((7S)-6-(methoxycarbonyl)-7-methyl-2-((1R)-(methylsulfinyl)(phenyl)methyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
799		(1R,3R)-3-((S)-2-((4-fluor-3-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
801		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
802		(1R,3R)-3-((S)-2-((3-fluorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
803		methyl (S)-7-methyl-2-((R)-1-phenylpropan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
805		(1S,4r)-4-((S)-2-((4-fluorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
807		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethoxy-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
808		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
809		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(p-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
810		(1R,3R)-3-((S)-2-(2-(4-chlor-1H-pyrazol-1-yl)ethoxy)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
811		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-((S)-pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
812		(1S,4r)-4-((S)-2-((S)-2-hydroxy-1-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
813		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
814		(1R,3R)-3-((S)-2-(benzylsulfonyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
815		(1S,4r)-4-((S)-2-((3-chlorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
816		(1R,3R)-3-((S)-2-((3,4-difluorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
819		(1R,3R)-3-((S)-2-((3-cyanophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
821		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((E)-1-phenoxyprop-1-en-1-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
823		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yloxy)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
824		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(3-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
825		(1R,3R)-3-((S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
827		(1R,3R)-3-((S)-2-((S)-1-(3-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
829		(R)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((R)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre







Forbindelse Nr.	Struktur	Navn
830		(1R,3R)-3-((S)-2-((1H-indazol-6-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
831		(1R,3R)-3-((S)-2-((4-chlorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
833		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(pyrazin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
834		methyl (S)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-((R)-1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
835		(1S,4r)-4-((S)-2-((S)-acetamido(phenyl)methyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
836		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
837		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
838		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(p-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
839		(1S,4r)-4-((S)-2-((2-chlorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
842		methyl (S)-3-((R)-azepan-4-yl)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
843		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
844		methyl (S)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-((S)-1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat







Forbindelse Nr.	Struktur	Navn
845		(R)-2-(3-fluor-4-methylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((R)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
846		(1R,3R)-3-((S)-2-((2-fluor-4-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
847		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(m-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
848		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(pyrazin-2-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
849		(R)-3-((S)-6-(methoxycarbonyl)-3-(4-methoxyphenyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
850		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((6-methoxypyridin-3-yl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
851		(1S,4r)-4-((S)-2-((2-fluor-4-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
852		(S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-1-yl)propionsyre
853		(1S,4r)-4-((S)-2-((1H-indazol-6-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
854		(1S,4r)-4-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
855		(1S,4r)-4-((S)-2-((S)-1-acetamido-2-phenylethyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
856		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(1-(pyrazin-2-yl)cyclopropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
857		(1S,4r)-4-((S)-2-((4-cyanophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
859		(1R,3R)-3-((S)-6-(methoxycarbonyl)-2-((2-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
860		methyl (S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((S)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
861		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-methyl-1H-indazol-6-yl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
862		(1R,3R)-3-((S)-2-((S)-1-(4-(difluormethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
865		(1S,4r)-4-((S)-2-((4-chlorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
866		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(m-tolylamino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
867		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
868		(S)-2-(3-(difluormethyl)phenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
869		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-2-methyl-1-phenylpropyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
870		(S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(naphthalen-2-yl)propionsyre
872		(S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre







Forbindelse Nr.	Struktur	Navn
873		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-phenethoxy-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
874		(1R,3R)-3-((S)-2-benzoyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
875		(1S,4r)-4-((S)-6-(methoxycarbonyl)-2-((4-methoxyphenyl)amino)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
876		(1R,3R)-3-((S)-2-((4-fluorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
877		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
878		(1R,3R)-3-((S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
879		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((3-methyl-1H-indazol-6-yl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
880		(1S,4r)-4-((S)-2-((4-fluorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
881		(1S,4r)-4-((S)-2-((3,4-difluorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
882		(1S,4r)-4-((S)-2-(benzylsulfonyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
883		(1S,4r)-4-((S)-2-((3-fluorphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
884		(1S,4r)-4-((S)-2-((3-cyanophenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
885		(S)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(m-tolyl)propionsyre
887		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(pyrazin-2-yloxy)ethyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
888		(S)-2-(4-isopropylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
891		(S)-3-((S)-3-((S)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
893		(R)-2-(4-chlorphenyl)-3-((S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
894		(1R,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
895		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
898		(1S,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((R)-1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
899		(1S,4r)-4-((S)-2-((4-fluor-3-methoxyphenyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
900		(S)-2-(4-chlorphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
901		(S)-2-(4-(difluormethyl)phenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
902		(S)-2-(4-(difluormethyl)phenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((R)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre







Forbindelse Nr.	Struktur	Navn
903		(S)-3-((S)-3-((R)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
904		(S)-2-(4-cyclopropylphenyl)-3-((S)-6-(methoxycarbonyl)-7-methyl-3-((S)-tetrahydro-2H-pyran-3-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
905		(S)-3-((S)-3-(3-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre
906		(R)-3-((S)-3-cyclopentyl-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(3-fluor-4-methylphenyl)propionsyre
907		(1R,4r)-4-((S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
908		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-phenoxy-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre







Forbindelse Nr.	Struktur	Navn
909		(1S,4r)-4-((S)-2-((3,5-dimethyl-1H-pyrazol-4-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
910		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
911		(1S,4r)-4-((S)-2-((1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
912		(1S,4r)-4-((S)-2-((S)-1-(4-(difluormethyl)-1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
913		(S)-3-((S)-3-((S)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre
914		(S)-3-((S)-3-(4-cyanophenyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-phenylpropionsyre







Forbindelse Nr.	Struktur	Navn
915		(1S,4r)-4-((S)-2-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
916		(1R,3R)-3-((S)-2-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
917		(1R,4r)-4-((S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
918		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
919		methyl (S)-7-methyl-2-((S)-1-phenylpropan-2-yl)-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
920		(R)-2-(4-(difluormethyl)phenyl)-3-((S)-3-((S)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre







Forbindelse Nr.	Struktur	Navn
921		methyl (S)-2-((S)-1-(3,4-difluorphenyl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
922		(1R,3R)-3-((S)-2-(cyclopentylcarbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
923		(1R,3R)-3-((S)-2-(cyclopentyl(methyl)carbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
924		(1R,3R)-3-((S)-2-((2-chlorphenyl)(methyl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
925		(1R,3R)-3-((S)-2-(cyclohexylcarbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
926		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-3-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat



Forbindelse Nr.	Struktur	Navn
927		(S)-3-((S)-3-((R)-5,5-difluortetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)-2-(p-tolyl)propionsyre
928		methyl (S)-7-methyl-2-((S)-1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
929		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-((S)-1-(2-oxopiperidin-1-yl)propan-2-yl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
930		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-3-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
931		methyl (S)-2-((S)-1-(3,4-difluorphenyl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
932		methyl (S)-3-((S)-azepan-4-yl)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat

Forbindelse Nr.	Struktur	Navn
933		(1S,4r)-4-((S)-2-((3-fluorpyridin-4-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
934		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(methyl(phenyl)carbamoyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
936		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(2-azaspiro[3.5]nonan-7-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
937		(S)-2-(4-(difluormethyl)phenyl)-3-((S)-3-((S)-5,5-difluorotetrahydro-2H-pyran-3-yl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-2-yl)propionsyre
938		methyl (S)-3-((R)-azepan-4-yl)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
939		(1R,3R)-3-((S)-2-(cyclohexyl(methyl)carbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre

Forbindelse Nr.	Struktur	Navn
940		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(7-azaspiro[3.5]nonan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
941		(1R,3R)-3-((S)-2-((3-fluorpyridin-4-yl)amino)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
942		methyl (S)-3-((R)-azepan-4-yl)-7-methyl-2-((S)-1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
943		(1S,4r)-4-((S)-6-(methoxycarbonyl)-7-methyl-2-((2-methylpyridin-4-yl)amino)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
944		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-((R)-pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
945		methyl (S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat

Forbindelse Nr.	Struktur	Navn
946		methyl (S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
947		methyl (S)-7-methyl-2-((S)-1-phenylpropan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
948		(1R,3R)-3-((S)-6-(methoxycarbonyl)-7-methyl-2-(phenylcarbamoyl)-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre
949		methyl (S)-3-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-((R)-1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
950		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-((S)-pyrrolidin-3-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
951		methyl (S)-7-methyl-2-((R)-1-(1-methyl-1H-pyrazol-4-yl)propan-2-yl)-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat

Forbindelse Nr.	Struktur	Navn
952		methyl (S)-2-((R)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(piperidin-4-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
953		methyl (S)-3-((R)-azepan-4-yl)-7-methyl-2-((R)-1-phenylpropan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
954		methyl (S)-2-((S)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((S)-1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
955		methyl (S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((R)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
956		methyl (S)-2-((R)-1-(1H-pyrazol-1-yl)propan-2-yl)-3-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
958		methyl (S)-3-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-7-methyl-2-((S)-1-(4-methyl-1H-pyrazol-1-yl)propan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat

Forbindelse Nr.	Struktur	Navn
959		methyl (S)-2-((S)-1-(4-chlor-1H-pyrazol-1-yl)propan-2-yl)-7-methyl-3-(6-azaspiro[3.4]octan-2-yl)-3,7,8,9-tetrahydro-6H-imidazo[4,5-f]quinolin-6-carboxylat
961		(1R,3R)-3-((S)-2-((2-chlorphenyl)carbamoyl)-6-(methoxycarbonyl)-7-methyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-f]quinolin-3-yl)cyclohexan-1-carboxylsyre

eller et farmaceutisk acceptabelt salt deraf.

18. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1-17 eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabel bærer.